FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Maciejewski, ML
Liu, CF
Kavee, AL
Olsen, MK
AF Maciejewski, Matthew L.
Liu, Chuan-Fen
Kavee, Andrew L.
Olsen, Maren K.
TI HOW PRICE RESPONSIVE IS THE DEMAND FOR SPECIALTY CARE?
SO HEALTH ECONOMICS
LA English
DT Article
DE costs; longitudinal; mixed model; random effects; health econometrics;
zero-inflated data; specialty care; co-payment; cost sharing
ID HEALTH MAINTENANCE ORGANIZATION; OFFICE VISIT COPAYMENTS; RISK
ADJUSTMENT; PREVENTIVE SERVICES; EMERGENCY; OUTCOMES; IMPACT; COSTS;
COINSURANCE; PERFORMANCE
AB Objectives Outpatient visit co-payments have increased in recent years. We estimate the patient response to a price change for specialty care, based on a co-payment increase from $15 to $50 per visit for veterans with hypertension. Design, Setting, and Patients A retrospective cohort of veterans required to pay co-payments was compared with veterans exempt from co-payments whose nonequivalence was reduced via propensity score matching. Specialty care expenditures in 20002003 were estimated via a two-part mixed model to account for the correlation of the use and level outcomes over time, and results from this correlated two-part model were compared with an uncorrelated two-part model and a correlated random intercept two-part mixed model. Results A $35 specialty visit co-payment increase had no impact on the likelihood of seeking specialty care but induced lower specialty expenditures over time among users who were required to pay co-payments. The log ratio of price responsiveness (semi-elasticity) for specialty care increased from -0.25 to -0.31 after the co-payment increase. Estimates were similar across the three models. Conclusion A significant increase in specialty visit co-payments reduced specialty expenditures among patients obtaining medications at the Veterans Affairs medical centers. Longitudinal expenditure analysis may be improved using recent advances in two-part model methods. Published 2011. This article is a US Government work and is in the public domain in the USA.
C1 [Maciejewski, Matthew L.; Kavee, Andrew L.; Olsen, Maren K.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Maciejewski, Matthew L.] Duke Univ, Div Gen Internal Med, Durham, NC USA.
[Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Olsen, Maren K.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, 205 Fulton St, Durham, NC USA.
EM mlm34@duke.edu
FU Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs [IIR 03-200];
Department of Veterans Affairs [RCS 10-391]; Novartis; Takeda
Pharmaceuticals; Surgical Review Corporation
FX This work was supported by the Office of Research and Development,
Health Services Research and Development Service, Department of Veterans
Affairs, project number IIR 03-200. Dr Maciejewski was also supported by
a Research Career Scientist award from the Department of Veterans
Affairs (RCS 10-391). The authors are grateful for the helpful comments
from the editor, two reviewers, Jim Burgess, Steve Pizer, Anirban Basu,
Courtney Van Houtven, Santanu Datta, Valerie Smith, and the seminar
participants at the ASA Health Policy Statistics meeting in 2008. Dr
Maciejewski has received consultation funds from Novartis, Takeda
Pharmaceuticals, Surgical Review Corporation, and owns a stock in Amgen.
The views expressed are those of the authors and do not reflect the
views of the Department of Veterans Affairs, the Duke University, or the
University of Washington.
NR 44
TC 3
Z9 3
U1 1
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9230
J9 HEALTH ECON
JI Health Econ.
PD AUG
PY 2012
VL 21
IS 8
BP 902
EP 912
DI 10.1002/hec.1759
PG 11
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 967KT
UT WOS:000305907400002
PM 21755570
ER
PT J
AU McDermott, PJ
Baicu, CF
Wahl, SR
Van Laer, AO
Zile, MR
AF McDermott, Paul J.
Baicu, Catalin F.
Wahl, Shaun R.
Van Laer, An O.
Zile, Michael R.
TI In vivo measurements of the contributions of protein synthesis and
protein degradation in regulating cardiac pressure overload hypertrophy
in the mouse
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Myocardium; Amino acids; Infusion; Inbred C57BL mice
ID MYOSIN HEAVY-CHAIN; VENTRICULAR HYPERTROPHY; VOLUME OVERLOAD; MICE;
TURNOVER; CANINE; HEART; DYSFUNCTION; MECHANISMS; PROTEASOME
AB Cardiac hypertrophy is generated in response to hemodynamic overload by altering steady-state protein metabolism such that the rate of protein synthesis exceeds the rate of protein degradation. To determine the relative contributions of protein synthesis and degradation in regulating cardiac hypertrophy in mice, a continuous infusion strategy was developed to measure myocardial protein synthesis rates in vivo. Osmotic mini-pumps were implanted in the abdominal cavity to infuse radiolabeled leucine in mice that are conscious and ambulatory. Protein synthesis rates were calculated by measuring incorporation of leucine into myocardial protein over 24 h prior to each time point and dividing by the specific radioactivity of plasma leucine. Compared to sham-operated controls, fractional rates of protein synthesis (K (s)) increased significantly at days 1 and 3 of TAC, but was lower on day 7 and returned to control values by day 14. These changes coincided with the curvilinear increase in LV mass that characterizes the hypertrophic response. Fractional rates of protein degradation (K (d)) were calculated by subtracting the rate of myocardial growth from the corresponding K (s) value. K (d) fell at days 1 and 3 of TAC, increased at day 7 and returned to control on day 14. Thus, the increase in LV mass generated in response to pressure overload is caused by acceleration of K (s) and suppression of K (d). As the growth rate slows, a new steady-state is achieved once the hypertrophic response is completed.
C1 [McDermott, Paul J.; Baicu, Catalin F.; Wahl, Shaun R.; Van Laer, An O.; Zile, Michael R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Charleston, SC 29403 USA.
[McDermott, Paul J.; Baicu, Catalin F.; Wahl, Shaun R.; Van Laer, An O.; Zile, Michael R.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Strom Thurmond Biomed Res Bldg,Room 303,114 Dough, Charleston, SC 29403 USA.
EM mcdermp@musc.edu
FU Department of Veterans Affairs
FX We thank Daisy Dominick and Dr. Harinath Kasiganesan for their excellent
technical assistance, and Dr. Francis G. Spinale for his help using
osmotic mini-pumps. This work was supported by Merit Review Awards (P.
J. McDermott and M. R. Zile) from the Health Services Research and
Development Program of the Department of Veterans Affairs.
NR 24
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD AUG
PY 2012
VL 367
IS 1-2
BP 205
EP 213
DI 10.1007/s11010-012-1334-7
PG 9
WC Cell Biology
SC Cell Biology
GA 964GX
UT WOS:000305683100021
PM 22610791
ER
PT J
AU Zile, MR
Baicu, CF
Gottdiener, JS
Hetzel, SJ
McMurray, JJ
Komajda, M
McKelvie, R
Massie, BM
Carson, PE
AF Zile, Michael R.
Baicu, Catalin F.
Gottdiener, John S.
Hetzel, Scott J.
McMurray, John J.
Komajda, Michel
McKelvie, Robert
Massie, Barry M.
Carson, Peter E.
CA I-PRESERVE Investigators
TI Response to Letters Regarding Article, "Prevalence and Significance of
Alterations in Cardiac Structure and Function in Patients With Heart
Failure and a Preserved Ejection Fraction"
SO CIRCULATION
LA English
DT Letter
C1 [Zile, Michael R.; Baicu, Catalin F.] RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA.
[Zile, Michael R.; Baicu, Catalin F.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Gottdiener, John S.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
[Hetzel, Scott J.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[McMurray, John J.] Univ Glasgow, British Heart Fdn, Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.
[Komajda, Michel] Univ Paris 06, Pitie Salpetriere Hosp, Paris, France.
[McKelvie, Robert] McMaster Univ, Hamilton, ON, Canada.
[Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Carson, Peter E.; I-PRESERVE Investigators] Georgetown Univ, Washington, DC USA.
[Carson, Peter E.] VAMC, Washington, DC USA.
RP Zile, MR (reprint author), RHJ Dept Vet Affairs Med Ctr, Charleston, SC USA.
OI mcmurray, john/0000-0002-6317-3975
NR 7
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUL 31
PY 2012
VL 126
IS 5
BP E64
EP E65
DI 10.1161/CIRCULATIONAHA.112.110809
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 981OK
UT WOS:000306977500008
ER
PT J
AU Eccles, MP
Foy, R
Sales, A
Wensing, M
Mittman, B
AF Eccles, Martin P.
Foy, Robbie
Sales, Anne
Wensing, Michel
Mittman, Brian
TI Implementation Science six years on-our evolving scope and common
reasons for rejection without review
SO IMPLEMENTATION SCIENCE
LA English
DT Editorial Material
AB Implementation Science has been published for six years and over that time has gone from receiving 100 articles in 2006 to receiving 354 in 2011; our impact factor has risen from 2.49 in June 2010 to 3.10 in June 2012. Whilst our article publication rate has also risen, it has risen much less slowly than our submission rate-we published 29 papers in 2006 and 134 papers in 2011 and we now publish only around 40 % of submissions. About one-half of submitted manuscripts are rejected without being sent out for peer review; it has become clear that there are a number of common issues that result in manuscripts being rejected at this stage. We hope that by publishing this editorial on our common reasons for rejection without peer review we can help authors to better judge the relevance of their papers to Implementation Science.
C1 [Eccles, Martin P.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
[Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9LJ, W Yorkshire, England.
[Wensing, Michel] Radboud Univ Nijmegen, Med Ctr, Sci Inst Qual Healthcare, NL-6525 ED Nijmegen, Netherlands.
[Mittman, Brian] VA Greater Los Angeles Healthcare Syst, VA Ctr Implementat Practice & Res Support, Sepulveda, CA 91343 USA.
[Sales, Anne] Ann Arbor VA HSR&D Ctr Excellence, VA Inpatient Evaluat Ctr, Ann Arbor, MI USA.
RP Eccles, MP (reprint author), Newcastle Univ, Inst Hlth & Soc, Baddiley Clark Bldg,Richardson Rd, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
EM martin.eccles@ncl.ac.uk
RI Wensing, Michel/H-8113-2014
OI Sales, Anne/0000-0001-9360-3334
NR 6
TC 15
Z9 15
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD JUL 27
PY 2012
VL 7
AR 71
DI 10.1186/1748-5908-7-71
PG 6
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 011HK
UT WOS:000309155500001
PM 22839967
ER
PT J
AU Rettig, M
Trinidad, K
Pezeshkpour, G
Frost, P
Sharma, S
Moatamed, F
Tamanoi, F
Mortazavi, F
AF Rettig, Matthew
Trinidad, Kenny
Pezeshkpour, G.
Frost, Patrick
Sharma, Sherven
Moatamed, Farhad
Tamanoi, Fuyuhiko
Mortazavi, Fariborz
TI PAK1 Kinase Promotes Cell Motility and Invasiveness through CRK-II
Serine Phosphorylation in Non-Small Cell Lung Cancer Cells
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; RHO-FAMILY GTPASES;
P120 CATENIN; ADAPTER PROTEINS; P21-ACTIVATED-KINASE-1 PAK1; CADHERIN
EXPRESSION; ONCOGENE PRODUCT; P120-CATENIN; APOPTOSIS
AB The role of c-Crk (CRK) in promoting metastasis is well described however the role of CRK phosphorylation and the corresponding signaling events are not well explained. We have observed CRK-II serine 41 phosphorylation is inversely correlated with p120-catenin and E-cadherin expressions in non-small cell lung cancer (NSCLC) cells. Therefore, we investigated the role of CRK-II serine 41 phosphorylation in the down-regulation of p120-catenin, cell motility and cell invasiveness in NSCLC cells. For this purpose, we expressed phosphomimetic and phosphodeficient CRK-II serine 41 mutants in NSCLC cells. NSCLC cells expressing phosphomimetic CRK-II seine 41 mutant showed lower p120-catenin level while CRK-II seine 41 phosphodeficient mutant expression resulted in higher p120-catenin. In addition, A549 cells expressing CRK-II serine 41 phosphomimetic mutant demonstrated more aggressive behavior in wound healing and invasion assays and, on the contrary, expression of phosphodeficient CRK-II serine 41 mutant in A549 cells resulted in reduced cell motility and invasiveness. We also provide evidence that PAK1 mediates CRK-II serine 41 phosphorylation. RNAi mediated silencing of PAK1 increased p120-catenin level in A549 and H157 cells. Furthermore, PAK1 silencing decreased cell motility and invasiveness in A549 cells. These effects were abrogated in A549 cells expressing phosphomimetic CRK-II serine 41. In summary, these data provide evidence for the role of PAK1 in the promotion of cell motility, cell invasiveness and the down regulation of p120-catenin through CRK serine 41 phosphorylation in NSCLC cells.
C1 [Rettig, Matthew; Trinidad, Kenny; Frost, Patrick; Mortazavi, Fariborz] W Los Angeles VA, Div Hematol Oncol, Los Angeles, CA USA.
[Rettig, Matthew; Sharma, Sherven; Mortazavi, Fariborz] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Rettig, Matthew; Tamanoi, Fuyuhiko; Mortazavi, Fariborz] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA.
[Pezeshkpour, G.; Moatamed, Farhad] W Los Angeles VA, Dept Pathol, Los Angeles, CA USA.
[Sharma, Sherven] W Los Angeles VA, Div Mol Med, Los Angeles, CA USA.
[Tamanoi, Fuyuhiko] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA.
RP Rettig, M (reprint author), W Los Angeles VA, Div Hematol Oncol, Los Angeles, CA USA.
EM fredmortazavi@ucla.edu
OI Frost, Patrick/0000-0003-3348-5983
NR 49
TC 22
Z9 22
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2012
VL 7
IS 7
AR e42012
DI 10.1371/journal.pone.0042012
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 981ER
UT WOS:000306950200146
PM 22848689
ER
PT J
AU Tokhtaeva, E
Clifford, RJ
Kaplan, JH
Sachs, G
Vagin, O
AF Tokhtaeva, Elmira
Clifford, Rebecca J.
Kaplan, Jack H.
Sachs, George
Vagin, Olga
TI Subunit Isoform Selectivity in Assembly of Na,K-ATPase alpha-beta
Heterodimers
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; CENTRAL-NERVOUS-SYSTEM; NA+-K+-ATPASE;
ADHESION MOLECULE; CELL-ADHESION; EXPRESSION; ISOZYMES; IDENTIFICATION;
EPILEPSY; GLIA
AB To catalyze ion transport, the Na,K-ATPase must contain one alpha and one beta subunit. When expressed by transfection in various expression systems, each of the four alpha subunit isoforms can assemble with each of the three beta subunit isoforms and form an active enzyme, suggesting the absence of selective alpha-beta isoform assembly. However, it is unknown whether in vivo conditions the alpha-beta assembly is random or isoform-specific. The alpha(2)-beta(2) complex was selectively immunoprecipitated by both anti-alpha(2) and anti-beta(2) antibodies from extracts of mouse brain, which contains cells co-expressing multiple Na,K-ATPase isoforms. Neither alpha(1)-beta(2) nor alpha(2)-beta(1) complexes were detected in the immunoprecipitates. Furthermore, in MDCK cells co-expressing alpha(1), beta(1), and beta(2) isoforms, a greater fraction of the beta(2) subunits was unassembled with alpha(1) as compared with that of the beta(1) subunits, indicating preferential association of the alpha(1) isoform with the beta(1) isoform. In addition, the alpha(1)-beta(2) complex was less resistant to various detergents than the alpha(1)-beta(1) complex isolated from MDCK cells or the alpha(2)-beta(2) complex isolated from mouse brain. Therefore, the diversity of the alpha-beta Na,K-ATPase heterodimers in vivo is determined not only by cell-specific co-expression of particular isoforms, but also by selective association of the alpha and beta subunit isoforms.
C1 [Tokhtaeva, Elmira; Sachs, George; Vagin, Olga] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA.
[Tokhtaeva, Elmira; Sachs, George; Vagin, Olga] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA.
[Clifford, Rebecca J.; Kaplan, Jack H.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA.
RP Vagin, O (reprint author), VAG LAHS W LA, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA.
EM olgav@ucla.edu
OI Kaplan, Jack/0000-0002-7048-6574
FU National Institutes of Health [DK077149, DK058333, GM39500]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants DK077149 (to O. V.), DK058333 (to G. S.), and GM39500 (to
J. H. K.).
NR 58
TC 24
Z9 24
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 27
PY 2012
VL 287
IS 31
BP 26115
EP 26125
DI 10.1074/jbc.M112.370734
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 980TN
UT WOS:000306916300039
PM 22696220
ER
PT J
AU Ramos, FJ
Chen, SC
Garelick, MG
Dai, DF
Liao, CY
Schreiber, KH
MacKay, VL
An, EH
Strong, R
Ladiges, WC
Rabinovitch, PS
Kaeberlein, M
Kennedy, BK
AF Ramos, Fresnida J.
Chen, Steven C.
Garelick, Michael G.
Dai, Dao-Fu
Liao, Chen-Yu
Schreiber, Katherine H.
MacKay, Vivian L.
An, Elroy H.
Strong, Randy
Ladiges, Warren C.
Rabinovitch, Peter S.
Kaeberlein, Matt
Kennedy, Brian K.
TI Rapamycin Reverses Elevated mTORC1 Signaling in Lamin A/C-Deficient
Mice, Rescues Cardiac and Skeletal Muscle Function, and Extends Survival
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID GENETICALLY HETEROGENEOUS MICE; GIRDLE MUSCULAR-DYSTROPHY; DILATED
CARDIOMYOPATHY; PRESSURE-OVERLOAD; HEART-FAILURE; SINGLE BOUT;
LIFE-SPAN; IN-VIVO; P70 S6; AUTOPHAGY
AB Mutations in LMNA, the gene that encodes A-type lamins, cause multiple diseases including dystrophies of the skeletal muscle and fat, dilated cardiomyopathy, and progeria-like syndromes (collectively termed laminopathies). Reduced A-type lamin function, however, is most commonly associated with skeletal muscle dystrophy and dilated cardiomyopathy rather than lipodystrophy or progeria. The mechanisms underlying these diseases are only beginning to be unraveled. We report that mice deficient in Lmna, which corresponds to the human gene LMNA, have enhanced mTORC1 (mammalian target of rapamycin complex 1) signaling specifically in tissues linked to pathology, namely, cardiac and skeletal muscle. Pharmacologic reversal of elevated mTORC1 signaling by rapamycin improves cardiac and skeletal muscle function and enhances survival in mice lacking A-type lamins. At the cellular level, rapamycin decreases the number of myocytes with abnormal desmin accumulation and decreases the amount of desmin in both muscle and cardiac tissue of Lmna(-/-) mice. In addition, inhibition of mTORC1 signaling with rapamycin improves defective autophagic-mediated degradation in Lmna(-/-) mice. Together, these findings point to aberrant mTORC1 signaling as a mechanistic component of laminopathies associated with reduced A-type lamin function and offer a potential therapeutic approach, namely, the use of rapamycin-related mTORC1 inhibitors.
C1 [Chen, Steven C.; Garelick, Michael G.; MacKay, Vivian L.; Kennedy, Brian K.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
[Ramos, Fresnida J.; Dai, Dao-Fu; An, Elroy H.; Rabinovitch, Peter S.; Kaeberlein, Matt] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Liao, Chen-Yu; Schreiber, Katherine H.; Kennedy, Brian K.] Buck Inst Res Aging, Novara, CA 94945 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Strong, Randy] S Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78284 USA.
[Strong, Randy] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78284 USA.
[Ladiges, Warren C.] Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA.
RP Kennedy, BK (reprint author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
EM kaeber@uw.edu; bkennedy@buckinstitute.org
FU National Institute on Aging [R01 AG024287, R01 AG033373, U01 AG022307];
NIH [T32AG000057, T32 HL007312]
FX This study was supported by National Institute on Aging grants R01
AG024287 and R01 AG033373 (to B. K. K.) and U01 AG022307 (to R. S.).
F.J.R. and M. G. G. are supported by NIH training grant T32AG000057. S.
C. C. is supported by the cardiovascular and pathology training grant
NIH T32 HL007312. M. K. is an Ellison Medical Foundation New Scholar in
Aging.
NR 63
TC 91
Z9 92
U1 3
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUL 25
PY 2012
VL 4
IS 144
AR 144ra103
DI 10.1126/scitranslmed.3003802
PG 11
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 981LC
UT WOS:000306968700006
PM 22837538
ER
PT J
AU Patel, A
Zhu, YH
Kuzhikandathil, EV
Banks, WA
Siegel, A
Zalcman, SS
AF Patel, Ankur
Zhu, Youhua
Kuzhikandathil, Eldo V.
Banks, William A.
Siegel, Allan
Zalcman, Steven S.
TI Soluble Interleukin-6 Receptor Induces Motor Stereotypies and
Co-Localizes with Gp130 in Regions Linked to
Cortico-Striato-Thalamo-Cortical Circuits
SO PLOS ONE
LA English
DT Article
ID BETA-PROTEIN ANTIBODY; BLOOD-BRAIN-BARRIER; IL-6 RECEPTOR;
RHEUMATOID-ARTHRITIS; ALZHEIMERS-DISEASE; MULTIPLE-MYELOMA; CYTOKINE
NETWORK; MOUSE MODEL; SCHIZOPHRENIA; AMPHETAMINE
AB Soluble cytokine receptors are normal constituents of body fluids that regulate peripheral cytokine and lymphoid activity and whose levels are increased in states of immune activation. Soluble interleukin-6 receptor (sIL-6R) levels positively correlate with disease progression in some autoimmune conditions and psychiatric disorders. Particularly strong links between levels of sIL-6R and the severity of psychotic symptoms occur in schizophrenia, raising the possibility that sIL-6R is involved in this disease. However, there is no evidence that peripheral sIL-6R induces relevant behavioral disturbances. We showed that single subcutaneous injections of sIL-6R (0-1 mu g), stimulated novelty stress-induced exploratory motor behaviors in male Balb/c mice within 20-40-min of injection. A progressive increase in vertical stereotypies was observed 40-80 min post injection, persisting for the remainder of the test session. Paralleling these stimulant-like effects, sIL-6R pretreatment significantly enhanced stereotypy scores following challenge with GBR 12909. We found that peripherally administered sIL-6R crossed the blood-brain barrier, localizing in brain regions associated with cortico-striatal-thalamo-cortical (CSTC) circuits, which are putative neuroanatomical substrates of disorders associated with repetitive stereotypies. Peripherally administered sIL-6R co-localized with gp130, a transmembrane protein involved in IL-6 trans-signaling, in the nucleus accumbens, caudate-putamen, motor and infralimbic cortices, and thalamic nuclei, but not with gp130 in the ventral tegmental area, substantia nigra, or sensorimotor cortex,. The results suggest that peripheral sIL-6R can act as a neuroimmune messenger, crossing the blood brain barrier (BBB) to selectively target CSTC circuits rich in IL-6 trans-signaling protein, and inducing repetitive stereotypies. As such sIL-6R may represent a novel therapeutic agent for relevant psychiatric disorders.
C1 [Patel, Ankur; Siegel, Allan] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA.
[Zhu, Youhua; Zalcman, Steven S.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA.
[Kuzhikandathil, Eldo V.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA.
[Banks, William A.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Gerontol & Geriatr Med, Dept Med,Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA.
RP Patel, A (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, 185 S Orange Ave, Newark, NJ 07103 USA.
EM dr.ankur@yahoo.com
FU National Institutes of Health [R01 MH74689, T32 5A74309]
FX This work was supported by National Institutes of Health Grant R01
MH74689 (SSZ) and National Institutes of Health Training Fellowship T32
5A74309 (AP). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 31
TC 12
Z9 12
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2012
VL 7
IS 7
AR e41623
DI 10.1371/journal.pone.0041623
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 977TM
UT WOS:000306687700127
PM 22911828
ER
PT J
AU Bao, YR
Dalrymple, L
Chertow, GM
Kaysen, GA
Johansen, KL
AF Bao, Yeran
Dalrymple, Lorien
Chertow, Glenn M.
Kaysen, George A.
Johansen, Kirsten L.
TI Frailty, Dialysis Initiation, and Mortality in End-Stage Renal Disease
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID PHYSICAL-ACTIVITY; HEMODIALYSIS; HARMFUL; ADULTS; OLDER
AB Background: In light of the recent trend toward earlier dialysis initiation and its association with mortality among patients with end-stage renal disease, we hypothesized that frailty is associated with higher estimated glomerular filtration rate (eGFR) at dialysis start and may confound the relation between earlier dialysis initiation and mortality.
Methods: We examined frailty among participants of the Comprehensive Dialysis Study (CDS), a special study of the US Renal Data System, which enrolled incident patients from September 1, 2005, through June 1, 2007. Patients were followed for vital status through September 30, 2009, and for time to first hospitalization through December 31, 2008. We used multivariate logistic regression to model the association of frailty with eGFR at dialysis start and proportional hazards regression to assess the outcomes of death or hospitalization.
Results: Among 1576 CDS participants included, the prevalence of frailty was 73%. In multivariate analysis, higher eGFR at dialysis initiation was associated with higher odds of frailty (odds ratio [OR], 1.44 [95% CI, 1.23-1.68] per 5 mL/min/1.73 m(2); P<.001). Frailty was independently associated with mortality (hazard ratio [HR], 1.57 [95% CI, 1.25-1.97]; P<.001) and time to first hospitalization (HR, 1.26 [95% CI, 1.09-1.45]; P < .001). While higher eGFR at dialysis initiation was associated with mortality (HR, 1.12 [95% CI, 1.02-1.23] per 5 mL/min/1.73 m2; P=.02), the association was no longer statistically significant after frailty was accounted for (HR, 1.08 [95% CI, 0.98-1.19] per 5 mL/min/1.73 m(2); P=.11).
Conclusions: Frailty is extremely common among patients starting dialysis in the United States and is associated with higher eGFR at dialysis initiation. Recognition of signs and symptoms of frailty by clinicians may prompt earlier initiation of dialysis and may explain, at least in part, the well-described association between eGFR at dialysis initiation and mortality.
C1 [Bao, Yeran] Univ Calif San Francisco, Div Endocrinol, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Dalrymple, Lorien; Kaysen, George A.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA.
[Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA.
[Chertow, Glenn M.; Kaysen, George A.; Johansen, Kirsten L.] USRDS Nutr Special Studies Ctr, San Francisco, CA USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
[Johansen, Kirsten L.] USRDS Rehabil Qual Life Special Studies Ctr, Atlanta, GA USA.
RP Bao, YR (reprint author), Univ Calif San Francisco, Div Endocrinol, 400 Parnassus Ave,A550,Box 1222, San Francisco, CA 94143 USA.
EM yeran.bao@ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[N01-DK-7-0005]; Graduate Medical Education funding through the VA
[69734]; National Institutes of Health [T32 2T32DK007418-31]; National
Center for Research Resources [UL1 RR024146]; NIDDK [1K24DK085153]
FX This work was supported through contracts N01-DK-7-0005 from the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK). Dr Bao's effort was supported by grant No. 69734 from the
Graduate Medical Education funding through the VA and by T32
2T32DK007418-31 from the National Institutes of Health. Dr Dalrymple's
effort was supported by grant No. UL1 RR024146 from the National Center
for Research Resources. A portion of Dr Johansen's effort was supported
by 1K24DK085153 from the NIDDK.
NR 21
TC 81
Z9 81
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUL 23
PY 2012
VL 172
IS 14
BP 1071
EP 1077
DI 10.1001/archinternmed.2012.3020
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 976JY
UT WOS:000306582000005
PM 22733312
ER
PT J
AU Perissinotto, CM
Cenzer, IS
Covinsky, KE
AF Perissinotto, Carla M.
Cenzer, Irena Stijacic
Covinsky, Kenneth E.
TI Loneliness in Older Persons A Predictor of Functional Decline and Death
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID DEPRESSIVE SYMPTOMS; SOCIAL SUPPORT; ADULTS; HEALTH; PEOPLE;
ASSOCIATION; IMPAIRMENT; MORTALITY; LIFE
AB Background: Loneliness is a common source of distress, suffering, and impaired quality of life in older persons. We examined the relationship between loneliness, functional decline, and death in adults older than 60 years in the United States.
Methods: This is a longitudinal cohort study of 1604 participants in the psychosocial module of the Health and Retirement Study, a nationally representative study of older persons. Baseline assessment was in 2002 and follow-up assessments occurred every 2 years until 2008. Subjects were asked if they (1) feel left out, (2) feel isolated, or (3) lack companionship. Subjects were categorized as not lonely if they responded hardly ever to all 3 questions and lonely if they responded some of the time or often to any of the 3 questions. The primary outcomes were time to death over 6 years and functional decline over 6 years on the following 4 measures: difficulty on an increased number of activities of daily living (ADL), difficulty in an increased number of upper extremity tasks, decline in mobility, or increased difficulty in stair climbing. Multivariate analyses adjusted for demographic variables, socioeconomic status, living situation, depression, and various medical conditions.
Results: The mean age of subjects was 71 years. Fifty-nine percent were women; 81% were white, 11%, black, and 6%, Hispanic; and 18% lived alone. Among the elderly participants, 43% reported feeling lonely. Loneliness was associated with all outcome measures. Lonely subjects were more likely to experience decline in ADL (24.8% vs 12.5%; adjusted risk ratio [RR], 1.59; 95% CI, 1.23-2.07); develop difficulties with upper extremity tasks (41.5% vs 28.3%; adjusted RR, 1.28; 95% CI, 1.08-1.52); experience decline in mobility (38.1% vs 29.4%; adjusted RR, 1.18; 95% CI, 0.99-1.41); or experience difficulty in climbing (40.8% vs 27.9%; adjusted RR, 1.31; 95% CI, 1.10-1.57). Loneliness was associated with an increased risk of death (22.8% vs 14.2%; adjusted HR, 1.45; 95% CI, 1.11-1.88).
Conclusion: Among participants who were older than 60 years, loneliness was a predictor of functional decline and death.
C1 [Perissinotto, Carla M.; Cenzer, Irena Stijacic; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
[Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Perissinotto, CM (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 3333 Calif St,Ste 380, San Francisco, CA 94143 USA.
EM carla.perissinotto@ucsf.edu
FU National Institute on Aging [5R01AG028481-03, 1K24AG029812-01A1];
Geriatric Academic Career Award, Health Resources and Services
Administration [K01HP20489]
FX This project was supported by grant 5R01AG028481-03 (Depressive
Symptoms, Aging, Disability and Health Outcomes) from the National
Institute on Aging. Dr Perissinotto is also supported in part by the
Geriatric Academic Career Award, Health Resources and Services
Administration (K01HP20489). Dr Covinsky is supported in part by grant
1K24AG029812-01A1 (Mid-career Mentoring Award for Patient-Oriented
Research in Aging) from the National Institute on Aging.
NR 27
TC 129
Z9 135
U1 1
U2 63
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUL 23
PY 2012
VL 172
IS 14
BP 1078
EP 1083
DI 10.1001/archinternined.2012.1993
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 976JY
UT WOS:000306582000006
PM 22710744
ER
PT J
AU Caverly, TJ
Al-Khatib, SM
Kutner, JS
Masoudi, FA
Matlock, DD
AF Caverly, Tanner J.
Al-Khatib, Sana M.
Kutner, Jean S.
Masoudi, Frederick A.
Matlock, Daniel D.
TI LESS IS MORE Patient Preference in the Decision to Place Implantable
Cardioverter-Defibrillators
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
ID HEART-FAILURE; CONSEQUENCES
C1 [Matlock, Daniel D.] Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med,Acad Off 1, Aurora, CO 80045 USA.
[Caverly, Tanner J.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Al-Khatib, Sana M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Duke Cardiovasc Ctr Educ & Res Therapeut, Durham, NC USA.
[Al-Khatib, Sana M.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA.
[Masoudi, Frederick A.; Matlock, Daniel D.] Colorado Cardiovasc Outcomes Res Inst, Denver, CO USA.
[Masoudi, Frederick A.; Matlock, Daniel D.] Kaiser Permanente, Colorado Inst Hlth Res, Denver, CO USA.
RP Matlock, DD (reprint author), Univ Colorado, Div Gen Internal Med, Dept Med, Sch Med,Acad Off 1, 12631 E 17th Ave,Campus Box B-180, Aurora, CO 80045 USA.
EM Daniel.Matlock@ucdenver.edu
FU AHRQ HHS [U18 HS016964, U18HS016964]; NCRR NIH HHS [UL1 RR025780,
UL1RR025780]; NIA NIH HHS [K23 AG040696, K23 AG040696-01]; PHS HHS
[T32HP1006]
NR 8
TC 9
Z9 9
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUL 23
PY 2012
VL 172
IS 14
BP 1104
EP 1105
DI 10.1001/archinternmed.2012.2177
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 976JY
UT WOS:000306582000013
PM 22688654
ER
PT J
AU Grady, D
Redberg, RF
AF Grady, Deborah
Redberg, Rita F.
TI A Different Perspective Regarding Prostate-Specific Antigen Testing In
reply
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Grady, Deborah; Redberg, Rita F.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA.
[Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Grady, D (reprint author), Univ Calif San Francisco, Dept Med, 1635 Divisadero St,Ste 600, San Francisco, CA 94115 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUL 23
PY 2012
VL 172
IS 14
BP 1111
EP 1111
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 976JY
UT WOS:000306582000019
PM 22825065
ER
PT J
AU Durant, RW
Parmar, G
Shuaib, F
Le, A
Brown, TM
Roth, DL
Hovater, M
Halanych, JH
Shikany, JM
Prineas, RJ
Samdarshi, TJ
Safford, MM
AF Durant, Raegan W.
Parmar, Gaurav
Shuaib, Faisal
Le, Anh
Brown, Todd M.
Roth, David L.
Hovater, Martha
Halanych, Jewell H.
Shikany, James M.
Prineas, Ronald J.
Samdarshi, Tandaw J.
Safford, Monika M.
TI Awareness and management of chronic disease, insurance status, and
health professional shortage areas in the REasons for Geographic And
Racial Differences in Stroke (REGARDS): a cross-sectional study
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
ID NUTRITION EXAMINATION SURVEY; PRIMARY-CARE; CARDIOVASCULAR-DISEASE;
NATIONAL-HEALTH; US ADULTS; MEDICARE BENEFICIARIES;
MYOCARDIAL-INFARCTION; RISK-FACTORS; HYPERTENSION; PREVALENCE
AB Background: Limited financial and geographic access to primary care can adversely influence chronic disease outcomes. We examined variation in awareness, treatment, and control of hypertension, diabetes, and hyperlipidemia according to both geographic and financial access to care.
Methods: We analyzed data on 17,458 participants in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study with either hypertension, hyperlipidemia, or diabetes and living in either complete Health Professional Shortage Area (HPSA) counties or non-HPSA counties in the U. S. All analyses were stratified by insurance status and adjusted for sociodemographics and health behaviors.
Results: 2,261 residents lived in HPSA counties and 15,197 in non-HPSA counties. Among the uninsured, HPSA residents had higher awareness of both hypertension (adjusted OR 2.30, 95% CI 1.08, 4.89) and hyperlipidemia (adjusted OR 1.50, 95% CI 1.01, 2.22) compared to non-HPSA residents. Also among the uninsured, HPSA residents with hypertension had lower blood pressure control (adjusted OR 0.45, 95% CI 0.29, 0.71) compared with non-HPSA residents. Similar differences in awareness and control according to HPSA residence were absent among the insured.
Conclusions: Despite similar or higher awareness of some chronic diseases, uninsured HPSA residents may achieve control of hypertension at lower rates compared to uninsured non-HPSA residents. Federal allocations in HPSAs should target improved quality of care as well as increasing the number of available physicians.
C1 [Durant, Raegan W.; Parmar, Gaurav; Shuaib, Faisal; Brown, Todd M.; Halanych, Jewell H.; Shikany, James M.; Safford, Monika M.] Univ Alabama Birmingham, Med Sch Birmingham, Birmingham, AL 35294 USA.
[Durant, Raegan W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA.
[Le, Anh; Roth, David L.; Hovater, Martha] Univ Alabama Birmingham, Birmingham Sch Publ Hlth, Birmingham, AL 35294 USA.
[Prineas, Ronald J.] Wake Forest Univ, Sch Med, Winston Salem, NC 27157 USA.
[Samdarshi, Tandaw J.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
RP Durant, RW (reprint author), Univ Alabama Birmingham, Med Sch Birmingham, 1717 11th Ave S, Birmingham, AL 35294 USA.
EM rdurant@dopm.uab.edu
FU National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Department of Health and Human Service [U01
NS041588]; National Heart, Lung and Blood Institute [R01 HL80477, R01
HL080477-02 S1]
FX This research project is supported by a cooperative agreement U01
NS041588 from the National Institute of Neurological Disorders and
Stroke, National Institutes of Health, Department of Health and Human
Service. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institute of Neurological Disorders and Stroke or the National
Institutes of Health. Representatives of the funding agency have been
involved in the review of the manuscript but not directly involved in
the collection, management, analysis or interpretation of the data. The
authors thank the other investigators, the staff, and the participants
of the REGARDS study for their valuable contributions. A full list of
participating REGARDS investigators and institutions can be found at
http://www.regardsstudy.org. Additional funding was provided by an
investigator-initiated grant R01 HL80477 and a supplemental grant R01
HL080477-02 S1 from the National Heart, Lung and Blood Institute.
NR 47
TC 5
Z9 5
U1 3
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD JUL 20
PY 2012
VL 12
AR 208
DI 10.1186/1472-6963-12-208
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 088DJ
UT WOS:000314813700001
PM 22818296
ER
PT J
AU Srivastava, MK
Zhu, L
Harris-White, M
Kar, U
Huang, M
Johnson, MF
Lee, JM
Elashoff, D
Strieter, R
Dubinett, S
Sharma, S
AF Srivastava, Minu K.
Zhu, Li
Harris-White, Marni
Kar, Upendra
Huang, Min
Johnson, Ming F.
Lee, Jay M.
Elashoff, David
Strieter, Robert
Dubinett, Steven
Sharma, Sherven
TI Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung
Cancer
SO PLOS ONE
LA English
DT Article
ID CYTOTOXIC T-LYMPHOCYTES; MHC CLASS-I; BONE-MARROW; TUMOR-ANTIGENS;
DENDRITIC CELLS; NK CELLS; TOLERANCE; INDUCTION; MECHANISM; ANERGY
AB Background: Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer.
Principal Findings: Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFN gamma, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1& 2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls.
Significance: Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion.
C1 [Srivastava, Minu K.; Zhu, Li; Lee, Jay M.; Elashoff, David; Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA.
[Lee, Jay M.; Elashoff, David; Dubinett, Steven; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Kar, Upendra] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
[Srivastava, Minu K.; Zhu, Li; Harris-White, Marni; Huang, Min; Johnson, Ming F.; Dubinett, Steven; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Gene Med Lab, Los Angeles, CA USA.
[Strieter, Robert] Univ Virginia, Dept Med, Charlottesville, VA USA.
RP Srivastava, MK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Dept Med, Los Angeles, CA 90095 USA.
EM ssharma@mednet.ucla.edu
FU University of California Los Angeles Lung Cancer Program; Department of
Veterans Affairs Medical Research Funds; National Institutes of Health
(NIH) [RO1 CA95686, RO1 CA126944, P50 CA90388]; National Center for
Advancing Translational Sciences [UL1TR000124]; Tobacco Related Disease
Program Award Program of University of California [15RT-0207, 20FT0082]
FX This work was supported by the University of California Los Angeles Lung
Cancer Program, Department of Veterans Affairs Medical Research Funds,
National Institutes of Health (NIH) Grants (RO1 CA95686, RO1 CA126944
and P50 CA90388), National Center for Advancing Translational Sciences,
Grant UL1TR000124, and Tobacco Related Disease Program Award Program of
University of California (15RT-0207 and 20FT0082). The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the NIH. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 40
TC 60
Z9 60
U1 2
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2012
VL 7
IS 7
AR e40677
DI 10.1371/journal.pone.0040677
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 974VS
UT WOS:000306466100054
PM 22815789
ER
PT J
AU Yates-Binder, CC
Rodgers, M
Jaynes, J
Wells, A
Bodnar, RJ
Turner, T
AF Yates-Binder, Cecelia C.
Rodgers, Margaret
Jaynes, Jesse
Wells, Alan
Bodnar, Richard J.
Turner, Timothy
TI An IP-10 (CXCL10)-Derived Peptide Inhibits Angiogenesis
SO PLOS ONE
LA English
DT Article
ID CHEMOKINE RECEPTOR CXCR3; PROTEIN-KINASE-A; INDUCIBLE PROTEIN-9; CELL
MOTILITY; GROWTH-FACTOR; MICE LACKING; WOUND REPAIR; CALPAIN;
KERATINOCYTES; ACTIVATION
AB Angiogenesis plays a critical role in processes such as organ development, wound healing, and tumor growth. It requires well-orchestrated integration of soluble and matrix factors and timely recognition of such signals to regulate this process. Previous work has shown that newly forming vessels express the chemokine receptor CXC receptor 3 (CXCR3) and, activation by its ligand IP-10 (CXCL10), both inhibits development of new vasculature and causes regression of newly formed vessels. To identify and develop new therapeutic agents to limit or reverse pathological angiogenesis, we identified a 21 amino acid fragment of IP-10, spanning the a-helical domain residues 77-98, that mimic the actions of the whole IP-10 molecule on endothelial cells. Treatment of the endothelial cells with the 22 amino acid fragment referred to as IP-10p significantly inhibited VEGF-induced endothelial motility and tube formation in vitro, properties critical for angiogenesis. Using a Matrigel plug assay in vivo, we demonstrate that IP-10p both prevented vessel formation and induced involution of nascent vessels. CXCR3 neutralizing antibody was able to block the inhibitory effects of the IP-10p, demonstrating specificity of the peptide. Inhibition of endothelial function by IP-10p was similar to that described for IP-10, secondary to CXCR3-mediated increase in cAMP production, activation of PKA inhibiting cell migration, and inhibition of VEGF-mediated m-calpain activation. IP-10p provides a novel therapeutic agent that inhibits endothelial cell function thus, allowing for the modulation of angiogenesis.
C1 [Yates-Binder, Cecelia C.; Jaynes, Jesse; Wells, Alan; Turner, Timothy] Tuskegee Univ, Ctr Canc Res, Tuskegee, AL 36088 USA.
[Yates-Binder, Cecelia C.; Wells, Alan; Bodnar, Richard J.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA.
[Yates-Binder, Cecelia C.; Rodgers, Margaret; Wells, Alan; Bodnar, Richard J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Yates-Binder, CC (reprint author), Tuskegee Univ, Ctr Canc Res, Tuskegee, AL 36088 USA.
EM cey4@pitt.edu; Rjb8@pitt.edu
OI Wells, Alan/0000-0002-1637-8150
FU National Center on Minority Health and Health Disparities, National
Institute of General Medical Science of the National Institutes of
Health [R01GM063569]
FX These studies were supported by grants from the National Center on
Minority Health and Health Disparities, National Institute of General
Medical Science of the National Institutes of Health (R01GM063569) and
in kind support from the Pittsburgh VA Medical Center. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 23
TC 16
Z9 17
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 16
PY 2012
VL 7
IS 7
AR e40812
DI 10.1371/journal.pone.0040812
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 974VS
UT WOS:000306466100073
PM 22815829
ER
PT J
AU Agassandian, M
Chen, BB
Pulijala, R
Kaercher, L
Glasser, JR
Mallampalli, RK
AF Agassandian, Marianna
Chen, Bill B.
Pulijala, Roopa
Kaercher, Leah
Glasser, Jennifer R.
Mallampalli, Rama K.
TI Calcium-calmodulin kinase I cooperatively regulates nucleocytoplasmic
shuttling of CCT alpha by accessing a nuclear export signal
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE SYNTHESIS;
TRANSCRIPTION FACTOR; DEPENDENT PATHWAYS; PROTEIN; ACTIVATION; CRM1;
LOCALIZATION; PURIFICATION; SPECIFICITY
AB We identified a new calmodulin kinase I (CaMKI) substrate, cytidyltransferase (CCT alpha), a crucial enzyme required for maintenance of cell membranes. CCT alpha becomes activated with translocation from the cytoplasm to the nuclear membrane, resulting in increased membrane phospholipids. Calcium-activated CCT alpha nuclear import is mediated by binding of its C-terminus to 14-3-3 zeta, a regulator of nuclear trafficking. Here CaMK1 phosphorylates residues within this C-terminus that signals association of CCT alpha with 14-3-3 zeta to initiate calcium-induced nuclear entry. CaMKI docks within the CCT alpha membrane-binding domain (residues 290-299), a sequence that displays similarities to a canonical nuclear export signal (NES) that also binds CRM1/exportin 1. Expression of a CFP-CCT alpha mutant lacking residues 290-299 in cells results in cytosolically retained enzyme. CRM1/exportin 1 was required for CCT alpha nuclear export, and its overexpression in cells was partially sufficient to trigger CCT alpha nuclear export despite calcium stimulation. An isolated CFP-290-299 peptide remained in the nucleus in the presence of leptomycin B but was able to target to the cytoplasm with farnesol. Thus CaMKI vies with CRM1/exportin 1 for access to a NES, and assembly of a CaMKI-14-3-3.-CCT alpha complex is a key effector mechanism that drives nuclear CCTa translocation.
C1 [Agassandian, Marianna; Chen, Bill B.; Pulijala, Roopa; Kaercher, Leah; Glasser, Jennifer R.; Mallampalli, Rama K.] Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA.
RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Acute Lung Injury Ctr Excellence, 930 Scaife Hall, Pittsburgh, PA 15213 USA.
EM mallampallirk@upmc.edu
FU Merit Review Award from the U.S. Department of Veterans Affairs and
National Institutes of Health [HL096376, HL097376, HL098174]; U.S.
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Biomedical Laboratory Research and
Development
FX We thank Jeffrey Brodsky for critical review of the manuscript. This
material is based on work supported, in part, by the U.S. Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development. This work
was supported by a Merit Review Award from the U.S. Department of
Veterans Affairs and National Institutes of Health RO1 Grants HL096376,
HL097376, and HL098174 (to R.K.M.). The contents presented do not
represent the views of the Department of Veterans Affairs of the United
States Government.
NR 45
TC 7
Z9 7
U1 1
U2 5
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD JUL 15
PY 2012
VL 23
IS 14
BP 2755
EP 2769
DI 10.1091/mbc.E11-10-0863
PG 15
WC Cell Biology
SC Cell Biology
GA 052SB
UT WOS:000312217600014
PM 22621903
ER
PT J
AU Feng, S
Shao, LJ
Yu, WD
Gavine, P
Ittmann, M
AF Feng, Shu
Shao, Longjiang
Yu, Wendong
Gavine, Paul
Ittmann, Michael
TI Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate
Cancer Progression
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID INTRAEPITHELIAL NEOPLASIA; INCREASED EXPRESSION; POTENTIAL TARGET;
REACTIVE STROMA; TYROSINE KINASE; DOWN-REGULATION; PROLIFERATION;
HYPERPLASIA; ACTIVATION; CARCINOMA
AB Purpose: Extensive correlative studies in human prostate cancer as well as studies in vitro and in mouse models indicate that fibroblast growth factor receptor (FGFR) signaling plays an important role in prostate cancer progression. In this study, we used a probe compound for an FGFR inhibitor, which potently inhibits FGFR-1-3 and significantly inhibits FGFR-4. The purpose of this study is to determine whether targeting FGFR signaling from all four FGFRs will have in vitro activities consistent with inhibition of tumor progression and will inhibit tumor progression in vivo.
Experimental Design: Effects of AZ8010 on FGFR signaling and invasion were analyzed using immortalized normal prostate epithelial (PNT1a) cells and PNT1a overexpressing FGFR-1 or FGFR-4. The effect of AZ8010 on invasion and proliferation in vitro was also evaluated in prostate cancer cell lines. Finally, the impact of AZ8010 on tumor progression in vivo was evaluated using a VCaP xenograft model.
Results: AZ8010 completely inhibits FGFR-1 and significantly inhibits FGFR-4 signaling at 100 nmol/L, which is an achievable in vivo concentration. This results in marked inhibition of extracellular signal-regulated kinase (ERK) phosphorylation and invasion in PNT1a cells expressing FGFR-1 and FGFR-4 and all prostate cancer cell lines tested. Treatment in vivo completely inhibited VCaP tumor growth and significantly inhibited angiogenesis and proliferation and increased cell death in treated tumors. This was associated with marked inhibition of ERK phosphorylation in treated tumors.
Conclusions: Targeting FGFR signaling is a promising new approach to treating aggressive prostate cancer. Clin Cancer Res; 18(14); 3880-8. (C)2012 AACR.
C1 [Feng, Shu; Shao, Longjiang; Yu, Wendong; Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Feng, Shu; Shao, Longjiang; Yu, Wendong; Ittmann, Michael] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA.
[Gavine, Paul] Astra Zeneca Res & Dev, Innovat Ctr China, Shanghai, Peoples R China.
RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM mittmann@bcm.tmc.edu
FU Department of Veterans Affairs; Prostate Cancer Foundation; NIH
[U01CA141497]
FX This work was supported by the Department of Veterans Affairs Merit
Review program (to M. Ittmann), the Prostate Cancer Foundation (to M.
Ittmann), and the NIH U01 Mouse Models of Human Cancer (U01CA141497; to
M. Ittmann), and by the use of the facilities of the Michael E. DeBakey
VAMC.
NR 40
TC 23
Z9 23
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2012
VL 18
IS 14
BP 3880
EP 3888
DI 10.1158/1078-0432.CCR-11-3214
PG 9
WC Oncology
SC Oncology
GA 988PN
UT WOS:000307503100018
PM 22573348
ER
PT J
AU Liu, QL
Rehman, H
Krishnasamy, Y
Ramshesh, VK
Theruvath, TP
Chavin, KD
Schnellmann, RG
Lemasters, JJ
Zhong, Z
AF Liu, Qinlong
Rehman, Hasibur
Krishnasamy, Yasodha
Ramshesh, Venkat K.
Theruvath, Tom P.
Chavin, Kenneth D.
Schnellmann, Rick G.
Lemasters, John J.
Zhong, Zhi
TI Role of inducible nitric oxide synthase in mitochondrial depolarization
and graft injury after transplantation of fatty livers
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE ALCOHOL; Inos; Liver; Transplantation; Mitochondrial; Depolarization;
Steatosis
ID N-TERMINAL KINASE; PERMEABILITY TRANSITION; REPERFUSION INJURY; HEPATIC
STEATOSIS; MOUSE-LIVER; ISCHEMIA/REPERFUSION INJURY; STORAGE/REPERFUSION
INJURY; UNCOUPLING PROTEIN-2; OXIDATIVE DAMAGE; RAT HEPATOCYTES
AB This study investigated the role of inducible nitric oxide synthase (iNOS) in failure of ethanol-induced fatty liver grafts. Rat livers were explanted 20 h after gavaging with ethanol (5 g/kg) and storing in UW solution for 24 h before implantation. Hepatic oil red O staining-positive areas increased from similar to 2 to similar to 33% after ethanol treatment, indicating steatosis. iNOS expression increased similar to 8-fold after transplantation of lean grafts (LG) and 25-fold in fatty grafts (FG). Alanine aminotransferase release, total bilirubin, hepatic necrosis, TUNEL-positive cells, and cleaved caspase-3 were higher in FG than LG. A specific iNOS inhibitor 1400W (5 mu M in the cold-storage solution) blunted these alterations by > 42% and increased survival of fatty grafts from 25 to 88%. Serum nitrite/nitrate and hepatic nitrotyrosine adducts increased to a greater extent after transplantation of FG than LG, indicating reactive nitrogen species (RNS) overproduction. Phospho-c-Jun and phospho-c-Jun N-terminal kinase-1/2 (JNK1/2) were higher in FG than in LG, indicating more JNK activation in fatty grafts. RNS formation and JNK activation were blunted by 1400W. Mitochondrial polarization and cell death were visualized by intravital multiphoton microscopy of rhodamine 123 and propidium iodide, respectively. After implantation, viable cells with depolarized mitochondria were 3-fold higher in FG than in LG and 1400W decreased mitochondrial depolarization in FG to the levels of LG. Taken together, iNOS is upregulated after transplantation of FG, leading to excessive RNS formation, JNK activation, mitochondrial dysfunction, and severe graft injury. The iNOS inhibitor 1400W could be an effective therapy for primary nonfunction of fatty liver grafts. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Liu, Qinlong; Rehman, Hasibur; Krishnasamy, Yasodha; Theruvath, Tom P.; Schnellmann, Rick G.; Lemasters, John J.; Zhong, Zhi] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
[Liu, Qinlong] Dalian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Dalian, Peoples R China.
[Ramshesh, Venkat K.; Schnellmann, Rick G.; Lemasters, John J.; Zhong, Zhi] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Chavin, Kenneth D.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29403 USA.
[Lemasters, John J.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
RP Zhong, Z (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM zhong@musc.edu
RI Ji, Haofeng/G-6206-2012
FU National Institutes of Health [DK70844, DK70844S1, AA017756, DK84632,
DK37034, 1P30 CA138313]
FX This study was supported, in part, by Grants DK70844, DK70844S1,
AA017756, DK84632, and DK37034 from the National Institutes of Health.
We thank the Cell & Molecular Imaging Core of the Hollings Cancer Center
at the Medical University of South Carolina supported by NIH Grant 1P30
CA138313 for providing instrumentation and assistance for
confocal/multiphoton microscopy.
NR 76
TC 10
Z9 10
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JUL 15
PY 2012
VL 53
IS 2
BP 250
EP 259
DI 10.1016/j.freeradbiomed.2012.05.012
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 977PS
UT WOS:000306677500008
PM 22609250
ER
PT J
AU Smith, MA
Covington, MD
Schnellmann, RG
AF Smith, Matthew A.
Covington, Marisa D.
Schnellmann, Rick G.
TI Loss of calpain 10 causes mitochondrial dysfunction during chronic
hyperglycemia
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Calpain 10; Kidney; Hyperglycemia; siRNA; Mitochondria; Dysfunction
ID TYPE-2 DIABETES-MELLITUS; OXIDATIVE STRESS; LON PROTEASE; BETA-CELLS;
EXPRESSION; MECHANISM; PARKIN; KIDNEY; INJURY; RATS
AB We showed that renal calpain 10, a mitochondrial and cytosolic Ca2+-regulated cysteine protease, is specifically decreased in kidneys of diabetic rats and mice, and is associated with diabetic nephropathy. The goals of this study were to examine renal calpain 10 and mitochondrial dysfunction in streptozotocin-induced hyperglycemic rats and determine the effects of siRNA-mediated knock down of renal calpain 10 on mitochondrial function. Four weeks after streptozotocin injection, calpain 10 protein and mRNA were decreased and calpain 10 substrates accumulated. We detected increased state 2 respiration in isolated renal mitochondria and increased markers of mitochondrial fission and mitophagy. All changes were prevented by daily insulin injection. Compared to scrambled siRNA, calpain 10 siRNA resulted in a marked decrease in renal calpain 10 at 2,5 and 7 days. In concert with the loss of renal calpain 10, calpain 10 substrates accumulated, mitochondrial fusion decreased, mitochondrial fission and mitophagy increased. In summary, insulin-sensitive hyperglycemia induced loss of renal calpain 10 is correlated with renal mitochondrial dysfunction, fission and mitophagy, and specific depletion of renal calpain 10 produces similar mitochondria! defects. These results provide evidence that diabetes-induced renal mitochondrial dysfunction and renal injury may directly result from the loss of renal calpain 10. Published by Elsevier Inc.
C1 [Smith, Matthew A.; Covington, Marisa D.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU NIH [GM 084147, C06 RR-015455]; NIEHS [ES-012239]; NIH/NIEHS
[T32ES012878HS]
FX This study was supported by NIH Grant [GM 084147], the NIEHS Grant
[ES-012239], the NIH/NIEHS Training Program in Environmental Stress
Signaling [T32ES012878HS Training Program in Environmental Stress Sig
and Development Program of the Department of Veterans Affairs. Animal
facilities were funded by NIH grant [C06 RR-015455].
NR 42
TC 7
Z9 9
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JUL 15
PY 2012
VL 523
IS 2
BP 161
EP 168
DI 10.1016/j.abb.2012.04.020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 959HR
UT WOS:000305304000004
PM 22568896
ER
PT J
AU Watkins, GR
Wang, N
Mazalouskas, MD
Gomez, RJ
Guthrie, CR
Kraemer, BC
Schweiger, S
Spiller, BW
Wadzinski, BE
AF Watkins, Guy R.
Wang, Ning
Mazalouskas, Matthew D.
Gomez, Rey J.
Guthrie, Chris R.
Kraemer, Brian C.
Schweiger, Susann
Spiller, Benjamin W.
Wadzinski, Brian E.
TI Monoubiquitination Promotes Calpain Cleavage of the Protein Phosphatase
2A (PP2A) Regulatory Subunit alpha 4, Altering PP2A Stability and
Microtubule-associated Protein Phosphorylation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID E3 UBIQUITIN LIGASE; OPITZ-SYNDROME; ALZHEIMERS-DISEASE; BINDING; TAU;
ENZYME; MID1; DEGRADATION; PROTEOLYSIS; RESOLUTION
AB Multiple neurodegenerative disorders are linked to aberrant phosphorylation of microtubule-associated proteins (MAPs). Protein phosphatase 2A (PP2A) is the major MAP phosphatase; however, little is known about its regulation at microtubules. alpha 4 binds the PP2A catalytic subunit (PP2Ac) and the microtubule-associated E3 ubiquitin ligase MID1, and through unknown mechanisms can both reduce and enhance PP2Ac stability. We show MID1-dependent monoubiquitination of alpha 4 triggers calpain-mediated cleavage and switches alpha 4's activity from protective to destructive, resulting in increased Tau phosphorylation. This regulatory mechanism appears important in MAP-dependent pathologies as levels of cleaved alpha 4 are decreased in Opitz syndrome and increased in Alzheimer disease, disorders characterized by MAP hypophosphorylation and hyperphosphorylation, respectively. These findings indicate that regulated inter-domain cleavage controls the dual functions of alpha 4, and dysregulation of alpha 4 cleavage may contribute to Opitz syndrome and Alzheimer disease.
C1 [Watkins, Guy R.; Wang, Ning; Mazalouskas, Matthew D.; Gomez, Rey J.; Spiller, Benjamin W.; Wadzinski, Brian E.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Guthrie, Chris R.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Kraemer, Brian C.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98104 USA.
[Schweiger, Susann] Univ Dundee, Sch Med, Med Res Inst, Div Neurosci, Dundee DD1 SY9, Scotland.
RP Wadzinski, BE (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 424 RRB, Nashville, TN 37232 USA.
EM brian.wadzinski@vanderbilt.edu
FU National Institutes of Health [DK070787, GM051366, NS064131, T32
GM07628]; American Cancer Society [IRG-58-009-49]; Department of
Veterans Affairs Merit Review Grant [114891]; Ataxia UK; Tenovus
Scotland
FX This work was supported by National Institutes of Health Grants DK070787
and GM051366 (to B. E. W.), NS064131 (to B. C. K.), and T32 GM07628 (to
G. R. W.); American Cancer Society IRG-58-009-49 (to B. W. S.);
Department of Veterans Affairs Merit Review Grant 114891 (to B. C. K.);
and Ataxia UK and Tenovus Scotland (to S. S.).
NR 36
TC 17
Z9 22
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 13
PY 2012
VL 287
IS 29
BP 24207
EP 24215
DI 10.1074/jbc.M112.368613
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 977IQ
UT WOS:000306651100015
PM 22613722
ER
PT J
AU Bensing, BA
Yen, YT
Seepersaud, R
Sullam, PM
AF Bensing, Barbara A.
Yen, Yihfen T.
Seepersaud, Ravin
Sullam, Paul M.
TI A Specific Interaction between SecA2 and a Region of the Preprotein
Adjacent to the Signal Peptide Occurs during Transport via the Accessory
Sec System
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BINDING PROTEIN-GSPB; STREPTOCOCCUS-PNEUMONIAE ADHESIN; SURFACE
GLYCOPROTEIN GSPB; STAPHYLOCOCCUS-AUREUS; HUMAN PLATELETS; ATPASE SECA;
GORDONII; EXPORT; GLYCOSYLATION; TRANSLOCATION
AB The accessory Sec systems of streptococci and staphylococci mediate the transport of a family of large, serine-rich glycoproteins to the bacterial cell surface. These systems are comprised of SecA2, SecY2, and three core accessory Sec proteins (Asp1-3). In Streptococcus gordonii, transport of the serine-rich glycoprotein GspB requires both a unique 90-residue N-terminal signal peptide and an adjacent 24-residue segment (the AST domain). We used in vivo site-specific photo-cross-linking to identify proteins that interact with the AST domain during transport. To facilitate this analysis, the entire accessory Sec system of S. gordonii was expressed in Escherichia coli. The determinants of GspB trafficking to the accessory Sec system in E. coli matched those in S. gordonii, establishing the validity of this approach. When the photo-cross-linker was placed within the AST domain, the preprotein was found to cross-link to SecA2. Importantly, no cross-linking to SecA was detected. Cross-linking of the N-terminal end of the AST domain to SecA2 occurred regardless of whether Asp1-3 were present. However, cross-linking to the C-terminal end was dependent on the Asps. The combined results indicate that full engagement of the AST domain by SecA2 is modulated by one or more of the Asps, and suggest that this process is important for initiating transport.
C1 San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
Univ Calif San Francisco, San Francisco, CA 94121 USA.
RP Sullam, PM (reprint author), VA Med Ctr, Div Infect Dis, 111W,4150 Clement St, San Francisco, CA 94121 USA.
EM paul.sullam@ucsf.edu
FU National Institutes of Health [RO1AI41513]; Dept. of Veterans Affairs;
VA Merit Review program; Northern California Institute for Research and
Education; American Heart Association
FX This work was supported, in whole or in part, by the National Institutes
of Health Grant RO1AI41513 (to P. S.), the Dept. of Veterans Affairs,
and the VA Merit Review program, the Northern California Institute for
Research and Education, and by a Postdoctoral Fellowship Award from the
American Heart Association (to Y. Y.).
NR 42
TC 7
Z9 7
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 13
PY 2012
VL 287
IS 29
BP 24438
EP 24447
DI 10.1074/jbc.M112.378059
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 977IQ
UT WOS:000306651100037
PM 22654116
ER
PT J
AU Ramos, TN
Darley, MM
Weckbach, S
Stahel, PF
Tomlinson, S
Barnum, SR
AF Ramos, Theresa N.
Darley, Meghan M.
Weckbach, Sebastian
Stahel, Philip F.
Tomlinson, Stephen
Barnum, Scott R.
TI The C5 Convertase Is Not Required for Activation of the Terminal
Complement Pathway in Murine Experimental Cerebral Malaria
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID EXPERIMENTAL SIMIAN MALARIA; C6 DEFICIENCY; TARGETED EXPRESSION;
PLASMINOGEN-BINDING; FACTOR-B; MICE; COAGULATION; COMPONENT; C3;
SUSCEPTIBILITY
AB Cerebral malaria (CM) is the most severe manifestation of clinical malaria syndromes and has a high fatality rate especially in the developing world. Recent studies demonstrated that C5(-/-) mice are resistant to experimental CM (ECM) and that protection was due to the inability to form the membrane attack complex. Unexpectedly, we observed that C4(-/-) and factor B-/- mice were fully susceptible to disease, indicating that activation of the classical or alternative pathways is not required for ECM. C3(-/-) mice were also susceptible to ECM, indicating that the canonical C5 convertases are not required for ECM development and progression. Abrogation of ECM by treatment with anti-C9 antibody and detection of C5a in serum of C3(-/-) mice confirmed that C5 activation occurs in ECM independent of C5 convertases. Our data indicate that activation of C5 in ECM likely occurs via coagulation enzymes of the extrinsic protease pathway.
C1 [Ramos, Theresa N.; Darley, Meghan M.; Barnum, Scott R.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
[Ramos, Theresa N.; Darley, Meghan M.; Barnum, Scott R.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Weckbach, Sebastian; Stahel, Philip F.] Univ Colorado, Dept Orthoped Surg, Denver, CO 80204 USA.
[Weckbach, Sebastian; Stahel, Philip F.] Univ Colorado, Dept Neurosurg, Denver, CO 80204 USA.
[Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Barnum, SR (reprint author), Univ Alabama Birmingham, Dept Microbiol, 845 19th St S,BBRB-842, Birmingham, AL 35294 USA.
EM sbarnum@uab.edu
FU National Institutes of Health [T32 AI07051, NS077811, AI08382, HL82485];
Veterans Affairs Grant [NURC-051-10F]; German Research Foundation
FX This work was supported, in whole or in part, by National Institutes of
Health Grants T32 AI07051 and NS077811 (to T. N. R.), AI08382 (to S. R.
B.), and HL82485 (to S. T.). This work was also supported by Veterans
Affairs Grant NURC-051-10F (to S. T.) and a research fellowship from the
German Research Foundation (to S. W.).
NR 44
TC 16
Z9 16
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 13
PY 2012
VL 287
IS 29
BP 24734
EP 24738
DI 10.1074/jbc.C112.378364
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 977IQ
UT WOS:000306651100066
PM 22689574
ER
PT J
AU Kar, UK
Jiang, JN
Champion, CI
Salehi, S
Srivastava, M
Sharma, S
Rabizadeh, S
Niazi, K
Kickhoefer, V
Rome, LH
Kelly, KA
AF Kar, Upendra K.
Jiang, Janina
Champion, Cheryl I.
Salehi, Sahar
Srivastava, Minu
Sharma, Sherven
Rabizadeh, Shahrooz
Niazi, Kayvan
Kickhoefer, Valerie
Rome, Leonard H.
Kelly, Kathleen A.
TI Vault Nanocapsules as Adjuvants Favor Cell-Mediated over
Antibody-Mediated Immune Responses following Immunization of Mice
SO PLOS ONE
LA English
DT Article
ID IN-VIVO; ANTIGEN PRESENTATION; CROSS-PRESENTATION; DELIVERY-SYSTEMS; DNA
VACCINES; T-CELLS; PROTEIN; VIRUS; NANOPARTICLES; LOCALIZATION
AB Background: Modifications of adjuvants that induce cell-mediated over antibody-mediated immunity is desired for development of vaccines. Nanocapsules have been found to be viable adjuvants and are amenable to engineering for desired immune responses. We previously showed that natural nanocapsules called vaults can be genetically engineered to elicit Th1 immunity and protection from a mucosal bacterial infection. The purpose of our study was to characterize immunity produced in response to OVA within vault nanoparticles and compare it to another nanocarrier.
Methodology and Principal Findings: We characterized immunity resulting from immunization with the model antigen, ovalbumin (OVA) encased in vault nanocapsules and liposomes. We measured OVA responsive CD8(+) and CD4(+) memory T cell responses, cytokine production and antibody titers in vitro and in vivo. We found that immunization with OVA contain in vaults induced a greater number of anti-OVA CD8(+) memory T cells and production of IFN gamma plus CD4(+) memory T cells. Also, modification of the vault body could change the immune response compared to OVA encased in liposomes.
Conclusions/Significance: These experiments show that vault nanocapsules induced strong anti-OVA CD8(+) and CD4(+) T cell memory responses and modest antibody production, which markedly differed from the immune response induced by liposomes. We also found that the vault nanocapsule could be modified to change antibody isotypes in vivo. Thus it is possible to create a vault nanocapsule vaccine that can result in the unique combination of immunogen-responsive CD8(+) and CD4(+) T cell immunity coupled with an IgG1 response for future development of vault nanocapsule-based vaccines against antigens for human pathogens and cancer.
C1 [Kar, Upendra K.; Kickhoefer, Valerie; Rome, Leonard H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
[Jiang, Janina; Champion, Cheryl I.; Salehi, Sahar; Kelly, Kathleen A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Srivastava, Minu; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA USA.
[Rabizadeh, Shahrooz; Niazi, Kayvan] Univ Calif Los Angeles, Samueli Sch Engn, Dept Bioengn, Los Angeles, CA USA.
[Rabizadeh, Shahrooz; Niazi, Kayvan; Kickhoefer, Valerie; Rome, Leonard H.; Kelly, Kathleen A.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA.
RP Kar, UK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
EM kkelly@mednet.ucla.edu
RI Rome, Leonard/E-8786-2016
OI Rome, Leonard/0000-0002-1236-2063; Kickhoefer,
Valerie/0000-0002-0048-0580
FU National Institutes of Health [AI026328]; Abraxis Bioscience, Inc
[20090918]
FX These studies were supported by the National Institutes of Health,
AI026328 (Dr. Kelly), sponsored research award from Abraxis Bioscience,
Inc (Dr. Kelly) and 20090918. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 53
TC 11
Z9 11
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 11
PY 2012
VL 7
IS 7
AR e38553
DI 10.1371/journal.pone.0038553
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 973LU
UT WOS:000306362400003
PM 22808011
ER
PT J
AU Kupersmith, J
Eisen, S
AF Kupersmith, Joel
Eisen, Seth
TI A New Approach to Health Services Research
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Kupersmith, Joel; Eisen, Seth] US Dept Vet Affairs, Off Res & Dev, Washington, DC 20420 USA.
[Eisen, Seth] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DC 20420 USA.
RP Kupersmith, J (reprint author), US Dept Vet Affairs, Off Res & Dev, 810 Vermont Ave NW, Washington, DC 20420 USA.
EM Joel.Kupersmith@va.gov
NR 3
TC 5
Z9 5
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUL 9
PY 2012
VL 172
IS 13
BP 1033
EP 1034
DI 10.1001/archinternmed.2012.2004
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 971FP
UT WOS:000306189500013
PM 22664894
ER
PT J
AU Stickrath, C
Druck, J
Hensley, N
Maddox, TM
Richlie, D
AF Stickrath, Chad
Druck, Jeffrey
Hensley, Nathan
Maddox, Thomas M.
Richlie, Daniel
TI Patient and Health Care Provider Discussions About the Risks of Medical
Imaging: Not Ready for Prime Time
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
ID INCIDENTAL FINDINGS; RADIATION; BENEFITS
C1 [Stickrath, Chad; Richlie, Daniel] Univ Colorado, Div Gen Internal Med, Denver Sch Med, Denver, CO 80202 USA.
[Maddox, Thomas M.] Univ Colorado, Div Cardiol, Denver Sch Med, Denver, CO 80202 USA.
[Druck, Jeffrey] Univ Colorado, Dept Med, Dept Emergency Med, Denver Sch Med, Denver, CO 80202 USA.
[Hensley, Nathan] Univ Colorado, Dept Radiol, Denver Sch Med, Denver, CO 80202 USA.
[Stickrath, Chad; Hensley, Nathan; Maddox, Thomas M.; Richlie, Daniel] Denver VA Med Ctr, Denver, CO 80220 USA.
RP Stickrath, C (reprint author), Denver VA Med Ctr, 1055 Clermont St 111, Denver, CO 80220 USA.
EM Chad.stickrath@va.gov
NR 6
TC 7
Z9 7
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD JUL 9
PY 2012
VL 172
IS 13
BP 1037
EP 1038
DI 10.1001/archinternmed.2012.1791
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 971FP
UT WOS:000306189500015
PM 22664652
ER
PT J
AU Asch, DA
Muller, RW
Volpp, KG
AF Asch, David A.
Muller, Ralph W.
Volpp, Kevin G.
TI Automated Hovering in Health Care - Watching Over the 5000 Hours
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID FINANCIAL INCENTIVES
C1 [Asch, David A.; Volpp, Kevin G.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Asch, David A.; Muller, Ralph W.; Volpp, Kevin G.] Univ Penn, Hlth Syst Ctr Innovat Hlth Care Financing, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Penn CMU Roybal Ctr Behav Econ & Hlth P30, Philadelphia, PA 19104 USA.
[Asch, David A.; Muller, Ralph W.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Perelman Sch, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
RP Asch, DA (reprint author), Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
OI Asch, David/0000-0002-7970-286X
NR 5
TC 46
Z9 46
U1 2
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUL 5
PY 2012
VL 367
IS 1
BP 1
EP 3
DI 10.1056/NEJMp1203869
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 968KJ
UT WOS:000305979400014
PM 22716935
ER
PT J
AU Eccles, MP
Grimshaw, JM
Shekelle, P
Schunemann, HJ
Woolf, S
AF Eccles, Martin P.
Grimshaw, Jeremy M.
Shekelle, Paul
Schuenemann, Holger J.
Woolf, Steven
TI Developing clinical practice guidelines: target audiences, identifying
topics for guidelines, guideline group composition and functioning and
conflicts of interest
SO IMPLEMENTATION SCIENCE
LA English
DT Article
ID RAPID ADVICE GUIDELINES; INDUSTRY; QUALITY; POLICY; INVOLVEMENT;
SOCIETIES; APPRAISAL
AB Clinical practice guidelines are one of the foundations of efforts to improve health care. In 1999, we authored a paper about methods to develop guidelines. Since it was published, the methods of guideline development have progressed both in terms of methods and necessary procedures and the context for guideline development has changed with the emergence of guideline clearing houses and large scale guideline production organisations (such as the UK National Institute for Health and Clinical Excellence). It therefore seems timely to, in a series of three articles, update and extend our earlier paper. In this first paper we discuss: the target audience(s) for guidelines and their use of guidelines; identifying topics for guidelines; guideline group composition (including consumer involvement) and the processes by which guideline groups function and the important procedural issue of managing conflicts of interest in guideline development.
C1 [Eccles, Martin P.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
[Grimshaw, Jeremy M.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
[Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
[Shekelle, Paul] RAND Corp, Santa Monica, CA 90407 USA.
[Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
[Schuenemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
[Woolf, Steven] Virginia Commonwealth Univ, Dept Family Med, Richmond, VA USA.
[Woolf, Steven] Virginia Commonwealth Univ, Ctr Human Needs, Richmond, VA USA.
RP Shekelle, P (reprint author), RAND Corp, Santa Monica, CA 90407 USA.
EM shekelle@rand.org
RI Grimshaw, Jeremy/D-8726-2013
OI Grimshaw, Jeremy/0000-0001-8015-8243
NR 47
TC 54
Z9 58
U1 1
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD JUL 4
PY 2012
VL 7
AR 60
DI 10.1186/1748-5908-7-60
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 066EZ
UT WOS:000313204500001
PM 22762776
ER
PT J
AU Shekelle, P
Woolf, S
Grimshaw, JM
Schunemann, HJ
Eccles, MP
AF Shekelle, Paul
Woolf, Steven
Grimshaw, Jeremy M.
Schuenemann, Holger J.
Eccles, Martin P.
TI Developing clinical practice guidelines: reviewing, reporting, and
publishing guidelines; updating guidelines; and the emerging issues of
enhancing guideline implementability and accounting for comorbid
conditions in guideline development
SO IMPLEMENTATION SCIENCE
LA English
DT Article
ID QUALITY; CARE; FRAMEWORK
AB Clinical practice guidelines are one of the foundations of efforts to improve health care. In 1999, we authored a paper about methods to develop guidelines. Since it was published, the methods of guideline development have progressed both in terms of methods and necessary procedures and the context for guideline development has changed with the emergence of guideline clearing houses and large scale guideline production organisations (such as the UK National Institute for Health and Clinical Excellence). It therefore seems timely to, in a series of three articles, update and extend our earlier paper. In this third paper we discuss the issues of: reviewing, reporting, and publishing guidelines; updating guidelines; and the two emerging issues of enhancing guideline implementability and how guideline developers should approach dealing with the issue of patients who will be the subject of guidelines having co-morbid conditions.
C1 [Shekelle, Paul] RAND Corp, Santa Monica, CA 90407 USA.
[Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Woolf, Steven] Virginia Commonwealth Univ, Dept Family Med, Richmond, VA USA.
[Woolf, Steven] Virginia Commonwealth Univ, Ctr Human Needs, Richmond, VA USA.
[Grimshaw, Jeremy M.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
[Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
[Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
[Schuenemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
[Eccles, Martin P.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
RP Shekelle, P (reprint author), RAND Corp, Santa Monica, CA 90407 USA.
EM shekelle@rand.org
RI Grimshaw, Jeremy/D-8726-2013
OI Grimshaw, Jeremy/0000-0001-8015-8243
NR 23
TC 58
Z9 60
U1 1
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD JUL 4
PY 2012
VL 7
AR 62
DI 10.1186/1748-5908-7-62
PG 7
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 044MJ
UT WOS:000311623400001
PM 22762242
ER
PT J
AU Woolf, S
Schunemann, HJ
Eccles, MP
Grimshaw, JM
Shekelle, P
AF Woolf, Steven
Schuenemann, Holger J.
Eccles, Martin P.
Grimshaw, Jeremy M.
Shekelle, Paul
TI Developing clinical practice guidelines: types of evidence and outcomes;
values and economics, synthesis, grading, and presentation and deriving
recommendations
SO IMPLEMENTATION SCIENCE
LA English
DT Article
ID SERVICES TASK-FORCE; SHARED DECISION-MAKING; HEALTH-CARE CONSUMERS;
QUALITY; STRENGTH; MEDICINE; PREFERENCES; CONSENSUS; NUMBERS; SYMBOLS
AB Clinical practice guidelines are one of the foundations of efforts to improve healthcare. In 1999, we authored a paper about methods to develop guidelines. Since it was published, the methods of guideline development have progressed both in terms of methods and necessary procedures and the context for guideline development has changed with the emergence of guideline clearinghouses and large scale guideline production organisations (such as the UK National Institute for Health and Clinical Excellence). It therefore seems timely to, in a series of three articles, update and extend our earlier paper. In this second paper, we discuss issues of identifying and synthesizing evidence: deciding what type of evidence and outcomes to include in guidelines; integrating values into a guideline; incorporating economic considerations; synthesis, grading, and presentation of evidence; and moving from evidence to recommendations.
C1 [Shekelle, Paul] RAND Corp, Santa Monica, CA 90407 USA.
[Shekelle, Paul] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Woolf, Steven] Virginia Commonwealth Univ, Dept Family Med, Richmond, VA USA.
[Woolf, Steven] Virginia Commonwealth Univ, Ctr Human Needs, Richmond, VA USA.
[Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
[Schuenemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
[Eccles, Martin P.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE2 4AX, Tyne & Wear, England.
[Grimshaw, Jeremy M.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada.
[Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada.
RP Shekelle, P (reprint author), RAND Corp, Santa Monica, CA 90407 USA.
EM shekelle@rand.org
RI Grimshaw, Jeremy/D-8726-2013
OI Grimshaw, Jeremy/0000-0001-8015-8243
NR 64
TC 35
Z9 39
U1 2
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD JUL 4
PY 2012
VL 7
AR 61
DI 10.1186/1748-5908-7-61
PG 12
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 001NG
UT WOS:000308466800001
PM 22762158
ER
PT J
AU Zhang, J
Xie, FL
Delzell, E
Chen, L
Winthrop, KL
Lewis, JD
Saag, KG
Baddley, JW
Curtis, JR
AF Zhang, Jie
Xie, Fenglong
Delzell, Elizabeth
Chen, Lang
Winthrop, Kevin L.
Lewis, James D.
Saag, Kenneth G.
Baddley, John W.
Curtis, Jeffrey R.
TI Association Between Vaccination for Herpes Zoster and Risk of Herpes
Zoster Infection Among Older Patients With Selected Immune-Mediated
Diseases
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RHEUMATOID-ARTHRITIS; UNITED-STATES; ADMINISTRATIVE DATABASE; VARICELLA;
RECOMMENDATIONS; CHILDREN; THERAPY; SAFETY; AGENTS; ADULTS
AB Context Based on limited data, the live attenuated herpes zoster (HZ) vaccine is contraindicated in patients taking anti-tumor necrosis factor (anti-TNF) therapies or other biologics commonly used to treat immune-mediated diseases. The safety and effectiveness of the vaccine are unclear for these patients.
Objective To examine the association between HZ vaccination and HZ incidence within and beyond 42 days after vaccination in patients with selected immune-mediated diseases and in relation to biologics and other therapies used to treat these conditions.
Design, Setting, and Patients Retrospective cohort study of 463 541 Medicare beneficiaries 60 years and older with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease using Medicare claims data from January 1, 2006, through December 31, 2009.
Main Outcome Measures Herpes zoster incidence rate within 42 days after vaccination (a safety concern) and beyond 42 days; hazard ratios estimated using Cox proportional hazards models for HZ comparing vaccinated vs unvaccinated patients.
Results Median duration of follow-up was 2.0 years (interquartile range, 0.8-3.0); 4.0% of patients received HZ vaccine. The overall crude HZ incidence rate was 7.8 cases per 1000 person-years (95% CI, 3.7-16.5) within 42 days after vaccination. The rate among the unvaccinated was 11.6 cases per 1000 person-years (95% CI, 11.4-11.9). Among 633 patients exposed to biologics at the time of vaccination or within the subsequent 42 days, no case of HZ or varicella occurred. After multivariable adjustment, HZ vaccination was associated with a hazard ratio of 0.61 (95% CI, 0.52-0.71) for HZ risk after 42 days.
Conclusions Receipt of HZ vaccine was not associated with a short-term increase in HZ incidence among Medicare beneficiaries with selected immune-mediated diseases, including those exposed to biologics. The vaccine was associated with a lower HZ incidence over a median of 2 years of follow-up. JAMA. 2012; 308(1):43-49 www.jama.com
C1 [Zhang, Jie; Delzell, Elizabeth; Curtis, Jeffrey R.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Xie, Fenglong; Chen, Lang; Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Baddley, John W.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL 35294 USA.
[Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Dept Med, Div Infect Dis, Portland, OR 97201 USA.
[Lewis, James D.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Curtis, JR (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, FOT 805D,510 20th St S, Birmingham, AL 35294 USA.
EM jcurtis@uab.edu
FU Amgen; Pfizer; UCB; Abbott; Centocor; Takeda; Shire; Merck;
Genentech/Roche; BMS; Agency for Healthcare Research and Quality (AHRQ)
[R01 HS018517, T32HS013852]; National Institutes of Health [AR 053351]
FX Dr Zhang reported having received research support from Amgen. Dr
Delzell reported having received research support from Amgen. Dr
Winthrop reported having received consulting fees from Pfizer, Amgen,
UCB, and Abbott and grants from Pfizer. Dr Lewis reported having
received research grants from Centocor, Takeda, and Shire and having
served as a consultant for Amgen, Abbott, Pfizer, and Millennium
Pharmaceuticals. Dr Saag is the chair of the American College of
Rheumatology Quality of Care Committee and reported having received
consulting fees from Merck. Dr Baddley reported having received
consulting fees from Abbott and Merck. Dr Curtis reported having
received research grants and consulting fees from Amgen, UCB, Abbott,
Genentech/Roche, Centocor, BMS, and Merck. No other disclosures were
reported.; This project was supported by the Agency for Healthcare
Research and Quality (AHRQ) (R01 HS018517). Dr Zhang received support
from the AHRQ (T32HS013852), and Dr Curtis received support from the
National Institutes of Health (AR 053351).
NR 23
TC 110
Z9 111
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 4
PY 2012
VL 308
IS 1
BP 43
EP 49
DI 10.1001/jama.2012.7304
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 971DD
UT WOS:000306183000022
PM 22760290
ER
PT J
AU Qaseem, A
Humphrey, LL
Shekelle, P
AF Qaseem, Amir
Humphrey, Linda L.
Shekelle, Paul
TI Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
[Humphrey, Linda L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Shekelle, Paul] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, Philadelphia, PA 19106 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUL 3
PY 2012
VL 157
IS 1
BP 76
EP 77
DI 10.7326/0003-4819-157-1-201207030-00019
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 992NS
UT WOS:000307784900013
ER
PT J
AU Zhang, XY
Chen, DC
Xiu, MH
Yang, FD
Haile, CN
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Chen, Da Chun
Xiu, Mei Hong
Yang, Fu De
Haile, Colin N.
Kosten, Therese A.
Kosten, Thomas R.
TI Gender Differences in Never-Medicated First-Episode Schizophrenia and
Medicated Chronic Schizophrenia Patients
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID 1ST EPISODE PSYCHOSIS; SEX-DIFFERENCES; CHINESE SCHIZOPHRENIA; VERBAL
MEMORY; ONSET; AGE; SMOKING; PREVALENCE; DISORDERS; ILLNESS
AB Background: Schizophrenia shows gender differences in patients' clinical presentation, neurocognitive impairment, course, and treatment outcome. The aims of this study were to compare gender differences in clinical features and cognitive functioning in first-episode and chronic schizophrenia among Han Chinese inpatients.
Method: We compared gender differences in 262 unmedicated first-episode schizophrenia and 960 chronic schizophrenia inpatients (diagnosed according to DSM-IV) to 804 matched healthy controls on sociodemographic characteristics, smoking behavior, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Patients were also rated on the Positive and Negative Syndrome Scale. The study was conducted from December 2006 to May 2008.
Results: Schizophrenia first occurred in both first-episode and chronic schizophrenia patients at a significantly earlier age in male than female patients (P < .05 and P < .001, respectively). The paranoid subtype of schizophrenia was more common in female patients only in chronic schizophrenia, not first-episode patients. Further, cigarette smoking was more common in male than female patients from both patient groups, and, among men, more chronic schizophrenia patients than controls smoked, while among women, fewer chronic schizophrenia patients than controls smoked. Female chronic schizophrenia patients had more severe positive and general psychopathological symptoms, whereas male patients had more severe negative symptoms. By contrast, first-episode schizophrenia patients showed no gender differences in symptoms and severity. Both first-episode and chronic schizophrenia patients performed worse than controls on most of the cognitive tasks. RBANS attention, delayed memory, and immediate memory were less impaired in female than male chronic schizophrenia patients, and first-episode schizophrenia patients showed no gender differences.
Conclusions: Chronic schizophrenia patients have notable gender differences in the age at onset, smoking, symptom severity, and cognitive function favoring women, but first-episode schizophrenia patients show few gender differences. J Clin Psychiatry 2012;73(7):1025-1033 (c) Copyright 2012 Physicians Postgraduate Press, Inc.
C1 [Zhang, Xiang Yang; Haile, Colin N.; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Chen, Da Chun; Xiu, Mei Hong; Yang, Fu De] Beijing HuiLongGuan Hosp, Ctr Psychiat Res, Beijing, Peoples R China.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu
OI Haile, Colin/0000-0001-8293-7291
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs, VISN 16, Mental Illness Research, Education, and
Clinical Center (MIRECC); United States National Institutes of Health
[K05-DA0454, P50-DA18827, U01-MH79639]
FX This study was funded by the Stanley Medical Research Institute (03T-459
and 05T-726); the Department of Veterans Affairs, VISN 16, Mental
Illness Research, Education, and Clinical Center (MIRECC); and United
States National Institutes of Health (K05-DA0454, P50-DA18827, and
U01-MH79639).
NR 42
TC 33
Z9 34
U1 3
U2 33
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUL
PY 2012
VL 73
IS 7
BP 1025
EP 1033
DI 10.4088/JCP.11m07422
PG 9
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 090SL
UT WOS:000315000200017
PM 22901352
ER
PT J
AU Riegel, B
Lee, CS
Ratcliffe, SJ
De Geest, S
Potashnik, S
Patey, M
Sayers, SL
Goldberg, LR
Weintraub, WS
AF Riegel, Barbara
Lee, Christopher S.
Ratcliffe, Sarah J.
De Geest, Sabina
Potashnik, Sheryl
Patey, Megan
Sayers, Steven L.
Goldberg, Lee R.
Weintraub, William S.
TI Predictors of Objectively Measured Medication Nonadherence in Adults
With Heart Failure
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE heart failure; medication adherence; patient compliance; self-care;
sleep; World Health Organization
ID SELF-CARE; ADHERENCE; ASSOCIATION; MIXTURE; HEALTH; QUESTIONNAIRE;
SLEEPINESS; REGIMENS; NUMBER; TRIAL
AB Background-Medication nonadherence rates are high. The factors predicting nonadherence in heart failure remain unclear.
Methods and Results-A sample of 202 adults with heart failure was enrolled from the northeastern United States and followed for 6 months. Specific aims were to describe the types of objectively measured medication adherence (eg, taking, timing, dosing, drug holidays) and to identify contributors to nonadherence 6 months after enrollment. Latent growth mixture modeling was used to identify distinct trajectories of adherence. Indicators of the 5 World Health Organization dimensions of adherence (socioeconomic, condition, therapy, patient, and healthcare system) were tested to identify contributors to nonadherence. Two distinct trajectories were identified and labeled persistent adherence (77.8%) and steep decline (22.3%). Three contributors to the steep decline in adherence were identified. Participants with lapses in attention (adjusted OR, 2.65; P=0.023), those with excessive daytime sleepiness (OR, 2.51; P=0.037), and those with >= 2 medication dosings per day (OR, 2.59; P=0.016) were more likely to have a steep decline in adherence over time than to have persistent adherence.
Conclusions-Two distinct patterns of adherence were identified. Three potentially modifiable contributors to nonadherence have been identified. (Circ Heart Fail. 2012; 5: 430-436.)
C1 [Riegel, Barbara] Univ Penn, Sch Nursing, Biobehav Res Ctr, Philadelphia, PA 19104 USA.
[Lee, Christopher S.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA.
[Ratcliffe, Sarah J.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[De Geest, Sabina] Univ Basel, Inst Nursing Sci, Basel, Switzerland.
[Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Dept Cardiol, Newark, DE USA.
RP Riegel, B (reprint author), Univ Penn, Sch Nursing, Biobehav Res Ctr, Claire M Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM briegel@nursing.upenn.edu
OI Goldberg, Lee/0000-0002-7906-9638
FU National Heart, Lung & Blood Institute [RO1 HL084394-01A1]; Philadelphia
Veterans Affairs Medical Center, VISN 4 Mental Illness Research,
Education, and Clinical Center (MIREC)
FX This work was funded by the National Heart, Lung & Blood Institute (RO1
HL084394-01A1) and by the Philadelphia Veterans Affairs Medical Center,
VISN 4 Mental Illness Research, Education, and Clinical Center (MIREC).
NR 41
TC 24
Z9 25
U1 3
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-3289
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD JUL
PY 2012
VL 5
IS 4
BP 430
EP 436
DI 10.1161/CIRCHEARTFAILURE.111.965152
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 071GJ
UT WOS:000313578100012
PM 22647773
ER
PT J
AU Nahab, FB
Handforth, A
Brown, T
Shin, C
Quesada, A
Dong, CH
Haubenberger, D
Hallett, M
AF Nahab, Fatta B.
Handforth, Adrian
Brown, Tyler
Shin, Christopher
Quesada, Arnulfo
Dong, Chuanhui
Haubenberger, Dietrich
Hallett, Mark
TI Octanoic Acid Suppresses Harmaline-Induced Tremor in Mouse Model of
Essential Tremor
SO NEUROTHERAPEUTICS
LA English
DT Article
DE 1-octanol; Octanoic acid; Essential tremor; Harmaline; Therapeutics
ID OPEN-LABEL; 1-OCTANOL
AB Recent work exploring the use of high-molecular weight alcohols to treat essential tremor (ET) has identified octanoic acid as a potential novel tremor-suppressing agent. We used an established harmaline-based mouse model of ET to compare tremor suppression by 1-octanol and octanoic acid. The dose-related effect on digitized motion power within the tremor bandwidth as a fraction of overall motion power was analyzed. Both 1-octanol and octanoic acid provided significant reductions in harmaline tremor. An 8-carbon alkyl alcohol and carboxylic acid each suppress tremor in a pre-clinical mouse model of ET. Further studies are warranted to determine the safety and efficacy of such agents in humans with ET.
C1 [Nahab, Fatta B.; Brown, Tyler; Dong, Chuanhui] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
[Handforth, Adrian] Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA.
[Shin, Christopher; Quesada, Arnulfo] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA.
[Quesada, Arnulfo] Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, Los Angeles, CA 90073 USA.
[Haubenberger, Dietrich] Med Univ Vienna, Dept Neurol, Vienna, Austria.
[Brown, Tyler; Haubenberger, Dietrich; Hallett, Mark] NINDS, Human Motor Control Sect, Med Neurol Branch, Bethesda, MD 20892 USA.
RP Nahab, FB (reprint author), Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
EM fnahab@med.miami.edu
FU Intramural division of the National Institute of Neurological Disorders
and Stroke; Ariston Pharmaceuticals
FX This work was supported by the Intramural division of the National
Institute of Neurological Disorders and Stroke and a collaborative
research and development agreement with Ariston Pharmaceuticals.
NR 16
TC 6
Z9 6
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1933-7213
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD JUL
PY 2012
VL 9
IS 3
BP 635
EP 638
DI 10.1007/s13311-012-0121-1
PG 4
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 006NV
UT WOS:000308826800014
PM 22454323
ER
PT J
AU Bradley, SM
Maynard, C
Bryson, CL
AF Bradley, Steven M.
Maynard, Charles
Bryson, Chris L.
TI Appropriateness of Percutaneous Coronary Interventions in Washington
State
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE appropriateness criteria; percutaneous coronary intervention;
utilization; quality improvement; health services research
ID CARDIOVASCULAR DATA REGISTRY; INTRAVENOUS THROMBOLYTIC THERAPY; ACUTE
MYOCARDIAL-INFARCTION; RANDOMIZED-TRIALS; METAANALYSIS; DISEASE; RISK;
ANGIOPLASTY; STRATEGIES; OUTCOMES
AB Background-In anticipation of applying Appropriate Use Criteria for percutaneous coronary intervention (PCI) quality improvement, we determined the prevalence of appropriate, uncertain, and inappropriate PCIs stratified by indication for all PCIs performed in the state of Washington.
Methods and Results-Within the Clinical Outcomes Assessment Program, we assigned appropriateness ratings to all PCIs performed in 2010 in accordance with published Appropriate Use Criteria. Of 13 291 PCIs, we successfully mapped the clinical scenario to the Appropriate Use Criteria in 9924 (75%) cases. Of the 3367 PCIs not classified, common failures to map to the criteria included nonacute PCI without prior noninvasive stress results (n = 1906; 57%) and unstable angina without high-risk features (n = 902; 27%). Of mapped PCIs, 8010 (71%) were for acute indications, with 7887 (98%) rated as appropriate, 39 (<1%) as uncertain, and 84 (1%) as inappropriate. Of 1914 mapped nonacute indications, 847 (44%) were rated as appropriate, 748 (39%) as uncertain, and 319 (17%) as inappropriate. Assuming results for noninvasive stress tests when data were missing, in the best-case scenario, 319 (8%) of nonacute PCIs were classified as inappropriate compared with 1459 (38%) in the worst-case scenario. Variation in inappropriate PCIs by facility was greatest for mapped nonacute indications (median = 14%; 25th to 75th percentiles = 9% to 24%) and nonacute indications with missing data precluding appropriateness classification (median = 54%; 25th to 75th percentiles = 35% to 66%).
Conclusions-In a complete cohort of PCIs performed in Washington state, 1% of PCIs for acute indications and 17% of PCIs for nonacute indications were classified as inappropriate. Missing data on noninvasive stress tests present a challenge in the application of the criteria for quality improvement. (Circ Cardiovasc Qual Outcomes. 2012; 5: 445-453.)
C1 [Bradley, Steven M.] VA Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO 80220 USA.
[Bradley, Steven M.] Univ Colorado, Denver, CO 80202 USA.
[Maynard, Charles; Bryson, Chris L.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev NW Ctr Excellence, Seattle, WA USA.
[Maynard, Charles; Bryson, Chris L.] Univ Washington, Seattle, WA 98195 USA.
[Maynard, Charles; Bryson, Chris L.] Fdn Hlth Care Qual, Clin Outcomes Assessment Program, Seattle, WA USA.
RP Bradley, SM (reprint author), VA Eastern Colorado Hlth Care Syst, Dept Vet Affairs, 1055 Clermont St 111B, Denver, CO 80220 USA.
EM Steven.Bradley@va.gov
RI Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
FU Health Services Research and Development Service; Health Services
Research and Development QuERI Program, Department of Veterans Affairs
[RRP 09-040]; VA Health Services Research and Development [1 IK2
HX000779-01]
FX This material is based upon work supported by Health Services Research
and Development Service and the Health Services Research and Development
QuERI Program, Department of Veterans Affairs (Project No.: RRP 09-040).
Dr. Steven Bradley is a Career Development Grant Awardee (1 IK2
HX000779-01, funding pending) from VA Health Services Research and
Development.
NR 24
TC 23
Z9 24
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JUL
PY 2012
VL 5
IS 4
BP 445
EP 453
DI 10.1161/CIRCOUTCOMES.111.964320
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002PO
UT WOS:000308544500008
PM 22570356
ER
PT J
AU Keyhani, S
Cheng, E
Arling, G
Li, XL
Myers, L
Ofner, S
Williams, LS
Phipps, M
Ordin, D
Bravata, DM
AF Keyhani, Salomeh
Cheng, Eric
Arling, Greg
Li, Xinli
Myers, Laura
Ofner, Susan
Williams, Linda S.
Phipps, Michael
Ordin, Diana
Bravata, Dawn M.
TI Does the Inclusion of Stroke Severity in a 30-Day Mortality Model Change
Standardized Mortality Rates at Veterans Affairs Hospitals?
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE stroke; outcome assessment (health care); hospital mortality
ID ISCHEMIC-STROKE; SCALE; OUTCOMES; SCORE; RISK
AB Background-The Centers for Medicare and Medicaid Services is considering developing a 30-day ischemic stroke hospital-level mortality model using administrative data. We examined whether inclusion of the National Institutes of Health Stroke Scale (NIHSS), a measure of stroke severity not included in administrative data, would alter 30-day mortality rates in the Veterans Health Administration.
Methods and Results-A total of 2562 veterans admitted with ischemic stroke to 64 Veterans Health Administration Hospitals in the fiscal year 2007 were included. First, we examined the distribution of unadjusted mortality rates across the Veterans Health Administration. Second, we estimated 30-day all-cause, risk standardized mortality rates (RSMRs) for each hospital by adjusting for age, sex, and comorbid conditions using hierarchical models with and without the inclusion of the NIHSS. Finally, we examined whether adjustment for the NIHSS significantly changed RSMRs for each hospital compared with other hospitals. The median unadjusted mortality rate was 3.6%. The RSMR interquartile range without the NIHSS ranged from 5.1% to 5.6%. Adjustment with the NIHSS did not change the RSMR interquartile range (5.1%-5.6%). Among veterans >= 65 years, the RSMR interquartile range without the NIHSS ranged from 9.2% to 10.3%. With adjustment for the NIHSS, the RSMR interquartile range changed from 9.4% to 10.0%. The plot of 30-day RSMRs estimated with and without the inclusion of the NIHSS in the model demonstrated overlapping 95% confidence intervals across all hospitals, with no hospital significantly below or above the mean-unadjusted 30-day mortality rate. The 30-day mortality measure did not discriminate well among hospitals.
Conclusion-The impact of the NIHSS on RSMRs was limited. The small number of stroke admissions and the narrow range of 30-day stroke mortality rates at the facility level in the Veterans Health Administration cast doubt on the value of using 30-day RSMRs as a means of identifying outlier hospitals based on their stroke care quality. (Circ Cardiovasc Qual Outcomes. 2012; 5: 508-513.)
C1 [Keyhani, Salomeh] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94121 USA.
[Keyhani, Salomeh] Univ Calif San Francisco, San Francisco VA Med Ctr HSR& REAP, San Francisco, CA 94121 USA.
[Cheng, Eric] VA Greater Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Cheng, Eric] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Li, Xinli; Myers, Laura; Williams, Linda S.; Bravata, Dawn M.] Richard L Roudebush VA Med Ctr, VHA HSR & Ctr Excellence Implementing Evidence Ba, Indianapolis, IN USA.
[Ofner, Susan] Indiana Univ Sch Med, Div Biostat, Indianapolis, IN USA.
[Cheng, Eric; Arling, Greg; Myers, Laura; Ofner, Susan; Williams, Linda S.; Bravata, Dawn M.] VHA HSR & Stroke Qual Enhancement Res Initiat Pro, Indianapolis, IN USA.
[Arling, Greg; Williams, Linda S.] Indiana Univ Sch Med, Indiana Univ Ctr Aging Res, Indianapolis, IN USA.
[Williams, Linda S.; Bravata, Dawn M.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Myers, Laura; Bravata, Dawn M.] Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN USA.
[Arling, Greg; Williams, Linda S.; Bravata, Dawn M.] Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA.
[Phipps, Michael] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA.
[Phipps, Michael] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
RP Keyhani, S (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Gen Internal Med, 4150 Clement 111A1, San Francisco, CA 94121 USA.
EM salomeh.keyhani@va.gov
OI Phipps, Michael/0000-0001-8398-5404
FU Department of Veterans Affairs; Veterans Health Administration; Office
of Quality and Performance and Health Services Research; Development
Service Quality Enhancement Research Initiative [RRP 09-184]; VA HSRD
FX The Department of Veterans Affairs, Veterans Health Administration,
Office of Quality and Performance and Health Services Research, and
Development Service Quality Enhancement Research Initiative (RRP 09-184)
supported this project. Dr Bravata is the principal investigator of this
project at the Richard L. Roudebush VA Medical Center (Indianapolis,
IN). Dr Keyhani is currently supported by a VA HSR&D career development
award. The views expressed in this article are those of the authors and
do not necessarily represent the views of the Department of Veterans
Affairs.
NR 15
TC 4
Z9 4
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JUL
PY 2012
VL 5
IS 4
BP 508
EP 513
DI 10.1161/CIRCOUTCOMES.111.962936
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002PO
UT WOS:000308544500016
PM 22787062
ER
PT J
AU Lambert-Kerzner, A
Del Giacco, EJ
Fahdi, IE
Bryson, CL
Melnyk, SD
Bosworth, HB
Davis, R
Mun, H
Weaver, J
Barnett, C
Radcliff, T
Hubbard, A
Bosket, KD
Carey, E
Virchow, A
Mihalko-Corbitt, R
Kaufman, A
Marchant-Miros, K
Ho, PM
AF Lambert-Kerzner, Anne
Del Giacco, Eric J.
Fahdi, Ibrahim E.
Bryson, Chris L.
Melnyk, S. Dee
Bosworth, Hayden B.
Davis, Ryan
Mun, Howard
Weaver, Jennifer
Barnett, Casey
Radcliff, Tiffany
Hubbard, Amanda
Bosket, Kevin D.
Carey, Evan
Virchow, Allison
Mihalko-Corbitt, Renee
Kaufman, Amy
Marchant-Miros, Kathy
Ho, P. Michael
CA Multifaceted Intervention Improve
TI Patient-Centered Adherence Intervention After Acute Coronary Syndrome
Hospitalization
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE acute coronary syndromes; adherence; medication adherence;
cost-effectiveness; treatment effectiveness
ID ACUTE MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; MEDICATION; CARE;
THERAPY; OUTCOMES; DISCONTINUATION; PREVALENCE; PREDICTORS; MORTALITY
AB Background-Adherence to cardioprotective medications in the year after acute coronary syndrome hospitalization is generally poor and is associated with increased risk of rehospitalization and mortality. Few interventions have specifically targeted this high-risk patient population to improve medication adherence. We hypothesize that a multifaceted patient-centered intervention could improve adherence to cardioprotective medications.
Methods and Results-To evaluate this intervention, we propose enrolling 280 patients with a recent acute coronary syndrome event into a multicenter randomized, controlled trial. The intervention comprises4 main components: (1) pharmacist-led medication reconciliation and tailoring; (2) patient education; (3) collaborative care between pharmacist and primary care provider/cardiologist; and (4) 2 types of voice messaging (educational and medication refill reminder calls). Patients in the intervention arm will visit with the study pharmacist approximate to 1 week post-hospital discharge. The pharmacist will work with the patient and collaborate with providers to reconcile medication issues. Voice messages will augment the educational process and remind patients to refill their cardioprotective medications. The study will compare the intervention versus usual care for 12 months. The primary outcome of interest is adherence using the ReComp method. Secondary and tertiary outcomes include achievement of targets for blood pressure and low-density lipoprotein, and reduction in the combined cardiovascular end points of myocardial infarction hospitalization, coronary revascularization, and all-cause mortality. Finally, we will also evaluate the cost-effectiveness of the intervention compared with usual care.
Conclusions-If the intervention is effective in improving medication adherence and demonstrating a lower cost, the intervention has the potential to improve cardiovascular outcomes in this high-risk patient population. (Circ Cardiovasc Qual Outcomes. 2012; 5: 571-576.)
C1 [Lambert-Kerzner, Anne; Davis, Ryan; Radcliff, Tiffany; Carey, Evan; Virchow, Allison; Multifaceted Intervention Improve] Denver VA Med Ctr, Denver, CO USA.
[Del Giacco, Eric J.; Fahdi, Ibrahim E.; Weaver, Jennifer; Barnett, Casey; Hubbard, Amanda; Mihalko-Corbitt, Renee; Marchant-Miros, Kathy] Little Rock VA Med Ctr, Little Rock, AR USA.
[Bryson, Chris L.; Mun, Howard; Bosket, Kevin D.] Puget Sound VA Med Ctr, Seattle, WA USA.
[Melnyk, S. Dee; Bosworth, Hayden B.; Kaufman, Amy] Durham VA Med Ctr, Durham, NC USA.
RP Lambert-Kerzner, A (reprint author), 1055 Clermont St, Denver, CO 80220 USA.
EM anne.lambert-kerzner@va.gov
FU Veterans Administration Health Services Research and Development Grant
[IIR 08-302]; VA HSR&D Career Development Award; VA HSR&D Career
Scientist Award [RCS 08-027]
FX The study is being funded by Veterans Administration Health Services
Research and Development Grant contract number IIR 08-302.; Dr Ho is
supported by a VA HSR&D Career Development Award.5-26 Dr
Bosworth was supported by a VA HSR&D Career Scientist Award (RCS
08-027).
NR 32
TC 13
Z9 14
U1 1
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JUL
PY 2012
VL 5
IS 4
BP 571
EP 576
DI 10.1161/CIRCOUTCOMES.111.962290
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002PO
UT WOS:000308544500024
PM 22811499
ER
PT J
AU De La Garza, BH
Li, G
Shih, YYI
Duong, TQ
AF De La Garza, Bryan H.
Li, Guang
Shih, Yen-Yu I.
Duong, Timothy Q.
TI Layer-Specific Manganese-Enhanced MRI of the Retina in Light and Dark
Adaptation
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL BLOOD-FLOW; OPTICAL COHERENCE TOMOGRAPHY; RAT RETINA;
FUNCTIONAL MRI; OUTER RETINA; IN-VIVO; OXYGEN DISTRIBUTION;
GLUCOSE-METABOLISM; CAT RETINA; CONSUMPTION
AB PURPOSE. To employ functional manganese-enhanced MRI (MEMRI) to image layer-specific changes in calcium-dependent activities in the rat retina during light versus dark adaptation.
METHODS. Functional MEMRI at 203203700 mu m was used to study light and dark adaptation in the same animals (N = 10) in which one eye was covered and the fellow eye was not. The activity encoding of the light and dark adaptation was achieved in awake conditions and imaged under anesthesia. T-1-weighted MRI at 11.7 tesla (T) was performed using two identical radiofrequency transceiver coils to allow interleaved MRI acquisitions of the two eyes. An intravascular contrast agent was also used to verify layer assignments.
RESULTS. MEMRI detected contrasts among the inner retina, outer retina, and choroid. Independent confirmation of the vascular layers and boundaries between layers was documented with an intravascular contrast agent. The retinal layer thicknesses agreed with published data. The outer retina had lower MEMRI activity in light compared with dark adaption (P < 0.001), consistent with the increased metabolic demand associated with the "dark current." The inner retina had higher MEMRI activity in light compared with dark adaption (P < 0.05). The choroid MEMRI activity was not statistically different between light and dark adaptation (P > 0.05).
CONCLUSIONS. This study demonstrated a high-resolution MEMRI protocol to image functional activities among different layers of the retinas in awake animals during light and dark adaptation. This approach could have potential applications in animal models of retinal dysfunction. (Invest Ophthalmol Vis Sci. 2012;53:4352-4358) DOI:10.1167/iovs.11-8826
C1 [De La Garza, Bryan H.; Li, Guang; Shih, Yen-Yu I.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Li, Guang/C-9539-2011
OI Li, Guang/0000-0002-7648-0464; Shih, Yen-Yu Ian/0000-0001-6529-911X
FU NIH/NEI [R01 EY014211, EY018855]; MERIT Award from the Department of
Veterans Affairs
FX Supported in part by NIH/NEI Grants R01 EY014211 and EY018855 and a
MERIT Award from the Department of Veterans Affairs.
NR 50
TC 11
Z9 11
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2012
VL 53
IS 8
BP 4352
EP 4358
DI 10.1167/iovs.11-8826
PG 7
WC Ophthalmology
SC Ophthalmology
GA 983DA
UT WOS:000307096400004
PM 22669725
ER
PT J
AU Wilson, R
Anzueto, A
Miravitlles, M
Arvis, P
Alder, J
Haverstock, D
Trajanovic, M
Sethi, S
AF Wilson, Robert
Anzueto, Antonio
Miravitlles, Marc
Arvis, Pierre
Alder, Jeff
Haverstock, Daniel
Trajanovic, Mila
Sethi, Sanjay
TI Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute
exacerbations of COPD: MAESTRAL results
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
DE Acute exacerbations of chronic obstructive pulmonary disease;
amoxicillin/clavulanic acid; antibiotic; clinical trial design;
exacerbation; moxifloxacin
ID OBSTRUCTIVE PULMONARY-DISEASE; GEORGES RESPIRATORY QUESTIONNAIRE; ACUTE
BACTERIAL EXACERBATIONS; LONG-TERM OUTCOMES; CHRONIC-BRONCHITIS;
ANTIBIOTIC-TREATMENT; TRACT INFECTION; LUNG-FUNCTION; HEALTH-STATUS;
FREE INTERVAL
AB Bacterial infections causing acute exacerbations of chronic obstructive pulmonary disease (AECOPD) frequently require antibacterial treatment. More evidence is needed to guide antibiotic choice.
The Moxifloxacin in Acute Exacerbations of Chronic Bronchitis TriaL (MAESTRAL) was a multiregional, randomised, double-blind non-inferiority outpatient study. Patients were aged >= 60 yrs, with an Anthonisen type I exacerbation, a forced expiratory volume in 1 s <60% predicted and two or more exacerbations in the last year. Following stratification by steroid use patients received moxifloxacin 400 mg p.o.q.d. (5 days) or amoxicillin/clavulanic acid 875/125 mg p.o. b.i.d. (7 days). The primary end-point was clinical failure 8 weeks post-therapy in the per protocol population.
Moxifloxacin was noninferior to amoxicillin/clavulanic acid at the primary end-point (111 (20.6%) out of 538, versus 114 (22.0%) out of 518, respectively; 95% CI -5.89-3.83%). In patients with confirmed bacterial AECOPD, moxifloxacin led to significantly lower clinical failure rates than amoxicillin/clavulanic acid (in the intent-to-treat with pathogens, 62 (19.0%) out of 327 versus 85 (25.4%) out of 335, respectively; p=0.016). Confirmed bacterial eradication at end of therapy was associated with higher clinical cure rates at 8 weeks post-therapy overall (p=0.0014) and for moxifloxacin (p=0.003). Patients treated with oral corticosteroids had more severe disease and higher failure rates.
The MAESTRAL study showed that moxifloxacin was as effective as amoxicillin/clavulanic acid in the treatment of outpatients with AECOPD. Both therapies were well tolerated.
C1 [Wilson, Robert] Royal Brompton Hosp, Host Def Unit, London SW3 6NP, England.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Alder, Jeff; Haverstock, Daniel] Bayer HealthCare Pharmaceut, Montville, NJ USA.
[Sethi, Sanjay] SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA.
[Miravitlles, Marc] Hosp Clin Barcelona, Ciber Enfermedades Resp CIBERES, IDIBAPS, Barcelona, Spain.
[Arvis, Pierre] Bayer HealthCare, Loos, France.
[Trajanovic, Mila] Bayer Inc, Toronto, ON, Canada.
RP Wilson, R (reprint author), Royal Brompton Hosp, Host Def Unit, Sydney St, London SW3 6NP, England.
EM r.wilson@rbht.nhs.uk
OI Miravitlles, Marc/0000-0002-9850-9520
FU Bayer HealthCare Pharmaceuticals AG, Berlin, Germany; NIHR Respiratory
Disease Biomedical Research Unit; Bayer HealthCare
FX This study was sponsored by Bayer HealthCare Pharmaceuticals AG, Berlin,
Germany. R. Wilson was supported by the NIHR Respiratory Disease
Biomedical Research Unit.; Highfield Communication Consultancy, Oxford,
UK, funded by Bayer HealthCare, provided editorial support in the
development of this paper. All analyses were carried out by the study
sponsor and the Data Review Committee was responsible for validating all
clinical failure data. The authors thank G. Farago (Bayer Inc., Toronto,
ON, Canada), study manager, for excellent and dedicated support
throughout the trial and R. Kay (RK Statistics Ltd, Bakewell, UK) for
independent statistical assessment. They are also grateful to all
physicians who enrolled patients in the study; a full list is given in
the online supplementary material.
NR 52
TC 33
Z9 36
U1 1
U2 3
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUL
PY 2012
VL 40
IS 1
BP 17
EP 27
DI 10.1183/09031936.00090311
PG 11
WC Respiratory System
SC Respiratory System
GA 985RS
UT WOS:000307287500007
PM 22135277
ER
PT J
AU Thase, ME
AF Thase, Michael E.
TI Social Skills Training for Depression and Comparative Efficacy Research:
A 30-Year Retrospective
SO BEHAVIOR MODIFICATION
LA English
DT Article
DE social skills training; depression; major depressive disorder;
comparative efficacy
ID COGNITIVE-BEHAVIOR THERAPY; UNIPOLAR DEPRESSION; MAJOR DEPRESSION;
PHARMACOTHERAPY; PSYCHOTHERAPY
AB By the late 1970s it was clear that cognitive and behavioral therapies were promising alternatives to antidepressant medications for treatment of depressed outpatients. One such model of therapy, Social Skills Training, was developed by Michel Hersen and his colleagues specifically for treatment of depressed women. Professor Hersen and his colleagues obtained funding from the National Institute of Mental Health to conduct the first well-controlled randomized trial of this intervention, contrasting Social Skills Training, in combination with either placebo or active amitriptyline, against two active standards: amitriptyline alone and time-limited, psychodynamic psychotherapy in combination with placebo. The results of this study suggested that Social Skills Training (plus placebo) was at least as effective as amitriptyline alone or psychodynamic psychotherapy (plus placebo), with superior mode-specific effects on measures of social skill. The current narrative, which provides an autobiographical perspective of four critical years (1980-1984) in the early career of the author that were intertwined with the conduct and completion of this clinical trial, is an homage to Professor Hersen's talents as a supervisor, researcher, and mentor.
C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Mood & Anxiety Sect, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Thase, Michael E.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA.
RP Thase, ME (reprint author), Univ Penn, Perelman Sch Med, Mood & Anxiety Sect, 3535 Market St,Suite 670, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
NR 20
TC 1
Z9 2
U1 2
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-4455
J9 BEHAV MODIF
JI Behav. Modificat.
PD JUL
PY 2012
VL 36
IS 4
SI SI
BP 545
EP 557
DI 10.1177/0145445512445610
PG 13
WC Psychology, Clinical
SC Psychology
GA 986IO
UT WOS:000307335500009
PM 22718283
ER
PT J
AU Gros, DF
Price, M
Strachan, M
Yuen, EK
Milanak, ME
Acierno, R
AF Gros, Daniel F.
Price, Matthew
Strachan, Martha
Yuen, Erica K.
Milanak, Melissa E.
Acierno, Ron
TI Behavioral Activation and Therapeutic Exposure: An Investigation of
Relative Symptom Changes in PTSD and Depression During the Course of
Integrated Behavioral Activation, Situational Exposure, and Imaginal
Exposure Techniques
SO BEHAVIOR MODIFICATION
LA English
DT Article
DE behavioral activation and therapeutic exposure; BA-TE; depression; PTSD;
comorbidity; transdiagnostic
ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE; MAJOR DEPRESSION;
RANDOMIZED-TRIAL; PRIMARY-CARE; COMORBIDITY; PREVALENCE; COMMUNITY;
VETERANS; VICTIMS
AB Effectiveness of exposure therapy for posttraumatic stress disorder (PTSD) may be adversely influenced by comorbid disorders. The present study investigated behavioral activation and therapeutic exposure (BA-TE), a new integrated treatment designed specifically for comorbid symptoms of PTSD and depression. Combat veterans with PTSD (N = 117) completed eight sessions of BA-TE that included two phases of treatment: (a) behavioral activation (BA) in which some activities involved situational exposures and (b) BA and situational exposures with imaginal exposures. Findings supported improvements in symptoms of PTSD, and overlapping symptoms of PTSD and depression, but not in nonoverlapping symptoms of depression. The findings also demonstrated a relatively consistent rate of change in PTSD and depression symptoms during BA-TE, despite the addition of imaginal exposures midway through the treatment. Together, these findings provide preliminary support for BA-TE as a treatment for PTSD and depression, and highlight the utility of transdiagnostic treatments in addressing comorbidity and symptom overlap.
C1 [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA.
[Milanak, Melissa E.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Ctr, Charleston, SC USA.
[Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Posttraumat Stress Disorder Clin Team, Charleston, SC 29401 USA.
RP Gros, DF (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
FU NIDA NIH HHS [R01 DA030143]
NR 54
TC 27
Z9 28
U1 7
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-4455
J9 BEHAV MODIF
JI Behav. Modificat.
PD JUL
PY 2012
VL 36
IS 4
SI SI
BP 580
EP 599
DI 10.1177/0145445512448097
PG 20
WC Psychology, Clinical
SC Psychology
GA 986IO
UT WOS:000307335500011
PM 22679240
ER
PT J
AU Volpe, EM
Hardie, TL
Cerulli, C
AF Volpe, Ellen M.
Hardie, Thomas L.
Cerulli, Catherine
TI Associations among Depressive Symptoms, Dating Violence, and
Relationship Power in Urban, Adolescent Girls
SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING
LA English
DT Article
DE dating violence; depression; relationship power; adolescent; aggression
ID INTIMATE PARTNER VIOLENCE; PHYSICAL HEALTH CONSEQUENCES; SEXUAL
RELATIONSHIP POWER; ROMANTIC RELATIONSHIPS; GENDER SYMMETRY;
UNITED-STATES; MENTAL-HEALTH; CES-D; RISK; AGGRESSION
AB Objective To explore the associations among dating violence (DV), aggression, relationship power, and depressive symptoms. Design A cross-sectional survey secondary analysis. Setting An urban, school based health center, October, 2009 through May, 2009. Participants Low income, adolescent girls (n = 155), ages 1418. Methods Descriptive and bivariate analyses were conducted to illustrate patterns and associations among variables. Key variables included depressive symptoms, DV victimization and aggression, and relationship power. We used mediation analyses to determine the direct and indirect effects among variables. Results Both DV victimization and aggression were reported frequently. Furthermore, DV victimization had a significant direct effect on depression and an indirect effect through relationship power. Depressive symptoms and relationship power were associated with DV aggression. Although relationship power did have a significant inverse effect on depressive symptoms, it was not through DV aggression. Conclusions Complex associations remain between mental health and DV; however, relationship power partially accounts for DV victimization's effect on depressive symptoms. Depressive symptoms are associated with DV victimization and aggression; therefore, nurses should address relationship power in clinical and community interventions.
C1 [Volpe, Ellen M.] Univ Penn, Ctr Hlth Equ Res, Sch Nursing, Philadelphia, PA 19104 USA.
[Volpe, Ellen M.] Univ Penn, Ctr Global Womans Hlth, Sch Nursing, Philadelphia, PA 19104 USA.
Univ Penn, Ctr Hlth Equ Res, Sch Nursing, Philadelphia, PA 19104 USA.
[Hardie, Thomas L.] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA.
[Cerulli, Catherine] Univ Rochester, Med Ctr, Dept Psychiat, Lab Interpersonal Violence & Victimizat, Rochester, NY 14642 USA.
RP Volpe, EM (reprint author), Univ Penn, Ctr Hlth Equ Res, Sch Nursing, 418 Curie Blvd,233L, Philadelphia, PA 19104 USA.
EM evolpe@nursing.upenn.edu
RI Hardie, Thomas/J-7776-2012
OI Hardie, Thomas/0000-0002-4547-7991
FU National Institutes of Health [F31MH082646-01A2]; National Institute of
Nursing Research [T32NR 007100]; Sigma Theta Tau; Epsilon Xi Chapter;
Susan B. Anthony Institute
FX Supported in part by grants from the National Institutes of Health, the
National Institutes of Mental Health (F31MH082646-01A2), the National
Institute of Nursing Research (T32NR 007100), Sigma Theta Tau, Epsilon
Xi Chapter, and Susan B. Anthony Institute. The authors thank Drs.
Morrison-Beedy, Tuttle, Fals-Stewart, and Sommers.
NR 73
TC 7
Z9 7
U1 2
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-2175
J9 JOGNN-J OBST GYN NEO
JI JOGNN
PD JUL-AUG
PY 2012
VL 41
IS 4
BP 506
EP 518
DI 10.1111/j.1552-6909.2012.01384.x
PG 13
WC Nursing; Obstetrics & Gynecology
SC Nursing; Obstetrics & Gynecology
GA 974ZN
UT WOS:000306476300007
PM 22697267
ER
PT J
AU Li, CY
Zeliadt, SB
Hall, IJ
Smith, JL
Ekwueme, DU
Moinpour, CM
Penson, DF
Thompson, IM
Keane, TE
Ramsey, SD
AF Li, Chunyu
Zeliadt, Steven B.
Hall, Ingrid J.
Smith, Judith Lee
Ekwueme, Donatus U.
Moinpour, Carol M.
Penson, David F.
Thompson, Ian M.
Keane, Thomas E.
Ramsey, Scott D.
TI Willingness to Pay for Prostate Cancer Treatment among Patients and
Their Family Members at 1 Year After Diagnosis
SO VALUE IN HEALTH
LA English
DT Article
DE family member; patient; prostate cancer; side effect; willingness to pay
ID QUALITY-OF-LIFE; TREATMENT DECISION-MAKING; SEER-MEDICARE DATA; CARE;
COSTS; TIME; MEN; SURGERY; COUPLES
AB Objectives: To explore an alternative approach to quantifying the burden of side effects at 1 year after treatment for prostate cancer among both patients and their partners. Methods: We analyzed data from 75 couples in the Family and Cancer Therapy Selection study. Paired patients and family members were independently asked about their willingness to pay (WTP) for a hypothetical new treatment that cures prostate cancer without side effects if they could reconsider their treatment decision by indicating the maximum amount they would be willing to pay given 11 separate "bids" ranging from $0 to $1500 per month. Descriptive and regression analyses were conducted for patients and family members controlling for sociodemographic characteristics and health status; Spearman correlations were also examined. Results: Among 75 couples analyzed, the income-adjusted mean WTP estimates per month were $400.8 (standard error [SE] $54.3) for patients and $650.2 (SE 72.2) for family members. The WTP between patients and family members was correlated (Pearson rho 0.30; P = 0.01). After adjusting for covariates, the adjusted mean WTP per month was $588.1 (SE 65.77) for patients and $819.4 (SE 74.33) for family members. Wanting to avoid side effects at baseline predicted higher WTP for patients (P = 0.010). Experiencing sexual side effects was predictive of higher WTP for family members (P = 0.047). Conclusions: Fairly high WTP amounts for a hypothetical treatment without side effects suggests that patients and their partners are experiencing important burdens 1 year after treatment. The higher amounts partners are willing to pay and the correlation with sexual side effects suggest that they are perceptive of significant treatment burdens.
C1 [Li, Chunyu; Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
[Zeliadt, Steven B.; Moinpour, Carol M.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Publ Hlth Serv Div, Seattle, WA 98104 USA.
[Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Penson, David F.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Med & Publ Hlth, Nashville, TN USA.
[Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
[Keane, Thomas E.] Med Univ S Carolina, Urol Serv, Charleston, SC 29425 USA.
RP Li, CY (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-55, Atlanta, GA 30341 USA.
EM Cli11@cdc.gov
FU Centers for Disease Control and Prevention, Prevention Research Centers
Program, through the University of Washington Health Promotion Research
Center [SIP 25-04 1-U48-DP-000050]
FX This study was supported by Cooperative Agreement Number SIP 25-04
1-U48-DP-000050 from the Centers for Disease Control and Prevention,
Prevention Research Centers Program, through the University of
Washington Health Promotion Research Center. The findings and
conclusions in this study are those of the authors and do not
necessarily represent the official position of the Centers for Disease
Control and Prevention.
NR 35
TC 4
Z9 4
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUL-AUG
PY 2012
VL 15
IS 5
BP 716
EP 723
DI 10.1016/j.jval.2012.03.003
PG 8
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 986AH
UT WOS:000307311100015
PM 22867781
ER
PT J
AU Duvvuri, U
Shiwarski, DJ
Xiao, D
Bertrand, C
Huang, X
Edinger, RS
Rock, JR
Harfe, BD
Henson, BJ
Kunzelmann, K
Schreiber, R
Seethala, RS
Egloff, AM
Chen, X
Lui, VW
Grandis, JR
Gollin, SM
AF Duvvuri, Umamaheswar
Shiwarski, Daniel J.
Xiao, Dong
Bertrand, Carol
Huang, Xin
Edinger, Robert S.
Rock, Jason R.
Harfe, Brian D.
Henson, Brian J.
Kunzelmann, Karl
Schreiber, Rainer
Seethala, Raja S.
Egloff, Ann Marie
Chen, Xing
Lui, Vivian W.
Grandis, Jennifer R.
Gollin, Susanne M.
TI TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and
Cancer Progression
SO CANCER RESEARCH
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; ACTIVATED CHLORIDE CHANNEL; CA2+-ACTIVATED
CL-CHANNELS; TRANSMEMBRANE CONDUCTANCE REGULATOR; GASTROINTESTINAL
STROMAL TUMORS; ORAL-CANCER; TRANSCRIPTOME ANALYSIS; INTERSTITIAL-CELLS;
EPITHELIAL-CELLS; 11Q13 AMPLICON
AB Frequent gene amplification of the receptor-activated calcium-dependent chloride channel TMEM16A (TAOS2 or ANO1) has been reported in several malignancies. However, its involvement in human tumorigenesis has not been previously studied. Here, we show a functional role for TMEM16A in tumor growth. We found TMEM16A overexpression in 80% of head and neck squamous cell carcinoma (SCCHN), which correlated with decreased overall survival in patients with SCCHN. TMEM16A overexpression significantly promoted anchorage-independent growth in vitro, and loss of TMEM16A resulted in inhibition of tumor growth both in vitro and in vivo. Mechanistically, TMEM16A-induced cancer cell proliferation and tumor growth were accompanied by an increase in extracellular signal-regulated kinase (ERK) 1/2 activation and cyclin D1 induction. Pharmacologic inhibition of MEK/ERK and genetic inactivation of ERK1/2 (using siRNA and dominant-negative constructs) abrogated the growth effect of TMEM16A, indicating a role for mitogen-activated protein kinase (MAPK) activation in TMEM16A-mediated proliferation. In addition, a developmental small-molecule inhibitor of TMEM16A, T16A-inh01 (A01), abrogated tumor cell proliferation in vitro. Together, our findings provide a mechanistic analysis of the tumorigenic properties of TMEM16A, which represents a potentially novel therapeutic target. The development of small-molecule inhibitors against TMEM16A may be clinically relevant for treatment of human cancers, including SCCHN. Cancer Res; 72(13); 3270-81. (C) 2012 AACR.
C1 [Duvvuri, Umamaheswar; Shiwarski, Daniel J.; Xiao, Dong; Egloff, Ann Marie; Chen, Xing; Lui, Vivian W.; Grandis, Jennifer R.; Gollin, Susanne M.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
[Bertrand, Carol] Univ Pittsburgh, Med Ctr, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA.
[Seethala, Raja S.; Gollin, Susanne M.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA.
[Grandis, Jennifer R.] Univ Pittsburgh, Med Ctr, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.
[Edinger, Robert S.] Univ Pittsburgh, Med Ctr, Renal & Electrolyte Div, Pittsburgh, PA 15213 USA.
[Huang, Xin] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.
[Huang, Xin] Univ Pittsburgh, Med Ctr, Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
[Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA.
[Henson, Brian J.; Gollin, Susanne M.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.
[Henson, Brian J.; Gollin, Susanne M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Rock, Jason R.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
[Harfe, Brian D.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA.
[Harfe, Brian D.] Univ Florida, Genet Inst, Gainesville, FL USA.
[Kunzelmann, Karl; Schreiber, Rainer] Univ Regensburg, Dept Physiol, Regensburg, Germany.
RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,W948 Biomed Sci Tower, Pittsburgh, PA 15213 USA.
EM duvvuriu@upmc.edu
RI Lui, Vivian/I-5458-2016
OI Kunzelmann, Karl/0000-0002-4583-7037; Shiwarski,
Daniel/0000-0001-6978-303X
FU Head and Neck Cancer SPORE grant [NIH P50CA097190]; Department of
Otolaryngology; Deutsche Krebshilfe Projekt [109438]; CPPF;
[P30CA047904]
FX This work was supported by the Head and Neck Cancer SPORE grant (NIH
P50CA097190 J.R. Grandis), through a Veterans Administration CDA; CPPF
(U. Duvvuri) and start-up funds from the Department of Otolaryngology
(U. Duvvuri). The molecular cytogenetic studies were carried out in the
University of Pittsburgh Cancer Institute Cytogenetics Facility,
supported in part by P30CA047904 to N.E. Davidson/R.B. Herberman/S.M.
Gollin. KK was supported by Deutsche Krebshilfe Projekt 109438.
NR 48
TC 96
Z9 102
U1 1
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2012
VL 72
IS 13
BP 3270
EP 3281
DI 10.1158/0008-5472.CAN-12-0475-T
PG 12
WC Oncology
SC Oncology
GA 986OB
UT WOS:000307350700017
PM 22564524
ER
PT J
AU Krassner, A
Dhaliwal, G
Baudendistel, TE
AF Krassner, Alexander
Dhaliwal, Gurpreet
Baudendistel, Thomas E.
TI Overcome by weakness
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID NOCARDIOSIS
C1 [Krassner, Alexander; Baudendistel, Thomas E.] Kaiser Oakland Med Ctr, Dept Med, Oakland, CA 94611 USA.
[Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Krassner, A (reprint author), Kaiser Oakland Med Ctr, Dept Med, 280 W MacArthur Blvd, Oakland, CA 94611 USA.
EM alexander.d.krassner@kp.org
NR 7
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD JUL-AUG
PY 2012
VL 7
IS 6
BP 513
EP 516
DI 10.1002/jhm.1930
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 982NW
UT WOS:000307053200010
PM 22407607
ER
PT J
AU Camacho-Soto, A
Sowa, GA
Perera, S
Weiner, DK
AF Camacho-Soto, Alejandra
Sowa, Gwendolyn A.
Perera, Subashan
Weiner, Debra K.
TI Fear Avoidance Beliefs Predict Disability in Older Adults With Chronic
Low Back Pain
SO PM&R
LA English
DT Article
ID GAIT SPEED; PHYSICAL FUNCTION; RISK-FACTORS; QUESTIONNAIRE; PEOPLE;
PREVALENCE; DEPRESSION; SURVIVAL; DECLINE; SCALE
AB Objectives: To determine whether fear avoidance beliefs (FABs) in older adults with chronic low back pain (CLBP) are significantly associated with gait speed decline and/or self-report of greater disability.
Design: Cross-sectional analysis.
Setting: An academic medical center (single site).
Participants: Two hundred English-speaking participants aged 65 years and older with CLBP every day or almost every day of moderate or greater intensity for >= 3 months.
Main Outcome Measurements: The physical activity portion of the FAB questionnaire assessed FABs. Disability was measured with gait speed and the Roland Morris Questionnaire. Covariates measured included age, gender, body mass index, chronic disease (Cumulative Illness Rating Scale), depression (Geriatric Depression Scale), and pain (McGill Pain Questionnaire Short Form).
Results: FABs were significantly associated with the Roland Morris Questionnaire (P < .0001) and gait speed (P = .002) after controlling for all covariates.
Conclusion: FABs related to physical activity in older adults with CLBP were significantly associated with both self-reported and performance-based disability after controlling for known confounders. Previous studies have reported similar associations between self-reported measures of disabling back pain and FABs. Ours is the first study to examine the relationship between FAB and gait speed, a powerful predictor of morbidity and mortality. Future work should examine whether targeting fear avoidance in addition to other psychosocial measures in older adults with CLBP improves gait speed and functional independence. PM R 2012;4:493-497
C1 [Camacho-Soto, Alejandra; Sowa, Gwendolyn A.] Univ Pittsburgh, Sch Med, Dept Med & Phys Med & Rehabil, Pittsburgh, PA USA.
[Perera, Subashan] Univ Pittsburgh, Sch Med, Dept Biostat & Med, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA.
[Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
RP Camacho-Soto, A (reprint author), 333 E Ontario 18048, Chicago, IL 60611 USA.
EM acamachosoto@gmail.com
RI Perera, Subashan/D-7603-2014
FU Pittsburgh Claude D. Pepper Older Americans Independence Center
[AG024827]; National Center for Complementary and Alternative Medicine
[R01 AT000985]; National Institute on Aging, National Institutes of
Health, Pitt Clinical Research Training Geriatrics/Gerontology [AG21885]
FX Research support: Pittsburgh Claude D. Pepper Older Americans
Independence Center, AG024827, grant R01 AT000985 from the National
Center for Complementary and Alternative Medicine and the National
Institute on Aging, National Institutes of Health, Pitt Clinical
Research Training Geriatrics/Gerontology, AG21885
NR 31
TC 13
Z9 13
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD JUL
PY 2012
VL 4
IS 7
BP 493
EP 497
DI 10.1016/j.pmrj.2012.01.017
PG 5
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 981RR
UT WOS:000306987800005
PM 22516436
ER
PT J
AU Schmidt, MG
Attaway, HH
Sharpe, PA
John, J
Sepkowitz, KA
Morgan, A
Fairey, SE
Singh, S
Steed, LL
Cantey, JR
Freeman, KD
Michels, HT
Salgado, CD
AF Schmidt, Michael G.
Attaway, Hubert H.
Sharpe, Peter A.
John, Joseph, Jr.
Sepkowitz, Kent A.
Morgan, Andrew
Fairey, Sarah E.
Singh, Susan
Steed, Lisa L.
Cantey, J. Robert
Freeman, Katherine D.
Michels, Harold T.
Salgado, Cassandra D.
TI Sustained Reduction of Microbial Burden on Common Hospital Surfaces
through Introduction of Copper
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; ACUTE-CARE HOSPITALS; ENVIRONMENTAL
CONTAMINATION; CLOSTRIDIUM-DIFFICILE; INFECTION; SURVIVAL; RISK;
ACQUISITION; HYGIENE; UNIT
AB The contribution of environmental surface contamination with pathogenic organisms to the development of health care-associated infections (HAI) has not been well defined. The microbial burden (MB) associated with commonly touched surfaces in intensive care units (ICUs) was determined by sampling six objects in 16 rooms in ICUs in three hospitals over 43 months. At month 23, copper-alloy surfaces, with inherent antimicrobial properties, were installed onto six monitored objects in 8 of 16 rooms, and the effect that this application had on the intrinsic MB present on the six objects was assessed. Census continued in rooms with and without copper for an additional 21 months. In concert with routine infection control practices, the average MB found for the six objects assessed in the clinical environment during the preintervention phase was 28 times higher (6,985 CFU/100 cm(2); n = 3,977 objects sampled) than levels proposed as benign immediately after terminal cleaning (< 250 CFU/100 cm(2)). During the intervention phase, the MB was found to be significantly lower for both the control and copper-surfaced objects. Copper was found to cause a significant (83%) reduction in the average MB found on the objects (465 CFU/100 cm(2); n = 2714 objects) compared to the controls (2,674 CFU/100 cm(2); n = 2,831 objects [P < 0.0001]). The introduction of copper surfaces to objects formerly covered with plastic, wood, stainless steel, and other materials found in the patient care environment significantly reduced the overall MB on a continuous basis, thereby providing a potentially safer environment for hospital patients, health care workers (HCWs), and visitors.
C1 [Schmidt, Michael G.; Attaway, Hubert H.; Morgan, Andrew; Fairey, Sarah E.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Sharpe, Peter A.] Irwin P Sharpe & Associates, W Orange, NJ USA.
[John, Joseph, Jr.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Sepkowitz, Kent A.; Singh, Susan] Mem Sloan Kettering Canc Ctr, Dept Med, Div Infect Dis, New York, NY 10021 USA.
[Steed, Lisa L.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Cantey, J. Robert; Salgado, Cassandra D.] Med Univ S Carolina, Dept Med, Div Infect Dis, Charleston, SC 29425 USA.
[Freeman, Katherine D.] Yeshiva Univ, Albert Einstein Coll Med, Montefiore Med Ctr, Dept Epidemiol & & Populat Hlth, Bronx, NY USA.
[Michels, Harold T.] Copper Dev Assoc, New York, NY USA.
RP Schmidt, MG (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
EM schmidtm@musc.edu
OI Schmidt, Michael G/0000-0002-7794-7265
FU U.S. Army Material Command [W81XWH-07-C-0053]
FX This work was supported by the U.S. Army Material Command (contract
W81XWH-07-C-0053).
NR 40
TC 56
Z9 56
U1 2
U2 21
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 2012
VL 50
IS 7
BP 2217
EP 2223
DI 10.1128/JCM.01032-12
PG 7
WC Microbiology
SC Microbiology
GA 986RB
UT WOS:000307360800008
PM 22553242
ER
PT J
AU O'Horo, JC
Jones, A
Stemke, M
Harper, C
Safdar, N
AF O'Horo, John C.
Jones, Amy
Stemke, Matthew
Harper, Christopher
Safdar, Nasia
TI Molecular Techniques for Diagnosis of Clostridium difficile Infection:
Systematic Review and Meta-analysis
SO MAYO CLINIC PROCEEDINGS
LA English
DT Review
ID REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; MEDIATED ISOTHERMAL
AMPLIFICATION; TOXIN-B GENE; STOOL SAMPLES; ENZYME-IMMUNOASSAY; RAPID
DETECTION; PROSPECTIVE MULTICENTER; LABORATORY DIAGNOSIS; TESTING
ALGORITHMS
AB Objective: To assess the usefulness of 2 rapid molecular diagnostic techniques, polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP), in Clostridium difficile infection (CDI).
Methods: We conducted a systematic review and meta-analysis to evaluate the accuracy of PCR and LAMP in diagnosis of CDI, including studies that used toxigenic culture or cytotoxicity assay as reference standard.
Results: A search of PubMed and CinAHL medical databases yielded 25 PCR studies, including 11,801 samples that met inclusion criteria and 6 heterogeneous studies that evaluated LAMP. With toxigenic culture as a standard, pooled sensitivity was 0.92 (95% confidence interval [Cl], 0.91-0.94); specificity, 0.94 (95% Cl, 0.94-0.95); and diagnostic odds ratio, 378 (95% Cl, 260-547). With cytotoxicity as a standard, pooled sensitivity was 0.87 (95% Cl, 0.84-0.90); specificity, 0.97 (95% Cl, 0.97-0.98); and diagnostic odds ratio, 370 (95% Cl, 226-606).
Conclusion: Polymerase chain reaction is a highly accurate test for identifying CDI. Heterogeneity in LAMP studies did not allow meta-analysis; however, further research into this promising method is warranted. (C) 2012 Mayo Foundation for Medical Education and Research Mayo Clin Proc. 2012:87(7):643-651
C1 [Safdar, Nasia] Univ Wisconsin Hosp & Clin, Sect Infect Dis, Dept Med, Madison, WI 53705 USA.
[O'Horo, John C.] Aurora UW Med Grp, Dept Grad Med Educ, Milwaukee, WI USA.
[Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Hosp, Madison, WI USA.
RP Safdar, N (reprint author), Univ Wisconsin Hosp & Clin, Sect Infect Dis, Dept Med, MFCB 5221, Madison, WI 53705 USA.
EM ns2@medicine.wisc.edu
RI O'Horo, John/A-8787-2013; O'Horo, John/N-8681-2013
OI O'Horo, John/0000-0002-0880-4498; O'Horo, John/0000-0002-0880-4498
NR 64
TC 29
Z9 31
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD JUL
PY 2012
VL 87
IS 7
BP 643
EP 651
DI 10.1016/j.mayocp.2012.02.024
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 980DC
UT WOS:000306872800007
PM 22766084
ER
PT J
AU Ruff, RL
Rutecki, P
AF Ruff, Robert L.
Rutecki, Paul
TI Faster, slower, but never better Mutations of the skeletal muscle
acetylcholine receptor
SO NEUROLOGY
LA English
DT Editorial Material
ID NICOTINIC RECEPTOR; AGONIST BINDING; SUBUNIT
C1 [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurol, Neurol Serv, Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
[Rutecki, Paul] Univ Wisconsin, Dept Neurol, William S Middleton Mem Vet Hosp, Neurol Serv, Madison, WI 53706 USA.
RP Ruff, RL (reprint author), Case Western Reserve Univ, Dept Neurol, Neurol Serv, Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
EM robert.ruff1@va.gov
NR 10
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUL
PY 2012
VL 79
IS 5
BP 404
EP 405
DI 10.1212/WNL.0b013e31825b5bee
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 984AY
UT WOS:000307161100009
PM 22592368
ER
PT J
AU Mohr, DC
Lovera, J
Brown, T
Cohen, B
Neylan, T
Henry, R
Siddique, J
Jin, L
Daikh, D
Pelletier, D
AF Mohr, David C.
Lovera, Jesus
Brown, Ted
Cohen, Bruce
Neylan, Thomas
Henry, Roland
Siddique, Juned
Jin, Ling
Daikh, David
Pelletier, Daniel
TI A randomized trial of stress management for the prevention of new brain
lesions in MS
SO NEUROLOGY
LA English
DT Article
ID TELEPHONE-ADMINISTERED PSYCHOTHERAPY; COGNITIVE-BEHAVIORAL THERAPY;
REMITTING MULTIPLE-SCLEROSIS; PSYCHOLOGICAL STRESS; DOUBLE-BLIND; LIFE
EVENTS; DEPRESSION; METAANALYSIS; DISABILITY; SYMPTOMS
AB Objectives: This trial examined the efficacy of a stress management program in reducing neuroimaging markers of multiple sclerosis (MS) disease activity.
Methods: A total of 121 patients with relapsing forms of MS were randomized to receive stress management therapy for MS (SMT-MS) or a wait-list control condition. SMT-MS provided 16 individual treatment sessions over 24 weeks, followed by a 24-week post-treatment follow-up. The primary outcome was the cumulative number of new gadolinium-enhancing (Gd+) brain lesions on MRI at weeks 8, 16, and 24. Secondary outcomes included new or enlarging T2 MRI lesions, brain volume change, clinical exacerbation, and stress.
Results: SMT-MS resulted in a reduction in cumulative Gd+ lesions (p = 0.04) and greater numbers of participants remained free of Gd+ lesions during the treatment (76.8% vs 54.7%, p = 0.02), compared to participants receiving the control treatment. SMT-MS also resulted in significantly reduced numbers of cumulative new T2 lesions (p = 0.005) and a greater number of participants remaining free of new T2 lesions (69.5% vs 42.7%, p = 0.006). These effects were no longer detectable during the 24-week post-treatment follow-up period.
Conclusions: This trial indicates that SMT-MS may be useful in reducing the development of new MRI brain lesions while patients are in treatment.
Classification of evidence: This study provides Class I evidence that SMT-MS, a manualized stress management therapy program, reduced the number of Gd+ lesions in patients with MS during a 24-week treatment period. This benefit was not sustained beyond 24 weeks, and there were no clinical benefits.
C1 [Mohr, David C.; Cohen, Bruce; Siddique, Juned; Jin, Ling] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Lovera, Jesus] Louisiana State Univ, Hlth Sci Ctr, Sch Med, New Orleans, LA USA.
[Brown, Ted] Evergreen Hosp Med Ctr, Seattle, WA USA.
[Neylan, Thomas; Henry, Roland; Daikh, David; Pelletier, Daniel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Neylan, Thomas; Daikh, David] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Mohr, DC (reprint author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
EM d-mohr@northwestern.edu
FU NIH; Lilly Inc.; Acorda; Teva Neuroscience; Northwestern University from
Biogen-Idec; EMD Serono; Novartis; Roche; CME program (through
Northwestern University) from Teva Neuroscience; Actelion; Glaxo Smith
Kline; National Institutes of Health, NINDS [R01NS062885]; NICHD
[R01-HD043323]
FX D. Mohr receives research funding from the NIH. J. Lovera has honoraria
for consulting and speaking from Biogen Idec, Serono, and Teva. T. Brown
has served as a consultant for Acorda, Biogen, EMD Serono, and Teva
Neuroscience and has received honoraria from Acorda, Pfizer, and Teva
and has been funded by research grants from Lilly Inc., Acorda, and Teva
Neuroscience. B. Cohen has received payments for consulting or speaking
honoraria from Accorda, Astellis, Bayer, Biogen-Idec, EMD Serono,
Genentech, Novartis, Pfizer, and Teva Neuroscience. He has received
research support through Northwestern University from Biogen-Idec, EMD
Serono, Novartis, Roche, and an Unrestricted Educational Grant in
support of a CME program (through Northwestern University) from Teva
Neuroscience. T. Neylan has received research support (supply of
investigative medication) from Actelion and Glaxo Smith Kline. R. Henry,
J. Siddique, L. Jin, and D. Daikh report no disclosures. D. Pelletier
receives research support from the National Institutes of Health, NINDS
(R01NS062885). Go to Neurology.org for full disclosures.; This study was
funded by NICHD grant R01-HD043323.
NR 33
TC 34
Z9 34
U1 5
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUL
PY 2012
VL 79
IS 5
BP 412
EP 419
DI 10.1212/WNL.0b013e3182616ff9
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 984AY
UT WOS:000307161100011
PM 22786596
ER
PT J
AU Even, C
Weintraub, D
AF Even, Christian
Weintraub, Daniel
TI Is depression in Parkinson's Disease (PD) a specific entity?
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Review
DE Depression; Parkinson's Disease; Mood disorders
ID SEROTONIN TRANSPORTER GENE; PLACEBO-CONTROLLED TRIAL; MAJOR DEPRESSION;
FUNCTIONAL POLYMORPHISM; STRIATAL DOPAMINE; ALLELIC VARIATION; INCREASED
RISK; DOUBLE-BLIND; LATE-LIFE; SYMPTOMS
AB Background: Clinical lore and research have suggested for a long time that depression and PD are closely related. We examined the validity of depression associated with PD (dPD) as a specific subtype of depression according to face validity, descriptive validity, construct validity and predictive validity.
Methods: The English literature was reviewed after searching the MEDLINE database up to June 2010.
Results: There appears to be three possible subtypes of comorbid depression: 1) patients who would have been depressed even if they had no PD (nonspecific-casual comorbid dPD), 2) patients who would have been depressed if they had had another disabling medical illness (nonspecific-reactive comorbid dPD) 3) those for which depression is directly related to the underlying pathophysiology of PD (specific comorbid dPD). These latter patients may more often present with particular clinical characteristics (descriptive validity): absence of history of depression or only within 5 years prior to onset of PD, absence of guilty thoughts and self-blame, absence of suicidal behavior, right-sided onset. However, dPD is only partly responsive to dopamine replacement and cannot be solely explained by dopamine deficiency. Other neurotransmitter systems are affected in PD and are involved in the pathophysiology of dPD. Their relative involvement however may differ from that in idiopathic depression (i.e.: lesser involvement of serotonergic systems).
Limitations: Therapeutic data are limited to few controlled trials.
Conclusions: Further research may allow differential diagnosis between dPD subtypes (i.e.: those who do and do not result from the underlying pathophysiological process of PD) and help inform treatment choice. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Even, Christian] Ctr Hosp St Anne, Clin Malad Mentales & Encephale, F-75674 Paris 14, France.
[Even, Christian] Univ Paris 05, INSERM, U894, Ctr Psychiat & Neurosci, Paris, France.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA.
RP Even, C (reprint author), Ctr Hosp St Anne, Clin Malad Mentales & Encephale, 100 Rue Sante, F-75674 Paris 14, France.
EM c.even@ch-sainte-anne.fr
FU Sanofi-Synthelabo; Novartis; Boehringer-Ingelheim
FX Dr Weintraub has received grants and honoraria from Sanofi-Synthelabo,
Novartis and Boehringer-Ingelheim.
NR 119
TC 7
Z9 7
U1 5
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD JUL
PY 2012
VL 139
IS 2
BP 103
EP 112
DI 10.1016/j.jad.2011.07.002
PG 10
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 975TV
UT WOS:000306535300001
PM 21794923
ER
PT J
AU Cunningham, MA
Naga, OS
Eudaly, JG
Scott, JL
Gilkeson, GS
AF Cunningham, Melissa A.
Naga, Osama S.
Eudaly, Jackie G.
Scott, Jennifer L.
Gilkeson, Gary S.
TI Estrogen receptor alpha modulates toll-like receptor signaling in murine
lupus
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Estrogen receptor alpha; Systemic lupus erythematosus; Dendritic cells;
Toll-like receptors
ID DENDRITIC CELL-DIFFERENTIATION; ANTIGEN-PRESENTING CELLS; BONE-MARROW;
AUTOANTIBODY PRODUCTION; NEUROPSYCHIATRIC LUPUS; CEREBROSPINAL-FLUID;
ERYTHEMATOSUS; EXPRESSION; PROMOTES; DISEASE
AB Systemic lupus erythematosus (SLE) is a disease that disproportionately affects females. Despite significant research effort, the mechanisms underlying the female predominance in this disease are largely unknown. Previously, we showed that estrogen receptor alpha knockout (ER alpha KO) lupus prone female mice had significantly less pathologic renal disease and proteinuria, and significantly prolonged survival. Since autoantibody levels and number and percentage of BIT cells were not significantly impacted by ER alpha genotype, we hypothesized that the primary benefit of ERa deficiency in lupus nephritis was via modulation of the innate immune response. Using BMDCs and spleen cells/B cells from female wild-type or ER alpha KO mice, we found that ER alpha KO-derived cells have a significantly reduced inflammatory response after stimulation with TLR agonists. Our results indicate that the inflammatory response to TLR ligands is significantly impacted by the presence of ER alpha despite the absence of estradiot, and may partially explain the protective effect of ER alpha deficiency in lupus-prone animals. (C) 2012 Published by Elsevier Inc.
C1 Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
Ralph H Johnson Vet Affairs Hosp, Charleston, SC 29425 USA.
RP Gilkeson, GS (reprint author), 96 Jonathan Lucas St,Suite 912,MSC637, Charleston, SC 29425 USA.
EM gilkeson@musc.edu
OI Cunningham, Melissa/0000-0002-9207-1986
FU NIAMS NIH HHS [T32 AR050958]
NR 44
TC 13
Z9 13
U1 1
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD JUL
PY 2012
VL 144
IS 1
BP 1
EP 12
DI 10.1016/j.clim.2012.04.001
PG 12
WC Immunology
SC Immunology
GA 977PX
UT WOS:000306678000001
PM 22659029
ER
PT J
AU Jacobs, RL
Harper, N
He, WJ
Andrews, CP
Rather, CG
Ramirez, DA
Ahuja, SK
AF Jacobs, Robert L.
Harper, Nathan
He, Weijing
Andrews, Charles P.
Rather, Cynthia G.
Ramirez, Daniel A.
Ahuja, Sunil K.
TI Responses to ragweed pollen in a pollen challenge chamber versus
seasonal exposure identify allergic rhinoconjunctivitis endotypes
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE Allergic diseases; environmental chamber; ragweed; endotypes
ID VALIDATION; NASAL; RHINITIS; ASTHMA; ONSET; UNIT
AB Background: The level of concordance between allergic symptoms induced on exposure to pollen in a pollen challenge chamber (PCC) versus the natural season is unknown.
Objective: We sought to test the hypothesis that the symptom levels of allergic rhinoconjunctivitis elicited after out-of-season exposure to short ragweed in a PCC and during the natural season for giant ragweed pollen are highly correlated.
Methods: Thirty-one ragweed-sensitive participants recorded symptoms for 15 days during the natural giant ragweed season in San Antonio, Texas. Twenty-six of these participants were challenged to short ragweed pollen in a PCC for 3 hours per day for up to 4 days.
Results: In the PCC participants were dichotomized into those in whom low versus high levels of symptoms developed slowly or rapidly (ie, slow/low vs rapid/high). Each successive exposure visit associated with a progressive increase in symptom levels that approximated those experienced during the natural season. Hierarchic clustering identified 3 endotypes: endotypes I and II reflected concordantly low (n = 7) versus high (n = 14) total symptom scores (TSSs) in both the natural season and the PCC, respectively. Accordingly, the correlation between the TSSs recorded in the natural season and in the PCC for these 21 participants was very high. Although participants with endotype III (n = 5) had greater TSSs in the natural season than in the PCC, the degree of correlation between the TSSs remained high.
Conclusions: Our findings affirm our hypothesis, underscore the high cross-reactivity between distinct pollens, and highlight the utility of the PCC to identify novel allergy endotypes that might have contrasting mechanistic underpinnings and potentially therapeutic responses. (J Allergy Clin Immunol 2012;130:122-7.)
C1 [Jacobs, Robert L.; Andrews, Charles P.; Rather, Cynthia G.; Ramirez, Daniel A.] Biogen Res Chamber LLC, San Antonio, TX 78229 USA.
[Harper, Nathan; He, Weijing; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX USA.
[Harper, Nathan; He, Weijing; Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
[Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
RP Jacobs, RL (reprint author), Biogen Res Chamber LLC, 8299 Fredericksburg Rd, San Antonio, TX 78229 USA.
EM robert.jacobs7025@sbcglobal.net
OI Andrews, Charles/0000-0002-8944-8404; Jacobs, Robert/0000-0002-2831-9086
FU Doris Duke Distinguished Clinical Scientist Award; Burroughs Wellcome
Clinical Scientist in Translational Research Award; Max and Minnie
Tomerlin Voelcker Scholar Award; Center for Personalized Medicine at the
South Texas Veterans Health Care System; National Institutes of Health
FX S.K.A. received support from the following grants: the Doris Duke
Distinguished Clinical Scientist Award, the Burroughs Wellcome Clinical
Scientist in Translational Research Award, the Max and Minnie Tomerlin
Voelcker Scholar Award, and the Center for Personalized Medicine at the
South Texas Veterans Health Care System.; Disclosure of potential
conflict of interest: R. L. Jacobs is the owner of the Biogenics
Research Chamber and Biogenics Research Institute. C. P. Andrews is a
partner in the Biogenics Research Chamber and Director of Clinical
Research at the Diagnostics Research Group. C. G. Rather is Executive
Director of the Biogenics Research Chamber. D. A. Ramirez is a partner
in the Biogenics Research Chamber. S. K. Ahuja has received research
support from the National Institutes of Health. The rest of the authors
declare that they have no relevant conflicts of interest.
NR 20
TC 24
Z9 24
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD JUL
PY 2012
VL 130
IS 1
BP 122
EP +
DI 10.1016/j.jaci.2012.03.031
PG 14
WC Allergy; Immunology
SC Allergy; Immunology
GA 977GN
UT WOS:000306644800017
PM 22554707
ER
PT J
AU Smith, T
Capitulo, KL
Griffin, MTQ
Fitzpatrick, JJ
AF Smith, Thomas
Capitulo, Kathleen Leask
Griffin, Mary T. Quinn
Fitzpatrick, Joyce J.
TI Structural empowerment and anticipated turnover among behavioural health
nurses
SO JOURNAL OF NURSING MANAGEMENT
LA English
DT Article
DE anticipated turnover; behavioural health nurse; registered nurse;
structural empowerment; workforce retention
ID WORK ENVIRONMENTS; SATISFACTION; STAFF; SETTINGS; MODEL; PERCEPTIONS;
WORKPLACE; INTENT; IMPACT; LEAVE
AB smith t., capitulo k.l., quinn griffin m.t. & fitzpatrick j.j. (2012) Journal of Nursing Management similar to 20, 679684 Structural empowerment and anticipated turnover among behavioural health nurses Aim The aim of this pilot study was to examine the relationship between structural empowerment and anticipated turnover among behavioural health nurses. Background There have been several studies relating structural empowerment to a range of organizational characteristics and personal attributes of nurses themselves. There are also previous studies linking the key variables in the present study, but no previous research of behavioural health nurses was available. Methods A quantitative design was used for this cross-sectional pilot study. All registered nurses (RN) working on inpatient units in the study facility were invited to participate (n = 97). An anonymous survey was sent to all potential participants. Results The response rate was 53% (n = 50). The majority of participants perceived themselves as moderately empowered. There was a significant negative correlation between empowerment and anticipated turnover. Conclusion The results of this pilot study among behavioural health nurses are similar to the results among nurses working in other clinical areas. Implications for nursing management Nurse managers should be cognizant of the factors that enhance nurses perceptions of empowerment, particularly related to issues of retention and anticipated turnover among behavioural health nurses.
C1 [Griffin, Mary T. Quinn; Fitzpatrick, Joyce J.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Smith, Thomas] Maimonides Hosp, Brooklyn, NY 11219 USA.
[Capitulo, Kathleen Leask] James J Peters VA Med Ctr, Bronx, NY USA.
RP Fitzpatrick, JJ (reprint author), Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
EM joyce.fitzpatrick@case.edu
NR 25
TC 5
Z9 5
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0966-0429
J9 J NURS MANAGE
JI J. Nurs. Manag.
PD JUL
PY 2012
VL 20
IS 5
SI SI
BP 679
EP 684
DI 10.1111/j.1365-2834.2012.01384.x
PG 6
WC Management; Nursing
SC Business & Economics; Nursing
GA 977IE
UT WOS:000306649300013
PM 22823224
ER
PT J
AU Robinson, TN
Wu, DS
Pointer, LF
Dunn, CL
Moss, M
AF Robinson, Thomas N.
Wu, Daniel S.
Pointer, Lauren F.
Dunn, Christina L.
Moss, Marc
TI Preoperative Cognitive Dysfunction Is Related to Adverse Postoperative
Outcomes in the Elderly
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article; Proceedings Paper
CT 119th Scientific Session of the Western-Surgical-Association
CY NOV, 2011
CL Tucson, AZ
SP Western Surg Assoc
ID INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CONFUSION
ASSESSMENT METHOD; MINI-COG; DISCHARGE INSTITUTIONALIZATION;
GERIATRIC-PATIENT; DELIRIUM; DEMENTIA; POPULATION; FRAILTY
AB BACKGROUND: Preoperative risk stratification is commonly performed by assessing end-organ function (such as cardiac and pulmonary) to define postoperative risk. Little is known about impaired preoperative cognition and outcomes. The purpose of this study was to evaluate the impact of baseline impaired cognition on postoperative outcomes in geriatric surgery patients.
STUDY DESIGN: Subjects 65 years and older undergoing a planned elective operation requiring postoperative ICU admission were recruited prospectively. Preoperative baseline cognition was assessed using the validated Mini-Cog test. Impaired cognition was defined as a Mini-Cog score of <= 3. Delirium was assessed using the Confusion Assessment Method-ICU by a trained research team. Adverse outcomes were defined using the Veterans Affairs Surgical Quality Improvement Program definitions.
RESULTS: One hundred and eighty-six subjects were included, with a mean age of 73 +/- 6 years. Eighty-two subjects (44%) had baseline impaired cognition. The impaired cognition group had the following unadjusted outcomes: increased incidence of 1 or more postoperative complications (41% vs 24%; p = 0.011), higher incidence of delirium (78% vs 37%; p < 0.001), longer hospital stays (15 +/- 14 vs 9 +/- 9 days; p = 0.001), higher rate of discharge institutionalization (42% vs 18%; p = 0.001), and higher 6-month mortality (13% vs 5%; p = 0.040). Adjusting for potential confounders determined by univariate analysis, logistic regression found impaired cognition was still associated with the occurrence of 1 or more postoperative complications (odds ratio = 2.401; 95% CI, 1.185 +/- 4.865; p = 0.015). Kaplan-Meier survival analysis revealed higher mortality in the impaired cognition group (log-rank p = 0.008).
CONCLUSIONS: Baseline cognitive impairment in older adults undergoing major elective operations is related to adverse postoperative outcomes including increased complications, length of stay, and long-term mortality. Improved understanding of baseline cognition and surgical outcomes can aid surgical decision making in older adults. (J Am Coll Surg 2012; 215: 12-18. (C) 2012 by the American College of Surgeons)
C1 [Robinson, Thomas N.; Wu, Daniel S.; Dunn, Christina L.] Univ Colorado, Denver Sch Med, Dept Surg, Aurora, CO 80045 USA.
[Moss, Marc] Univ Colorado, Denver Sch Med, Dept Med, Aurora, CO USA.
[Robinson, Thomas N.; Wu, Daniel S.] Denver Vet Affairs Med Ctr, Dept Surg, Denver, CO USA.
[Pointer, Lauren F.] Denver Vet Affairs Med Ctr, Dept Biostat, Denver, CO USA.
RP Robinson, TN (reprint author), Univ Colorado, Denver Sch Med, Dept Surg, 12631 E 17th Ave,MS C313, Aurora, CO 80045 USA.
EM thomas.robinson@ucdenver.edu
FU NHLBI NIH HHS [K24 HL089223, K24-HL-089223]; NIA NIH HHS [K23 AG034632,
K23AG034632]
NR 28
TC 44
Z9 45
U1 3
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD JUL
PY 2012
VL 215
IS 1
BP 12
EP 17
DI 10.1016/j.jamcollsurg.2012.02.007
PG 6
WC Surgery
SC Surgery
GA 977GE
UT WOS:000306643900002
PM 22626912
ER
PT J
AU Hussar, DA
Hallinan, SE
AF Hussar, Daniel A.
Hallinan, Sarah E.
TI Clobazam, ezogabine, and tafluprost
SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
LA English
DT News Item
C1 [Hussar, Daniel A.] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA 19104 USA.
[Hallinan, Sarah E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Hussar, DA (reprint author), Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER PHARMACEUTICAL ASSOC
PI WASHINGTON
PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA
SN 1544-3191
J9 J AM PHARM ASSOC
JI J. Am. Pharm. Assoc.
PD JUL-AUG
PY 2012
VL 52
IS 4
BP 546
EP 550
DI 10.1331/JAPhA.2012.12529
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 977GG
UT WOS:000306644100019
PM 22825237
ER
PT J
AU Penson, DF
Lange, PH
AF Penson, David F.
Lange, Paul H.
TI Systemic therapy and the urologic oncologist: A unique opportunity for
the specialty to provide comprehensive care that ultimately benefits the
patient
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Systemic therapy; Urologic cancers; Practice models
ID CANCER
AB The changing healthcare environment will demand greater integration and coordination of care for patients. By incorporating systemic therapies into the practice of urologic oncology, our specialty has the opportunity to take the lead in this initiative. By learning how to deliver these therapies to patients in need, urologic oncologists likely will improve communication and trust, as patients often will already have a long and positive relationship with their urologist. In turn, this will likely lead to increased satisfaction with care and possibly improved outcomes. The development of comprehensive urologic oncology practices that include the administration of systemic therapy will maintain the relevance of the specialty and ultimately benefit our patients. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Penson, David F.] Vanderbilt Univ, Dept Urol Surg, Nashville, TN 37203 USA.
[Penson, David F.] VA Tennessee Valley Geriatr Res Educ & Clin Ctr G, Nashville, TN 37203 USA.
[Lange, Paul H.] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
[Lange, Paul H.] VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA.
RP Penson, DF (reprint author), Vanderbilt Univ, Dept Urol Surg, Nashville, TN 37203 USA.
EM david.penson@vanderbilt.edu
NR 4
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD JUL-AUG
PY 2012
VL 30
IS 4
SU S
BP S2
EP S4
DI 10.1016/j.urolonc.2011.04.008
PG 3
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 977EI
UT WOS:000306638800002
PM 22795076
ER
PT J
AU Baicu, CF
Zhang, YH
Van Laer, AO
Renaud, L
Zile, MR
Bradshaw, AD
AF Baicu, Catalin F.
Zhang, Yuhua
Van Laer, An O.
Renaud, Ludivine
Zile, Michael R.
Bradshaw, Amy D.
TI Effects of the absence of procollagen C-endopeptidase enhancer-2 on
myocardial collagen accumulation in chronic pressure overload
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE procollagen; procollagen C-proteinase enhancer-2; fibrosis; hypertrophy
ID BONE MORPHOGENETIC PROTEIN-1; FRIZZLED-RELATED PROTEIN-2; DIASTOLIC
HEART-FAILURE; FIBRILLAR COLLAGEN; LEFT-VENTRICLE; RAT-HEART;
EXPRESSION; GENE; INFARCTION; FIBROSIS
AB Baicu CF, Zhang Y, Van Laer AO, Renaud L, Zile MR, Bradshaw AD. Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am J Physiol Heart Circ Physiol 303: H234-H240, 2012. First published May 18, 2012; doi:10.1152/ajpheart.00227.2012.-Cardiac interstitial fibrillar collagen accumulation, such as that associated with chronic pressure overload (PO), has been shown to impair left ventricular diastolic function. Therefore, insight into cellular mechanisms that mediate excessive collagen deposition in the myocardium is pivotal to this important area of research. Collagen is secreted as a soluble procollagen molecule with NH2- and COOH (C)-terminal propeptides. Cleavage of these propeptides is required for collagen incorporation to insoluble collagen fibrils. The C-procollagen proteinase, bone morphogenic protein 1, cleaves the C-propeptide of procollagen. Procollagen C-endopeptidase enhancer (PCOLCE) 2, an enhancer of bone morphogenic protein-1 activity in vitro, is expressed at high levels in the myocardium. However, whether the absence of PCOLCE2 affects collagen content at baseline or after PO induced by transverse aortic constriction (TAC) has never been examined. Accordingly, in vivo procollagen processing and deposition were examined in wild-type (WT) and PCOLCE2-null mice. No significant differences in collagen content or myocardial stiffness were detected in non-TAC (control) PCOLCE2-null versus WT mice. After TAC-induced PO, PCOLCE2-null hearts demonstrated a lesser collagen content (PCOLCE2-null TAC collagen volume fraction, 0.41% +/- 0.07 vs. WT TAC, 1.2% +/- 0.3) and lower muscle stiffness compared with WT PO hearts [PCOLCE2-null myocardial stiffness (beta), 0.041 +/- 0.002 vs. WT myocardial stiffness, 0.065 +/- 0.001]. In addition, in vitro, PCOLCE2-null cardiac fibroblasts exhibited reductions in efficiency of C-propeptide cleavage, as demonstrated by increases in procollagen alpha 1(I) and decreased levels of processed collagen alpha 1(I) versus WT cardiac fibroblasts. Hence, PCOLCE2 is required for efficient procollagen processing and deposition of fibrillar collagen in the PO myocardium. These results support a critical role for procollagen processing in the regulation of collagen deposition in the heart.
C1 [Bradshaw, Amy D.] Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, Charleston, SC 29425 USA.
Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA.
RP Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Med, Div Cardiol, Gazes Cardiac Res Inst, 114 Doughty St,Rm 223 Gazes Strom Thurmond Res Bl, Charleston, SC 29425 USA.
EM bradshad@musc.edu
FU Research Service of the Department of Veterans Affairs; National
Institutes of Health [PO1-HL-48788, HL-094517, P20-RR-017696]
FX This study was supported by the Research Service of the Department of
Veterans Affairs (to M. R. Zile and A. D. Bradshaw) and National
Institutes of Health Grants PO1-HL-48788 (to M. R. Zile), HL-094517 (to
A. D. Bradshaw), and P20-RR-017696 (to A. D. Bradshaw).
NR 27
TC 17
Z9 17
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD JUL
PY 2012
VL 303
IS 2
BP H234
EP H240
DI 10.1152/ajpheart.00227.2012
PG 7
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA 974JD
UT WOS:000306429900011
PM 22610170
ER
PT J
AU Scheuner, MT
Hilborne, L
Brown, J
Lubin, IM
AF Scheuner, Maren T.
Hilborne, Lee
Brown, Julie
Lubin, Ira M.
CA RAND Mol Genetic Test Report Advis
TI A Report Template for Molecular Genetic Tests Designed to Improve
Communication Between the Clinician and Laboratory
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
ID CANCER-RISK; MEDICINE; GUIDELINES; PHYSICIANS; ERRORS; EXPERIENCE;
DISEASE; HEALTH
AB Aim: Errors are most likely to occur during the pre- and postanalytic phases of the genetic testing process, which can contribute to underuse, overuse, and misuse of genetic tests. To mitigate these errors, we created a template for molecular genetic test reports that utilizes the combined features of synoptic reporting and narrative interpretation. Methods: A variation of the Delphi consensus process with an expert panel was used to create a draft report template, which was further informed by focus group discussions with primary care physicians. Results: There was agreement that molecular genetic test reports should present information in groupings that flow in a logical manner, and most participants preferred the following order of presentation: patient and physician information, test performed, test results and interpretation, guidance on next steps, and supplemental information. We define data elements for the report as "required," "optional," "possible," and "not necessary"; provide recommendations regarding the grouping of these data elements; and describe the ideal design of the report template, including the preferred order of the report sections, formatting of data, and length of the report. Discussion: With input from key stakeholders and building upon prior work, we created a template for molecular genetic test reports designed to improve clinical decision making at the point of care. The template design should lead to more effective communication between the laboratory and ordering clinician. Studies are needed to assess the usefulness and effectiveness of molecular genetic test reports generated using this template.
C1 [Scheuner, Maren T.] Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA USA.
[Scheuner, Maren T.; Hilborne, Lee; Brown, Julie] RAND Corp, Santa Monica, CA USA.
[Scheuner, Maren T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Hilborne, Lee] Quest Diagnost, Canoga Pk, CA USA.
[Hilborne, Lee] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Lubin, Ira M.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA USA.
RP Scheuner, MT (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 500,Room 3218, Los Angeles, CA 90073 USA.
EM maren.scheuner@va.gov
OI Weck, Karen/0000-0002-8516-333X
NR 28
TC 14
Z9 15
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD JUL
PY 2012
VL 16
IS 7
BP 761
EP 769
DI 10.1089/gtmb.2011.0328
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 974ZB
UT WOS:000306475100021
PM 22731646
ER
PT J
AU Uomoto, JM
AF Uomoto, Jay M.
TI Best Practices in Veteran Traumatic Brain Injury Care Preface
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Editorial Material
ID POSTTRAUMATIC-STRESS-DISORDER
C1 US Dept Vet Affairs, Off Mental Hlth Serv, Washington, DC USA.
RP Uomoto, JM (reprint author), US Dept Vet Affairs, Off Mental Hlth Serv, Washington, DC USA.
NR 9
TC 1
Z9 1
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-9701
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD JUL-AUG
PY 2012
VL 27
IS 4
BP 241
EP 243
DI 10.1097/HTR.0b013e31825ee26a
PG 3
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 975PJ
UT WOS:000306523000001
PM 22767071
ER
PT J
AU Williams, RM
Bambara, J
Turner, AP
AF Williams, Rhonda M.
Bambara, Jennifer
Turner, Aaron P.
TI A Scoping Study of One-to-One Peer Mentorship Interventions and
Recommendations for Application With Veterans With Postdeployment
Syndrome
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Article
DE mutual support; OIF/OEF; peer mentorship; polytrauma; postdeployment
syndrome; Veterans
ID RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE;
SELF-EFFICACY; PROVIDED SERVICES; MENTORING PROGRAM; SUPPORT PROGRAM;
SOCIAL SUPPORT; BREAST-CANCER; CARE
AB Background: We employ the term postdeployment syndrome (PDS) to characterize the combinations of physical, psychological, and social difficulties frequently encountered by Veterans returning from combat. Objectives: To conduct a scoping review to identify and describe one-to-one peer mentorship (PM) interventions, identify elements associated with positive outcome and of relevance to Veterans with PDS, and summarize current practice in a way that informs the development of such interventions for this population. Methods: Scoping review methodology was used to identify and summarize key practices and concepts in the one-to-one PM literature between 1980 and 2012. Of 196 articles initially identified, 33 were retained for further examination. Eighteen met full-study criteria and were retained in the analyses. Three reviewers reached consensus on articles to include, and 2 coders independently extracted information from each article. Results: A range of populations was targeted in the interventions. Most identified the provision of support as the primary goal, although some also included other educational and behavioral goals. Most employed selection and training strategies for their mentors and offered ongoing supervision and consultation. Most studies indicated that participants found PM to be beneficial. Conclusions: This review supports the application in this population and proposes next steps for the development and systematic evaluation of PM interventions.
C1 [Williams, Rhonda M.] VA Puget Sound Hlth Care Syst, Dept Rehabil Med, Rehabil Care Serv, Seattle, WA 98108 USA.
[Williams, Rhonda M.; Turner, Aaron P.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Williams, RM (reprint author), VA Puget Sound Hlth Care Syst, Dept Rehabil Med, Rehabil Care Serv, S-117 RCS,1660 S Columbian Way, Seattle, WA 98108 USA.
EM Rhonda.Williams1@va.gov
OI Turner, Aaron/0000-0001-6897-8003
FU US Department of Veterans Affairs, Office of Research and Development,
Health Services Research and Development Polytrauma and Blast-Related
QUERI [07-289, 09-134]; Langeloth Foundation; US Department of Veterans
Affairs, Office of Research and Development, Rehabilitation Research and
Development [B4927W]
FX This material is based upon the work supported by the US Department of
Veterans Affairs, Office of Research and Development, Health Services
Research and Development Polytrauma and Blast-Related QUERI (RRP #
07-289 and RRP # 09-134; Dr Williams, PI), the Langeloth Foundation, and
by the US Department of Veterans Affairs, Office of Research and
Development, Rehabilitation Research and Development (Career Development
Award B4927W; Dr Turner, PI).
NR 53
TC 4
Z9 4
U1 5
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-9701
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD JUL-AUG
PY 2012
VL 27
IS 4
BP 261
EP 273
DI 10.1097/HTR.0b013e3182585cb6
PG 13
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 975PJ
UT WOS:000306523000004
PM 22767074
ER
PT J
AU Lyddon, R
Navarrett, S
Dracheva, S
AF Lyddon, Rebecca
Navarrett, Scott
Dracheva, Stella
TI Ionotropic glutamate receptor mRNA editing in the prefrontal cortex: no
alterations in schizophrenia or bipolar disorder
SO JOURNAL OF PSYCHIATRY & NEUROSCIENCE
LA English
DT Article
ID SEROTONIN 2C RECEPTOR; MOLECULAR DETERMINANT; KINETIC-PROPERTIES;
KAINATE RECEPTORS; 5-HT2C RECEPTOR; MOTOR-NEURONS; AMPA; EPILEPSY;
CHANNELS; GLUR2
AB Background: Dysfunction of glutamate neurotransmission has been implicated in the pathology of schizophrenia and bipolar disorder, and one mechanism by which glutamate signalling can be altered is through RNA editing of ionotropic glutamate receptors (iGluRs). The objectives of the present study were to evaluate the editing status of iGluRs in the human prefrontal cortex, determine whether iGluR editing is associated with psychiatric disease or suicide and evaluate a potential association between editing and alternative splicing in the a-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) iGluR subunits' pre-mRNA. Methods: We studied specimens derived from patients with antemortem diagnoses of bipolar disorder (n = 31) or schizophrenia (n = 34) who died by suicide or other causes, and from psychiatrically healthy controls (n = 34) who died from causes other than suicide. The RNA editing at all 8 editing sites within AMPA (GluA2-4 subunits) and kainate (GluK1-2 subunits) iGluRs was analyzed using a novel real-time quantitative polymerase chain reaction assay. Results: No differences in editing were detected among schizophrenia, bipolar or control groups or between suicide completers and patients who died from causes other than suicide. The editing efficiency was significantly higher in the flop than in the flip splicoforms of GluA3-4 AMPA subunits (all p < 0.001). Limitations: The study is limited by the near absence of specimens from medicationnaive psychiatric patients and considerable variation in medication regimens among individuals, both of which introduce considerable uncertainty into the analysis of potential medication effects. Conclusion: We found that iGluR RNA editing status was not associated with bipolar disorder, schizophrenia or suicide. Differences in editing between flip and flop splicoforms suggest that glutamate sensitivity of receptors containing GluA3 and/or GluA4 flop subunits is moderated as a result of increased editing.
C1 [Lyddon, Rebecca; Navarrett, Scott; Dracheva, Stella] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Navarrett, Scott; Dracheva, Stella] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
RP Dracheva, S (reprint author), Bronx VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Stella.Dracheva@mssm.edu
FU Department of Veterans Affairs (VA), Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; VA Merit award; NIMH/NIH [MH090352]; American Foundation
for Suicide Prevention; VISN3 Mental Illness Research and Education
Clinical Center; Stanley Medical Research Institute
FX This study was supported by the Department of Veterans Affairs (VA),
Veterans Health Administration, Office of Research and Development,
Biomedical Laboratory Research and Development, by a VA Merit award (S.
Dracheva), NIMH/NIH grant MH090352 (S. Dracheva), a grant from the
American Foundation for Suicide Prevention (S. Dracheva) and by the
VISN3 Mental Illness Research and Education Clinical Center (S.
Dracheva). Postmortem brain tissue was donated by The Stanley Medical
Research Institute.
NR 43
TC 5
Z9 5
U1 0
U2 2
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 1180-4882
J9 J PSYCHIATR NEUROSCI
JI J. Psychiatry Neurosci.
PD JUL
PY 2012
VL 37
IS 4
BP 267
EP 272
DI 10.1503/jpn.110107
PG 6
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 974LV
UT WOS:000306437800008
PM 22469055
ER
PT J
AU Fryer, SL
AF Fryer, Susanna L.
TI Another Step Forward in Relating Facial and Brain Dysmorphologies
Associated with Prenatal Alcohol Exposure
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
ID SPECTRUM DISORDERS; CORPUS-CALLOSUM; CHILDREN; ADULTS; FMRI
C1 Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Fryer, SL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, Psychiat Serv 116D,4150 Clement St, San Francisco, CA 94121 USA.
EM susanna.fryer@ucsf.edu
FU [T32MH089920]
FX This work was funded by T32MH089920.
NR 13
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUL
PY 2012
VL 36
IS 7
BP 1131
EP 1133
DI 10.1111/j.1530-0277.2012.01849.x
PG 3
WC Substance Abuse
SC Substance Abuse
GA 971QR
UT WOS:000306219400003
PM 22780985
ER
PT J
AU Carrillo, MC
Bain, LJ
Frisoni, GB
Weiner, MW
AF Carrillo, Maria C.
Bain, Lisa J.
Frisoni, Giovanni B.
Weiner, Michael W.
TI Worldwide Alzheimer's Disease Neuroimaging Initiative
SO ALZHEIMERS & DEMENTIA
LA English
DT Article
DE Alzheimer's disease; Neuroimaging; Biomarkers
ID ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE;
RECOMMENDATIONS; DISCOVERY; MILD
AB The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2003 to speed drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public private partnership, the first phase of ADNI (ADNI 1) set a new standard for data sharing without embargo. In addition, it has been extended to 2017 by additional funding (North American-ADNI Grand Opportunities and ADNI 2) as well as multiple projects around the world, collectively known as Worldwide ADNI (WW-ADNI). The goal of WW-ADNI is to harmonize projects and results across different geographical sites and to encourage and harmonize data management and availability to investigators around the world. WW-ADNI projects are currently underway in North America, Europe, Japan, Australia, Korea, Taiwan, and Argentina, with a nascent program in China and a possible future program in Brazil. (C) 2012 The Alzheimer's Association. All rights reserved.
C1 [Carrillo, Maria C.] Alzheimers Assoc, Med cfc Sci Relat, Chicago, IL USA.
[Frisoni, Giovanni B.] IRCCS, Ctr San Giovanni Dio Fatebenefratelli, Lab Neuroimaging, Brescia, Italy.
[Weiner, Michael W.] San Francisco VA Med Ctr, No Calif Inst Res, San Francisco, CA USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
RP Carrillo, MC (reprint author), Alzheimers Assoc, Med cfc Sci Relat, Chicago, IL USA.
EM Maria.Carrillo@alz.org
RI Frisoni, Giovanni B/K-1360-2016
OI Frisoni, Giovanni B/0000-0002-6419-1753
FU National Institute on Aging of the National Institutes of Health
[U01-AG024904]; Alzheimer's Association; PharmaCog from the European
Commission's Innovative Medicine Initiative [115009]; grant Programma
Strategico [RF07.39.2]; grant Programma Strategico 2007, conv. PS39
[RF07.39.2]
FX NA-ADNI was supported with a grant (U01-AG024904) from the National
Institute on Aging of the National Institutes of Health. The pilot
E-ADNI was funded by the Alzheimer's Association. E-ADNI is funded
through PharmaCog from the European Commission's Innovative Medicine
Initiative under grant agreement number 115009 (Prediction of cognitive
properties of new drug candidates for neurodegenerative diseases in
early clinical development, PharmaCog). Italian ADNI has been funded by
the grant Programma Strategico 2007 (RF07.39.2), conv. PS39.
NR 14
TC 43
Z9 44
U1 4
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUL
PY 2012
VL 8
IS 4
BP 337
EP 342
DI 10.1016/j.jalz.2012.04.007
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 973XW
UT WOS:000306394900010
PM 22748939
ER
PT J
AU Schopfer, DW
Whooley, MA
Stamos, TD
AF Schopfer, David W.
Whooley, Mary A.
Stamos, Thomas D.
TI Hospital compliance with performance measures and 30-day outcomes in
patients with heart failure
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID QUALITY-OF-CARE; OPTIMIZE-HF; MORTALITY; ASSOCIATION; SURVIVAL;
DEFIBRILLATOR; MORBIDITY; ENALAPRIL; PROGRAM; TRIAL
AB Background In 2005, the American College of Cardiology/American Heart Association published performance measures to provide a standard of care for hospitalized patients with heart failure ( HF). Despite increasing compliance with these measures, hospital mortality and readmission rates remain stagnant. Whether compliance with HF performance measures improves patient outcomes at the hospital level is unclear.
Methods We evaluated compliance with HF performance measures at 3,655 US hospitals. Patients admitted with a diagnosis of HF in 2008 were identified using the US Department of Health and Human Services Hospital Compare database. Compliance with 4 specific performance measures was examined: evaluation of left ventricular systolic function, administration of angiotensin-converting enzyme inhibitor I or angiotensin-receptor blocker for left ventricular systolic dysfunction, offering smoking cessation advice and counseling, and providing discharge instructions. Thirty-day mortality and readmission rate were recorded.
Results Hospitals reporting greater compliance with the 4 performance measures had significantly lower 30-day mortality rates. However, these hospitals were also located in areas of higher socioeconomic status and treated higher volumes of patients with HF. After adjusting for socioeconomic and hospital factors, only evaluation of left ventricular systolic function was associated with lower 30-day mortality, and evaluation of left ventricular systolic function and smoking cessation counseling were associated with lower readmission rates.
Conclusions We found that socioeconomic factors and hospital volume were stronger predictors of mortality than compliance with HF performance measures. After adjusting for socioeconomic factors and hospital volume, only 1 of the 4 performance measures was associated with lower 30-day mortality and 2 were associated with lower readmissions. (Am Heart J 2012;164:80-6.)
C1 [Schopfer, David W.; Stamos, Thomas D.] Univ Illinois, Coll Med, Cardiol Sect, Chicago, IL USA.
[Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Schopfer, DW (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM david.schopfer@ucsf.edu
NR 31
TC 4
Z9 4
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD JUL
PY 2012
VL 164
IS 1
BP 80
EP 86
DI 10.1016/j.ahj.2012.04.017
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 973NM
UT WOS:000306366900012
PM 22795286
ER
PT J
AU Ingraham, AM
Haas, B
Cohen, ME
Ko, CY
Nathens, AB
AF Ingraham, Angela M.
Haas, Barbara
Cohen, Mark E.
Ko, Clifford Y.
Nathens, Avery B.
TI Comparison of Hospital Performance in Trauma vs Emergency and Elective
General Surgery Implications for Acute Care Surgery Quality Improvement
SO ARCHIVES OF SURGERY
LA English
DT Article
ID SURGICAL CARE; RISK; MARKER
AB Hypotheses: As emergency general surgery (EMGS) and trauma care are increasingly being provided by the same personnel with overlapping resources, we postulated that the quality of care provided to EMGS and trauma patients would be similar. We also evaluated the relationship between trauma and elective general surgery (ELGS) care, believing that performance would be similar across these services as it reflects institutional culture.
Design: Retrospective cohort study comparing hospital performance in trauma and EMGS care and in trauma and ELGS care. Regression models for mortality and serious morbidity were constructed for trauma, EMGS, and ELGS hospitals contributing to both the National Trauma Data Bank (2007) and American College of Surgeons National Surgical Quality Improvement Program (2005-2008).
Setting: Forty - six hospitals.
Main Outcome Measures: Correlations of observed to expected ratios were examined. Outlier status (hospitals with CIs of observed to expected ratios excluding 1.0) was compared using weighted kappa.
Results: There was no significant relationship between trauma and EMGS mortality (r=-0.01, P=.94; kappa=-0.10, P=.61) or between trauma and ELGS mortality (r=0.23, P=.12; kappa=0.07, P=.62). There was no significant relationship between trauma and EMGS morbidity (r=0.21, P=.17; kappa=0.04, P=.63) or between trauma and ELGS morbidity (r=0.16, P=.30; kappa=0.11, P=.37). No hospitals were consistently low or high outliers across all 3 groups.
Conclusions: Trauma performance improvement programs are well established compared with those for EMGS. Although EMGS patients use similar structures and processes as trauma patients, there is a lack of correlation between the quality of care provided to trauma and EMGS patients; EMGS should be incorporated into trauma performance improvement programs.
C1 [Ingraham, Angela M.] Univ Cincinnati, Dept Surg, Coll Med, Cincinnati, OH 45267 USA.
[Ingraham, Angela M.; Cohen, Mark E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Haas, Barbara; Nathens, Avery B.] Inst St Michaels Hosp, Div Surg & Trauma, Keenan Res Ctr Li Ka Shing Knowledge, Toronto, ON, Canada.
[Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA.
RP Ingraham, AM (reprint author), Univ Cincinnati, Dept Surg, Coll Med, Mail Locat 0558,231 Albert Sabin Way,Room 1586, Cincinnati, OH 45267 USA.
EM angieingraham@gmail.com
FU Clinical Scholars in Residence Program at the ACS; Canadian Institutes
of Health Research; Canada Research Chair in Systems of Trauma Care
FX Dr Ingraham is supported by the Clinical Scholars in Residence Program
at the ACS. Dr Haas is supported by a Canadian Institutes of Health
Research fellowship. Dr Nathens is supported by a Canada Research Chair
in Systems of Trauma Care.
NR 20
TC 9
Z9 9
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD JUL
PY 2012
VL 147
IS 7
BP 591
EP 598
DI 10.1001/archsurg.2012.71
PG 8
WC Surgery
SC Surgery
GA 974GB
UT WOS:000306417900004
PM 22430094
ER
PT J
AU Maciejewski, ML
Livingston, EH
Smith, VA
Kahwati, LC
Henderson, WG
Arterburn, DE
AF Maciejewski, Matthew L.
Livingston, Edward H.
Smith, Valerie A.
Kahwati, Leila C.
Henderson, William G.
Arterburn, David E.
TI Health Expenditures Among High-Risk Patients After Gastric Bypass and
Matched Controls
SO ARCHIVES OF SURGERY
LA English
DT Article
ID MORBIDLY OBESE-PATIENTS; LONG-TERM MORTALITY; BARIATRIC SURGERY;
COST-EFFECTIVENESS; MEDICAL EXPENDITURES; PROPENSITY SCORE; SELECTION
BIAS; WEIGHT-LOSS; CARE COSTS; ADJUSTMENT
AB Objective: To determine whether bariatric surgery is associated with reduced health care expenditures in a multisite cohort of predominantly older male patients with a substantial disease burden.
Design: Retrospective cohort study of bariatric surgery. Outpatient, inpatient, and overall health care expenditures within Department of Veterans Affairs (VA) medical centers were examined via generalized estimating equations in the propensity-matched cohorts.
Setting: Bariatric surgery programs in VA medical centers.
Participants: Eight hundred forty-seven veterans who were propensity matched to 847 nonsurgical control subjects from the same 12 VA medical centers.
Intervention: Bariatric surgical procedures.
Main Outcome Measure: Health expenditures through December 2006.
Results: Outpatient, inpatient, and total expenditures trended higher for bariatric surgical cases in the 3 years leading up to the procedure and then converged back to the lower expenditure levels of nonsurgical controls in the 3 years after the procedure.
Conclusions: Based on analyses of a cohort of predominantly older men, bariatric surgery does not appear to be associated with reduced health care expenditures 3 years after the procedure.
C1 [Maciejewski, Matthew L.; Smith, Valerie A.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA.
[Maciejewski, Matthew L.] Duke Univ, Dept Med, Div Gen Internal Med, Durham, NC USA.
[Kahwati, Leila C.] Vet Hlth Adm, Natl Ctr Hlth Promot & Dis Prevent, Off Patient Care Serv, Durham, NC USA.
[Livingston, Edward H.] Univ Texas SW Med Ctr Dallas, Div Gastrointestinal & Endocrine Surg, Dallas, TX 75390 USA.
[Livingston, Edward H.] VA N Texas Hlth Care Syst, Dallas, TX USA.
[Livingston, Edward H.] Univ Texas Arlington, Biomed Engn Grad Program, Arlington, TX USA.
[Henderson, William G.] Denver VA Med Ctr, Denver, CO USA.
[Henderson, William G.] Univ Colorado, Dept Biostat, Sch Publ Hlth, Aurora, CO USA.
[Henderson, William G.] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA.
[Arterburn, David E.] Univ Washington, Grp Hlth Res Inst, Seattle, WA 98195 USA.
[Arterburn, David E.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA.
RP Maciejewski, ML (reprint author), Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Mail Stop 152,411 W Chapel Hill St,Ste 600, Durham, NC 27705 USA.
EM matthew.maciejewski@va.gov
FU Takeda Pharmaceuticals, Novartis; Surgical Review Corporation; Texas
Instruments; Office of Research and Development, Health Services
Research and Development Service, Department of Veterans Affairs [IIR
05-201, SHP 08-137]; Department of Veterans Affairs [RCS 10-391]
FX Dr Maciejewski has received consultation funds from Takeda
Pharmaceuticals, Novartis, and the Surgical Review Corporation and owns
stock in Amgen. Dr Livingston has received consulting funds from Texas
Instruments and serves as a contributing editor to JAMA. Dr Arterburn
receives research funding and has received salary support as a medical
editor for the not-for-profit (501[c][3]) Foundation for Informed
Medical Decision Making (http://www.fimdm.org), which develops content
for patient education programs. The Foundation has an arrangement with a
for-profit company, Health Dialog, to coproduce and market these
programs to health care organizations. Dr Arterburn was formerly with
the Cincinnati VA, and Dr Livingston was formerly with the Dallas VA.;
This study was supported by grants IIR 05-201 and SHP 08-137 from the
Office of Research and Development, Health Services Research and
Development Service, Department of Veterans Affairs, and by Research
Career Scientist award RCS 10-391 from the Department of Veterans
Affairs (Dr Maciejewski).
NR 37
TC 26
Z9 26
U1 5
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD JUL
PY 2012
VL 147
IS 7
BP 633
EP 640
PG 8
WC Surgery
SC Surgery
GA 974GB
UT WOS:000306417900014
PM 22802057
ER
PT J
AU Marshall, DT
Savage, SJ
Garrett-Mayer, E
Keane, TE
Hollis, BW
Horst, RL
Ambrose, LH
Kindy, MS
Gattoni-Celli, S
AF Marshall, David T.
Savage, Stephen J.
Garrett-Mayer, Elizabeth
Keane, Thomas E.
Hollis, Bruce W.
Horst, Ronald L.
Ambrose, Linda H.
Kindy, Mark S.
Gattoni-Celli, Sebastiano
TI Vitamin D-3 Supplementation at 4000 International Units Per Day for One
Year Results in a Decrease of Positive Cores at Repeat Biopsy in
Subjects with Low-Risk Prostate Cancer under Active Surveillance
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID CONSERVATIVE MANAGEMENT; SOLAR-RADIATION; LEUKEMIA-CELLS; DOUBLE-BLIND;
LNCAP CELLS; MORTALITY; TRIAL; APOPTOSIS; CALCIUM; WOMEN
AB Context: We wanted to investigate vitamin D in low-risk prostate cancer.
Objectives: The objective of the study was to determine whether vitamin D-3 supplementation at 4000 IU/d for 1 yr is safe and would result in a decrease in serum levels of prostate-specific antigen (PSA) or in the rate of progression.
Design: In this open-label clinical trial (Investigational New Drug 77,839), subjects were followed up until repeat biopsy.
Setting: All subjects were enrolled through the Medical University of South Carolina and the Ralph H. Johnson Veterans Affairs Medical Center, both in Charleston, SC.
Patients and Other Participants: All subjects had a diagnosis of low-risk prostate cancer. Fifty-two subjects were enrolled in the study, 48 completed 1 yr of supplementation, and 44 could be analyzed for both safety and efficacy objectives.
Intervention: The intervention included vitamin D-3 soft gels (4000 IU).
Main Outcome Measures: Adverse events were monitored throughout the study. PSA serum levels were measured at entry and every 2 months for 1 yr. Biopsy procedures were performed before enrollment (for eligibility) and after 1 yr of supplementation.
Results: No adverse events associated with vitamin D-3 supplementation were observed. No significant changes in PSA levels were observed. However, 24 of 44 subjects (55%) showed a decrease in the number of positive cores or decrease in Gleason score; five subjects (11%) showed no change; 15 subjects (34%) showed an increase in the number of positive cores or Gleason score.
Conclusion: Patients with low-risk prostate cancer under active surveillance may benefit from vitamin D-3 supplementation at 4000 IU/d. (J Clin Endocrinol Metab 97: 2315-2324, 2012)
C1 [Marshall, David T.; Ambrose, Linda H.; Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA.
[Savage, Stephen J.; Keane, Thomas E.] Med Univ S Carolina, Dept Urol, Charleston, SC 29425 USA.
[Garrett-Mayer, Elizabeth] Med Univ S Carolina, Dept Med Biostat, Charleston, SC 29425 USA.
[Hollis, Bruce W.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Kindy, Mark S.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Savage, Stephen J.; Kindy, Mark S.; Gattoni-Celli, Sebastiano] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
[Horst, Ronald L.] Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.
RP Gattoni-Celli, S (reprint author), Strom Thurmond Biomed Res Bldg,Room 338C,114 Doug, Charleston, SC 29403 USA.
EM gattonis@musc.edu
FU Gateway for Cancer Research Grant [G-06-068]; Health Services Research
and Development Program of the Department of Veterans Affairs, Veterans
Affairs Merit Award [CX000163]; Biostatistics Shared Resource, Hollings
Cancer Center's Support Grant [P30 CA138313]; National Institutes of
Health/National Center for Research Resources [UL1 RR029881]; South
Carolina Clinical and Translational Research Institute [UL1 RR029882]
FX This work was supported in part by Gateway for Cancer Research Grant
G-06-068), the Health Services Research and Development Program of the
Department of Veterans Affairs, Veterans Affairs Merit Award CX000163,
the Biostatistics Shared Resource, Hollings Cancer Center's Support
Grant P30 CA138313 (National Institutes of Health/National Center for
Research Resources Grant UL1 RR029881), and South Carolina Clinical and
Translational Research Institute Grant UL1 RR029882.
NR 40
TC 38
Z9 38
U1 0
U2 0
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2012
VL 97
IS 7
BP 2315
EP 2324
DI 10.1210/jc.2012-1451
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 972OJ
UT WOS:000306286100054
PM 22508710
ER
PT J
AU Ingram, KH
Hill, H
Moellering, DR
Hill, BG
Lara-Castro, C
Newcomer, B
Brandon, LJ
Ingalls, CP
Penumetcha, M
Rupp, JC
Garvey, WT
AF Ingram, Katherine H.
Hill, Helliner
Moellering, Douglas R.
Hill, Bradford G.
Lara-Castro, Cristina
Newcomer, Bradley
Brandon, L. Jerome
Ingalls, Christopher P.
Penumetcha, Meera
Rupp, Jeffrey C.
Garvey, W. Timothy
TI Skeletal Muscle Lipid Peroxidation and Insulin Resistance in Humans
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID OXIDATIVE STRESS; BIOMARKERS; ALDEHYDES; EXERCISE; OBESITY; DISEASE;
PLASMA
AB Objective: The relationships among skeletal muscle lipid peroxidation, intramyocellular lipid content (IMCL), and insulin sensitivity were evaluated in nine insulin-sensitive (IS), 13 insulin-resistant (IR), and 10 adults with type 2 diabetes (T2DM).
Design: Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp [ glucose disposal rate (GDR)]. Lipid peroxidation was assessed by 4-hydroxynonenal (HNE)-protein adducts and general oxidative stress by protein carbonyl content. All patients were sedentary.
Results: Protein-HNE adducts were elevated 1.6-fold in T2DM compared with IS adults, whereas IR showed intermediate levels of HNE-modified proteins. Protein-HNE adducts correlated with GDR, waist circumference, and body mass index. IMCL was increased by 4.0- and 1.9-fold in T2DM and IR patients, respectively, compared with IS, and was correlated with GDR and waist circumference but not BMI. Protein carbonyls were not different among groups and did not correlate with any of the measured variables. Correlations were detected between IMCL and protein-HNE.
Conclusion: Our data show for the first time that skeletal muscle protein-HNE adducts are related to the severity of insulin resistance in sedentary adults. These results suggest that muscle lipid peroxidation could be involved in the development of insulin resistance. (J Clin Endocrinol Metab 97: E1182-E1186, 2012)
C1 [Ingram, Katherine H.; Moellering, Douglas R.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Newcomer, Bradley] Univ Alabama Birmingham, Dept Clin & Diagnost Sci, Birmingham, AL 35294 USA.
[Hill, Helliner] Novo Nordisk, Dept Field Med Affairs, Div Diabet, Princeton, NJ 08540 USA.
[Hill, Bradford G.] Univ Louisville, Inst Mol Cardiol, Louisville, KY 40202 USA.
[Lara-Castro, Cristina] Univ S Carolina, Sch Med, Dept Internal Med, Columbia, SC 29208 USA.
[Brandon, L. Jerome; Ingalls, Christopher P.] Georgia State Univ, Dept Kinesiol & Hlth, Atlanta, GA 30302 USA.
[Rupp, Jeffrey C.] Life Univ, Marietta, GA 30060 USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
[Penumetcha, Meera] Georgia State Univ, Dept Nutr, Atlanta, GA 30302 USA.
RP Ingram, KH (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 232 Webb Nutr Sci Bldg,1675 Univ Blvd, Birmingham, AL 35294 USA.
EM khingram@uab.edu
RI Hill, Bradford/F-9228-2011; Hill, Bradford/I-4154-2013
OI Hill, Bradford/0000-0001-5332-8286
FU National Institutes of Health [DK-038765, DK-083562, PO1 HL-55782]; T32
Training Grant "UAB Obesity Training Program" [HL-079888]; Department of
Veterans Affairs; Gatorade Sports Science Institute; UAB Center for
Clinical and Translational Science [UL1 RR025777]; Nutrition and Obesity
Research Center [P30 DK56336]; Diabetes Research and Training Center
[P60 DK079626]
FX This work was supported by Grants DK-038765, DK-083562, and PO1 HL-55782
from the National Institutes of Health; T32 Training Grant (HL-079888)
entitled "UAB Obesity Training Program"; the Merit Review program of the
Department of Veterans Affairs; and the Gatorade Sports Science
Institute (dissertation grant). We also acknowledge support from the UAB
Center for Clinical and Translational Science (Grant UL1 RR025777), the
Nutrition and Obesity Research Center (Grant P30 DK56336), and the
Diabetes Research and Training Center (Grant P60 DK079626).
NR 19
TC 14
Z9 15
U1 0
U2 7
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2012
VL 97
IS 7
BP E1182
EP E1186
DI 10.1210/jc.2011-2963
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 972OJ
UT WOS:000306286100013
PM 22496506
ER
PT J
AU Dixon, CE
Yan, HQ
Jenkins, LW
Ma, XC
Li, YM
Shin, SS
Dixon, CE
AF Dixon, C. Edward
Yan, Hong Q.
Jenkins, Larry W.
Ma, Xiecheng
Li, Youming
Shin, Samuel S.
Dixon, C. Edward
TI THE EFFECTS OF TBI ON HIPPOCAMPAL SNARE-COMPLEX ASSEMBLY AND ATTENUATION
BY CHRONIC LITHIUM THERAPY
SO JOURNAL OF NEUROTRAUMA
LA English
DT Meeting Abstract
CT 30th Annual National Neurotrauma Symposium
CY JUL 22-25, 2012
CL Phoenix, AZ
DE TBI; vesicles; lithium; hippocampus
C1 [Shin, Samuel S.] Univ Pittsburgh, Sch Med, Ctr Neurosci & Neurosurg, Pittsburgh, PA 15260 USA.
[Dixon, C. Edward] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUL
PY 2012
VL 29
IS 10
BP A22
EP A23
PG 2
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA 971YV
UT WOS:000306244400034
ER
PT J
AU Crittenden, DB
Lehmann, RA
Schneck, L
Keenan, RT
Shah, B
Greenberg, JD
Cronstein, BN
Sedlis, SP
Pillinger, MH
AF Crittenden, Daria B.
Lehmann, R. Aaron
Schneck, Laura
Keenan, Robert T.
Shah, Binita
Greenberg, Jeffrey D.
Cronstein, Bruce N.
Sedlis, Steven P.
Pillinger, Michael H.
TI Colchicine Use Is Associated with Decreased Prevalence of Myocardial
Infarction in Patients with Gout
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE GOUT; COLCHICINE; MYOCARDIAL INFARCTION; MORTALITY; C-REACTIVE PROTEIN
ID C-REACTIVE PROTEIN; FAMILIAL MEDITERRANEAN FEVER;
CORONARY-ARTERY-DISEASE; ENDOTHELIAL-CELLS; HUMAN LEUKOCYTES; ORAL
COLCHICINE; T-LYMPHOCYTES; L-SELECTIN; INFLAMMATION; ATHEROSCLEROSIS
AB Objective. The ability of antiinflammatory strategies to alter cardiovascular risk has not been rigorously examined. Colchicine is an antiinflammatory agent that affects macrophages, neutrophils, and endothelial cells, all of which are implicated in the pathogenesis of cardiovascular disease. We examined whether colchicine use was associated with a reduced risk of myocardial infarction (MI) in patients with gout.
Methods. We conducted a retrospective, cross-sectional study of all patients with an International Classification of Diseases, 9th ed, code for gout in the electronic medical record (EMR) of the New York Harbor Healthcare System Veterans Affairs network and 1 hospital visit between August 2007 and August 2008. Hospital pharmacy data were used to identify patients who had filled at least 1 colchicine prescription versus those who had not. Demographics and CV comorbidities were collected by EMR review. The primary outcome was diagnosis of MI. Secondary outcomes included all-cause mortality and C-reactive protein (CRP) level.
Results. In total. 1288 gout patients were identified. Colchicine (n = 576) and no colchicine (n = 712) groups had similar baseline demographics and serum urate levels. Prevalence of MI was 1.2% in the colchicine versus 2.6% in the no-colchicine group (p = 0.03). Colchicine users also had fewer deaths and lower CRP levels, although these did not achieve statistical significance. Colchicine effects persisted when allopurinol users were excluded from the analysis.
Conclusion. In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take colchicine. (First Release June 1 2012; J Rheumatol 2012;39:1458-64; doi:10.3899/jrheum.111533)
C1 NYU, Div Rheumatol, Crystal Dis Study Grp, Sch Med, New York, NY 10003 USA.
NYU, Div Cardiol, Sch Med, New York, NY 10003 USA.
US Dept Vet Affairs, Dept Med, New York Harbor Healthcare Syst, New York, NY USA.
Duke Univ, Med Ctr, Div Rheumatol, Durham, NC USA.
[Shah, Binita; Greenberg, Jeffrey D.; Cronstein, Bruce N.] NYU, Clin & Translat Sci Inst, Sch Med, New York, NY 10003 USA.
RP Crittenden, DB (reprint author), NYU, Hosp Joint Dis, Div Rheumatol, 301 E 17th St,Room 1410, New York, NY 10003 USA.
EM daria.crittenden@nyumc.org
OI Sedlis, Steven/0000-0002-8194-8017; Pillinger,
Michael/0000-0003-3168-1542
FU US National Institutes of Health [5T32AR007176]
FX Drs. Keenan and Lehmann were supported by US National Institutes of
Health T32 training grant 5T32AR007176.
NR 59
TC 44
Z9 45
U1 0
U2 8
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUL
PY 2012
VL 39
IS 7
BP 1458
EP 1464
DI 10.3899/jrheum.111533
PG 7
WC Rheumatology
SC Rheumatology
GA 973VQ
UT WOS:000306388300024
PM 22660810
ER
PT J
AU Shastri, S
Katz, R
Rifkin, DE
Fried, LF
Odden, MC
Peralta, CA
Chonchol, M
Siscovick, D
Shlipak, MG
Newman, AB
Sarnak, MJ
AF Shastri, Shani
Katz, Ronit
Rifkin, Dena E.
Fried, Linda F.
Odden, Michelle C.
Peralta, Carmen A.
Chonchol, Michel
Siscovick, David
Shlipak, Michael G.
Newman, Anne B.
Sarnak, Mark J.
TI Kidney Function and Mortality in Octogenarians: Cardiovascular Health
Study All Stars
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE octogenarians; kidney function; mortality
ID SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; OLDER-ADULTS; ELDERLY
PERSONS; HEART-FAILURE; RISK-FACTOR; DISEASE; PREVALENCE; CREATININE;
OUTCOMES
AB Objectives To examine the association between kidney function and all-cause mortality in octogenarians. Design Retrospective analysis of prospectively collected data. Setting Community. Participants Serum creatinine and cystatin C were measured in 1,053 Cardiovascular Health Study (CHS) All Stars participants. Measurements Estimated glomerular filtration rate (eGFR) was determined using the Chronic Kidney Disease Epidemiology Collaboration creatinine (eGFRCR) and cystatin C one-variable (eGFRCYS) equations. The association between quintiles of kidney function and all-cause mortality was analyzed using unadjusted and adjusted Cox proportional hazards models. Results Mean age of the participants was 85, 64% were female, 66% had hypertension, 14% had diabetes mellitus, and 39% had prevalent cardiovascular disease. There were 154 deaths over a median follow-up of 2.6 years. The association between eGFRCR and all-cause mortality was U-shaped. In comparison with the reference quintile (6475 mL/min per 1.73 m2), the highest (=75 mL/min per 1.73 m2) and lowest (=43 mL/min per 1.73 m2) quintiles of eGFRCR were independently associated with mortality (hazard ratio (HR) = 2.49, 95% confidence interval (CI) = 1.364.55; HR = 2.28, 95% CI = 1.264.10, respectively). The association between eGFRCYS and all-cause mortality was linear in those with eGFRCYS of less than 60 mL/min per 1.73 m2, and in the multivariate analyses, the lowest quintile of eGFRCYS (<52 mL/min per 1.73 m2) was significantly associated with mortality (HR = 2.04, 95% CI = 1.123.71) compared with the highest quintile (>0.88 mL/min per 1.73 m2). Conclusion Moderate reduction in kidney function is a risk factor for all-cause mortality in octogenarians. The association between eGFRCR and all-cause mortality differed from that observed with eGFRCYS; the relationship was U-shaped for eGFRCR, whereas the risk was primarily present in the lowest quintile for eGFRCYS.
C1 [Shastri, Shani] Univ Texas SW, Div Nephrol, Dallas, TX USA.
[Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Rifkin, Dena E.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA.
[Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA.
[Odden, Michelle C.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Dept Epidemiol, Corvallis, OR 97331 USA.
[Peralta, Carmen A.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA.
[Siscovick, David] Univ Washington, Dept Med & Epidemiol, Seattle, WA 98195 USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Newman, Anne B.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Dept Epidemiol, Pittsburgh, PA USA.
[Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA.
RP Shastri, S (reprint author), UT SW, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Shani.Shastri@UTSouthwestern.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU National Institute on Aging (NIA) [AG-023629]; National Heart, Lung, and
Blood Institute (NHLBI) [N01-HC-85239, N01-HC-85079, N01-HC-85086,
N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133];
NHLBI [HL080295]; Department of Veterans Affairs, Veterans Integrated
Service Network 4 from the National Heart, Lung and Blood Institute [R01
HL-075366]; University of Pittsburgh Claude. D. Pepper Older Americans
Independence Center [P30-AG-024827]; [K24 DK078204]
FX The research reported in this article was supported by National
Institute on Aging (NIA) Grant AG-023629. CHS was supported by National
Heart, Lung, and Blood Institute (NHLBI) Contracts N01-HC-85239,
N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01
HC-55222, N01-HC-75150, and N01-HC-45133 and NHLBI Grant HL080295, with
additional contribution from the National Institute of Neurological
Disorders and Stroke. Additional support was provided through AG-023629,
AG-15928, AG-20098, and AG-027058 from the NIA. A full list of principal
CHS investigators and institutions can be found at
http://www.chsnhlbi.org/pi.htm. This material is also based on work
supported in part by the Department of Veterans Affairs, Veterans
Integrated Service Network 4, R01 HL-075366 from the National Heart,
Lung and Blood Institute, and the University of Pittsburgh Claude. D.
Pepper Older Americans Independence Center P30-AG-024827. Dr. Sarnak is
supported by K24 DK078204.
NR 27
TC 19
Z9 19
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2012
VL 60
IS 7
BP 1201
EP 1207
DI 10.1111/j.1532-5415.2012.04046.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 972WJ
UT WOS:000306311600001
PM 22724391
ER
PT J
AU Gellad, WF
Good, CB
Amuan, ME
Marcum, ZA
Hanlon, JT
Pugh, MJV
AF Gellad, Walid F.
Good, Chester B.
Amuan, Megan E.
Marcum, Zachary A.
Hanlon, Joseph T.
Pugh, Mary Jo V.
TI Facility-Level Variation in Potentially Inappropriate Prescribing for
Older Veterans
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE potentially inappropriate prescribing; HEDIS measures; quality of care;
pharmacoepidemiology
ID ADVERSE DRUG-REACTIONS; RISK-ADJUSTED MORTALITY; MEDICATION USE; BEERS
CRITERIA; EXPLICIT CRITERIA; ELDERLY PEOPLE; ADULTS; OUTCOMES; QUALITY;
CARE
AB Objectives To describe facility-level variation in two measures of potentially inappropriate prescribing prevalent in Veterans Affairs (VA) facilitiesexposure to high-risk medications in elderly adults (HRME) and drugdisease interactions (Rx-DIS)and to identify facility characteristics associated with high-quality prescribing. Design Cross-sectional. Setting VA Healthcare System. Participants Veterans aged 65 and older with at least one inpatient or outpatient visit in 20052006 (N = 2,023,477; HRME exposure) and a subsample with a history of falls or hip fractures, dementia, or chronic renal failure (n = 305,059; Rx-DIS exposure). Measurements Incident use of any HRME (iHRME) and incident Rx-DIS (iRx-DIS) and facility-level rates and facility-level predictors of iHRME and iRx-DIS exposure, adjusting for differences in patient characteristics. Results Overall, 94,692 (4.7%) veterans had iHRME exposure. At the facility level, iHRME exposure ranged from 1.6% at the lowest facility to 12.8% at the highest (median 4.7%). In the subsample, 9,803 (3.2%) veterans had iRx-DIS exposure, with a facility-level range from 1.3% to 5.8% (median 3.2%). In adjusted analyses, veterans seen in facilities with formal geriatric education had lower odds of iHRME (odds ratio (OR) = 0.86, 95% confidence interval (CI) = 0.770.96) and iRx-DIS (OR = 0.95, 95% CI = 0.881.01). Patients seen in facilities caring for fewer older veterans had greater odds of iHRME (OR = 1.54, 95% CI = 1.351.75) and iRx-DIS exposure (OR = 1.22, 95% CI = 1.111.33). Conclusion Substantial variation in the quality of prescribing for older adults exists across VA facilities, even after adjusting for patient characteristics. Higher-quality prescribing is found in facilities caring for a larger number of older veterans and facilities with formal geriatric education.
C1 [Gellad, Walid F.; Good, Chester B.; Hanlon, Joseph T.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Gellad, Walid F.; Good, Chester B.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA USA.
[Gellad, Walid F.; Hanlon, Joseph T.] Univ Pittsburgh, Div Geriatr Pharmaceut, Pittsburgh, PA USA.
[Gellad, Walid F.; Hanlon, Joseph T.] Univ Pittsburgh, Geroinformat Res & Training Program, Pittsburgh, PA USA.
[Gellad, Walid F.] RAND Corp, Pittsburgh, PA USA.
[Good, Chester B.] Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA.
[Amuan, Megan E.] Edith Nourse Rogers Mem Vet Hosp, Vet Affairs Ctr Hlth Qual, Bedford, MA USA.
[Marcum, Zachary A.; Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Pittsburgh Vet Affairs, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Pugh, Mary Jo V.] S Texas Vet Healthcare Syst, Vet Evidence Based Res Disseminat & Implementat C, Res Enhancement Award Program, San Antonio, TX USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
[Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78229 USA.
RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM walid.gellad@va.gov
OI Pugh, Mary Jo/0000-0003-4196-7763
FU VA Career Development Award CDA [09-207]; VA Health Services Research
and Development Grant [IIR 06-062]; National Institute on Aging
[P30AG024827, T32 AG021885, K07AG033174, R01AG034056, R56AG027017];
National Institute of Nursing Research [R01 NR010135]; Agency for
Healthcare Research and Quality [R01 HS017695, R01 HS018721, K12
HS019461]; VA HSRD DHI [09-237]; VA HSRD [IIR-06-062, SDR-07-042,
IIR-05-121, IAF-06-080, IIR-09-335, SHP 08-140, TRX 01-091]; VA HSR D
IIR [08-274]; Department of Defense CDMRP [09090014]; National
Institutes of Health [R01-NR010828]; Kelsey Seybold Research Foundation
FX Conflict of Interest: All authors are employed by the VA. This study was
supported by VA Career Development Award CDA 09-207 and a VA Health
Services Research and Development Grant (IIR 06-062); National Institute
on Aging Grants P30AG024827, T32 AG021885, K07AG033174, R01AG034056, and
R56AG027017; National Institute of Nursing Research Grant R01 NR010135;
and Agency for Healthcare Research and Quality Grants R01 HS017695, R01
HS018721, and K12 HS019461. Dr. Pugh has received research funding from
VA HSR&D DHI 09-237 (PI); VA HSR&D IIR-06-062 PI, Epilepsy Foundation
PI, VA HSR&D PPO 09-295 PI, VA HSR&D IIR 02-274 PI. Pugh as co-I: VA
HSR&D IIR 08-274, VA HSR&D SDR-07-042, IIR-05-121, IAF-06-080,
IIR-09-335, SHP 08-140, TRX 01-091 Department of Defense CDMRP 09090014,
National Institutes of Health R01-NR010828, Pugh Speaker Honoraria: 2009
Kelsey Seybold Research Foundation $ 400.
NR 42
TC 11
Z9 11
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2012
VL 60
IS 7
BP 1222
EP 1229
DI 10.1111/j.1532-5415.2012.04042.x
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 972WJ
UT WOS:000306311600004
PM 22726206
ER
PT J
AU Spira, AP
Covinsky, K
Rebok, GW
Stone, KL
Redline, S
Yaffe, K
AF Spira, Adam P.
Covinsky, Kenneth
Rebok, George W.
Stone, Katie L.
Redline, Susan
Yaffe, Kristine
TI Objectively Measured Sleep Quality and Nursing Home Placement in Older
Women
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE sleep; actigraphy; nursing home; placement; women
ID ELDERLY PERSONS; DEPRESSION; INFLAMMATION; VARIABILITY; DURATION;
DISEASE
AB Objectives To determine the association between objectively measured sleep and subsequent placement in a nursing home or a personal care home. Design Prospective cohort. Setting Participants' homes and sites of the Study of Osteoporotic Fractures. Participants One thousand six hundred sixty-four community-dwelling women with a mean age of 83 +/- 4. Measurements At baseline, participants completed an average of 4 nights of wrist actigraphy; they provided data on place of residence at baseline and at follow-up, 5 years later. Results At baseline, participants had a mean total sleep time of 408 +/- 72 minutes, mean wake after sleep onset of 71 +/- 43 minutes, and mean sleep efficiency of 79 +/- 11%. At follow-up, 71 (4%) were residing in a nursing home, and 127 (8%) were in a personal care home. Women with the most wake after sleep onset (by quartile) had more than twice the odds as those with the least of placement in a nursing home (adjusted odds ratio (AOR) = 2.94, 95% confidence interval (CI) = 1.346.44) or a personal care home (AOR = 2.33, 95% CI = 1.264.30). Similarly, women with the lowest sleep efficiency had more than three times the odds as those with the highest of nursing home placement (AOR = 3.25, 95% CI = 1.35, 7.82) and more than twice the odds of placement in a personal care home (AOR = 2.38, 95% CI = 1.33, 4.24). There was no association between sleep duration and placement. Conclusion In very old community-dwelling women, greater wake after sleep onset and lower sleep efficiency are risk factors for placement in a nursing home or personal care home. Sleep duration alone does not appear to increase the risk of placement in these long-term care settings.
C1 [Spira, Adam P.; Rebok, George W.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Covinsky, Kenneth] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
[Covinsky, Kenneth] San Francisco VA Med Ctr, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Stone, Katie L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Redline, Susan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Sleep Med, Boston, MA USA.
[Redline, Susan] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA.
RP Spira, AP (reprint author), 624 N Broadway,Hampton House,Rm 794, Baltimore, MD 21205 USA.
EM aspira@jhsph.edu
FU National Institutes of Health (NIH) [R01 AG005407, R01 AR35582, R01
AR35583, R01 AR35584, R01 AG026720, R01 AG027574, R01 AG027576, R01
AG005394]; Alzheimer's Association [IIRG-08-88872]; National Institute
on Aging (NIA) [K01AG033195, K24AG031155]; NIH, National Heart, Lung,
and Blood Institute; ResMed Foundation; NIH; National Institute of
Mental Health; National Institute of Diabetes and Digestive and Kidney
Diseases; Department of Defense; Department of Veterans Affairs;
Alzheimer's Association
FX Conflict of Interest: Supported by National Institutes of Health (NIH)
Grants R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01
AG026720, R01 AG027574, R01 AG027576, and R01 AG005394 and Alzheimer's
Association Award IIRG-08-88872. Dr. Spira is supported by Mentored
Research Scientist Development Award K01AG033195 from the National
Institute on Aging (NIA). Dr. Yaffe is partially supported by Midcareer
Investigator Award in Patient-Oriented Research K24AG031155 from the
NIA. Dr. Spira received honoraria while serving as a clinical editor for
the International Journal of Sleep and Wakefulness-Primary Care, which
receives pharmaceutical company support, and from a private sleep
medicine practice for a continuing education presentation on adverse
outcomes of late-life sleep disturbance. Drs. Covinsky and Rebok are
supported by grants from the National Institute on Aging. Dr. Redline is
supported by grants from the NIH, National Heart, Lung, and Blood
Institute and has received a subcontract from California Pacific Medical
Center for work on this study. She also has received a research grant
from ResMed Foundation to support ancillary data collection for an
NIHfunded clinical trial. She is a member of the Board of Directors for
the American Academy of Sleep Medicine and is the first incumbent of an
endowed professorship donated to the Harvard Medical School by Dr. Peter
Farrell, the founder and Board Chairman of ResMed, through a charitable
remainder trust instrument, with annual support equivalent to the
endowment payout provided to the Harvard Medical School during Dr.
Farrell's lifetime by the ResMed Company through an irrevocable gift
agreement. Dr. Stone reports that NIH funding has been obtained for this
work. Dr. Yaffe has received grants from the NIA, National Institute of
Mental Health, National Institute of Diabetes and Digestive and Kidney
Diseases, Department of Defense, Department of Veterans Affairs, the
Alzheimer's Association, and an anonymous donor. She has served on data
safety monitoring bards for Pfizer and Medivation, and received
honoraria from Novartis as an advisory board member. She is a member of
the boards of the Beeson Program; National Institute of Mental Health;
and National Heart, Lung, and Blood Institute.
NR 22
TC 11
Z9 11
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2012
VL 60
IS 7
BP 1237
EP 1243
DI 10.1111/j.1532-5415.2012.04044.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 972WJ
UT WOS:000306311600006
PM 22702839
ER
PT J
AU Holmes, HM
Luo, R
Hanlon, JT
Elting, LS
Suarez-Almazor, M
Goodwin, JS
AF Holmes, Holly M.
Luo, Ruili
Hanlon, Joseph T.
Elting, Linda S.
Suarez-Almazor, Maria
Goodwin, James S.
TI Ethnic Disparities in Adherence to Antihypertensive Medications of
Medicare Part D Beneficiaries
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE medication adherence; ethnic disparities; Medicare Part D
ID D PROGRAMS; NONADHERENCE; IMPACT; PREDICTORS; DIAGNOSIS; SURVIVAL;
OUTCOMES; BENEFIT; BREAST; CANCER
AB Objectives To determine the level of adherence to medications and characteristics of Part D beneficiaries associated with higher levels of antihypertensive medication adherence. Design Retrospective cohort study. Setting Medicare claims and Part D event files. Participants Medicare Part D enrollees with prevalent uncomplicated hypertension who filled at least one antihypertensive prescription in 2006 and two prescriptions in 2007. Measurements Medication adherence was defined as an average medication possession ratio of 80% or greater. Potential factors associated with adherence evaluated were age, sex, race or ethnicity, socioeconomic factors, comorbidity, medication use, copayments, being in the coverage gap, and number of unique prescribers. Results Overall adherence was 79.5% of 168,522 Medicare Part D enrollees with prevalent uncomplicated hypertension receiving antihypertensive medicines in 2007. In univariate analysis, adherence varied significantly according to most patient factors. In multivariable analysis, lower odds of adherence persisted for blacks (odds ratio (OR) = 0.53, 95% confidence interval (CI) = 0.510.55), Hispanics (OR = 0.58, 95% CI = 0.550.61), and other non-white races (OR = 0.80 95% CI = 0.750.85) than for whites. Greater comorbidity and concurrent medication use were also associated with poorer adherence. Adherence was significantly different across several geographic regions. Conclusion A number of associations were identified between patient factors and adherence to antihypertensive drugs, with significant differences in adherence according to ethnicity. Improving adherence could have significant public health implications and could improve outcomes specific to hypertension, as well as improving cost and healthcare utilization.
C1 [Holmes, Holly M.; Luo, Ruili; Suarez-Almazor, Maria] UT MD Anderson Canc Ctr, Dept Gen Internal Med, Houston, TX 77030 USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Div Geriatr Med, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Div Geriatr Med, Pittsburgh, PA 15261 USA.
[Hanlon, Joseph T.] Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Elting, Linda S.] UT MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
[Goodwin, James S.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA.
[Goodwin, James S.] Univ Texas Med Branch, Sealy Ctr Aging, Galveston, TX USA.
RP Holmes, HM (reprint author), UT MD Anderson Canc Ctr, Dept Gen Internal Med, 1515 Holcombe Blvd,Unit 1465, Houston, TX 77030 USA.
EM hholmes@mdanderson.org
FU Hartford Geriatrics Health Outcomes Research Scholars Award; National
Institute on Aging [K23AG038476, R56AG 0207017, P30AG024827, T32
AG021885, K07AG033174, R01AG034056, 3U01 AG012553]; National Institute
of Mental Health [R34 MH082682]; National Institute of Nursing Research
[R01 NR010135]; Agency for Healthcare Research and Quality [R01
HS017695, K12 HS019461, R01HS018721]; Veterans Affairs Health Services
Research [IIR-06062]; National Institute of Arthritis and
Musculoskeletal and Skin Diseases [K24 AR053593]; Cancer Prevention and
Research Institute of Texas [RP 101207]; National Cancer Institute [K05
CA134923]
FX Conflict of Interest: Dr. Holmes was supported by a Hartford Geriatrics
Health Outcomes Research Scholars Award and by a grant from the National
Institute on Aging (K23AG038476). Dr. Hanlon was supported in part by
National Institute on Aging grants and contracts (R56AG 0207017,
P30AG024827, T32 AG021885, K07AG033174, R01AG034056, 3U01 AG012553), a
National Institute of Mental Health grant (R34 MH082682), a National
Institute of Nursing Research grant (R01 NR010135), Agency for
Healthcare Research and Quality grants (R01 HS017695, K12 HS019461,
R01HS018721), and a Veterans Affairs Health Services Research grant
(IIR-06062). Dr. Suarez-Almazor is supported by a grant from the
National Institute of Arthritis and Musculoskeletal and Skin Diseases
(K24 AR053593). Drs. Elting, Suarez-Almazor, and Goodwin are supported
by a grant from the Cancer Prevention and Research Institute of Texas
(RP 101207). Dr. Goodwin was supported by an Established Investigator
Grant from the National Cancer Institute (K05 CA134923). The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health.
NR 30
TC 22
Z9 22
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUL
PY 2012
VL 60
IS 7
BP 1298
EP 1303
DI 10.1111/j.1532-5415.2012.04037.x
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 972WJ
UT WOS:000306311600015
PM 22702464
ER
PT J
AU Zhang, YA
Benmohamed, R
Zhang, W
Kim, J
Edgerly, CK
Zhu, YQ
Morimoto, RI
Ferrante, RJ
Kirsch, DR
Silverman, RB
AF Zhang, Yinan
Benmohamed, Radhia
Zhang, Wei
Kim, Jinho
Edgerly, Christina K.
Zhu, Yaoqiu
Morimoto, Richard I.
Ferrante, Robert J.
Kirsch, Donald R.
Silverman, Richard B.
TI Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent
Protein Aggregation for the Treatment of ALS
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Cyclohexane 1,3-diones; superoxide dismutase 1 (SOD1); protein
aggregation; amyotrophic lateral sclerosis (ALS); mutant SOD1; PC-12
cells; cortical neurons
ID AMYOTROPHIC-LATERAL-SCLEROSIS; POTENTIAL APPLICATION; RILUZOLE;
TOXICITY; DESIGN
AB Cyclohexane 1,3-diones were identified as a class of molecules exhibiting a protective effect against mutant SOD1 induced toxicity in PC-12 cells, but an optimized analogue had little or no effect on life extension in the G93A SOD1 mouse model for amyotrophic lateral sclerosis (ALS). Additional testing showed that these compounds were inactive in neurons, and further analogue synthesis was carried out to identify compounds with neuronal activity. Starting from two racemic derivatives that were active in cortical neurons, two potent analogues (1b and 2b) were resolved, which were protective against mutant SOD1 induced toxicity in PC 12 cells. Both compounds were found to be active in cortical neurons and presented good ADME profiles in vitro. On the basis of these results, an ALS mouse trial with 1b was carried out, which showed slightly greater life extension than the FDA approved ALS drug riluzole, thereby validating cyclohexane 1,3-diones as a novel therapeutic class for the treatment of ALS.
C1 [Zhang, Yinan; Zhang, Wei; Silverman, Richard B.] Northwestern Univ, Dept Chem, Chem Life Proc Inst,Ctr Mol Innovat & Drug Discov, Dept Mol Biosci, Evanston, IL 60208 USA.
[Benmohamed, Radhia; Kirsch, Donald R.] Cambria Pharmaceut, Cambridge, MA 02142 USA.
[Kim, Jinho; Edgerly, Christina K.; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA.
[Kim, Jinho; Edgerly, Christina K.; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.
[Kim, Jinho; Edgerly, Christina K.; Ferrante, Robert J.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA.
[Kim, Jinho; Edgerly, Christina K.; Ferrante, Robert J.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, Pittsburgh, PA 15206 USA.
[Zhu, Yaoqiu] MetabQuest Res & Consulting, Beijing 100871, Peoples R China.
[Morimoto, Richard I.] Northwestern Univ, Rice Inst Biomed Res, Dept Mol Biosci, Evanston, IL 60208 USA.
RP Silverman, RB (reprint author), Northwestern Univ, Dept Chem, Chem Life Proc Inst,Ctr Mol Innovat & Drug Discov, Dept Mol Biosci, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM Agman@chem.northwestern.edu
RI Zhu, Yaoqiu/D-4624-2013; Zhang, Yinan/D-5769-2016
OI Zhang, Yinan/0000-0002-0362-1473
FU National Institutes of Health [1R43NS057849]
FX We thank the National Institutes of Health (Grant 1R43NS057849), the ALS
Association (TREAT program), and the Department of Defense (AL093052),
for their generous support of this research.
NR 19
TC 6
Z9 6
U1 1
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD JUL
PY 2012
VL 3
IS 7
BP 584
EP 587
DI 10.1021/ml3000963
PG 4
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 972GP
UT WOS:000306265600014
PM 22837812
ER
PT J
AU Jensen, J
Tantiwong, P
Stuenaes, JT
Molina-Carrion, M
DeFronzo, RA
Sakamoto, K
Musi, N
AF Jensen, Jorgen
Tantiwong, Puntip
Stuenaes, Jorid T.
Molina-Carrion, Marjorie
DeFronzo, Ralph A.
Sakamoto, Kei
Musi, Nicolas
TI Effect of acute exercise on glycogen synthase in muscle from obese and
diabetic subjects
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE insulin resistance
ID HUMAN SKELETAL-MUSCLE; GLUCOSE-UPTAKE; INSULIN-RESISTANCE;
EPITROCHLEARIS MUSCLES; SYNTHETASE ACTIVITY; ACTIVITY CONTRIBUTE;
KINETIC-PROPERTIES; UDP-GLUCOSE; PHOSPHORYLATION; ACTIVATION
AB Jensen J, Tantiwong P, Stuenaes JT, Molina-Carrion M, DeFronzo RA, Sakamoto K, Musi N. Effect of acute exercise on glycogen synthase in muscle from obese and diabetic subjects. Am J Physiol Endocrinol Metab 303: E82-E89, 2012. First published April 17, 2012; doi: 10.1152/ajpendo.00658.2011.-Insulin stimulates glycogen synthase (GS) through dephosphorylation of serine residues, and this effect is impaired in skeletal muscle from insulin-resistant [obese and type 2 diabetic (T2DM)] subjects. Exercise also increases GS activity, yet it is not known whether the ability of exercise to affect GS is impaired in insulin-resistant subjects. The objective of this study was to examine the effect of acute exercise on GS phosphorylation and enzyme kinetic properties in muscle from insulin-resistant individuals. Lean normal glucose-tolerant (NGT), obese NGT, and obese T2DM subjects performed 40 min of moderate-intensity cycle exercise (70% of Vo(2max)). GS kinetic properties and phosphorylation were measured in vastus lateralis muscle before exercise, immediately after exercise, and 3.5 h postexercise. In lean subjects, GS fractional activity increased twofold after 40 min of exercise, and it remained elevated after the 3.5-h rest period. Importantly, exercise also decreased GS K-m for UDP-glucose from approximate to 0.5 to approximate to 0.2 mM. In lean subjects, exercise caused significant dephosphorylation of GS by 50-70% (Ser(641), Ser(645), and Ser(645,649,653,657)), and phosphorylation of these sites remained decreased after 3.5 h; Ser(7) phosphorylation was not regulated by exercise. In obese NGT and T2DM subjects, exercise increased GS fractional activity, decreased K-m for UDP-glucose, and decreased GS phosphorylation as effectively as in lean NGT subjects. We conclude that the molecular regulatory process by which exercise promotes glycogen synthesis in muscle is preserved in insulin-resistant subjects.
C1 [Jensen, Jorgen] Norwegian Sch Sport Sci, Dept Phys Performance, Oslo, Norway.
[Jensen, Jorgen; Stuenaes, Jorid T.] Natl Inst Occupat Hlth, Dept Work Related Musculoskeletal Disorders, Oslo, Norway.
[Tantiwong, Puntip; Molina-Carrion, Marjorie; DeFronzo, Ralph A.; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA.
[Tantiwong, Puntip; Molina-Carrion, Marjorie; DeFronzo, Ralph A.; Musi, Nicolas] Texas Diabet Inst, San Antonio, TX USA.
[Sakamoto, Kei] Univ Dundee, Coll Life Sci, MRC, Prot Phosphorylat Unit, Dundee, Scotland.
[Musi, Nicolas] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA.
RP Musi, N (reprint author), Audie L Murphy VA Hosp, GRECC 182,7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM musi@uthscsa.edu
RI Jensen, Jorgen/O-2245-2013
FU American Diabetes Association; National Institutes of Health [AG-030979,
DK-80157, DK-089229, DK-24092]; San Antonio Nathan Shock Center; South
Texas Health Research Center; US Department of Veterans Affairs; Novo
Nordisk Foundation; United Kingdom (UK) Medical Research Council;
Diabetes UK; Dundee and District of Diabetes UK Volunteer Group
FX This study was supported by grants from the American Diabetes
Association (N. Musi and R. A. DeFronzo), the National Institutes of
Health (AG-030979, DK-80157, and DK-089229 to N. Musi and DK-24092 to R.
A. DeFronzo), the San Antonio Nathan Shock Center (N. Musi), the South
Texas Health Research Center (N. Musi), the US Department of Veterans
Affairs (R. A. DeFronzo), the Novo Nordisk Foundation (J. Jensen), the
United Kingdom (UK) Medical Research Council (K. Sakamoto), Diabetes UK
(K. Sakamoto), and the Dundee and District of Diabetes UK Volunteer
Group (K. Sakamoto).
NR 45
TC 4
Z9 4
U1 0
U2 6
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JUL
PY 2012
VL 303
IS 1
BP E82
EP E89
DI 10.1152/ajpendo.00658.2011
PG 8
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 974EG
UT WOS:000306412000007
PM 22510711
ER
PT J
AU Separovic, D
Breen, P
Joseph, N
Bielawski, J
Pierce, JS
Van Buren, E
Gudz, TI
AF Separovic, Duska
Breen, Paul
Joseph, Nicholas
Bielawski, Jacek
Pierce, Jason S.
Van Buren, Eric
Gudz, Tatyana I.
TI siRNA-Mediated Down-regulation of Ceramide Synthase 1 Leads to Apoptotic
Resistance in Human Head and Neck Squamous Carcinoma Cells after
Photodynamic Therapy
SO ANTICANCER RESEARCH
LA English
DT Article
DE Apoptosis; ceramide; ceramide synthase 1; dihydroceramide; PDT;
sphingolipids; head and neck squamous carcinomas cells UM-SCC-22A
ID LONGEVITY ASSURANCE GENE-1; DE-NOVO SPHINGOLIPIDS; PHOTOSENSITIZED
CELLS; FAMILY-MEMBERS; ACCUMULATION; 1-PHOSPHATE; SPECIFICITY;
INHIBITION; GROWTH; DEATH
AB Background: The effectiveness of photodynamic therapy (PDT) for cancer treatment correlates with apoptosis. We previously observed that the knockdown of ceramide synthase 6, an enzyme from the de novo sphingolipid biosynthesis pathway, is associated with marked reduction in C18-dihydroceramide and makes cells resistant to apoptosis post-PDT. Down-regulation of ceramide synthase 1 (CERS1) can also render cells resistant to anticancer drugs. Aim: To explore the impact of CERS1 knockdown on apoptosis and the sphingolipid profile, post-PDT, with the silicone phthalocyanine Pc 4, in a human head and neck squamous carcinoma cell line. Materials and Methods: Besides siRNA transfection and PDT treatment, the following methods were used: immunoblotting for protein expression, mass spectrometry for sphingolipid analysis, spectroflurometry and flow cytometry for apoptosis detection, and trypan blue assay for cell viability evaluation. Results: CERS1 knockdown led to inhibition of PDT-induced caspase 3-like (DEVDase) activation, of apoptosis and cell death. CERS1 knockdown was associated with global and selective decreases in ceramides and dihydroceramides, in particular C18-, C18:1- and C20-ceramide post-PDT. Conclusion: Our novel findings are consistent with the notion that CERS1 regulates apoptotic resistance to PDT, partly via C18- and C20-ceramide, and that CERS1 is a molecular target for controlling resistance to PDT.
C1 [Separovic, Duska; Breen, Paul; Joseph, Nicholas] Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48201 USA.
[Separovic, Duska; Van Buren, Eric] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA.
[Bielawski, Jacek; Pierce, Jason S.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Gudz, Tatyana I.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
RP Separovic, D (reprint author), Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm & Hlth Sci, 259 Mack Ave, Detroit, MI 48201 USA.
EM dseparovic@wayne.edu
FU U.S. Public Health Service from the National Cancer Institute, National
Institutes of Health [R01 CA77475]; Veterans Administration; NCI
[IPO1CA097132, P30 CA 138313]; NIH/NCRR SC COBRE [P20 RR017677]; NIH;
Extramural Research Facilities Program of the National Center for
Research Resources [C06 RR018823]
FX This work was supported by U.S. Public Health Service Grant R01 CA77475
from the National Cancer Institute, National Institutes of Health (DS)
and the Veterans Administration Merit Awards from RR&D and BLRD programs
(TIG). The MS-related work was performed by the Lipidomics Shared
Resource (Medical University of South Carolina), supported by NCI
grants: IPO1CA097132 and P30 CA 138313 and NIH/NCRR SC COBRE Grant P20
RR017677. Laboratory space for the Lipidomics Shared Resource was
supported by the NIH, grant C06 RR018823 from the Extramural Research
Facilities Program of the National Center for Research Resources. We
thank Drs. Besim Ogretmen and Can Emre Senkal for helpful discussions
over the manuscript.
NR 29
TC 9
Z9 9
U1 0
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD JUL
PY 2012
VL 32
IS 7
SI SI
BP 2479
EP 2485
PG 7
WC Oncology
SC Oncology
GA 972CO
UT WOS:000306254300010
PM 22753704
ER
PT J
AU Khan, BA
Guzman, O
Campbell, NL
Walroth, T
Tricker, JL
Hui, SL
Perkins, A
Zawahiri, M
Buckley, JD
Farber, MO
Ely, EW
Boustani, MA
AF Khan, Babar A.
Guzman, Oscar
Campbell, Noll L.
Walroth, Todd
Tricker, Jason L.
Hui, Siu L.
Perkins, Anthony
Zawahiri, Mohammed
Buckley, John D.
Farber, Mark O.
Ely, E. Wesley
Boustani, Malaz A.
TI Comparison and Agreement Between the Richmond Agitation-Sedation Scale
and the Riker Sedation-Agitation Scale in Evaluating Patients'
Eligibility for Delirium Assessment in the ICU
SO CHEST
LA English
DT Article
ID INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CRITICALLY-ILL
PATIENTS; CONFUSION ASSESSMENT METHOD; MONITORING SEDATION; ADULT;
RELIABILITY; VALIDITY; EFFICACY; PROTOCOL
AB Background: Delirium evaluation in patients in the ICU requires the use of an arousal/sedation assessment tool prior to assessing consciousness. The Richmond Agitation-Sedation Scale (BASS) and the Riker Sedation-Agitation Scale (SAS) are well-validated arousal/sedation tools. We sought to assess the concordance of BASS and SAS assessments in determining eligibility of patients in the ICU for delirium screening using the confusion assessment method for the ICU (CAM-ICU).
Methods: We performed a prospective cohort study in the adult medical, surgical, and progressive (step-down) ICUs of a tertiary care, university-affiliated, urban hospital in Indianapolis, Indiana. The cohort included 975 admissions to the ICU between January and October 2009.
Results: The outcome measures of interest were the correlation and agreement between RASS and SAS measurements. In 2,469 RASS and SAS paired screens, the rank correlation using the Spearman correlation coefficient was 0.91, and the agreement between the two screening tools for assessing CAM-ICU eligibility as estimated by the K coefficient was 0.93. Analysis showed that 70.1% of screens were eligible for CAM-ICU assessment using BASS (7.1% sedated [BASS -3 to -1]; 62.6% calm [0]; and 0.4% restless, agitated [+1 to +3]), compared with 72.1% using SAS (5% sedated [SAS 3]; 66.5% calm [4]; and 0.6% anxious, agitated [5, 6]). In the mechanically ventilated subgroup, RASS identified 19.1% CAM-ICU eligible patients compared with 24.6% by SAS. The correlation coefficient in this subgroup was 0.70 and the agreement was 0.81.
Conclusion: Both SAS and BASS led to similar rates of delirium assessment using the CAM-ICU. CHEST 2012; 142(1):48-54
C1 [Khan, Babar A.; Hui, Siu L.; Buckley, John D.; Farber, Mark O.; Boustani, Malaz A.] Indiana Univ Sch Med, Indianapolis, IN USA.
[Guzman, Oscar] Westchester Cty Med Ctr, Dept Pharm, Westchester, NY USA.
[Khan, Babar A.; Campbell, Noll L.; Hui, Siu L.; Perkins, Anthony; Zawahiri, Mohammed; Boustani, Malaz A.] Regenstrief Inst Inc, Indianapolis, IN USA.
[Walroth, Todd; Tricker, Jason L.] Wishard Hlth Serv, Indianapolis, IN USA.
[Khan, Babar A.; Campbell, Noll L.; Hui, Siu L.; Boustani, Malaz A.] Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA.
[Campbell, Noll L.] Purdue Univ, Coll Pharm, Dept Pharm Practice, W Lafayette, IN 47907 USA.
[Ely, E. Wesley] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
[Ely, E. Wesley] US Dept Vet Affairs, Tennessee Valley Geriatr Res Educ Clin Ctr, Nashville, TN USA.
RP Khan, BA (reprint author), 410 W 10th St,Ste 2000, Indianapolis, IN 46202 USA.
EM bakhan@iupui.edu
FU National Institute on Aging [R01AG034205-01A1]; National Institutes of
Health; Forest Pharmaceuticals; Novartis
FX The study was supported by a grant from the National Institute on Aging
[Grant R01AG034205-01A1].; Financial/nonfinancial disclosures: Dr
Boustani has received grant funds from the National Institute on Aging
and the National Institutes of Health, grant funds from Forest
Pharmaceuticals and Novartis, and serves on the speakers' bureau for
Pfizer Inc and an advisory board for Eli Lilly and Company. All other
authors have reported to CHEST that no potential conflicts of interest
exist with any companies/organizations whose products or services may be
discussed in this article.
NR 34
TC 16
Z9 19
U1 3
U2 12
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUL
PY 2012
VL 142
IS 1
BP 48
EP 54
DI 10.1378/chest.11-2100
PG 7
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 971NE
UT WOS:000306209800013
PM 22539644
ER
PT J
AU Leung, JM
Udris, EM
Uman, J
Au, DH
AF Leung, Janice M.
Udris, Edmunds M.
Uman, Jane
Au, David H.
TI The Effect of End-of-Life Discussions on Perceived Quality of Care and
Health Status Among Patients With COPD
SO CHEST
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; LUNG-CANCER; COMMUNICATION; VENTILATION;
PREFERENCES; CLINICIAN; PROGNOSIS; INSIGHTS; BARRIERS; DEATH
AB Background: Despite strong preferences for discussions about end-of-life care, patients with COPD do not often have these discussions with their providers. Our objective was to determine whether patients who reported having end-of-life discussions also reported higher perceived markers of quality of care and health status.
Methods: A cross-sectional study of data collected at baseline for a trial to improve the occurrence and quality of end-of-life communication in patients with COPD was conducted. The primary exposure was self-reported acknowledgment of having discussions about end-of-life planning with their physicians. The primary outcome measures were patient-reported quality of care and satisfaction with care, which were dichotomized as best imaginable quality of care vs other ratings of quality and highest satisfaction vs other ratings of satisfaction. We adjusted for confounding factors, including patient and provider characteristics, using logistic regression clustered by provider.
Results: Three hundred seventy-six patients were enrolled, of whom 55 (14.6%) reported having end-of-life discussions. Individuals who reported having end-of-life discussions with their physicians were significantly more likely to rate their quality of care as the best imaginable (OR, 2.07; 95% CI, 1.05-4.09) and to be very satisfied with their medical care (OR, 1.98; 95% CI, 1.10-3.55). Discussions were more likely to have occurred among patients with worse health status as measured by St. George Respiratory Questionnaire total and impact scores.
Conclusions: Patients who reported having end-of-life care discussions with their physicians had higher perceived quality of care and satisfaction with their physicians. Discussing end-of-life care with patients who have COPD may improve their perceived overall quality of and satisfaction with care. CHEST 2012; 142(1):128-133
C1 [Leung, Janice M.] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA.
[Leung, Janice M.; Au, David H.] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA USA.
[Udris, Edmunds M.; Uman, Jane; Au, David H.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
RP Leung, JM (reprint author), 10 Ctr Dr,2C145, Bethesda, MD 20892 USA.
EM Janice.Leung@nih.gov
FU Department of Veterans Affairs [IIR-0292]; Department of Veterans
Affairs; National Heart, Lung, and Blood Institute; Agency of Healthcare
Research and Quality; Gilead Sciences
FX This study was supported by the Department of Veterans Affairs
[IIR-0292].; Financial/nonfinancial disclosures: The authors have
reported to CHEST the following conflicts of interest: Dr Au is a
research advisor for Bosch. He receives research funding from the
Department of Veterans Affairs; the National Heart, Lung, and Blood
Institute; Agency of Healthcare Research and Quality; and Gilead
Sciences. Dr Leung, Mr Udris, and Ms Uman have reported that no
potential conflicts of interest exist with any companies/organizations
whose products or services may be discussed in this article.
NR 24
TC 11
Z9 11
U1 0
U2 13
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUL
PY 2012
VL 142
IS 1
BP 128
EP 133
DI 10.1378/chest.11-2222
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 971NE
UT WOS:000306209800022
PM 22241761
ER
PT J
AU Rodriguez, RA
AF Rodriguez, Rudolph A.
TI Dialysis and Mortality: Does It Matter Where You Live?
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID PERITONEAL-DIALYSIS; KIDNEY-TRANSPLANTATION; UNITED-STATES; REMOTE
C1 [Rodriguez, Rudolph A.] Puget Sound VA Med Ctr, Nephrol & Renal Dialysis Unit, Seattle, WA 98108 USA.
[Rodriguez, Rudolph A.] Univ Washington, Seattle, WA 98195 USA.
[Rodriguez, Rudolph A.] VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA.
RP Rodriguez, RA (reprint author), Puget Sound VA Med Ctr, Nephrol & Renal Dialysis Unit, Bldg 100,Room 5B113,1660 S Columbian Way, Seattle, WA 98108 USA.
EM rudyrod@u.washington.edu
NR 10
TC 1
Z9 1
U1 1
U2 2
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUL
PY 2012
VL 7
IS 7
BP 1055
EP 1057
DI 10.2215/CJN.05410512
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 970QX
UT WOS:000306148500001
PM 22723448
ER
PT J
AU Yenchek, RH
Ix, JH
Shlipak, MG
Bauer, DC
Rianon, NJ
Kritchevsky, SB
Harris, TB
Newman, AB
Cauley, JA
Fried, LF
AF Yenchek, Robert H.
Ix, Joachim H.
Shlipak, Michael G.
Bauer, Douglas C.
Rianon, Nahiof J.
Kritchevsky, Stephen B.
Harris, Tamara B.
Newman, Anne B.
Cauley, Jane A.
Fried, Linda F.
CA Hlth Aging & Body Composition Stud
TI Bone Mineral Density and Fracture Risk in Older Individuals with CKD
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE;
HEMODIALYSIS-PATIENTS; HIP FRACTURE; DIALYSIS PATIENTS; OSTEOPOROTIC
FRACTURE; RENAL OSTEODYSTROPHY; DIABETES-MELLITUS; HOMOCYSTEINE;
ULTRASOUND
AB Background and objectives Kidney Disease Improving Global Outcomes guidelines recommend against bone mineral density (BMD) screening in CKD patients with mineral bone disease, due to a lack of association of BMD with fractures in cross-sectional studies in CKD. We assessed whether BMD is associated with fractures in participants with and without CKD in the Health, Aging, and Body Composition study, a prospective study of well functioning older individuals.
Design, setting, participants, & measurements Hip BMD was measured by dual-energy x-ray absorptiometry. Osteoporosis was defined as a femoral neck BMD (FNBMD) T score below -2.5 and CKD as an estimated GFR <60 ml/min per 1.73 m(2). The association of BMD with incident nonspine, fragility fractures to study year 11 was analyzed using Cox proportional hazards analyses, adjusting for age, race, sex, body mass index, hyperparathyroidism, low vitamin D level, and CKD. Interaction terms were used to assess whether the association of BMD with fracture differed in those with and without CKD.
Results There were 384 incident fractures in 2754 individuals (mean age 73.6 years). Lower FNBMD was associated with greater fracture, regardless of CKD status. After adjustment, the hazard ratios (95% confidence intervals) were 2.74 (1.99, 3.77) and 2.15 (1.80, 2.57) per lower SD FNBMD for those with and without CKD, respectively (interaction P=0.68), and 2.10 (1.23, 3.59) and 1.63 (1.18, 2.23) among those with osteoporosis in patients with and without CKD, respectively (interaction P=0.75).
Conclusions BMD provides information on risk for fracture in older individuals with or without moderate CKD. Clin J Am Soc Nephrol 7: 1130-1136, 2012. doi: 10.2215/CJN.12871211
C1 [Yenchek, Robert H.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Sch Med, Pittsburgh, PA 15213 USA.
[Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
[Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Shlipak, Michael G.; Bauer, Douglas C.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA.
[Rianon, Nahiof J.] Univ Texas Houston, Sch Med, Dept Family & Community Med, Houston, TX USA.
[Kritchevsky, Stephen B.] Wake Forest Sch Med, Stricht Ctr Aging, Wake Forest, NC USA.
[Harris, Tamara B.] NIA, NIH, Bethesda, MD 20892 USA.
[Newman, Anne B.; Cauley, Jane A.; Fried, Linda F.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Fried, Linda F.] Vet Affairs Pittsburgh Hlth Care Syst, Renal Sect, Pittsburgh, PA USA.
RP Yenchek, RH (reprint author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Sch Med, 200 Lothrop St,C1100 PUH, Pittsburgh, PA 15213 USA.
EM yenchekrh@upmc.edu
RI Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150; Kritchevsky,
Stephen/0000-0003-3336-6781; Cauley, Jane A/0000-0003-0752-4408
FU Intramural Research Program of the National Institutes of Health;
National Institute on Aging [N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106, R01-AG028050, R01-AG029364]; National Institute of
Nursing Research [R01-NR012459]; NIDDK [T32DK061296]
FX This research was supported in part by the Intramural Research Program
of the National Institutes of Health, as well as the National Institute
on Aging (Contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106; and
Grants R01-AG028050 and R01-AG029364) and the National Institute of
Nursing Research (Grant R01-NR012459). R.H.Y. is supported by NIDDK
Grant T32DK061296.
NR 32
TC 52
Z9 54
U1 1
U2 5
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUL
PY 2012
VL 7
IS 7
BP 1130
EP 1136
DI 10.2215/CJN.12871211
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 970QX
UT WOS:000306148500012
PM 22516286
ER
PT J
AU Hernandez-Tejada, MA
Campbell, JA
Walker, RJ
Smalls, BL
Davis, KS
Egede, LE
AF Hernandez-Tejada, Melba A.
Campbell, Jennifer A.
Walker, Rebekah J.
Smalls, Brittany L.
Davis, Kimberly S.
Egede, Leonard E.
TI Diabetes Empowerment, Medication Adherence and Self-Care Behaviors in
Adults with Type 2 Diabetes
SO DIABETES TECHNOLOGY & THERAPEUTICS
LA English
DT Article
ID EDUCATION-PROGRAM; MANAGEMENT; KNOWLEDGE; SCALE
AB Background: Evidence suggests that empowerment is an important factor to address everyday aspects of dealing with a chronic disease. This study evaluated the effect of diabetes empowerment on medication adherence and self-care behaviors in adults with type 2 diabetes.
Subjects and Methods: Data on 378 subjects with type 2 diabetes recruited from two primary care clinics in the southeastern United States were examined. Previously validated scales were used to measure diabetes empowerment, medication adherence, diabetes knowledge, and diabetes self-care behaviors (including diet, physical activity, blood sugar testing, and foot care). Multiple linear regression was used to assess the independent effect of diabetes empowerment on medication adherence and self-care behaviors controlling for relevant covariates.
Results: Eighty-three percent were non-Hispanic blacks, 69% were women, 22% were 65 years or older, 68% were not married, 26% had less than high school education, 60% were unemployed, 39% were uninsured, and 47% had a yearly income <$10,000. Empowerment had significant correlations with medication adherence (r = 0.17, P < 0.003), diabetes knowledge (r = 0.16, P = 0.007), diet (r = 0.24, P < 0.001), exercise (r = 0.25, P < 0.001), blood sugar testing (r = 0.12, P = 0.043), and foot care (r = 0.18, P = 0.002). In the regression model, diabetes empowerment was significantly associated with medication adherence (beta = -0.04, P = 0.001), diabetes knowledge (beta = 0.09, P = 0.012), diet (beta = 0.09, P < 0.001), exercise (beta = 0.10, P < 0.001), blood sugar testing (beta = 0.07, P = 0.016), and foot care (beta = 0.08, P = 0.001).
Conclusions: In this sample, diabetes empowerment was related to better diabetes knowledge, medication adherence and improved self-care behaviors. Emphasis on empowerment and self-efficacy is relevant to improve outcomes in the management of diabetes.
C1 [Hernandez-Tejada, Melba A.; Campbell, Jennifer A.; Walker, Rebekah J.; Smalls, Brittany L.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Davis, Kimberly S.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston VA REAP, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institute for Diabetes and Digestive and Kidney Diseases
[T35DK007431]
FX This work was supported by grant T35DK007431 from the National Institute
for Diabetes and Digestive and Kidney Diseases.
NR 28
TC 16
Z9 17
U1 1
U2 20
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1520-9156
J9 DIABETES TECHNOL THE
JI Diabetes Technol. Ther.
PD JUL
PY 2012
VL 14
IS 7
BP 630
EP 634
DI 10.1089/dia.2011.0287
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 971ZF
UT WOS:000306245600014
PM 22524548
ER
PT J
AU Hawkins, EJ
Malte, CA
Imel, ZE
Saxon, AJ
Kivlahan, DR
AF Hawkins, Eric J.
Malte, Carol A.
Imel, Zac E.
Saxon, Andrew J.
Kivlahan, Daniel R.
TI Prevalence and trends of benzodiazepine use among Veterans Affairs
patients with posttraumatic stress disorder, 2003-2010
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Trends in benzodiazepine use; Posttraumatic stress disorder; Opioid
analgesics use
ID SUBSTANCE USE DISORDERS; CHRONIC NONCANCER PAIN; MENTAL-HEALTH;
PHARMACOLOGICAL-TREATMENT; ADMINISTRATIVE DATA; ANXIETY DISORDERS;
OPIOID OVERDOSE; ALCOHOL-USE; RISK; ASSOCIATION
AB Background: Although the Veterans Affairs and Department of Defense (VA/DoD) clinical guidelines for management of posttraumatic stress disorder (PTSD) recommend against routine benzodiazepine use, little is known about the trends and clinical and prescription profiles of benzodiazepine use since these guidelines were released in 2004.
Methods: This retrospective study included 64,872 patients with a PTSD diagnosis received from care at facilities in VA Northwest Veterans Integrated Service Network (VISN 20) during 2003-2010. Annual prevalence of any use was defined as any prescription for benzodiazepines, and long-term use was defined as >90 days' supply, in a year. Gender-specific logistic regressions were fit to estimate any and long-term benzodiazepine use, test for linear trends over 8-years and explore factors associated with trends.
Results: The trend of age-adjusted benzodiazepine use over 8-years rose significantly from 25.0 to 26.8% among men and 31.2 to 38.8% among women. Long-term use in men and women increased from 15.4 to 16.4% and 18.0 to 22.7%, respectively. Comorbid psychiatric and alcohol use disorders (AUD) were associated with a greater increase in long-term use of benzodiazepines. In 2010, 61% of benzodiazepine users received >90 days' supply. Among those prescribed benzodiazepines long-term, 11% had AUD and 47% were also prescribed opioids long-term.
Conclusion: Despite VA/DoD clinical guidelines recommending against routine use of benzodiazepines for PTSD, the adjusted prevalence of long-term use increased among men and women with PTSD in VISN 20. Widespread concomitant use of benzodiazepines and opioids suggests risk management systems and research on the efficacy and safety of these medications are needed. Published by Elsevier Ireland Ltd.
C1 [Hawkins, Eric J.] VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Hlth Serv Res & Dev, Seattle, WA 98108 USA.
[Hawkins, Eric J.; Malte, Carol A.; Saxon, Andrew J.; Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA.
[Saxon, Andrew J.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
[Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Imel, Zac E.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.
RP Hawkins, EJ (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div S116ATC, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Eric.Hawkins@va.gov
OI imel, zachary/0000-0001-9645-7184
FU VA Puget Sound Health Care System, Center of Excellence in Substance
Abuse Treatment & Education, Seattle, WA
FX This material is the result of work supported by resources from the VA
Puget Sound Health Care System, Center of Excellence in Substance Abuse
Treatment & Education, Seattle, WA. Supporting organizations had no
further role in study design; in the collection, analysis and
interpretation of data; in the writing of the report; or in the decision
to submit the paper for publication. The views expressed in this article
are those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs or the University of
Washington.
NR 52
TC 21
Z9 21
U1 2
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD JUL 1
PY 2012
VL 124
IS 1-2
BP 154
EP 161
DI 10.1016/j.drugalcdep.2012.01.003
PG 8
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 969IJ
UT WOS:000306048600021
PM 22305658
ER
PT J
AU Smalls, BL
Walker, RJ
Hernandez-Tejada, MA
Campbell, JA
Davis, KS
Egede, LE
AF Smalls, Brittany L.
Walker, Rebekah J.
Hernandez-Tejada, Melba A.
Campbell, Jennifer A.
Davis, Kimberly S.
Egede, Leonard E.
TI Associations between coping, diabetes knowledge, medication adherence
and self-care behaviors in adults with type 2 diabetes
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
DE Coping; Medication adherence; Self-care; Diabetes
ID EMOTIONAL APPROACH; MANAGEMENT; SCALE
AB Background: Few studies have examined the emotional approach to coping on diabetes outcomes. This study examined the relationship between emotional coping and diabetes knowledge, medication adherence and self-care behaviors in adults with type 2 diabetes.
Methods: Data on 378 subjects with type 2 diabetes recruited from two primary care clinics in the southeastern United States were examined. Previously validated scales were used to measure coping, medication adherence, diabetes knowledge and diabetes self-care behaviors (including diet, physical activity, blood sugar testing and foot care). Multiple linear regression was used to assess the independent effect of coping through emotional approach on medication adherence and self-care behaviors while controlling for relevant covariates.
Results: Significant correlations were observed between emotional coping [as measured by emotional expression (EE) and emotional processing (EP)] and self-care behaviors. In the linear regression model, EP was significantly associated with medication adherence [beta -0.17, 95% confidence interval (CI) -0.32 to -0.015], diabetes knowledge (beta 0.76, 95% CI 0.29 to 1.24), diet (beta 0.52, 95% CI 0.24 to 0.81), exercise (beta 0.51, 95% CI 0.19 to 0.82), blood sugar testing (beta 0.54, 95% CI 0.16 to 0.91) and foot care (beta 0.32, 95% CI -0.02 to 0.67). On the other hand, EE was associated with diet (beta 0.38, 95% CI 0.13 to 0.64), exercise (beta 0.54, 95% CI 0.27 to 0.82), blood sugar testing (beta 0.42, 95% CI 0.09 to 0.76) and foot care (beta 0.36, 95% CI 0.06 to 0.66), but it was not associated with diabetes knowledge.
Conclusion: These findings indicate that coping through an emotional approach is significantly associated with behaviors that lead to positive diabetes outcomes. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Smalls, Brittany L.; Walker, Rebekah J.; Hernandez-Tejada, Melba A.; Campbell, Jennifer A.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Davis, Kimberly S.; Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA REAP, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, POB 250593 Charleston, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institute for Diabetes, Digestive and Kidney Disease
[T35DK007431]
FX Supported by grant no. T35DK007431 from the National Institute for
Diabetes, Digestive and Kidney Disease.
NR 19
TC 13
Z9 13
U1 2
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD JUL-AUG
PY 2012
VL 34
IS 4
BP 385
EP 389
DI 10.1016/j.genhosppsych.2012.03.018
PG 5
WC Psychiatry
SC Psychiatry
GA 972TI
UT WOS:000306302700009
PM 22554428
ER
PT J
AU Collins, EG
O'Connell, S
McBurney, C
Jelinek, C
Butler, J
Reda, D
Gerber, BS
Hurt, C
Grabiner, M
AF Collins, Eileen G.
O'Connell, Susan
McBurney, Conor
Jelinek, Christine
Butler, Jolene
Reda, Domenic
Gerber, Ben S.
Hurt, Christopher
Grabiner, Mark
TI Comparison of Walking With Poles and Traditional Walking for Peripheral
Arterial Disease Rehabilitation
SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION
LA English
DT Article
DE peripheral arterial disease; rehabilitation; walking exercise
ID INTERMITTENT CLAUDICATION; NORDIC WALKING; PHYSIOLOGICAL-RESPONSES;
ENERGY-EXPENDITURE; EXERCISE; PAIN
AB PURPOSE: The purpose of this study was to compare the effects of a 24-week walking with poles rehabilitation program with a traditional 24-week walking program on physical function in patients with peripheral arterial disease (PAD).
METHODS: Patients with PAD (n = 103, age = 69.7 +/- 8.9 years, ankle-brachial index < 0.90 or evidence of calcified vessels) were randomized into a rehabilitation program of traditional walking (n = 52) or walking with poles (n = 51). Patients exercised 3 times per week for 24 weeks. Exercise endurance was measured by time walked on a constant work rate treadmill test at 6, 12, and 24 weeks. Perceived physical function was measured by the Medical Outcomes Study Short Form-36 and Walking Impairment Questionnaire. Tissue oxygenation was measured using near-infrared spectroscopy.
RESULTS: Patients assigned to the traditional walking group walked longer at 24 weeks than those assigned to the pole walking group (21.10 +/- 17.07 minutes and 15.02 +/- 12.32 minutes, respectively, P = .037). There were no differences between the groups in tissue oxygenation. However, there was a significant lengthening of time for which it took to reach minimum tissue oxygenation values (P < .001) within the groups on the constant work rate test. There were no differences between the groups in perceived physical function as measured by the Physical Function subscale on the Medical Outcomes Study Short Form-36 or perceived walking distance as measured by the Walking Distance subscale on the Walking Impairment Scale.
CONCLUSIONS: Traditional walking was superior to walking with poles in increasing walking endurance on a constant work rate treadmill test for patients with PAD.
C1 [Collins, Eileen G.; O'Connell, Susan; McBurney, Conor; Jelinek, Christine; Butler, Jolene; Gerber, Ben S.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Dept Vet Affairs, Hines, IL 60141 USA.
[Reda, Domenic] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Cooperat Studies Program, Dept Vet Affairs, Hines, IL 60141 USA.
[Collins, Eileen G.] Univ Illinois, Dept Biobehav Hlth Sci, Coll Nursing, Chicago, IL 60612 USA.
[Gerber, Ben S.] Univ Illinois, Sect Hlth Promot Res, Dept Med, Chicago, IL 60612 USA.
[Hurt, Christopher; Grabiner, Mark] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL 60612 USA.
RP Collins, EG (reprint author), Univ Illinois, Dept Biobehav Hlth Sci, Coll Nursing MC802, 845 S Damen Ave, Chicago, IL 60612 USA.
EM ecollins@uic.edu
OI Gerber, Ben/0000-0003-4367-6396
FU National Institute of Nursing Research [RO1 NR008877-01]; Research
Career Scientist Award, Rehabilitation Research & Development,
Department of Veterans Affairs
FX This work was supported by a grant from the National Institute of
Nursing Research (RO1 NR008877-01) and a Research Career Scientist Award
(Collins), Rehabilitation Research & Development, Department of Veterans
Affairs. The contents of this article do not represent the views of the
National Institutes of Health, the Department of Veterans Affairs, or
the US Government. The authors have no affiliation with Exerstrider.
NR 23
TC 8
Z9 8
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1932-7501
J9 J CARDIOPULM REHABIL
JI J. Cardiopulm. Rehabil. Prev.
PD JUL-AUG
PY 2012
VL 32
IS 4
BP 210
EP 218
DI 10.1097/HCR.0b013e31825828f4
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 970GF
UT WOS:000306115400007
PM 22595894
ER
PT J
AU Roth, CP
Ganz, DA
Nickels, L
Martin, D
Beckman, R
Wenger, NS
AF Roth, Carol P.
Ganz, David A.
Nickels, Lorraine
Martin, David
Beckman, Robin
Wenger, Neil S.
TI Nurse Care Manager Contribution to Quality of Care in a Dual-Eligible
Special Needs Plan
SO JOURNAL OF GERONTOLOGICAL NURSING
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; URINARY-INCONTINENCE; OLDER-PATIENTS;
VULNERABLE ELDERS; DEMENTIA; HEALTH; FALLS; MODEL; INTERVENTIONS;
DEPRESSION
AB We evaluated the quality of care provided to older patients with complex needs in a dual-eligible, community-based Medicare Special Needs Plan that used a nurse care manager model. Care provided by physicians was substantially supplemented by nurse care managers, as measured by Assessing Care of Vulnerable Elders quality indicators. We describe selected nurse care manager activities for six geriatric conditions (falls, dementia, depression, nutrition, urinary incontinence, and end-of-life care) during provision of patient care coordination and management for patients in the highest decile of clinical complexity. We identify areas of high nurse performance (i.e., falls screening, functional assessment, behavioral interventions for dementia problems, advance care planning) and areas of potential missed opportunities (i.e., follow up for new memory problems, targeted dementia counseling, nutrition, and behavioral approaches to urinary incontinence). Increasing the collaborative interaction between nurses providing care in this model and physicians has the potential to enhance nurses' contributions to primary care for vulnerable older adults.
C1 [Roth, Carol P.; Ganz, David A.; Beckman, Robin; Wenger, Neil S.] RAND Hlth, Santa Monica, CA 90407 USA.
[Nickels, Lorraine] UnitedHealthcare, Clin Qual Improvement, Minnetonka, MN USA.
[Martin, David] UnitedHealthcare Medicare & Retirement, Clin Innovat, Minnetonka, MN USA.
[Ganz, David A.] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Serv, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Wenger, Neil S.] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Roth, CP (reprint author), RAND Hlth, 1776 Main St, Santa Monica, CA 90407 USA.
EM roth@rand.org
FU UnitedHealthcare
FX Ms. Roth, Dr. Ganz, Ms. Beckman, and Dr. Wenger have disclosed no
potential conflicts of interest, financial or otherwise. Ms. Nickels and
Dr. Martin disclose that they are United Healthcare shareholders. This
project was supported by a contract from UnitedHealthcare to the RAND
Corporation.
NR 42
TC 3
Z9 3
U1 3
U2 10
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0098-9134
J9 J GERONTOL NURS
JI J. Gerontol. Nurs.
PD JUL
PY 2012
VL 38
IS 7
BP 44
EP 54
DI 10.3928/00989134-20120606-10
PG 11
WC Geriatrics & Gerontology; Gerontology; Nursing
SC Geriatrics & Gerontology; Nursing
GA 971OH
UT WOS:000306213200007
PM 22833891
ER
PT J
AU Saldarriaga, OA
Travi, BL
Choudhury, GG
Melby, PC
AF Saldarriaga, Omar A.
Travi, Bruno L.
Choudhury, Goutam Ghosh
Melby, Peter C.
TI Identification of hamster inducible nitric oxide synthase (iNOS)
promoter sequences that influence basal and inducible iNOS expression
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE C/EBP-beta; transcriptional regulation; NF-IL-6; NOS2
ID BINDING PROTEIN BETA; FACTOR-KAPPA-B; INTERFERON-GAMMA; ALVEOLAR
MACROPHAGES; SPECIES-DIFFERENCES; MOUSE MACROPHAGES; RESPONSE ELEMENT;
REACTIVE OXYGEN; ENDOTOXIC-SHOCK; MESSENGER-RNA
AB IFN-gamma/LPS-activated hamster (Mesocricetus auratus) macrophages express significantly less iNOS (NOS2) than activated mouse macrophages, which contributes to the hamster's susceptibility to intracellular pathogens. We determined a mechanism responsible for differences in iNOS promoter activity in hamsters and mice. The HtPP (1.2 kb) showed low basal and inducible promoter activity when compared with the mouse, and sequences within a 100-bp region (-233 to -133) of the mouse and hamster promoters influenced this activity. Moreover, within this 100 bp, we identified a smaller region (44 bp) in the mouse promoter, which recovered basal promoter activity when swapped into the hamster promoter. The mouse homolog (100-bp region) contained a cis-element for NF-IL-6 (-153/-142), which was absent in the hamster counterpart. EMSA and supershift assays revealed that the hamster sequence did not support the binding of NF-IL-6. Introduction of a functional NF-IL-6 binding sequence into the hamster promoter or its alteration in the mouse promoter revealed the critical importance of this transcription factor for full iNOS promoter activity. Furthermore, the binding of NF-IL-6 to the iNOS promoter (-153/-142) in vivo was increased in mouse cells but was reduced in hamster cells after IFN-gamma/LPS stimulation. Differences in the activity of the iNOS promoters were evident in mouse and hamster cells, so they were not merely a result of species-specific differences in transcription factors. Thus, we have identified unique DNA sequences and a critical transcription factor, NF-IL-6, which contribute to the overall basal and inducible expression of hamster iNOS. J. Leukoc. Biol. 92: 205-218; 2012.
C1 [Saldarriaga, Omar A.; Travi, Bruno L.; Choudhury, Goutam Ghosh; Melby, Peter C.] S Texas Vet Hlth Care Syst, Res Serv, Dept Vet Affairs Med Ctr, San Antonio, TX USA.
[Saldarriaga, Omar A.; Travi, Bruno L.; Choudhury, Goutam Ghosh; Melby, Peter C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Saldarriaga, Omar A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA.
RP Melby, PC (reprint author), Univ Texas Med Branch, Dept Internal Med, Div Infect Dis, 301 Univ Blvd,Rte 0435, Galveston, TX 77555 USA.
EM pcmelby@utmb.edu
FU U.S. National Institutes of Health (NIH) [AI61624]; U.S. NIH [RO1 DK
50,190]; VA Merit Review; JDRF [1-2008-185]; U.S. Department of Veterans
Affairs
FX This work was supported by U.S. National Institutes of Health (NIH)
grant AI61624 (P. C. M.). G. G. C. is supported by U.S. NIH RO1 DK
50,190, VA Merit Review, and JDRF 1-2008-185 grants. G. G. C. is a
recipient of a Senior Research Career Scientists award from the U.S.
Department of Veterans Affairs. We thank Dr. Sunil Ahuja and Dr.
Srinivas Mummidi for their scientific input and Sheela Rani for her
advice with the ChiP assays.
NR 46
TC 7
Z9 7
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD JUL
PY 2012
VL 92
IS 1
BP 205
EP 218
DI 10.1189/jlb.1010568
PG 14
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 966KS
UT WOS:000305837100022
PM 22517919
ER
PT J
AU Arcenas, RC
Spadoni, S
Mohammad, A
Kiechle, FL
Walker, K
Fader, RC
Perdreau-Remington, F
Osiecki, J
Liesenfeld, O
Hendrickson, S
Rao, A
AF Arcenas, Rodney C.
Spadoni, Stacey
Mohammad, Amin
Kiechle, Frederick L.
Walker, Kimberly
Fader, Robert C.
Perdreau-Remington, Francoise
Osiecki, John
Liesenfeld, Oliver
Hendrickson, Shelby
Rao, Arundhati
TI Multicenter Evaluation of the LightCycler MRSA Advanced Test, the Xpert
MRSA Assay, and MRSASelect Directly Plated Culture with Simulated
Workflow Comparison for the Detection of Methicillin-Resistant
Staphylococcus aureus in Nasal Swabs
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Article
ID REAL-TIME PCR; CHROMAGAR MRSA; SURVEILLANCE CULTURES; CHROMOGENIC MEDIA;
MOLECULAR ASSAYS; RAPID DETECTION; EPIDEMIOLOGY; INFECTIONS; RISK;
IDENTIFICATION
AB Rapid detection of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) followed by appropriate infection control procedures reduces MRSA infection and transmission. We compared the performance and workflow of two Food and Drug Administration-approved nucleic acid amplification assays, the LightCycler MRSA Advanced Test and the Xpert MRSA test, with those of directly plated culture (MRSASelect) using 1202 nasal swabs collected at three U.S. sites. The sensitivity of the LightCycler test (95.2%; 95% CI, 89.1% to 98.4%) and Xpert assay (99%; 95% CI, 94.8% to 100%) did not differ compared with that of culture; the specificity of the two assays was identical (95.5%; 95% CI, 94.1% to 96.7%) compared with culture. However, sequencing performed on 71 samples with discordant results among the three methods confirmed the presence of MRSA in 40% of samples that were positive by both molecular methods but negative by culture. Workflow analysis from all sites including batch runs revealed average hands-on sample preparation times of 1.40, 2.35, and 1.44 minutes per sample for the LightCycler, Xpert, and MRSASelect methods, respectively. Discrete event simulation analysis of workflow efficiencies revealed that the LightCycler test used less hands-on time for the assay when greater than eight batched samples were run. The high sensitivity and specificity, low hands-on time, and efficiency gains using hatching capabilities make the LightCycler test suitable for rapid batch screening of MRSA colonization. (J Mol Diagn 2012, 14: 367-375; http://dx.doi.org/10.1016/j.jmoldx.2012.01.015)
C1 [Mohammad, Amin; Walker, Kimberly; Fader, Robert C.; Hendrickson, Shelby; Rao, Arundhati] Scott & White Healthcare, Texas A&M Hlth Sci Ctr, Dept Pathol, Temple, TX 76508 USA.
[Arcenas, Rodney C.; Kiechle, Frederick L.] Mem Reg Hosp S, Dept Pathol, Hollywood, FL USA.
[Spadoni, Stacey] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Pathol, Hines, IL 60141 USA.
[Perdreau-Remington, Francoise] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA USA.
[Osiecki, John] Roche Diagnost Corp, Med & Sci Affairs, Indianapolis, IN USA.
[Liesenfeld, Oliver] Roche Mol Diagnost, Med & Sci Affairs, Pleasanton, CA USA.
RP Rao, A (reprint author), Scott & White Healthcare, Texas A&M Hlth Sci Ctr, Dept Pathol, 2401 S 31st St, Temple, TX 76508 USA.
EM arao@swmail.sw.org
FU Roche Diagnostics Corp.
FX Supported in part by Roche Diagnostics Corp.
NR 34
TC 4
Z9 4
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-1578
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD JUL
PY 2012
VL 14
IS 4
BP 367
EP 375
DI 10.1016/j.jmoldx.2012.01.015
PG 9
WC Pathology
SC Pathology
GA 972AC
UT WOS:000306247900009
PM 22584139
ER
PT J
AU Craft, S
Foster, TC
Landfield, PW
Maier, SF
Resnick, SM
Yaffe, K
AF Craft, Suzanne
Foster, Thomas C.
Landfield, Philip W.
Maier, Steven F.
Resnick, Susan M.
Yaffe, Kristine
TI Session III: Mechanisms of Age-Related Cognitive Change and Targets for
Intervention: Inflammatory, Oxidative, and Metabolic Processes
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Aging; Cognition; Inflammation; Oxidative stress; Metabolism
ID ALZHEIMER-DISEASE; IMPAIRMENT; DECLINE; MEMORY; RISK; HIPPOCAMPUS;
PREVALENCE; DEMENTIA; LATINOS; PROTEIN
AB There is increasing evidence from basic science and human epidemiological studies that inflammation, oxidative stress, and metabolic abnormalities are associated with age-related cognitive decline and impairment. This article summarizes selected research on these topics presented at the Cognitive Aging Summit II. Speakers in this session presented evidence highlighting the roles of these processes and pathways on age-related cognitive decline, pointing to possible targets for intervention in nondemented older adults. Specific areas discussed included age differences in the production of cytokines following injury or infection, mechanisms underlying oxidative stress-induced changes in memory consolidation, insulin effects on brain signaling and memory, and the association between metabolic syndrome and cognitive decline in older adults. These presentations emphasize advances in our understanding of mechanisms and modifiers of age-related cognitive decline and provide insights into potential targets to promote cognitive health in older adults.
C1 [Resnick, Susan M.] NIA, Lab Behav Neurosci, BRC, Baltimore, MD 21224 USA.
[Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Geriatr Res Educ & Clin Ctr, Seattle, WA 98195 USA.
[Foster, Thomas C.] Univ Florida, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32610 USA.
[Landfield, Philip W.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Coll Med, Lexington, KY 40506 USA.
[Maier, Steven F.] Univ Colorado, Dept Psychol, Boulder, CO 80309 USA.
[Maier, Steven F.] Univ Colorado, Dept Neurosci, Boulder, CO 80309 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Resnick, SM (reprint author), NIA, Lab Behav Neurosci, BRC, Room 4B335,251 Bayview Blvd, Baltimore, MD 21224 USA.
EM susan.resnick@nih.gov
FU Intramural NIH HHS [ZIA AG000191-15]; NCATS NIH HHS [UL1 TR000064]; NIA
NIH HHS [R01 AG014979, P30 AG028740, R01 AG034605, R37 AG036800]
NR 26
TC 29
Z9 30
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD JUL
PY 2012
VL 67
IS 7
BP 754
EP 759
DI 10.1093/gerona/gls112
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 970PD
UT WOS:000306143700008
PM 22570133
ER
PT J
AU Craft, S
AF Craft, Suzanne
TI Insulin resistance and AD-extending the translational path
SO NATURE REVIEWS NEUROLOGY
LA English
DT Editorial Material
ID TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; AMYLOIDOSIS; OLIGOMERS;
BRAIN
AB Two recent studies have carefully characterized amyloid-related brain insulin resistance in animal models of, and patients with, Alzheimer disease (AD). The researchers show that exendin-4, a glucagon-like peptide 1 receptor agonist, ameliorates pathology and symptoms in a mouse model of AD, suggesting a novel therapeutic approach to this disease.
C1 Vet Affairs Puget Sound, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
RP Craft, S (reprint author), Vet Affairs Puget Sound, Geriatr Res Educ & Clin Ctr, S-182,1660 S Columbian Way, Seattle, WA 98108 USA.
EM scraft@u.washington.edu
NR 9
TC 46
Z9 47
U1 1
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD JUL
PY 2012
VL 8
IS 7
BP 360
EP 362
DI 10.1038/nrneurol.2012.112
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA 970BU
UT WOS:000306103900002
PM 22710630
ER
PT J
AU Delgado-Escueta, AV
AF Delgado-Escueta, Antonio V.
TI Lafora progressive myoclonus epilepsy Glycogen storage disease vs
neurodegenerative disease
SO NEUROLOGY
LA English
DT Editorial Material
ID MALIN; MICE
C1 [Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Delgado-Escueta, Antonio V.] VA Greater Los Angeles Healthcare Syst, VA Epilepsy Ctr Excellence, Los Angeles, CA USA.
RP Delgado-Escueta, AV (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM escueta@ucla.edu
OI Delgado-Escueta, Antonio V./0000-0002-1581-6999
FU NINDS NIH HHS [R01 NS042376]
NR 10
TC 3
Z9 3
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUL
PY 2012
VL 79
IS 1
BP 21
EP 22
DI 10.1212/WNL.0b013e31825dcea6
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 971BE
UT WOS:000306176000008
PM 22622859
ER
PT J
AU Weaver, FM
Follett, KA
Stern, M
Luo, P
Harris, CL
Hur, K
Marks, WJ
Rothlind, J
Sagher, O
Moy, C
Pahwa, R
Burchiel, K
Hogarth, P
Lai, EC
Duda, JE
Holloway, K
Samii, A
Horn, S
Bronstein, JM
Stoner, G
Starr, PA
Simpson, R
Baltuch, G
De Salles, A
Huang, GD
Reda, DJ
AF Weaver, Frances M.
Follett, Kenneth A.
Stern, Matthew
Luo, Ping
Harris, Crystal L.
Hur, Kwan
Marks, William J., Jr.
Rothlind, Johannes
Sagher, Oren
Moy, Claudia
Pahwa, Rajesh
Burchiel, Kim
Hogarth, Penelope
Lai, Eugene C.
Duda, John E.
Holloway, Kathryn
Samii, Ali
Horn, Stacy
Bronstein, Jeff M.
Stoner, Gatana
Starr, Philip A.
Simpson, Richard
Baltuch, Gordon
De Salles, Antonio
Huang, Grant D.
Reda, Domenic J.
CA CSP 468 Study Grp
TI Randomized trial of deep brain stimulation for Parkinson disease
Thirty-six-month outcomes
SO NEUROLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; 5-YEAR FOLLOW-UP; PALLIDAL STIMULATION;
GLOBUS-PALLIDUS; SUBTHALAMIC NUCLEUS; MOTOR FLUCTUATIONS; MEDICAL
THERAPY; MULTICENTER; VALIDATION; EFFICACY
AB Objectives: Our objective was to compare long-term outcomes of deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) for patients with Parkinson disease (PD) in a multicenter randomized controlled trial.
Methods: Patients randomly assigned to GPi (n = 89) or STN DBS (n = 70) were followed for 36 months. The primary outcome was motor function on stimulation/off medication using the Unified Parkinson's Disease Rating Scale motor subscale. Secondary outcomes included quality of life and neurocognitive function.
Results: Motor function improved between baseline and 36 months for GPi (41.1 to 27.1; 95% confidence interval [CI] -16.4 to -10.8; p < 0.001) and STN (42.5 to 29.7; 95% CI -15.8 to -9.4; p < 0.001); improvements were similar between targets and stable over time (p = 0.59). Health-related quality of life improved at 6 months on all subscales (all p values significant), but improvement diminished over time. Mattis Dementia Rating Scale scores declined faster for STN than GPi patients (p = 0.01); other neurocognitive measures showed gradual decline overall.
Conclusions: The beneficial effect of DBS on motor function was stable and comparable by target over 36 months. Slight declines in quality of life following initial gains and gradual decline in neurocognitive function likely reflect underlying disease progression and highlight the importance of nonmotor symptoms in determining quality of life.
Classification of Evidence: This study provides Class III evidence that improvement of motor symptoms of PD by DBS remains stable over 3 years and does not differ by surgical target. Neurology (R) 2012; 79:55-65
C1 [Weaver, Frances M.] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA.
[Weaver, Frances M.] Loyola Univ Stritch Sch Med, Maywood, IL USA.
[Follett, Kenneth A.] Iowa City VA Med Ctr, Iowa City, IA USA.
[Follett, Kenneth A.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Stern, Matthew; Horn, Stacy; Baltuch, Gordon] Univ Penn Hlth Syst, Philadelphia, PA USA.
[Luo, Ping; Hur, Kwan; Reda, Domenic J.] Hines VA Hosp, Cooperat Studies Coordinating Ctr, Hines, IL USA.
[Harris, Crystal L.] VA Cooperat Studies Program, Albuquerque, NM USA.
[Marks, William J., Jr.; Rothlind, Johannes; Starr, Philip A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Marks, William J., Jr.; Rothlind, Johannes; Starr, Philip A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Sagher, Oren] Univ Michigan Med Ctr, Ann Arbor, MI USA.
[Moy, Claudia] NINDS, Rockville, MD USA.
[Pahwa, Rajesh] Univ Kansas Med Ctr, Kansas City, KS USA.
[Burchiel, Kim] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Burchiel, Kim; Hogarth, Penelope] Portland VA Med Ctr, Portland, OR USA.
[Lai, Eugene C.; Simpson, Richard] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Lai, Eugene C.; Simpson, Richard] Methodist Neurol Inst, Houston, TX USA.
[Stern, Matthew; Duda, John E.; Baltuch, Gordon] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Holloway, Kathryn] Richmond VA Med Ctr, Richmond, VA USA.
[Samii, Ali] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Bronstein, Jeff M.; De Salles, Antonio] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Bronstein, Jeff M.; De Salles, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Stoner, Gatana] Univ Iowa Hlth Care, Iowa City, IA USA.
[Huang, Grant D.] US Dept Vet Affairs, Cooperat Studies Program, Cent Off, Washington, DC USA.
RP Weaver, FM (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA.
EM Frances.Weaver@va.gov
FU Medtronic Neurological, Inc.; Cooperative Studies Program, Department of
Veterans Affairs Office of Research and Development; NINDS; Teva; Ipsen;
Medtronic; Adamas Pharma; Schering-Plough; GSK; GE Healthcare; EMD
Serono; Boehringer Ingelheim; St Jude Medical; Impax Pharma; Novartis;
Biogen; Xenoport; Solvay; Eisai; NIH/NINDS; NPF; Allon; Acadia; Valeant;
Kyowa; Johnson Johnson; Schering; Santhera
FX Medtronic Neurological, Inc. provided financial support. The Cooperative
Studies Program, Department of Veterans Affairs Office of Research and
Development, provided financial support and contributed to the study
design. NINDS provided financial support and contributed to the design
of the study.; F. Weaver reports no disclosures relevant to the
manuscript. K. Follett reports serving as a consultant for Medtronic
Neurological (safety monitoring panel). M. Stern reports receiving
consulting fees from Teva, Ipsen, Medtronic, Adamas Pharma,
Schering-Plough, payment for speakers bureaus from Teva, Novartis, and
the Movement Disorder Society, payment for development of educational
presentations from Teva and Medtronic. P. Luo, C. Harris, and K. Hur
report no disclosures relevant to the manuscript. W. Marks reports
receiving consulting fees from Medtronic and lecture fees from
Medtronic. J. Rothlind, O. Sagher, and C. Moy report no disclosures
relevant to the manuscript. R. Pahwa reports receiving consulting fees
from Teva, GSK, GE Healthcare, EMD Serono, Boehringer Ingelheim,
Medtronic, St Jude Medical, Impax Pharma, Novartis, Adamas Pharma, and
Biogen, providing expert testimony, grants/grants pending from Teva,
Novartis, Xenoport, Impax Pharma, Boehringer Ingelheim, Solvay, EMD
Serono, Eisai, NIH/NINDS, NPF, Allon, Acadia, GSK, Valeant, Kyowa,
Johnson & Johnson, Santhera, and Schering, payment for lectures from
Teva, GSK, and Medtronic, royalties from Oxford Press and Informa
Healthcare, payment for development of educational presentations from
Medscape, Co-Editor in Chief International Journal of Neuroscience, and
DSMB member (Ceregene). K. Burchiel reports grants/grants pending from
Medtronic, and owning stock/stock options in Medtronic. P. Hogarth, E.
Lai, and J. Duda report no disclosures relevant to the manuscript. K.
Holloway reports receiving consulting fees and grant/grants pending from
Medtronic. A. Samii reports receiving payment for lectures from Teva,
Ipsen, and Boehringer Ingelheim. S. Horn, J. Bronstein, and G. Stoner
report no disclosures relevant to the manuscript. P. Starr reports
receiving consulting fees from Medtronic. R. Simpson reports
participating on advisory board and receiving consulting fees from
Medtronic, and providing expert testimony. G. Baltuch, A. DeSalles, G.
Huang, and D. Reda report no disclosures relevant to the manuscript. Go
to Neurology.org for full disclosures.
NR 30
TC 114
Z9 118
U1 2
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUL
PY 2012
VL 79
IS 1
BP 55
EP 65
DI 10.1212/WNL.0b013e31825dcdc1
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 971BE
UT WOS:000306176000014
PM 22722632
ER
PT J
AU Cheng, EM
Keyhani, S
Ofner, S
Williams, LS
Hebert, PL
Ordin, DL
Bravata, DM
AF Cheng, Eric M.
Keyhani, Salomeh
Ofner, Susan
Williams, Linda S.
Hebert, Paul L.
Ordin, Diana L.
Bravata, Dawn M.
TI Lower use of carotid artery imaging at minority-serving hospitals
SO NEUROLOGY
LA English
DT Article
ID ASSOCIATION/AMERICAN STROKE ASSOCIATION; HEALTH-CARE PROFESSIONALS;
ETHNIC DISPARITIES; ISCHEMIC-STROKE; ENDARTERECTOMY; AMERICAN; RACE;
QUALITY; MODELS; SYSTEM
AB Objective: We determined whether site of care explains a previously identified racial disparity in carotid artery imaging.
Methods: In this retrospective cohort study, data were obtained from a chart review of veterans hospitalized with ischemic stroke at 127 Veterans Administration hospitals in 2007. Extensive exclusion criteria were applied to obtain a sample who should have received carotid artery imaging. Minority-serving hospitals were defined as the top 10% of hospitals ranked by the proportion of stroke patients who were black. Population level multivariate logistic regression models with adjustment for correlation of patients in hospitals were used to calculate predictive probabilities of carotid artery imaging by race and minority-service hospital status. Bootstrapping was used to obtain 95% confidence intervals (CIs).
Results: The sample consisted of 1,534 white patients and 628 black patients. Nearly 40% of all black patients were admitted to 1 of 13 minority-serving hospitals. No racial disparity in receipt of carotid artery imaging was detected within nonminority serving hospitals. However, the predicted probability of receiving carotid artery imaging for white patients at nonminority-serving hospitals (89.7%, 95% CI [87.3%, 92.1%]) was significantly higher than both white patients (78.0% [68.3%, 87.8%] and black patients (70.5% [59.3%, 81.6%]) at minority-serving hospitals.
Conclusions: Underuse of carotid artery imaging occurred most often among patients hospitalized at minority-serving hospitals. Further work is required to explore why site of care is a mechanism for racial disparities in this clinically important diagnostic test. Neurology (R) 2012;79:138-144
C1 [Cheng, Eric M.] VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Cheng, Eric M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Keyhani, Salomeh] UCSF, Div Gen Internal Med, Dept Med, San Francisco, CA USA.
[Keyhani, Salomeh] San Francisco VA Med Ctr, Res Enhancement Award Program, San Francisco, CA USA.
[Ofner, Susan] Indiana Univ Sch Med, Div Biostat, Indianapolis, IN USA.
[Williams, Linda S.] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA.
[Bravata, Dawn M.] Indiana Univ Sch Med, Dept Internal Med, Indianapolis, IN USA.
[Williams, Linda S.; Ordin, Diana L.; Bravata, Dawn M.] Richard L Roudebush VA Med Ctr, HSR & D Ctr Implementing Evidence Based Practice, Indianapolis, IN USA.
[Williams, Linda S.] Richard L Roudebush VA Med Ctr, Dept Neurol, Indianapolis, IN USA.
[Hebert, Paul L.] Puget Sound Med Ctr, Ctr Excellence, VA HSR & D NW Ctr Outcomes Res Older Adults, Seattle, WA USA.
[Ordin, Diana L.] Dept Vet Affairs, Off Informat & Analyt, Washington, DC USA.
RP Cheng, EM (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
EM eric.cheng@va.gov
FU Veterans Administration [RRP 09-184, RRP 09-185]; VHA HSR&D Center of
Excellence on Implementing Evidence-Based Practice (CIEBP); Richard L.
Roudebush VA Medical Center, Indianapolis; VHA HSR&D Stroke Quality
Enhancement Research Initiative (QUERI) Program, Indianapolis, IN;
Career Development Award from NIH/NINDS [K23NS058571]; Project EXPORT
(NCMHD) [P20MD000182]; UCLA Outcomes Research Center; American Heart
Association Pharmaceutical Roundtable and David and Stevie Spina; Career
Development Award from the Veterans Administration
FX Supported by Veterans Administration RRP 09-184 (PI: Dr. Bravata) and
RRP 09-185 (PI: Dr. Keyhani) and by the VHA HSR&D Center of Excellence
on Implementing Evidence-Based Practice (CIEBP), Richard L. Roudebush VA
Medical Center, Indianapolis, and the VHA HSR&D Stroke Quality
Enhancement Research Initiative (QUERI) Program, Indianapolis, IN. Dr.
Cheng is supported by a Career Development Award from NIH/NINDS
(K23NS058571), by Project EXPORT (NCMHD grants P20MD000182), and by the
UCLA Outcomes Research Center, funded through the American Heart
Association Pharmaceutical Roundtable and David and Stevie Spina. Dr.
Keyhani is supported by a Career Development Award from the Veterans
Administration. The views expressed in this article are those of the
authors and do not necessarily represent the views of the Department of
Veterans Affairs.
NR 34
TC 12
Z9 12
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUL
PY 2012
VL 79
IS 2
BP 138
EP 144
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 971XV
UT WOS:000306241000011
PM 22700815
ER
PT J
AU Yeh, BM
Yee, J
AF Yeh, Benjamin M.
Yee, Judy
TI State-of-the-Art PET/CT of the Pancreas: Current Role and Emerging
Indications Invited Commentary
SO RADIOGRAPHICS
LA English
DT Editorial Material
ID CT
C1 [Yeh, Benjamin M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Yee, Judy] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA.
RP Yeh, BM (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
NR 7
TC 0
Z9 0
U1 0
U2 1
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271-5333
J9 RADIOGRAPHICS
JI Radiographics
PD JUL-AUG
PY 2012
VL 32
IS 4
BP 1158
EP 1160
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 972OE
UT WOS:000306285600018
ER
PT J
AU Bauman, WA
Biering-Sorensen, F
Krassioukov, A
AF Bauman, W. A.
Biering-Sorensen, F.
Krassioukov, A.
TI International spinal cord injury endocrine and metabolic basic data set
(version 1.2)
SO SPINAL CORD
LA English
DT Letter
C1 [Bauman, W. A.] James J Peters Vet Affairs Med Ctr, Vet Affairs Rehabil Res & Dev Ctr Excellence Med, Bronx, NY USA.
[Biering-Sorensen, F.] Univ Copenhagen, Rigshosp, Clin Spinal Cord Injuries, Ctr Neurosci, DK-2100 Copenhagen, Denmark.
[Biering-Sorensen, F.] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark.
[Krassioukov, A.] Univ British Columbia, Dept Med, ICORD, Vancouver, BC, Canada.
[Krassioukov, A.] Vancouver Coastal Hlth, Vancouver, BC, Canada.
RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Vet Affairs Rehabil Res & Dev Ctr Excellence Med, Bronx, NY USA.
EM william.bauman@va.gov
NR 1
TC 4
Z9 4
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD JUL
PY 2012
VL 50
IS 7
BP 567
EP 567
DI 10.1038/sc.2012.37
PG 1
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 972NB
UT WOS:000306282700021
PM 22508533
ER
PT J
AU Shea, JA
Weissman, A
McKinney, S
Silber, JH
Volpp, KG
AF Shea, Judy A.
Weissman, Arlene
McKinney, Sean
Silber, Jeffrey H.
Volpp, Kevin G.
TI Internal Medicine Trainees' Views of Training Adequacy and Duty Hours
Restrictions in 2009
SO ACADEMIC MEDICINE
LA English
DT Article
ID WORK-HOURS; RESIDENTS PERCEPTIONS; ACCREDITATION-COUNCIL; SURGICAL
RESIDENTS; HOURS REGULATIONS; SLEEP; MORTALITY; REFORM; IMPACT;
REQUIREMENTS
AB Purpose
To gauge internal medicine (IM) trainees' perceptions regarding aspects of their inpatient rotations, including supervision, educational opportunities, the perceived effect of duty hours regulations on quality of patient care, the causes of medical errors, and sleep.
Method
The authors analyzed the results of questionnaires administered to trainees following the October 2009 in-training examinations (ITE).
Results
Of the 21,768 IM trainees in postgraduate years 1 through 3 who took the IM-ITE, 18,272 (83.9%) responded. The majority of these trainees (87.7%) reported that supervision was adequate, and nearly half (46.3%) reported insufficient or minimal time to participate in learning activities. Two-thirds or more thought that specific work regulations such as limited shift length and more time off after nights and extended shifts would at least "occasionally," if not "usually" or "always," improve patient care. IM trainees at least "occasionally" attributed errors to workload (68.8% of respondents), fatigue (66.9%), inexperience or lack of knowledge (61.0%), incomplete handoffs (60.2%), and insufficient ancillary staff (53.5%). IM trainees' sleep hours were limited during extended and overnight shifts.
Conclusions
IM trainees agree that limited educational opportunities are the weakest part of the average inpatient rotation. Few have complaints about the adequacy of supervision. These trainees' optimism regarding the positive influence of potential work hours restrictions on patient care and their views of likely causes of medical errors suggest the need for innovative patient care schedules and education curricula.
C1 [Shea, Judy A.; Silber, Jeffrey H.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weissman, Arlene] Amer Coll Physicians, Res Ctr, Philadelphia, PA USA.
[McKinney, Sean] Amer Coll Physicians, Self Assessment Programs, Philadelphia, PA USA.
[Silber, Jeffrey H.; Volpp, Kevin G.] Univ Penn, Wharton Sch Business, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Philadelphia Vet Affairs Med Ctr, CHERP, Philadelphia, PA 19104 USA.
RP Shea, JA (reprint author), Univ Penn, Perelman Sch Med, 1223 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM sheaja@mail.med.upenn.edu
FU NHLBI [1R01HL094593]
FX The work was supported by NHLBI grant #1R01HL094593: Work Hour
Regulation for Physician Trainees: Educational and Clinical Outcomes
(Volpp).
NR 30
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD JUL
PY 2012
VL 87
IS 7
BP 889
EP 894
DI 10.1097/ACM.0b013e3182582583
PG 6
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 967HL
UT WOS:000305897400017
PM 22622211
ER
PT J
AU Shea, JA
Willett, LL
Borman, KR
Itani, KMF
McDonald, FS
Call, SA
Chaudhry, S
Adams, M
Chacko, KM
Volpp, KG
Arora, VM
AF Shea, Judy A.
Willett, Lisa L.
Borman, Karen R.
Itani, Kamal M. F.
McDonald, Furman S.
Call, Stephanie A.
Chaudhry, Saima
Adams, Michael
Chacko, Karen M.
Volpp, Kevin G.
Arora, Vineet M.
TI Anticipated Consequences of the 2011 Duty Hours Standards: Views of
Internal Medicine and Surgery Program Directors
SO ACADEMIC MEDICINE
LA English
DT Article
ID RESIDENCY PROGRAM; ACCREDITATION COUNCIL; SURGICAL RESIDENTS;
NATIONAL-SURVEY; HOURS REFORM; IMPACT; ACGME; REGULATIONS; EDUCATION;
MORTALITY
AB Purpose
To assess internal medicine (IM) and surgery program directors' views of the likely effects of the 2011 Accreditation Council for Graduate Medical Education duty hours regulations.
Method
In fall 2010, investigators surveyed IM and surgery program directors, assessing their views of the likely impact of the 2011 duty hours standards on learning environment, workload, education opportunities, program administration, and patient outcomes.
Results
Of 381 IM program directors, 287 (75.3%) responded; of 225 surgery program directors, 118 (52.4%) responded. Significantly more surgeons than internists indicated that the new regulations would likely negatively impact learning climate, including faculty morale and residents' relationships (P < .001). Most leaders in both specialties (80.8% IM, 80.2% surgery) felt that the regulations would likely increase faculty workload (P = .73). Both IM (82.2%) and surgery (96.6%) leaders most often rated, of all education opportunities, first-year resident clinical experience to be adversely affected (P < .001). Respondents from both specialties indicated that they will hire more nonphysician/midlevel providers (59.5% IM, 89.0% surgery, P < .001) and use more nonteaching services (66.8% IM, 70.1% surgery, P = .81). Respondents expect patient safety (45.1% IM, 76.9% surgery, P < .001) and continuity of care (83.6% IM across all training levels, 97.5% surgery regarding first-year residents) to decrease.
Conclusions
IM and surgery program directors agree that the 2011 duty hours regulations will likely negatively affect the quality of the learning environment, workload, education opportunities, program administration, and patient outcomes. Careful evaluation of actual impact is important.
C1 [Shea, Judy A.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Willett, Lisa L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Borman, Karen R.] Abington Mem Hosp, Philadelphia, PA USA.
[Borman, Karen R.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
[Itani, Kamal M. F.] Vet Affairs Boston Hlth Care Syst, Surg Serv, Boston, MA USA.
[Itani, Kamal M. F.] Boston Univ, Boston, MA 02215 USA.
[McDonald, Furman S.] Mayo Clin Internal Med Residency, Rochester, MN USA.
[Call, Stephanie A.] Virginia Commonwealth Univ, Richmond, VA USA.
[Chaudhry, Saima] Hofstra N Shore LIJ Sch Med, Residency Program Internal Med, Hempstead, NY USA.
[Adams, Michael] MedStar Georgetown Univ Hosp, Washington, DC USA.
[Chacko, Karen M.] Univ Colorado, Primary Care Internal Med Residency Training Prog, Denver, CO 80202 USA.
[Volpp, Kevin G.] Univ Penn, CHERP, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Wharton Sch Business, Philadelphia, PA 19104 USA.
[Arora, Vineet M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
RP Shea, JA (reprint author), Univ Penn, Perelman Sch Med, 1223 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM sheaja@mail.med.upenn.edu
OI Arora, Vineet/0000-0002-4745-7599
FU National Heart, Lung, and Blood Institute [1R01HL094593]
FX The work was supported by National Heart, Lung, and Blood Institute
grant no. 1R01HL094593: Work Hour Regulation for Physician Trainees:
Educational and Clinical Outcomes (Volpp).
NR 32
TC 21
Z9 21
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD JUL
PY 2012
VL 87
IS 7
BP 895
EP 903
DI 10.1097/ACM.0b013e3182584118
PG 9
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 967HL
UT WOS:000305897400018
PM 22622221
ER
PT J
AU Hauer, KE
Carney, PA
Chang, A
Satterfield, J
AF Hauer, Karen E.
Carney, Patricia A.
Chang, Anna
Satterfield, Jason
TI Behavior Change Counseling Curricula for Medical Trainees: A Systematic
Review
SO ACADEMIC MEDICINE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; PATIENT-CENTERED APPROACH; FAMILY-PRACTICE
RESIDENTS; SEXUAL HISTORY INQUIRY; PRIMARY-CARE PRACTICE;
SMOKING-CESSATION; STANDARDIZED PATIENTS; HEALTH-CARE; UNITED-STATES;
EDUCATION RESEARCH
AB Purpose
Unhealthy behaviors contribute to half of U. S. deaths. However, physicians lack sufficient skill in counseling patients to change behaviors. Characterizing effective published curricular interventions for behavior change counseling for medical trainees would inform educators toward improved training.
Method
The authors conducted a systematic literature search of studies published between 1965 and 2011 evaluating curricula on behavior change counseling for medical trainees. Included studies described behavior change counseling, teaching interventions for medical trainees, and assessment of interventions. The authors extracted eligible articles, rated outcomes for learners and patients using Kirkpatrick's hierarchy, and determined study quality.
Results
Of 2,788 identified citations, 109 met inclusion criteria. Most studies were performed in the United States (98), 93 at a single institution, and 81 in primary care settings. Curricular topics for counseling included smoking (67 studies), nutrition (30), alcohol/drug use (26), and exercise (22). Although most studies did not include theoretical frameworks, 39 used the Transtheoretical Model of Change. Sixty-two studies involved eight or fewer hours of curricular time, and 51 spanned four or fewer weeks. The studies with highest-level outcomes and quality employed multiple curricular techniques and included practice of counseling techniques in either simulated or actual clinical settings.
Conclusions
Existing literature suggests that trainees learn behavior change counseling through active, realistic practice and implementation of reminder and feedback systems within actual clinical practice settings. Multiinstitutional medical education research on methods of teaching behavior change counseling that influence patients' health outcomes are needed to ensure trainees' clinical competence and improve patient care.
C1 [Hauer, Karen E.; Satterfield, Jason] Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA.
[Carney, Patricia A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Chang, Anna] Dept Med, Div Geriatr, San Francisco, CA USA.
[Chang, Anna] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Hauer, KE (reprint author), Univ Calif San Francisco, Dept Med, Sch Med, 505 Parnassus Ave,M1078,Box 0120, San Francisco, CA 94143 USA.
EM karen.hauer@ucsf.edu
FU NIH/NCCAM [K07 AT003131]; NIH.NCI [CA121457]; University of California,
San Francisco Department of Medicine; Haile T. Debas Academy of Medical
Educators
FX This study was funded in part by NIH/NCCAM (K07 AT003131-Drs.
Satterfield, Hauer), the Gold-Headed Cane Endowed Education Chair in
Internal Medicine (University of California, San Francisco Department of
Medicine and the Haile T. Debas Academy of Medical Educators) (Dr.
Hauer), and NIH.NCI CA121457 (Dr. Carney).
NR 86
TC 20
Z9 20
U1 2
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-2446
J9 ACAD MED
JI Acad. Med.
PD JUL
PY 2012
VL 87
IS 7
BP 956
EP 968
DI 10.1097/ACM.0b013e31825837be
PG 13
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA 967HL
UT WOS:000305897400026
PM 22622220
ER
PT J
AU McBane, S
Thomas, T
Karr, S
Kelley, KW
AF McBane, Sarah
Thomas, Tyan
Karr, Samantha
Kelley, Kristi W.
TI Serving as a student preceptor: Focus on emerging challenges
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Editorial Material
ID EDUCATION
C1 [McBane, Sarah] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
[Thomas, Tyan] Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA USA.
[Thomas, Tyan] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Karr, Samantha] Midwestern Univ, Coll Pharm Glendale, Glendale, AZ USA.
[Kelley, Kristi W.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
[Kelley, Kristi W.] Baptist Hlth Syst Inc, Continu Clin, Trinity Med Ctr, Birmingham, AL USA.
RP McBane, S (reprint author), Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0719, La Jolla, CA 92093 USA.
EM smcbane@ucsd.edu
NR 9
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD JUL 1
PY 2012
VL 69
IS 13
BP 1110
EP 1111
DI 10.2146/ajhp110291
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 969EB
UT WOS:000306037400013
PM 22722589
ER
PT J
AU Singh, RP
Waldron, RT
Hahn, BH
AF Singh, Ram P.
Waldron, Richard T.
Hahn, Bevra H.
TI Genes, tolerance and systemic autoimmunity
SO AUTOIMMUNITY REVIEWS
LA English
DT Review
DE Autoimmunity; Systemic lupus erythematosus; Genes; Tolerance; CD8(+)Ti
ID REGULATORY T-CELLS; VERSUS-HOST-DISEASE; GENERATED EX-VIVO;
COMPLEMENTARITY-DETERMINING REGION-1; INTERFERON-INDUCIBLE GENE;
LUPUS-LIKE DISEASE; MURINE LUPUS; MEDIATED SUPPRESSION; SUSCEPTIBILITY
GENE; PROGRAMMED DEATH-1
AB The characterization of functional CD8(+) inhibitory or regulatory T cells and their gene regulation remains a critical challenge in the field of tolerance and autoimmunity. Investigating the genes induced in regulatory cells and the regulatory networks and pathways that underlie mechanisms of immune resistance and prevent apoptosis in the CD8(+) T cell compartment are crucial to understanding tolerance mechanisms in systemic autoimmunity. Little is currently known about the genetic control that governs the ability of CD8(+) Ti or regulatory cells to suppress anti-DNA Ab production in B cells. Silencing genes with siRNA or shRNA and overexpression of genes with lentiviral cDNA transduction are established approaches to identifying and understanding the function of candidate genes in tolerance and immunity. Elucidation of interactions between genes and proteins, and their synergistic effects in establishing cell-cell cross talk, including receptor modulation/antagonism, are essential for delineating the roles of these cells. In this review, we will examine recent reports which describe the modulation of cells from lupus prone mice or lupus patients to confer anti-inflammatory and protective gene expression and novel associated phenotypes. We will highlight recent findings on the role of selected genes induced by peptide tolerance in CD8(+) Ti. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Singh, Ram P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Pancreat Res Grp, VA Greater Los Angeles Healthcare Syst,Dept Med,D, Los Angeles, CA 90095 USA.
RP Singh, RP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA.
EM rpsingh@mednet.ucla.edu
FU NIH [AR54034, AI083894, AI65645]; UCLA Clinical Translational Seed Grant
(CTSG); American Autoimmune Related Disease Association grant (AARDA);
TEVA Pharmaceuticals; UCLA Senate Core Grant
FX RPS is supported by NIH grants AR54034, AI083894, AI65645, UCLA Clinical
Translational Seed Grant (CTSG) and the American Autoimmune Related
Disease Association grant (AARDA). BHH is supported by an award from
TEVA Pharmaceuticals. BHH and RPS are also supported by UCLA Senate Core
Grant.
NR 114
TC 15
Z9 15
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1568-9972
J9 AUTOIMMUN REV
JI Autoimmun. Rev.
PD JUL
PY 2012
VL 11
IS 9
BP 664
EP 669
DI 10.1016/j.autrev.2011.11.017
PG 6
WC Immunology
SC Immunology
GA 967TU
UT WOS:000305931500010
PM 22155015
ER
PT J
AU El-Serag, HB
AF El-Serag, Hashem B.
TI The New Board of Editors for Clinical Gastroenterology and Hepatology:
Our Vision and Plans
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
C1 Baylor Coll Med, Houston VA Med Ctr, Houston, TX 77030 USA.
RP El-Serag, HB (reprint author), Baylor Coll Med, Houston VA Med Ctr, Houston, TX 77030 USA.
EM hasheme@bcm.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JUL
PY 2012
VL 10
IS 7
BP 690
EP 691
DI 10.1016/j.cgh.2012.05.001
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 969QA
UT WOS:000306069300003
PM 22721437
ER
PT J
AU Ezra, N
Hamid, O
Behroozan, D
AF Ezra, Navid
Hamid, Omid
Behroozan, Daniel
TI Eruptive Squamous Cell Carcinomas Associated with BRAF-Inhibitor Therapy
in a Patient with Metastatic Melanoma
SO DERMATOLOGIC SURGERY
LA English
DT Editorial Material
ID RAF INHIBITORS; RAS/RAF/MEK/ERK PATHWAY; ACTINIC KERATOSES; GENE
MUTATION; MAPK PATHWAY; HUMAN SKIN; CANCER; SORAFENIB; KERATOACANTHOMAS;
PROGRESSION
C1 [Behroozan, Daniel] Dermatol Inst So Calif, Santa Monica, CA 90405 USA.
[Ezra, Navid; Behroozan, Daniel] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Dept Med, Los Angeles, CA 90095 USA.
[Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA.
[Behroozan, Daniel] W Los Angeles Vet Adm Med Ctr, Dept Dermatol, Los Angeles, CA USA.
RP Behroozan, D (reprint author), Dermatol Inst So Calif, 2221 Lincoln Blvd,Suite 100, Santa Monica, CA 90405 USA.
EM db@dermsurgery.net
NR 39
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1076-0512
EI 1524-4725
J9 DERMATOL SURG
JI Dermatol. Surg.
PD JUL
PY 2012
VL 38
IS 7
BP 1086
EP 1090
DI 10.1111/j.1524-4725.2012.02396.x
PN 1
PG 5
WC Dermatology; Surgery
SC Dermatology; Surgery
GA 967XC
UT WOS:000305940400022
PM 22563699
ER
PT J
AU Sosenko, JM
Skyler, JS
Mahon, J
Krischer, JP
Beam, CA
Boulware, DC
Greenbaum, CJ
Rafkin, LE
Cowie, C
Cuthbertson, D
Palmer, JP
AF Sosenko, Jay M.
Skyler, Jay S.
Mahon, Jeffrey
Krischer, Jeffrey P.
Beam, Craig A.
Boulware, David C.
Greenbaum, Carla J.
Rafkin, Lisa E.
Cowie, Catherine
Cuthbertson, David
Palmer, Jerry P.
CA Type 1 Diabet TrialNet & Diabet Pr
TI The Application of the Diabetes Prevention Trial-Type 1 Risk Score for
Identifying a Preclinical State of Type 1 Diabetes
SO DIABETES CARE
LA English
DT Article
ID BETA-CELL FUNCTION; GLUCOSE-TOLERANCE; INSULIN; ONSET; TRIAL-TYPE-1;
MELLITUS; PARTICIPANTS; PROGRESSION; ANTIBODIES
AB OBJECTIVE-We assessed the utility of the Diabetes Prevention Trial Type 1 Risk Score (DPTRS) for identifying individuals who are highly likely to progress to type 1 diabetes (T ID) within 2 years.
RESEARCH DESIGN AND METHODS-The DPTRS was previously developed from Diabetes Prevention Trial Type 1 (DPT-1) data and was subsequently validated in the TrialNet Natural History Study (TNNHS). DPTRS components included C-peptide and glucose indexes from oral glucose tolerance testing, along with age and BM1. The cumulative incidence of T ID was determined after DPTRS thresholds were first exceeded and after the first occurrences of glucose abnormalities.
RESULTS-The 2-year risks after the 9.00 DPTRS threshold was exceeded were 0.88 and 0.77 in DPT-1 (n = 90) and the TNNHS (n = 69), respectively. In DPT-1, the 2-year risks were much lower after dysglycemia first occurred (0.37; n = 306) and after a 2-h glucose value between 190 and 199 mg/dL was first reached (0.64; n = 59). Among those who developed T1D in DPT-1, the 9.00 threshold was exceeded 0.81 +/- 0.53 years prior to the conventional diagnosis. Post-challenge C-peptide levels were substantially higher (P = 0.001 for 30 min; P < 0.001 for other time points) when the 9.00 threshold was first exceeded compared with the levels at diagnosis.
CONCLUSIONS-A DPTRS threshold of 9.00 identifies individuals who are very highly likely to progress to the conventional diagnosis of T ID within 2 years and, thus, are essentially in a preclinical diabetic state. The 9.00 threshold is exceeded well before diagnosis, when stimulated C-peptide levels are substantially higher. Diabetes Care 35:1552-1555,2012
C1 [Sosenko, Jay M.; Skyler, Jay S.; Rafkin, Lisa E.] Univ Miami, Div Endocrinol, Miami, FL 33136 USA.
[Mahon, Jeffrey] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada.
[Krischer, Jeffrey P.; Beam, Craig A.; Boulware, David C.] Univ S Florida, Div Informat & Biostat, Tampa, FL USA.
[Greenbaum, Carla J.] Benaroya Res Inst Virginia Mason, Seattle, WA USA.
[Cowie, Catherine] NIDDK, NIH, Bethesda, MD USA.
[Cuthbertson, David] Univ S Florida, Pediat Epidemiol Ctr, Tampa, FL USA.
[Palmer, Jerry P.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, Miami, FL 33136 USA.
EM jsosenko@med.miami.edu
RI Skyler, Jay/F-4211-2016
FU National Institutes of Health through the National Institute of Diabetes
and Digestive and Kidney Diseases; National Institute of Allergy and
Infectious Diseases; Eunice Kennedy Shriver National Institute for Child
Health and Human Development; National Center for Research Resources;
Juvenile Diabetes Research Foundation International; American Diabetes
Association
FX This work was funded by the National Institutes of Health through the
National Institute of Diabetes and Digestive and Kidney Diseases, the
National Institute of Allergy and Infectious Diseases, the Eunice
Kennedy Shriver National Institute for Child Health and Human
Development, and the National Center for Research Resources; by the
Juvenile Diabetes Research Foundation International; and by the American
Diabetes Association.
NR 20
TC 17
Z9 17
U1 0
U2 1
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUL
PY 2012
VL 35
IS 7
BP 1552
EP 1555
DI 10.2337/dc12-0011
PG 4
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 962MJ
UT WOS:000305548900026
PM 22547092
ER
PT J
AU Machado-Salas, J
Avila-Costa, MR
Guevara, P
Guevara, J
Duron, RM
Bai, DS
Tanaka, M
Yamakawa, K
Delgado-Escueta, AV
AF Machado-Salas, Jesus
Rosa Avila-Costa, Maria
Guevara, Patricia
Guevara, Jorge
Duron, Reyna M.
Bai, Dongsheng
Tanaka, Miyabi
Yamakawa, Kazuhiro
Delgado-Escueta, Antonio V.
TI Ontogeny of Lafora bodies and neurocytoskeleton changes in
Laforin-deficient mice
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Lafora body disease; Laforin protein; Mouse; Cytoskeleton
ID PROGRESSIVE MYOCLONUS EPILEPSY; GLYCOGEN-SYNTHASE KINASE-3; POLYGLUCOSAN
BODIES; BIELSCHOWSKY BODIES; INCLUSION-BODIES; NERVOUS-SYSTEM;
TAU-PROTEIN; EPM2A GENE; AGED DOGS; DISEASE
AB Lafora disease (LD) is an autosomal recessive, always fatal progressive myoclonus epilepsy with rapid cognitive and neurologic deterioration. One of the pathological hallmarks of LD is the presence of cytoplasmic PAS + polyglucosan inclusions called Lafora bodies (LBs). Current clinical and neuropathological views consider LBs to be the cause of neurological derangement of patients. A systematic study of the ontogeny and structural features of the LBs has not been done in the past. Therefore, we undertook a detailed microscopic analysis of the neuropile of a Laforin-deficient (epm2a-/-) mouse model. Wild type and epm2a-/- mice were sacrificed at different ages and their encephalon processed for light microscopy. Luxol-fast-blue, PAS, Bielschowski techniques, as well as immunocytochemistry (TUNEL, Caspase-3, Apaf-1, Cytochrome-C and Neurofilament L antibodies) were used. Young null mice (11 days old) showed necrotic neuronal death in the absence of LBs. Both cell death and LBs showed a progressive increment in size and number with age. Type I LBs emerged at two weeks of age and were distributed in somata and neurites. Type 11 LBs appeared around the second month of age and always showed a complex architecture and restricted to neuronal somata. Their number was considerably less than type I LBs. Bielschowski method showed neurofibrillary degeneration and senile-like plaques. These changes were more prominent in the hippocampus and ventral pons. Neurofibrillary tangles were already present in 11 days-old experimental animals, whereas senile-like plaques appeared around the third to fourth month of life. The encephalon of null mice was not uniformly affected: Diencephalic structures were spared, whereas cerebral cortex, basal ganglia, pons, hippocampus and cerebellum were notoriously affected. This uneven distribution was present even within the same structure, i.e., hippocampal sectors. Of special relevance, was the observation of the presence of immunoreactivity to neurofilament L on the external rim of type II LBs. Perhaps, type II LB is not the end point of a metabolic abnormality. Instead, we suggest that type II LB is a highly specialized structural and functional entity that emerges as a neuronal response to major carbohydrate metabolism impairment. Early necrotic cell death, neurocytoskeleton derangement, different structural and probably functional profiles for both forms of LBs, a potential relationship between the external rim of the LB type II and the cytoskeleton and an uneven distribution of these abnormalities indicate that LD is both a complex neurodegenerative disease and a glycogen metabolism disorder. Our findings are critical for future studies on disease mechanisms and therapies for LD. Interestingly, the neurodegenerative changes observed in this LD model can also be useful for understanding the process of dementia. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Machado-Salas, Jesus; Duron, Reyna M.; Bai, Dongsheng; Tanaka, Miyabi; Delgado-Escueta, Antonio V.] VA Greater Los Angeles Healthcare Syst, W Los Angeles Med Ctr, Epilepsy Ctr Excellence Neurol & Res Serv, Epilepsy Genet Genom Labs, Los Angeles, CA USA.
[Rosa Avila-Costa, Maria] Univ Nacl Autonoma Mexico, UNAM, Neurosci Dept FES Iztacala, Mexico City, DF, Mexico.
[Guevara, Patricia] Natl Inst Neurol & Neurosurg Manuel Velasco Suare, Mexico City, DF, Mexico.
[Guevara, Jorge] Univ Nacl Autonoma Mexico, UNAM, Fac Med, Dept Biochem, Mexico City, DF, Mexico.
[Yamakawa, Kazuhiro] RIKEN Brain Sci Inst, Saitama, Japan.
[Machado-Salas, Jesus; Duron, Reyna M.; Bai, Dongsheng; Tanaka, Miyabi; Delgado-Escueta, Antonio V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Machado-Salas, J (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Genet Genom Labs, Los Angeles, CA 90073 USA.
EM msmdphd@hotmail.com
RI Yamakawa, Kazuhiro/N-5050-2015
OI Duron, Reyna M./0000-0002-9425-2289; Delgado-Escueta, Antonio
V./0000-0002-1581-6999
FU National Institutes of Health [1RO1NS055057]; Chelsea's Hope Foundation
for Lafora Disease; Programa de Apoyo a Proyectos de Investigacion e
Innovacion Tecnologica-DGAPA UNAM [IN214609, 1220111, PAPCA 2010-2011]
FX This work was supported by the grants from: National Institutes of
Health [1RO1NS055057], Chelsea's Hope Foundation for Lafora Disease,
Programa de Apoyo a Proyectos de Investigacion e Innovacion
Tecnologica-DGAPA UNAM [IN214609, 1220111 and PAPCA 2010-2011].
NR 51
TC 2
Z9 2
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
EI 1090-2430
J9 EXP NEUROL
JI Exp. Neurol.
PD JUL
PY 2012
VL 236
IS 1
BP 131
EP 140
DI 10.1016/j.expneurol.2012.04.008
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 959IM
UT WOS:000305306100015
PM 22542948
ER
PT J
AU De Costa, AMA
Justis, DN
Schuyler, CA
Young, MRI
AF De Costa, Anna-Maria A.
Justis, Danielle N.
Schuyler, Corinne A.
Young, M. Rita I.
TI Administration of a vaccine composed of dendritic cells pulsed with
premalignant oral lesion lysate to mice bearing carcinogen-induced
premalignant oral lesions stimulates a protective immune response
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE HNSCC; Premalignant; Immunotherapy; Dendritic cell vaccination
ID NECK-CANCER; TH17 CELLS; T-CELLS; HEAD; SUPPRESSION; GENERATION;
REACTIVITY; CYTOKINES
AB The use of dendritic cell (DC) vaccines as treatment for malignancy is complicated by immune evasion tactics often employed by carcinomas such as head and neck squamous cell carcinoma (HNSCC). The present study aims to determine if an immune response can be elicited by administering a DC vaccine during the premalignant stages of HNSCC, prior to development of immune escape. Mice treated with the carcinogen 4-nitroquinoline 1-oxide (4NQO) in drinking water develop premalignant oral lesions that progress to HNSCC. As previous studies demonstrated that premalignant lesions and HNSCC overexpress common tumor antigens, bone marrow-derived DCs were pulsed with premalignant lesion lysate (DCpm) and administered to 4NQO-treated mice exhibiting premalignant lesions. Lesion progression was tracked through endoscopy. which revealed that DCpm vaccination and control vaccination with dendritic cells pulsed with normal tongue epithelium lysate (DCnt) significantly decreased lesion burden at 8 weeks. Analysis of lymph node cells revealed that while DCnt vaccination resulted in a rapid increase in total lymphocyte count, levels of activated conventional CD4(+) T cells and Th1, Tc1, Th17, Tc17, and Th2 cells, DCpm vaccination results in a delayed, yet substantial, increase in these immune effector mechanisms. This suggests that dendritic cell vaccination may have a beneficial effect on clinical outcome regardless of type of antigenic stimulation. Also, pulsing DCs with premalignant lysate rather than normal tongue epithelium lysate affects the dendritic cells in a way that delays the immune effector response upon vaccination of premalignant lesion-bearing mice. Published by Elsevier B.V.
C1 [De Costa, Anna-Maria A.; Schuyler, Corinne A.; Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
[De Costa, Anna-Maria A.; Justis, Danielle N.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29401 USA.
[De Costa, Anna-Maria A.; Justis, Danielle N.; Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29401 USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA.
EM rita.young@va.gov
FU Biomedical Laboratory and Clinical Sciences Programs of the Department
of Veterans Affairs; National Institute of Health (MRIY) [101-CX000100,
R01-CA128837, R01-DE018268]
FX This work has been supported by awards from the Biomedical Laboratory
and Clinical Sciences Programs of the Department of Veterans Affairs and
by grants from the National Institute of Health (MRIY, 101-CX000100,
R01-CA128837 and R01-DE018268).
NR 26
TC 6
Z9 8
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUL
PY 2012
VL 13
IS 3
BP 322
EP 330
DI 10.1016/j.intimp.2012.05.004
PG 9
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 969EC
UT WOS:000306037500014
PM 22609090
ER
PT J
AU High, KP
Brennan-Ing, M
Clifford, DB
Cohen, MH
Currier, J
Deeks, SG
Deren, S
Effros, RB
Gebo, K
Goronzy, JJ
Justice, AC
Landay, A
Levin, J
Miotti, PG
Munk, RJ
Nass, H
Rinaldo, CR
Shlipak, MG
Tracy, R
Valcour, V
Vance, DE
Walston, JD
Volberding, P
AF High, Kevin P.
Brennan-Ing, Mark
Clifford, David B.
Cohen, Mardge H.
Currier, Judith
Deeks, Steven G.
Deren, Sherry
Effros, Rita B.
Gebo, Kelly
Goronzy, Joerg J.
Justice, Amy C.
Landay, Alan
Levin, Jules
Miotti, Paolo G.
Munk, Robert J.
Nass, Heidi
Rinaldo, Charles R., Jr.
Shlipak, Michael G.
Tracy, Russell
Valcour, Victor
Vance, David E.
Walston, Jeremy D.
Volberding, Paul
CA OAR Working Grp HIV Aging
TI HIV and Aging: State of Knowledge and Areas of Critical Need for
Research. A Report to the NIH Office of AIDS Research by the HIV and
Aging Working Group
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE aging; HIV/AIDS; co-morbidity; research priorities
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONIC KIDNEY-DISEASE; OLDER-ADULTS;
CARDIOVASCULAR-DISEASE; INFECTED PATIENTS; IMMUNE-SYSTEM; COHORT;
BIOMARKERS; RISK; INFLAMMATION
AB HIV risk behaviors, susceptibility to HIV acquisition, progression of disease after infection, and response to antiretroviral therapy all vary by age. In those living with HIV, current effective treatment has increased the median life expectancy to >70 years of age. Biologic, medical, individual, social, and societal issues change as one ages with HIV infection, but there has been only a small amount of research in this field. Therefore, the Office of AIDS Research of the National Institutes of Health commissioned a working group to develop an outline of the current state of knowledge and areas of critical need for research in HIV and Aging; the working groups' findings and recommendations are summarized in this report. Key overarching themes identified by the group included the following: multimorbidity, polypharmacy, and the need to emphasize maintenance of function; the complexity of assessing HIV versus treatment effects versus aging versus concurrent disease; the inter-related mechanisms of immune senescence, inflammation, and hypercoagulability; the utility of multivariable indices for predicting outcomes; a need to emphasize human studies to account for complexity; and a required focus on issues of community support, caregivers, and systems infrastructure. Critical resources are needed to enact this research agenda and include expanded review panel expertise in aging, functional measures, and multimorbidity, and facilitated use and continued funding to allow long-term follow-up of cohorts aging with HIV.
C1 [High, Kevin P.] Wake Forest Univ, Baptist Med Ctr, Infect Dis Sect, Dept Internal Med,Wake Forest Sch Med, Winston Salem, NC 27157 USA.
[Brennan-Ing, Mark] ACRIA Ctr HIV & Aging, New York, NY USA.
[Clifford, David B.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
[Cohen, Mardge H.] Rush Univ, Dept Internal Med, WIHS, Chicago, IL 60612 USA.
[Currier, Judith; Effros, Rita B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Currier, Judith; Effros, Rita B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Deren, Sherry] NYU, Coll Nursing, New York, NY USA.
[Gebo, Kelly] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
[Goronzy, Joerg J.] Stanford Univ, Sch Med, Dept Immunol & Rheumatol, Stanford, CA 94305 USA.
[Justice, Amy C.] Yale Univ, Dept Med, Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA.
[Landay, Alan] Rush Univ, Med Ctr, Dept Immunol & Microbiol, Chicago, IL 60612 USA.
[Levin, Jules] Natl AIDS Treatment Advocacy Project, Off AIDS Res, New York, NY USA.
[Miotti, Paolo G.] NIH, Off AIDS Res, DHHS, Rockville, MD USA.
[Munk, Robert J.] AIDS InfoNet, Arroyo Seco, NM USA.
[Rinaldo, Charles R., Jr.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
[Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, San Francisco, CA USA.
[Tracy, Russell] Univ Vermont, Coll Med, Dept Pathol & Biochem, Colchester, VT USA.
[Valcour, Victor] Univ Calif San Francisco, Dept Neurol, Div Geriatr Med, Memory & Aging Ctr, San Francisco, CA USA.
[Vance, David E.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA.
[Volberding, Paul] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Walston, Jeremy D.] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD USA.
RP High, KP (reprint author), Wake Forest Univ, Baptist Med Ctr, Infect Dis Sect, Dept Internal Med,Wake Forest Sch Med, 100 Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM khigh@wakehealth.edu
FU Office of AIDS Research, National Institutes of Health
FX Supported by the Office of AIDS Research, National Institutes of Health.
NR 88
TC 160
Z9 162
U1 5
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUL 1
PY 2012
VL 60
SU 1
BP S1
EP S18
PG 18
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 968ZH
UT WOS:000306024400001
PM 22688010
ER
PT J
AU Dille, MF
Wilmington, D
McMillan, GP
Helt, W
Fausti, SA
Konrad-Martin, D
AF Dille, Marilyn F.
Wilmington, Debra
McMillan, Garnett P.
Helt, Wendy
Fausti, Stephen A.
Konrad-Martin, Dawn
TI Development and Validation of a Cisplatin Dose-Ototoxicity Model
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE Cisplatin; ototoxicity; ototoxicity monitoring; Veterans
ID PRODUCT OTOACOUSTIC EMISSIONS; TESTICULAR CANCER; HEARING-LOSS;
RISK-FACTORS; CHEMOTHERAPY; SENSITIVITY; TOXICITY; CHILDREN; TINNITUS;
PROTOCOL
AB Background: Cisplatin is effective in the treatment of several cancers but is a known ototoxin resulting in shifts to hearing sensitivity in up to 50-60% of patients. Cisplatin-induced hearing shifts tend to occur first within an octave of a patient's high frequency hearing limit, termed the sensitive range for ototoxicity (SRO), and progress to lower frequencies. While it is currently not possible to know which patients will experience ototoxicity without testing their hearing directly, monitoring the SRO provides an early indication of damage. A tool to help forecast susceptibility to ototoxic-induced changes in the SRO in advance of each chemotherapy treatment visit may prove useful for ototoxicity monitoring efforts, patient counseling, and therapeutic planning.
Purpose: This project was designed to (1) establish pretreatment risk curves that quantify the probability that a new patient will suffer hearing loss within the SRO during treatment with cisplatin and (2) evaluate the accuracy of these predictions in an independent sample of Veterans receiving cisplatin for the treatment of cancer.
Study Sample: Two study samples were used. The Developmental sample contained 23 subjects while the Validation sample consisted of 12 subjects.
Data Collection and Analysis: Risk curve predictions for SRO threshold shifts following cisplatin exposure were developed using a Developmental sample comprised of data from a total of 155 treatment visits obtained in 45 ears of 23 Veterans. Pure-tone thresholds were obtained within each subject's SRO at each treatment visit and compared with baseline measures. The risk of incurring an SRO shift was statistically modeled as a function of factors related to chemotherapy treatment (cisplatin dose, radiation treatment, doublet medication) and patient status (age, pre-exposure hearing, cancer location and stage). The model was reduced so that only statistically significant variables were included. Receiver-operating characteristic (ROC) curve analyses were then used to determine the accuracy of the risk curve predictions in an independent Validation sample of observations from over 62 treatment visits obtained in 24 ears of 12 Veterans.
Results: Only cumulative cisplatin dose and pre-exposure hearing were found to be significantly related to the risk for hearing shift. The dose-ototoxicity risk curve predictions developed from the Developmental sample yielded area under the ROC curve accuracy estimates of 0.85 when applied to an independent Validation sample.
Conclusions: Cumulative cisplatin dose in combination with pre-exposure hearing provides an indication of whether hearing will shift in the SRO in advance of cisplatin administration. The validated dose-ototoxicity risk curves described herein can be used before and during treatment to anticipate hearing loss. While having such a tool would not replace serial hearing testing, it would be of great benefit to an ototoxicity monitoring program. It would promote relevant pretreatment counseling. Furthermore, for those found to be at risk of SRO shifts within the speech frequencies, the oncology treatment plan could incorporate anticipated dosing adjustments-that could stave off the impact that ototoxicity might bring.
C1 [Dille, Marilyn F.; Wilmington, Debra; McMillan, Garnett P.; Helt, Wendy; Fausti, Stephen A.; Konrad-Martin, Dawn] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res, Portland, OR 97201 USA.
[Dille, Marilyn F.; Wilmington, Debra; Fausti, Stephen A.; Konrad-Martin, Dawn] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA.
[McMillan, Garnett P.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
RP Dille, MF (reprint author), Portland VA Med Ctr, VA RR&D Natl Ctr Rehabil Auditory Res NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM Marilyn.Dille@va.gov
FU Department of Veterans Affairs RRD Service [C4183R, C7113N]; VA RR&D
National Center for Rehabilitative Auditory Research, Portland, OR;
Office of Rehabilitation Research and Development (RR&D) Service,
Department of Veterans Affairs [C4183R, C4447K]
FX Work supported by the Department of Veterans Affairs RR&D Service
(grants C4183R and C7113N) and the VA RR&D National Center for
Rehabilitative Auditory Research, Portland, OR.; This work was supported
by the Office of Rehabilitation Research and Development (RR&D) Service,
Department of Veterans Affairs (Grants C4183R and C4447K) and the VA
RR&D National Center for Rehabilitative Auditory Research, Portland, OR.
NR 44
TC 8
Z9 8
U1 1
U2 5
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD JUL-AUG
PY 2012
VL 23
IS 7
BP 510
EP 521
DI 10.3766/jaaa.23.7.3
PG 12
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA 969HI
UT WOS:000306045900003
PM 22992258
ER
PT J
AU Rodriguez-Ortiz, ME
Lopez, I
Munoz-Castaneda, JR
Martinez-Moreno, JM
Ramirez, AP
Pineda, C
Canalejo, A
Jaeger, P
Aguilera-Tejero, E
Rodriguez, M
Felsenfeld, A
Almaden, Y
AF Rodriguez-Ortiz, Maria E.
Lopez, Ignacio
Munoz-Castaneda, Juan R.
Martinez-Moreno, Julio M.
Peralta Ramirez, Alan
Pineda, Carmen
Canalejo, Antonio
Jaeger, Philippe
Aguilera-Tejero, Escolastico
Rodriguez, Mariano
Felsenfeld, Arnold
Almaden, Yolanda
TI Calcium Deficiency Reduces Circulating Levels of FGF23
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; VITAMIN-D METABOLISM; GROWTH-FACTOR 23;
SECONDARY HYPERPARATHYROIDISM; TRANSPLANT RECIPIENTS;
PARATHYROID-HORMONE; RECEPTOR 1; EXPRESSION; PHOSPHATE; KLOTHO
AB Fibroblast growth factor (FGF) 23 inhibits calcitriol production, which could exacerbate calcium deficiency or hypocalcemia unless calcium itself modulates FGF23 in this setting. In Wistar rats with normal renal function fed a diet low in both calcium and vitamin D, the resulting hypocalcemia was associated with low FGF23 despite high parathyroid hormone (PTH) and high calcitriol levels. FGF23 correlated positively with calcium and negatively with PTH. Addition of high dietary phosphorus to this diet increased FGF23 except in rats with hypocalcemia despite high PTH levels. In parathyroidectomized rats, an increase in dietary calcium for 10 days increased serum calcium, with an associated increase in FGF23, decrease in calcitriol, and no change in phosphorus. Also in parathyroidectomized rats, FGF23 increased significantly 6 hours after administration of calcium gluconate. Taken together, these results suggest that hypocalcemia reduces the circulating concentrations of FGF23. This decrease in FGF23 could be a response to avoid a subsequent reduction in calcitriol, which could exacerbate hypocalcemia.
C1 [Rodriguez, Mariano] Hosp Univ Reina Sofia, Unidad Invest, Serv Nefrol, IMIBIC, Cordoba 14004, Spain.
[Rodriguez-Ortiz, Maria E.; Munoz-Castaneda, Juan R.; Martinez-Moreno, Julio M.; Almaden, Yolanda] Hosp Univ Reina Sofia, IMIBIC, Res Unit, Cordoba 14004, Spain.
[Lopez, Ignacio; Pineda, Carmen; Aguilera-Tejero, Escolastico] Univ Cordoba, Dept Med & Cirugia Anim, Cordoba, Spain.
[Canalejo, Antonio] Univ Huelva, Dept Biol Ambiental & Salud Publ, Huelva, Spain.
[Jaeger, Philippe] UCL, Ctr Nephrol, London, England.
[Felsenfeld, Arnold] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Felsenfeld, Arnold] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Rodriguez, M (reprint author), Hosp Univ Reina Sofia, Unidad Invest, Serv Nefrol, IMIBIC, Avda Menendez Pidal S-N, Cordoba 14004, Spain.
EM juanm.rodriguez.sspa@juntadeandalucia.es
RI Canalejo, Antonio/L-8407-2014
OI Canalejo, Antonio/0000-0003-2098-8960; Pineda Martos, Carmen
Maria/0000-0002-3664-8699
FU Instituto Carlos III [FIS 07/0287, FIS 07/0315, 010/1311]; Consejeria de
Salud [JA 0127/2008]; UE Grant from Framework Programme 7 Syskid (FP7)
[241544]; Consejeria de Innovacion, Ciencia y Empresa of Junta de
Andalucia [CTS-5205, CTS-170]; Fundacion Progreso y Salud, Consejeria de
Salud (Junta de Andalucia); Amgen; Fresenius; Abbott; Shire
FX This study was supported by Instituto Carlos III (FIS 07/0287, FIS
07/0315, 010/1311), Consejeria de Salud (JA 0127/2008), a UE Grant from
Framework Programme 7 Syskid (FP7-241544), and Consejeria de Innovacion,
Ciencia y Empresa (CTS-5205 and CTS-170) of Junta de Andalucia. Y.A. is
a senior researcher supported by the Fundacion Progreso y Salud,
Consejeria de Salud (Junta de Andalucia).; M.R. has received research
grants from Amgen and Fresenius and lecture fees from the following
companies: Amgen, Abbott, Shire, and Fresenius.
NR 25
TC 82
Z9 84
U1 1
U2 31
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUL
PY 2012
VL 23
IS 7
BP 1190
EP 1197
DI 10.1681/ASN.2011101006
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 968ZZ
UT WOS:000306026800012
PM 22581996
ER
PT J
AU Reilly, LM
Rapp, JH
Grenon, SM
Hiramoto, JS
Sobel, J
Chuter, TAM
AF Reilly, Linda M.
Rapp, Joseph H.
Grenon, S. Marlene
Hiramoto, Jade S.
Sobel, Julia
Chuter, Timothy A. M.
TI Efficacy and durability of endovascular thoracoabdominal aortic aneurysm
repair using the caudally directed cuff technique
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
ID STENT-GRAFTS; HYBRID PROCEDURES; SURGICAL REPAIR; UNITED-STATES;
EXPERIENCE; MORTALITY; ENDOGRAFTS; MORBIDITY; OUTCOMES; IV
AB Purpose: This study determined early and intermediate results of multibranched endovascular thoracoabdominal (TAAA) and pararenal aortic aneurysm (PRAA) repair using a uniform operative technique.
Methods: Eighty-one patients (mean age, 73 +/- 8 years, 19 [23.5%] women) underwent endovascular TAAA repair in a prospective trial using self-expanding covered stents connecting axially oriented, caudally directed cuffs to target aortic branches. Mean aneurysm diameter was 67 +/- 10 mm. Thirty-nine TAAA (48.1%) were Crawford type II, III, or V; 42 (51.9%) were type IV or pararenal. Thirty-three procedures (40.7%) were staged. The insertion approach was femoral for aortic components and brachial for branch components. Follow-up assessments were performed at 1, 6, and 12 months, and yearly thereafter.
Results: All devices (n = 81) and branches (n = 306) were successfully inserted and deployed, with no conversions to open repair. Overall mortality was 6.2% (n = 5), including three perioperative (3.7%) and two late treatment-related deaths (2.5%). Permanent paraplegia occurred in three patients (3.7%), and transient paraplegia/paraparesis occurred in 16 (19.8%). Four patients (4.9%) required dialysis postoperatively, three permanently and one transiently. Women accounted for 67% of the paraplegia, 75% of the perioperative dialysis, and 60% of the perioperative or treatment-related deaths. During a mean follow-up of 21.2 months, no aneurysms ruptured, but four (4.9%) enlarged: two were successfully treated, one was unsuccessfully treated, and one was not treated. No late onset spinal cord ischemia symptoms developed. Of the five patients starting dialysis during follow-up, two resulted from renal branch occlusion. Sixteen branches occluded (nine renal, two celiac) or developed stenoses (four renal, one superior mesenteric artery), requiring stenting. Primary patency was 94.8%, and primary-assisted patency was 95.1%. Thirty-two patients (39.5%) underwent 42 reinterventions. Of 25 early reinterventions (<= 45 days), 10 were to treat access or insertion complications, and 5 were for endoleak. Of 17 late reinterventions, eight were for endoleak and five were for branch stenosis/occlusion. New endoleaks developed in two patients during follow-up. Overall, 73 of 81 patients (90.1%) were treated without procedure-related death, dialysis, paralysis, aneurysm rupture, or conversion to open repair.
Conclusions: Total endovascular TAAA/PRAA repair using caudally directed cuffs is safe, effective, and durable in the intermediate term. The most common form of late failure, renal artery occlusion, rarely had a clinically significant consequence (dialysis). The trend toward worse outcome in women needs further study. (J Vasc Surg 2012;)
C1 [Reilly, Linda M.; Hiramoto, Jade S.; Sobel, Julia; Chuter, Timothy A. M.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA.
[Rapp, Joseph H.; Grenon, S. Marlene] San Francisco VA Med Ctr, Vasc Surg Sect, San Francisco, CA USA.
RP Reilly, LM (reprint author), Univ Calif San Francisco, Div Vasc Surg, Rm A-581,400 Parnassus Ave, San Francisco, CA 94143 USA.
EM linda.reilly@ucsfmedctr.org
FU Cook Medical, Inc
FX Dr Chuter receives royalties from licensed patents, travel expenses and
research funding from Cook Medical, Inc, the manufacturer of the
multibranched thoracoabdominal stent graft.
NR 44
TC 40
Z9 40
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUL
PY 2012
VL 56
IS 1
BP 53
EP 64
DI 10.1016/j.jvs.2012.01.006
PG 13
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 968GJ
UT WOS:000305965000010
PM 22560233
ER
PT J
AU Zhu, S
Pan, W
Song, XY
Liu, Y
Shao, XR
Tang, YJ
Liang, D
He, DY
Wang, HL
Liu, WJ
Shi, YF
Harley, JB
Shen, N
Qian, YC
AF Zhu, Shu
Pan, Wen
Song, Xinyang
Liu, Yan
Shao, Xinrui
Tang, Yuanjia
Liang, Dong
He, Dongyi
Wang, Honglin
Liu, Wenjun
Shi, Yufang
Harley, John B.
Shen, Nan
Qian, Youcun
TI The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation
by targeting TAB2, TAB3 and IKK-alpha
SO NATURE MEDICINE
LA English
DT Article
ID CD4(+) T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; KAPPA-B-ZETA;
RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; IMMUNE-RESPONSES;
MESSENGER-RNA; EXPRESSION; RECEPTOR; DISEASE
AB Inflammatory cytokines such as interleukin-17 (IL-17) promote inflammatory autoimmune diseases. Although several microRNAs (miRNAs) have been shown to regulate autoimmune pathogenesis by affecting lymphocyte development and function, the role of miRNAs in resident cells present in inflammatory lesions remains unclear. Here we show that miR-23b is downregulated in inflammatory lesions of humans with lupus or rheumatoid arthritis, as well as in the mouse models of lupus, rheumatoid arthritis or multiple sclerosis. IL-17 downregulates miR-23b expression in human fibroblast-like synoviocytes, mouse primary kidney cells and astrocytes and is essential for the downregulation of miR-23b during autoimmune pathogenesis. In turn, miR-23b suppresses IL-17-, tumor necrosis factor alpha (TNF-alpha)- or IL-1 beta-induced NF-kappa B activation and inflammatory cytokine expression by targeting TGF-beta-activated kinase 1/MAP3K7 binding protein 2 (TAB2), TAB3 and inhibitor of nuclear factor kappa-B kinase subunit alpha (IKK-alpha) and, consequently, represses autoimmune inflammation. Thus, IL-17 contributes to autoimmune pathogenesis by suppressing miR-23b expression in radio-resident cells and promoting proinflammatory cytokine expression.
C1 [Zhu, Shu; Pan, Wen; Song, Xinyang; Liu, Yan; Shao, Xinrui; Shi, Yufang; Shen, Nan; Qian, Youcun] Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai 200031, Peoples R China.
[Tang, Yuanjia; Shen, Nan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Renji Hosp, Shanghai Inst Rheumatol, Shanghai 200030, Peoples R China.
[Liang, Dong; Harley, John B.; Shen, Nan] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH USA.
[Liang, Dong; Harley, John B.; Shen, Nan] Cincinnati Childrens Hosp Med Ctr, CAGE, Cincinnati, OH USA.
[Wang, Honglin] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Shanghai Inst Immunol, Shanghai 200030, Peoples R China.
[He, Dongyi] Guanghua Rheumatol Hosp, Shanghai, Peoples R China.
[Liu, Wenjun] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada.
[Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
RP Qian, YC (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai 200031, Peoples R China.
EM nanshensibs@gmail.com; ycqian@sibs.ac.cn
RI Pan, Wen/I-9965-2016
FU National Natural Science Foundation of China and 973 program [30930084,
2010CB529705, 91029708, 30871298]; Chinese Academy of Sciences
[KSCX2-YW-R-146]; Science and Technology Commission of Shanghai
Municipality [10JC1416600]; National Natural Science Foundation of China
[30971632, 81025016]; Chinese Ministry of Health [201202008]; Program of
the Shanghai Commission of Science and Technology [10JC1409300]
FX We thank R. Flavell (Yale University) for providing Pi 17a-deficient
mice. This work is supported by grants from National Natural Science
Foundation of China and 973 program (30930084, 2010CB529705, 91029708
and 30871298), Chinese Academy of Sciences (KSCX2-YW-R-146) and the
Science and Technology Commission of Shanghai Municipality (10JC1416600)
to Y.Q.; as well as National Natural Science Foundation of China
(30971632 and 81025016), Chinese Ministry of Health (201202008) and the
Program of the Shanghai Commission of Science and Technology
(10JC1409300) to N. S.
NR 58
TC 151
Z9 166
U1 1
U2 35
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
J9 NAT MED
JI Nat. Med.
PD JUL
PY 2012
VL 18
IS 7
BP 1077
EP +
DI 10.1038/nm.2815
PG 11
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 970IM
UT WOS:000306121600037
PM 22660635
ER
PT J
AU Pellegrini, CN
AF Pellegrini, Cara N.
TI Can AV Node Ablation Help Save AV Conduction?
SO PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
LA English
DT Editorial Material
ID SLOW PATHWAY ABLATION; REENTRANT TACHYCARDIA; RADIOFREQUENCY ABLATION;
ATRIOVENTRICULAR-BLOCK; JUNCTIONAL TACHYCARDIA; KOCHS TRIANGLE;
PREDICTS; ECTOPY; RISK
C1 [Pellegrini, Cara N.] VA Med Ctr, Cardiol Sect, San Francisco, CA USA.
[Pellegrini, Cara N.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Pellegrini, CN (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Cardiol 111C, San Francisco, CA 94121 USA.
EM pellegrinic@medicine.ucsf.edu
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0147-8389
J9 PACE
JI PACE-Pacing Clin. Electrophysiol.
PD JUL
PY 2012
VL 35
IS 7
BP 785
EP 786
DI 10.1111/j.1540-8159.2012.03390.x
PG 2
WC Cardiac & Cardiovascular Systems; Engineering, Biomedical
SC Cardiovascular System & Cardiology; Engineering
GA 967HM
UT WOS:000305897500015
PM 22519423
ER
PT J
AU Beidas, RS
Edmunds, JM
Marcus, SC
Kendall, PC
AF Beidas, Rinad S.
Edmunds, Julie M.
Marcus, Steven C.
Kendall, Philip C.
TI Training and Consultation to Promote Implementation of an Empirically
Supported Treatment: A Randomized Trial
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; PSYCHOTHERAPY-RESEARCH; DISSEMINATION;
CLINICIAN; MODEL
AB Objective: The study evaluated the efficacy of three training modalities and the impact of ongoing consultation after training. Cognitive-behavioral therapy (CBT) for anxiety among youths, an empirically supported treatment, was used as the exemplar. Participants were randomly assigned to one of three one-day workshops to examine the efficacy of training modality: routine training (training as usual), computer training (computerized version of training as usual), and augmented training (training that emphasized active learning). After training, all participants received three months of ongoing consultation that included case consultation, didactics, and problem solving. Methods: Participants were 115 community therapists (mean age of 35.9 years; 90% were women). Outcome measures included the Adherence and Skill Checklist, used to rate a performance-based role-play; a knowledge test; and the Training Satisfaction Bating Scale. Results: All three training modalities resulted in limited gains in therapist adherence, skill, and knowledge. There was no significant effect of modality on adherence, skill, or knowledge from pretraining to posttraining. Participants were more satisfied with augmented and routine training than with Computer training. Most important, number of consultation hours after training significantly predicted higher therapist adherence and skill at the three-month follow-up. Conclusions: The findings suggest that training alone did not result in therapist behavior change. The inclusion of ongoing consultation was critical to influencing therapist adherence and skill. Implications for implementation science and mental health services research are discussed. (Psychiatric Services 63:660-665, 2012; doi: 10.1176/appi.ps.201100401)
C1 [Beidas, Rinad S.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Edmunds, Julie M.; Kendall, Philip C.] Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA.
[Marcus, Steven C.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA.
[Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
RP Beidas, RS (reprint author), Univ Penn, Dept Psychiat, 3535 Market St,Room 3015, Philadelphia, PA 19104 USA.
EM rbeidas@upenn.edu
FU National Institute of Mental Health [F31-MH083333]; Shipley Research
Prize; Ortho-McNeil Janssen; Forest Research Institute
FX This study was funded by grant F31-MH083333 from the National Institute
of Mental Health and by the Shipley Research Prize awarded to Dr.
Beidas. The authors thank Robert Fauber, Ph.D., Philip Hineline, Ph.D.,
and David Mandell, Sc.D., for comments on drafts of this article. The
authors thank the following individuals for their help as consultants:
Kathleen Carroll, Ph.D., Wench Cross, Ph.D., and Kimberly Hoagwood,
Ph.D. The authors thank the following research assistants: Stacey
Austin, Kayla Brehm, Mamatha Chary, Margaret Downey, Philip Fizur, Kyle
Peer, and Anna Slavachevskaya.; Dr. Marcus has received grant support
from Ortho-McNeil Janssen and Forest Research Institute and has served
as a consultant to Astra-Zeneca. Dr. Kendall reports receiving royalties
from sales of materials related to the treatment of anxiety among
youths. The other authors report no competing interests.
NR 28
TC 73
Z9 73
U1 0
U2 16
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUL
PY 2012
VL 63
IS 7
BP 660
EP 665
DI 10.1176/appi.ps.201100401
PG 6
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 967TY
UT WOS:000305931900008
PM 22549401
ER
PT J
AU Harris, AHS
Oliva, E
Bowe, T
Humphreys, KN
Kivlahan, DR
Trafton, JA
AF Harris, Alex H. S.
Oliva, Elizabeth
Bowe, Thomas
Humphreys, Keith N.
Kivlahan, Daniel R.
Trafton, Jodie A.
TI Pharmacotherapy of Alcohol Use Disorders by the Veterans Health
Administration: Patterns of Receipt and Persistence
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID MEDICATION COMPLIANCE; NALTREXONE; DEFINITIONS; TRENDS; CARE
AB Objective: This study assessed changes since 2007 at Veterans Health Administration (VHA) facilities (N=129) in use of the medications approved by the U.S. Food and Drug Administration for treatment of alcohol use disorders. Methods: VHA data from fiscal years (FYs) 2008 and 2009 were used to identify patients with a diagnosis of an alcohol use disorder who received oral or extended-release naltrexone, disulfiram, or acamprosate as well as the proportion of days covered (PDC) in the 180 days after initiation and the time to first ten-day gap in possession (persistence) for each medication. Multilevel, mixed-effects logistic regression models examined the association between patient and facility characteristics and use of medications. Results: Nationally, 3.4% of VHA patients with an alcohol use disorder received medications in FY 2009 (11,165 of 331,635 patients), up from 3.0% in FY 2007. Use of medications by patients at the facilities ranged from 0% to 12%. In fully adjusted analyses, facilities offering evening and weekend services had higher rates of medication receipt, but other facility characteristics, such as having prescribers on the addiction program's staff or using medication to treat opioid or tobacco dependence, were unrelated to medication receipt. The mean PDC of acamprosate was significantly lower than mean PDCs of the other medications (p<.05), and persistence in use of naltrexone was significantly greater than use of acamprosate and significantly less than use of disulfiram (p<.05). Conclusions: Use of these medications is increasing but remains variable across the VHA system. Interventions are needed to optimize initiation of and persistence in use of these medications. (Psychiatric Services 63: 679-685, 2012; doi: 10.1176/appi.ps.201000553)
C1 [Harris, Alex H. S.; Oliva, Elizabeth; Bowe, Thomas; Humphreys, Keith N.; Kivlahan, Daniel R.; Trafton, Jodie A.] US Dept Vet Affairs VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
[Harris, Alex H. S.; Oliva, Elizabeth; Bowe, Thomas; Humphreys, Keith N.; Kivlahan, Daniel R.; Trafton, Jodie A.] Stanford Univ, Sch Med, Menlo Pk, CA 94025 USA.
[Kivlahan, Daniel R.] Univ Washington, Sch Med, Seattle, WA USA.
[Kivlahan, Daniel R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Harris, AHS (reprint author), US Dept Vet Affairs VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd,152-MPD, Menlo Pk, CA 94025 USA.
EM alexander.harris2@va.gov
NR 19
TC 26
Z9 26
U1 0
U2 1
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUL
PY 2012
VL 63
IS 7
BP 679
EP 685
DI 10.1176/appi.ps.201000553
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 967TY
UT WOS:000305931900011
PM 22549276
ER
PT J
AU Bradley, KA
Rubinsky, AD
Sun, HL
Blough, DK
Tonnesen, H
Hughes, G
Beste, LA
Bishop, MJ
Hawn, MT
Maynard, C
Harris, ASH
Hawkins, EJ
Bryson, CL
Houston, TK
Henderson, WG
Kivlahan, DR
AF Bradley, Katharine A.
Rubinsky, Anna D.
Sun, Haili
Blough, David K.
Tonnesen, Hanne
Hughes, Grant
Beste, Lauren A.
Bishop, Michael J.
Hawn, Mary T.
Maynard, Charles
Harris, Alex S. H.
Hawkins, Eric J.
Bryson, Chris L.
Houston, Thomas K.
Henderson, William G.
Kivlahan, Daniel R.
TI Prevalence of alcohol misuse among men and women undergoing major
noncardiac surgery in the Veterans Affairs health care system
SO SURGERY
LA English
DT Article
ID DISORDERS IDENTIFICATION TEST; PROSTATE-CANCER; SCREENING SCORES;
AUDIT-C; RISK; CONSUMPTION; QUALITY; COMPLICATIONS; ASSOCIATION;
MORBIDITY
AB Background. Patients who screen positive for alcohol misuse on the Alcohol Use Disorder Identification Test Consumption Questionnaire (AUDIT-C >= 5 points) have significantly increased postoperative complications. Severe alcohol misuse (AUDIT-C >= 9 points) is associated with increased postoperative health care use; however, little is known about the prevalence of alcohol misuse in demographic and clinical subgroups of surgical patients.
Methods. The prevalence of alcohol misuse was evaluated among 10,284 patients (9,771 men and 513 women) who underwent major noncardiac surgery in Veterans Affairs (VA) hospitals during the fiscal years 2004 to 2006 and completed the AUDIT-C. Sex-stratified analyses evaluated prevalence rates of alcohol misuse (AUDIT-C >= 5) and severe misuse (AUDIT-C >= 9) across demographic and clinical subgroups.
Results. Overall, 1,607(16%) men and 24 (5%) women screened positive for alcohol misuse (AUDIT-C >= 5) in the year before operation, with 4% and 2% screening positive for severe misuse (AUDIT-C >= 9), respectively. Alcohol misuse was more common among men who were <60 years of age, divorced or separated, current smokers, or American Stoke Association class 1 or 2, and those with cirrhosis/hepatitis or substance use disorders. Among patients with alcohol misuse, 36% of men and 58% of women were American Society Of Anesthesiologists class I or 2, and most did not have diagnoses that were commonly associated with alcohol misuse.
Conclusion. Alcohol misuse is relatively common in male surgical patients. Moreover, surgical patients undergoing operation who screen positive for alcohol misuse are often relatively healthy, without health problems that might alert providers to their alcohol misuse in the absence of screening. (Surgery 2012;152:69-81.)
C1 [Bradley, Katharine A.] Univ Washington, Grp Hlth Res Inst, Seattle, WA 98101 USA.
[Bradley, Katharine A.; Hawkins, Eric J.; Kivlahan, Daniel R.] Univ Washington, Dept Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98101 USA.
[Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA 98101 USA.
[Bradley, Katharine A.; Rubinsky, Anna D.; Beste, Lauren A.; Maynard, Charles] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA.
[Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98101 USA.
[Tonnesen, Hanne] Bispebjerg Hosp, World Hlth Org Collaborating Ctr Evidence Based H, Copenhagen, Denmark.
[Hughes, Grant; Henderson, William G.] Dept Vet Affairs Eastern Colorado Healthcare Syst, Denver, CO USA.
[Bryson, Chris L.] Univ Washington, Dept Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA 98101 USA.
[Hawn, Mary T.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
[Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Harris, Alex S. H.] Dept Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA.
[Houston, Thomas K.] Bedford Vet Affairs Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Houston, Thomas K.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Henderson, William G.] Univ Colorado, Hlth Outcomes Program, Aurora, CO USA.
RP Bradley, KA (reprint author), Univ Washington, Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.
EM bradley.k@ghc.org
RI Houston, Thomas/F-2469-2013; Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development and Health Services Research and Development
(HSRD) [IAC 06-021]; US Department of Veterans Affairs, Office of
Research and Development
FX Supported by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development and Health Services
Research and Development (HSR & D; project IAC 06-021). Dr Bradley was
an investigator at the Veterans Affairs Northwest HSR&D Center of
Excellence and at the Center of Excellence in Substance Abuse Treatment
and Education, VA Puget Sound Health Care System, Seattle, WA, while
this work was conducted.; This material is based upon work supported by
the US Department of Veterans Affairs, Office of Research and
Development. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States Government.
NR 38
TC 9
Z9 9
U1 2
U2 3
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6060
J9 SURGERY
JI Surgery
PD JUL
PY 2012
VL 152
IS 1
BP 69
EP 81
DI 10.1016/j.surg.2012.02.007
PG 13
WC Surgery
SC Surgery
GA 966QZ
UT WOS:000305853800011
PM 22503319
ER
PT J
AU Yin, XM
Latif, R
Bahn, R
Davies, TF
AF Yin, Xiaoming
Latif, Rauf
Bahn, Rebecca
Davies, Terry F.
TI Genetic Profiling in Graves' Disease: Further Evidence for Lack of a
Distinct Genetic Contribution to Graves' Ophthalmopathy
SO THYROID
LA English
DT Article
ID AUTOIMMUNE THYROID-DISEASE; INTERLEUKIN-23 RECEPTOR GENE; T-LYMPHOCYTE
ANTIGEN-4; THYROTROPIN RECEPTOR; RHEUMATOID-ARTHRITIS; FUNCTIONAL
VARIANTS; SUSCEPTIBILITY GENE; TSH-RECEPTOR; ASSOCIATION; CTLA-4
AB Background: Graves' disease (GD), including Graves' ophthalmopathy or orbitopathy (GO), is an autoimmune disease with an environmental and genetic component to its etiology. The genetic contribution to the GO clinical phenotype remains unclear. Previous data from our laboratory and others have suggested that GO has no specific genetic component distinct from GD itself, while other reports have occasionally appeared suggesting that polymorphisms in genes such as CTLA4 and IL23R specifically increase the risk for GO. One of the criticisms of all these reports has been the clinical definition of the GO phenotype as distinct from hyperthyroid GD devoid of clinically significant eye involvement. The objective of this study was to take advantage of a phenotypically pure group of GD patients with GO and examine a series of genes associated with GD to determine if any were more definitively associated with GO rather than Graves' thyroid disease itself.
Methods: To further examine whether specific susceptibility genes are associated with GO, we have performed further genetic association studies using highly characterized GO patients, many of whom had undergone orbital decompression surgery for their exophthalmos. We genotyped HLA, CTLA4, IL23R, and TSHR genes in a group of 256 Caucasian patients with severe GO (n = 199) and less severe GO (n = 57), and 90 patients with GD but no clinically apparent GO.
Results: We found that the allele and genotype frequencies were not statistically different between GO and non-GO patients for any of the genes and gene combinations assessed.
Conclusions: These results provide further evidence that patients with GO do not have a distinct genetic susceptibility to their eye disease and again suggest that environmental and/or epigenetic influences are at play.
C1 [Yin, Xiaoming; Latif, Rauf; Davies, Terry F.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, New York, NY 10468 USA.
[Bahn, Rebecca] Mayo Clin, Sch Med, Div Endocrinol, Rochester, MN USA.
RP Yin, XM (reprint author), James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, Room 2F-26,130 W Kingsbridge Rd, New York, NY 10468 USA.
EM xiaoming.yin@mssm.edu
OI latif, rauf/0000-0002-4226-3728
FU NIH-NIDDK the David Owen Segal Endowment [DK052464, DK69713]; James J.
Peters VAMC; VA Merit Award program
FX This work was supported in part by DK052464 and DK69713 from NIH-NIDDK
the David Owen Segal Endowment, the James J. Peters VAMC, and the VA
Merit Award program. We thank our colleague Dr. Yaron Tomer for his help
and advice.
NR 58
TC 16
Z9 18
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
J9 THYROID
JI Thyroid
PD JUL
PY 2012
VL 22
IS 7
BP 730
EP 736
DI 10.1089/thy.2012.0007
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 968JE
UT WOS:000305974400011
PM 22663548
ER
PT J
AU Fischer, MJ
Xie, DW
Jordan, N
Kop, WJ
Krousel-Wood, M
Tamura, MK
Kusek, JW
Ford, V
Rosen, LK
Strauss, L
Teal, VL
Yaffe, K
Powe, NR
Lash, JP
AF Fischer, Michael J.
Xie, Dawei
Jordan, Neil
Kop, Willem J.
Krousel-Wood, Marie
Tamura, Manjula Kurella
Kusek, John W.
Ford, Virginia
Rosen, Leigh K.
Strauss, Louise
Teal, Valerie L.
Yaffe, Kristine
Powe, Neil R.
Lash, James P.
CA CRIC Study Grp Investigators
TI Factors Associated With Depressive Symptoms and Use of Antidepressant
Medications Among Participants in the Chronic Renal Insufficiency Cohort
(CRIC) and Hispanic-CRIC Studies
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Depression; chronic kidney disease; disparities; antidepressants
ID CHRONIC KIDNEY-DISEASE; QUALITY-OF-LIFE; NATIONAL COMORBIDITY SURVEY;
BASE-LINE CHARACTERISTICS; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS;
PRIMARY-CARE; AFRICAN-AMERICANS; MAJOR DEPRESSION; COMMUNITY SAMPLE
AB Background: Depressive symptoms are correlated with poor health outcomes in adults with chronic kidney disease (CKD). The prevalence, severity, and treatment of depressive symptoms and potential risk factors, including level of kidney function, in diverse populations with CKD have not been well studied.
Study Design: Cross-sectional analysis.
Settings & Participants: Participants at enrollment into the Chronic Renal Insufficiency Cohort (CRIC) and Hispanic-CRIC (H-CRIC) Studies. CRIC enrolled Hispanics and non-Hispanics at 7 centers in 2003-2007, and H-CRIC enrolled Hispanics at the University of Illinois in 2005-2008.
Measurement: Depressive symptoms measured by Beck Depression Inventory (BDI).
Predictors: Demographic and clinical factors.
Outcomes: Elevated depressive symptoms (BDI score >= 11) and antidepressant medication use.
Results: Of 3,853 participants, 27.4% had evidence of elevated depressive symptoms and 18.2% were using antidepressant medications; 31.0% of persons with elevated depressive symptoms were using antidepressants. The prevalence of elevated depressive symptoms varied by level of kidney function: 23.6% for participants with estimated glomerular filtration rate (eGFR) >= 60 mL/min/1.73 m(2) and 33.8% of those with eGFR <30 mL/min/1.73 m(2). Lower eGFR (OR per 10-mL/min/1.73 m(2) decrease, 1.10; 95% CI, 1.04-1.17), and non-Hispanic black race (OR, 1.42; 95% CI, 1.16-1.74) were each associated with increased odds of elevated depressive symptoms after controlling for other factors. In regression analyses incorporating BDI score, whereas female sex was associated with greater odds of antidepressant use, Hispanic ethnicity, non-Hispanic black race, and higher urine albumin levels were associated with decreased odds of antidepressant use (P < 0.05 for each).
Limitations: Absence of clinical diagnosis of depression and use of nonpharmacologic treatments.
Conclusions: Although elevated depressive symptoms were common in individuals with CKD, use of antidepressant medications is low. Individuals of racial and ethnic minority background and with more advanced CKD had a greater burden of elevated depressive symptoms and lower use of antidepressant medications. Am J Kidney Dis. 60(1): 27-38. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use.
C1 [Fischer, Michael J.; Lash, James P.] Univ Illinois, Med Ctr, Chicago, IL USA.
[Fischer, Michael J.; Lash, James P.] Jesse Brown VA Med Ctr, Chicago, IL USA.
[Xie, Dawei; Ford, Virginia; Rosen, Leigh K.; Teal, Valerie L.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Jordan, Neil] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Kop, Willem J.] Univ Maryland, Baltimore, MD 21201 USA.
[Kop, Willem J.] Tilburg Univ, NL-5000 LE Tilburg, Netherlands.
[Krousel-Wood, Marie] Tulane Univ, New Orleans, LA 70118 USA.
[Krousel-Wood, Marie] Ochsner Clin Fdn, Ctr Hlth Res, New Orleans, LA USA.
[Tamura, Manjula Kurella] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Kusek, John W.] NIDDK, NIH, Bethesda, MD USA.
[Strauss, Louise] Univ Hosp Cleveland, Case Med Ctr, Cleveland, OH 44106 USA.
[Yaffe, Kristine; Powe, Neil R.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Powe, Neil R.] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Fischer, Michael J.; Jordan, Neil] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
RP Fischer, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H, Hines, IL 60141 USA.
EM fischerm@uic.edu
RI Krousel-Wood, Marie Antoinette/D-4718-2011; Kurella Tamura,
Manjula/C-8284-2014
OI Kurella Tamura, Manjula/0000-0001-5227-2479
FU National Institute of Diabetes and Digestive and Kidney Diseases
[5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028,
5U01DK60980, 5U01DK060963, 5U01DK060902, R01 DK072231]; Clinical
Translational Science Awards (CTSA); National Institutes of Health (NIH)
Johns Hopkins University [UL1 RR-025005]; National Institutes of Health
(NIH) University of Maryland GRCR [M01 RR-16500]; National Institutes of
Health (NIH) Case Western Reserve University Clinical and Translational
Science Collaborative (University Hospitals of Cleveland, Cleveland
Clinic Foundation, and MetroHealth) [UL1 RR-024989]; National Institutes
of Health (NIH) University of Michigan GCRC [M01 RR-000042, CTSA UL1
RR-024986]; National Institutes of Health (NIH) University of Illinois
at Chicago Clinical Research Center [M01 RR-013987-06]; National
Institutes of Health (NIH) Tulane/LSU/Charity Hospital General Clinical
Research Center [RR-05096]; National Institutes of Health (NIH) Kaiser
NIH/National Center for Research Resources UCSF-CTSI [UL1 RR-024131,
5K24DK002651]
FX In addition to funding under a cooperative agreement from the National
Institute of Diabetes and Digestive and Kidney Diseases (5U01DK060990,
5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028, 5U01DK60980,
5U01DK060963, and 5U01DK060902) and R01 DK072231 (H-CRIC), this work was
supported in part by the following institutional Clinical Translational
Science Awards (CTSA) and other National Institutes of Health (NIH)
grants: Johns Hopkins University UL1 RR-025005, University of Maryland
GRCR M01 RR-16500, Case Western Reserve University Clinical and
Translational Science Collaborative (University Hospitals of Cleveland,
Cleveland Clinic Foundation, and MetroHealth) UL1 RR-024989, University
of Michigan GCRC M01 RR-000042, CTSA UL1 RR-024986, University of
Illinois at Chicago Clinical Research Center, M01 RR-013987-06,
Tulane/LSU/Charity Hospital General Clinical Research Center RR-05096,
and Kaiser NIH/National Center for Research Resources UCSF-CTSI UL1
RR-024131, 5K24DK002651. Additional support provided by the National
Center for Minority Health and Health Disparities, NIH, and Department
of Veterans Affairs Health Services Research and Development Service
(Career Development Award to Dr Fischer).
NR 49
TC 9
Z9 10
U1 1
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUL
PY 2012
VL 60
IS 1
BP 27
EP 38
DI 10.1053/j.ajkd.2011.12.033
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA 960RJ
UT WOS:000305406200007
PM 22497791
ER
PT J
AU Choi, JC
Bakaeen, FG
Cornwell, LD
Dao, TK
Coselli, JS
LeMaire, SA
Chu, D
AF Choi, Justin C.
Bakaeen, Faisal G.
Cornwell, Lorraine D.
Dao, Tam K.
Coselli, Joseph S.
LeMaire, Scott A.
Chu, Danny
TI Morbid Obesity Is Associated With Increased Resource Utilization in
Coronary Artery Bypass Grafting
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID BODY-MASS INDEX; AMERICAN-HEART-ASSOCIATION; QUALITY-OF-LIFE;
CARDIOVASCULAR-DISEASE; CARDIAC-SURGERY; UNITED-STATES;
PHYSICAL-ACTIVITY; OPERATING-ROOM; WEIGHT-LOSS; RISK-FACTOR
AB Background. Studies have shown good outcomes for morbidly obese patients who undergo cardiac surgery. However, little is known about how much additional resource utilization treating these challenging patients requires. We hypothesized that morbidly obese patients (body mass index >= 40 kg/m(2)) undergoing coronary artery bypass grafting needed longer operating room times and had longer hospital and intensive care unit stays than non-morbidly obese patients.
Methods. We reviewed data from all morbidly obese patients (n = 56, body mass index = 42.7 +/- 2.6 kg/m(2)) who underwent coronary artery bypass grafting at our institution between 1999 and 2009. These patients' outcomes were compared with those of non-morbidly obese patients (n = 168, body mass index = 30.0 +/- 2.8 kg/m(2)) who were propensity-matched 3: 1 with the morbidly obese patients.
Results. Of the 14 preoperative characteristics examined, only 1, creatinine level, differed significantly between the two groups (p = 0.02). Intraoperative and postoperative complication rates and the mortality rate were similar between groups (p > 0.09). However, morbidly obese patients had longer operating times (449 +/- 70 versus 420 +/- 59 minutes; p = 0.002), intensive care unit stays (5.2 versus 3.3 days; p < 0.005), and postoperative hospital stays (14.2 versus 9.5 days; p < 0.005) than the non-morbidly obese patients.
Conclusions. Although good outcomes can be achieved for morbidly obese patients who undergo coronary artery bypass grafting, these patients require considerably more resource utilization in the operating room and intensive care unit, and they spend more time in the hospital after surgery. At a cardiac surgical operating room cost of approximately $50 per minute and $4,500 per intensive care unit day, the financial implications for morbidly obese patients who need coronary artery bypass grafting are not insignificant.
C1 [Chu, Danny] Baylor Coll Med, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg,Div Cardiothorac Surg, Houston, TX 77030 USA.
Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77030 USA.
St Lukes Episcopal Hosp, Texas Heart Inst, Div Cardiovasc Surg, Houston, TX USA.
Univ Houston, Dept Educ Psychol, Houston, TX USA.
RP Chu, D (reprint author), Baylor Coll Med, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Dept Surg,Div Cardiothorac Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM dchu@bcm.edu
NR 39
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUL
PY 2012
VL 94
IS 1
BP 23
EP 28
DI 10.1016/j.athoracsur.2012.03.036
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 965XS
UT WOS:000305801600014
PM 22607785
ER
PT J
AU Schumacher, HR
AF Schumacher, H. Ralph, Jr.
TI The need to compare rilonacept against active treatment for prevention
of gout flares: comment on the article by Schumacher et al Reply
SO ARTHRITIS AND RHEUMATISM
LA English
DT Letter
ID ARTHRITIS
C1 [Schumacher, H. Ralph, Jr.] Univ Penn, Philadelphia, PA 19104 USA.
[Schumacher, H. Ralph, Jr.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Schumacher, HR (reprint author), Univ Penn, Philadelphia, PA 19104 USA.
NR 2
TC 0
Z9 0
U1 2
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD JUL
PY 2012
VL 64
IS 7
BP 2416
EP 2416
DI 10.1002/art.34475
PG 1
WC Rheumatology
SC Rheumatology
GA 965CD
UT WOS:000305742800041
ER
PT J
AU Liel, MS
Greenberg, DL
Recht, M
Vanek, C
Klein, RF
Taylor, JA
AF Liel, Meghan S.
Greenberg, Daniel L.
Recht, Michael
Vanek, Chaim
Klein, Robert F.
Taylor, Jason A.
TI Decreased bone density and bone strength in a mouse model of severe
factor VIII deficiency
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
DE haemophilia; factor VIII; bone density; osteoporosis
ID HEMOPHILIA; OSTEOPOROSIS; RISK
C1 [Liel, Meghan S.; Greenberg, Daniel L.; Recht, Michael; Taylor, Jason A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA.
[Liel, Meghan S.; Klein, Robert F.; Taylor, Jason A.] Portland VA Med Ctr, Med Serv, Portland, OR USA.
[Vanek, Chaim; Klein, Robert F.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Portland, OR 97201 USA.
RP Liel, MS (reprint author), Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97201 USA.
EM taylojas@ohsu.edu
NR 10
TC 11
Z9 11
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD JUL
PY 2012
VL 158
IS 1
BP 140
EP 143
DI 10.1111/j.1365-2141.2012.09101.x
PG 4
WC Hematology
SC Hematology
GA 956ZC
UT WOS:000305127100015
PM 22469061
ER
PT J
AU Kaunitz, JD
AF Kaunitz, Jonathan D.
TI Digestive Diseases and Sciences: Sadness, Satisfaction, and Sanguinity
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA.
RP Kaunitz, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA.
EM Jonathan.Kaunitz@va.gov
NR 4
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD JUL
PY 2012
VL 57
IS 7
BP 1742
EP 1744
DI 10.1007/s10620-012-2287-0
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 965DH
UT WOS:000305746100002
ER
PT J
AU Kanwal, F
Kramer, JR
Buchanan, P
Asch, SM
Assioun, Y
Bacon, BR
Li, J
El-Serag, HB
AF Kanwal, Fasiha
Kramer, Jennifer R.
Buchanan, Paula
Asch, Steven M.
Assioun, Youssef
Bacon, Bruce R.
Li, Juan
El-Serag, Hashem B.
TI The Quality of Care Provided to Patients With Cirrhosis and Ascites in
the Department of Veterans Affairs
SO GASTROENTEROLOGY
LA English
DT Article
DE SBP; Best Practices; Quality Measurement; Predictors
ID SPONTANEOUS BACTERIAL PERITONITIS; CHRONIC HEPATITIS-C; LIVER-DISEASE;
UNITED-STATES; MANAGEMENT; PROPHYLAXIS; MORTALITY; SURVIVAL; COHORT;
PREDICT
AB BACKGROUND & AIMS: Ascites are the most common complication of cirrhosis. Evidence-based guidelines define the criteria and standards of care for patients with cirrhosis and ascites. However, little is known about the extent to which patients with ascites meet these standards. METHODS: We evaluated the quality of ascites care, measured by 8 explicit Delphi panel-derived quality indicators, in 774 patients with cirrhosis and ascites, seen at 3 Veterans Affairs Medical Centers between 2000 and 2007. We also conducted a structured implicit review of patients' medical charts to determine whether patient refusal, outside care, or other justifiable exceptions to care processes account for nonadherence to the quality indicators. RESULTS: Quality scores (maximum 100%) varied among individual indicators, ranging from 30% for secondary prophylaxis of spontaneous bacterial peritonitis, to 90% for assays for cell number and type in the paracentesis fluid. In general, care targeted at treatment was more likely to meet standards than preventive care. Only 33.2% (95% confidence interval [CI]: 29.9% - 32.9%) of patients received all recommended care. Patients with no comorbidity (Deyo index 0 vs >3; odds ratio = 2.21; 95% CI: 1.43 - 3.43), who saw a gastroenterologist (odds ratio = 1.33; 95% CI, 1.01 - 1.74), or were seen in a facility with academic affiliation (odds ratio = 1.73; 95% CI: 1.29 - 2.35) received higher-quality care. Justifiable exceptions to indicated care, documented in charts, were common for patients with paracentesis after diagnosis with ascites, patients that received antibiotics for gastrointestinal bleeding, and patients that required diuretics. However, most patients did not have an explanation documented for nonadherence to recommended care. CONCLUSIONS: Health care quality, measured by whether patients received recommended services, was suboptimal for patients with cirrhosis-related ascites. Care that included gastroenterologists was associated with high quality. However, for some of the quality indicators, too many denominator exceptions existed to allow for accurate automated measurement.
C1 [Kanwal, Fasiha] Michael E DeBakey VA Med Ctr, Dept Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Kanwal, Fasiha; Kramer, Jennifer R.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Buchanan, Paula] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA.
[Asch, Steven M.] Greater Los Angeles VA Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Assioun, Youssef; Bacon, Bruce R.; Li, Juan] St Louis Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA.
RP Kanwal, F (reprint author), Michael E DeBakey VA Med Ctr, Dept Gastroenterol & Hepatol, 2002 Holcombe Blvd,152, Houston, TX 77030 USA.
EM fasiha.kanwal@va.gov
FU American Society of Gastrointestinal Endoscopy Quality of Care Award;
American College of Gastroenterology Clinical Research Award; Veteran's
Affairs Health Services Research and Development (HSR&D) Investigator
Initiated Research Award [IIR-07-111]; Houston VA HSR&D Center of
Excellence [HFP90-020]
FX This material is based upon work supported by the 2008 American Society
of Gastrointestinal Endoscopy Quality of Care Award and by the 2009
American College of Gastroenterology Clinical Research Award. Dr Kanwal
is supported by Veteran's Affairs Health Services Research and
Development (HSR&D) Investigator Initiated Research Award IIR-07-111.
This material is also supported in part by the Houston VA HSR&D Center
of Excellence (HFP90-020).
NR 26
TC 38
Z9 38
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUL
PY 2012
VL 143
IS 1
BP 70
EP 77
DI 10.1053/j.gastro.2012.03.038
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 965QE
UT WOS:000305781500030
PM 22465432
ER
PT J
AU Gordon, PL
Doyle, JW
Johansen, KL
AF Gordon, Patricia L.
Doyle, Julie W.
Johansen, Kirsten L.
TI Association of 1,25-Dihydroxyvitamin D Levels With Physical Performance
and Thigh Muscle Cross-sectional Area in Chronic Kidney Disease Stage 3
and 4
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID CHRONIC-RENAL-FAILURE; QUALITY-OF-LIFE; VITAMIN-D INSUFFICIENCY;
SKELETAL-MUSCLE; HEMODIALYSIS-PATIENTS; RESISTANCE EXERCISE;
25-HYDROXYVITAMIN D; BODY-COMPOSITION; CONTROLLED-TRIAL; 6-MINUTE WALK
AB Background: Declines in 1,25-dihydroxyvitamin D (1,25(OH)(2)D) levels and physical functioning follow the course of chronic kidney disease (CKD). Although the molecular actions of vitamin D in skeletal muscle are well known, and muscle weakness and atrophy are observed in vitamin D-deficient states, there is little information regarding vitamin D and muscle function and size in CKD.
Objective: To examine associations of vitamin D with physical performance (PF) and muscle size.
Design: Cross-sectional.
Setting: CKD clinic.
Subjects: Twenty-six patients (61 +/- 13 years, 92% men) with CKD stage 3 or 4.
Main Outcome Measures: Gait speed, 6-minute walk, sit-to-stand time, 1-legged balance, and thigh muscle cross-sectional area (MCSA), measured by magnetic resonance imaging (MRI).
Results: Overall, 73% were 25-hydroxyvitamin D(25(OH)D) deficient (n = 10) or insufficient (n = 9) (Kidney Disease Outcomes Quality Initiative guidelines). 25(OH)D level was associated with normal gait speed only (r = 0.41, P = .04). Normal and fast gait speed, the distance walked in 6 minutes, and sit-to-stand time were best explained by 1,25(OH)(2)D and body mass index (P < .05 for all) and 1-legged stand by 1,25(OH)(2)D (r = 0.40, P < .05) only. There were no associations of age, estimated glomerular filtration rate (eGFR), intact parathyroid hormone (iPTH), or albumin with any PF measures. MCSA was associated with eGFR (r = 0.54, P < .01) only. Variance in MCSA was best explained by a model containing 1,25(OH)(2)D, plasma Ca2+, and daily physical activity (by accelerometry) (P < .05 for all). Once these variables were in the model, there was no contribution of eGFR.
Conclusion: These results suggest that 1,25(OH)(2)D is a determinant of PF and muscle size in patients with stage 3 and 4 CKD. (C) 2012 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Gordon, Patricia L.] Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94121 USA.
[Gordon, Patricia L.; Doyle, Julie W.; Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
RP Gordon, PL (reprint author), Univ Calif San Francisco, Div Nephrol, Dept Med, Box 111J,4150 Clement St, San Francisco, CA 94121 USA.
EM patricia.gordon@ucsf.edu
FU Abbott Laboratories
FX This study was funded through investigator-initiated funding by Abbott
Laboratories. P.L.G. and K.L.J. have received financial support for this
study from Abbott Laboratories.
NR 59
TC 4
Z9 5
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
J9 J RENAL NUTR
JI J. Renal Nutr.
PD JUL
PY 2012
VL 22
IS 4
BP 423
EP 433
DI 10.1053/j.jrn.2011.10.006
PG 11
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA 965DY
UT WOS:000305748100008
PM 22227183
ER
PT J
AU Subramanian, A
Timberlake, M
Mittakanti, H
Lara, M
Brandt, ML
AF Subramanian, Anuradha
Timberlake, Matthew
Mittakanti, Harsha
Lara, Michael
Brandt, Mary L.
TI Novel Educational Approach for Medical Students: Improved Retention
Rates Using Interactive Medical Software Compared with Traditional
Lecture-Based Format
SO JOURNAL OF SURGICAL EDUCATION
LA English
DT Article
DE web-based; surgical education; interactive tool
AB BACKGROUND: Mannequin and computer-based simulators are useful for the practice of patient management, physical procedures, and competency. However, they are ineffective in teaching clinical medicine. StepStone Interactive Medical Software (SS) is a web-based medical learning modality that provides the user with a highly focused set of evaluative and interventional tasks to treat memorable virtual patients in a visual case-based format.
OBJECTIVE: To determine whether the SS learning modality is superior to traditional lecture format in medical student learning and retention.
METHODS: After Institutional Review Board (IRB) approval was obtained and the consents were signed, 30 third-year medical students were assigned randomly to 2 groups of 15 students each: The control group received two 30-minute PowerPoint lectures (Microsoft Corporation, Redmond, Washington) about torsades de pointes (TdP) and pulseless electrical activity (PEA), and the SS group was given 1 hour to review 2 SS cases teaching TdP and PEA. A preintervention test was given to assess their baseline knowledge. An immediate postintervention test was given to both groups. Twenty-two days later, a long-term retention test was administered. The results were analyzed using a Student t test for continuous variables.
RESULTS: The mean scores for the preintervention test in the control and SS groups were 44.9 +/- 3% and 44.1 +/- 2%, respectively (p = 0.41). The mean scores for the postintervention test in the control and SS groups were 61.7 +/- 2% and 86.7 +/- 2%, respectively (p < 0.001). Improvement from baseline knowledge was calculated, and the mean improvement was 16.8 +/- 3% in the control group and 42.5 +/- 2% in the SS group (p < 0.001). The long-term retention test revealed the mean scores of 55.8 +/- 3% in the control group and 70.1 +/- 3% in the SS group (p < 0.001). Long-term improvement from baseline knowledge was calculated and the control group improved by 10.9 +/- 4%, whereas the SS group improved by 26 +/- 3% (p = 0.002).
CONCLUSIONS: The SS learning modality demonstrated a significant improvement in student learning retention compared to traditional didactic lecture format. SS is an effective web-based medical education tool. (J Surg 69:449-452. (C) 2012 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved.)
C1 [Subramanian, Anuradha] Baylor Coll Med, VA Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
RP Subramanian, A (reprint author), Baylor Coll Med, VA Med Ctr, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM asubrama@bcm.edu
NR 6
TC 14
Z9 14
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1931-7204
J9 J SURG EDUC
JI J. Surg. Educ.
PD JUL-AUG
PY 2012
VL 69
IS 4
BP 449
EP 452
DI 10.1016/j.jsurg.2012.05.013
PG 4
WC Education, Scientific Disciplines; Surgery
SC Education & Educational Research; Surgery
GA 960CS
UT WOS:000305366200003
PM 22677580
ER
PT J
AU Zhang, XY
Liang, J
Chen, DC
Xiu, MH
Yang, FD
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Liang, Jun
Chen, Da Chun
Xiu, Mei Hong
Yang, Fu De
Kosten, Therese A.
Kosten, Thomas R.
TI Low BDNF is associated with cognitive impairment in chronic patients
with schizophrenia
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Schizophrenia; Cognition; Brain-derived neurotrophic factor; Serum
ID NEUROTROPHIC FACTOR LEVELS; LONG-TERM TREATMENT; LOW SERUM-LEVELS;
BIPOLAR DISORDER; 1ST-EPISODE SCHIZOPHRENIA; NEUROPSYCHOLOGICAL STATUS;
ATYPICAL ANTIPSYCHOTICS; VAL66MET POLYMORPHISM; TARDIVE-DYSKINESIA;
REPEATABLE BATTERY
AB Several lines of evidence suggest that brain-derived neurotrophic factor (BDNF) plays a critical role in activity-dependent neuroplasticity underlying learning and memory in the hippocampus. Schizophrenia has a range of cognitive deficits that may evolve from decreased BDNF, and this study examines this association of BDNF with cognitive deficits in schizophrenia.
We recruited 251 chronic schizophrenic patients and 206 healthy control subjects and examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and serum BDNF in both groups. Schizophrenic symptoms were assessed using the Positive and Negative Syndrome Scale.
BDNF levels were significantly lower in patients than controls (p < 0.001). Cognitive scores on the RBANS and nearly all of its five subscales (all p < 0.001) except for the visuospatial/constructional index (p > 0.05) were significantly lower in schizophrenic patients than normal controls. For the patients, BDNF was positively associated with immediate memory in schizophrenia.
Our findings suggest that BDNF may be involved in the pathophysiology of schizophrenia, and its associated cognitive impairment, especially immediate memory.
C1 [Zhang, Xiang Yang; Kosten, Thomas R.] VA Med Ctr, Houston, TX 77030 USA.
[Chen, Da Chun; Xiu, Mei Hong; Yang, Fu De] Beijing HuiLongGuan Hosp, Beijing 100096, Peoples R China.
[Liang, Jun] Peking Univ, Inst Mental Hlth, Beijing 100083, Peoples R China.
[Zhang, Xiang Yang; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs, VISN 16, Mental Illness Research, Education and
Clinical Center (MIRECC), United States National Institute of Health
[K05-DA0454, P50-DA18827, U01-MH79639]
FX This study was funded by the Stanley Medical Research Institute (03T-459
and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental
Illness Research, Education and Clinical Center (MIRECC), United States
National Institute of Health K05-DA0454, P50-DA18827, and U01-MH79639.
NR 55
TC 44
Z9 47
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUL
PY 2012
VL 222
IS 2
BP 277
EP 284
DI 10.1007/s00213-012-2643-y
PG 8
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 964GI
UT WOS:000305681600009
PM 22274000
ER
PT J
AU Moschak, TM
Stang, KA
Phillips, TJ
Mitchell, SH
AF Moschak, Travis M.
Stang, Katherine A.
Phillips, Tamara J.
Mitchell, Suzanne H.
TI Behavioral inhibition in mice bred for high vs. low levels of
methamphetamine consumption or sensitization
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Inhibition; Go/no-go; Behavioral sensitization; Self-administration;
Selected lines; Methamphetamine; Impulsivity
ID REACTION-TIME-TASK; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; GO/NO-GO
TASK; D-AMPHETAMINE; STOP-SIGNAL; RATS; PERFORMANCE; IMPULSIVITY;
LESIONS; METHYLPHENIDATE
AB Research indicates that genetics influence methamphetamine self-administration as well as sensitization to the psychomotor-stimulating effects of methamphetamine (MA). Other studies have suggested that heightened levels of impulsivity, including low levels of behavioral inhibition, are associated with the use of drugs, including MA.
The current study examined whether lines of mice selected for traits associated with a heightened risk of developing MA dependence would also exhibit low levels of drug-na < ve inhibition and whether administration of MA would result in different levels of inhibition in animals selected to consume or respond more to MA.
A go/no-go task was used to assess inhibition in male and female mice selected for low or high levels of MA consumption or selected for high or low levels of locomotor sensitization to repeated injections of MA.
Mice selected for MA sensitization differed in false alarms, precue response rates (measures of behavioral inhibition), and also hits (measure of operant responding). Mice selected for MA consumption did not differ in measures of behavioral inhibition, though hits differed. When MA was administered prior to the task, false alarms, precue response rates, and hits decreased for mice from all selected lines. Female high drinking mice were particularly resistant to MA's effects on hits, but not precue response rate or false alarms.
These data suggest a shared, but complex, genetic association between inhibition processes, general levels of operant responding, and MA sensitization or consumption.
C1 [Moschak, Travis M.; Stang, Katherine A.; Phillips, Tamara J.; Mitchell, Suzanne H.] Oregon Hlth & Sci Univ, Dept Behav Neurosci L470, Portland, OR 97239 USA.
[Mitchell, Suzanne H.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
[Phillips, Tamara J.; Mitchell, Suzanne H.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA.
[Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR USA.
RP Mitchell, SH (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci L470, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM mitchesu@ohsu.edu
OI Mitchell, Suzanne/0000-0002-0225-7200
FU Methamphetamine Abuse Research Center [P50 DA018165]; Department of
Veterans Affairs; Portland Alcohol Research Center [P60 AA10760]; NIAAA
[AA007468]
FX SHM and TJP designed the study, TMM and KAS collected the data with help
from Noah Gubner and Ryan McLaughlin, data analysis was performed by
TMM, KAS and SHM, all authors were involved in data interpretation and
manuscript preparation. This research was supported by the
Methamphetamine Abuse Research Center (P50 DA018165), the Department of
Veterans Affairs, and the Portland Alcohol Research Center (P60
AA10760). TMM was supported by NIAAA T32 training grant AA007468. All
research was conducted in compliance with laws in USA.
NR 49
TC 7
Z9 7
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUL
PY 2012
VL 222
IS 2
BP 353
EP 365
DI 10.1007/s00213-012-2650-z
PG 13
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 964GI
UT WOS:000305681600017
PM 22311384
ER
PT J
AU Yilmaz-Rastoder, E
Gold, MS
Hough, KA
Gebhart, GF
Williams, BA
AF Yilmaz-Rastoder, Eser
Gold, Michael S.
Hough, Karen A.
Gebhart, G. F.
Williams, Brian A.
TI Effect of Adjuvant Drugs on the Action of Local Anesthetics in Isolated
Rat Sciatic Nerves
SO REGIONAL ANESTHESIA AND PAIN MEDICINE
LA English
DT Article
ID PERIPHERAL BENZODIAZEPINE-RECEPTORS; PERINEURAL INFUSION; CLONIDINE;
ROPIVACAINE; ANALGESIA; BLOCK; DEXAMETHASONE; NEUROTOXICITY;
BUPIVACAINE; CONDUCTION
AB Background and Objectives: There is increasing clinical use of adjuvant drugs to prolong the duration of local anesthetic-induced block of peripheral nerves. However, the mechanistic understanding regarding drug interactions between these compounds in the periphery is quite limited. Accordingly, we undertook this study to determine whether selected adjuvant drugs are efficacious in blocking action potential propagation in peripheral nerves at concentrations used clinically and whether these drugs influence peripheral nerve block produced by local anesthetics.
Methods: Isolated rat sciatic nerves were used to assess (1) the efficacy of buprenorphine, clonidine, dexamethasone, or midazolam, alone and in combination, on action potential propagation; and (2) their influence on the blocking actions of local anesthetics ropivacaine and lidocaine. Compound action potentials (CAPs) from A- and C-fibers were studied before and after drug application.
Results: At estimated clinical concentrations, neither buprenorphine nor dexamethasone affected either A- or C-waves of the CAP. Clonidine produced a small but significant attenuation of the C-wave amplitude. Midazolam attenuated both A- and C-wave amplitudes, but with greater potency on the C-wave. The combination of clonidine, buprenorphine, and dexamethasone had no influence on the potency or duration of local anesthetic- or midazolam-induced block of A- and C-waves of the CAP.
Conclusions: These results suggest that the reported clinical efficacy of clonidine, buprenorphine, and dexamethasone influences the actions of local anesthetics via indirect mechanisms. Further identification of these indirect mechanisms may enable the development of novel approaches to achieve longer-duration, modality-specific peripheral nerve block.
C1 [Yilmaz-Rastoder, Eser; Gold, Michael S.; Hough, Karen A.; Gebhart, G. F.; Williams, Brian A.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Ctr Pain Res, Pittsburgh, PA 15261 USA.
[Williams, Brian A.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
RP Williams, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Ctr Pain Res, W-1403 BST WR, Pittsburgh, PA 15261 USA.
EM williamsba@anes.upmc.edu
OI Gold, Michael/0000-0002-2083-6206
FU Department of Defense grant [OR090012]
FX This research is supported by a Department of Defense grant (OR090012)
to Drs. Williams, Gold, and Gebhart. The article review by Department of
Defense grant coprincipal investigator Chester C. Buckenmaier, III, MD
(Walter Reed Army Medical Center), is also acknowledged.
NR 20
TC 18
Z9 18
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1098-7339
J9 REGION ANESTH PAIN M
JI Region. Anesth. Pain Med.
PD JUL-AUG
PY 2012
VL 37
IS 4
BP 403
EP 409
DI 10.1097/AAP.0b013e3182485965
PG 7
WC Anesthesiology
SC Anesthesiology
GA 965QI
UT WOS:000305781900008
PM 22430023
ER
PT J
AU Burke, LE
Styn, MA
Sereika, SM
Conroy, MB
Ye, L
Glanz, K
Sevick, MA
Ewing, LJ
AF Burke, Lora E.
Styn, Mindi A.
Sereika, Susan M.
Conroy, Molly B.
Ye, Lei
Glanz, Karen
Sevick, Mary Ann
Ewing, Linda J.
TI Using mHealth Technology to Enhance Self-Monitoring for Weight Loss A
Randomized Trial
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID LIFE-STYLE MODIFICATION; LOSS MAINTENANCE; TREATMENT PREFERENCE;
PHYSICAL-ACTIVITY; CLINICAL-TRIAL; MOBILE PHONE; OBESE ADULTS; PROGRAM;
INTERVENTIONS; MANAGEMENT
AB Background: Self-monitoring for weight loss has traditionally been performed with paper diaries. Technologic advances could reduce the burden of self-monitoring and provide feedback to enhance adherence.
Purpose: To determine if self-monitoring diet using a PDA only or the PDA with daily tailored feedback ( PDA + feedback [FB]), was superior to using a paper diary on weight loss and maintenance.
Design: The Self-Monitoring and Recording Using Technology (SMART) Trial was a 24-month randomized clinical trial; participants were randomly assigned to one of three self-monitoring groups.
Setting/participants: From 2006 to 2008, a total of 210 overweight/obese adults (84.8% female, 78.1% white) were recruited from the community. Data were analyzed in 2011.
Intervention: Participants received standard behavioral treatment for weight loss that included dietary and physical activity goals, encouraged the use of self-monitoring, and was delivered in group sessions.
Main outcome measures: Percentage weight change at 24 months, adherence to self-monitoring over time.
Results: Study retention was 85.6%. The mean percentage weight loss at 24 months was not different among groups (paper diary: -1.94%, 95% CI = -3.88, 0.01; PDA: -1.38%, 95% CI = -3.38, 0.62; PDA + FB: -2.32%, 95% CI = -4.29, -0.35); only the PDA + FB group (p = 0.02) demonstrated a significant loss. For adherence to self-monitoring, there was a time-by-treatment group interaction between the combined PDA groups and the paper diary group (p = 0.03) but no difference between PDA and PDA + FB groups (p = 0.49). Across all groups, weight loss was greater for those who were adherent >= 60% versus <30% of the time (p < 0.001).
Conclusions: PDA + FB use resulted in a small weight loss at 24 months; PDAuse resulted in greater adherence to dietary self-monitoring over time. However, for sustained weight loss, adherence to self-monitoring is more important than the method used to self-monitor. A daily feedback message delivered remotely enhanced adherence and improved weight loss, which suggests that technology can play a role in improving weight loss.
Trial registration: This study is registered at clinicaltrials. gov NCT00277771. (Am J Prev Med 2012;43(1):20-26) (C) 2012 American Journal of Preventive Medicine
C1 [Burke, Lora E.; Styn, Mindi A.; Sereika, Susan M.; Ye, Lei] Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15261 USA.
[Burke, Lora E.; Styn, Mindi A.; Sereika, Susan M.; Conroy, Molly B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Sereika, Susan M.; Ye, Lei] Univ Pittsburgh, Dept Biostat, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Conroy, Molly B.; Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA.
[Ewing, Linda J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Sevick, Mary Ann] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Glanz, Karen] Univ Penn, Sch Med & Nursing, Philadelphia, PA 19104 USA.
RP Burke, LE (reprint author), Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, 3500 Victoria St,415 Victoria Bldg, Pittsburgh, PA 15261 USA.
EM lbu100@pitt.edu
RI Emchi, Karma/Q-1952-2016
FU NIH [NIH/NIDDK R01-DK071817, R01-DK071817-04S1, R01-DK071817-05S1,
NIH/NINR K24-NR010742]; Data Management Core of the Center for Research
in Chronic Disorders at the University of Pittsburgh School of Nursing
[NIH-NINR P30-NR03924]; General Clinical Research Center [NIH-NCRR-GCRC
5M01-RR000056]; Clinical Translational Research Center (NIH/NCRR/CTSA)
at University of Pittsburgh [UL1 RR024153]
FX This work was supported by NIH grants NIH/NIDDK R01-DK071817,
R01-DK071817-04S1, R01-DK071817-05S1, and NIH/NINR K24-NR010742. The
conduct of the study also was supported by the Data Management Core of
the Center for Research in Chronic Disorders at the University of
Pittsburgh School of Nursing (NIH-NINR P30-NR03924), the General
Clinical Research Center (NIH-NCRR-GCRC 5M01-RR000056) and the Clinical
Translational Research Center (NIH/NCRR/CTSA Grant UL1 RR024153) at the
University of Pittsburgh.
NR 32
TC 76
Z9 76
U1 9
U2 43
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD JUL
PY 2012
VL 43
IS 1
BP 20
EP 26
DI 10.1016/j.amepre.2012.03.016
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 959VJ
UT WOS:000305344000003
PM 22704741
ER
PT J
AU Hale, GA
Shrestha, S
Le-Rademacher, J
Burns, LJ
Gibson, J
Inwards, DJ
Freytes, CO
Bolwell, BJ
Hsu, JW
Slavin, S
Isola, L
Rizzieri, DA
Gale, RP
Laport, GG
Montoto, S
Lazarus, HM
Hari, PN
AF Hale, Gregory A.
Shrestha, Smriti
Le-Rademacher, Jennifer
Burns, Linda J.
Gibson, John
Inwards, David J.
Freytes, Cesar O.
Bolwell, Brian J.
Hsu, Jack W.
Slavin, Shimon
Isola, Luis
Rizzieri, David A.
Gale, Robert Peter
Laport, Ginna G.
Montoto, Silvia
Lazarus, Hillard M.
Hari, Parameswaran N.
TI Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin
Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR
SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
LA English
DT Article
DE Non-Hodgkin lymphoma; HCT
ID ALLOGENEIC TRANSPLANTATION; MARROW-TRANSPLANTATION; RETROSPECTIVE
ANALYSIS; HOST DISEASE; FOLLOW-UP; GRAFT; SURVIVAL; REGIMEN; LEUKEMIA;
OUTCOMES
AB We analyzed the outcomes of 248 (61% male) adult recipients of HLA-matched unrelated and HLA-mismatched related donor hematopoietic cell transplantation (HCT) for non-Hodgkin lymphoma (NHL) after reduced or lower intensity conditioning (RIC), reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1997 to 2004. Median age was 52 (range: 18-72 years); 31% had a Karnofsky performance score <90. Follicular NHL (43%) was the major histology. Incidence of grades II-IV acute graft-versus-host disease (aGVHD) was 43% at 100 days; and chronic GVHD (cGVHD) was 44% at 3 years. Treatment-related mortality (TRM) at 100 days was 24%. Three-year overall survival (OS) and progression-free survival (PFS) were 41% and 32%, respectively. In multivariate analysis, use of antithymocyte globulin (ATG) and HLA mismatch were associated with increased TRM. High-grade histology, ATG use, and chemotherapy resistance were associated with lower PFS. Older age, shorter interval from diagnosis to HCT, non total body irridiation (TBI) conditioning regimens, ex vivo T cell depletion, and HLA-mismatched unrelated donors were associated with mortality. GVHD did not influence relapse or PFS. Older age, aggressive histology, and chemotherapy resistance correlated with poorer survival. For selected patients with NHL, lack of an available sibling donor should not be a barrier to allogeneic HCT. Biol Blood Marrow Transplant 18: 1036-1043 (2012) (C) 2012 American Society for Blood and Marrow Transplantation
C1 [Shrestha, Smriti; Le-Rademacher, Jennifer; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplantat Res, Milwaukee, WI 53226 USA.
[Hale, Gregory A.] Univ S Florida, All Childrens Hosp, St Petersburg, FL 33701 USA.
[Burns, Linda J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
[Gibson, John] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia.
[Inwards, David J.] Mayo Clin, Rochester, MN USA.
[Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Bolwell, Brian J.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Hsu, Jack W.] Univ Florida, Shands Hosp, Gainesville, FL USA.
[Slavin, Shimon] Int Ctr Cell Therapy & Canc Immunotherapy, Tel Aviv, Israel.
[Isola, Luis] Mt Sinai Hosp, New York, NY 10029 USA.
[Rizzieri, David A.] Duke Univ, Med Ctr, Durham, NC USA.
[Gale, Robert Peter] Celgene Corp, Summit, NJ USA.
[Laport, Ginna G.] Stanford Hosp & Clin, Stanford, CA USA.
[Montoto, Silvia] Queen Mary Univ London, Sch Med, London, England.
[Lazarus, Hillard M.] Univ Hosp, Case Med Ctr, Cleveland, OH USA.
RP Hari, PN (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplantat Res, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA.
EM phari@mcw.edu
OI Hari, Parameswaran/0000-0002-8800-297X
FU National Cancer Institute (NCI) [U24-CA76518, 5U01HL069294]; National
Heart, Lung and Blood Institute (NHLBI) [U24-CA76518, 5U01HL069294];
National Institute of Allergy and Infectious Diseases (NIAID)
[U24-CA76518]; Health Resources and Services Administration (HRSA/DHHS)
[HHSH234200637015C]; Office of Naval Research [N00014-06-1-0704,
N00014-08-1-0058]; Allos, Inc.; Amgen, Inc.; Angioblast
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement U24-CA76518 from the National Cancer Institute (NCI), the
National Heart, Lung and Blood Institute (NHLBI), and the National
Institute of Allergy and Infectious Diseases (NIAID); a
Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract
HHSH234200637015C with Health Resources and Services Administration
(HRSA/DHHS); 2 grants, N00014-06-1-0704 and N00014-08-1-0058, from the
Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.;
Angioblast; anonymous donation to the Medical College of Wisconsin;
Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association;
Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix,
GmbH; Children's Leukemia Research Association; Fresenius-Biotech North
America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.;
Genzyme Corporation; GlaxoSmithKline; Kiadis Pharma; The Leukemia &
Lymphoma Society; The Medical College of Wisconsin; Millennium
Pharmaceuticals, Inc.; Milliman USA, Inc.; Miltenyi Biotec, Inc.;
National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Otsuka
America Pharmaceutical, Inc.; Seattle Genetics; Sigma-Tau
Pharmaceuticals; Soligenix, Inc.; Swedish Orphan Biovitrum; THERAKOS,
Inc.; and Wellpoint, Inc. The views expressed in this article do not
reflect the official policy or position of the National Institute of
Health, the Department of the Navy, the Department of Defense, or any
other agency of the U.S. Government.
NR 23
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1083-8791
EI 1523-6536
J9 BIOL BLOOD MARROW TR
JI Biol. Blood Marrow Transplant.
PD JUL
PY 2012
VL 18
IS 7
BP 1036
EP 1043
DI 10.1016/j.bbmt.2011.11.026
PG 8
WC Hematology; Immunology; Transplantation
SC Hematology; Immunology; Transplantation
GA 964BE
UT WOS:000305667900008
PM 22155506
ER
PT J
AU Merkow, RP
Bilimoria, KY
McCarter, MD
Chow, WB
Gordon, HS
Stewart, AK
Ko, CY
Bentrem, DJ
AF Merkow, Ryan P.
Bilimoria, Karl Y.
McCarter, Martin D.
Chow, Warren B.
Gordon, Howard S.
Stewart, Andrew K.
Ko, Clifford Y.
Bentrem, David J.
TI Effect of histologic subtype on treatment and outcomes for esophageal
cancer in the United States
SO CANCER
LA English
DT Article
DE esophageal cancer; tumor histology; surgery; survival; hospital type;
adenocarcinoma; squamous cell carcinoma; treatment utilization; outcomes
ID PROPENSITY SCORE; SURGERY; CARCINOMA; CHEMORADIATION; ADENOCARCINOMA;
PATTERNS; THERAPY; CARE
AB BACKGROUND: Esophageal adenocarcinoma (AC) and squamous cell carcinoma (SCC) have distinct clinico-pathologic characteristics; however, it is unclear whether treatment patterns differ by histologic subtype. The objective of this study was to examine differences in treatment use and outcomes by histologic subtype for esophageal cancer in the United States. METHODS: From the National Cancer Data Base, patients with esophageal cancer were identified. Regression models were formulated to assess the influence of histologic subtype on treatment use and overall survival. RESULTS: From 1998 to 2007, 80,961 patients were identified with esophageal cancer in the United States. A higher percentage of patients with nonmetastatic AC underwent surgical resection compared with patients with nonmetastatic SCC (AC, 65.7%; SCC, 36.0%; P<.001), who were more often treated with chemoradiotherapy alone (AC, 25.7%; SCC, 54.1%; P<.001). High-volume academic centers used surgery more frequently for both AC and SCC than did other centers, yet even at high-volume academic centers, surgery was used much less often to treat SCC than AC (AC, 79.3%; SCC, 53.7%; P<.001). The likelihood of operative treatment for nonmetastatic disease was significantly lower in patients with SCC compared with patients with AC (P<.001). Overall survival was lower for patients with stage II/III disease of either histologic subtype treated with chemoradiotherapy alone compared with surgery plus chemoradiotherapy (P<.001). CONCLUSION: A large proportion of patients with esophageal cancer are being treated nonoperatively, and treatment use varies according to tumor histology, particularly by center type. Cancer 2011. (c) 2011 American Cancer Society.
C1 [Merkow, Ryan P.; Bilimoria, Karl Y.; Bentrem, David J.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Bentrem, David J.] Jesse Brown VA Med Ctr, Dept Surg, Chicago, IL USA.
[Merkow, Ryan P.; McCarter, Martin D.] Univ Colorado, Dept Surg, Sch Med, Aurora, CO USA.
[Bilimoria, Karl Y.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
[Gordon, Howard S.] Univ Illinois, Coll Med, VA Ctr Management Complex Chron Care, Jesse Brown VA Med Ctr,Dept Med, Chicago, IL USA.
[Stewart, Andrew K.] Amer Coll Surg, Canc Programs, Chicago, IL USA.
[Chow, Warren B.; Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Chow, Warren B.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bentrem, DJ (reprint author), 676 N St Clair St,Suite 650, Chicago, IL 60611 USA.
EM dbentrem@nmff.org
RI Gordon, Howard/E-4420-2010
OI Gordon, Howard/0000-0002-6712-5954
FU Health Services Research Division, Department of Veterans Affairs
FX D.J.B. is supported by a Career Development Award from the Health
Services Research Division, Department of Veterans Affairs.
NR 32
TC 12
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUL 1
PY 2012
VL 118
IS 13
BP 3268
EP 3276
DI 10.1002/cncr.26608
PG 9
WC Oncology
SC Oncology
GA 960LM
UT WOS:000305389500011
PM 22006369
ER
PT J
AU Ahdout, J
Kotlerman, J
Elashoff, D
Kim, J
Chiu, MW
AF Ahdout, J.
Kotlerman, J.
Elashoff, D.
Kim, J.
Chiu, M. W.
TI Modifiable lifestyle factors associated with metabolic syndrome in
patients with psoriasis
SO CLINICAL AND EXPERIMENTAL DERMATOLOGY
LA English
DT Article
ID DISEASE; PREVALENCE; RISK; EPIDEMIOLOGY; SMOKING; OBESITY; STRESS; DIET
AB Background. Psoriasis is a chronic inflammatory skin disease, which is associated with obesity and with cardiovascular morbidity and mortality. Aim. To evaluate modifiable lifestyle factors including stress level, physical activity and nutrition, which may be associated with metabolic syndrome in patients with psoriasis. Methods. In total, 65 patients with psoriasis and 52 control subjects from our university dermatology clinic were enrolled in this casecontrol pilot study. The study questionnaire included the Perceived Stress Scale (PSS), the Godin Leisure-Time Exercise Questionnaire (GLTEQ) and the Rapid Eating Assessment for patients (REAP). For subjects with psoriasis, the Psoriasis Area and Severity Index (PASI) was measured. Results. Subjects with psoriasis (mean BMI 27.72) displayed a trend towards a higher BMI compared with controls (mean BMI 25.67). Subjects with psoriasis were not found to have an increased prevalence of self-reported metabolic syndrome-associated diseases including diabetes, heart disease, high cholesterol, hypertension or stroke compared with controls (P = 0.25, P = 0.46, P = 0.96, P = 0.26, and P = 0.16, respectively). There was no significant difference in exercise or stress between patients with psoriasis and controls (P = 0.06 and P = 0.26, respectively). However, compared with controls, subjects with psoriasis (mean REAP score = 2.23) did report poorer overall nutrition as assessed by the REAP score (mean = 2.38, P < 0.01). Among subjects with psoriasis, the factors of stress, smoking and systemic therapy were associated with increased PASI (r = 0.13, r = 3.47 and r = 3.19, respectively). Conclusions. Our study suggests that poor dietary and exercise habits may be factors contributing to obesity and metabolic syndrome in patients with psoriasis. Further studies with larger numbers are needed to confirm these results.
C1 [Ahdout, J.] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92697 USA.
[Kotlerman, J.; Elashoff, D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med Stat Core, Los Angeles, CA 90095 USA.
[Kim, J.; Chiu, M. W.] Univ Calif Los Angeles, David Geffen Sch Med, Div Dermatol, Dept Med, Los Angeles, CA 90095 USA.
[Kim, J.; Chiu, M. W.] Greater Los Angeles Vet Affairs Healthcare Syst, Dermatol Serv, Los Angeles, CA USA.
RP Ahdout, J (reprint author), Univ Calif Irvine, Dept Dermatol, C340 Med Sci 1, Irvine, CA 92697 USA.
EM jahdout@gmail.com
FU UCLA Department of Medicine, Division of Dermatology; Dermatologic
Research Foundation of California
FX This study was supported in part by the UCLA Department of Medicine,
Division of Dermatology and the Dermatologic Research Foundation of
California. The sponsors had no role in the design and conduct of the
study, the collection, analysis and interpretation of the data, or in
the preparation, review or approval of the manuscript.
NR 25
TC 9
Z9 9
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0307-6938
J9 CLIN EXP DERMATOL
JI Clin. Exp. Dermatol.
PD JUL
PY 2012
VL 37
IS 5
BP 477
EP 483
DI 10.1111/j.1365-2230.2012.04360.x
PG 7
WC Dermatology
SC Dermatology
GA 961ZX
UT WOS:000305509800003
PM 22712856
ER
PT J
AU Riegel, B
Ratcliffe, SJ
Weintraub, WS
Sayers, SL
Goldberg, LR
Potashnik, S
Weaver, TE
Pressler, SJ
AF Riegel, Barbara
Ratcliffe, Sarah J.
Weintraub, William S.
Sayers, Steven L.
Goldberg, Lee R.
Potashnik, Sheryl
Weaver, Terri E.
Pressler, Susan J.
TI Double jeopardy: the influence of excessive daytime sleepiness and
impaired cognition on health-related quality of life in adults with
heart failure
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Heart failure; Quality of life; Sleep; Cognition
ID SYMPTOM BURDEN; APNEA; VALIDATION; QUESTIONNAIRE; DEPRESSION; INSOMNIA;
PROGRAM; SYSTEM; IMPACT; CARE
AB To determine how excessive daytime sleepiness (EDS) and impaired cognition contribute to health-related quality of life (HRQL) in heart failure (HF).
Adults with chronic HF were enrolled into a prospective cohort study. Data were obtained from 280 subjects enrolled from three sites in the northeastern USA; 242 completed the 6-month study. At baseline, cohorts with and without EDS were identified using the Epworth Sleepiness Scale. Each EDS group was further subdivided into those with and without impaired cognition using a battery of five neuropsychological tests. Two disease-specific measures, the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Functional Outcomes of Sleep Questionnaire (FOSQ), were used to measure HRQL. General linear modelling of square-transformed variables was used to test the hypothesis that cohort membership was a significant predictor of HRQL. At 6 months the remaining sample was 62.5 [standard deviation (SD) 12] years old, mostly male (63), white (65), and functionally compromised [72 New York Heart Association (NYHA) class III/IV]. The cohort with both EDS and impaired cognition had the lowest KCCQ overall summary score (60.5 22.5) compared with the cohort without EDS or impaired cognition (74.6 17.4, P 0.001). A similar effect was seen on the FOSQ (16.0 2.8 vs. 18.5 2.2, P 0.001).
Impaired cognition alone did not explain poor HRQL, but the addition of EDS poses a significant risk for poor HRQL. Interventions designed to influence EDS may improve HRQL in this population.
C1 [Riegel, Barbara; Potashnik, Sheryl] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Ratcliffe, Sarah J.; Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA.
[Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Weaver, Terri E.] Univ Illinois, Coll Nursing, Chicago, IL USA.
[Pressler, Susan J.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
RP Riegel, B (reprint author), Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
EM briegel@nursing.upenn.edu
OI Goldberg, Lee/0000-0002-7906-9638; Ratcliffe, Sarah/0000-0002-6644-8284
FU National Heart, Lung, and Blood Institute at the National Institutes of
Health [RO1 HL084394-01A1]; Philadelphia Veterans Affairs Medical
Center; VISN 4 Mental Illness Research, Education, and Clinical Center
(MIREC)
FX The National Heart, Lung, and Blood Institute (RO1 HL084394-01A1) at the
National Institutes of Health; the Philadelphia Veterans Affairs Medical
Center; VISN 4 Mental Illness Research, Education, and Clinical Center
(MIREC).
NR 42
TC 6
Z9 6
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JUL
PY 2012
VL 14
IS 7
BP 730
EP 736
DI 10.1093/eurjhf/hfs054
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 963OT
UT WOS:000305632300007
PM 22510422
ER
PT J
AU Chirinos, JA
Segers, P
Gillebert, TC
Gupta, AK
De Buyzere, ML
De Bacquer, D
St John-Sutton, M
Rietzschel, ER
AF Chirinos, Julio A.
Segers, Patrick
Gillebert, Thierry C.
Gupta, Amit K.
De Buyzere, Marc L.
De Bacquer, Dirk
St John-Sutton, Martin
Rietzschel, Ernst R.
CA Asklepios Investigators
TI Arterial Properties as Determinants of Time-Varying Myocardial Stress in
Humans
SO HYPERTENSION
LA English
DT Article
DE myocardial stress; arterial load; afterload; wave reflections; sex
differences
ID LEFT-VENTRICULAR HYPERTROPHY; SYSTOLIC PRESSURE; WAVE REFLECTION;
HEART-FAILURE; IMPEDANCE; VOLUME
AB Myocardial and arterial load are time-varying phenomena. Despite their importance in myocardial function, the arterial properties that determine time-resolved myocardial wall stress are unknown. We aimed to assess arterial properties as determinants of time-resolved myocardial stress among 1214 men and women enrolled in the Asklepios Study. Time-resolved central pressure, flow, and left ventricular geometry were measured with carotid tonometry, Doppler, and speckle-tracking echocardiography, respectively, for computation of arterial load and ejection-phase time-varying myocardial wall stress. For any given end-diastolic left ventricular geometry and cardiac output, peak myocardial stress correlated directly with systemic vascular resistance (standardized beta=1.12; P<0.0001) and aortic characteristic impedance (standardized beta=0.17; P<0.0001). The ejection-phase stress-time integral correlated with systemic vascular resistance (standardized beta=1.06; P<0.0001), lower total arterial compliance (standardized beta=-0.13; P=0.0008), and earlier return of wave reflections (standardized beta=-0.10; P<0.0001) but not with reflection magnitude, whereas end-systolic wall stress correlated with systemic vascular resistance (standardized beta=1.06; P<0.0001) and reflection magnitude (standardized beta=0.12; P<0.0001). After adjustment for age, all of the measured arterial properties, end-diastolic left ventricular geometry, and cardiac output, women demonstrated greater peak (534 versus 507 kdyne/cm(2); P<0.0001), end-systolic (335 versus 320 kdyne/cm(2); P<0.0001), and ejection-phase stress-time integral (157 versus 142 kdyne . s . cm(-2); P<0.0001). In conclusion, different arterial properties have selective effects on time-resolved ejection-phase myocardial wall stress, which are not apparent from single-time point measurements. Women demonstrate less efficient myocardial-arterial coupling, with higher wall stress development for any given left ventricular geometry, arterial properties, and flow output. These observations may relate to the differential susceptibility of women to heart failure. (Hypertension. 2012;60:64-70.). Online Data Supplement
C1 [Chirinos, Julio A.; St John-Sutton, Martin] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Segers, Patrick] Ghent Univ Hosp, Inst Biomed Technol, Ghent, Belgium.
[Gillebert, Thierry C.; De Buyzere, Marc L.; Rietzschel, Ernst R.] Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium.
[De Bacquer, Dirk; Rietzschel, Ernst R.] Ghent Univ Hosp, Dept Publ Hlth, Ghent, Belgium.
[Gupta, Amit K.] Baylor Coll Med, Houston, TX 77030 USA.
RP Chirinos, JA (reprint author), Room 8B111,5800 Woodland Ave, Philadelphia, PA 19143 USA.
EM julio.chirinos@uphs.upenn.edu
OI Gillebert, Thierry/0000-0002-3832-919X
FU Fonds voor Wetenschappelijk Onderzoek Vlaanderen [G.0.838.10]; American
Heart Association [0885031N]; National Institutes of Health
FX This study was supported by Fonds voor Wetenschappelijk Onderzoek
Vlaanderen grant G.0.838.10 and American Heart Association research
award 0885031N.; J.A.C. has received significant (more than $10 000)
grants from the National Institutes of Health and the American Heart
Association for research studies related to arterial hemodynamics and
has received minor support (equipment loans) from Atcor Medical,
Cardiodynamics, and APC Cardiovascular.
NR 16
TC 31
Z9 31
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD JUL
PY 2012
VL 60
IS 1
BP 64
EP 70
DI 10.1161/HYPERTENSIONAHA.112.190710
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 962VF
UT WOS:000305574200022
PM 22665121
ER
PT J
AU Holodniy, M
Oda, G
Schirmer, PL
Lucero, CA
Khudyakov, YE
Xia, GL
Lin, YL
Valdiserri, R
Duncan, WE
Davey, VJ
Cross, GM
AF Holodniy, Mark
Oda, Gina
Schirmer, Patricia L.
Lucero, Cynthia A.
Khudyakov, Yury E.
Xia, Guoliang
Lin, Yulin
Valdiserri, Ronald
Duncan, William E.
Davey, Victoria J.
Cross, Gerald M.
TI Results from a Large-Scale Epidemiologic Look-Back Investigation of
Improperly Reprocessed Endoscopy Equipment
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID HEPATITIS-C VIRUS; GASTROINTESTINAL ENDOSCOPY; UNITED-STATES; DISEASE
TRANSMISSION; FLEXIBLE ENDOSCOPY; INFECTION-CONTROL; BRITISH-SOCIETY;
WORKING PARTY; DISINFECTION; RISK
AB OBJECTIVE. To determine whether improper high-level disinfection practices during endoscopy procedures resulted in bloodborne viral infection transmission.
DESIGN. Retrospective cohort study.
SETTING. Four Veterans Affairs medical centers (VAMCs).
PATIENTS. Veterans who underwent colonoscopy and laryngoscopy (ear, nose, and throat [ENT]) procedures from 2003 to 2009.
METHODS. Patients were identified through electronic health record searches and serotested for human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV). Newly discovered case patients were linked to a potential source with known identical infection, whose procedure occurred no more than 1 day prior to the case patient's procedure. Viral genetic testing was performed for case/proximate pairs to determine relatedness.
RESULTS. Of 10,737 veterans who underwent endoscopy at 4 VAMCs, 9,879 patients agreed to viral testing. Of these, 90 patients were newly diagnosed with 1 or more viral bloodborne pathogens (BBPs). There were no case/proximate pairings found for patients with either HIV or HBV; 24 HCV case/proximate pairings were found, of which 7 case patients and 8 proximate patients had sufficient viral load for further genetic testing. Only 2 of these cases, both of whom underwent laryngoscopy, and their 4 proximates agreed to further testing. None of the 4 remaining proximate patients who underwent colonoscopy agreed to further testing. Mean genetic distance between the 2 case patients and 4 proximate patients ranged from 13.5% to 19.1%.
CONCLUSIONS. Our investigation revealed that exposure to improperly reprocessed ENT endoscopes did not result in viral transmission in those patients who had viral genetic analysis performed. Any potential transmission of BBPs from colonoscopy remains unknown. Infect Control Hosp Epidemiol 2012;33(7):649-656
C1 [Holodniy, Mark; Oda, Gina; Schirmer, Patricia L.; Lucero, Cynthia A.; Davey, Victoria J.] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA.
[Holodniy, Mark] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA.
[Khudyakov, Yury E.; Xia, Guoliang; Lin, Yulin] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA.
[Valdiserri, Ronald] US Dept HHS, Off HIV AIDS Policy, Washington, DC 20201 USA.
[Duncan, William E.] US Dept Vet Affairs, Off Qual & Safety, Washington, DC USA.
[Cross, Gerald M.] US Dept Vet Affairs, Off Patient Care Serv, Washington, DC USA.
RP Holodniy, M (reprint author), Off Publ Hlth Surveillance & Res, 3801 Miranda Ave 132, Palo Alto, CA 94304 USA.
EM mark.holodniy@va.gov
FU Department of Veterans Affairs
FX Financial support. This study was funded by intramural funds from the
Department of Veterans Affairs.
NR 39
TC 14
Z9 14
U1 0
U2 1
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD JUL
PY 2012
VL 33
IS 7
BP 649
EP 656
DI 10.1086/666345
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 955DW
UT WOS:000304998300001
PM 22669224
ER
PT J
AU Kelley, AS
Ettner, SL
Morrison, RS
Du, QL
Sarkisian, CA
AF Kelley, Amy S.
Ettner, Susan L.
Morrison, R. Sean
Du, Qingling
Sarkisian, Catherine A.
TI Disability and Decline in Physical Function Associated with Hospital Use
at End of Life
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE disability; end-of-life decisions; functional decline; Medicare; Medigap
ID OLDER PERSONS PREFERENCES; LAST 6 MONTHS; TREATMENT INTENSITY; CARE;
ILLNESS; OUTCOMES; ADULTS; DEATH; DETERMINANTS; MORTALITY
AB Hospital use near the end of life is often undesirable to patients, represents considerable Medicare cost, and varies widely across regions.
To concurrently examine regional and patient factors, including disability and functional decline, associated with end-of-life hospital use.
We sampled decedents aged 65 and older (n = 2,493) from the Health and Retirement Study (2000-2006), and linked data from individual Medicare claims and the Dartmouth Atlas of Health Care. Two-part regression models estimated the relationship between total hospital days in the last 6 months and patient characteristics including physical function, while adjusting for regional resources and hospital care intensity (HCI).
Median hospital days was 7 (range = 0-183). 53% of respondents had functional decline. Compared with decedents without functional decline, those with severe disability or decline had more regression-adjusted hospital days (range 3.47-9.05, depending on category). Dementia was associated with fewer days (-3.02); while chronic kidney disease (2.37), diabetes (2.40), stroke or transient ischemic attack (2.11), and congestive heart failure (1.74) were associated with more days. African Americans and Hispanics had more days (5.91 and 4.61, respectively). Those with family nearby had 1.62 fewer days and hospice enrollees had 1.88 fewer days. Additional hospital days were associated with urban residence (1.74) and residence in a region with more specialists (1.97) and higher HCI (2.27).
Functional decline is significantly associated with end-of-life hospital use among older adults. To improve care and reduce costs, health care programs and policies should address specific needs of patients with functional decline and disability.
C1 [Kelley, Amy S.; Morrison, R. Sean; Du, Qingling] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Ettner, Susan L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA.
[Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA.
[Sarkisian, Catherine A.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA.
RP Kelley, AS (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM amy.kelley@mssm.edu
FU National Institute on Aging [K24 AG022345]; National Palliative Care
Research Center; VA Greater Los Angeles Healthcare System Geriatric
Research Education Clinical Center
FX Dr. Kelley is a Brookdale Leadership in Aging Fellow. Dr. Morrison is
the recipient of a Mid-Career Investigator Award in Patient-Oriented
Research (K24 AG022345) from the National Institute on Aging and
supported by the National Palliative Care Research Center. Dr. Sarkisian
is supported by the VA Greater Los Angeles Healthcare System Geriatric
Research Education Clinical Center. No sponsors or funders had any role
in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; or preparation, review, or
approval of the manuscript.
NR 41
TC 11
Z9 11
U1 2
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
IS 7
BP 794
EP 800
DI 10.1007/s11606-012-2013-9
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 962ET
UT WOS:000305524400011
PM 22382455
ER
PT J
AU Kertesz, SG
Khodneva, Y
Richman, J
Tucker, JA
Safford, MM
Jones, B
Schumacher, J
Pletcher, MJ
AF Kertesz, Stefan G.
Khodneva, Yulia
Richman, Joshua
Tucker, Jalie A.
Safford, Monika M.
Jones, Bobby
Schumacher, Joseph
Pletcher, Mark J.
TI Trajectories of Drug Use and Mortality Outcomes Among Adults Followed
Over 18 Years
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE opioids; stimulants; cocaine; trajectory; epidemiology; longitudinal
data
ID ARTERY RISK DEVELOPMENT; YOUNG-ADULTS; SCREENING-TEST; CARDIA; ALCOHOL;
HEALTH; RECRUITMENT; MARIJUANA; SMOKING; DISEASE
AB For adults in general population community settings, data regarding long-term course and outcomes of illicit drug use are sparse, limiting the formulation of evidence-based recommendations for drug use screening of adults in primary care.
To describe trajectories of three illicit drugs (cocaine, opioids, amphetamines) among adults in community settings, and to assess their relation to all-cause mortality.
Longitudinal cohort, 1987/88 - 2005/06.
Community-based recruitment from four cities (Birmingham, Chicago, Oakland, Minneapolis).
Healthy adults, balanced for race (black and white) and gender were assessed for drug use from 1987/88-2005/06, and for mortality through 12/31/2008 (n = 4301)
Use of cocaine, amphetamines, and opioids (last 30 days) was queried in the following years: 1987/88, 1990/91, 1992/93, 1995/96, 2000/01, 2005/06. Survey-based assessment of demographics and psychosocial characteristics. Mortality over 18 years.
Trajectory analysis identified four groups: Nonusers (n = 3691, 85.8%), Early Occasional Users (n = 340, 7.9%), Persistent Occasional Users (n = 160, 3.7%), and Early Frequent/Later Occasional Users (n = 110, 2.6%). Trajectories conformed to expected patterns regarding demographics, other substance use, family background and education. Adjusting for demographics, baseline health status, health behaviors (alcohol, tobacco), and psychosocial characteristics, Early Frequent/Later Occasional Users had greater all-cause mortality (Hazard Ratio, HR = 4.94, 95% CI = 1.58-15.51, p = 0.006).
Study is restricted to three common drugs, and trajectory analyses represent statistical approximations rather than identifiable "types". Causal inferences are tentative.
Four trajectories describe illicit drug use from young adulthood to middle age. Two trajectories, representing over one third of adult users, continued use into middle age. These persons were more likely to continue harmful risk behaviors such as smoking, and more likely to die.
C1 [Kertesz, Stefan G.; Safford, Monika M.; Schumacher, Joseph] Univ Alabama Birmingham, Div Prevent Med, Sch Med, Birmingham, AL 35294 USA.
[Jones, Bobby] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA.
[Pletcher, Mark J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Richman, Joshua] Univ Alabama Birmingham, Sch Med, Dept Surg, Birmingham, AL 35294 USA.
[Kertesz, Stefan G.; Khodneva, Yulia; Tucker, Jalie A.] Univ Alabama Birmingham, Dept Hlth Behav, Sch Publ Hlth, Birmingham, AL 35294 USA.
[Kertesz, Stefan G.] Birmingham VA Med Ctr, Ctr Surg Med & Acute Care Res, Birmingham, AL USA.
RP Kertesz, SG (reprint author), Univ Alabama Birmingham, Div Prevent Med, Sch Med, 1530 3rd Ave S,MT608, Birmingham, AL 35294 USA.
EM skertesz@uab.edu
FU [NIDA: R01-DA-025067]; [NHLBI: N01-HC-95095]; [NO1-HC-48047]
FX Support: NIDA: R01-DA-025067; NHLBI: N01-HC-95095 AND NO1-HC-48047
NR 41
TC 17
Z9 17
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
IS 7
BP 808
EP 816
DI 10.1007/s11606-011-1975-3
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 962ET
UT WOS:000305524400013
PM 22274889
ER
PT J
AU Madaras-Kelly, KJ
Remington, RE
Sloan, KL
Fan, VS
AF Madaras-Kelly, Karl J.
Remington, Richard E.
Sloan, Kevin L.
Fan, Vincent S.
TI Guideline-Based Antibiotics and Mortality in Healthcare-Associated
Pneumonia
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE pneumonia; anti bacterial agents; guideline; methicillin resistant
Staphylococcus aureus; Pseudomonas aeruginosa; healthcare-associated
infection
ID HOSPITAL-ACQUIRED PNEUMONIA; RESISTANT BACTERIA; THERAPY; OUTCOMES;
INFECTION; ADMISSION; ACCURACY; UNIT
AB Guidelines recommend administration of antibiotics with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa for treatment of healthcare-associated pneumonia (HCAP). It is unclear if this therapy improves outcomes for patients with HCAP.
To determine if administration of guideline-similar therapy (GST) was associated with a reduction in 30-day mortality for HCAP.
Multi-center retrospective study.
Thirteen hundred and eleven admissions for HCAP in six Veterans Affairs Medical Centers.
Each admission was classified as receiving GST, anti-MRSA or anti-pseudomonal components of GST, or other non-HCAP therapy initiated within 48 hours of hospitalization. Association between 30-day mortality and GST was estimated with a logistic regression model that included GST, propensity to receive GST, probability of recovering an organism from culture resistant to antibiotics traditionally used to treat community-acquired pneumonia (CAP-resistance), and a GST by CAP-resistance probability interaction.
Odds ratios and 95% confidence intervals [OR (95% CI)] of 30-day mortality for patients treated with GST and predicted probability of recovering a CAP-resistant organism, and ratio of odds ratios [ROR (95% CI)] for treatment by CAP-resistance probability interaction.
Receipt of GST was associated with increased odds of 30-day mortality [OR = 2.11 (1.11, 4.04), P = 0.02)] as was the predicted probability of recovering a CAP-resistant organism [OR = 1.67 (1.26, 2.20), P < 0.001 for a 25% increase in probability]. An interaction between predicted probability of recovering a CAP-resistant organism and receipt of GST demonstrated lower mortality with GST at high probability of CAP resistance [ROR = 0.71(a parts per thousand currency sign1.00) for a 25% increase in probability, P = 0.05].
For HCAP patients with high probability of CAP-resistant organisms, GST was associated with lower mortality. Consideration of the magnitude of patient-specific risk for CAP-resistant organisms should be considered when selecting HCAP therapy.
C1 [Madaras-Kelly, Karl J.] Vet Affairs Med Ctr, Clin Pharm Serv 119A, Boise, ID 83702 USA.
[Remington, Richard E.] Vet Affairs Med Ctr, Res Serv, Boise, ID 83702 USA.
[Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA.
[Madaras-Kelly, Karl J.; Remington, Richard E.] Idaho State Univ, Dept Pharm Practice & Adm Sci, Coll Pharm, Meridian, ID USA.
[Fan, Vincent S.] Univ Washington, Sch Med, Dept Pulm & Crit Care Med, Seattle, WA USA.
RP Madaras-Kelly, KJ (reprint author), Vet Affairs Med Ctr, Clin Pharm Serv 119A, 500 W Ft St, Boise, ID 83702 USA.
EM KMK@pharmacy.isu.edu
FU National Institute of Allergy and Infectious Diseases
[RO3AI074894-01A2]; Boise and Puget Sound Health Care System Veterans
Affairs Medical Centers
FX This study was supported through a grant from the National Institute of
Allergy and Infectious Diseases (RO3AI074894-01A2). This work was
supported in part with resources of the Boise and Puget Sound Health
Care System Veterans Affairs Medical Centers.
NR 26
TC 15
Z9 15
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
IS 7
BP 845
EP 852
DI 10.1007/s11606-012-2011-y
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 962ET
UT WOS:000305524400018
PM 22396110
ER
PT J
AU Kim, JS
Bashir, MM
Werth, VP
AF Kim, Jessica S.
Bashir, Muhammad M.
Werth, Victoria P.
TI Gottron's Papules Exhibit Dermal Accumulation of CD44 Variant 7 (CD44v7)
and Its Binding Partner Osteopontin: A Unique Molecular Signature
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-CELL ACTIVATION; AUTOIMMUNE-DISEASE;
MONONUCLEAR-CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSE; DENDRITIC CELLS;
EXPRESSION; DERMATOMYOSITIS; SKIN
AB The accumulated mucin in non-Gottron's dermatomyositis (DM) lesions is primarily chondroitin-4-sulfate (C4S), which is immunomodulatory in vitro. Gottron's papules are a particularly resistant manifestation of DM that often persist after other lesions have resolved with therapy. We examined non-Gottron's DM lesions and Gottron's papule skin biopsies for C4S, CD44 variant 7 (CD44v7), a chondroitin sulfate-binding isoform causally implicated in autoimmunity, and osteopontin (OPN), a CD44v7 ligand implicated in chronic inflammation. Gottron's papule dermis contained more C4S and CD44v7 than non-Gottron's lesions. Normal skin showed less CD44v7 over joints relative to Gottron's lesions. All DM dermis had increased OPN compared with healthy skin. Mechanically stretching cultured fibroblasts for 6 hours induced CD44v7 mRNA and protein, whereas IFN-gamma treatment induced OPN mRNA and protein. OPN alone did not induce CD44v7, but stretching dermal fibroblasts in the presence of OPN increased human acute monocytic leukemia cell line (THP-1) monocyte binding, which is blunted by anti-CD44v7 blocking antibody. C4S, CD44v7, and OPN are three molecules uniquely present in Gottron's papules that contribute to inflammation individually and in association with one another. We propose that stretch-induced CD44v7 over joints, in concert with dysregulated OPN levels in the skin of DM patients, increases local inflammatory cell recruitment and contributes to the pathogenesis and resistance of Gottron's papules. Journal of Investigative Dermatology (2012) 132, 1825-1832; doi:10.1038/jid.2012.54; published online 29 March 2012
C1 [Kim, Jessica S.; Bashir, Muhammad M.; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Kim, Jessica S.] NYU, Sch Med, New York, NY USA.
[Kim, Jessica S.; Bashir, Muhammad M.; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Werth, VP (reprint author), Univ Penn, Dept Dermatol, 2 Maloney Bldg,36th & Spruce St, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU Lupus Foundation of America; Department of Veterans Affairs (Veterans
Health Administration, Office of Research and Development, Biomedical
Laboratory Research and Development); National Institutes of Health [NIH
K24-AR 02207]
FX This material is based on the work supported by the Lupus Foundation of
America and in part by a Merit Review Grant from the Department of
Veterans Affairs (Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development) and by the
National Institutes of Health (NIH K24-AR 02207) to VPW. The authors
state no conflict of interest.
NR 49
TC 6
Z9 7
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUL
PY 2012
VL 132
IS 7
BP 1825
EP 1832
DI 10.1038/jid.2012.54
PG 8
WC Dermatology
SC Dermatology
GA 961TR
UT WOS:000305492900014
PM 22456539
ER
PT J
AU Valente, AJ
Clark, RA
Siddesha, JM
Siebenlist, U
Chandrasekar, B
AF Valente, Anthony J.
Clark, Robert A.
Siddesha, Jalahalli M.
Siebenlist, Ulrich
Chandrasekar, Bysani
TI CIKS (Act1 or TRAF3IP2) mediates Angiotensin-II-induced Interleukin-18
expression, and Nox2-dependent cardiomyocyte hypertrophy
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE RAAS; NADPH oxidase; Act1; TRAF3IP2; Fibrosis; Cardiac hypertrophy
ID NF-KAPPA-B; INDUCED CARDIAC-HYPERTROPHY; NOX2-CONTAINING NADPH OXIDASE;
HEART-FAILURE; SIGNALING PATHWAYS; GENE-EXPRESSION; PROTEIN-KINASE;
IN-VIVO; ACTIVATION; REQUIREMENT
AB Chronic elevation of angiotensin (Ang)-II can lead to myocardial inflammation, hypertrophy and cardiac failure. The adaptor molecule CIKS (connection to IKK and SAPK/JNK) activates the I kappa B kinase/nuclear factor (NF)-kappa B and JNK/activator protein (AP)-1 pathways in autoimmune and inflammatory diseases. Since Ang-II is a potent activator of NF-kappa B and AP-1, we investigated whether CIKS is critical in Ang-II-mediated cardiac hypertrophy. Here we report that Ang-II induced CIKS mRNA and protein expression, CIKS binding to IKK and JNK perhaps functioning as a scaffold protein, CIKS-dependent IKK/NF-kappa B and JNK/AP-1 activation, p65 and c-Jun phosphorylation and nuclear translocation, NF-kappa B- and AP-1-dependent IL-18 and MMP-9 induction, and hypertrophy of adult cardiomyocytes isolated from WT, but not CIKS-null mice. These results were recapitulated in WT-cardiomyocytes following CIKS knockdown. Infusion of Ang-II for 7 days induced cardiac hypertrophy, increased collagen content, and upregulated CIKS mRNA and protein expression in WT mice, whereas cardiac hypertrophy and collagen deposition were markedly attenuated in the CIKS-null mice, despite a similar increase in systolic blood pressure and DPI-inhibitable superoxide generation in both types of animals. Further, Ang-II-induced IKK/p65 and JNK/c-Jun phosphorylation, NF-kappa B and AP-1 activation, and IL-18 and MMP-9 expression were also markedly attenuated in CIKS-null mice. These results demonstrate that CIKS is critical in Ang-II-induced cardiomyocyte hypertrophy and fibrosis, and that CIKS is an important intermediate in Ang-II-induced redox signaling. CIKS is a potential therapeutic target in cardiac hypertrophy, fibrosis, and congestive heart failure. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Siddesha, Jalahalli M.; Chandrasekar, Bysani] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA.
[Valente, Anthony J.; Clark, Robert A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Valente, Anthony J.; Clark, Robert A.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Siebenlist, Ulrich] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Chandrasekar, Bysani] SE Louisiana Vet Hlth Care Syst, Res Serv, New Orleans, LA 70161 USA.
RP Chandrasekar, B (reprint author), Tulane Univ, Sch Med, Inst Heart & Vasc, 1430 Tulane Ave,SL-48, New Orleans, LA 70112 USA.
EM bchandra@tulane.edu
FU Veterans Affairs Office of Research and Development Biomedical
Laboratory Research and Development Service Award [1IO1BX000246];
NIH/NHLBI [HL-86787]
FX This work was supported by Veterans Affairs Office of Research and
Development Biomedical Laboratory Research and Development Service Award
1IO1BX000246 and the NIH/NHLBI Grant HL-86787 (to BC). The contents of
this report do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 45
TC 25
Z9 25
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD JUL
PY 2012
VL 53
IS 1
BP 113
EP 124
DI 10.1016/j.yjmcc.2012.04.009
PG 12
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA 963AI
UT WOS:000305592100014
PM 22575763
ER
PT J
AU Wills, LP
Trager, RE
Beeson, GC
Lindsey, CC
Peterson, YK
Beeson, CC
Schnellmann, RG
AF Wills, Lauren P.
Trager, Richard E.
Beeson, Gyda C.
Lindsey, Christopher C.
Peterson, Yuri K.
Beeson, Craig C.
Schnellmann, Rick G.
TI The beta(2)-Adrenoceptor Agonist Formoterol Stimulates Mitochondrial
Biogenesis
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID PGC-1-ALPHA MESSENGER-RNA; PROXIMAL TUBULE CELLS; HUMAN SKELETAL-MUSCLE;
REUPTAKE INHIBITORS; PROMOTES RECOVERY; GENE-EXPRESSION; RECEPTOR;
METABOLISM; EXERCISE; CULTURE
AB Mitochondrial dysfunction is a common mediator of disease and organ injury. Although recent studies show that inducing mitochondrial biogenesis (MB) stimulates cell repair and regeneration, only a limited number of chemicals are known to induce MB. To examine the impact of the beta-adrenoceptor (beta-AR) signaling pathway on MB, primary renal proximal tubule cells (RPTC) and adult feline cardiomyocytes were exposed for 24 h to multiple beta-AR agonists: isoproterenol (nonselective beta-AR agonist), (+/-)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl] amino]propyl]phenoxy] acetic acid sodium hydrate (BRL 37344) (selective beta(3)-AR agonist), and formoterol (selective beta(2)-AR agonist). The Seahorse Biosciences (North Billerica, MA) extracellular flux analyzer was used to quantify carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP)-uncoupled oxygen consumption rate (OCR), a marker of maximal electron transport chain activity. Isoproterenol and BRL 37244 did not alter mitochondrial respiration at any of the concentrations examined. Formoterol exposure resulted in increases in both FCCP-uncoupled OCR and mitochondrial DNA (mtDNA) copy number. The effect of formoterol on OCR in RPTC was inhibited by the beta-AR antagonist propranolol and the beta(2)-AR inverse agonist 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol hydrochloride (ICI-118,551). Mice exposed to formoterol for 24 or 72 h exhibited increases in kidney and heart mtDNA copy number, peroxisome proliferator-activated receptor gamma coactivator 1 alpha, and multiple genes involved in the mitochondrial electron transport chain (F0 subunit 6 of transmembrane F-type ATP synthase, NADH dehydrogenase subunit 1, NADH dehydrogenase subunit 6, and NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8). Cheminformatic modeling, virtual chemical library screening, and experimental validation identified nisoxetine from the Sigma Library of Pharmacologically Active Compounds and two compounds from the ChemBridge DIVERSet that increased mitochondrial respiratory capacity. These data provide compelling evidence for the use and development of beta(2)-AR ligands for therapeutic MB.
C1 [Wills, Lauren P.; Trager, Richard E.; Beeson, Gyda C.; Lindsey, Christopher C.; Peterson, Yuri K.; Beeson, Craig C.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA.
[Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Ctr Cell Death Injury & Regenerat, 280 Calhoun St,MSC140, Charleston, SC 29425 USA.
EM schnell@musc.edu
FU National Institutes of Health National Cancer Institute [T32
CA119945-04]; National Institutes of Health National Institute of
Environmental Health Sciences [F32 ES020103-01, ES012878]; National
Institutes of Health National Institute of Diabetes and Digestive and
Kidney Diseases [DK062028, DK071997]; National Institutes of Health
National Institute of General Medical Sciences [GM084147]; Biomedical
Laboratory Research and Development Program of the Department of
Veterans Affairs; National Institutes of Health National Center for
Research Resources [C06 RR-015455]
FX L.P.W. is funded by the National Institutes of Health National Cancer
Institute [Grant T32 CA119945-04] and the National Institutes of Health
National Institute of Environmental Health Sciences [Grant F32
ES020103-01]. R.G.S. is funded by the National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases [Grants
DK062028, DK071997], the National Institutes of Health National
Institute of Environmental Health Sciences [Grant ES012878], the
National Institutes of Health National Institute of General Medical
Sciences [Grant GM084147], and the Biomedical Laboratory Research and
Development Program of the Department of Veterans Affairs. Animal
facilities were funded by the National Institutes of Health National
Center for Research Resources [Grant C06 RR-015455].
NR 42
TC 27
Z9 27
U1 0
U2 8
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JUL
PY 2012
VL 342
IS 1
BP 106
EP 118
DI 10.1124/jpet.112.191528
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 960NO
UT WOS:000305395400012
PM 22490378
ER
PT J
AU Ellingson, LD
Colbert, LH
Cook, DB
AF Ellingson, Laura D.
Colbert, Lisa H.
Cook, Dane B.
TI Physical Activity Is Related to Pain Sensitivity in Healthy Women
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE ACCELEROMETER; VIGOROUS; PAIN RATINGS; PHYSICAL ACTIVITY RECOMMENDATIONS
ID UNITED-STATES; SEDENTARY BEHAVIOR; EXERCISE; ACCELEROMETER;
FIBROMYALGIA; NEUROANATOMY; CALIBRATION; RESPONSES; SAMPLE; ADULTS
AB ELLINGSON, L. D., L. H. COLBERT, and D. B. COOK. Physical Activity Is Related to Pain Sensitivity in Healthy Women. Med. Sci. Sports Exerc., Vol. 44, No. 7, pp. 1401-1406, 2012. There are many benefits associated with meeting current physical activity recommendations. At present, it is unknown whether a reduced sensitivity to pain is included among these benefits. Purpose: The study's purpose was to assess the relationship between pain sensitivity and physical activity and sedentary behaviors in a sample of healthy women. Methods: Self-reported and accelerometer measures of physical activity and sedentary behavior were collected and compared with pain intensity and unpleasantness ratings to noxious thermal stimuli in a sample of 21 healthy women (age = 30.0 +/- 5.8 yr). On the basis of accelerometer data, participants were classified into two groups: meets recommendations (n = 12) and insufficiently active (n = 9). Independent-samples t-tests were conducted to compare pain ratings and physical activity behaviors between groups, and correlation coefficients (Spearman rho) were calculated between average minutes per day spent in moderate, vigorous, and sedentary behaviors, and average intensity and unpleasantness ratings. Results: Participants meeting physical activity recommendations had significantly lower unpleasantness ratings than their insufficiently active peers. Correlational analyses demonstrated a significant relationship between minutes spent in vigorous physical activity and both pain intensity and pain unpleasantness ratings. Relationships were not significant for moderate activity or sedentary behavior. Conclusions: These results provide preliminary evidence that meeting current physical activity recommendations may be beneficial for pain in women. Moreover, participation in vigorous activity seems to account for the decreased pain sensitivity. In our sample, sedentary behavior did not seem to have a deleterious effect on pain. Results from this study have many potential applications including aiding our understanding of why exercise functions as a treatment for those with chronic pain conditions and providing a rationale for including physical activity assessment in pain research.
C1 [Cook, Dane B.] Univ Wisconsin Madison, Sch Educ, Dept Kinesiol, Unit Gymnasium Natatorium 2, Madison, WI 53706 USA.
[Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Cook, DB (reprint author), Univ Wisconsin Madison, Sch Educ, Dept Kinesiol, Unit Gymnasium Natatorium 2, 2000 Observ Dr, Madison, WI 53706 USA.
EM dcook@education.wisc.edu
NR 32
TC 29
Z9 29
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD JUL
PY 2012
VL 44
IS 7
BP 1401
EP 1406
DI 10.1249/MSS.0b013e318248f648
PG 6
WC Sport Sciences
SC Sport Sciences
GA 961NX
UT WOS:000305473200027
PM 22217571
ER
PT J
AU Zhao, J
Wei, JX
Mialki, RK
Mallampalli, DF
Chen, BB
Coon, T
Zou, CB
Mallampalli, RK
Zhao, YT
AF Zhao, Jing
Wei, Jianxin
Mialki, Rachel K.
Mallampalli, Daniel F.
Chen, Bill B.
Coon, Tiffany
Zou, Chunbin
Mallampalli, Rama K.
Zhao, Yutong
TI F-box protein FBXL19-mediated ubiquitination and degradation of the
receptor for IL-33 limits pulmonary inflammation
SO NATURE IMMUNOLOGY
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; AIRWAY INFLAMMATION; INDUCED ARTHRITIS; CELLS;
INTERLEUKIN-33; EXPRESSION; ACTIVATION; CORTACTIN; GENE; INHIBITION
AB The ST2L receptor for interleukin 33 (IL-33) mediates pulmonary inflammation and immune system-related disorders, such as asthma and rheumatoid arthritis. At present, very little is known about the molecular regulation of ST2L expression. Here we found that FBXL19, an 'orphan' member of the Skp1-Cullin-F-box family of E3 ubiquitin ligases, selectively bound to ST2L to mediate its polyubiquitination and elimination in the proteasome. Degradation of ST2L involved phosphorylation of ST2L at Ser442 catalyzed by the kinase GSK3 beta. Overexpression of FBXL19 abrogated the proapoptotic and inflammatory effects of IL-33 and lessened the severity of lung injury in mouse models of pneumonia. Our results suggest that modulation of the IL-33-ST2L axis by ubiquitin ligases might serve as a unique strategy for lessening pulmonary inflammation.
C1 [Zhao, Jing; Wei, Jianxin; Mialki, Rachel K.; Mallampalli, Daniel F.; Chen, Bill B.; Coon, Tiffany; Zou, Chunbin; Mallampalli, Rama K.; Zhao, Yutong] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.
[Zhao, Jing; Wei, Jianxin; Mialki, Rachel K.; Mallampalli, Daniel F.; Chen, Bill B.; Coon, Tiffany; Zou, Chunbin; Mallampalli, Rama K.; Zhao, Yutong] Univ Pittsburgh, Sch Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
RP Zhao, YT (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.
EM zhaoy3@upmc.edu
RI Wei, Jianxin/P-5431-2016
FU US Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; US Department of Veterans Affairs; US National Institutes
of Health [R01 HL01916, R01 HL096376, R01 HL097376, R01 HL098174];
American Heart Association [12SDG9050005]
FX We thank L. Wallace for technical assistance. This study is based on
work supported in part by the US Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development,
Biomedical Laboratory Research and Development. Supported by the US
Department of Veterans Affairs (Merit Review Award), the US National
Institutes of Health (R01 HL01916 to Y.Z. and R01 HL096376, R01 HL097376
and R01 HL098174 to R. K. M.) and the American Heart Association
(12SDG9050005 to J.Z.). The contents presented do not represent the
views of the Department of Veterans Affairs or the United States
Government.
NR 44
TC 45
Z9 50
U1 1
U2 15
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JUL
PY 2012
VL 13
IS 7
BP 651
EP +
DI 10.1038/ni.2341
PG 9
WC Immunology
SC Immunology
GA 961QZ
UT WOS:000305483800010
PM 22660580
ER
PT J
AU Mackey, K
Parchman, ML
Leykum, LK
Lanham, HJ
Noel, PH
Zeber, JE
AF Mackey, Katherine
Parchman, Michael L.
Leykum, Luci K.
Lanham, Holly J.
Noel, Polly H.
Zeber, John E.
TI Impact of the Chronic Care Model on medication adherence when patients
perceive cost as a barrier
SO PRIMARY CARE DIABETES
LA English
DT Article
DE Diabetes; Medication adherence; Chronic care delivery; Out-of-pocket
cost
ID CHRONIC ILLNESS CARE; CONCEPTUALLY BASED APPROACH; SELF-MANAGEMENT;
BIPOLAR DISORDER; RANDOMIZED-TRIAL; NONADHERENCE; PRESCRIPTIONS;
VALIDATION; PRESSURES; OUTCOMES
AB Aims: Cost burdens represent a significant barrier to medication adherence among chronically ill patients, yet financial pressures may be mitigated by clinical or organizational factors, such as treatment aligned with the Chronic Care Model (CCM). This study examines how perceptions of chronic illness care attenuate the relationship between adherence and cost burden.
Methods: Surveys were administered to patients at 40 small community-based primary care practices. Medication adherence was assessed using the 4-item Morisky scale, while five cost-related items documented recent pharmacy restrictions. CCM experiences were assessed via the 20-item Patient Assessment of Chronic Illness Care (PACIC). Nested random effects models determined if chronic care perceptions modified the association between medication adherence and cost-related burden.
Results: Of 1823 respondents reporting diabetes and other chronic diseases, one-quarter endorsed intrapersonal adherence barriers, while 23% restricted medication due of cost. Controlling for age and health status, the relationship between medication cost and CCM with adherence was significant; including PACIC scores attenuated cost-related problems patients with adequate or problematic adherence behavior.
Conclusions: Patients experiencing treatment more consistent with the CCM reported better adherence and lower cost-related burden. Fostering highly activated patients and shared clinical decision making may help alleviate medication cost pressures and improve adherence. Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.
C1 [Zeber, John E.] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX 76502 USA.
[Mackey, Katherine; Parchman, Michael L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA.
[Parchman, Michael L.; Leykum, Luci K.; Lanham, Holly J.; Noel, Polly H.] S Texas Vet Hlth Care Syst VERDICT HSR&D, Dept Vet Affairs, San Antonio, TX USA.
[Leykum, Luci K.; Lanham, Holly J.; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, San Antonio, TX 78229 USA.
[Zeber, John E.] Cent Texas Vet Hlth Care Syst, Temple, TX USA.
RP Zeber, JE (reprint author), Scott & White Healthcare, Ctr Appl Hlth Res, 2102 Birdcreek DriveTemple, Temple, TX 76502 USA.
EM zeber@uthscsa.edu
OI Parchman, Michael/0000-0001-7129-2889
FU National Institute of Diabetes and Digestive and Kidney Diseases
[NIH/NIDDK R18DK075692]
FX The authors would like to thank Nedal Arar, Raymond Palmer, and Laurel
Copeland for additional suggestions and contributions to this
manuscript. This project was supported by funding provided through award
number NIH/NIDDK R18DK075692 from the National Institute of Diabetes and
Digestive and Kidney Diseases. The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Institute of Diabetes and Digestive and Kidney Diseases or
the National Institutes of Health.
NR 30
TC 9
Z9 11
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1751-9918
EI 1878-0210
J9 PRIM CARE DIABETES
JI Prim. Care Diabetes
PD JUL
PY 2012
VL 6
IS 2
BP 137
EP 142
DI 10.1016/j.pcd.2011.12.004
PG 6
WC Endocrinology & Metabolism; Primary Health Care
SC Endocrinology & Metabolism; General & Internal Medicine
GA 960HJ
UT WOS:000305378300007
PM 22264426
ER
PT J
AU Shih, YYI
Muir, ER
Li, G
De La Garza, BH
Duong, TQ
AF Shih, Yen-Yu I.
Muir, Eric R.
Li, Guang
De La Garza, Bryan H.
Duong, Timothy Q.
TI High-Resolution 3D MR Microangiography of the Rat Ocular Circulation
SO RADIOLOGY
LA English
DT Article
ID RETINAL BLOOD-FLOW; SCANNING LASER OPHTHALMOSCOPY; FUNCTIONAL MRI;
CARBON-DIOXIDE; OXYGEN; HYPEROXIA
AB Purpose:
To develop high-spatial-resolution magnetic resonance (MR) microangiography techniques to image the rat ocular circulation.
Materials and Methods:
Animal experiments were performed with institutional Animal Care Committee approval. MR microangiography (resolution, 84 x 84 x 84 mu m or 42 x 42 x 84 mu m) of the rat eye (eight rats) was performed by using a custom-made small circular surface coil with an 11.7-T MR unit before and after monocrystalline iron oxide nanoparticle (MION) injection. MR microangiography measurements were made during air, oxygen, and carbogen inhalation. From three-dimensional MR microangiography, the retina was virtually flattened to enable en face views of various retinal depths, including the retinal and choroidal vascular layers. Signal intensity changes within the retinal or choroidal arteries and veins associated with gas challenges were analyzed. Statistical analysis was performed by using paired t tests, with P < .05 considered to indicate a significant difference. Bonferroni correction was used to adjust for multiple comparisons.
Results:
The central retinal artery, long posterior ciliary arteries, and choroidal vasculature could be distinguished on MR microangiograms of the eye. With MR microangiography, retinal arteries and veins could be distinguished on the basis of blood oxygen level-dependent contrast. Carbogen inhalation-enhanced MR microangiography signal intensity in both the retina (P = .001) and choroid (P = .027) compared with oxygen inhalation. Carbogen inhalation showed significantly higher signal intensity changes in the retinal arteries (P = .001, compared with oxygen inhalation), but not in the veins (P = .549). With MION administration, MR microangiography depicted retinal arterial vasoconstriction when the animals were breathing oxygen (P = .02, compared with animals breathing air).
Conclusion:
MR microangiography of the eye allows depth-resolved imaging of small angiographic details of the ocular circulation. This approach may prove useful in studying microvascular pathologic findings and neurovascular dysfunction in the eye and retina. (C) RSNA, 2012
C1 [Shih, Yen-Yu I.] Univ N Carolina, Dept Neurol, Biomed Res Imaging Ctr, Chapel Hill, NC 27599 USA.
[Shih, Yen-Yu I.; Muir, Eric R.; Li, Guang; De La Garza, Bryan H.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Shih, YYI (reprint author), Univ N Carolina, Dept Neurol, Biomed Res Imaging Ctr, 130 Mason Farm Rd,Bioinformat Bldg,CB 7513, Chapel Hill, NC 27599 USA.
EM shihy@unc.edu
RI Duong, Timothy/B-8525-2008; Li, Guang/C-9539-2011; Muir,
Eric/H-8830-2013
OI Li, Guang/0000-0002-7648-0464; Shih, Yen-Yu Ian/0000-0001-6529-911X
FU National Institutes of Health [5T32HL007446-29]; American Heart
Association [10P0ST4290091]; Clinical Translational Science Award
[UL1RR025767]; San Antonio Area Foundation; MERIT Award from the
Department of Veterans Affairs and San Antonio Life Science Institute;
National Eye Institute [R01 EY014211, EY018855]; National Institute of
Neurological Disorders and Stroke [R01-NS45879]
FX Y.Y.I.S. No potential conflicts of interest to disclose. E. R. M.
Financial activities related to the present article: salary during some
of the work has been partially paid by a stipend from the National
Institutes of Health training grant 5T32HL007446-29. Financial
activities not related to the present article: none to disclose. Other
relationships: none to disclose. G. L. No potential conflicts of
interest to disclose. B. H. D. L. G. No potential conflicts of interest
to disclose. T. Q. D. No potential conflicts of interest to disclose.;
From the Research Imaging Institute (Y.Y.I.S., E. R. M., G. L., B. H. D.
L. G., T. Q. D.) and Departments of Ophthalmology, Radiology, and
Physiology (T. Q. D.), University of Texas Health Science Center at San
Antonio, San Antonio, Tex; and South Texas Veterans Health Care System,
San Antonio, Tex (T. Q. D.). Received September 30, 2011; revision
requested November 9; final revision received December 5; accepted
December 29; final version accepted January 13, 2012. Supported in part
by the American Heart Association (10P0ST4290091) and the Clinical
Translational Science Award (parent grant UL1RR025767). Y.Y.I.S.
supported in part by the San Antonio Area Foundation. E. R. M. supported
in part by National Institutes of Health training grant T32HL007446-29.
T. Q. D. supported in part by the MERIT Award from the Department of
Veterans Affairs and San Antonio Life Science Institute.; This research
was supported by the National Eye Institute (grants R01 EY014211,
EY018855), the National Institute of Neurological Disorders and Stroke
(grant R01-NS45879), and the National Institutes of Health (grant
T32HL007446-29).
NR 21
TC 14
Z9 14
U1 0
U2 4
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUL
PY 2012
VL 264
IS 1
BP 234
EP 241
DI 10.1148/radiol.12112033
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 963NA
UT WOS:000305626500028
PM 22523323
ER
PT J
AU Ko, CY
Merkow, RP
AF Ko, Clifford Y.
Merkow, Ryan P.
TI Outcomes Research in Surgical Oncology Preface
SO SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90095 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Ko, Clifford Y.; Merkow, Ryan P.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Merkow, Ryan P.] Northwestern Univ, Feinberg Sch Med, Dept Surg & Surg Outcomes, Chicago, IL 60611 USA.
[Merkow, Ryan P.] Northwestern Univ, Feinberg Sch Med, Qual Improvement Ctr, Chicago, IL 60611 USA.
[Merkow, Ryan P.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO USA.
RP Ko, CY (reprint author), Univ Calif Los Angeles, Dept Surg, 10833 LeConte Ave,72-215 CHS, Los Angeles, CA 90095 USA.
EM CKo@mednet.ucla.edu; Ryan.Merkow@ucdenver.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1055-3207
J9 SURG ONCOL CLIN N AM
JI Surg. Oncol. Clin. N. Am.
PD JUL
PY 2012
VL 21
IS 3
BP XV
EP XVI
DI 10.1016/j.soc.2012.04.001
PG 2
WC Oncology; Surgery
SC Oncology; Surgery
GA 959YS
UT WOS:000305354700002
PM 22583999
ER
PT J
AU Rochefort, MM
Tomlinson, JS
AF Rochefort, Matthew M.
Tomlinson, James S.
TI Unexpected Readmissions After Major Cancer Surgery An Evaluation of
Readmissions as a Quality-of-Care Indicator
SO SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Surgery; Readmission; Rehospitalization; Oncology; Quality care
ID VALIDATION; MORTALITY
AB Readmissions following major oncologic operation are common affecting patient treatment, outcome, and hospital resources. The Center for Medicare and Medicaid Services mandates reporting of certain disease-specific readmissions and Congress is considering using individual hospital readmission rates as a performance measure. Studies using administrative data demonstrate that readmission rates following major cancer surgery are high. Administrative data cannot determine causes. Single-institution studies demonstrate length of hospital stay and comorbidities as risk factors. Discharge processes and outpatient healthcare utilization can be improved. Until studies on readmission rate are conducted, using readmission rates as a measure of quality should be pursued cautiously.
C1 [Rochefort, Matthew M.; Tomlinson, James S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Tomlinson, James S.] Greater Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA.
RP Tomlinson, JS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,Room 54-140 CHS,Box 9511782, Los Angeles, CA 90095 USA.
EM jtomlinson@mednet.ucla.edu
NR 16
TC 12
Z9 12
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1055-3207
J9 SURG ONCOL CLIN N AM
JI Surg. Oncol. Clin. N. Am.
PD JUL
PY 2012
VL 21
IS 3
BP 397
EP +
DI 10.1016/j.soc.2012.03.004
PG 10
WC Oncology; Surgery
SC Oncology; Surgery
GA 959YS
UT WOS:000305354700006
PM 22583989
ER
PT J
AU Lawson, EH
Gibbons, MM
Ko, CY
AF Lawson, Elise H.
Gibbons, Melinda Maggard
Ko, Clifford Y.
TI Appropriate Use of Surgical Procedures for Patients with Cancer
SO SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Cancer; Appropriateness method; Surgery; Overuse; Underuse
ID CAROTID-ENDARTERECTOMY; CORONARY REVASCULARIZATION; MEDICAL PROCEDURES;
PHYSICIAN RATINGS; PANEL; CARE; GUIDELINES; HYSTERECTOMY; NECESSITY;
UNDERUSE
AB With increasing focus on improving quality and promoting patient-centered care, ensuring that patients receive appropriate surgical procedures is paramount. The appropriateness method was developed to determine which patients should and should not undergo surgical intervention versus medical therapy. This method combines the best available evidence in the literature with expert opinion to produce explicit guidance for clinicians on the relative risks and benefits of a procedure for specific clinical indications. A coordinated effort to produce appropriateness criteria for surgical oncology could improve the quality of surgical care for patients with cancer if these criteria are integrated into routine clinical practice.
C1 [Lawson, Elise H.] Univ Calif Los Angeles, Med Ctr, Dept Surg, Los Angeles, CA 90095 USA.
[Lawson, Elise H.; Gibbons, Melinda Maggard; Ko, Clifford Y.] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
RP Lawson, EH (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Surg, CHS 72-215,10833 LeConte Ave, Los Angeles, CA 90095 USA.
EM elawson@mednet.ucla.edu
NR 25
TC 2
Z9 2
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1055-3207
J9 SURG ONCOL CLIN N AM
JI Surg. Oncol. Clin. N. Am.
PD JUL
PY 2012
VL 21
IS 3
BP 479
EP +
DI 10.1016/j.soc.2012.03.008
PG 9
WC Oncology; Surgery
SC Oncology; Surgery
GA 959YS
UT WOS:000305354700012
PM 22583995
ER
PT J
AU Batki, SL
Lasher, BA
Herbst, E
Prathikanti, S
Metzler, T
Tarasovsky, G
Waldrop, A
Neylan, TC
Petrakis, I
Coetzee, J
AF Batki, Steven L.
Lasher, Brooke A.
Herbst, Ellen
Prathikanti, Sridhar
Metzler, Thomas
Tarasovsky, Gary
Waldrop, Angela
Neylan, Thomas C.
Petrakis, Ismene
Coetzee, John
TI Topiramate Treatment of Alcohol Dependence in Veterans with PTSD:
Baseline Alcohol Use and PTSD Severity
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 UCSF, Dept Psychiat, San Francisco, CA 94143 USA.
San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD JUL-AUG
PY 2012
VL 21
IS 4
MA 3
BP 382
EP 382
PG 1
WC Substance Abuse
SC Substance Abuse
GA 956XH
UT WOS:000305122400015
ER
PT J
AU Meszaros, ZS
Abdul-Malak, Y
Dimmock, JA
Wang, DL
Batki, SL
AF Meszaros, Zsuzsa Szombathyne
Abdul-Malak, Ynesse
Dimmock, Jacqueline A.
Wang, Dongliang
Batki, Steven L.
TI Varenicline Treatment of Alcohol and Nicotine Dependence in
Schizophrenia: Problems Encountered in a Pilot Trial
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Meeting Abstract
C1 [Batki, Steven L.] SUNY Upstate Med Univ, Dept Psychiat, San Francisco VA Med Ctr, Syracuse, NY 13210 USA.
[Wang, Dongliang] SUNY Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA.
[Batki, Steven L.] UCSF, Dept Psychiat, San Francisco, CA 94143 USA.
NR 0
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD JUL-AUG
PY 2012
VL 21
IS 4
MA 36
BP 393
EP 394
PG 2
WC Substance Abuse
SC Substance Abuse
GA 956XH
UT WOS:000305122400044
ER
PT J
AU Lu, ZY
Li, YC
Jin, JF
Zhang, XM
Lopes-Virella, MF
Huang, Y
AF Lu, Zhongyang
Li, Yanchun
Jin, Junfei
Zhang, Xiaoming
Lopes-Virella, Maria F.
Huang, Yan
TI Toll-Like Receptor 4 Activation in Microvascular Endothelial Cells
Triggers a Robust Inflammatory Response and Cross Talk With Mononuclear
Cells via Interleukin-6
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE endothelial cells; gene expression; inflammation; interleukin-6;
toll-like receptor
ID HUMAN ATHEROSCLEROSIS; CORONARY ATHEROSCLEROSIS; CHLAMYDIA-PNEUMONIAE;
PLAQUE VULNERABILITY; ADHESION MOLECULE-1; EXPRESSION;
NEOVASCULARIZATION; ANGIOGENESIS; PATHOGENESIS; MACROPHAGES
AB Objective-It is known that toll-like receptor 4 (TLR4) plays an important role in atherosclerosis. Because both microvascular (MIC) and macrovascular (MAC) endothelial cells (ECs) are present in atherosclerotic lesions, the present study compared TLR4-triggered inflammatory response and cross talk with mononuclear cells between MIC and MAC ECs.
Methods and Results-ELISA, real-time polymerase chain reaction, and gene expression profiling showed that TLR4 activation by lipopolysaccharide stimulated a much higher expression of inflammatory genes including cytokines, chemokines, growth factors, and adhesion molecules in MIC ECs than MAC ECs. Furthermore, coculture studies showed that TLR4 activation in MIC ECs, but not MAC ECs, induced a cross talk with U937 mononuclear cells through MIC EC-released interleukin-6 to upregulate matrix metalloproteinase-1 expression in U937 cells. To explore molecular mechanisms underlying the different responses to TLR4 activation between MIC and MAC ECs, we showed that MIC ECs had a higher expression of TLR4 and CD14 and a higher TLR4-mediated nuclear factor-kappaB activity than MAC ECs.
Conclusion-The present study showed that TLR4 activation triggers a more robust inflammatory response in MIC ECs than MAC ECs. Given the importance of inflammatory cytokines and matrix metalloproteinases in plaque rupture, MIC ECs may play a key role in plaque destabilization through a TLR4-dependent mechanism. (Arterioscler Thromb Vasc Biol. 2012;32:1696-1706)
C1 [Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29403 USA.
[Lu, Zhongyang; Li, Yanchun; Jin, Junfei; Zhang, Xiaoming; Lopes-Virella, Maria F.; Huang, Yan] Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, Charleston, SC 29403 USA.
RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St, Charleston, SC 29403 USA.
EM huangyan@musc.edu
FU Department of Veterans Affairs, National Institutes of Health [DE016353,
DK081352]
FX This work was supported by the Biomedical Laboratory Research and
Development Program of the Department of Veterans Affairs, National
Institutes of Health grant DE016353 (to Y. Huang) and DK081352 (to M.F.
Lopes-Virella).
NR 50
TC 19
Z9 21
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JUL
PY 2012
VL 32
IS 7
BP 1696
EP 1706
DI 10.1161/ATVBAHA.112.251181
PG 11
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 959SK
UT WOS:000305333100021
PM 22596222
ER
PT J
AU Postupna, N
Rose, SE
Bird, TD
Gonzalez-Cuyar, LF
Sonnen, JA
Larson, EB
Keene, CD
Montine, TJ
AF Postupna, Nadia
Rose, Shannon E.
Bird, Thomas D.
Gonzalez-Cuyar, Luis F.
Sonnen, Joshua A.
Larson, Eric B.
Keene, C. Dirk
Montine, Thomas J.
TI Novel Antibody Capture Assay for Paraffin-Embedded Tissue Detects
Wide-Ranging Amyloid Beta and Paired Helical Filament-Tau Accumulation
in Cognitively Normal Older Adults
SO BRAIN PATHOLOGY
LA English
DT Article
DE aging; Alzheimer's disease; ELISA; immunohistochemistry
ID ALZHEIMERS-DISEASE; SYNAPTIC PROTEINS; NATIONAL-INSTITUTE; DEMENTIA;
PATHOLOGY; IMPAIRMENT; DIAGNOSIS; RECOMMENDATIONS; NEUROPATHOLOGY;
QUANTITATION
AB Quantifying antigens in formalin-fixed tissue is challenging and limits investigation in population-based studies of brain aging. To address this major limitation, we have developed a new technique that we call Histelide: immunohistochemistry (HIST-) and enzyme-linked immunosorbent assay (ELISA) (-EL-) performed on a glass slide (-IDE). We validated Histelide in sections of prefrontal cortex from 20 selected cases: 12 subjects with clinically and neuropathologically diagnosed Alzheimer's disease (AD), either autosomal dominant or late-onset forms, and 8 clinical and neuropathologic controls. AD cases had significantly increased amyloid beta (A beta) peptide and paired helical filament (PHF-) tau per area of neocortex that was proteinase K-sensitive, and significantly decreased amount of synaptophysin. We next investigated prefrontal cortex from 81 consecutive cases of high-cognitive performers from the Adult Changes in Thought (ACT) study, a population-based study of brain aging and incident dementia. As expected, latent AD was common in this group; however, our results quantified widely individually varying levels of A beta peptides and PHF-tau among these high-cognitive performers. This novel approach obtains quantitative data from population-based studies, and our initial studies with high-cognitive performers provide important quantitative insights into latent AD that should help guide expectations from neuroimaging and prevention studies.
C1 [Postupna, Nadia; Rose, Shannon E.; Gonzalez-Cuyar, Luis F.; Sonnen, Joshua A.; Keene, C. Dirk; Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98104 USA.
[Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA 98104 USA.
[Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98104 USA.
[Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Clin & Educ Ctr, Seattle, WA USA.
[Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, 300 9th Ave,Roomm 703, Seattle, WA 98104 USA.
EM tmontine@uw.edu
RI Sonnen, 37382016/H-3738-2016; Keene, Christopher/N-1806-2015
OI Sonnen, 37382016/0000-0001-9267-8705;
FU NIH [AG05136, AG23801, AG006781, NS62684, T32AG000258, T32ES007032];
Nancy and Buster Alvord Endowment
FX This work was supported by grants from the NIH (AG05136, AG23801,
AG006781, NS62684, T32AG000258, T32ES007032), and the Nancy and Buster
Alvord Endowment. We thank Dr. Kathy Montine for editorial assistance.
NR 41
TC 7
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1015-6305
J9 BRAIN PATHOL
JI Brain Pathol.
PD JUL
PY 2012
VL 22
IS 4
BP 472
EP 484
DI 10.1111/j.1750-3639.2011.00542.x
PG 13
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 958KH
UT WOS:000305234900003
PM 21999410
ER
PT J
AU Armah, KA
McGinnis, K
Baker, J
Gibert, C
Butt, AA
Bryant, KJ
Goetz, M
Tracy, R
Oursler, KK
Rimland, D
Crothers, K
Rodriguez-Barradas, M
Crystal, S
Gordon, A
Kraemer, K
Brown, S
Gerschenson, M
Leaf, DA
Deeks, SG
Rinaldo, C
Kuller, LH
Justice, A
Freiberg, M
AF Armah, Kaku A.
McGinnis, Kathleen
Baker, Jason
Gibert, Cynthia
Butt, Adeel A.
Bryant, Kendall J.
Goetz, Matthew
Tracy, Russell
Oursler, Krisann K.
Rimland, David
Crothers, Kristina
Rodriguez-Barradas, Maria
Crystal, Steve
Gordon, Adam
Kraemer, Kevin
Brown, Sheldon
Gerschenson, Mariana
Leaf, David A.
Deeks, Steven G.
Rinaldo, Charles
Kuller, Lewis H.
Justice, Amy
Freiberg, Matthew
TI HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation,
Altered Coagulation, and Monocyte Activation
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID C-REACTIVE PROTEIN; APPARENTLY HEALTHY-MEN; T-CELL DEPLETION;
MYOCARDIAL-INFARCTION; MICROBIAL TRANSLOCATION; DIABETES-MELLITUS;
ANTIRETROVIRAL THERAPY; BLOOD-PRESSURE; SOLUBLE CD14; INFECTION
AB Background. Biomarkers of inflammation, altered coagulation, and monocyte activation are associated with mortality and cardiovascular disease (CVD) in the general population and among human immunodeficiency virus (HIV)-infected people. We compared biomarkers for inflammation, altered coagulation, and monocyte activation between HIV-infected and uninfected people in the Veterans Aging Cohort Study (VACS).
Methods. Biomarkers of inflammation (interleukin-6 [IL-6]), altered coagulation (D-dimer), and monocyte activation (soluble CD14 [sCD14]) were measured in blood samples from 1525 HIV-infected and 843 uninfected VACS participants. Logistic regression was used to determine the association between HIV infection and prevalence of elevated (>75th percentile) biomarkers, adjusting for confounding comorbidities.
Results. HIV-infected veterans had less prevalent CVD, hypertension, diabetes, obesity, hazardous drinking, and renal disease, but more dyslipidemia, hepatitis C, and current smoking than uninfected veterans. Compared to uninfected veterans, HIV-infected veterans with HIV-1 RNA >= 500 copies/mL or CD4 count <200 cells/mu L had a significantly higher prevalence of elevated IL-6 (odds ratio [OR], 1.54; 95% confidence interval [CI], 1.14-2.09; OR, 2.25; 95% CI, 1.60-3.16, respectively) and D-dimer (OR, 1.97; 95% CI, 1.44-2.71, OR, 1.68; 95% CI, 1.22-2.32, respectively) after adjusting for comorbidities. HIV-infected veterans with a CD4 cell count <200 cells/mu L had significantly higher prevalence of elevated sCD14 compared to uninfected veterans (OR, 2.60; 95% CI, 1.64-4.14). These associations still persisted after restricting the analysis to veterans without known confounding comorbid conditions.
Conclusions. These data suggest that ongoing HIV replication and immune depletion significantly contribute to increased prevalence of elevated biomarkers of inflammation, altered coagulation, and monocyte activation. This contribution is independent of and in addition to the substantial contribution from comorbid conditions.
C1 [Armah, Kaku A.; Kuller, Lewis H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Gordon, Adam] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Sch Med, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA 15260 USA.
[Baker, Jason] Univ Minnesota, Dept Med, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA.
[Gibert, Cynthia] VA Med Ctr, Washington, DC USA.
[Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Butt, Adeel A.] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates.
[Bryant, Kendall J.] NIAAA, NIH, Bethesda, MD USA.
[Goetz, Matthew; Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Tracy, Russell] Univ Vermont, Dept Pathol, Coll Med, Burlington, VT 05405 USA.
[Tracy, Russell] Univ Vermont, Dept Biochem, Coll Med, Burlington, VT 05405 USA.
[Oursler, Krisann K.] Univ Maryland, Baltimore VA Med Ctr, Sch Med, Baltimore, MD USA.
[Rimland, David] Emory Univ, Sch Med, VA Med Ctr, Atlanta, GA USA.
[Crothers, Kristina] Univ Washington, Div Pulm & Crit Care, Dept Internal Med, Seattle, WA 98195 USA.
[Rodriguez-Barradas, Maria] Baylor Coll Med, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Crystal, Steve] Rutgers State Univ, Ctr Pharmacotherapy Chron Dis Management & Outcom, Inst Hlth, New Brunswick, NJ 08903 USA.
[Crystal, Steve] Rutgers State Univ, Sch Social Work, New Brunswick, NJ 08903 USA.
[Gordon, Adam] Univ Pittsburgh, Sch Med, Ctr Hlth Equity Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA.
[Gordon, Adam] Univ Pittsburgh, Sch Med, Ctr Res Healthcare, Pittsburgh, PA 15260 USA.
[Kraemer, Kevin] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA.
[Brown, Sheldon] Mt Sinai Med Ctr, Dept Internal Med, New York, NY 10029 USA.
[Brown, Sheldon] Bronx Vet Affairs Med Ctr, New York, NY USA.
[Gerschenson, Mariana] Univ Hawaii Manoa, Hawaii AIDS Clin Res Program, Dept Med, Honolulu, HI 96822 USA.
[Gerschenson, Mariana] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA.
[Deeks, Steven G.] San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA 94110 USA.
[Rinaldo, Charles] Presbyterian Univ Hosp, Dept Microbiol, Dept Pathol, Pittsburgh, PA USA.
[Justice, Amy] Yale Univ, Sch Med, Sect Gen Med, New Haven, CT USA.
[Justice, Amy] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Freiberg, Matthew] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
RP Freiberg, M (reprint author), 230 McKee Pl,Ste 623, Pittsburgh, PA 15213 USA.
EM freibergms@upmc.edu
OI Goetz, Matthew/0000-0003-4542-992X
FU National Institute on Alcohol Abuse and Alcoholism (NIAAA); National
Heart Lung and Blood Institute (NHLBI) at the National Institutes of
Health (NIH) [K23AA015914-0651, R01HC095136-04, 5R01HC095126-04,
U10AA013566-10]; NIH/NHLBI/NIAAA; Yale University; US Department of
Veterans Affairs (VA) through the University of Pittsburgh
FX This work was supported by the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) and National Heart Lung and Blood Institute (NHLBI)
at the National Institutes of Health (NIH; grant numbers
K23AA015914-0651, R01HC095136-04, 5R01HC095126-04 to M. F.; and
U10AA013566-10 to A. J.).; K. A., K. A. O., A. G., K. K., S. B., S. D.,
A. J., and M. F. received NIH/NHLBI/NIAAA grant funding for this work.
M. G. has received grant funding and support from Yale University for
this work. R. T. has received grant funding from the US Department of
Veterans Affairs (VA) through the University of Pittsburgh for this
work. R. T. owns Haematologic Technologies and has received funding from
Tibotec, Merck, and Abbott, none of which pertain to this work. All
other authors report no potential conflicts.
NR 37
TC 95
Z9 95
U1 1
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL 1
PY 2012
VL 55
IS 1
BP 126
EP 136
DI 10.1093/cid/cis406
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 956KM
UT WOS:000305088500020
PM 22534147
ER
PT J
AU Richardson, J
Tjoelker, R
AF Richardson, Jeannette
Tjoelker, Rita
TI Beyond the Central Line-Associated Bloodstream Infection Bundle The
Value of the Clinical Nurse Specialist in Continuing Evidence-Based
Practice Changes
SO CLINICAL NURSE SPECIALIST
LA English
DT Article
DE catheter-related infections; evidence-based practice; quality
improvement
ID NETWORK NHSN REPORT; CRITICALLY-ILL PATIENTS; MORTALITY
AB Purpose:
The purpose of this project was to demonstrate the value of clinical nurse specialist (CNS)-led efforts to optimize patient outcomes through continued monitoring and management of a previously implemented evidence-based practice project.
Background:
Central line-associated bloodstream infections (CLABSIs) significantly impact patient morbidity/mortality and cost of care. In 2006, the critical care unit (CCU) of the Portland VA Medical Center implemented national recommendations for the prevention of CLABSIs through use of the Institute of Healthcare Improvement Central Line Bundle. This practice change was led by the CCU and infection control CNSs, and compliance in the completion of bundle items has remained consistently high (>90%). Although the CCU has maintained CLABSI rates below the national benchmark, it experienced a 4-month period of increased incidence in late 2008.
Description:
Clinical nurse specialists in CCU and infection control organized a "Hot Team" of nurses from multiple departments throughout the hospital to evaluate processes/data related to the recent increase in infections. Using national guidelines, the team focused on interdisciplinary implementation of strategies beyond the Central Line Bundle components. Consideration of cost and workflow patterns was critical to decision making.
Outcome:
Infection rates in CCU decreased from a high of 1.5 per 1000 line days down to 0 in June 2011, with the last CLABSI occurring in May 2010.
Conclusion:
The formation and efforts of a CNS-led team of nurses has been successful in decreasing infection rates through implementation of multiple innovative strategies.
Implications:
Clinical nurse specialist surveillance, management, and leadership following project implementation are valuable strategies for continued optimal patient outcomes.
C1 [Richardson, Jeannette; Tjoelker, Rita] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Richardson, J (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM jeannette.richardson@va.gov
NR 17
TC 8
Z9 10
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD JUL-AUG
PY 2012
VL 26
IS 4
BP 205
EP 211
DI 10.1097/NUR.0b013e31825aebab
PG 7
WC Nursing
SC Nursing
GA 958YU
UT WOS:000305277700006
PM 22678186
ER
PT J
AU Kim, S
Millard, SP
Yu, CE
Leong, L
Radant, A
Dobie, D
Tsuang, DW
Wijsman, EM
AF Kim, Sulgi
Millard, Steven P.
Yu, Chang-En
Leong, Lesley
Radant, Allen
Dobie, Dorcas
Tsuang, Debby W.
Wijsman, Ellen M.
TI Inheritance Model Introduces Differential Bias in CNV Calls Between
Parents and Offspring
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE Schizophrenia; calling algorithm; family-based study; CNV burden
ID COPY NUMBER VARIATION; BIPOLAR-DISORDER; INCREASE RISK; SCHIZOPHRENIA;
ASSOCIATION; DELETIONS; DISEASE
AB Copy Number Variation (CNV) is increasingly implicated in disease pathogenesis. CNVs are often identified by statistical models applied to data from single nucleotide polymorphism panels. Family information for samples provides additional information for CNV inference. Two modes of PennCNV (the Joint-call and Posterior-call), which are some of the most well-developed family-based CNV calling methods, use a Joint-model as a main component. This models all family members CNV states together with Mendelian inheritance. Methods based on the Joint-model are used to infer CNV calls of cases and controls in a pedigree, which may be compared to each other to test an association. Although benefits from the Joint-model have been shown elsewhere, equality of call rates in parents and offspring has not been evaluated previously. This can affect downstream analyses in studies that compare CNV rates in cases vs. controls in pedigrees. In this paper, we show that the Joint-model can introduce different CNV call rates among family members in the absence of a true difference. We show that the Joint-model may analytically introduce differential CNV calls because of asymmetry of the model. We demonstrate these differential call rates using single-marker simulations. We show that call rates using the two modes of PennCNV also differ between parents and offspring in one multimarker simulated dataset and two real datasets. Our results advise need for caution in use of the Joint-model calls in CNV association studies with family-based datasets. Genet. Epidemiol. 36:488-498, 2012. (C) 2012 Wiley Periodicals, Inc.
C1 [Wijsman, Ellen M.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Millard, Steven P.; Tsuang, Debby W.] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Yu, Chang-En] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Yu, Chang-En] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
[Leong, Lesley; Radant, Allen; Dobie, Dorcas; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Wijsman, Ellen M.] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Wijsman, Ellen M.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA.
RP Wijsman, EM (reprint author), Univ Washington, Sch Med, Dept Med, Div Med Genet, Box 357720, Seattle, WA 98195 USA.
EM wijsman@u.washington.edu
RI Tsuang, Debby/L-7234-2016
OI Tsuang, Debby/0000-0002-4716-1894; Wijsman, Ellen/0000-0002-2725-6669
FU NIH [R01MH065558, R01MH065554]; U.S. Department of Veterans Affairs,
Office of Research Development Biomedical Laboratory Research
FX This work is supported by NIH: R01MH065558 and R01MH065554; the U.S.
Department of Veterans Affairs, Office of Research Development
Biomedical Laboratory Research: Merit Review; and VISN-20 MIRECC. We
thank Jeremy Silverman and Larry Siever for contributing schizophrenia
trios, and the NIMH Genetics Initiative on schizophrenia for providing
DNA sample. The funding agencies did not play a role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 36
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-0395
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD JUL
PY 2012
VL 36
IS 5
BP 488
EP 498
DI 10.1002/gepi.21643
PG 11
WC Genetics & Heredity; Mathematical & Computational Biology
SC Genetics & Heredity; Mathematical & Computational Biology
GA 956YP
UT WOS:000305125800008
PM 22628073
ER
PT J
AU Zhang, XY
Chen, DC
Xiu, MH
Haile, CN
Luo, XG
Xu, K
Zhang, HP
Zuo, LJ
Zhang, ZJ
Zhang, XR
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Chen, Da Chun
Xiu, Mei Hong
Haile, Colin N.
Luo, Xingguang
Xu, Ke
Zhang, Hui Ping
Zuo, Lingjun
Zhang, Zhijun
Zhang, Xiangrong
Kosten, Therese A.
Kosten, Thomas R.
TI Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism
in patients with schizophrenia and normal controls
SO HUMAN GENETICS
LA English
DT Article
ID ACTIVITY-DEPENDENT SECRETION; NEUROTROPHIC FACTOR GENE;
LONG-TERM-MEMORY; NEUROPSYCHOLOGICAL STATUS; REPEATABLE BATTERY; BIPOLAR
DISORDER; CHINESE-HAN; MET ALLELE; BRAIN; ASSOCIATION
AB Studies suggest that a functional polymorphism of the brain-derived neurotrophic factor gene (BDNF Val66Met) may mediate hippocampal-dependent cognitive functions. A few studies have reported its role in cognitive deficits in schizophrenia including its association with peripheral BDNF levels as a mediator of these cognitive deficits. We assessed 657 schizophrenic inpatients and 445 healthy controls on the repeatable battery for the assessment of neuropsychological status (RBANS), the presence of the BDNF Val66Met polymorphism and serum BDNF levels. We assessed patient psychopathology using the Positive and Negative Syndrome Scale. We showed that visuospatial/constructional abilities significantly differed by genotype but not genotype x diagnosis, and the Val allele was associated with better visuospatial/constructional performance in both schizophrenic patients and healthy controls. Attention performance showed a significant genotype by diagnosis effect. Met allele-associated attention impairment was specific to schizophrenic patients and not shown in healthy controls. In the patient group, partial correlation analysis showed a significant positive correlation between serum BDNF and the RBANS total score. Furthermore, the RBANS total score showed a statistically significant BDNF level x genotype interaction. We demonstrated an association between the BDNF Met variant and poor visuospatial/constructional performance. Furthermore, the BDNF Met variant may be specific to attentional decrements in schizophrenic patients. The association between decreased BDNF serum levels and cognitive impairment in schizophrenia is dependent on the BDNF Val66Met polymorphism.
C1 [Zhang, Xiang Yang; Kosten, Thomas R.] VA Med Ctr, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Haile, Colin N.; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Chen, Da Chun; Xiu, Mei Hong] Beijing HuiLongGuan Hosp, Ctr Psychiat Res, Beijing, Peoples R China.
[Luo, Xingguang; Xu, Ke; Zhang, Hui Ping; Zuo, Lingjun] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Zhang, Zhijun; Zhang, Xiangrong] Southeast Univ, Dept Neurol, Affiliated ZhongDa Hosp, Nanjing, Peoples R China.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu; kosten@bcm.edu
OI Haile, Colin/0000-0001-8293-7291
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs, VISN 16, Mental Illness Research, Education and
Clinical Center (MIRECC), United States National Institute of Health
[K05-DA0454, P50-DA18827, U01-MH79639]
FX This study was funded by the Stanley Medical Research Institute (03T-459
and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental
Illness Research, Education and Clinical Center (MIRECC), United States
National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639.
NR 51
TC 34
Z9 35
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
J9 HUM GENET
JI Hum. Genet.
PD JUL
PY 2012
VL 131
IS 7
BP 1187
EP 1195
DI 10.1007/s00439-012-1150-x
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 957VV
UT WOS:000305195400017
PM 22362486
ER
PT J
AU Sonnenberg, A
Walker, JT
AF Sonnenberg, Amnon
Walker, James T.
TI Occupational mortality associated with inflammatory bowel disease in the
United States 1984-1998
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE Crohn's disease; environmental risk factors; epidemiology; industry;
occupation; occupational mortality statistics; proportional mortality
ratio; ulcerative colitis
ID CROHNS-DISEASE; ULCERATIVE-COLITIS
AB Background: The occurrence of Crohn's disease (CD) and ulcerative colitis (UC) is shaped by environmental influences. Many such environmental risk factors vary potentially with occupational exposure. We used a large national database to study the occupational variation of mortality associated with CD and UC. Methods: The National Occupational Mortality Surveillance database contains data from the death certificate linked with information about the occupation and industry of each deceased individual. Deaths were grouped by gender, ethnicity, disease type, occupation, and industry. Mortality by occupation and industry were expressed as age-adjusted proportional mortality ratio. Results: A total of 3110 inflammatory bowel disease (IBD) patients were included in the present analysis. IBD mortality was low among blue collar workers and high among white collar workers. It was low among farming occupations, manufacturing occupations, and manual laborers. It was high among secretaries, professionals, sales workers, homemakers, managerial occupations, and teachers. There was a strong correlation between the occupational distribution of CD and UC that applied to men and women alike. The overall distribution among different industries corroborated the patterns observed with respect to the occupational distribution. Conclusions: The correlations between the occupational distribution of CD and UC support the contention that environmental influences shape the occurrence of both diseases. Such influence must vary by occupation and, to a lesser extent, also by industry. It must be similar for both types of IBD. (Inflamm Bowel Dis 2011;)
C1 [Sonnenberg, Amnon] Dept Vet Affairs Med Ctr, Portland, OR USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Walker, James T.] NIOSH, Cincinnati, OH 45226 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 17
TC 4
Z9 4
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1078-0998
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUL
PY 2012
VL 18
IS 7
BP 1249
EP 1253
DI 10.1002/ibd.21807
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 956IP
UT WOS:000305083600010
PM 21710539
ER
PT J
AU Rubinow, KB
Vaisar, T
Tang, CR
Matsumoto, AM
Heinecke, JW
Page, ST
AF Rubinow, Katya B.
Vaisar, Tomas
Tang, Chongren
Matsumoto, Alvin M.
Heinecke, Jay W.
Page, Stephanie T.
TI Testosterone replacement in hypogonadal men alters the HDL proteome but
not HDL cholesterol efflux capacity
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE cardiovascular disease; lipoproteins; lipids; atherosclerosis; androgens
ID HIGH-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; APOLIPOPROTEIN-A-I;
CARDIOVASCULAR-DISEASE; HEPATIC LIPASE; APOC-I; ANTIINFLAMMATORY
PROPERTIES; POSTMENOPAUSAL WOMEN; MASS-SPECTROMETRY; THERAPY
AB The effects of androgens on cardiovascular disease (CVD) risk in men remain unclear. To better characterize the relationship between androgens and HDL, we investigated the effects of testosterone replacement on HDL protein composition and serum HDL-mediated cholesterol efflux in hypogonadal men. Twenty-three older hypogonadal men (ages 51-83, baseline testosterone < 280 ng/dl) were administered replacement testosterone therapy (1% transdermal gel) with or without the 5 alpha-reductase inhibitor dutasteride. At baseline and after three months of treatment, we determined fasting lipid concentrations, HDL protein composition, and the cholesterol efflux capacity of serum HDL. Testosterone replacement did not affect HDL cholesterol (HDL-C) concentrations but conferred significant increases in HDL-associated paraoxonase 1 (PON1) and fibrinogen alpha chain (FGA) (P = 0.022 and P = 0.023, respectively) and a decrease in apolipoprotein A-IV (apoA-IV) (P = 0.016). Exogenous testosterone did not affect the cholesterol efflux capacity of serum HDL. No differences were observed between men who received testosterone alone and those who also received dutasteride.(Jlr) Testosterone replacement in older hypogonadal men alters the protein composition of HDL but does not significantly change serum HDL-mediated cholesterol efflux. These effects appear independent of testosterone conversion to dihydrotestosterone. Further research is needed to determine how changes in HDL protein content affect CVD risk in men. Rubinow, K. B., T. Vaisar, C. Tang, A. M. Matsumoto, J. W. Heinecke, and S. T. Page. Testosterone replacement in hy
C1 [Rubinow, Katya B.; Page, Stephanie T.] Univ Washington, Sch Med, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA.
[Vaisar, Tomas; Tang, Chongren; Heinecke, Jay W.] Univ Washington, Sch Med, Diabet & Obes Ctr Excellence, Seattle, WA USA.
[Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
RP Rubinow, KB (reprint author), Univ Washington, Sch Med, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA.
EM rubinow@uw.edu
FU National Institutes of Health [RO1-AG-037603, U54-HD-42454,
P50-CA-097186, DK-017047, T32-DK-007247, P30-DK-035816, R01-HL-089504,
P30-DK-017047, P01-HL-112625, R01-HL-086798, P01-HL-092969]; Department
of Veterans Affairs Puget Sound Health Care System; American Heart
Association [083-0231N]
FX This work was supported by National Institutes of Health Grants
RO1-AG-037603, U54-HD-42454, P50-CA-097186, DK-017047, T32-DK-007247 (K.
B. R.), P30-DK-035816 (T. V.), R01-HL-089504 (T. V.), P30-DK-017047,
P01-HL-112625 (J. W. H.), R01-HL-086798 (J. W. H.), and P01-HL-092969
(J. W. H.); by the Department of Veterans Affairs Puget Sound Health
Care System (A. M. M.); and by American Heart Association Grant
083-0231N (T. V.). Its contents are solely the responsibility of the
authors and do not necessarily represent the official views of the
National Institutes of Health. Transdermal placebo and testosterone gels
were provided by Abbott Laboratories (formerly Solvay Pharmaceuticals),
and dutasteride and oral placebo were provided by GlaxoSmithKline,
neither of which had any input into the study design, analyses, or
manuscript preparation.
NR 47
TC 12
Z9 12
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD JUL
PY 2012
VL 53
IS 7
BP 1376
EP 1383
DI 10.1194/jlr.P026005
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 957IZ
UT WOS:000305156400014
PM 22504910
ER
PT J
AU Cardo, LF
Coto, E
de Mena, L
Ribacoba, R
Lorenzo-Betancor, O
Pastor, P
Samaranch, L
Mata, IF
Diaz, M
Moris, G
Menendez, M
Corao, AI
Alvarez, V
AF Cardo, Lucia F.
Coto, Eliecer
de Mena, Lorena
Ribacoba, Rene
Lorenzo-Betancor, Oswaldo
Pastor, Pau
Samaranch, LLuis
Mata, Ignacio F.
Diaz, Marta
Moris, German
Menendez, Manuel
Corao, Ana I.
Alvarez, Victoria
TI A Search for SNCA 3 ' UTR Variants Identified SNP rs356165 as a
Determinant of Disease Risk and Onset Age in Parkinson's Disease
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Parkinson's disease; Alpha-synuclein; DNA polymorphisms; Genetic risk
ID ALPHA-SYNUCLEIN GENE; GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY; MUTATION;
POPULATION; EXPRESSION; REGIONS
AB Alpha-synuclein gene (SNCA) polymorphisms have been associated with the common sporadic form of Parkinson's disease (PD). We searched for DNA variants at the SNCA 3' UTR through single strand conformation analysis and direct sequencing in a cohort of Spanish PD patients and controls. We have genotyped the rs356165 SNCA 3' UTR polymorphism in a total of 1,135 PD patients and 772 healthy controls from two Spanish cohorts (Asturias and Navarre). We identified six SNCA 3' UTR variants. Single nucleotide polymorphism (SNP) rs356165 was significantly associated with PD risk in the Spanish cohort (p = 0.0001; odd ratio = 1.37, 95%CI = 1.19-1.58). This SNP was also significantly associated with early age at onset of PD. Our work highlights rs356165 as an important determinant of the risk of developing PD and early age at onset and encourages future research to identify a functional effect on SNCA expression.
C1 [Cardo, Lucia F.; Coto, Eliecer; de Mena, Lorena; Diaz, Marta; Corao, Ana I.; Alvarez, Victoria] Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain.
[Ribacoba, Rene; Moris, German; Menendez, Manuel] Hosp Univ Cent Asturias, Asturias, Spain.
[Lorenzo-Betancor, Oswaldo; Pastor, Pau; Samaranch, LLuis] Univ Navarra Clin, Ctr Appl Med Res, Div Neurosci, Neurogenet Lab, Pamplona, Spain.
[Ribacoba, Rene; Moris, German; Menendez, Manuel] Alvarez Buylla Mieres, Asturias, Spain.
[Coto, Eliecer] Univ Oviedo, Dept Med, Oviedo, Spain.
[Lorenzo-Betancor, Oswaldo; Pastor, Pau] Univ Navarra Clin, Dept Neurol, Pamplona, Spain.
[Mata, Ignacio F.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Mata, Ignacio F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
RP Alvarez, V (reprint author), Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain.
EM victoria.alvarez@sespa.princast.es
RI Pastor, Pau/C-9834-2009
OI Pastor, Pau/0000-0002-7493-8777; Fernandez Mata,
Ignacio/0000-0003-1198-0633; Moris, German/0000-0001-7608-2194
FU Fundacion Parkinson Asturias; Obra Social Cajastur; Spanish European
Union [FIS-05/008, 08/0915]; FICYT-Principado de Asturias; Spanish
Ministry of Science and Technology; European Social Fund; Spanish
Ministry of Education and Science [SAF2006-10126]; Fundacio La Marato de
TV3 [061131]; UTE, Spain
FX Authors thank the "Fundacion Parkinson Asturias" and "Obra Social
Cajastur" for their support. This work was supported by grants from the
Spanish "Fondo de Investigaciones Sanitarias-Fondos FEDER" European
Union (FIS-05/008 and 08/0915). LFC and LDM are predoctoral fellowships
of FICYT-Principado de Asturias. LS held a "Torres Quevedo" fellowship
from the Spanish Ministry of Science and Technology, co-financed by the
European Social Fund. This study was supported by a grant from the
Spanish Ministry of Education and Science (SAF2006-10126, 2006-2009) by
the project 061131 from the "Fundacio La Marato de TV3" and by the UTE
project FIMA, Spain to PP.
NR 26
TC 14
Z9 17
U1 0
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD JUL
PY 2012
VL 47
IS 3
BP 425
EP 430
DI 10.1007/s12031-011-9669-1
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 958DV
UT WOS:000305217600002
PM 22076805
ER
PT J
AU Wong, ES
Piette, JD
Liu, CF
Perkins, M
Maciejewski, ML
Jackson, GL
Blough, DK
Fihn, SD
Au, DH
Bryson, CL
AF Wong, Edwin S.
Piette, John D.
Liu, Chuan-Fen
Perkins, Mark
Maciejewski, Matthew L.
Jackson, George L.
Blough, David K.
Fihn, Stephan D.
Au, David H.
Bryson, Chris L.
TI Measures of Adherence to Oral Hypoglycemic Agents at the Primary Care
Clinic Level The Role of Risk Adjustment
SO MEDICAL CARE
LA English
DT Article
DE risk adjustment; adherence; diabetes; organization of care; veterans
ID MEDICATION ADHERENCE; PERFORMANCE-MEASURES; MEANINGFUL VARIATION;
VETERANS-AFFAIRS; THERAPY; QUALITY; PERSISTENCE; MORTALITY; DISEASE;
COSTS
AB Background: Prior research found that in the Veterans Affairs health care system (VA), the proportion of patients adherent to oral hypoglycemic agents varies from 50% to 80% across primary care clinics. This study examined whether variation in patient and facility characteristics determined those differences.
Methods: Retrospective cohort study of 444,418 VA primary care patients with diabetes treated in 559 clinics in fiscal year (FY) 2006-2007. Patients' adherence to each oral hypoglycemic agent was computed for the first 3 months of FY2007, and averaged across agents to produce an adherence score for the patient's overall regimen. Patients with an adherence score over 0.8 were defined as adherent. Risk adjustment used hierarchical logistic regression accounting for patient factors and facility effects by clustering patients within clinics and clinics within parent VA medical centers. We then assessed the influence of risk adjustment using observed-to-expected (O/E) ratios computed for each clinic.
Results: The mean unadjusted proportion of adherent patients in clinics was 0.715 (interdecile range 0.559-0.826). The percent variation in patient's likelihood of being adherent explained at the patient, clinic, and parent VA medical center levels was 2.94%, 0.27%, and 0.76%, respectively. The mean clinic-level observed-to-expected ratio was 1.001 (interdecile range 0.975-1.027).
Conclusions: The variation in the proportion of patients adherent across clinics remained large after risk adjustment. As patient and facility effects explained only 4% of the variance in adherence, comparing clinics based on unadjusted scores is a reasonable starting point unless more predictive patient, provider, and facility factors are identified.
C1 [Wong, Edwin S.; Liu, Chuan-Fen; Perkins, Mark] VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, Seattle, WA 98101 USA.
[Wong, Edwin S.; Liu, Chuan-Fen] Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA.
[Piette, John D.] VA Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Piette, John D.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Maciejewski, Matthew L.; Jackson, George L.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Maciejewski, Matthew L.; Jackson, George L.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA.
[Blough, David K.] Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.
[Fihn, Stephan D.; Au, David H.; Bryson, Chris L.] Univ Washington, Dept Med, Seattle, WA USA.
RP Wong, ES (reprint author), VA Puget Sound Hlth Care Syst, NW Ctr Outcomes Res Older Adults, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM eswong@uw.edu
FU Department of Veterans Affairs, Health Services Research and Development
[IIR 07-068-2]; VA Health Services Research and Development Postdoctoral
Fellowship [TPP 61-024]; VA Career Development Award [03-177]; Gilead
Sciences
FX This research was supported by an Investigator Initiated Research Award
(IIR 07-068-2) from the Department of Veterans Affairs, Health Services
Research and Development. Dr Wong is supported by VA Health Services
Research and Development Postdoctoral Fellowship TPP 61-024. Dr Bryson
was supported by VA Career Development Award 03-177. An earlier version
of this manuscript was presented as a poster at the Academy Health's
Annual Research Meeting in Boston, MA in 2010.; Dr. Wong reports owning
stock in Merck & Co., Inc. and the SPDR Health Care Select Sector
Exchange Traded Fund. Dr. Fihn reports receiving
travel/accomodations/meeting expenses from the Alliance for Academic
Internal Medicine. Dr. Au reports serving as a consultant for Bosch Inc.
and receiving grants from Gilead Sciences. All other authors declare no
conflict of interest.
NR 49
TC 11
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUL
PY 2012
VL 50
IS 7
BP 591
EP 598
DI 10.1097/MLR.0b013e318249cb74
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 959DT
UT WOS:000305292900006
PM 22354208
ER
PT J
AU Donohue, JF
Anzueto, A
Brooks, J
Mehta, R
Kalberg, C
Crater, G
AF Donohue, James F.
Anzueto, Antonio
Brooks, Jean
Mehta, Rashmi
Kalberg, Christopher
Crater, Glenn
TI A randomized, double-blind dose-ranging study of the novel LAMA
GSK573719 in patients with COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Long-acting muscarinic receptor antagonist; Long-acting bronchodilator;
Anticholinergic; Chronic obstructive pulmonary disease; G5K573719
ID OBSTRUCTIVE PULMONARY-DISEASE; MUSCARINIC ANTAGONIST; IPRATROPIUM;
TIOTROPIUM; ACLIDINIUM
AB Background: This study evaluated the dose-response and dosing interval of the novel long-acting muscarinic receptor antagonist (LAMA) GSK573719 in patients with COPD.
Methods: This randomized, double-blind, placebo-controlled, 3-way cross-over, incomplete block study evaluated 5 once-daily doses of GSK573719 (62.5-1000 mu g), 3 twice-daily doses (62.5-250 mu g), and open-label tiotropium for 14 days in patients (N = 176) with COPD (FEV1 of 35-70% predicted). The primary endpoint was morning trough FEV1 at Day 15. Secondary endpoints included 0-24 h weighted mean FEV1 and serial FEV1 values over 28 h. Safety measures and pharmacokinetics were assessed.
Results: All once-daily doses of GSK573719 significantly increased trough FEV1 at Day 15 with improvements ranging from 95 to 186 mL over placebo (p <= 0.006), from 79 to 172 mL with twice-daily dosing (p <= 0.03), and 105 mL with tiotropium (p = 0.003). No clear dose ordering was observed. Once-daily doses significantly (p < 0.001) increased 0-24 h weighted mean FEV1 at Day 14 by 131-143 mL over placebo, comparable to increases with the twice-daily doses (120-142 mL) and tiotropium (127 mL). Significant reductions in rescue albuterol use and improvements in FVC were also observed with once-daily dosing. Plasma C-max occurred within 5-15 min of dosing after which the drug was rapidly cleared and eliminated. GSK573719 was well tolerated, with no apparent treatment-related changes in vital signs, ECG and Hotter assessments, or clinical laboratory parameters.
Conclusion: Once-daily dosing with GSK573719 in COPD provides clinically significant and sustained improvement in lung function over 24 h with similar efficacy to twice-daily dosing. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Donohue, James F.] Univ N Carolina, Coll Med, Dept Med, Chapel Hill, NC 27599 USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Anzueto, Antonio] Audie L Murphy Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Brooks, Jean] GlaxoSmithKline, Resp Med Dev Ctr, Stockley Pk UB11 1BT, England.
[Mehta, Rashmi; Kalberg, Christopher; Crater, Glenn] GlaxoSmithKline, Resp Med Dev Ctr, Res Triangle Pk, NC 27709 USA.
RP Donohue, JF (reprint author), Univ N Carolina, Coll Med, Dept Med, 4125 Bioinformat Bldg, Chapel Hill, NC 27599 USA.
EM james_donohue@med.unc.edu; Anzueto@uthscsa.edu; jean.2.brooks@gsk.com;
rashmi.s.mehta@gsk.com; chris.j.kalberg@gsk.com; glenn.d.crater@gsk.com
OI Crater, Glenn/0000-0002-1159-1323
FU Boehringer Ingelheim; GlaxoSmithKline; Novartis; NHLBI; Lilly; Pfizer;
Pneuma pharmaceuticals
FX J.F.D. has served as consultant to Almirall, AstraZeneca, Boehringer
Ingelheim, Dey, Elevation Pharmaceuticals, Forest Laboratories,
GlaxoSmithKline, Novartis, Pearl Pharmaceuticals, Pfizer and Sunovion;
and has received research grants from Boehringer Ingelheim,
GlaxoSmithKline and Novartis. A.A. is an advisor, consultant, and
speaker for Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck,
Bayer-Schering Pharma, Dey Pharma, Forest laboratories and has
investigational grants with the NHLBI, GlaxoSmithKline, Lilly, Pfizer,
and Pneuma pharmaceuticals. J.B., R.M., C.K., G.C. are employees of and
hold stocks/shares in GlaxoSmithKline.
NR 16
TC 46
Z9 48
U1 0
U2 4
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2012
VL 106
IS 7
BP 970
EP 979
DI 10.1016/j.rmed.2012.03.012
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA 957LM
UT WOS:000305164500008
PM 22498110
ER
PT J
AU Cecere, LM
Williams, EC
Sun, H
Bryson, CL
Clark, BJ
Bradley, KA
Au, DH
AF Cecere, Laura M.
Williams, Emily C.
Sun, Haili
Bryson, Chris L.
Clark, Brendan J.
Bradley, Katharine A.
Au, David H.
TI Smoking cessation and the risk of hospitalization for pneumonia
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Pneumonia; Smoking cessation; COPD
ID COMMUNITY-ACQUIRED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; ALCOHOL
SCREENING SCORES; UNITED-STATES; HEALTH-STATUS; OLDER-ADULTS; MORTALITY;
CARE; POPULATION; VETERANS
AB Background: Smoking increases the risk of hospitalization for pneumonia, yet it is unknown if smoking cessation changes this risk. We sought to determine if smoking cessation and the duration of abstinence from tobacco reduce the risk of pneumonia hospitalization.
Methods: We performed secondary analysis of data collected from male United States Veterans participating in a randomized trial. We used Cox proportional-hazard models to estimate risk of hospitalization for pneumonia within one year of enrollment. We adjusted for confounders, including: demographics, comorbidity, alcohol use, prior pneumonia, inhaled corticosteroid use, and intensity of tobacco exposure. Among a restricted cohort excluding never smokers, we assessed for effect modification by a diagnosis of chronic obstructive pulmonary disease (COPD).
Results: Of the 25,235 participants, we identified 6720 current, 13,625 former, and 4890 never smokers. Compared to current smokers, never smokers had a decreased (adjusted HR 0.48, 95% Cl 0.31-0.74), while former smokers had no difference in (adjusted HR 0.83, 95% Cl 0.63-1.09) risk of hospitalization for pneumonia. Among participants without COPD, former smokers had a lower risk of hospitalization (adjusted HR 0.65, 95% Cl 0.45-0.95). However, this lower risk was isolated to those who quit tobacco more than 10 years previously (adjusted HR 0.62, 95% CI 0.41-0.93). Among those with COPD, there was no difference in risk with smoking cessation or duration of remaining tobacco-free.
Conclusions: Tobacco cessation is likely important in reducing hospital admissions for pneumonia, but its benefit depends on duration of smoking cessation and is likely attenuated in the presence of COPD. Published by Elsevier Ltd.
C1 [Cecere, Laura M.; Williams, Emily C.; Sun, Haili; Bryson, Chris L.; Bradley, Katharine A.; Au, David H.] Puget Sound Hlth Care Syst, Dept Vet Affairs, NW Ctr Excellence, HSR&D, Seattle, WA USA.
[Cecere, Laura M.; Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, Seattle, WA USA.
[Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Bryson, Chris L.; Bradley, Katharine A.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA USA.
[Clark, Brendan J.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
[Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA.
RP Cecere, LM (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM lcecere@uw.edu
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development (HSRD) [IAC 05-206-1]; VA HSRD [TPM
61-037]; Giliad Sciences
FX This study was supported by a Department of Veterans Affairs, Veterans
Health Administration, Health Services Research and Development (HSR&D)
grant [IAC 05-206-1]. Dr. Cecere is supported by a VA HSR&D fellowship
[TPM 61-037]. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs.; Drs. Au and Bryson are co-investigators
on a grant from Giliad Sciences for work which is unrelated to this
manuscript. Dr. Au is a research consultant for Bosch LLC. Drs. Cecere,
Williams, Sun, Clark, and Bradley have no potential conflicts of
interest to disclose.
NR 44
TC 5
Z9 6
U1 1
U2 3
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
J9 RESP MED
JI Respir. Med.
PD JUL
PY 2012
VL 106
IS 7
BP 1055
EP 1062
DI 10.1016/j.rmed.2012.03.018
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA 957LM
UT WOS:000305164500018
PM 22541719
ER
PT J
AU Richman, JS
Hosokawa, PW
Min, SJ
Tomeh, MG
Neumayer, L
Campbell, DA
Henderson, WG
Hawn, MT
AF Richman, Joshua S.
Hosokawa, Patrick W.
Min, Sung-Joon
Tomeh, Majed G.
Neumayer, Leigh
Campbell, Darrell A., Jr.
Henderson, William G.
Hawn, Mary T.
TI Toward Prospective Identification of High-Risk Surgical Patients
SO AMERICAN SURGEON
LA English
DT Article
AB The purpose of this study was to explore the feasibility of prospectively identifying patients at high risk for surgical complications using automatable methods focused on patient characteristics. We used data from the Michigan Surgical Quality Collaborative (60,411 elective surgeries) performed between 2003 and 2008. Regression models for postoperative mortality, overall morbidity, cardiac, thromboembolic, pulmonary, renal, and surgical site infection complications were developed using preoperative patient and planned procedure data. Risk was categorized by quartiles of predicted probability: "low'' risk corresponding to the bottom quartile, "average'' to the middle two quartiles, and "high'' to the top quartile. C-indices were calculated to measure discrimination; model validity was assessed by cross-validation. Models were repeated using only patient characteristics. Risk category was closely related to event rates; 80 to 90 per cent of mortality and cardiac, renal, and pulmonary complications occurred among the 25 per cent of "high-risk" patients. Although thromboembolisms and surgical site infections were less predictable, 60 to 70 per cent of events occurred among high-risk patients. Cross-validation results were consistent and only slightly attenuated when predictors were restricted to patient characteristics alone. Adverse postoperative events are concentrated among patients identifiable preoperatively as high risk. Preoperative risk assessment could allow for efficient interventions targeted to high-risk patients.
C1 [Richman, Joshua S.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, C SMART, Birmingham, AL USA.
[Richman, Joshua S.; Hawn, Mary T.] Univ Alabama Birmingham, Sch Med, Gastrointestinal Sect, Div Gen Surg, Birmingham, AL USA.
[Hosokawa, Patrick W.; Min, Sung-Joon; Henderson, William G.] Univ Colorado, Sch Med, Colorado Hlth Outcomes Program, Denver, CO USA.
[Tomeh, Majed G.] QCMetrix, Waltham, MA USA.
[Neumayer, Leigh] Univ Utah, Salt Lake City, UT USA.
[Campbell, Darrell A., Jr.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
[Henderson, William G.] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Denver, CO 80202 USA.
RP Richman, JS (reprint author), BVAMC, 700 South 19th St,REAP Mail Stop 151, Birmingham, AL 35222 USA.
EM jrichman@uab.edu
NR 17
TC 5
Z9 5
U1 0
U2 2
PU SOUTHEASTERN SURGICAL CONGRESS
PI CUMMING
PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA
SN 0003-1348
EI 1555-9823
J9 AM SURGEON
JI Am. Surg.
PD JUL
PY 2012
VL 78
IS 7
BP 755
EP 760
PG 6
WC Surgery
SC Surgery
GA V32LX
UT WOS:000208953800013
PM 22748533
ER
PT J
AU Goh, AC
Kowalkowski, MA
Bailey, DE
Kazer, MW
Knight, SJ
Latini, DM
AF Goh, Alvin C.
Kowalkowski, Marc A.
Bailey, Donald E., Jr.
Kazer, Meredith W.
Knight, Sara J.
Latini, David M.
TI Perception of cancer and inconsistency in medical information are
associated with decisional conflict: a pilot study of men with prostate
cancer who undergo active surveillance
SO BJU INTERNATIONAL
LA English
DT Article
DE prostate cancer; decision-making; active surveillance; quality of life;
uncertainty
AB OBJECTIVE
To understand the factors associated with decision-making, we conducted a telephone-based survey as part of a pilot study to develop a psychoeducational intervention for men with prostate cancer who undergo active surveillance.
PATIENTS AND METHODS
From 2007 to 2008, we conducted a cross-sectional study of 34 individuals on active surveillance for prostate cancer.
We examined how specific mental health, quality of life and sociodemographic characteristics relate to decision-making.
Five validated decision-making scales were used as primary outcomes reflecting the amount of satisfaction, regret and conflict a participant experienced about his decision to undergo active surveillance.
A multivariate regression model was developed to identify specific psychosocial factors related to the decision-making outcomes.
RESULTS
Primary analyses focused on the decisional satisfaction and conflict measures, as the decisional regret measure showed poor reliability (alpha < 0.70) in this sample.
Four psychosocial measures showed strong associations across the decision-making subscales, including the Fife Constructed Meaning Scale (Pearson r > 0.26), Mishel Uncertainty in Illness Scale - Inconsistency (r > 0.32), Mental Health Index-5 (r > 0.33), and Lepore self-efficacy for prostate symptom management scale (r > 0.33).
Individuals with higher self-efficacy for prostate cancer symptom management (P = 0.02) and higher positive meaning for cancer (P = 0.03) were less likely to express decision-making conflict as the result of uncertainty.
Individuals reporting higher positive meaning for cancer (P = 0.01) and less uncertainty in illness attributed to inconsistency (P = 0.02) were less likely to exhibit decision-making conflict related to the perceived effectiveness of treatment.
CONCLUSIONS
Men choosing active surveillance represent a patient group with unique vulnerabilities that require new psychoeducational interventions to provide information and support that will maintain and improve quality of life.
We describe specific characteristics that may put patients at higher risk during the decision-making process and indicate their increased need for such interventions.
C1 [Goh, Alvin C.; Latini, David M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
[Kowalkowski, Marc A.; Latini, David M.] Michael E DeBakey VA Med Ctr, VA Hlth Serv Res, Houston, TX USA.
[Kowalkowski, Marc A.; Latini, David M.] Michael E DeBakey VA Med Ctr, Dev Ctr Excellence, Houston, TX USA.
[Kowalkowski, Marc A.; Latini, David M.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA.
[Bailey, Donald E., Jr.] Duke Univ, Sch Nursing, Durham, NC USA.
[Kazer, Meredith W.] Fairfield Univ, Fairfield, CT 06430 USA.
[Knight, Sara J.] Univ Calif San Francisco, Dept Urol, San Francisco VA Med Ctr, San Francisco, CA USA.
[Knight, Sara J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Latini, David M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
RP Goh, AC (reprint author), Baylor Coll Med, Scott Dept Urol, 6620 Main St Ste 1325, Houston, TX 77030 USA.
EM acg622@gmail.com
OI Kowalkowski, Marc/0000-0003-2624-4209; Latini, David/0000-0002-6161-4861
FU American Cancer Society [06-083-01-CPPB]
FX This material is partly the result of work supported with resources and
the use of facilities at the Health Services Research & Development
Center of Excellence (HFP90-020), Michael E. DeBakey Veterans Affairs
Medical Center. Dr Latini is supported by Mentored Research Scholar
Grant 06-083-01-CPPB from the American Cancer Society. The views
expressed reflect those of the authors and not necessarily those of the
Department of Veterans Affairs or Baylor College of Medicine.
NR 25
TC 16
Z9 16
U1 2
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD JUL
PY 2012
VL 110
IS 2B
BP E50
EP E56
DI 10.1111/j.1464-410X.2011.10791.x
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA V31JY
UT WOS:000208881100008
PM 22145791
ER
PT J
AU Fernandez, JF
Sibila, O
Restrepo, MI
AF Fernandez, Juan F.
Sibila, Oriol
Restrepo, Marcos I.
TI Predicting ICU admission in community-acquired pneumonia: clinical
scores and biomarkers
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE biomarkers; community-acquired infections; ICU; pneumonia; score;
severity
AB Community-acquired pneumonia (CAP) remains a common and serious worldwide health problem. Despite all the advances in therapy, significant interest has focused on the identification of patients with CAP who require intensive care unit admission to improve their outcomes. The severity assessment of CAP provides an important guide to clinicians in deciding the site of care and the use of empiric antibiotics and adjuvant therapy. For years, several clinical assessment scores have been suggested and validated to achieve this goal. The recent introduction of biomarkers as prognostic indicators of severe CAP, whether used alone or in conjunction with other clinical severity of illness scores, has been investigated. An objective scoring system with a high level of sensitivity and specificity to predict the severity of CAP and the need for high levels of care do not exist. Today, the addition of clinical scores and biomarkers to clinical judgment is the best approach to optimize the care of severe CAP. Future research will allow validation of these and newer tools to improve the prognosis of patients with CAP.
C1 [Fernandez, Juan F.; Sibila, Oriol; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, San Antonio, TX 78229 USA.
[Sibila, Oriol] Hosp Santa Creu & Sant Pau, Serv Pneumol, Barcelona, Spain.
[Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Div Pulm Crit Care Med, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.] South Texas Vet Hlth Care Syst ALMD, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX 78229 USA.
RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU National Heart, Lung and Blood Institute [K23HL096054]; Instituto de
Salud Carlos III [BAE11/00102]; Sociedad Espanola de Neumologia y
Cirugia Toracica (SEPAR); Societat Catalana de Pneumologia (SOCAP)
FX MI Restrepo has participated in advisory boards for
Ortho-McNeil-Janssen, Theravan, Forest Laboratories, Johnson & Johnson,
Trius and Novartis. He is a former speaker for Covidien, BARD, Inc,
Johnson & Johnson (Ortho-McNeil-Janssen) and Pfizer, and is also a
consultant for Theravan, Trius and Pfizer (Wyeth). His time is partially
protected by Award Number K23HL096054 from the National Heart, Lung and
Blood Institute. O Sibila is supported by Instituto de Salud Carlos III
(BAE11/00102), Sociedad Espanola de Neumologia y Cirugia Toracica
(SEPAR) and Societat Catalana de Pneumologia (SOCAP). The authors have
no other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 119
TC 4
Z9 5
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD JUL
PY 2012
VL 5
IS 4
BP 445
EP 458
DI 10.1586/ECP.12.28
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V37PS
UT WOS:000209288300016
PM 22943124
ER
PT J
AU Meyer, JD
Stegner, AJ
Natelson, BH
Cook, DB
AF Meyer, Jacob D.
Stegner, Aaron J.
Natelson, Benjamin H.
Cook, Dane B.
TI Psychobiological Response To Exercise Differs Between Chronic Fatigue
Syndrome (CFS) And CFS With Comorbid Fibromyalgia
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Meyer, Jacob D.; Stegner, Aaron J.] Univ Wisconsin, Madison, WI USA.
[Natelson, Benjamin H.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA.
[Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
EM jdmeyer3@wisc.edu
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
MA 1496
BP 325
EP 326
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142901253
ER
PT J
AU Ahluwalia, S
AF Ahluwalia, Sangeeta
TI IMPROVING THE STATE OF QUALITY MEASUREMENT: LESSONS FROM "DOWN UNDER"
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Ahluwalia, Sangeeta] Vet Adm Greater Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S226
EP S226
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900296
ER
PT J
AU Caverly, T
Richlie, D
Prochazka, AV
Cook-Shimanek, MK
Pawlak, M
Woodward, J
Stickrath, C
AF Caverly, Tanner
Richlie, Daniel
Prochazka, Allan V.
Cook-Shimanek, Margaret K.
Pawlak, Mary
Woodward, Jennifer
Stickrath, Chad
TI RISK-BENEFIT DISCUSSION PRIOR TO COMPUTED TOMOGRAPHY IMAGING -
INFREQUENT AND INEFFECTIVE?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Caverly, Tanner; Prochazka, Allan V.; Cook-Shimanek, Margaret K.; Pawlak, Mary; Woodward, Jennifer; Stickrath, Chad] Univ Colorado, Denver, CO 80202 USA.
[Caverly, Tanner; Richlie, Daniel; Prochazka, Allan V.; Stickrath, Chad] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S302
EP S303
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900484
ER
PT J
AU Chang, E
Rose, D
Yano, EM
Wells, K
Lee, M
Rubenstein, LV
AF Chang, Evelyn
Rose, Danielle
Yano, Elizabeth M.
Wells, Kenneth
Lee, Martin
Rubenstein, Lisa V.
TI DETERMINANTS OF READINESS FOR PRIMARY CARE-MENTAL HEALTH INTEGRATION
(PC-MHI) IN THE VA HEALTH CARE SYSTEM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Chang, Evelyn] VA Greater Los Angeles, Los Angeles, CA USA.
[Rose, Danielle; Yano, Elizabeth M.; Lee, Martin; Rubenstein, Lisa V.] VA HSR&D Ctr Excellence Study Healthcare Provider, North Hills, CA USA.
[Wells, Kenneth] Univ Calif Los Angeles, Los Angeles, CA USA.
[Wells, Kenneth; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S158
EP S158
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900143
ER
PT J
AU Cordasco, KM
Zephyrin, LC
Canelo, I
Kessler, C
Mallard, M
Rubenstein, LV
Yano, EM
AF Cordasco, Kristina M.
Zephyrin, Laurie C.
Canelo, Ismelda
Kessler, Chad
Mallard, Merri
Rubenstein, Lisa V.
Yano, Elizabeth M.
TI 2011 VETERANS' HEALTH ADMINISTRATION EMERGENCY SERVICES FOR WOMEN (ESW)
SURVEY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Cordasco, Kristina M.; Canelo, Ismelda; Rubenstein, Lisa V.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Cordasco, Kristina M.; Rubenstein, Lisa V.] Univ Calif Los Angeles, David Geffin Sch Med, Los Angeles, CA USA.
[Zephyrin, Laurie C.; Mallard, Merri] Vet Hlth Adm, Washington, DC USA.
[Zephyrin, Laurie C.] VA New York Harbor Healthcare Syst, New York, NY USA.
[Kessler, Chad] Jesse Brown VA Hosp, Chicago, IL USA.
[Kessler, Chad] Univ Illinois, Chicago, IL USA.
[Yano, Elizabeth M.] UCLA Sch Publ Hlth, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S99
EP S99
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900002
ER
PT J
AU Durant, RW
Redmond, N
You, ZY
Hullett, S
Sheppard, AR
Scarinci, I
AF Durant, Raegan W.
Redmond, Nicole
You, Zhiying
Hullett, Sandral
Sheppard, A. Robert
Scarinci, Isabel
TI RACIAL DIFFERENCES IN SELF-EFFICACY AMONG AFRICAN-AMERICANS AND WHITES
WITH HEART FAILURE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Durant, Raegan W.; Redmond, Nicole; You, Zhiying; Sheppard, A. Robert; Scarinci, Isabel] Univ Alabama Birmingham, Birmingham, AL USA.
[Durant, Raegan W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Redmond, Nicole; Hullett, Sandral] Cooper Green Mercy Hosp, Birmingham, AL USA.
[Sheppard, A. Robert] DCH Reg Med Ctr, Tuscaloosa, AL USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S292
EP S292
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900457
ER
PT J
AU Edelman, EJ
Gordon, KS
Becker, W
Goulet, JL
Skanderson, M
Gaither, JR
Braden, JB
Gordon, A
Kerns, R
Justice, AC
Fiellin, DA
AF Edelman, E. J.
Gordon, Kirsha S.
Becker, William
Goulet, Joseph L.
Skanderson, Melissa
Gaither, Julie R.
Braden, Jennifer B.
Gordon, Adam
Kerns, Robert
Justice, Amy C.
Fiellin, David A.
TI HIV STATUS IS AN INDEPENDENT PREDICTOR OF RECEIVING OPIOID ANALGESICS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Edelman, E. J.; Becker, William; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, New Haven, CT USA.
[Gordon, Kirsha S.; Becker, William; Goulet, Joseph L.; Skanderson, Melissa; Kerns, Robert; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Gordon, Kirsha S.] Columbia Univ, Sch Publ Hlth, New York, NY USA.
[Gaither, Julie R.] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Braden, Jennifer B.] Univ Washington, Seattle, WA 98195 USA.
[Gordon, Adam] Univ Pittsburgh, Pittsburgh, PA USA.
[Gordon, Adam] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S203
EP S204
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900247
ER
PT J
AU Kangovi, S
Grande, D
Ryan, DA
Meehan, P
Mitra, N
Shannon, R
Long, JA
AF Kangovi, Shreya
Grande, David
Ryan, Daniel A.
Meehan, Patricia
Mitra, Nandita
Shannon, Richard
Long, Judith A.
TI PERCEPTIONS OF READMITTED PATIENTS ON THE TRANSITION FROM HOSPITAL TO
HOME
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kangovi, Shreya; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Kangovi, Shreya; Ryan, Daniel A.] Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA USA.
[Grande, David; Shannon, Richard; Long, Judith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Grande, David; Mitra, Nandita] Univ Penn, Philadelphia, PA 19104 USA.
[Meehan, Patricia] Univ Penn Hlth Syst, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S271
EP S271
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900405
ER
PT J
AU Kertesz, S
Pollio, DE
Holt, C
Steward, JL
Gordon, A
Kim, TW
Stringfellow, E
Austin, E
Golden, J
Johnson, N
Davis, LL
AF Kertesz, Stefan
Pollio, David E.
Holt, Cheryl
Steward, Jocelyn L.
Gordon, Adam
Kim, Theresa W.
Stringfellow, Erin
Austin, Erika
Golden, Joya
Johnson, Nancy
Davis, Lori L.
TI COMPARISON OF TAILORED VERSUS MAINSTREAM PRIMARY CARE DELIVERY FOR
HOMELESS PERSONS: A NEW, VALIDATED PATIENT ASSESSMENT TOOL
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kertesz, Stefan; Austin, Erika; Johnson, Nancy] Birmingham VAMC, Homewood, AL USA.
[Kertesz, Stefan; Pollio, David E.; Steward, Jocelyn L.; Davis, Lori L.] Univ Alabama Birmingham, Birmingham, AL USA.
[Kim, Theresa W.; Stringfellow, Erin] Boston Hlth Care Homeless, Boston, MA USA.
[Holt, Cheryl] Univ Maryland, Baltimore, MD 21201 USA.
[Golden, Joya] VA Greater Los Angeles, Los Angeles, CA USA.
[Gordon, Adam] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S147
EP S147
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900118
ER
PT J
AU Korthuis, T
Marshall, R
Beach, MC
Saha, S
Mori, T
Loveless, MO
Hibbard, JH
Cohn, JA
Sharp, VL
AF Korthuis, Todd
Marshall, Rebecca
Beach, Mary Catherine
Saha, Somnath
Mori, Tomi
Loveless, Mark O.
Hibbard, Judith H.
Cohn, Jonathan A.
Sharp, Victoria L.
TI PATIENT ACTIVATION AND IMPROVED OUTCOMES IN HIV-INFECTED PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Korthuis, Todd; Marshall, Rebecca; Saha, Somnath; Mori, Tomi; Loveless, Mark O.; Hibbard, Judith H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Hibbard, Judith H.] Univ Oregon, Eugene, OR 97403 USA.
[Cohn, Jonathan A.] Wayne State Univ, Detroit, MI USA.
[Sharp, Victoria L.] St Lukes Roosevelt Hosp, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S261
EP S262
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900381
ER
PT J
AU Kullgren, JT
Loewenstein, G
Troxel, AB
Norton, L
Wesby, L
Zhu, JS
Tao, YY
Volpp, KG
AF Kullgren, Jeffrey T.
Loewenstein, George
Troxel, Andrea B.
Norton, Laurie
Wesby, Lisa
Zhu, Jingsan
Tao, Yuanyuan
Volpp, Kevin G.
TI A RANDOMIZED CONTROLLED TRIAL OF FINANCIAL INCENTIVES TO PROMOTE WEIGHT
LOSS AMONG OBESE EMPLOYEES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kullgren, Jeffrey T.; Norton, Laurie; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Kullgren, Jeffrey T.; Troxel, Andrea B.; Norton, Laurie; Wesby, Lisa; Zhu, Jingsan; Tao, Yuanyuan; Volpp, Kevin G.] Univ Penn, Philadelphia, PA 19104 USA.
[Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
NR 0
TC 0
Z9 0
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S102
EP S103
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900010
ER
PT J
AU Lam, KD
Miao, YH
Steinman, MA
AF Lam, Khoa D.
Miao, Yinghui
Steinman, Michael A.
TI CUMULATIVE CHANGES IN USE OF CHRONIC MEDICATIONS: A NEW MEASURE OF
PRESCRIBING INTENSITY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lam, Khoa D.; Steinman, Michael A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Miao, Yinghui; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S151
EP S151
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900128
ER
PT J
AU Lawrence, V
Noel, PH
Yoder, LH
Cornell, JE
Johnson, AE
Hsu, JR
Wolf, SE
AF Lawrence, Valerie
Noel, Polly H.
Yoder, Linda H.
Cornell, John E.
Johnson, Anthony E.
Hsu, Joseph R.
Wolf, Steven E.
TI MENTAL HEALTH STATUS AND PHYSICAL FUNCTION OF COMBAT-INJURED MILITARY
PERSONNEL AT HOSPITAL DISCHARGE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lawrence, Valerie; Noel, Polly H.; Cornell, John E.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Lawrence, Valerie; Noel, Polly H.; Cornell, John E.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Yoder, Linda H.] Univ Texas Austin, Austin, TX 78712 USA.
[Yoder, Linda H.; Hsu, Joseph R.] US Army Inst Surg Res, Ft Sam Houston, TX USA.
[Johnson, Anthony E.; Hsu, Joseph R.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA.
[Wolf, Steven E.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S246
EP S247
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900347
ER
PT J
AU Liu, CF
Perkins, M
Wong, E
Bryson, CL
AF Liu, Chuan-Fen
Perkins, Mark
Wong, Edwin
Bryson, Christopher L.
TI SURVEY RESPONSES AND MEDICATION ADHERENCE AMONG DIABETIC PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Liu, Chuan-Fen; Perkins, Mark; Wong, Edwin; Bryson, Christopher L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Liu, Chuan-Fen; Bryson, Christopher L.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S312
EP S312
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900507
ER
PT J
AU Lynch, CP
Gebregziabher, M
Hunt, KJ
Echols, C
Gilbert, G
Egede, LE
AF Lynch, Cheryl P.
Gebregziabher, Mulugeta
Hunt, Kelly J.
Echols, Carrae
Gilbert, Gregory
Egede, Leonard E.
TI IMPACT OF MEDICAL AND PSYCHIATRIC COMORBIDITY BURDEN AND MORTALITY IN
VETERANS WITH TYPE 2 DIABETES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lynch, Cheryl P.; Gebregziabher, Mulugeta; Hunt, Kelly J.; Echols, Carrae; Gilbert, Gregory; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Lynch, Cheryl P.; Gebregziabher, Mulugeta; Hunt, Kelly J.; Egede, Leonard E.] Med Univ S Carolina, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S219
EP S220
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900280
ER
PT J
AU Lynch, CP
Gebregziabher, M
Axon, RN
Hunt, KJ
Echols, C
Egede, LE
AF Lynch, Cheryl P.
Gebregziabher, Mulugeta
Axon, R. Neal
Hunt, Kelly J.
Echols, Carrae
Egede, Leonard E.
TI COMPARISON OF COMORBIDITY RISK ADJUSTMENT METHODS IN A NATIONAL COHORT
OF VETERANS WITH DIABETES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lynch, Cheryl P.; Gebregziabher, Mulugeta; Axon, R. Neal; Hunt, Kelly J.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Lynch, Cheryl P.; Gebregziabher, Mulugeta; Axon, R. Neal; Hunt, Kelly J.; Echols, Carrae; Egede, Leonard E.] Med Univ S Carolina, Charleston, SC 29425 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S146
EP S147
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900117
ER
PT J
AU Simonetti, JA
Fine, MJ
Simak, DM
Chen, YF
Hess, R
AF Simonetti, Joseph A.
Fine, Michael J.
Simak, Deborah M.
Chen, Yi-Fan
Hess, Rachel
TI RACIAL DISPARITIES IN INTERMEDIATE OUTCOMES OF DIABETES CARE IN A
PATIENT-CENTERED MEDICAL HOME
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Simonetti, Joseph A.; Fine, Michael J.; Simak, Deborah M.; Hess, Rachel] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Chen, Yi-Fan] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S291
EP S291
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900455
ER
PT J
AU Snyder, E
Castiglioni, A
Estrada, C
You, ZY
Kertesz, S
Schumacher, JE
AF Snyder, Erin
Castiglioni, Analia
Estrada, Carlos
You, Zhiying
Kertesz, Stefan
Schumacher, Joseph E.
TI AN EDUCATIONAL INTERVENTION TO IMPROVE OPIATE PRESCRIBING PRACTICES IN
RESIDENT CLINIC
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Snyder, Erin; Castiglioni, Analia; Estrada, Carlos; You, Zhiying; Kertesz, Stefan; Schumacher, Joseph E.] Univ Alabama Birmingham, Birmingham, AL USA.
[Snyder, Erin; Castiglioni, Analia; Estrada, Carlos; Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S119
EP S120
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900050
ER
PT J
AU Stickrath, C
Griffiths, M
Prochazka, AV
Aagaard, EM
Anderson, M
Deloughry, MN
AF Stickrath, Chad
Griffiths, Megan
Prochazka, Allan V.
Aagaard, Eva M.
Anderson, Melver
Deloughry, Melissa N.
TI MAXIMIZING TEACHING EFFECTIVENESS: PREDICTORS OF LEARNER SATISFACTION
WITH TEACHING ON ROUNDS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Stickrath, Chad; Prochazka, Allan V.; Anderson, Melver] Denver VA Med Ctr, Denver, CO USA.
[Stickrath, Chad; Griffiths, Megan; Prochazka, Allan V.; Aagaard, Eva M.; Anderson, Melver; Deloughry, Melissa N.] Univ Colorado Denver, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S244
EP S244
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900341
ER
PT J
AU Volpp, KG
Norton, L
Shea, JA
Zhu, JS
Small, D
Basner, M
Ecker, A
Dinges, D
Mollicone, D
Novak, C
Bellini, L
AF Volpp, Kevin G.
Norton, Laurie
Shea, Judy A.
Zhu, Jingsan
Small, Dylan
Basner, Mathias
Ecker, Adrian
Dinges, David
Mollicone, Daniel
Novak, Cristina
Bellini, Lisa
TI A RANDOMIZED CONTROLLED TRIAL OF THE FEASIBILITY OF A PROTECTED SLEEP
PERIOD FOR MEDICAL INTERNS IN THE HOSPITAL FOR PROLONGED DUTY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Volpp, Kevin G.; Norton, Laurie; Shea, Judy A.; Zhu, Jingsan; Small, Dylan; Basner, Mathias; Ecker, Adrian; Dinges, David; Novak, Cristina; Bellini, Lisa] Univ Penn, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Norton, Laurie; Novak, Cristina] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Mollicone, Daniel] Pulsar Informat, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S103
EP S103
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900011
ER
PT J
AU Wamsley, MA
Batki, SL
Dunlop, M
Julian, K
McCance-Katz, E
O'Sullivan, PS
Satterfield, J
AF Wamsley, Maria A.
Batki, Steven L.
Dunlop, Miranda
Julian, Katherine
McCance-Katz, Elinore
O'Sullivan, Patricia S.
Satterfield, Jason
TI A BRIEF CURRICULAR INTERVENTION TO IMPROVE SCREENING AND BRIEF
INTERVENTIONS FOR SUBSTANCE ABUSE IN THE PRIMARY CARE SETTING DOES NOT
IMPROVE PERFORMANCE ON A STANDARDIZED PATIENT ASSESSMENT
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Wamsley, Maria A.; Batki, Steven L.; Dunlop, Miranda; Julian, Katherine; McCance-Katz, Elinore; O'Sullivan, Patricia S.; Satterfield, Jason] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Batki, Steven L.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S100
EP S100
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900003
ER
PT J
AU Williams, B
Ahalt, C
AF Williams, Brie
Ahalt, Cyrus
TI PAYING THE PRICE: THE DEARTH OF PUBLICALLY AVAILABLE PRISON HEALTHCARE
COST DATA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
C1 [Williams, Brie; Ahalt, Cyrus] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Williams, Brie] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUL
PY 2012
VL 27
SU 2
BP S269
EP S269
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA V35IG
UT WOS:000209142900400
ER
PT J
AU Lam, J
Simpson, PC
Yang, PC
Dash, R
AF Lam, Justin
Simpson, Paul C.
Yang, Phillip C.
Dash, Rajesh
TI Synthesis of an In vivo MRI-detectable Apoptosis Probe
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Molecular Biology; Issue 65; Biomedical Engineering; conjugation;
annexin; iron oxide; nanoparticle; MRI; molecular imaging
AB Cellular apoptosis is a prominent feature of many diseases, and this programmed cell death typically occurs before clinical manifestations of disease are evident. A means to detect apoptosis in its earliest, reversible stages would afford a pre-clinical 'window' during which preventive or therapeutic measures could be taken to protect the heart from permanent damage. We present herein a simple and robust method to conjugate human Annexin V (ANX), which avidly binds to cells in the earliest, reversible stages of apoptosis, to superparamagnetic iron oxide (SPIO) nanoparticles, which serve as an MRI-detectable contrast agent. The conjugation method begins with an oxidation of the SPIO nanoparticles, which oxidizes carboxyl groups on the polysaccharide shell of SPIO. Purified ANX protein is then added in the setting of a sodium borate solution to facilitate covalent interaction of ANX with SPIO in a reducing buffer. A final reduction step with sodium borohydride is performed to complete the reduction, and then the reaction is quenched. Unconjugated ANX is removed from the mix by microcentrifuge filtration. The size and purity of the ANX-SPIO product is verified by dynamic light scattering (DLS). This method does not require addition to, or modification of, the polysaccharide SPIO shell, as opposed to cross-linked iron oxide particle conjugation methods or biotin-labeled nanoparticles. As a result, this method represents a simple, robust approach that may be extended to conjugation of other proteins of interest.
C1 [Lam, Justin; Yang, Phillip C.; Dash, Rajesh] Stanford Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA.
[Simpson, Paul C.] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.
[Simpson, Paul C.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Dash, R (reprint author), Stanford Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA.
EM rdash@cvmed.stanford.edu
FU National Institutes of Health, NHLBI; American Heart Association;
Stanford University, VPUE Grant
FX National Institutes of Health, NHLBI (RD, PY, PS).; American Heart
Association (JL).; Stanford University, VPUE Grant (JL).
NR 12
TC 1
Z9 1
U1 1
U2 2
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUL
PY 2012
IS 65
AR UNSP e3775
DI 10.3791/3775
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36PJ
UT WOS:000209223200011
ER
PT J
AU Maguen, S
Lau, KM
Madden, E
Seal, K
AF Maguen, Shira
Lau, Karen M.
Madden, Erin
Seal, Karen
TI Factors Associated With Completing Comprehensive Traumatic Brain Injury
Evaluation
SO MILITARY MEDICINE
LA English
DT Article
AB This study examined factors associated with Iraq and Afghanistan Veterans following up with the Department of Veterans Affairs (VA) comprehensive traumatic brain injury (TBI) evaluation after a positive first-level VA TBI screen. Participants included 465 Iraq and Afghanistan Veterans at one VA Medical Center and its five affiliated community-based outpatient clinics, with a positive initial TBI screen between April 1, 2007 and June 1, 2010. We found that 75% of Veterans completed the comprehensive TBI evaluation. Women were three times less likely to complete the comprehensive TBI evaluation than men, and those who endorsed post-traumatic stress disorder avoidance symptoms were nearly two times less likely to complete the comprehensive TBI evaluation. In contrast, headaches, Hispanic ethnicity, and the season of the initial TBI screen (summer vs. winter) were positively associated with completing a comprehensive TBI evaluation. A substantial minority of Veterans who screen positive on the VA initial TBI screen fail to present for the comprehensive TBI evaluation. Addressing specific gender-related issues, avoidance, and the timing of referrals in the context of VA polytrauma programs may increase the likelihood that Veterans receive further assessment, education, and early intervention for TBI or other mental health problems to prevent chronic postdeployment disability.
C1 [Maguen, Shira; Lau, Karen M.; Madden, Erin; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Maguen, Shira; Seal, Karen] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Maguen, Shira; Seal, Karen] Hlth Serv Res, Dev Res Enhancement Award Program, San Francisco, CA 94121 USA.
RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.
FU Department of Defense Psychological Health and Traumatic Brain Injury
(PH/TBI) Research Program [W81XWH-05-2-0094]; VA Health Sciences
Research and Development Career Development Award [RCD06042A]
FX We thank Gary Abrams, MD; Don Donati; Thomas Neylan, MD; Richard Pham,
PhD; and Guiomar Scheid for their contributions. This research was
supported by grants to Shira Maguen, PhD, by the Department of Defense
Psychological Health and Traumatic Brain Injury (PH/TBI) Research
Program (W81XWH-05-2-0094) and VA Health Sciences Research and
Development Career Development Award (RCD06042A).
NR 20
TC 3
Z9 3
U1 1
U2 1
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD JUL
PY 2012
VL 177
IS 7
BP 797
EP 803
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA V33NZ
UT WOS:000209026800007
PM 22808886
ER
PT J
AU Maguen, S
Cohen, B
Cohen, G
Madden, E
Bertenthal, D
Seal, K
AF Maguen, Shira
Cohen, Beth
Cohen, Greg
Madden, Erin
Bertenthal, Daniel
Seal, Karen
TI Eating Disorders and Psychiatric Comorbidity among Iraq and Afghanistan
Veterans
SO WOMENS HEALTH ISSUES
LA English
DT Article
AB Objective: Individuals with mental health problems are at elevated risk for eating disorders. Veterans serving in support of the conflicts in Afghanistan and Iraq (OEF/OIF) have a high prevalence of deployment-related mental health problems, but little is known about their risk for eating disorders. Our aim was to determine rates of eating disorder diagnoses among OEF/OIF veterans with mental health problems, particularly among those with comorbid mental health problems.
Methods: This retrospective, cross-sectional analysis of nationwide VA healthcare facilities used descriptive statistics and regression analyses to determine eating disorder rates in OEF/OIF veterans who were new users of VA healthcare from October 7, 2001 to December 31, 2010 (N = 593,739).
Results: Although the prevalence of eating disorder diagnoses was 0.007% (n = 465) in women and <0.001% (n = 192) in men, veterans diagnosed with mental health problems were significantly more likely to have an eating disorder than those without mental health diagnoses. Eating disorders were significantly more common in women with depression, posttraumatic stress disorder, and alcohol and/or drug use disorders than in women veterans without these mental health disorders. Among men, the associations between eating disorder diagnoses and comorbid mental health diagnoses closely paralleled those observed in women.
Conclusions: Rates of eating disorders are significantly higher among returning veterans with comorbid mental health problems compared with those without mental health diagnoses. Further research should examine methods to improve detection and treatment of eating disorders in this population.
C1 [Maguen, Shira; Cohen, Beth; Cohen, Greg; Madden, Erin] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Bertenthal, Daniel] San Francisco VA Med Ctr, Mental Illness Res Educ & Clin Ctr, San Francisco, CA 94121 USA.
[Seal, Karen] San Francisco VA Med Ctr, Iraq Afghanistan Vet Integrated Care Clin, San Francisco, CA 94121 USA.
[Maguen, Shira; Cohen, Beth; Seal, Karen] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St,116-P, San Francisco, CA 94121 USA.
EM Shira.Maguen@va.gov
FU NHLBI NIH HHS [K23 HL 094765-01]
NR 19
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD JUL-AUG
PY 2012
VL 22
IS 4
BP E403
EP E406
DI 10.1016/j.whi.2012.04.005
PG 4
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA V33SS
UT WOS:000209039100009
PM 22749199
ER
PT J
AU Seo, SW
Lee, JM
Im, K
Park, JS
Kim, SH
Kim, ST
Ahn, HJ
Chin, J
Cheong, HK
Weiner, MW
Na, DL
AF Seo, Sang Won
Lee, Jong-Min
Im, Kiho
Park, Jun-Sung
Kim, Sook-Hui
Kim, Sung Tae
Ahn, Hyun-Jung
Chin, Juhee
Cheong, Hae-Kwan
Weiner, Michael W.
Na, Duk L.
TI Cortical thinning related to periventricular and deep white matter
hyperintensities
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE White matter hyperintensities; Periventricle white matter
hyperintensities; Deep white matter hyperintensities; Cortical
thickness; Cognitive impairment; Dementia; Mild cognitive impairment
ID MILD COGNITIVE IMPAIRMENT; SUBCORTICAL VASCULAR DEMENTIA;
ALZHEIMERS-DISEASE; CEREBRAL MICROANGIOPATHY; CEREBROVASCULAR-DISEASE;
CHOLINERGIC PATHWAYS; LESIONS; BRAIN; MRI; DECLINE
AB Previous studies showed that white matter hyperintensities (WMH) are related to cognitive decline in patients with mild cognitive impairment (MCI) or dementia. Moreover, periventricular WMH (periventricular white matter hyperintensities (PWMH)) and deep WMH (deep white matter hyperintensities (DWMH)) may have different effects on cognition. The purpose of this study is to investigate the contributions of PWMH and DWMH to the topography of cortical thinning and to investigate the relationship among WMH, cortical thinning, and cognitive impairments. Participants included 226 patients with Alzheimer's disease or subcortical vascular dementia, and 135 patients with amnestic MCI or subcortical vascular MCI. Cortical thickness was measured using the surface based method. The topography of cortical thinning related to WMH was distributed in the frontal and perisylvian regions, which was similar to that of PWMH. In contrast, there were only small areas of cortical thinning inversely associated with DWMH, which were distributed in medial frontal and lingual gyrus. PWMH, but not DWMH, were associated with the frontal thinning and executive dysfunction; where both PWMH and frontal thinning were independently associated with executive dysfunction. Our results suggest that PWMH are associated with frontal thinning, which is further associated with frontal executive dysfunction. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Seo, Sang Won; Ahn, Hyun-Jung; Chin, Juhee; Na, Duk L.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea.
[Lee, Jong-Min] Hanyang Univ, Dept Biomed Engn, Seoul 133791, South Korea.
[Im, Kiho; Park, Jun-Sung] Harvard Univ, Div Newborn Med, Childrens Hosp Boston, Sch Med, Cambridge, MA 02138 USA.
[Kim, Sook-Hui] Konkuk Univ, Dept Neurol, Konkuk Univ Hosp, Sch Med, Seoul, South Korea.
[Kim, Sung Tae] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, Seoul, South Korea.
[Cheong, Hae-Kwan] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Social & Prevent Med, Seoul, South Korea.
[Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
RP Na, DL (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea.
EM dukna@skku.edu
RI Na, Duk Lyul/C-9598-2011
OI Cheong, Hae-Kwan/0000-0003-2758-9399
FU Ministry for Health, Welfare and family Affairs, Republic of Korea
[A050079]; Korean Science and Engineering Foundation (KOSEF) NRL; Korean
government (MEST) [R0A-2007-000-20068-0]; Samsung Medical Center
[CRL-108011, CRS 110-14-1]
FX This study was supported by a grant from the Korean Healthcare
Technology R&D Project, Ministry for Health, Welfare and family Affairs,
Republic of Korea (A050079), a Korean Science and Engineering Foundation
(KOSEF) NRL program grant funded by the Korean government (MEST;
R0A-2007-000-20068-0), and a Samsung Medical Center Clinical Research
Development Program grant (CRL-108011 and CRS 110-14-1).
NR 55
TC 33
Z9 34
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUL
PY 2012
VL 33
IS 7
BP 1156
EP +
DI 10.1016/j.neurobiolaging.2010.12.003
PG 13
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 953GG
UT WOS:000304854300006
PM 21316813
ER
PT J
AU Beeri, MS
Schmeidler, J
Lesser, GT
Maroukian, M
West, R
Leung, S
Wysocki, M
Perl, DP
Purohit, DP
Haroutunian, V
AF Beeri, Michal Schnaider
Schmeidler, James
Lesser, Gerson T.
Maroukian, Maria
West, Rebecca
Leung, Stephanie
Wysocki, Michael
Perl, Daniel P.
Purohit, Dushyant P.
Haroutunian, Vahram
TI Corticosteroids, but not NSAIDs, are associated with less Alzheimer
neuropathology
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Glucocorticoids; Corticosteroids; Nonsteroidal anti-inflammatory drugs
(NSAIDs); Neuritic plaques; Neurofibrillary tangles
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE FUNCTION; P-GLYCOPROTEIN; CACHE
COUNTY; DISEASE; BRAIN; INFLAMMATION; DEMENTIA; GLUCOCORTICOIDS;
PREDNISOLONE
AB The objective of this study was to test the hypothesis that corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) medications are associated with less global and regional Alzheimer's disease (AD) neuropathology. This postmortem study was based on 694 brains of subjects from the Mount Sinai School of Medicine Brain Bank who did not have neuropathologies other than neuritic plaques (NPs), neurofibrillary tangles (NFTs), or cerebrovascular disease. Densities of NPs and of NFTs were assessed in several neocortical regions and in the hippocampus, entorhinal cortex, and amygdala. Counts of NPs in several neocortical regions were also assessed. For each neuropathology measure, analyses of covariance controlling for age at death and sex compared subjects who received only corticosteroids (n = 54) or those who received only NSAIDs (n = 56) to the same comparison group, subjects who received neither (n = 576). Subjects receiving corticosteroids had significantly lower ratings and counts of NPs for all neuropathological measures, and NFTs overall and in the cerebral cortex and amygdala. In contrast, no measures were significant for subjects who received NSAIDs. Use of corticosteroids was associated with approximately 50% fewer NPs and NFTs in most brain regions examined, compared with nonmedicated subjects. In contrast, use of NSAIDs was not substantially associated with the reductions in hallmark lesions of AD. Because corticosteroids have anti-inflammatory as well as a myriad of other neurobiological effects, more direct studies in model systems could reveal novel therapeutic targets and mechanisms for AD lesion reduction. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Beeri, Michal Schnaider; Schmeidler, James; Maroukian, Maria; West, Rebecca; Leung, Stephanie; Wysocki, Michael; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Lesser, Gerson T.] Jewish Home & Hosp, New York, NY USA.
[Perl, Daniel P.; Purohit, Dushyant P.] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA.
[Haroutunian, Vahram] James J Peters VA Med Ctr, Bronx, NY USA.
RP Beeri, MS (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave Levy Pl,Box 1230, New York, NY 10029 USA.
EM michal.beeri@mssm.edu
FU NIA [K01 AG023515-01, R01 AG034087, P01 AG02219]; Graubard Fund; Berkman
Trust; Leir Foundation; ADRC [P50 AG05138]
FX Study funding: supported by NIA grants K01 AG023515-01 and R01 AG034087
(MSB), P01 AG02219 (VH), and P50 AG05138 (ADRC- Dr. M. Sano), as well as
by the Graubard Fund (MSB) and the Berkman Trust and Leir Foundation
(VH).
NR 43
TC 9
Z9 9
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUL
PY 2012
VL 33
IS 7
BP 1258
EP 1264
DI 10.1016/j.neurobiolaging.2011.02.011
PG 7
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 953GG
UT WOS:000304854300016
PM 21458888
ER
PT J
AU Ksiezak-Reding, H
Ho, L
Santa-Maria, I
Diaz-Ruiz, C
Wang, J
Pasinetti, GM
AF Ksiezak-Reding, Hanna
Ho, Lap
Santa-Maria, Ismael
Diaz-Ruiz, Carmen
Wang, Jun
Pasinetti, Giulio Maria
TI Ultrastructural alterations of Alzheimer's disease paired helical
filaments by grape seed-derived polyphenols
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Alzheimer's disease; Paired helical filaments; Tau protein;
Ultrastructure; Grape seed polyphenols; Immunogold labeling
ID AMYLOID FIBRIL FORMATION; CROSS-BETA-STRUCTURE; IN-VITRO; TAU
AGGREGATION; NEUROFIBRILLARY TANGLES; CORE DOMAIN; PROTEIN-TAU; BINDING;
INHIBITION; EXTRACT
AB Abnormal folding of the microtubule-associated protein tau leads to aggregation of tau into paired helical filaments (PHFs) and neurofibrillary tangles, the major hallmark of Alzheimer's disease (AD). We have recently shown that grape seed polyphenol extract (GSPE) reduces tau pathology in the TMHT mouse model of tauopathy (Wang et al., 2010). In the present studies we assessed the impact of GSPE exposure on the ultrastructure of PHFs isolated from Alzheimer's disease brain. Transmission electron microscopy revealed that GSPE induced profound dose-and time-dependent alterations in the morphology of PHFs with partial disintegration of filaments. Filaments showed similar to 2-fold enlargement in width and displayed numerous protrusions and splayed ends consistent with unfolding of tau and diminished structural stability. In addition, GSPE induced a reduction in immunogold labeling with antibodies against the C-terminal half (12E8, PHF-1) and the middle region of tau (AT8, Tau5, pSer214 tau, and AT180) but not the C-terminal end (Tau46). In comparison, labeling of N-terminus (Alz50) was enhanced. It is unlikely that alterations in immunogold labeling were due to biochemical alterations, e. g., protein phosphatase or proteolytic activities potentially stimulated by GSPE, because western blotting studies have shown the preservation of full length polypeptides of tau and their phospho-epitopes in GSPE-treated samples. The GSPE mechanism may include a noncovalent interaction of polyphenols with proline residues in the proline-rich domain of tau, with Pin1 sites at P213 and P232 most seriously affected as judged by suppression of labeling. Collectively, our results suggest that GSPE has a significant potential for therapeutic development by neutralizing phospho-epitopes and disrupting fibrillary conformation leading to disintegration of PHFs. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Ksiezak-Reding, Hanna; Ho, Lap; Santa-Maria, Ismael; Diaz-Ruiz, Carmen; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Ksiezak-Reding, Hanna; Ho, Lap; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Santa-Maria, Ismael] Queen Sofia Fdn, CIEN Fdn, Alzheimer Dis Res Unit, Madrid, Spain.
RP Ksiezak-Reding, H (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.
EM hanna.reding@mssm.edu
OI Diaz-Ruiz, Carmen/0000-0002-0112-0595
FU Society for Progressive Supranuclar Palsy; NIH [PO1 AT004511]; Veterans
Administration
FX The authors gratefully acknowledge the financial support from the
Society for Progressive Supranuclar Palsy, NIH PO1 AT004511, and support
in part from MERIT Review grant from Veterans Administration to GMP.
NR 52
TC 22
Z9 25
U1 1
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUL
PY 2012
VL 33
IS 7
BP 1427
EP 1439
DI 10.1016/j.neurobiolaging.2010.11.006
PG 13
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 953GG
UT WOS:000304854300033
PM 21196065
ER
PT J
AU Bedimo, R
Kyriakides, T
Brown, S
Weidler, J
Lie, Y
Coakley, E
Holodniy, M
AF Bedimo, R.
Kyriakides, T.
Brown, S.
Weidler, J.
Lie, Y.
Coakley, E.
Holodniy, M.
TI Predictive value of HIV-1 replication capacity and phenotypic
susceptibility scores in antiretroviral treatment-experienced patients
SO HIV MEDICINE
LA English
DT Article
DE antiretroviral therapy; HIV; phenotypic susceptibility score;
replication capacity; resistance
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION;
REVERSE-TRANSCRIPTASE; RESISTANCE MUTATIONS; VIROLOGICAL FAILURE; DRUG
SUSCEPTIBILITY; INFECTED PATIENTS; CLINICAL-TRIAL; EX-VIVO; THERAPY
AB Objectives The aim of the study was to determine the prognostic value of HIV replication capacity (RC) for subsequent antiretroviral (ARV) treatment response in ARV-experienced patients. Methods RC and phenotypic resistance testing were performed at baseline and week 12 on plasma samples from patients randomized to undergo a 12-week ARV drug-free period (ARDFP) or initiate immediate salvage therapy (no-ARDFP group) in the Options in Management with Antiretrovirals (OPTIMA) trial. Dichotomous and incremental phenotypic susceptibility scores (dPSSs and iPSSs, respectively) were calculated. The predictive value of RC and PSS for ARV therapy response and/or ARDFP was evaluated using multivariate regression analysis and Pearson correlations. Results In 146 no-ARDFP subjects, baseline RC (50.8%) did not change at week 12 and was not correlated with CD4 cell count or viral load changes at week 12 (P?=?0.33 and P?=?0.79, respectively) or at week 24 (P?=?0.96 and P?=?0.14, respectively). dPSS predicted virological but not CD4 cell count response to ARV therapy at weeks 12, 24 and 48 (P?=?0.002, P?0.001 and P?=?0.005, respectively). RC was significantly correlated with dPSS and iPSS at baseline, but did not increase their predictive value. In the 137 ARDFP patients, RC increased significantly (from 52.4 to 85.8%), but did not predict CD4 cell count and viral load changes during ARDFP (P?=?0.92 and P?=?0.26, respectively). RC after ARDFP did not predict subsequent CD4 cell count and viral load changes 12 weeks following ARV treatment reinitiation (P?=?0.90 and P?=?0.29, respectively). Conclusions We found no additional predictive value of replication capacity for virological or immunological responses (above what PSS provides) in patients undergoing salvage ARV treatment.
C1 [Bedimo, R.] Univ Texas SW, Dallas, TX USA.
[Kyriakides, T.] W Haven Cooperat Studies Program Coordinating Ctr, West Haven, CT USA.
[Brown, S.] James J Peters VA Med Ctr, Bronx, NY USA.
[Brown, S.] Mt Sinai Sch Med, New York, NY USA.
[Weidler, J.; Lie, Y.; Coakley, E.] Monogram Biosci Inc, San Francisco, CA USA.
[Holodniy, M.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Holodniy, M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Bedimo, R.] Vet Affairs N Texas Hlth Care Syst, Dallas, TX USA.
RP Bedimo, R (reprint author), Dallas VAMC, 4500 S Lancaster Rd, Dallas, TX 75216 USA.
EM roger.bedimo@va.gov
RI brown, stephen/E-2085-2012
FU Department of Veterans Affairs; Monogram BioSciences Inc.
FX This study was funded by the Department of Veterans Affairs Cooperative
Studies Program and, in part, by a Department of Veterans Affairs grant
to MH, and by Monogram BioSciences Inc., who provided support for
performance of the PhenoSense (TM) and replication capacity assays.
NR 33
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
J9 HIV MED
JI HIV Med.
PD JUL
PY 2012
VL 13
IS 6
BP 345
EP 351
DI 10.1111/j.1468-1293.2011.00981.x
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 952AN
UT WOS:000304762200004
PM 22276745
ER
PT J
AU Holt, CL
Schulz, E
Williams, BR
Clark, EM
Wang, MQ
AF Holt, Cheryl L.
Schulz, Emily
Williams, Beverly R.
Clark, Eddie M.
Wang, Min Qi
TI Social, Religious and Spiritual Capital and Physical/Emotional
Functioning in a National Sample of African Americans
SO JOURNAL OF COMMUNITY & APPLIED SOCIAL PSYCHOLOGY
LA English
DT Article
DE social capital; religious capital; spiritual capital; physical
functioning; emotional functioning
ID MENTAL-HEALTH; SOCIOECONOMIC-STATUS; SUPPORT; ADULTS; RACE; RELIABILITY;
VALIDITY; INVOLVEMENT; POPULATION; BEHAVIORS
AB Spiritual and religious capital are forms of the broader construct of social capital. The present study, using probability-based sampling methods, surveyed a national sample of African American adults to examine the relative contributions of spiritual and religious capital to their physical and emotional functioning. Analyses were conducted to determine if these constructs made a unique contribution above and beyond general social capital. African American men and women (N?=?803) were interviewed by telephone. Hierarchical linear regressions revealed that, across the full sample, although social capital was a positive predictor of physical and emotional functioning (p?.05 and p?.001), neither religious nor spiritual capital made an additional contribution to these outcomes. However, the relationships among these variables differed for men and women. Among men, social capital predicted positive emotional functioning (p?.001) but not physical functioning; spiritual and religious capital made no additional contribution to either outcome variable. Among women, social capital predicted positive emotional functioning (p?.01) but not physical functioning. However, religious capital did make a significant additional contribution to the prediction of emotional functioning (?R2, p?.01). Dividing the sample into different age groups did not produce any different findings from those found with the sample as a whole. Findings are discussed in terms of implications for church- and faith-based health promotion interventions aimed at health disparities reduction. Copyright (c) 2011 John Wiley & Sons, Ltd.
C1 [Holt, Cheryl L.; Wang, Min Qi] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA.
[Schulz, Emily] Arizona Sch Hlth Sci, Dept Occupat Therapy, Mesa, AZ USA.
[Williams, Beverly R.] Birmingham VA Med Ctr, Dept Med, Div Gerontol Geriatr Palliat Care, Birmingham, AL USA.
[Williams, Beverly R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Clark, Eddie M.] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA.
RP Holt, CL (reprint author), Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, 2369 Publ Hlth Bldg 255, College Pk, MD 20742 USA.
EM cholt14@umd.edu
NR 47
TC 5
Z9 5
U1 1
U2 10
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1052-9284
J9 J COMMUNITY APPL SOC
JI J. Community Appl. Soc. Psychol.
PD JUL-AUG
PY 2012
VL 22
IS 4
BP 346
EP 362
DI 10.1002/casp.1116
PG 17
WC Psychology, Social
SC Psychology
GA 942KX
UT WOS:000304044000005
ER
PT J
AU Che, AM
Gomez, RG
Keller, J
Lembke, A
Tennakoon, L
Cohen, GH
Schatzberg, AF
AF Che, Andrea M.
Gomez, Rowena G.
Keller, Jennifer
Lembke, Anna
Tennakoon, Lakshika
Cohen, Gregory H.
Schatzberg, Alan F.
TI The relationships of positive and negative symptoms with
neuropsychological functioning and their ability to predict verbal
memory in psychotic major depression
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Mood disorders; Cognition; Neuropsychology
ID WORKING-MEMORY; 1ST-EPISODE SCHIZOPHRENIA; NONPSYCHOTIC DEPRESSION;
COGNITIVE FUNCTION; RATING-SCALES; DEFICITS; FEATURES; METAANALYSIS;
IMPAIRMENT; DISORDERS
AB Neuropsychological functioning, in relation to positive and negative symptoms in psychotic major depression (PMD), has not been as thoroughly studied as it has been in schizophrenia. Thus, the current study investigated the associations between positive and negative symptoms with cognitive functioning, with an emphasis on verbal memory in PMD. Attention, working memory, and the executive functioning domains were analyzed among 49 PMD participants. Positive symptoms did not correlate significantly with any measures of verbal memory but did correlate with one measure of attention, working memory, and executive functioning. Negative symptoms correlated significantly with two California Verbal Learning Test-II (CVLT-II) measures of verbal memory and three measures of executive function. Hierarchical regressions were conducted to determine if negative symptoms could predict verbal memory performance after controlling for depression. Of the two verbal memory measures, negative symptoms significantly explained additional variance for CVLT Recognition, but not for CVLT Trials 1-5 total score. Our results provide some evidence that, consistent with the schizophrenia literature, negative symptoms contributed more to verbal memory deficits in PMD than positive symptoms, regardless of depression severity. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Che, Andrea M.; Gomez, Rowena G.] Palo Alto Univ, Pacific Grad Sch Psychol, Palo Alto, CA 94304 USA.
[Gomez, Rowena G.; Keller, Jennifer; Lembke, Anna; Tennakoon, Lakshika; Schatzberg, Alan F.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Cohen, Gregory H.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
RP Gomez, RG (reprint author), Palo Alto Univ, Pacific Grad Sch Psychol, 1791 Arastradero Rd, Palo Alto, CA 94304 USA.
EM rgomez@paloaltou.edu
NR 40
TC 2
Z9 2
U1 2
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD JUN 30
PY 2012
VL 198
IS 1
BP 34
EP 38
DI 10.1016/j.psychres.2011.12.001
PG 5
WC Psychiatry
SC Psychiatry
GA 074XK
UT WOS:000313848200007
PM 22410589
ER
PT J
AU Erickson, MA
Hartvigson, PE
Morofuji, Y
Owen, JB
Butterfield, DA
Banks, WA
AF Erickson, Michelle A.
Hartvigson, Pehr E.
Morofuji, Yoichi
Owen, Joshua B.
Butterfield, D. Allan
Banks, William A.
TI Lipopolysaccharide impairs amyloid beta efflux from brain: altered
vascular sequestration, cerebrospinal fluid reabsorption, peripheral
clearance and transporter function at the blood-brain barrier
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Alzheimer's disease; amyloid beta; blood-brain barrier; inflammation;
lipopolysaccharide; LRP1; Pgp; ABCB1; MDR1; cerebrospinal fluid
ID RECEPTOR-RELATED PROTEIN-1; GLYCATION-END-PRODUCTS;
CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; P-GLYCOPROTEIN; IN-VITRO;
PRECURSOR PROTEIN; OXIDATIVE STRESS; MOUSE MODEL; COGNITIVE IMPAIRMENT
AB Background: Defects in the low density lipoprotein receptor related protein-1 (LRP-1) and p-glycoprotein (Pgp) clearance of amyloid beta (A beta) from brain are thought to contribute to Alzheimer's disease (AD). We have recently shown that induction of systemic inflammation by lipopolysaccharide (LPS) results in impaired efflux of A beta from the brain. The same treatment also impairs Pgp function. Here, our aim is to determine which physiological routes of A beta clearance are affected following systemic inflammation, including those relying on LRP-1 and Pgp function at the blood-brain barrier.
Methods: CD-1 mice aged between 6 and 8 weeks were treated with 3 intraperitoneal injections of 3 mg/kg LPS at 0, 6, and 24 hours and studied at 28 hours. I-125-A beta(1-42) or I-125-alpha-2-macroglobulin injected into the lateral ventricle of the brain (intracerebroventricular (ICV)) or into the jugular vein (intravenous (IV)) was used to quantify LRP-1-dependent partitioning between the brain vasculature and parenchyma and peripheral clearance, respectively. Disappearance of ICV-injected C-14-inulin from brain was measured to quantify bulk flow of cerebrospinal fluid (CSF). Brain microvascular protein expression of LRP-1 and Pgp was measured by immunoblotting. Endothelial cell localization of LRP-1 was measured by immunofluorescence microscopy. Oxidative modifications to LRP-1 at the brain microvasculature were measured by immunoprecipitation of LRP-1 followed by immunoblotting for 4-hydroxynonenal and 3-nitrotyrosine.
Results: We found that LPS: caused an LRP-1-dependent redistribution of ICV-injected A beta from brain parenchyma to brain vasculature and decreased entry into blood; impaired peripheral clearance of IV-injected A beta; inhibited reabsorption of CSF; did not significantly alter brain microvascular protein levels of LRP-1 or Pgp, or oxidative modifications to LRP-1; and downregulated LRP-1 protein levels and caused LRP-1 mislocalization in cultured brain endothelial cells.
Conclusions: These results suggest that LRP-1 undergoes complex functional regulation following systemic inflammation which may depend on cell type, subcellular location, and post-translational modifications. Our findings that systemic inflammation causes deficits in both A beta transport and bulk flow like those observed in AD indicate that inflammation could induce and promote the disease.
C1 [Erickson, Michelle A.; Hartvigson, Pehr E.; Morofuji, Yoichi; Owen, Joshua B.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA.
[Morofuji, Yoichi; Owen, Joshua B.; Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA.
[Butterfield, D. Allan] Univ Kentucky, Dept Chem, Ctr Membrane Sci & Sander Brown Ctr Aging, Lexington, KY 40506 USA.
[Erickson, Michelle A.] St Louis Univ, Dept Pharmacol & Physiol, St Louis, MO 63104 USA.
RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, GRECC, 1600 S Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@uw.edu
FU NIGMS [5T32GM008306-20]; NIH [AG-029839]
FX We would like to thank Dr Guojun Bu for providing technical advice on
the immunodetection of LRP-1. This project was funded by NIGMS
5T32GM008306-20 and NIH AG-029839.
NR 70
TC 37
Z9 37
U1 1
U2 18
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JUN 29
PY 2012
VL 9
AR 150
DI 10.1186/1742-2094-9-150
PG 15
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 986ST
UT WOS:000307365600001
PM 22747709
ER
PT J
AU Wei, CC
Chen, YW
Powell, LC
Zheng, JY
Shi, K
Bradley, WE
Powell, PC
Ahmad, S
Ferrario, CM
Dell'Italia, LJ
AF Wei, Chih-Chang
Chen, Yuanwen
Powell, Lindsay C.
Zheng, Junying
Shi, Ke
Bradley, Wayne E.
Powell, Pamela C.
Ahmad, Sarfaraz
Ferrario, Carlos M.
Dell'Italia, Louis J.
TI Cardiac Kallikrein-Kinin System Is Upregulated in Chronic Volume
Overload and Mediates an Inflammatory Induced Collagen Loss
SO PLOS ONE
LA English
DT Article
ID MAST-CELL CHYMASE; HEART-FAILURE; MATRIX-METALLOPROTEINASE;
PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; GENE-EXPRESSION;
NITRIC-OXIDE; BRADYKININ; RATS; RECEPTOR
AB Background: The clinical problem of a "pure volume overload'' as in isolated mitral or aortic regurgitation currently has no documented medical therapy that attenuates collagen loss and the resultant left ventricular (LV) dilatation and failure. Here, we identify a potential mechanism related to upregulation of the kallikrein - kinin system in the volume overload of aortocaval fistula (ACF) in the rat.
Methodology/Principal Findings: LV interstitial fluid (ISF) collection, hemodynamics, and echocardiography were performed in age - matched shams and 4 and 15 wk ACF rats. ACF rats had LV dilatation and a 2 - fold increase in LV end-diastolic pressure, along with increases in LV ISF bradykinin, myocardial kallikrein and bradykinin type - 2 receptor (BK2R) mRNA expression. Mast cell numbers were increased and interstitial collagen was decreased at 4 and 15 wk ACF, despite increases in LV ACE and chymase activities. Treatment with the kallikrein inhibitor aprotinin preserved interstitial collagen, prevented the increase in mast cells, and improved LV systolic function at 4 wk ACF. To establish a cause and effect between ISF bradykinin and mast cell - mediated collagen loss, direct LV interstitial bradykinin infusion in vivo for 24 hrs produced a 2 - fold increase in mast cell numbers and a 30% decrease in interstitial collagen, which were prevented by BK2R antagonist. To further connect myocardial stretch with cellular kallikrein - kinin system upregulation, 24 hrs cyclic stretch of adult cardiomyocytes and fibroblasts produced increased kallikrein, BK2R mRNA expressions, bradykinin protein and gelatinase activity, which were all decreased by the kallikrein inhibitor - aprotinin.
Conclusions/Significance: A pure volume overload is associated with upregulation of the kallikrein - kinin system and ISF bradykinin, which mediates mast cell infiltration, extracellular matrix loss, and LV dysfunction - all of which are improved by kallikrein inhibition. The current investigation provides important new insights into future potential medical therapies for the volume overload of aortic and mitral regurgitation.
C1 [Wei, Chih-Chang; Dell'Italia, Louis J.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Wei, Chih-Chang; Powell, Lindsay C.; Zheng, Junying; Shi, Ke; Bradley, Wayne E.; Powell, Pamela C.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
[Chen, Yuanwen] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China.
[Ahmad, Sarfaraz; Ferrario, Carlos M.] Wake Forest Univ, Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27109 USA.
RP Wei, CC (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
EM chih@uab.edu
FU American Heart Association [0130306N]; Department of Veteran Affairs
[84781]; National Institutes of Health for the SCCOR (Specialized
Centers of Clinically Oriented Research) in Cardiac Dysfunction
[P50-HL077100]
FX This work was supported by the American Heart Association for National
Scientist Development Grant Program [Grant 0130306N to CCW], by the
Department of Veteran Affairs for Merit Review [Grant 84781 to CCW], and
by the National Institutes of Health for the SCCOR (Specialized Centers
of Clinically Oriented Research) in Cardiac Dysfunction [Grant
P50-HL077100 to LJD]. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 35
TC 18
Z9 18
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 29
PY 2012
VL 7
IS 6
AR e40110
DI 10.1371/journal.pone.0040110
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 967FO
UT WOS:000305892100207
PM 22768235
ER
PT J
AU Gold, PW
Pavlatou, MG
Carlson, PJ
Luckenbaugh, DA
Costello, R
Bonne, O
Csako, G
Drevets, WC
Remaley, AT
Charney, DS
Neumeister, A
Kling, MA
AF Gold, Philip W.
Pavlatou, Maria G.
Carlson, Paul J.
Luckenbaugh, David A.
Costello, Rene
Bonne, Omer
Csako, Gyorgy
Drevets, Wayne C.
Remaley, Alan T.
Charney, Dennis S.
Neumeister, Alexander
Kling, Mitchel A.
TI Unmedicated, remitted patients with major depression have decreased
serum immunoglobulin A
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Major depression; Immunoglobulin IgA; Proinflammatory state
ID IGA DEFICIENCY; BODY-COMPOSITION; DISEASE; CELLS; INTERLEUKIN-6;
CYTOKINES; DISORDER; CHILDREN; IMMUNITY; MARKERS
AB Patents with major depression have evidence of a proinflammatory state with consistent elevations in acute phase proteins and in the levels of inflammatory mediators such as interleukin-6 and tumor necrosis factor-alpha. We report here a study of the serum levels of immunoglobulin A (IgA) in medication-free patients with major depression in the remitted state (ruMDD). Selective IgA deficiency is the most common form of immunoglobulin abnormality, and is often associated with a higher than expected incidence of proinflammatory and autoimmune phenomena. We measured serum IgG, IgM, and IgA in 28 ruMDD patients and 27 healthy subjects (Ctrl) at 0 (pretreatment), 7, and 24 h following sham depletion and tryptophan (TrpD) depletion conducted at least 8 days apart under balanced, randomized, blinded conditions. Immunoglobulins were measured by automated immunonephelometry. Data were analyzed by repeated measures ANOVA with diagnosis as a fixed effect and drug (TrpD vs. sham), and time as repeated measures factors. Serum IgA was consistently lower in ruMDD patients vs. Ctrl at all time points examined (p < 0.04 for main effect of diagnosis). Serum IgG and IgM levels did not show significant differences by diagnosis. Medication-free patients with major depression in the remitted state have a significant reduction in serum IgA levels measured on multiple occasions. In the light of the fact that IgA serves many immunomodulatory, anti-inflammatory roles, this finding supports the concept that major depressive illness represents a proinflammatory state. Published by Elsevier Ireland Ltd.
C1 [Gold, Philip W.; Pavlatou, Maria G.; Kling, Mitchel A.] NIMH, Clin Neuroendocrinol Branch, NIH, Bethesda, MD 20892 USA.
[Carlson, Paul J.] Univ Utah, Dept Psychiat, Sch Med, Salt Lake City, UT 84132 USA.
[Carlson, Paul J.] Salt Lake VA Med Ctr, Salt Lake City, UT 84132 USA.
[Luckenbaugh, David A.] NIMH, Expt Therapeut & Pathophysiol Branch, NIH, Bethesda, MD 20892 USA.
[Costello, Rene; Csako, Gyorgy; Remaley, Alan T.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA.
[Bonne, Omer] Hadassah Hebrew Univ Med Ctr, Dept Psychiat, IL-91120 Jerusalem, Israel.
[Drevets, Wayne C.] Laureate Inst Brain Res, Tulsa, OK 74136 USA.
[Charney, Dennis S.] Mt Sinai Sch Med, Off Dean, New York, NY 10029 USA.
[Neumeister, Alexander] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Kling, Mitchel A.] Philadelphia VA Med Ctr, Behav Hlth Serv, Philadelphia, PA USA.
[Kling, Mitchel A.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
RP Gold, PW (reprint author), NIMH, Clin Neuroendocrinol Branch, NIH, Bldg 10-2D-46-12824,10 Ctr Dr, Bethesda, MD 20892 USA.
EM philipgold@mail.nih.gov; pavlatom@mail.nih.gov;
paul.carlson@hsc.utah.edu; luckenbd@mail.nih.gov;
rcostello@mail.nih.gov; BONNE@hadassah.org.il; LMCSJ@aol.com;
wdrevets@laureateinstitute.org; aremaley1@cc.nih.gov;
dennis.charney@mssm.edu; alexander.neumeister@mssm.edu;
Mitchel.Kling@uphs.upenn.edu
OI Kling, Mitchel/0000-0002-2232-1409
FU NIMH DIRP
FX Dr. Philip W. Gold, Dr. Maria G. Pavlatou, Dr. Paul J. Carlson, Dr.
David A. Luckenbaughc, Mr. Rene Costello, Dr. Omer Bonne, Dr.
Gyorgy Csako, Dr. Alan Remaley, Dr. Alexander Neumeister, and Dr.
Mitchel A. King have no conflicts to disclose. Dr. Wayne C. Drevets has
reported that the research support for this project was provided
entirely by the NIMH DIRP. Although Dr. Drevets has no financial
conflicts that are relevant to the subject matter of the manuscript,
during the past two years he has served as a consultant for the
following companies: Pfizer, Eisai, Rules Based Medicine, Johnson and
Johnson. Dr. Drevets also is named as co-inventor for a Use Patent filed
by the NIMH for Scopolamine in the Treatment of Depression. Dr. Dennis
S. Charney has reported that he and Mount Sinai School of Medicine have
been named on a use patent of Ketamine for the treatment of depression.
If Ketamine were shown to be effective in the treatment of depression
and received approval from the Food and Drug Administration (FDA) for
this indication, Dr. Charney and Mount Sinai School of Medicine could
benefit financially. Dr. Charney has also disclosed that he is not
currently engaged in any consulting activity and has had no activity for
the past three years.
NR 32
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JUN 27
PY 2012
VL 520
IS 1
BP 1
EP 5
DI 10.1016/j.neulet.2012.04.072
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 969AE
UT WOS:000306027300001
PM 22579817
ER
PT J
AU Pietrzak, RH
Tracy, M
Galea, S
Kilpatrick, DG
Ruggiero, KJ
Hamblen, JL
Southwick, SM
Norris, FH
AF Pietrzak, Robert H.
Tracy, Melissa
Galea, Sandro
Kilpatrick, Dean G.
Ruggiero, Kenneth J.
Hamblen, Jessica L.
Southwick, Steven M.
Norris, Fran H.
TI Resilience in the Face of Disaster: Prevalence and Longitudinal Course
of Mental Disorders following Hurricane Ike
SO PLOS ONE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHIATRIC INTERVIEW MINI; NATIONAL
COMORBIDITY SURVEY; INTIMATE PARTNER VIOLENCE; MASS TRAUMATIC EVENT; IV
ALCOHOL-ABUSE; DSM-IV; PTSD CHECKLIST; PSYCHOLOGICAL RESILIENCE;
PSYCHOMETRIC PROPERTIES
AB Objectives: Natural disasters may increase risk for a broad range of psychiatric disorders, both in the short-and in the medium-term. We sought to determine the prevalence and longitudinal course of posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), panic disorder (PD), depression, and suicidality in the first 18 months after Hurricane Ike.
Methods: Six hundred fifty-eight adults representative of Galveston and Chambers Counties, Texas participated in a random, population-based survey. The initial assessment was conducted 2 to 5 months after Hurricane Ike struck Galveston Bay on September 13, 2008. Follow-up assessments were conducted at 5 to 9 and 14 to 18 months after Hurricane Ike.
Results: Past-month prevalence of any mental disorder (20.6% to 10.9%) and hurricane-related PTSD (6.9% to 2.5%) decreased over time. Past-month prevalence of PTSD related to a non-disaster traumatic event (5.8% to 7.1%), GAD (3.1% to 1.8%), PD (0.8% to 0.7%), depression (5.0% to 5.6%), and suicidality (2.6% to 4.2%) remained relatively stable over time.
Conclusions: PTSD, both due to the hurricane and due to other traumatic events, was the most prevalent psychiatric disorder 2 to 5 months after Hurricane Ike. Prevalence of psychiatric disorders declined rapidly over time, suggesting that the vast majority of individuals exposed to this natural disaster 'bounced back' and were resilient to long-term mental health consequences of this large-scale traumatic event.
C1 [Pietrzak, Robert H.; Southwick, Steven M.] Vet Affairs Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA.
[Pietrzak, Robert H.; Southwick, Steven M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Pietrzak, Robert H.; Tracy, Melissa; Galea, Sandro; Kilpatrick, Dean G.; Ruggiero, Kenneth J.; Hamblen, Jessica L.; Southwick, Steven M.; Norris, Fran H.] Natl Ctr Disaster Mental Hlth Res, White River Jct, VT USA.
[Tracy, Melissa; Galea, Sandro] Columbia Univ, Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Kilpatrick, Dean G.; Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Kilpatrick, Dean G.; Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Hamblen, Jessica L.; Norris, Fran H.] White River Junct Vet Affairs Med Ctr, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA.
[Norris, Fran H.] Geisel Sch Med Dartmouth, Hanover, NH USA.
RP Pietrzak, RH (reprint author), Vet Affairs Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA.
EM robert.pietrzak@yale.edu
FU National Center for Disaster Mental Health Research (National Institute
of Mental Health) [5 P60 MH082598]; National Center for Posttraumatic
Stress Disorder; Claude D. Pepper Older Americans Independence Center at
Yale University School of Medicine (NIA) [P30AG21342]
FX This research was supported by the National Center for Disaster Mental
Health Research (National Institute of Mental Health Grant 5 P60
MH082598), Fran H. Norris, Center Director, Sandro Galea, Research
Director. Preparation of this report was supported in part by the
National Center for Posttraumatic Stress Disorder and a Research Career
Development Award to Dr. Pietrzak from the Claude D. Pepper Older
Americans Independence Center at Yale University School of Medicine (NIA
Grant P30AG21342). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 61
TC 23
Z9 23
U1 8
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2012
VL 7
IS 6
AR e38964
DI 10.1371/journal.pone.0038964
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 966AK
UT WOS:000305808700014
PM 22761716
ER
PT J
AU Dohgu, S
Ryerse, JS
Robinson, SM
Banks, WA
AF Dohgu, Shinya
Ryerse, Jan S.
Robinson, Sandra M.
Banks, William A.
TI Human Immunodeficiency Virus-1 Uses the Mannose-6-Phosphate Receptor to
Cross the Blood-Brain Barrier
SO PLOS ONE
LA English
DT Article
ID MANNOSE 6-PHOSPHATE RECEPTOR; ENVELOPE GLYCOPROTEIN GP120;
LYSOSOMAL-ENZYME; ADSORPTIVE ENDOCYTOSIS; MEDIATED TRANSPORT;
ENDOTHELIAL-CELLS; SURFACE-PROTEINS; HIV-1 GP120; RAT-BRAIN; MOUSE
AB HIV-1 circulates both as free virus and within immune cells, with the level of free virus being predictive of clinical course. Both forms of HIV-1 cross the blood-brain barrier (BBB) and much progress has been made in understanding the mechanisms by which infected immune cells cross the blood-brain barrier BBB. How HIV-1 as free virus crosses the BBB is less clear as brain endothelial cells are CD4 and galactosylceramide negative. Here, we found that HIV-1 can use the mannose-6 phosphate receptor (M6PR) to cross the BBB. Brain perfusion studies showed that HIV-1 crossed the BBB of all brain regions consistent with the uniform distribution of M6PR. Ultrastructural studies showed HIV-1 crossed by a transcytotic pathway consistent with transport by M6PR. An in vitro model of the BBB was used to show that transport of HIV-1 was inhibited by mannose, mannan, and mannose-6 phosphate and that enzymatic removal of high mannose oligosaccharide residues from HIV-1 reduced transport. Wheatgerm agglutinin and protamine sulfate, substances known to greatly increase transcytosis of HIV-1 across the BBB in vivo, were shown to be active in the in vitro model and to act through a mannose-dependent mechanism. Transport was also cAMP and calcium-dependent, the latter suggesting that the cation-dependent member of the M6PR family mediates HIV-1 transport across the BBB. We conclude that M6PR is an important receptor used by HIV-1 to cross the BBB.
C1 [Dohgu, Shinya] Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Fukuoka 81401, Japan.
[Ryerse, Jan S.] St Louis Univ, Hlth Sci Ctr, Dept Pathol, St Louis, MO 63103 USA.
[Robinson, Sandra M.] St Louis Univ, Sch Med, Div Geriatr Med, Dept Internal Med, St Louis, MO 63104 USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Dohgu, S (reprint author), Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, 8-19-1 Nanakuma, Fukuoka 81401, Japan.
EM wabanks1@u.washington.edu
FU Veterans Affairs merit review; National Institutes of Health [RO-1
AG029839]
FX The funders were Veterans Affairs merit review
(http://www.research.va.gov/programs/csrd/merit_review.cfm) and National
Institutes of Health RO-1 AG029839. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 49
TC 14
Z9 14
U1 2
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2012
VL 7
IS 6
AR e39565
DI 10.1371/journal.pone.0039565
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 965QG
UT WOS:000305781700049
PM 22761827
ER
PT J
AU Jutras-Aswad, D
Jacobs, MM
Yiannoulos, G
Roussos, P
Bitsios, P
Nomura, Y
Liu, X
Hurd, YL
AF Jutras-Aswad, Didier
Jacobs, Michelle M.
Yiannoulos, Georgia
Roussos, Panos
Bitsios, Panos
Nomura, Yoko
Liu, Xun
Hurd, Yasmin L.
TI Cannabis-Dependence Risk Relates to Synergism between Neuroticism and
Proenkephalin SNPs Associated with Amygdala Gene Expression:
Case-Control Study
SO PLOS ONE
LA English
DT Article
ID POPULATION-BASED SAMPLE; STOP SIGNAL INHIBITION; D2 RECEPTOR GENE;
ENVIRONMENTAL-INFLUENCES; PRE-PROENKEPHALIN; NEGATIVE AFFECT;
WORKING-MEMORY; SUBSTANCE USE; FEMALE TWINS; DRUG-USE
AB Background: Many young people experiment with cannabis, yet only a subgroup progress to dependence suggesting individual differences that could relate to factors such as genetics and behavioral traits. Dopamine receptor D2 (DRD2) and proenkephalin (PENK) genes have been implicated in animal studies with cannabis exposure. Whether polymorphisms of these genes are associated with cannabis dependence and related behavioral traits is unknown.
Methodology/Principal Findings: Healthy young adults (18-27 years) with cannabis dependence and without a dependence diagnosis were studied (N = 50/group) in relation to a priori-determined single nucleotide polymorphisms (SNPs) of the DRD2 and PENK genes. Negative affect, Impulsive Risk Taking and Neuroticism-Anxiety temperamental traits, positive and negative reward-learning performance and stop-signal reaction times were examined. The findings replicated the known association between the rs6277 DRD2 SNP and decisions associated with negative reinforcement outcomes. Moreover, PENK variants (rs2576573 and rs2609997) significantly related to Neuroticism and cannabis dependence. Cigarette smoking is common in cannabis users, but it was not associated to PENK SNPs as also validated in another cohort (N = 247 smokers, N = 312 non-smokers). Neuroticism mediated (15.3%-19.5%) the genetic risk to cannabis dependence and interacted with risk SNPs, resulting in a 9-fold increase risk for cannabis dependence. Molecular characterization of the postmortem human brain in a different population revealed an association between PENK SNPs and PENK mRNA expression in the central amygdala nucleus emphasizing the functional relevance of the SNPs in a brain region strongly linked to negative affect.
Conclusions/Significance: Overall, the findings suggest an important role for Neuroticism as an endophenotype linking PENK polymorphisms to cannabis-dependence vulnerability synergistically amplifying the apparent genetic risk.
C1 [Jutras-Aswad, Didier; Jacobs, Michelle M.; Yiannoulos, Georgia; Roussos, Panos; Nomura, Yoko; Liu, Xun; Hurd, Yasmin L.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Jacobs, Michelle M.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY USA.
[Bitsios, Panos; Hurd, Yasmin L.] Univ Crete, Fac Med, Dept Psychiat & Behav Sci, Iraklion, Crete, Greece.
[Liu, Xun] Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China.
[Nomura, Yoko] Queens Coll, Dept Psychol, Queens, NY USA.
[Hurd, Yasmin L.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA.
[Hurd, Yasmin L.] James J Peters VA Med Ctr, New York, NY USA.
RP Jutras-Aswad, D (reprint author), Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada.
EM Yasmin.hurd@mssm.edu
RI Liu, Xun/C-2400-2009; Roussos, Panos/J-7090-2013
OI Liu, Xun/0000-0003-1366-8926; Roussos, Panos/0000-0002-4640-6239
FU Mount Sinai School of Medicine Fund; Centre Hospitalier de l'Universite
de Montreal Research Fellowship Award; National Institutes of Health
[DA15446, T32 DA007135]
FX This research was supported by Mount Sinai School of Medicine Fund
(YLH), Centre Hospitalier de l'Universite de Montreal Research
Fellowship Award (DJA) and National Institutes of Health [DA15446 (YLH),
T32 DA007135 (MMJ)]. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 40
TC 15
Z9 16
U1 3
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2012
VL 7
IS 6
AR e39243
DI 10.1371/journal.pone.0039243
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 964XV
UT WOS:000305730900038
PM 22745721
ER
PT J
AU Elvington, M
Huang, YX
Morgan, BP
Qiao, F
van Rooijen, N
Atkinson, C
Tomlinson, S
AF Elvington, Michelle
Huang, Yuxiang
Morgan, B. Paul
Qiao, Fei
van Rooijen, Nico
Atkinson, Carl
Tomlinson, Stephen
TI Atargeted complement-dependent strategy to improve the outcome of mAb
therapy, and characterization in a murine model of metastatic cancer
SO BLOOD
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; CD20 MONOCLONAL-ANTIBODIES;
DECAY-ACCELERATING FACTOR; IN-VIVO; TUMOR-CELLS; INHIBITORY PROTEINS;
IMMUNE-RESPONSE; FACTOR-H; ACTIVATION; IMMUNOTHERAPY
AB Complement inhibitors expressed on tumor cells provide an evasion mechanism against mAb therapy and may modulate the development of an acquired antitumor immune response. Here we investigate a strategy to amplify mAb-targeted complement activation on a tumor cell, independent of a requirement to target and block complement inhibitor expression or function, which is difficult to achieve in vivo. We constructed a murine fusion protein, CR2Fc, and demonstrated that the protein targets to C3 activation products deposited on a tumor cell by a specific mAb, and amplifies mAb-dependent complement activation and tumor cell lysis in vitro. In syngeneic models of metastatic lymphoma (EL4) and melanoma (B16), CR2Fc significantly enhanced the outcome of mAb therapy. Subsequent studies using the EL4 model with various genetically modified mice and macrophage-depleted mice revealed that CR2Fc enhanced the therapeutic effect of mAb therapy via both macrophage-dependent Fc gamma R-mediated antibody-dependent cellular cytotoxicity, and by direct complement-mediated lysis. Complement activation products can also modulate adaptive immunity, but we found no evidence that either mAb or CR2Fc treatment had any effect on an antitumor humoral or cellular immune response. CR2Fc represents a potential adjuvant treatment to increase the effectiveness of mAb therapy of cancer. (Blood. 2012; 119(25): 6043-6051)
C1 [Elvington, Michelle; Huang, Yuxiang; Qiao, Fei; Atkinson, Carl; Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, Charleston, SC 29425 USA.
[Morgan, B. Paul] Cardiff Univ, Dept Infect Immun & Biochem, Sch Med, Cardiff, S Glam, Wales.
[van Rooijen, Nico] Free Univ Amsterdam, Dept Cell Biol & Immunol, Amsterdam, Netherlands.
[Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, 173 Ashley Ave,BSB 201, Charleston, SC 29425 USA.
EM tomlinss@musc.edu
FU National Institutes of Health [RO1CA158179]; Department of Defense
[BC061523]
FX This work was supported by the National Institutes of Health (grant
RO1CA158179, S.T.) and the Department of Defense (BC061523 fellowship,
M.E.).
NR 44
TC 12
Z9 13
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 21
PY 2012
VL 119
IS 25
BP 6043
EP 6051
DI 10.1182/blood-2011-10-383232
PG 9
WC Hematology
SC Hematology
GA 987EG
UT WOS:000307398700019
PM 22442351
ER
PT J
AU Seal, K
Krebs, E
Neylan, T
AF Seal, Karen
Krebs, Erin
Neylan, Thomas
TI Posttraumatic Stress Disorder and Opioid Use Among US Veterans Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID CHRONIC NONCANCER PAIN
C1 [Seal, Karen; Neylan, Thomas] San Francisco VA Med Ctr, San Francisco, CA USA.
[Krebs, Erin] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN USA.
RP Seal, K (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.
EM karen.seal@ucsf.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 20
PY 2012
VL 307
IS 23
BP 2485
EP 2486
DI 10.1001/jama.2012.6236
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 960MB
UT WOS:000305391400014
ER
PT J
AU Maselli, DJ
Anzueto, A
AF Maselli, Diego J.
Anzueto, Antonio
TI The need to further understand who gets hospitalized for a COPD
exacerbation
SO MULTIDISCIPLINARY RESPIRATORY MEDICINE
LA English
DT Editorial Material
ID OBSTRUCTIVE PULMONARY-DISEASE; MORTALITY; PREVENTION
C1 [Maselli, Diego J.; Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Med,Div Pulm Crit Care Med, San Antonio, TX 78229 USA.
RP Maselli, DJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Med,Div Pulm Crit Care Med, San Antonio, TX 78229 USA.
EM masellicacer@uthscsa.edu
NR 12
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2049-6958
J9 MULTIDISCIP RESP MED
JI Multidscip. Respir. Med.
PD JUN 19
PY 2012
VL 7
AR 7
DI 10.1186/2049-6958-7-7
PG 2
WC Respiratory System
SC Respiratory System
GA 984YL
UT WOS:000307229700002
PM 22958418
ER
PT J
AU Farbota, KD
Bendlin, BB
Alexander, AL
Rowley, HA
Dempsey, RJ
Johnson, SC
AF Farbota, Kimberly D.
Bendlin, Barbara B.
Alexander, Andrew L.
Rowley, Howard A.
Dempsey, Robert J.
Johnson, Sterling C.
TI Longitudinal diffusion tensor imaging and neuropsychological correlates
in traumatic brain injury patients
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE traumatic brain injury; diffusion tensor imaging; longitudinal;
neuropsychology; recovery; DTI; TBI
ID CORPUS-CALLOSUM MICROSTRUCTURE; WHITE-MATTER INTEGRITY; AXONAL INJURY;
DAMAGE; MODEL; MRI; ADOLESCENTS; ACTIVATION; PLASTICITY; FASCICULUS
AB Traumatic brain injury (TBI) often involves focal cortical injury and white matter (WM) damage that can be measured shortly after injury. Additionally, slowly evolving WM change can be observed but there is a paucity of research on the duration and spatial pattern of long-term changes several years post-injury. The current study utilized diffusion tensor imaging to identify regional WM changes in 12 TBI patients and nine healthy controls at three time points over a four year period. Neuropsychological testing was also administered to each participant at each time point. Results indicate that TBI patients exhibit longitudinal changes to WM indexed by reductions in fractional anisotropy (FA) in the corpus callosum, as well as FA increases in bilateral regions of the superior longitudinal fasciculus (SLF) and portions of the optic radiation (OR). FA changes appear to be driven by changes in radial (not axial) diffusivity, suggesting that observed longitudinal FA changes may be related to changes in myelin rather than to axons. Neuropsychological correlations indicate that regional FA values in the corpus callosum and sagittal stratum (SS) correlate with performance on finger tapping and visuomotor speed tasks (respectively) in TBI patients, and that longitudinal increases in FA in the SS, SLF, and OR correlate with improved performance on the visuomotor speed (SS) task as well as a derived measure of cognitive control (SLF, OR). The results of this study showing progressive WM deterioration for several years post-injury contribute to a growing literature supporting the hypothesis that TBI should be viewed not as an isolated incident but as a prolonged disease state. The observations of long-term neurological and functional improvement provide evidence that some ameliorative change may be occurring concurrently with progressive degeneration.
C1 [Farbota, Kimberly D.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA.
[Farbota, Kimberly D.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53705 USA.
[Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53705 USA.
[Dempsey, Robert J.] Univ Wisconsin, Dept Neurol Surg, Sch Med & Publ Hlth, Madison, WI 53705 USA.
RP Johnson, SC (reprint author), Univ Wisconsin, William S Middleton Mem VA Hosp, Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM scj@medicine.wisc.edu
OI Bendlin, Barbara/0000-0002-0580-9875
FU Department of Veterans Affairs; NIH [MH65723, AG000213]
FX This study was supported by a Merit Review Grant from the Department of
Veterans Affairs, the NIH MH65723 (SCJ), NIH AG000213 and by the
facilities and resources of the William S. Middleton Memorial Veterans
Hospital. The assistance of Lisa Newman, Amy Hawley, Donald McLaren, and
Erik Kastman is greatly appreciated. We would also like to acknowledge
the support of researchers and staff at the Waisman Center , University
of Wisconsin, Madison, where MR imaging took place . Finally, we thank
all the patients who took part in this study . The contents of this
report do not necessarily represent the views of the Department of
Veterans Affairs or the United States Government.
NR 59
TC 34
Z9 36
U1 1
U2 14
PU FRONTIERS RES FOUND
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD JUN 19
PY 2012
VL 6
AR 160
DI 10.3389/fnhum.2012.00160
PG 15
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA 965SK
UT WOS:000305787400001
PM 22723773
ER
PT J
AU Adachi, MS
Taylor, AB
Hart, PJ
Fitzpatrick, PF
AF Adachi, Mariya S.
Taylor, Alexander B.
Hart, P. John
Fitzpatrick, Paul F.
TI Mechanistic and Structural Analyses of the Role of His67 in the Yeast
Polyarnine Oxidase Fmsl
SO BIOCHEMISTRY
LA English
DT Article
ID MONOMERIC SARCOSINE OXIDASE; AMINO-ACID OXIDASE; N-METHYLTRYPTOPHAN
OXIDASE; OXYGEN ACTIVATION SITE; POLYAMINE OXIDASE;
SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; TRYPTOPHAN 2-MONOOXYGENASE;
HETEROLOGOUS EXPRESSION; KINETIC MECHANISM
AB The flavoprotein oxidase Fms1 from Saccharomyces cerevisiae catalyzes the oxidation of spermine and N-1-acetylspermine to spermidine and 3-aminopropanal or N-acetyl-3-aminopropanal. Within the active site of Fms1, His67 is positioned to form hydrogen bonds with the polyamine substrate. This residue is also conserved in other polyamine oxidases. The catalytic properties of H67Q, H67N, and H67A Fms1 have been characterized to evaluate the role of this residue in catalysis. With both spermine and N-1-acetylspermine as the amine substrate, the value of the first-order rate constant for flavin reduction decreases 2-3 orders of magnitude, with the H67Q mutation having the smallest effect and H67N the largest. The k(cat)/K-O2 value changes very little upon mutation with N-1-acetylspermine as the amine substrate and decreases only an order of magnitude with spermine. The k(cat)/K-M-pH profiles with N-1-acetylspermine are bell-shaped for all the mutants; the similarity to the profile of the wild-type enzyme rules out His67 as being responsible for either of the pK(a) values. The pH profiles for the rate constant for flavin reduction for all the mutant enzymes similarly show the same pK(a) as wild-type Fms1, about similar to 7.4; this pK(a) is assigned to the substrate N4. The k(cat)/K-O2-pH profiles for wild-type Fms1 and the H67A enzyme both show a pK(a) of about similar to 6.9; this suggests His67 is not responsible for this pH behavior. With the H67Q, H67N, and H67A enzymes the k(cat) value decreases when a single residue is protonated, as is the case with the wild-type enzyme. The structure of H67Q Fms1 has been determined at a resolution of 2.4 angstrom. The structure shows that the mutation disrupts a hydrogen bond network in the active site, suggesting that His67 is important both for direct interactions with the substrate and to maintain the overall active site structure.
C1 [Adachi, Mariya S.; Taylor, Alexander B.; Hart, P. John; Fitzpatrick, Paul F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Audie Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Fitzpatrick, PF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM fitzpatrick@biochem.uthscsa.edu
FU NIH [GM058698]; The Welch Foundation [AQ-1399, AQ1245]; National Center
for Research Resources [5P41RR015301-10]; National Institute of General
Medical Sciences from the National Institutes of Health [8 P41
GM103403-10]; U.S. DOE [DE-AC02-06CH11357]; Department of Veterans
Affairs; Veterans Health Administration; Office of Research Development;
Biomedical Laboratory Research and Development; UTHSCSA Executive
Research Committee; Cancer Therapy Research Center
FX This work was supported in part by the NIH, grant GM058698 (to P.F.F.),
and The Welch Foundation, grants AQ-1399 (to P.J.H.) and AQ1245 (to
P.F.F.). This work is based upon research conducted at the Advanced
Photon Source on the Northeastern Collaborative Access Team beamlines,
which are supported by grants from the National Center for Research
Resources (5P41RR015301-10) and the National Institute of General
Medical Sciences (8 P41 GM103403-10) from the National Institutes of
Health. Use of the Advanced Photon Source, an Office of Science User
Facility operated for the U.S. Department of Energy (DOE) Office of
Science by Argonne National Laboratory, was supported by the U.S. DOE
under Contract DE-AC02-06CH11357.; This material is based upon work
supported in part by the Department of Veterans Affairs, Veterans Health
Administration, Office of Research Development, Biomedical Laboratory
Research and Development. Support for the X-ray Crystallography Core
Laboratory by the UTHSCSA Executive Research Committee and the Cancer
Therapy Research Center is gratefully acknowledged.
NR 44
TC 4
Z9 4
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUN 19
PY 2012
VL 51
IS 24
BP 4888
EP 4897
DI 10.1021/bi300517s
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 959NZ
UT WOS:000305320800012
PM 22642831
ER
PT J
AU Abrol, R
Edderkaoui, M
Goddard, WA
Pandol, SJ
AF Abrol, Ravinder
Edderkaoui, Mouad
Goddard, William A., III
Pandol, Stephen J.
TI Molecular basis for the interplay of apoptosis and proliferation
mediated by Bcl-xL:Bim interactions in pancreatic cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Bcl-2 family; Mutagenesis; Apoptosis; Proliferation; Computational
biochemistry
ID INHIBITION; MODEL; EXPRESSION; BIOLOGY; BAX
AB A major mechanism through which cancer cells avoid apoptosis is by promoting the association of antiapoptotic members of the pro-survival Bcl-2 protein family (like Bcl-2 and Bcl-xL) with BH3 domain-only proteins (like Bim and Bid). Apoptosis and cell proliferation have been shown to be linked for many cancers but the molecular basis for this link is far from understood. We have identified the Bcl-xL:Bim protein-protein interface as a direct regulator of proliferation and apoptosis in pancreatic cancer cells. We were able to predict and subsequently verify experimentally the effect of various Bcl-xL single-point mutants (at the position A142) on binding to Bim by structural analysis and computational modeling of the inter-residue interactions at the Bcl-xL:Bim protein-protein interface. The mutants A142N, A142Q and A142Y decreased binding of Bim to Bcl-xL and A142S increased this binding. The Bcl-xL mutants, with decreased affinity for Bim, caused an increase in apoptosis and a corresponding decrease in cell proliferation. However, we could prevent these effects by introducing a small interfering RNA (siRNA) targeted at Bim. These results show a novel role played by the Bcl-xL:Bim interaction in regulating proliferation of pancreatic cancer cells at the expense of apoptosis. This study presents a physiologically relevant model of the Bcl-xL:Bim interface that can be used for rational therapeutic design for the inhibition of proliferation and cancer cell resistance to apoptosis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Abrol, Ravinder; Goddard, William A., III] CALTECH, Div Chem & Chem Engn, Mat & Proc Simulat Ctr, Pasadena, CA 91125 USA.
[Edderkaoui, Mouad; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Edderkaoui, Mouad; Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA 90073 USA.
RP Abrol, R (reprint author), CALTECH, Div Chem & Chem Engn, Mat & Proc Simulat Ctr, MC 139-74, Pasadena, CA 91125 USA.
EM abrol@wag.caltech.edu; stephen.pandol@va.gov
RI babakinejad, babak/G-2674-2012; Abrol, Ravinder/B-4980-2010
FU Department of Veterans Affairs; UCLA Center for Excellence in Pancreatic
Diseases; National Center for Complementary and Alternative Medicine [1
P01 AT003960]; National Institute on Alcohol Abuse and Alcoholism
[1K01AA019996]
FX This work was supported by the Department of Veterans Affairs and the
UCLA Center for Excellence in Pancreatic Diseases and National Center
for Complementary and Alternative Medicine (1 P01 AT003960), National
Institute on Alcohol Abuse and Alcoholism (1K01AA019996), and in part
through gifts to the Materials and Process Simulation Center at Caltech.
NR 27
TC 2
Z9 2
U1 1
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 15
PY 2012
VL 422
IS 4
BP 596
EP 601
DI 10.1016/j.bbrc.2012.05.032
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 974NU
UT WOS:000306443900012
PM 22609401
ER
PT J
AU Schepp-Berglind, J
Atkinson, C
Elvington, M
Qiao, F
Mannon, P
Tomlinson, S
AF Schepp-Berglind, Jennifer
Atkinson, Carl
Elvington, Michelle
Qiao, Fei
Mannon, Peter
Tomlinson, Stephen
TI Complement-Dependent Injury and Protection in a Murine Model of Acute
Dextran Sulfate Sodium-Induced Colitis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; DECAY-ACCELERATING FACTOR;
ULCERATIVE-COLITIS; CROHNS-DISEASE; ISCHEMIA/REPERFUSION INJURY;
ALTERNATIVE PATHWAY; ACTIVATION; EXPRESSION; EPITHELIUM; RECEPTOR
AB Complement plays a key role in the pathophysiology of many inflammatory diseases, and in this study, we investigated the role of complement in the pathogenesis of inflammatory bowel disease. Compared to wild-type mice, mice deficient in C3 or factor B were protected from acute dextran sulfate sodium (DSS)-induced colitis. C1q/mannose-binding lectin (MBL) double-deficient mice, however, exhibited more severe colitis than wild-type mice. When mice were allowed to recover after DSS treatment, all C1q/MBL-/- mice died by day 2 of recovery period, and, surprisingly, all C3(-/-) and factor B-/- mice died by day 5. Serum endotoxin levels were significantly increased in complement-deficient mice prior to death, particularly in C1q/MBL-/- mice, and antibiotic treatment prevented the lethal effect of DSS in all complement-deficient mice. In contrast to complement deficiency, targeted complement inhibition with either complement receptor 2 (CR2)-Crry (blocks all pathways at C3 activation) or CR2-factor H (blocks alternative pathway) was highly protective at treating established acute colitis. Endotoxin levels remained low in complement-inhibited mice, and complement inhibition also reduced inflammatory cytokines, leukocyte infiltration, and tissue injury while improving wound repair and mucosal healing. CR2-factor H provided more effective protection than CR2-Crry. Thus, complement has both pathogenic and protective roles in acute DSS-induced colitis, and whereas the alternative pathway appears to play a key role in tissue inflammation and injury, the classical/lectin pathway provides important protection in terms of host defense and wound repair. Targeted inhibition of the alternative pathway may represent a therapeutic modality for treating acute phases of inflammatory bowel disease. The Journal of Immunology, 2012, 188: 6309-6318.
C1 [Schepp-Berglind, Jennifer; Atkinson, Carl; Elvington, Michelle; Qiao, Fei; Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, Charleston, SC 29425 USA.
[Mannon, Peter] Univ Alabama Birmingham, Dept Gastroenterol & Hepatol, Birmingham, AL 35294 USA.
[Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Tomlinson, S (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Childrens Res Inst, Charleston, SC 29425 USA.
EM tomlinss@musc.edu
FU Crohn's and Colitis Foundation of America; National Institutes of Health
[T32 AR050958]
FX This work was supported by a grant from the Crohn's and Colitis
Foundation of America (to S.T.) and National Institutes of Health
Training Grant T32 AR050958 (to J.S.-B.).
NR 31
TC 20
Z9 21
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUN 15
PY 2012
VL 188
IS 12
BP 6309
EP 6318
DI 10.4049/jimmunol.1200553
PG 10
WC Immunology
SC Immunology
GA 956GK
UT WOS:000305077900056
PM 22566568
ER
PT J
AU Lipsky, BA
Berendt, AR
Cornia, PB
Pile, JC
Peters, EJG
Armstrong, DG
Deery, HG
Embil, JM
Joseph, WS
Karchmer, AW
Pinzur, MS
Senneville, E
AF Lipsky, Benjamin A.
Berendt, Anthony R.
Cornia, Paul B.
Pile, James C.
Peters, Edgar J. G.
Armstrong, David G.
Deery, H. Gunner
Embil, John M.
Joseph, Warren S.
Karchmer, Adolf W.
Pinzur, Michael S.
Senneville, Eric
TI 2012 Infectious Diseases Society of America Clinical Practice Guideline
for the Diagnosis and Treatment of Diabetic Foot Infections
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID GRADE; RECOMMENDATIONS; CONSENSUS
AB Foot infections are a common and serious problem in persons with diabetes. Diabetic foot infections (DFIs) typically begin in a wound, most often a neuropathic ulceration. While all wounds are colonized with microorganisms, the presence of infection is defined by >= 2 classic findings of inflammation or purulence. Infections are then classified into mild (superficial and limited in size and depth), moderate (deeper or more extensive), or severe (accompanied by systemic signs or metabolic perturbations). This classification system, along with a vascular assessment, helps determine which patients should be hospitalized, which may require special imaging procedures or surgical interventions, and which will require amputation. Most DFIs are polymicrobial, with aerobic gram-positive cocci (GPC), and especially staphylococci, the most common causative organisms. Aerobic gram-negative bacilli are frequently copathogens in infections that are chronic or follow antibiotic treatment, and obligate anaerobes may be copathogens in ischemic or necrotic wounds.
Wounds without evidence of soft tissue or bone infection do not require antibiotic therapy. For infected wounds, obtain a post-debridement specimen (preferably of tissue) for aerobic and anaerobic culture. Empiric antibiotic therapy can be narrowly targeted at GPC in many acutely infected patients, but those at risk for infection with antibiotic-resistant organisms or with chronic, previously treated, or severe infections usually require broader spectrum regimens. Imaging is helpful in most DFIs; plain radiographs may be sufficient, but magnetic resonance imaging is far more sensitive and specific. Osteomyelitis occurs in many diabetic patients with a foot wound and can be difficult to diagnose (optimally defined by bone culture and histology) and treat (often requiring surgical debridement or resection, and/or prolonged antibiotic therapy). Most DFIs require some surgical intervention, ranging from minor (debridement) to major (resection, amputation). Wounds must also be properly dressed and off-loaded of pressure, and patients need regular follow-up. An ischemic foot may require revascularization, and some nonresponding patients may benefit from selected adjunctive measures. Employing multidisciplinary foot teams improves outcomes. Clinicians and healthcare organizations should attempt to monitor, and thereby improve, their outcomes and processes in caring for DFIs.
C1 [Lipsky, Benjamin A.; Cornia, Paul B.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.
[Berendt, Anthony R.] Oxford Univ Hosp NHS Trust, Nuffield Orthopaed Ctr, Bone Infect Unit, Oxford, England.
[Pile, James C.] Metrohlth Med Ctr, Div Hosp Med, Cleveland, OH USA.
[Pile, James C.] Metrohlth Med Ctr, Div Infect Dis, Cleveland, OH USA.
[Peters, Edgar J. G.] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Amsterdam, Netherlands.
[Armstrong, David G.] Univ Arizona, Dept Surg, So Arizona Limb Salvage Alliance, Tucson, AZ USA.
[Deery, H. Gunner] No Michigan Infect Dis, Petoskey, MI USA.
[Embil, John M.] Univ Manitoba, Dept Med, Winnipeg, MB, Canada.
[Joseph, Warren S.] Roxborough Mem Hosp, Dept Surg, Div Podiatr Surg, Philadelphia, PA USA.
[Karchmer, Adolf W.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis,Dept Med, Boston, MA 02215 USA.
[Pinzur, Michael S.] Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA.
[Senneville, Eric] Dron Hosp, Dept Infect Dis, Tourcoing, France.
RP Lipsky, BA (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM balipsky@uw.edu
RI Peters, Edgar /B-7790-2014
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Infectious Diseases Society of America
FX Support for these guidelines was provided by the Infectious Diseases
Society of America.
NR 6
TC 32
Z9 38
U1 0
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2012
VL 54
IS 12
BP 1679
EP 1684
DI 10.1093/cid/cis460
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 948YT
UT WOS:000304541000007
PM 22619239
ER
PT J
AU Lipsky, BA
Berendt, AR
Cornia, PB
Pile, JC
Peters, EJG
Armstrong, DG
Deery, HG
Embil, JM
Joseph, WS
Karchmer, AW
Pinzur, MS
Senneville, E
AF Lipsky, Benjamin A.
Berendt, Anthony R.
Cornia, Paul B.
Pile, James C.
Peters, Edgar J. G.
Armstrong, David G.
Deery, H. Gunner
Embil, John M.
Joseph, Warren S.
Karchmer, Adolf W.
Pinzur, Michael S.
Senneville, Eric
TI 2012 Infectious Diseases Society of America Clinical Practice Guideline
for the Diagnosis and Treatment of Diabetic Foot Infections
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; COLONY-STIMULATING FACTOR;
SKIN-STRUCTURE INFECTIONS; PERIPHERAL ARTERIAL-DISEASE; TO-BONE TEST;
PRESSURE WOUND THERAPY; RANDOMIZED CONTROLLED-TRIAL; LOWER-EXTREMITY
INFECTIONS; HYPERBARIC-OXYGEN THERAPY; COMPLICATED SKIN
AB Foot infections are a common and serious problem in persons with diabetes. Diabetic foot infections (DFIs) typically begin in a wound, most often a neuropathic ulceration. While all wounds are colonized with microorganisms, the presence of infection is defined by >= 2 classic findings of inflammation or purulence. Infections are then classified into mild (superficial and limited in size and depth), moderate (deeper or more extensive), or severe (accompanied by systemic signs or metabolic perturbations). This classification system, along with a vascular assessment, helps determine which patients should be hospitalized, which may require special imaging procedures or surgical interventions, and which will require amputation. Most DFIs are polymicrobial, with aerobic gram-positive cocci (GPC), and especially staphylococci, the most common causative organisms. Aerobic gram-negative bacilli are frequently copathogens in infections that are chronic or follow antibiotic treatment, and obligate anaerobes may be copathogens in ischemic or necrotic wounds.
Wounds without evidence of soft tissue or bone infection do not require antibiotic therapy. For infected wounds, obtain a post-debridement specimen (preferably of tissue) for aerobic and anaerobic culture. Empiric antibiotic therapy can be narrowly targeted at GPC in many acutely infected patients, but those at risk for infection with antibiotic-resistant organisms or with chronic, previously treated, or severe infections usually require broader spectrum regimens. Imaging is helpful in most DFIs; plain radiographs may be sufficient, but magnetic resonance imaging is far more sensitive and specific. Osteomyelitis occurs in many diabetic patients with a foot wound and can be difficult to diagnose (optimally defined by bone culture and histology) and treat (often requiring surgical debridement or resection, and/or prolonged antibiotic therapy). Most DFIs require some surgical intervention, ranging from minor (debridement) to major (resection, amputation). Wounds must also be properly dressed and off-loaded of pressure, and patients need regular follow-up. An ischemic foot may require revascularization, and some nonresponding patients may benefit from selected adjunctive measures. Employing multidisciplinary foot teams improves outcomes. Clinicians and healthcare organizations should attempt to monitor, and thereby improve, their outcomes and processes in caring for DFIs.
C1 [Lipsky, Benjamin A.; Cornia, Paul B.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA.
[Berendt, Anthony R.] Oxford Univ Hosp NHS Trust, Nuffield Orthopaed Ctr, Bone Infect Unit, Oxford, England.
[Pile, James C.] Metrohlth Med Ctr, Div Hosp Med, Cleveland, OH USA.
[Pile, James C.] Metrohlth Med Ctr, Div Infect Dis, Cleveland, OH USA.
[Peters, Edgar J. G.] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Amsterdam, Netherlands.
[Armstrong, David G.] Univ Arizona, Dept Surg, So Arizona Limb Salvage Alliance, Tucson, AZ USA.
[Deery, H. Gunner] No Michigan Infect Dis, Petoskey, MI USA.
[Embil, John M.] Univ Manitoba, Dept Med, Winnipeg, MB, Canada.
[Joseph, Warren S.] Roxborough Mem Hosp, Dept Surg, Div Podiatr Surg, Philadelphia, PA USA.
[Karchmer, Adolf W.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis,Dept Med, Boston, MA 02215 USA.
[Pinzur, Michael S.] Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA.
[Senneville, Eric] Dron Hosp, Dept Infect Dis, Tourcoing, France.
RP Lipsky, BA (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM balipsky@uw.edu
RI Peters, Edgar /B-7790-2014
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Infectious Diseases Society of America
FX Support for these guidelines was provided by the Infectious Diseases
Society of America.
NR 358
TC 217
Z9 237
U1 9
U2 50
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2012
VL 54
IS 12
BP E132
EP U232
DI 10.1093/cid/cis346
PG 42
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 948YT
UT WOS:000304541000005
PM 22619242
ER
PT J
AU Hall, DE
Hanusa, BH
Switzer, GE
Fine, MJ
Arnold, RM
AF Hall, Daniel E.
Hanusa, Barbara H.
Switzer, Galen E.
Fine, Michael J.
Arnold, Robert M.
TI The Impact of iMedConsent on Patient Decision-Making Regarding
Cholecystectomy and Inguinal Herniorrhaphy
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE informed consent; decision-making; information preference; participation
preference; ethics; trust; anxiety
ID SURGICAL INFORMED-CONSENT; BONE-MARROW DONATION; SHORT-FORM; CLINICAL
ANESTHESIA; SURGERY RESEARCH; PHYSICIAN SCALE; CANCER-PATIENTS; ANXIETY;
INFORMATION; DONORS
AB Background. The Veterans Affairs Healthcare System implemented a computer-based tool (iMedConsent) to improve the quality of informed consent in 2004. The impact of this tool on the process of informed consent remains unknown. Our aim was to determine the impact of iMedConsent on patient information preference, anxiety, trust in the surgeon, ambivalence about the surgical decision, and comprehension of procedure-specific risk, benefits, and alternatives.
Materials and Methods. We prospectively enrolled a consecutive cohort of patients presenting to a general surgery clinic for possible cholecystectomy or inguinal herniorrhaphy from October 2009 to August 2010. We administered questionnaires before and after the clinic visit.
Results. Seventy-five patients completed pre-visit questionnaires. After evaluation by the surgeon, 42 patients were offered surgery and documented their informed consent using iMedConsent, of whom 38 (90%) also completed a post-visit questionnaire. Among the participants who completed both pre- and post-visit questionnaires, participant comprehension of procedure-specific risks benefits and alternatives improved from 50% at baseline to 60% after the clinic visit (P < 0.001). No differences were noted in ambivalence, trust, or anxiety. After the clinic visit, significantly more patients expressed a preference for participating in decision making with their surgeon (98% versus 71%, P = 0.008). However, significantly fewer expressed a preference for knowing all possible details about their illness (25% to 83%, P <= 0.001).
Conclusions. The informed consent process using iMedConsent improves patient comprehension of procedure-specific risks, benefits, and alternatives. It also increases patient preferences for participating more actively in the decision-making process. However, the process may provide more detail than patients want regarding their illness. Published by Elsevier Inc.
C1 [Hall, Daniel E.; Hanusa, Barbara H.; Switzer, Galen E.; Fine, Michael J.] Healthcare Syst, VA Pittsburgh, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Hall, Daniel E.] Univ Pittsburgh, Dept Gen Surg, Pittsburgh, PA USA.
[Switzer, Galen E.; Fine, Michael J.; Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
RP Hall, DE (reprint author), VA Pittsburgh Healthcare Syst, 7180 Highland Dr 151C-H, Pittsburgh, PA 15206 USA.
EM hallde@upmc.edu
RI Hall, Daniel/H-4843-2013
OI Hall, Daniel/0000-0001-6382-0522
FU VA HSRD [CDA 08-281]; VISN4 [XVA 72-057]; CHERP [LIP 72-043]
FX The authors thank Drs. Aaron Fink and Alan Prochazka for their gracious
advice regarding the design of this study. This research was funded by
grants from VA HSR&D (CDA 08-281), VISN4 Competitive Pilot Project Fund
(XVA 72-057), and the CHERP Pilot Project Program (LIP 72-043).
NR 33
TC 3
Z9 3
U1 2
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD JUN 15
PY 2012
VL 175
IS 2
BP 227
EP 233
DI 10.1016/j.jss.2011.04.056
PG 7
WC Surgery
SC Surgery
GA 939AB
UT WOS:000303774400016
PM 21704336
ER
PT J
AU Hattler, B
Messenger, JC
Shroyer, AL
Collins, JF
Haugen, SJ
Garcia, JA
Baltz, JH
Cleveland, JC
Novitzky, D
Grover, FL
AF Hattler, Brack
Messenger, John C.
Shroyer, A. Laurie
Collins, Joseph F.
Haugen, Scott J.
Garcia, Joel A.
Baltz, Janet H.
Cleveland, Joseph C., Jr.
Novitzky, Dimitri
Grover, Frederick L.
CA Vet Affairs Randomized On Off
TI Off-Pump Coronary Artery Bypass Surgery Is Associated With Worse
Arterial and Saphenous Vein Graft Patency and Less Effective
Revascularization Results From the Veterans Affairs Randomized On/Off
Bypass (ROOBY) Trial
SO CIRCULATION
LA English
DT Article
DE coronary artery bypass; coronary artery bypass; off-pump
ID TERM-FOLLOW-UP; ON-PUMP; LIFE OUTCOMES; HEART; MORTALITY; SURVIVAL;
PRAGUE-4; FATE
AB Background-The Department of Veterans Affairs Randomized On/Off Bypass (ROOBY) trial compared clinical and angiographic outcomes in off-pump versus on-pump coronary artery bypass graft (CABG) surgery to ascertain the relative efficacy of the 2 techniques.
Methods and Results-From February 2002 to May 2007, the ROOBY trial randomized 2203 patients to off-pump versus on-pump CABG. Follow-up angiography was obtained in 685 off-pump (62%) and 685 on-pump (62%) patients. Angiograms were analyzed (blinded to treatment) for FitzGibbon classification (A=widely patent, B=flow limited, O=occluded) and effective revascularization. Effective revascularization was defined as follows: All 3 major coronary territories with significant disease were revascularized by a FitzGibbon A-quality graft to the major diseased artery, and there were no new postanastomotic lesions. Off-pump CABG resulted in lower FitzGibbon A patency rates than on-pump CABG for arterial conduits (85.8% versus 91.4%; P=0.003) and saphenous vein grafts (72.7% versus 80.4%; P<0.001). Fewer off-pump patients were effectively revascularized (50.1% versus 63.9% on-pump; P<0.001). Within each major coronary territory, effective revascularization was worse off pump than on pump (all P<0.001). The 1-year adverse cardiac event rate was 16.4% in patients with ineffective revascularization versus 5.9% in patients with effective revascularization (P<0.001).
Conclusions-Off-pump CABG resulted in significantly lower FitzGibbon A patency for arterial and saphenous vein graft conduits and less effective revascularization than on-pump CABG. At 1 year, patients with less effective revascularization had higher adverse event rates.
C1 [Hattler, Brack; Shroyer, A. Laurie; Baltz, Janet H.; Cleveland, Joseph C., Jr.; Grover, Frederick L.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO USA.
[Hattler, Brack; Messenger, John C.; Garcia, Joel A.] Univ Colorado Hosp Denver, Dept Med, Aurora, CO USA.
[Hattler, Brack; Messenger, John C.; Garcia, Joel A.; Cleveland, Joseph C., Jr.; Grover, Frederick L.] Hlth Sci Ctr, Aurora, CO USA.
[Shroyer, A. Laurie] Northport Vet Affairs Med Ctr, Northport, NY USA.
[Collins, Joseph F.] Vet Affairs Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA.
[Haugen, Scott J.] Bellevue Med Ctr, Grp Hlth Cooperat, Bellevue, WA USA.
[Cleveland, Joseph C., Jr.; Grover, Frederick L.] Univ Colorado Hosp Denver, Dept Surg, Aurora, CO USA.
[Novitzky, Dimitri] James A Haley Vet Hosp, Tampa, FL 33612 USA.
RP Hattler, B (reprint author), Denver VAMC, 1055 Clermont St,111B, Denver, CO 80220 USA.
EM brack.hattler@va.gov
RI Shroyer, Annie Laurie/B-8836-2016
OI Shroyer, Annie Laurie/0000-0001-6461-0623
FU VA Office of Research and Development; VA Central Office, Office of
Patient Care Services; Office of Research and Development at the Eastern
Colorado Health Care System; Office of Denver VA Medical Center; Office
of Northport VA Medical Center
FX This work was supported by the Cooperative Studies Program of the VA
Office of Research and Development and the VA Central Office, Office of
Patient Care Services, and in part by the Offices of Research and
Development at the Eastern Colorado Health Care System, Denver VA
Medical Center, and the Northport VA Medical Center.
NR 25
TC 74
Z9 79
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 12
PY 2012
VL 125
IS 23
BP 2827
EP 2835
DI 10.1161/CIRCULATIONAHA.111.069260
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 981NM
UT WOS:000306975100022
PM 22592900
ER
PT J
AU Lustgarten, MS
Bhattacharya, A
Muller, FL
Jang, YC
Shimizu, T
Shirasawa, T
Richardson, A
Van Remmen, H
AF Lustgarten, Michael S.
Bhattacharya, Arunabh
Muller, Florian L.
Jang, Youngmok C.
Shimizu, Takahiko
Shirasawa, Takuji
Richardson, Arlan
Van Remmen, Holly
TI Complex I generated, mitochondrial matrix-directed superoxide is
released from the mitochondria through voltage dependent anion channels
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mitochondria; Superoxide; Voltage dependent anion channels
ID BENZODIAZEPINE-RECEPTOR; SKELETAL-MUSCLE; OXIDATIVE STRESS; CELL-DEATH;
MEMBRANES; PERMEABILITY; DISMUTASE; DIPHENYLENEIODONIUM; PROTEIN;
CYTOSOL
AB Mitochondrial complex I has previously been shown to release superoxide exclusively towards the mitochondrial matrix, whereas complex III releases superoxide to both the matrix and the cytosol. Superoxide produced at complex III has been shown to exit the mitochondria through voltage dependent anion channels (VDAC). To test whether complex I-derived, mitochondrial matrix-directed superoxide can be released to the cytosol, we measured superoxide generation in mitochondria isolated from wild type and from mice genetically altered to be deficient in MnSOD activity (TnIFastCreSod2(fl/fl)). Under experimental conditions that produce superoxide primarily by complex I (glutamate/malate plus rotenone, GM + R), MnSOD-deficient mitochondria release similar to 4-fold more superoxide than mitochondria isolated from wild type mice. Exogenous CuZnSOD completely abolished the EPR-derived GM + R signal in mitochondria isolated from both genotypes, evidence that confirms mitochondrial superoxide release. Addition of the VDAC inhibitor DIDS significantly reduced mitochondrial superoxide release (similar to 75%) in mitochondria from either genotype respiring on GM + R. Conversely, inhibition of potential inner membrane sites of superoxide exit, including the matrix face of the mitochondrial permeability transition pore and the inner membrane anion channel did not reduce mitochondrial superoxide release in the presence of GM + R in mitochondria isolated from either genotype. These data support the concept that complex I-derived mitochondrial superoxide release does indeed occur and that the majority of this release occurs through VDACs. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lustgarten, Michael S.; Bhattacharya, Arunabh; Muller, Florian L.; Jang, Youngmok C.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Bhattacharya, Arunabh; Muller, Florian L.; Jang, Youngmok C.; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA.
[Shimizu, Takahiko] Chiba Univ, Grad Sch Med, Dept Adv Aging Med, Chiba, Japan.
[Shirasawa, Takuji] Juntendo Univ, Grad Sch Med, Dept Aging Control Med, Tokyo, Japan.
RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Sam & Ann Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78229 USA.
EM vanremmen@uthscsa.edu
FU NIH [P01 AG020591]; NIA [5T3-AG021890-02]
FX This work was funded by NIH Grant P01 AG020591 (to H.V.R.) and NIA
Training Grant 5T3-AG021890-02.
NR 30
TC 30
Z9 30
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 8
PY 2012
VL 422
IS 3
BP 515
EP 521
DI 10.1016/j.bbrc.2012.05.055
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 974NT
UT WOS:000306443800027
PM 22613204
ER
PT J
AU Santa-Maria, I
Varghese, M
Ksiezak-Reding, H
Dzhun, A
Wang, J
Pasinetti, GM
AF Santa-Maria, Ismael
Varghese, Merina
Ksiezak-Reding, Hanna
Dzhun, Anastasiya
Wang, Jun
Pasinetti, Giulio M.
TI Paired Helical Filaments from Alzheimer Disease Brain Induce
Intracellular Accumulation of Tau Protein in Aggresomes
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PROGRESSIVE SUPRANUCLEAR PALSY; SEED POLYPHENOLIC EXTRACT; NEURONAL
CELLS; NEUROFIBRILLARY DEGENERATION; NEURODEGENERATIVE DISEASES;
EXTRACELLULAR TAU; ALPHA-SYNUCLEIN; EXOSOMES; TAUOPATHY; MODEL
AB Abnormal folding of tau protein leads to the generation of paired helical filaments (PHFs) and neurofibrillary tangles, a key neuropathological feature in Alzheimer disease and tauopathies. A specific anatomical pattern of pathological changes developing in the brain suggests that once tau pathology is initiated it propagates between neighboring neuronal cells, possibly spreading along the axonal network. We studied whether PHFs released from degenerating neurons could be taken up by surrounding cells and promote spreading of tau pathology. Neuronal and non-neuronal cells overexpressing green fluorescent protein-tagged tau (GFP-Tau) were treated with isolated fractions of human Alzheimer disease-derived PHFs for 24 h. We found that cells internalized PHFs through an endocytic mechanism and developed intracellular GFP-Tau aggregates with attributes of aggresomes. This was particularly evident by the perinuclear localization of aggregates and redistribution of the vimentin intermediate filament network and retrograde motor protein dynein. Furthermore, the content of Sarkosyl-insoluble tau, a measure of abnormal tau aggregation, increased 3-fold in PHF-treated cells. An exosome-related mechanism did not appear to be involved in the release of GFP-Tau from untreated cells. The evidence that cells can internalize PHFs, leading to formation of aggresome-like bodies, opens new therapeutic avenues to prevent propagation and spreading of tau pathology.
C1 [Santa-Maria, Ismael; Varghese, Merina; Ksiezak-Reding, Hanna; Dzhun, Anastasiya; Wang, Jun; Pasinetti, Giulio M.] Mt Sinai Sch Med, Ctr Excellence Res Complementary & Alternat Med A, Ctr Excellence Novel Approaches Neurodiagnost & N, Brain Inst,Dept Neurol, New York, NY 10029 USA.
[Varghese, Merina; Ksiezak-Reding, Hanna; Dzhun, Anastasiya; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA.
[Santa-Maria, Ismael] Queen Sofia Fdn, Ctr Invest Enfermedades Neurol Fdn, Alzheimer Dis Res Unit, Madrid 28031, Spain.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Ctr Excellence Res Complementary & Alternat Med A, Ctr Excellence Novel Approaches Neurodiagnost & N, Brain Inst,Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
OI Varghese, Merina/0000-0002-1517-3903
FU NCI, National Institutes of Health [5R24 CA095823-04, PO1 AT004511];
National Institutes of Health Shared Instrumentation [1 S10 RR0
9145-01]; Society for Progressive Supranuclear Palsy; Veterans Affairs
merit review grant; National Science Foundation Major Research
Instrumentation [DBI-9724504]
FX Confocal laser scanning microscopy was performed at the James J. Peters
Veteran Affairs Medical Center and conventional fluorescence microscopy
was performed at the Mount Sinai School of Medicine Microscopy Shared
Resource Facility supported with funding from NCI, National Institutes
of Health Shared Resource Grant 5R24 CA095823-04, National Science
Foundation Major Research Instrumentation Grant DBI-9724504, and
National Institutes of Health Shared Instrumentation Grant 1 S10 RR0
9145-01. We thank Jesus Avila (Universidad Auto noma de Madrid, Madrid,
Spain) for help with preparing GFP and GFP-Tau plasmids. We also thank
Miguel Gama-Sosa (Mount Sinai School of Medicine, New York, NY) for
lending his expertise in confocal microscopy.; This work was supported,
in whole or in part, by National Institutes of Health Grant PO1 AT004511
(to G. M. P.). This work was also supported by the Society for
Progressive Supranuclear Palsy and in part by Veterans Affairs merit
review grant (to G. M. P.). Dr. Pasinetti has filed a patent application
(pending) through Mount Sinai School of Medicine related to grape seed
polyphenolic extract. In the event that the pending patent is licensed,
Dr. Pasinetti would be entitled to a share of any proceeds Mount Sinai
School of Medicine receives from the license.
NR 67
TC 44
Z9 46
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 8
PY 2012
VL 287
IS 24
BP 20522
EP 20533
DI 10.1074/jbc.M111.323279
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 974FB
UT WOS:000306414500073
PM 22496370
ER
PT J
AU Sonnenberg, GF
Monticelli, LA
Alenghat, T
Fung, TC
Hutnick, NA
Kunisawa, J
Shibata, N
Grunberg, S
Sinha, R
Zahm, AM
Tardif, MR
Sathaliyawala, T
Kubota, M
Farber, DL
Collman, RG
Shaked, A
Fouser, LA
Weiner, DB
Tessier, PA
Friedman, JR
Kiyono, H
Bushman, FD
Chang, KM
Artis, D
AF Sonnenberg, Gregory F.
Monticelli, Laurel A.
Alenghat, Theresa
Fung, Thomas C.
Hutnick, Natalie A.
Kunisawa, Jun
Shibata, Naoko
Grunberg, Stephanie
Sinha, Rohini
Zahm, Adam M.
Tardif, Melanie R.
Sathaliyawala, Taheri
Kubota, Masaru
Farber, Donna L.
Collman, Ronald G.
Shaked, Abraham
Fouser, Lynette A.
Weiner, David B.
Tessier, Philippe A.
Friedman, Joshua R.
Kiyono, Hiroshi
Bushman, Frederic D.
Chang, Kyong-Mi
Artis, David
TI Innate Lymphoid Cells Promote Anatomical Containment of
Lymphoid-Resident Commensal Bacteria
SO SCIENCE
LA English
DT Article
ID ALCALIGENES-XYLOSOXIDANS; INTESTINAL BACTERIA; HOST-DEFENSE; MICROBIOTA;
ACHROMOBACTER; INFLAMMATION; HOMEOSTASIS; IDENTIFICATION; IMMUNITY;
SYSTEM
AB The mammalian intestinal tract is colonized by trillions of beneficial commensal bacteria that are anatomically restricted to specific niches. However, the mechanisms that regulate anatomical containment remain unclear. Here, we show that interleukin-22 (IL-22)-producing innate lymphoid cells (ILCs) are present in intestinal tissues of healthy mammals. Depletion of ILCs resulted in peripheral dissemination of commensal bacteria and systemic inflammation, which was prevented by administration of IL-22. Disseminating bacteria were identified as Alcaligenes species originating from host lymphoid tissues. Alcaligenes was sufficient to promote systemic inflammation after ILC depletion in mice, and Alcaligenes-specific systemic immune responses were associated with Crohn's disease and progressive hepatitis C virus infection in patients. Collectively, these data indicate that ILCs regulate selective containment of lymphoid-resident bacteria to prevent systemic inflammation associated with chronic diseases.
C1 [Sonnenberg, Gregory F.; Monticelli, Laurel A.; Alenghat, Theresa; Fung, Thomas C.; Grunberg, Stephanie; Sinha, Rohini; Bushman, Frederic D.; Artis, David] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
[Sonnenberg, Gregory F.; Monticelli, Laurel A.; Alenghat, Theresa; Fung, Thomas C.; Grunberg, Stephanie; Sinha, Rohini; Bushman, Frederic D.; Artis, David] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.
[Hutnick, Natalie A.; Weiner, David B.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Kunisawa, Jun; Shibata, Naoko; Kiyono, Hiroshi] Univ Tokyo, Inst Med Sci, Div Mucosal Immunol, Tokyo 1088639, Japan.
[Kunisawa, Jun; Shibata, Naoko; Kiyono, Hiroshi] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Chiba 2778562, Japan.
[Zahm, Adam M.; Friedman, Joshua R.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat,Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
[Tardif, Melanie R.; Tessier, Philippe A.] Univ Laval, Fac Med, CHU Laval, Ctr Rech Infectiol, Quebec City, PQ G1K 7P4, Canada.
[Sathaliyawala, Taheri; Kubota, Masaru; Farber, Donna L.] Columbia Univ, Med Ctr, Dept Surg, New York, NY 10032 USA.
[Sathaliyawala, Taheri; Kubota, Masaru; Farber, Donna L.] Columbia Univ, Med Ctr, Columbia Ctr Translat Immunol, New York, NY 10032 USA.
[Collman, Ronald G.; Chang, Kyong-Mi] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Shaked, Abraham] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
[Fouser, Lynette A.] Pfizer Worldwide R&D, Inflammat & Immunol Res Unit, Biotherapeut Res & Dev, Cambridge, MA 02140 USA.
[Kiyono, Hiroshi] Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Tokyo 1020075, Japan.
[Chang, Kyong-Mi] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Artis, David] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA.
RP Artis, D (reprint author), Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
EM dartis@mail.med.upenn.edu
RI Weiner, David/H-8579-2014
OI Tessier, Philippe/0000-0001-7177-7763; Bushman,
Frederic/0000-0003-4740-4056
FU NIH [AI061570, AI087990, AI074878, AI083480, AI095466, AI095608,
T32-AI007532, T32-AI055428, T32-RR007063, K08-DK093784, AI47619, P30 AI
045008]; Burroughs Wellcome Fund Investigator in Pathogenesis of
Infectious Disease Award; Philadelphia VA Medical Research and Merit
Review; American Gastroenterological Association; Ministry of Education,
Culture, Sports, Science and Technology of Japan; Program for Promotion
of Basic and Applied Researches for Innovations in Bio-Oriented
Industry; Matthew J. Ryan Veterinary Hospital Pathology Lab, the
National Institute of Diabetes and Digestive and Kidney Disease Center
for the Molecular Studies in Digestive and Liver Disease Molecular
Pathology and Imaging Core [P30DK50306]; National Cancer Institute (NCI)
Comprehensive Cancer Center [2-P30 CA016520]
FX We thank members of the Artis laboratory for discussions and critical
reading of the manuscript. We also thank S. Olland, R. Zollner, K. Lam,
and A. Root at Pfizer for the preparation of IL-22 cytokine and
antibodies. The research is supported by the NIH (grants AI061570,
AI087990, AI074878, AI083480, AI095466, and AI095608 to D. A.;
T32-AI007532 to G. F. S and L. A. M.; T32-AI055428 to G. F. S.;
T32-RR007063 and K08-DK093784 to T. A.; and AI47619 to K.-M. C.); the
NIH-funded Penn Center for AIDS Research (grant P30 AI 045008 to G. F.
S. and D. A.); the Burroughs Wellcome Fund Investigator in Pathogenesis
of Infectious Disease Award (to D. A.); the Philadelphia VA Medical
Research and Merit Review and American Gastroenterological Association
(to K.-M. C.); the Ministry of Education, Culture, Sports, Science and
Technology of Japan (to J.K., N.S., and H. K); and the Program for
Promotion of Basic and Applied Researches for Innovations in
Bio-Oriented Industry (to J.K.). We also thank the Matthew J. Ryan
Veterinary Hospital Pathology Lab, the National Institute of Diabetes
and Digestive and Kidney Disease Center for the Molecular Studies in
Digestive and Liver Disease Molecular Pathology and Imaging Core (grant
P30DK50306), the Penn Microarray Facility, and the Abramson Cancer
Center Flow Cytometry and Cell Sorting Resource Laboratory [partially
supported by National Cancer Institute (NCI) Comprehensive Cancer Center
Support grant # 2-P30 CA016520] for technical advice and support.
Several human tissue samples were provided by the Cooperative Human
Tissue Network, which is funded by the NCI. The data presented in the
paper are tabulated in the main paper and in the supplementary
materials.
NR 29
TC 257
Z9 266
U1 1
U2 38
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JUN 8
PY 2012
VL 336
IS 6086
BP 1321
EP 1325
DI 10.1126/science.1222551
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 953WV
UT WOS:000304905300051
PM 22674331
ER
PT J
AU Bendlin, BB
Carlsson, CM
Johnson, SC
Zetterberg, H
Blennow, K
Willette, AA
Okonkwo, OC
Sodhi, A
Ries, ML
Birdsill, AC
Alexander, AL
Rowley, HA
Puglielli, L
Asthana, S
Sager, MA
AF Bendlin, Barbara B.
Carlsson, Cynthia M.
Johnson, Sterling C.
Zetterberg, Henrik
Blennow, Kaj
Willette, Auriel A.
Okonkwo, Ozioma C.
Sodhi, Aparna
Ries, Michele L.
Birdsill, Alex C.
Alexander, Andrew L.
Rowley, Howard A.
Puglielli, Luigi
Asthana, Sanjay
Sager, Mark A.
TI CSF T-Tau/A beta(42) Predicts White Matter Microstructure in Healthy
Adults at Risk for Alzheimer's Disease
SO PLOS ONE
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID BIOMARKERS; VOXEL-BASED
MORPHOMETRY; CORPUS-CALLOSUM ATROPHY; APOE EPSILON-4 ALLELE; BRAIN
ATROPHY; IN-VIVO; NEUROFILAMENT PROTEIN; PHOSPHORYLATED-TAU; MYELIN
BREAKDOWN
AB Cerebrospinal fluid (CSF) biomarkers T-Tau and A beta(42) are linked with Alzheimer's disease (AD), yet little is known about the relationship between CSF biomarkers and structural brain alteration in healthy adults. In this study we examined the extent to which AD biomarkers measured in CSF predict brain microstructure indexed by diffusion tensor imaging (DTI) and volume indexed by T1-weighted imaging. Forty-three middle-aged adults with parental family history of AD received baseline lumbar puncture and MRI approximately 3.5 years later. Voxel-wise image analysis methods were used to test whether baseline CSF A beta(42), total tau (T-Tau), phosphorylated tau (P-Tau) and neurofilament light protein predicted brain microstructure as indexed by DTI and gray matter volume indexed by T1-weighted imaging. T-Tau and T-Tau/A beta(42) were widely correlated with indices of brain microstructure (mean, axial, and radial diffusivity), notably in white matter regions adjacent to gray matter structures affected in the earliest stages of AD. None of the CSF biomarkers were related to gray matter volume. Elevated P-Tau and P-Tau/A beta(42) levels were associated with lower recognition performance on the Rey Auditory Verbal Learning Test. Overall, the results suggest that CSF biomarkers are related to brain microstructure in healthy adults with elevated risk of developing AD. Furthermore, the results clearly suggest that early pathological changes in AD can be detected with DTI and occur not only in cortex, but also in white matter.
C1 [Bendlin, Barbara B.; Carlsson, Cynthia M.; Johnson, Sterling C.; Willette, Auriel A.; Okonkwo, Ozioma C.; Sodhi, Aparna; Ries, Michele L.; Birdsill, Alex C.; Puglielli, Luigi; Asthana, Sanjay; Sager, Mark A.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA.
[Bendlin, Barbara B.; Carlsson, Cynthia M.; Johnson, Sterling C.; Willette, Auriel A.; Okonkwo, Ozioma C.; Sodhi, Aparna; Ries, Michele L.; Birdsill, Alex C.; Puglielli, Luigi; Asthana, Sanjay; Sager, Mark A.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA.
[Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden.
[Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA.
[Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
RP Bendlin, BB (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA.
EM bbb@medicine.wisc.edu
OI Bendlin, Barbara/0000-0002-0580-9875
FU National Institute on Aging [R01 AG027161, K23 AG026752, ADRC P50
AG033514]; University of Wisconsin Institute for Clinical and
Translational Research; National Center for Research Resources/National
Institutes of Health Clinical and Translational Science Award
[1UL1RR025011]; program of the National Center for Research Resources,
United States National Institutes of Health; Swedish Research Council;
Pfizer Inc.; Innogenetics; Vastra Gotalandsregionen, Sweden; Swedish
Brain Power Project; Swedish Council for Working Life and Social
Research; Swedish Alzheimer Foundation; Stiftelsen for Gamla
Tjanarinnor; King Gustaf V and Queen Victoria Foundation; Alzheimer's
Association; Royal Swedish Academy of Sciences
FX This project was supported in part by the National Institute on Aging
(R01 AG027161 [MAS], K23 AG026752 [CMC]; ADRC P50 AG033514 [SA]), the
University of Wisconsin Institute for Clinical and Translational
Research, funded through a National Center for Research
Resources/National Institutes of Health Clinical and Translational
Science Award, 1UL1RR025011, a program of the National Center for
Research Resources, United States National Institutes of Health, and the
Swedish Research Council. The project was also facilitated by the
facilities and resources at the Geriatric Research, Education, and
Clinical Center (GRECC) of the William S. Middleton Memorial Veterans
Hospital, Madison, WI. GRECC MS # 2011-19. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.; Dr. Blennow has served on scientific
advisory boards for Adlyfe Inc., Bayer Schering Pharma, Bristol-Myers
Squibb, and Merz Pharmaceuticals GmbH; received a speaker honorarium
from Pfizer Inc.; serves as a consultant for Wyeth, AstraZeneca,
Bristol-Myers Squibb, and Eli Lilly and Company; and has received
research support from Pfizer Inc., Innogenetics, the Swedish Research
Council, Vastra Gotalandsregionen, Sweden, the Swedish Brain Power
Project, the Swedish Council for Working Life and Social Research, the
Swedish Alzheimer Foundation, Stiftelsen for Gamla Tjanarinnor, and the
King Gustaf V and Queen Victoria Foundation. Dr. Zetterberg has served
on a scientific advisory board for GlaxoSmithKline; serves as an
Associate Editor for the Journal of Alzheimer's Disease; and receives
research support from the Swedish Research Council, the Alzheimer's
Association, and the Royal Swedish Academy of Sciences. This does not
alter the authors' adherence to all the PLoS ONE policies on sharing
data and materials.
NR 123
TC 24
Z9 24
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2012
VL 7
IS 6
AR e37720
DI 10.1371/journal.pone.0037720
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959WK
UT WOS:000305348400018
PM 22701578
ER
PT J
AU Renquist, BJ
Murphy, JG
Larson, EA
Olsen, D
Klein, RF
Ellacott, KLJ
Cone, RD
AF Renquist, Benjamin J.
Murphy, Jonathan G.
Larson, Emily A.
Olsen, Dawn
Klein, Robert F.
Ellacott, Kate L. J.
Cone, Roger D.
TI Melanocortin-3 receptor regulates the normal fasting response
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE energy homeostasis; nonesterified fatty acid; corticotrophin-releasing
hormone; hormone-sensitive lipase
ID AGOUTI-RELATED PROTEIN; WHITE ADIPOSE-TISSUE; MONOCYTE CHEMOATTRACTANT
PROTEIN-1; SYMPATHETIC NERVOUS-SYSTEM; PITUITARY-ADRENAL AXIS;
INSULIN-RESISTANCE; BONE MASS; PROOPIOMELANOCORTIN PEPTIDES; FRAMESHIFT
MUTATION; TRIGLYCERIDE LIPASE
AB The melanocortin-3 receptor-deficient (MC3-R-/-) mouse exhibits mild obesity without hyperphagia or hypometabolism. MC3-R deletion is reported to increase adiposity, reduce lean mass and white adipose tissue inflammation, and increase sensitivity to salt-induced hypertension. We show here that the MC3-R-/- mouse exhibits defective fasting-induced white adipose tissue lipolysis, fasting-induced liver triglyceride accumulation, fasting-induced refeeding, and fasting-induced regulation of the adipostatic and hypothalamic-adrenal-pituitary axes. Close examination of the hypothalamic-pituitary-adrenal axis showed that MC3-R-/- mice exhibit elevated nadir corticosterone as well as a blunted fasting-induced activation of the axis. The previously described phenotypes of this animal and the reduced bone density reported here parallel those of Cushing syndrome. Thus, MC3-R is required for communicating nutritional status to both central and peripheral tissues involved in nutrient partitioning, and this defect explains much of the metabolic phenotype in the model.
C1 [Renquist, Benjamin J.; Ellacott, Kate L. J.; Cone, Roger D.] Vanderbilt Univ Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
[Murphy, Jonathan G.] Univ Colorado Denver Sch Med, Dept Pharmacol, Aurora, CO 80045 USA.
[Larson, Emily A.; Olsen, Dawn; Klein, Robert F.] Oregon Hlth & Sci Univ, Dept Med, Bone & Mineral Unit, Portland, OR 97201 USA.
[Olsen, Dawn; Klein, Robert F.] Portland VA Med Ctr, Portland, OR 97201 USA.
RP Cone, RD (reprint author), Vanderbilt Univ Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
EM roger.cone@vanderbilt.edu
OI Ellacott, Kate/0000-0001-5261-7465
FU National Institutes of Health [DK078850]; VA Medical Research Service
and National Institutes of Health [R01 AR44659]
FX We thank Savannah Y. Williams and Katelijn Van Munster for technical
assistance. This work was supported by National Institutes of Health
Grant DK078850 (to R.D.C.), and by the VA Medical Research Service and
National Institutes of Health Grant R01 AR44659 (to R.F.K.).
NR 56
TC 27
Z9 27
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 5
PY 2012
VL 109
IS 23
BP E1489
EP E1498
DI 10.1073/pnas.1201994109
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 955BC
UT WOS:000304991100008
PM 22573815
ER
PT J
AU Dey, N
Das, F
Ghosh-Choudhury, N
Mandal, CC
Parekh, DJ
Block, K
Kasinath, BS
Abboud, HE
Choudhury, GG
AF Dey, Nirmalya
Das, Falguni
Ghosh-Choudhury, Nandini
Mandal, Chandi Charan
Parekh, Dipen J.
Block, Karen
Kasinath, Balakuntalam S.
Abboud, Hanna E.
Choudhury, Goutam Ghosh
TI microRNA-21 Governs TORC1 Activation in Renal Cancer Cell Proliferation
and Invasion
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR RECEPTOR; HIPPEL-LINDAU GENE;
NF-KAPPA-B; KIDNEY CANCER; BREAST-CANCER; HIGH GLUCOSE; GLIOBLASTOMA
CELLS; PROGNOSTIC-FACTORS; MAMMALIAN TARGET
AB Metastatic renal cancer manifests multiple signatures of gene expression. Deviation in expression of mature miRNAs has been linked to human cancers. Importance of miR-21 in renal cell carcinomas is proposed from profiling studies using tumor tissue samples. However, the role of miR-21 function in causing renal cancer cell proliferation and invasion has not yet been shown. Using cultured renal carcinoma cells, we demonstrate enhanced expression of mature miR-21 along with pre-and pri-miR-21 by increased transcription compared to normal proximal tubular epithelial cells. Overexpression of miR-21 Sponge to quench endogenous miR-21 levels inhibited proliferation, migration and invasion of renal cancer cells. In the absence of mutation in the PTEN tumor suppressor gene, PTEN protein levels are frequently downregulated in renal cancer. We show that miR-21 targets PTEN mRNA 3'untranslated region to decrease PTEN protein expression and augments Akt phosphorylation in renal cancer cells. Downregulation of PTEN as well as overexpression of constitutively active Akt kinase prevented miR-21 Sponge-induced inhibition of renal cancer cell proliferation and migration. Moreover, we show that miR-21 Sponge inhibited the inactivating phosphorylation of the tumor suppressor protein tuberin and attenuated TORC1 activation. Finally, we demonstrate that expression of constitutively active TORC1 attenuated miR-21 Sponge-mediated suppression of proliferation and migration of renal cancer cells. Our results uncover a layer of post-transcriptional regulation of PTEN by transcriptional activation of miR-21 to force the canonical oncogenic Akt/TORC1 signaling conduit to drive renal cancer cell proliferation and invasion.
C1 [Dey, Nirmalya; Das, Falguni; Block, Karen; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini; Block, Karen; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Vet Adm Res, San Antonio, TX USA.
[Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
[Ghosh-Choudhury, Nandini; Mandal, Chandi Charan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Parekh, Dipen J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
RP Dey, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU United States National Institutes of Health (NIH) [RO1 DK50190]; VA
Research Service Merit Review; Juvenile Diabetes Research Foundation
[1-2008-185]; VA Senior Research Career Scientist Award; VA Merit
Review, NIH [RO1 AR 52425]; Cancer Therapy and Research Center, San
Antonio, Texas; VA Research Service Career Scientist Award; Merit Review
Awards; [NIH RO1 CA 131272]; [NIH RO1 DK 077295]; [NIH RO1 DK078971];
[NIH RC2A 036613]
FX A United States National Institutes of Health (NIH) RO1 DK50190 grant to
GGC supported this work. Part of this work was also supported by VA
Research Service Merit Review grant to GGC. GGC is also supported by
Juvenile Diabetes Research Foundation 1-2008-185 grants and is recipient
of VA Senior Research Career Scientist Award. NGC is supported by VA
Merit Review, NIH RO1 AR 52425 grants and Ronald P. Williams Orthopedic
Oncology Developmental Research Award from Cancer Therapy and Research
Center, San Antonio, Texas. KB, BSK and HEA are supported by grants, NIH
RO1 CA 131272 (KB), NIH RO1 DK 077295 (BSK), NIH RO1 DK078971 (HEA), NIH
RC2A 036613 (BSK) and VA Research Service Career Scientist Award (KB)
and Merit Review Awards (KB, BSK and HEA).
NR 118
TC 35
Z9 35
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2012
VL 7
IS 6
AR e37366
DI 10.1371/journal.pone.0037366
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UU
UT WOS:000305341700013
PM 22685542
ER
PT J
AU Souza, P
Hoover, E
Gallun, F
AF Souza, Pamela
Hoover, Eric
Gallun, Frederick
TI Application of the Envelope Difference Index to Spectrally Sparse Speech
SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH
LA English
DT Article
DE compression; consonant recognition; envelope; vocoding
ID HEARING-IMPAIRED LISTENERS; PHONEME RECOGNITION; AMPLITUDE COMPRESSION;
NOISE; INTELLIGIBILITY; INFORMATION; CHANNELS; QUALITY; CUES; MODULATION
AB Purpose: Amplitude compression is a common hearing aid processing strategy that can improve speech audibility and loudness comfort but also has the potential to alter important cues carried by the speech envelope. In previous work, a measure of envelope change, the Envelope Difference Index (EDI; Fortune, Woodruff, & Preves, 1994), was moderately related to recognition of spectrally robust consonants. This follow-up study investigated the relationship between the EDI and recognition of spectrally sparse consonants.
Method: Stimuli were vowel-consonant-vowel tokens processed to reduce spectral cues. Compression parameters were chosen to achieve a range of EDI values. Recognition was measured for 20 listeners with normal hearing.
Results: Both overall recognition and perception of consonant features were reduced at higher EDI values. Similar effects were noted with noise-vocoded and sine-vocoded processing and regardless of whether periodicity cues were available.
Conclusion: The data provide information about the acceptable limits of envelope distortion under constrained conditions. These limits can be used to consider the impact of envelope distortions in situations where other cues are available to varying extents.
C1 [Souza, Pamela; Hoover, Eric] Northwestern Univ, Evanston, IL 60208 USA.
[Gallun, Frederick] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR USA.
RP Souza, P (reprint author), Northwestern Univ, Evanston, IL 60208 USA.
EM p-souza@northwestern.edu
OI Gallun, Frederick/0000-0002-4145-2199
FU National Institutes of Health [R01 DC0060014]; Department of Veterans
Affairs Rehabilitation Research and Development Service [C4963W];
National Center for Rehabilitative Auditory Research
FX This work was supported by National Institutes of Health Grant R01
DC0060014 to Pamela Souza, by Department of Veterans Affairs
Rehabilitation Research and Development Service Grant C4963W to
Frederick Gallun, and by the National Center for Rehabilitative Auditory
Research. We thank Steve Armstrong and the Gennum Corporation for
providing the hearing aid simulation software; Stuart Rosen for sharing
the FIX program and vocoding algorithms; and Ashley Arrington, Alexandra
Dykhouse, Louisa Ha, and Marcee Wickline for assistance in data
collection.
NR 56
TC 4
Z9 4
U1 1
U2 5
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1092-4388
J9 J SPEECH LANG HEAR R
JI J. Speech Lang. Hear. Res.
PD JUN 1
PY 2012
VL 55
IS 3
BP 824
EP 837
DI 10.1044/1092-4388(2011/10-0301)
PG 14
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 084FO
UT WOS:000314523500013
PM 22232401
ER
PT J
AU Ford, JM
Dierks, T
Fisher, DJ
Herrmann, CS
Hubl, D
Kindler, J
Koenig, T
Mathalon, DH
Spencer, KM
Strik, W
van Lutterveld, R
AF Ford, Judith M.
Dierks, Thomas
Fisher, Derek J.
Herrmann, Christoph S.
Hubl, Daniela
Kindler, Jochen
Koenig, Thomas
Mathalon, Daniel H.
Spencer, Kevin M.
Strik, Werner
van Lutterveld, Remko
TI Neurophysiological Studies of Auditory Verbal Hallucinations
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE auditory hallucinations; EEG; MEG; ERPs
ID MULTI-FEATURE PARADIGM; MISMATCH NEGATIVITY; SCHIZOPHRENIA; P300;
ATTENTION; SYMPTOMS; CORTEX; SYNCHRONIZATION; METAANALYSIS; PERCEPTION
AB We discuss 3 neurophysiological approaches to study auditory verbal hallucinations (AVH). First, we describe "state" (or symptom capture) studies where periods with and without hallucinations are compared "within" a patient. These studies take 2 forms: passive studies, where brain activity during these states is compared, and probe studies, where brain responses to sounds during these states are compared. EEG (electroencephalography) and MEG (magnetoencephalography) data point to frontal and temporal lobe activity, the latter resulting in competition with external sounds for auditory resources. Second, we discuss "trait" studies where EEG and MEG responses to sounds are recorded from patients who hallucinate and those who do not. They suggest a tendency to hallucinate is associated with competition for auditory processing resources. Third, we discuss studies addressing possible mechanisms of AVH, including spontaneous neural activity, abnormal self-monitoring, and dysfunctional interregional communication. While most studies show differences in EEG and MEG responses between patients and controls, far fewer show symptom relationships. We conclude that efforts to understand the pathophysiology of AVH using EEG and MEG have been hindered by poor anatomical resolution of the EEG and MEG measures, poor assessment of symptoms, poor understanding of the phenomenon, poor models of the phenomenon, decoupling of the symptoms from the neurophysiology due to medications and comorbidites, and the possibility that the schizophrenia diagnosis breeds truer than the symptoms it comprises. These problems are common to studies of other psychiatric symptoms and should be considered when attempting to understand the basic neural mechanisms responsible for them.
C1 [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Psychiat Serv, Dept Psychiat, San Francisco, CA 94121 USA.
[Dierks, Thomas; Hubl, Daniela; Kindler, Jochen; Koenig, Thomas; Strik, Werner] Univ Bern, Univ Hosp Psychiat, Bern, Switzerland.
[Fisher, Derek J.] Mt St Vincent Univ, Dept Psychol, Halifax, NS B3M 2J6, Canada.
[Fisher, Derek J.] Univ Ottawa, Neuroelectrophysiol Unit, Mental Hlth Res Inst, Ottawa, ON, Canada.
[Herrmann, Christoph S.] Carl von Ossietzky Univ Oldenburg, Dept Expt Psychol, D-2900 Oldenburg, Germany.
[Spencer, Kevin M.] Harvard Univ, Sch Med, Res Serv, Vet Affairs Boston Healthcare Syst, Boston, MA USA.
[Spencer, Kevin M.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[van Lutterveld, Remko] Univ Med Ctr, Dept Psychiat, Utrecht, Netherlands.
[van Lutterveld, Remko] Rudolf Magnus Inst Neurosci, Dept Psychiat, NL-3508 TA Utrecht, Netherlands.
RP Ford, JM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Psychiat Serv, Dept Psychiat, 116D,4150 Clement St, San Francisco, CA 94121 USA.
EM judith.ford@ucsf.edu
RI Dierks, Thomas/B-7092-2012; Koenig, Thomas/F-6454-2010; Fisher,
Derek/H-2297-2013; Strik, Werner/N-7807-2013
OI Dierks, Thomas/0000-0002-4173-5308; Mathalon,
Daniel/0000-0001-6090-4974; Koenig, Thomas/0000-0002-1472-4638; Fisher,
Derek/0000-0003-2366-8225; Strik, Werner/0000-0001-7108-1993; Spencer,
Kevin/0000-0002-5500-7627
FU National Institutes of Health [MH080187, MH076989, MH058262]; VA Merit
Award; National Alliance for Research on Schizophrenia and Depression;
Canadian Institutes of Health Research; Dutch Science Organization
(Nederlandse Wetenschappelijke Organisatie)
FX National Institutes of Health (MH080187 to K.M.S., MH076989 to D.H.M.,
and MH058262 to J.M.F.); VA Merit Award (K.M.S. and J.M.F.); National
Alliance for Research on Schizophrenia and Depression (to D.H.M);
Canadian Institutes of Health Research (to D.J.F.); Dutch Science
Organization (Nederlandse Wetenschappelijke Organisatie) (to R.v.L.).
NR 49
TC 26
Z9 27
U1 2
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JUN
PY 2012
VL 38
IS 4
BP 715
EP 723
DI 10.1093/schbul/sbs009
PG 9
WC Psychiatry
SC Psychiatry
GA 979ZX
UT WOS:000306864500012
PM 22368236
ER
PT J
AU Green, MF
Bearden, CE
Cannon, TD
Fiske, AP
Hellemann, GS
Horan, WP
Kee, K
Kern, RS
Lee, J
Sergi, MJ
Subotnik, KL
Sugar, CA
Ventura, J
Yee, CM
Nuechterlein, KH
AF Green, Michael F.
Bearden, Carrie E.
Cannon, Tyrone D.
Fiske, Alan P.
Hellemann, Gerhard S.
Horan, William P.
Kee, Kimmy
Kern, Robert S.
Lee, Junghee
Sergi, Mark J.
Subotnik, Kenneth L.
Sugar, Catherine A.
Ventura, Joseph
Yee, Cindy M.
Nuechterlein, Keith H.
TI Social Cognition in Schizophrenia, Part 1: Performance Across Phase of
Illness
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE social cognition; illness phase; schizophrenia
ID FACIAL AFFECT RECOGNITION; NEUROCOGNITIVE ENDOPHENOTYPES; EMOTIONAL
INTELLIGENCE; PERCEPTION DEFICITS; FUNCTIONAL STATUS; PSYCHOSIS; MIND;
SCHIZOTYPY; METAANALYSIS; RISK
AB Social cognitive impairments are consistently reported in schizophrenia and are associated with functional outcome. We currently know very little about whether these impairments are stable over the course of illness. In the current study, 3 different aspects of social cognition were assessed (emotion processing, Theory of Mind [ToM], and social relationship perception) at 3 distinct developmental phases of illness: prodromal, first episode, and chronic. In this cross-sectional study, participants included 50 individuals with the prodromal risk syndrome for psychosis and 34 demographically comparable controls, 81 first-episode schizophrenia patients and 46 demographically comparable controls, and 53 chronic schizophrenia patients and 47 demographically comparable controls. Outcome measures included total and subtest scores on 3 specialized measures of social cognition: (1) emotion processing assessed with the Mayer-Salovey-Caruso Emotional Intelligence Test, (2) ToM assessed with The Awareness of Social Inference Test, and (3) social relationship perception assessed the Relationships Across Domains Test. Social cognitive performance was impaired across all domains of social cognition and in all clinical samples. Group differences in performance were comparable across phase of illness, with no evidence of progression or improvement. Age had no significant effect on performance for either the clinical or the comparison groups. The findings suggest that social cognition in these 3 domains fits a stable pattern that has outcome and treatment implications. An accompanying article prospectively examines the longitudinal stability of social cognition and prediction of functional outcome in the first-episode sample.
C1 [Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Green, Michael F.; Horan, William P.; Kee, Kimmy; Kern, Robert S.; Lee, Junghee; Sergi, Mark J.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Bearden, Carrie E.; Cannon, Tyrone D.; Yee, Cindy M.; Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Fiske, Alan P.] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA.
[Kee, Kimmy] Calif State Univ, Dept Psychol, Camarillo, CA USA.
[Sergi, Mark J.] Calif State Univ Northridge, Dept Psychol, Northridge, CA 91330 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA.
RP Green, MF (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, 300 Med Plaza,Room 2263, Los Angeles, CA 90095 USA.
EM mgreen@ucla.edu
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU National Institute of Mental Health Center [P50 MH066286, MH037705,
MH043292]
FX National Institute of Mental Health Center grant (P50 MH066286 and
MH037705 to K.H.N.; MH043292 to M.F.G.).
NR 65
TC 134
Z9 139
U1 7
U2 44
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JUN
PY 2012
VL 38
IS 4
BP 854
EP 864
DI 10.1093/schbul/sbq171
PG 11
WC Psychiatry
SC Psychiatry
GA 979ZX
UT WOS:000306864500027
PM 21345917
ER
PT J
AU Horan, WP
Green, MF
DeGroot, M
Fiske, A
Hellemann, G
Kee, K
Kern, RS
Lee, J
Sergi, MJ
Subotnik, KL
Sugar, CA
Ventura, J
Nuechterlein, KH
AF Horan, William P.
Green, Michael F.
DeGroot, Michael
Fiske, Alan
Hellemann, Gerhard
Kee, Kimmy
Kern, Robert S.
Lee, Junghee
Sergi, Mark J.
Subotnik, Kenneth L.
Sugar, Catherine A.
Ventura, Joseph
Nuechterlein, Keith H.
TI Social Cognition in Schizophrenia, Part 2: 12-Month Stability and
Prediction of Functional Outcome in First-Episode Patients
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE functional outcome; emotional processing; theory of mind; social
perception; cross-lagged panel analyses; longitudinal prediction
ID FACIAL AFFECT RECOGNITION; EMOTIONAL INTELLIGENCE; NEUROCOGNITIVE
ENDOPHENOTYPES; PERCEPTION DEFICITS; 1ST EPISODE; MIND; SCHIZOTYPY;
PSYCHOSIS; VULNERABILITY; REMISSION
AB This study evaluated the longitudinal stability and functional correlates of social cognition during the early course of schizophrenia. Fifty-five first-episode schizophrenia patients completed baseline and 12-month follow-up assessments of 3 key domains of social cognition (emotional processing, theory of mind, and social/relationship perception), as well as clinical ratings of real-world functioning and symptoms. Scores on all 3 social cognitive tests demonstrated good longitudinal stability with test-retest correlations exceeding .70. Higher baseline and 12-month social cognition scores were both robustly associated with significantly better work functioning, independent living, and social functioning at the 12-month follow-up assessment. Furthermore, cross-lagged panel analyses were consistent with a causal model in which baseline social cognition drove later functional outcome in the domain of work, above and beyond the contribution of symptoms. Social cognitive impairments are relatively stable, functionally relevant features of early schizophrenia. These results extend findings from a companion study, which showed stable impairments across patients in prodromal, first-episode, and chronic phases of illness on the same measures. Social cognitive impairments may serve as useful vulnerability indicators and early clinical intervention targets.
C1 [Horan, William P.] Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Horan, William P.; Green, Michael F.; DeGroot, Michael; Kee, Kimmy; Kern, Robert S.; Lee, Junghee; Sergi, Mark J.; Subotnik, Kenneth L.; Sugar, Catherine A.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Fiske, Alan] Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA.
[Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
[Kee, Kimmy] Calif State Univ, Dept Psychol, Channel Islands, CA USA.
[Sergi, Mark J.] Calif State Univ Northridge, Dept Psychol, Northridge, CA 91330 USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, Semel Inst, Dept Psychiat & Biobehav Sci, 300 Med Plaza,Room 2263, Los Angeles, CA 90095 USA.
EM horan@ucla.edu
RI Lee, Junghee/C-5226-2014
OI Lee, Junghee/0000-0001-9567-8700
FU National Institute of Mental Health Center [MH066286, MH037705,
MH043292]
FX National Institute of Mental Health Center grant P50 (MH066286, MH037705
to K.H.N., MH043292 to M.F.G.).
NR 55
TC 90
Z9 95
U1 3
U2 24
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JUN
PY 2012
VL 38
IS 4
BP 865
EP 872
DI 10.1093/schbul/sbr001
PG 8
WC Psychiatry
SC Psychiatry
GA 979ZX
UT WOS:000306864500028
PM 21382881
ER
PT J
AU DuPriest, EA
Kupfer, P
Lin, B
Sekiguchi, K
Morgan, TK
Saunders, KE
Chatkupt, TT
Denisenko, ON
Purnell, JQ
Bagby, SP
AF DuPriest, E. A.
Kupfer, P.
Lin, B.
Sekiguchi, K.
Morgan, T. K.
Saunders, K. E.
Chatkupt, T. T.
Denisenko, O. N.
Purnell, J. Q.
Bagby, S. P.
TI Altered adipocyte structure and function in nutritionally programmed
microswine offspring
SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE
LA English
DT Article
DE adipose tissue; catch-up growth; maternal protein restriction
ID FOR-GESTATIONAL-AGE; PITUITARY-ADRENAL AXIS; LOW-BIRTH-WEIGHT;
ADIPONECTIN GENE-EXPRESSION; PLASMA-CORTISOL CONCENTRATIONS; MATERNAL
PROTEIN RESTRICTION; INSULIN-RESISTANCE SYNDROME; ADIPOSE-TISSUE;
11-BETA-HYDROXYSTEROID DEHYDROGENASE; VISCERAL ADIPOSITY
AB Adipose tissue (AT) dysfunction links obesity of any cause with cardiometabolic disease, but whether early-life nutritional deficiency can program adipocyte dysfunction independently of obesity is untested. In 3-5-month-old juvenile microswine offspring exposed to isocaloric perinatal maternal protein restriction (MPR) and exhibiting accelerated prepubertal fat accrual without obesity, we assessed markers of acquired obesity: adiponectin and tumor necrosis factor (TNF)-alpha messenger ribonucleic acid (mRNA) levels and adipocyte size in intra-abdominal (ABD-AT) and subcutaneous (SC-AT) adipose tissues. Plasma cortisol, leptin and insulin levels were measured in fetal, neonatal and juvenile offspring. In juvenile low-protein offspring (LPO), adipocyte size in ABD-AT was reduced 22% (P = 0.011 v. controls), whereas adipocyte size in SC-AT was increased in female LPO (P = 0.05) and normal in male LPO; yet, adiponectin mRNA in LPO was low in both sexes and in both depots (P < 0.001). Plasma leptin (P = 0.004) and cortisol (P < 0.05) were reduced only in neonatal LPO during MPR. In juveniles, correlations between % body fat and adiponectin mRNA, TNF-alpha mRNA or plasma leptin were significant in normal-protein offspring (NPO) but absent in LPO. Plasma glucose in juvenile LPO was increased in males but decreased in females (interaction, P = 0.023); plasma insulin levels and insulin sensitivity were unaffected. Findings support nutritional programming of adipocyte size and gene expression and subtly altered glucose homeostasis. Reduced adiponectin mRNA and adipokine dysregulation in juvenile LPO following accelerated growth occurred independently of obesity, adipocyte hypertrophy or inflammatory markers; thus, perinatal MPR and/or growth acceleration can alter adipocyte structure and disturb adipokine homeostasis in metabolically adverse patterns predictive of enhanced disease risk.
C1 [Bagby, S. P.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, Portland, OR 97239 USA.
[DuPriest, E. A.; Bagby, S. P.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA.
[DuPriest, E. A.; Kupfer, P.; Lin, B.; Sekiguchi, K.; Bagby, S. P.] Portland VA Med Ctr, Res Serv, Portland, OR USA.
[DuPriest, E. A.] Warner Pacific Coll, Dept Nat Sci & Hlth, Portland, OR USA.
[Morgan, T. K.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA.
[Saunders, K. E.; Chatkupt, T. T.] Oregon Hlth & Sci Univ, Dept Comparat Med, Portland, OR 97239 USA.
[Denisenko, O. N.] Univ Washington, Dept Med, Seattle, WA USA.
RP Bagby, SP (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Dept Med, 3303 SW Bond Ave,CH12R, Portland, OR 97239 USA.
EM bagbys@ohsu.edu
FU NIH/NICHD [1P01 HD34430, R01 HD042570]; Medical Research Foundation of
Oregon; Eagles Foundation of Spokane, WA; American Heart Association
Pacific Mountain Affiliate Predoctoral Fellowship Award [0415530Z];
Oregon Health & Science University Tartar Trust Fellowship
FX Work was supported by NIH/NICHD 1P01 HD34430, R01 HD042570, Medical
Research Foundation of Oregon, and the Eagles Foundation of Spokane, WA.
EA DuPriest was supported by American Heart Association Pacific Mountain
Affiliate Predoctoral Fellowship Award no. 0415530Z and by the Oregon
Health & Science University Tartar Trust Fellowship.
NR 69
TC 0
Z9 0
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 2040-1744
J9 J DEV ORIG HLTH DIS
JI J. Dev. Orig. Health Dis.
PD JUN
PY 2012
VL 3
IS 3
BP 198
EP 209
DI 10.1017/S2040174412000232
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 984IL
UT WOS:000307183200009
PM 25102010
ER
PT J
AU Puppin, C
Passon, N
Hershman, JM
Filetti, S
Bulotta, S
Celano, M
Russo, D
Damante, G
AF Puppin, Cinzia
Passon, Nadia
Hershman, Jerome M.
Filetti, Sebastiano
Bulotta, Stefania
Celano, Marilena
Russo, Diego
Damante, Giuseppe
TI Cooperative effects of SAHA and VPA on NIS gene expression and
proliferation of thyroid cancer cells
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; SODIUM-IODIDE SYMPORTER; SODIUM/IODIDE
SYMPORTER; NA+/I-SYMPORTER; UPSTREAM ENHANCER; BREAST-CANCER; VALPROIC
ACID; ACETYLATION; H3; IDENTIFICATION
AB Histone deacetylase inhibitors (HDACi) have shown both anti-proliferative and redifferentiating effects in thyroid cancer cells. Also, they induce the expression of the sodium-iodide symporter gene (NIS (SLC5A5)), a crucial step for radioiodine treatment of thyroid malignancies. Here we investigated the effects of suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA) on BCPAP and FRO thyroid cancer cells, extending our analysis on the epigenetic mechanisms underlying the NIS gene expression stimulation. In both cell lines we found a cooperative effect of the two compounds on either cell viability and NIS gene expression, resulting in acquired/increased ability to uptake the radioiodine. Such effect was specific since it was not observed for expression of other genes or when SAHA was used in combination with trichostatin A. By using chromatin immunoprecipitation, we investigated epigenetic mechanisms underlying SAHA and VPA effects. Cooperation among the two HDACi occurred on H3 histone trimethylation at lysine 4 (H3K4me3) and not on histone acetylation. However, effects on H3K4me3 were detected only at the level of NIS Proximal Basal Promoter (NIS-PBP) in FRO cells and only at the level of NIS Upstream Enhancer (NIS-NUE) in BCPAP cells. Our data indicate that epigenetic changes are involved in the synergistic effects of VPA and SAHA on NIS gene expression and that the cellular context modifies effects of HDACi in terms of H3K4me3 target sequence. Investigation of cooperation among different HDACi may provide clues for better defining their mechanism of action in view of their use in thyroid cancer treatment. Journal of Molecular Endocrinology (2012) 48, 217-227
C1 [Puppin, Cinzia; Passon, Nadia; Damante, Giuseppe] Univ Udine, Dipartimento Sci Med & Biol, I-33100 Udine, Italy.
[Hershman, Jerome M.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Filetti, Sebastiano] Univ Roma La Sapienza, Dipartimento Med Interna & Specialita Med, Rome, Italy.
[Bulotta, Stefania; Celano, Marilena; Russo, Diego] Univ Catanzaro, Dipartimento Sci Farmacobiol, Catanzaro, Italy.
[Damante, Giuseppe] Univ S Maria della Misericordia, Azienda Osped, Udine, Italy.
RP Damante, G (reprint author), Univ Udine, Dipartimento Sci Med & Biol, Piazzale Kolbe 1, I-33100 Udine, Italy.
EM giuseppe.damante@uniud.it
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 10296]; MIUR
(PRIN) [20093WAPIK_003]
FX This work was supported by grants to G D from Associazione Italiana per
la Ricerca sul Cancro (AIRC) (grant number IG 10296) and MIUR (PRIN
grant number 20093WAPIK_003).
NR 51
TC 8
Z9 8
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 0952-5041
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD JUN
PY 2012
VL 48
IS 3
BP 217
EP 227
DI 10.1530/JME-11-0063
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 985PI
UT WOS:000307279100006
ER
PT J
AU Hosain, GMM
Khan, MM
Amiel, GE
Lerner, SP
Latini, DM
Chen, GJ
AF Hosain, G. M. Monawar
Khan, Myrna M.
Amiel, Gilad E.
Lerner, Seth P.
Latini, David M.
Chen, G. John
TI RACIAL/ETHNIC DIFFERENCES IN UPPER-TRACT UROTHELIAL CANCER
SO ETHNICITY & DISEASE
LA English
DT Article
DE Race/ethnicity; Urothelial Cancer; Difference; SEER Program
ID UPPER URINARY-TRACT; BLADDER-CANCER; AFRICAN-AMERICAN; PROSTATE-CANCER;
BREAST-CANCER; LYMPH-NODES; PELVIC LYMPHADENECTOMY; RACIAL DISPARITY;
BLACK PATIENTS; WHITE PATIENTS
AB Objectives: Information on clinical characteristics, pattern of initial treatment and survival in patient with upper-tract urothelial carcinomas (UTUC) is scarce. Our study examined the racial/ethnic differences in patients diagnosed with incident UTUC.
Design: Observational study. The data analyses included: proportion and ANOVA for categorical and continuous variables, respectively; Kaplan-Meier method for calculating overall survival; and Cox-proportional hazards models for obtaining adjusted hazard-ratios.
Setting: Regions of the Surveillance, Epidemiology and End Results (SEER).
Patients or Participants: 16,702 incident UTUC patients identified from the SEER dataset 1988-2007 (14,192 White, 967 Hispanic, 718 African American and 825 Asian).
Interventions: None.
Main Outcome Measures: Race/ethnicity-specific distributions of demographics, tumor characteristics, patterns of initial treatment, and survival.
Results: African American and Hispanic patients were diagnosed at a younger age than Whites and Asians (P=.001). Hispanics were more likely to be diagnosed with larger tumor size than Whites and Asians (P<.0001). Asians were more likely to be diagnosed with advanced stage and higher tumor grade. Cox-regression revealed that Whites and Asians were significantly less likely to die after UTUC diagnosis than African Americans (HR=.78, 95% CI=.67.91 and HR=.75, 95% C1.61.91, respectively; all P=<.01).
Conclusions: Our study found that Asians had worse tumor characteristics at the initial presentation than the other groups in this study, but that their risk of dying was lower. Further research is needed to include a larger number of Asian patients to examine subgroup differences and to confirm the paradoxical finding of higher survival with poor clinical characteristics. (Ethn Dis. 2012;22[3]:295-301)
C1 [Hosain, G. M. Monawar; Khan, Myrna M.; Chen, G. John] VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA.
[Khan, Myrna M.; Amiel, Gilad E.; Lerner, Seth P.; Latini, David M.; Chen, G. John] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
RP Hosain, GMM (reprint author), DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM monawarhosain@gmail.com
OI Latini, David/0000-0002-6161-4861
FU Houston VA HSR&D Center of Excellence [HFP90-020]
FX This work was supported in part by the Houston VA HSR&D Center of
Excellence (HFP90-020). The views expressed reflect those of the authors
and not necessarily those of the Department of Veterans Affairs (Baylor
College of Medicine).
NR 37
TC 1
Z9 2
U1 1
U2 2
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2012
VL 22
IS 3
BP 295
EP 301
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 978EP
UT WOS:000306723700007
PM 22870572
ER
PT J
AU Sawers, A
Hahn, ME
AF Sawers, Andrew
Hahn, Michael E.
TI Regulation of whole-body frontal plane balance varies within a step
during unperturbed walking
SO GAIT & POSTURE
LA English
DT Article
DE Balance; Gait; Variability; Motor control; Rehabilitation
ID LATERAL MOTION; STABILIZATION
AB This study sought to determine whether the need to actively control lateral balance is consistent within a step. Variability of the frontal plane COM-Ankle angle was calculated over 50 strides at discrete gait events for twenty-one healthy young adults to quantify active control of lateral balance within a step. Frontal plane COM-Ankle angle variability was found to vary significantly between all gait events, decreasing progressively within a step. This suggests that active control of lateral balance varies significantly within a step and that the greatest degree of active control occurs at heel-strike. The increased active control of lateral balance during heel-strike indicates a degree of preparation to ensure sufficient lateral balance control prior to more challenging events. These results provide insight into the mechanisms of lateral balance control and how to assess and treat locomotor balance control impairments. Published by Elsevier B.V.
C1 [Sawers, Andrew; Hahn, Michael E.] Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Dept Vet Affairs VA, VA Puget Sound, Seattle, WA 98108 USA.
[Sawers, Andrew] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Hahn, Michael E.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
RP Hahn, ME (reprint author), Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Dept Vet Affairs VA, VA Puget Sound, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM mehahn@u.washington.edu
FU Center of Excellence grant from the Department of Veterans Affairs,
Rehabilitation Research and Development [A4843C]
FX This research was supported by a Center of Excellence grant (A4843C)
from the Department of Veterans Affairs, Rehabilitation Research and
Development.
NR 16
TC 7
Z9 7
U1 1
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0966-6362
J9 GAIT POSTURE
JI Gait Posture
PD JUN
PY 2012
VL 36
IS 2
BP 322
EP 324
DI 10.1016/j.gaitpost.2012.03.003
PG 3
WC Neurosciences; Orthopedics; Sport Sciences
SC Neurosciences & Neurology; Orthopedics; Sport Sciences
GA 976YP
UT WOS:000306623600030
PM 22465707
ER
PT J
AU Flint, LA
Sudore, RL
Widera, E
AF Flint, Lynn A.
Sudore, Rebecca L.
Widera, Eric
TI Assessing Financial Capacity Impairment in Older Adults
SO GENERATIONS-JOURNAL OF THE AMERICAN SOCIETY ON AGING
LA English
DT Article
ID COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; DEMENTIA; COMPETENCE;
CAREGIVERS; ABILITIES
C1 [Flint, Lynn A.; Sudore, Rebecca L.; Widera, Eric] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Flint, Lynn A.; Sudore, Rebecca L.; Widera, Eric] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
RP Flint, LA (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
EM lynn.flint@ucsf.edu; rebecca.sudore@ucsf.edu; eric.widera@ucsf.edu
NR 17
TC 3
Z9 3
U1 0
U2 2
PU AMER SOC AGING
PI SAN FRANCISCO
PA 833 MARKET ST, STE 511, SAN FRANCISCO, CA 94103-1824 USA
SN 0738-7806
J9 GENERATIONS
JI Generations-J. Am. Soc. Aging
PD SUM
PY 2012
VL 36
IS 2
BP 59
EP 65
PG 7
WC Gerontology
SC Geriatrics & Gerontology
GA 970DL
UT WOS:000306108200010
ER
PT J
AU Leykum, L
Kumar, P
Parchman, M
McDaniel, RR
Lanham, H
Agar, M
AF Leykum, Luci
Kumar, Pradeep
Parchman, Michael
McDaniel, Reuben R.
Lanham, Holly
Agar, Michael
TI Use of an Agent-Based Model to Understand Clinical Systems
SO JASSS-THE JOURNAL OF ARTIFICIAL SOCIETIES AND SOCIAL SIMULATION
LA English
DT Article
DE Healthcare Delivery; Sensemaking; Clinical Systems
ID RANDOMIZED-TRIAL; PRIMARY-CARE; INTERVENTION; REMINDERS
AB Health care improvement efforts often focus on changing the behavior of individuals while the interdependencies among individuals are overlooked. The application of complex adaptive systems approach to studying healthcare delivery changes the focus of improvement efforts from the individual to the relationships and interdependencies among individuals in the system. Sensemaking and improvising are social activities that take place in the context of relationships between individuals. We explore the impact of sensemaking and improvising on patient outcomes in healthcare settings. We conducted an in-depth observational study of relationships in inpatient general medicine teams. Data collection focused on examining associations between team relationship behaviors of sensemaking and improvising and patient outcomes. Data analysis revealed that these activities were positively associated with patient outcomes. Based on these observational data and findings, we developed an agent-based model to further explore and clarify the relationships between sensemaking and improvising on physician teams and patient outcomes. Specifically, we used the agent-based model to simulate the impact of variation in physicians' sensemaking and improvisation abilities on patient length of stay, the likelihood of a patient worsening or developing complications, the need for transfer to a higher level of care, and mortality. Our in-depth study indicates that systematic differences in patient outcomes are associated with differences in the capacity of physician teams to effectively make sense and improvise in the dynamic conditions inherent in healthcare systems. The results of our simulation demonstrate that an agent-based modeling approach is feasible and useful for exploring the impact of physician team behaviors on patient outcomes. This finding suggests the need for new tools and approaches to improve sensemaking and improvisation in physician care teams as strategies to improve patient outcomes.
C1 [Leykum, Luci; Lanham, Holly] UTHSCSA, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Kumar, Pradeep] Univ Texas, Austin, TX USA.
[Parchman, Michael] Univ Texas Hlth Sci Ctr, San Antonio, TX USA.
[McDaniel, Reuben R.] McCombs Sch Business, Austin, TX USA.
[Agar, Michael] Ethknoworks, Santa Fe, NM USA.
RP Leykum, L (reprint author), Univ Texas Hlth Sci Ctr, Sch Med, Off Dean 373L,7703 Floyd Curl Dr, San Antonio, TX 78209 USA.
EM leykum@uthscsa.edu; pradeepkumar23@ymail.com; parchman@uthscsa.edu;
reuben.mcdaniel@mccombs.utexas.edu; lanham@uthscsa.edu;
magar@anth.umd.edu
NR 25
TC 4
Z9 4
U1 1
U2 13
PU J A S S S
PI GUILDFORD
PA UNIV SURREY, DEPT SOCIOLOGY, GUILDFORD GU2 7XH, SURREY, ENGLAND
SN 1460-7425
J9 JASSS-J ARTIF SOC S
JI JASSS
PD JUN
PY 2012
VL 15
IS 3
AR 2
PG 25
WC Social Sciences, Interdisciplinary
SC Social Sciences - Other Topics
GA 976FY
UT WOS:000306567500008
ER
PT J
AU Zhao, J
Wei, JX
Mialki, R
Zou, CB
Mallampalli, RK
Zhao, YT
AF Zhao, Jing
Wei, Jianxin
Mialki, Rachel
Zou, Chunbin
Mallampalli, Rama K.
Zhao, Yutong
TI Extracellular Signal-regulated Kinase (ERK) Regulates Cortactin
Ubiquitination and Degradation in Lung Epithelial Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID LIGHT-CHAIN KINASE; F-BOX PROTEINS; KAPPA-B-ALPHA; ARP2/3 COMPLEX;
TYROSINE PHOSPHORYLATION; ACTIN POLYMERIZATION; BETA-TRCP; BARRIER
ENHANCEMENT; PROTEASOME PATHWAY; MIGRATION
AB Cortactin, an actin-binding protein, is essential for cell growth and motility. We have shown that cortactin is regulated by reversible phosphorylation, but little is known regarding cortactin protein stability. Here, we show that lipopolysaccharide (LPS)-induced cortactin degradation is mediated by extracellular regulated signal kinase (ERK). LPS induces cortactin serine phosphorylation, ubiquitination, and degradation in mouse lung epithelia, an effect abrogated by ERK inhibition. Serine phosphorylation sites mutant, cortactin(S405A/S418A), enhances its protein stability. Cortactin is polyubiquitinated and degraded within the proteasome, whereas a cortactin(K79R) mutant exhibited proteolytic stability during cyclohexamide (CHX) or LPS treatment. The E3 ligase subunit beta-Trcp interacts with cortactin, and its overexpression reduced cortactin protein levels, an effect attenuated by ERK inhibition. Overexpression of beta-Trcp was sufficient to reduce the protective effects of exogenous cortactin on epithelial cell barrier integrity, an effect not observed after expression of a cortactin(K79R) mutant. These results provide evidence that LPS modulation of cortactin stability is coordinately regulated by stress kinases and the ubiquitin-proteasomal network.
C1 [Zhao, Jing; Wei, Jianxin; Mialki, Rachel; Zou, Chunbin; Mallampalli, Rama K.; Zhao, Yutong] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA.
RP Zhao, J (reprint author), Univ Pittsburgh, Dept Med, 3459 5th Ave,MUH NW628, Pittsburgh, PA 15213 USA.
EM zhaoj@upmc.edu
RI Wei, Jianxin/P-5431-2016
FU National Institutes of Health [R01 HL091916, R01 HL096376, R01 HL097376,
R01 HL098174]; United States Department of Veterans Affairs; American
Heart Association Scientist Development [12SDG9050005]; United States
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Biomedical Laboratory Research and
Development
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01 HL091916 (to Y. Z.), and R01 HL096376, R01 HL097376,
and R01 HL098174 (to R. K. M.). This work was also supported by a Merit
Review Award from the United States Department of Veterans Affairs and
American Heart Association Scientist Development Grant 12SDG9050005 (to
J. Z.). This material is based upon work supported, in part, by the
United States Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development.
NR 52
TC 12
Z9 12
U1 2
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 1
PY 2012
VL 287
IS 23
BP 19105
EP 19114
DI 10.1074/jbc.M112.339507
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 974EF
UT WOS:000306411900021
PM 22514278
ER
PT J
AU Kearney, DJ
Milton, ML
Malte, CA
McDermott, KA
Martinez, M
Simpson, TL
AF Kearney, David J.
Milton, Meredith L.
Malte, Carol A.
McDermott, Kelly A.
Martinez, Michelle
Simpson, Tracy L.
TI Participation in mindfulness-based stress reduction is not associated
with reductions in emotional eating or uncontrolled eating
SO NUTRITION RESEARCH
LA English
DT Article
DE Food intake; Posttraumatic stress disorders; Eating behavior;
Meditation; Longitudinal studies; Veterans
ID DIALECTICAL BEHAVIOR-THERAPY; FOOD-FREQUENCY QUESTIONNAIRE; TERM
WEIGHT-LOSS; BODY-MASS INDEX; QUALITY-OF-LIFE; COGNITIVE THERAPY; WOMEN;
OBESITY; PROGRAM; DISINHIBITION
AB The adverse health effects and increasing prevalence of obesity in the United States make interventions for obesity a priority in health research. Diet-focused interventions generally do not result in lasting reductions in weight. Behavioral interventions that increase awareness of eating cues and satiety have been postulated to result in healthier eating habits. We hypothesized that participation in a program called mindfulness-based stress reduction (MBSR) would positively influence the eating behaviors and nutritional intake of participants through changes in emotional eating (EE), uncontrolled eating (UE), and type and quantity of food consumed. Forty-eight veterans at a large urban Veterans Administration medical center were assessed before MBSR, after MBSR, and 4 months later. For all participants (N = 48), MBSR participation was not associated with significant changes in EE or UE. In addition, there were no significant differences in the intake of energy, fat, sugar, fruit, or vegetables at either follow-up time point as compared with baseline.. Enhanced mindfulness skills and reduced depressive symptoms were seen over time with medium to large effect sizes. Changes in mindfulness skills were significantly and negatively correlated with changes in EE and UE over time. Overall, there was no evidence that participation in MBSR was associated with beneficial changes in eating through reductions in disinhibited eating or significant changes in dietary intake. Randomized studies are needed to further define the relationship between mindfulness program participation and eating behaviors. Published by Elsevier Inc.
C1 [Kearney, David J.] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA.
[Milton, Meredith L.] Bastyr Univ, Sch Nutr & Exercise Sci, Kenmore, WA USA.
[Malte, Carol A.; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA.
[Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA USA.
[Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Kearney, DJ (reprint author), Seattle VAMC 111GI, Seattle, WA 98108 USA.
EM david.kearney@va.gov
NR 52
TC 16
Z9 17
U1 6
U2 69
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD JUN
PY 2012
VL 32
IS 6
BP 413
EP 420
DI 10.1016/j.nutres.2012.05.008
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 973XE
UT WOS:000306392800004
PM 22749177
ER
PT J
AU Zhang, Y
Nateras, OS
Peng, Q
Rosende, CA
Duong, TQ
AF Zhang, Yi
Nateras, Oscar San Emeterio
Peng, Qi
Rosende, Carlos A.
Duong, Timothy Q.
TI Blood Flow MRI of the Human Retina/Choroid during Rest and Isometric
Exercise
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INTRAOCULAR-PRESSURE; OCULAR HEMODYNAMICS; PERFUSION; AUTOREGULATION;
INVERSION; RELAXATION; EFFICIENCY; RETINA; RABBIT; WATER
AB PURPOSE. To investigate blood flow (BF) in the human retina/choroid during rest and handgrip isometric exercise using magnetic resonance imaging (MRI).
METHODS. Four healthy volunteers (25-36 years old) in multiple sessions (1-3) on different days. MRI studies were performed on a 3-Tesla scanner using a custom-made surface coil (7 x 5cm in diameter) at the spatial resolution of 0.5 x 0.8 x 6.0 mm. BF was measured using the pseudo-continuous arterial-spin-labeling technique with background suppression and turbo-spin-echo acquisition. During MRI, subjects rested for 1 minute followed by 1 minute of handgrip, repeating three times, while maintaining stable eye fixation on a target with cued eye blinks at the end of each data acquisition (every 4.6 seconds).
RESULTS. Robust BF of the unanesthetized human retina/choroid was detected. Basal BF in the posterior retina/choroid was 149 +/- 48 mL/100 mL/min with a mean heart rate of 60 +/- 5 beats per minute, mean arterial pressure of 78 +/- 5 mm Hg, ocular perfusion pressure of 67 +/- 4 mm Hg at rest (mean +/- SD, n = 4 subjects). Handgrip significantly increased retina/choroid BF by 25% +/- 7%, heart rate by 19% +/- 8%, mean arterial pressure by 22% +/- 5% (measured at the middle of the handgrip task), and ocular perfusion pressure by 25% +/- 6% (averaged across the entire handgrip task) (P < 0.01), but did not change intraocular pressure, arterial oxygen saturation, end-tidal CO2, and respiration rate (P > 0.05).
CONCLUSIONS. This study demonstrates a novel MRI application to image quantitative BF of the human retina/choroid during rest and isometric exercise. Retina/choroid BF increases during brief handgrip exercise, paralleling increases in mean arterial pressure. Handgrip exercise changes ocular perfusion pressure free of potential drug side effect and can be done in the MRI scanner. MRI offers quantitative BF with large field of view without depth limitation, potentially providing insights into retinal pathophysiology. (Invest Ophthalmol Vis Sci. 2012;53:4299-4305) DOI:10.1167/iovs.11-9384
C1 [Zhang, Yi; Nateras, Oscar San Emeterio; Peng, Qi; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Rosende, Carlos A.; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Zhang, Yi; Peng, Qi; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008
FU Pilot grant via the Clinical Translational Science Award (CTSA)
[UL1RR025767]; Translational Technology Resource grant via the Clinical
Translational Science Award (CTSA) [UL1RR025767]; NIH/NEI [R01 EY014211,
EY018855]; Department of Veterans Affairs
FX Supported by a Pilot grant (TQD) and a Translational Technology Resource
grant (QP) via the Clinical Translational Science Award (CTSA, Parent
Grant UL1RR025767), NIH/NEI Grants R01 EY014211 and EY018855 (TQD), and
a MERIT award from the Department of Veterans Affairs (TQD).
NR 39
TC 15
Z9 15
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2012
VL 53
IS 7
BP 4299
EP 4305
DI 10.1167/iovs.11-9384
PG 7
WC Ophthalmology
SC Ophthalmology
GA 971CM
UT WOS:000306181200121
PM 22661466
ER
PT J
AU Shores, MM
Smith, NL
Forsberg, CW
Anawalt, BD
Matsumoto, AM
AF Shores, Molly M.
Smith, Nicholas L.
Forsberg, Christopher W.
Anawalt, Bradley D.
Matsumoto, Alvin M.
TI Testosterone Treatment and Mortality in Men with Low Testosterone Levels
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID LOW SERUM TESTOSTERONE; ANDROGEN DEFICIENCY SYNDROMES; CLINICAL-PRACTICE
GUIDELINE; QUALITY-OF-LIFE; ELDERLY-MEN; VETERANS-AFFAIRS;
HEART-FAILURE; DOUBLE-BLIND; OLDER MEN; RISK
AB Context: Low testosterone levels in men have been associated with increased mortality. However, the influence of testosterone treatment on mortality in men with low testosterone levels is not known.
Objective: The objective of the study was to examine the association between testosterone treatment and mortality in men with low testosterone levels.
Design: This was an observational study of mortality in testosterone-treated compared with untreated men, assessed with time-varying, adjusted Cox proportional hazards regression models. Effect modification by age, diabetes, and coronary heart disease was tested a priori.
Setting: The study was conducted with a clinical database that included seven Northwest Veterans Affairs medical centers.
Patients: Patients included a cohort of 1031 male veterans, aged older than 40 yr, with low total testosterone [<= 250 ng/dl (8.7 nmol/liter)] and no history of prostate cancer, assessed between January 2001 and December 2002 and followed up through the end of 2005.
Main Outcome Measure: Total mortality in testosterone-treated compared with untreated men was measured.
Results: Testosterone treatment was initiated in 398 men (39%) during routine clinical care. The mortality in testosterone-treated men was 10.3% compared with 20.7% in untreated men (P<0.0001) with a mortality rate of 3.4 deaths per 100 person-years for testosterone-treated men and 5.7 deaths per 100 person-years in men not treated with testosterone. After multivariable adjustment including age, body mass index, testosterone level, medical morbidity, diabetes, and coronary heart disease, testosterone treatment was associated with decreased risk of death (hazard ratio 0.61; 95% confidence interval 0.42-0.88; P = 0.008). No significant effect modification was found by age, diabetes, or coronary heart disease.
Conclusions: In an observational cohort of men with low testosterone levels, testosterone treatment was associated with decreased mortality compared with no testosterone treatment. These results should be interpreted cautiously because residual confounding may still be a source of bias. Large, randomized clinical trials are needed to better characterize the health effects of testosterone treatment in older men with low testosterone levels. (J Clin Endocrinol Metab 97: 2050-2058, 2012)
C1 [Shores, Molly M.; Smith, Nicholas L.; Forsberg, Christopher W.; Matsumoto, Alvin M.] Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Smith, Nicholas L.; Forsberg, Christopher W.] VA Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA.
[Matsumoto, Alvin M.] VA Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.
[Shores, Molly M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98105 USA.
[Smith, Nicholas L.] Univ Washington, Dept Epidemiol, Seattle, WA 98105 USA.
[Anawalt, Bradley D.; Matsumoto, Alvin M.] Univ Washington, Dept Med, Seattle, WA 98105 USA.
[Smith, Nicholas L.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA.
RP Shores, MM (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116PES, Seattle, WA 98108 USA.
EM molly.shores@va.gov
FU Abbott; GSK; BHR Pharmaceuticals; Department of Veterans Affairs, Office
of Research and Development; Veterans Affairs Puget Sound Health Care
System; Royalty Research Fund of the University of Washington
FX This manuscript is based on work supported in part by the Department of
Veterans Affairs, Office of Research and Development, and the Veterans
Affairs Puget Sound Health Care System, and the Royalty Research Fund of
the University of Washington. Analytic support was provided by the
Cooperative Studies Seattle Epidemiologic Research and Information
Center of the Veterans Affairs Office of Research and Development,
Seattle, Washington. The content of this article does not necessarily
represent the views of the Department of Veterans Affairs or the U. S.
Government. We thank Daniel Kivlahan, Ph.D., who provided excellent
consultation for the grant proposal for this study, and Margaret Moroz
for technical support. M.M.S. had full access to all of the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.; Disclosure Summary: A.M.M. received
research support from Abbott, GSK, and BHR Pharmaceuticals and served on
advisory boards for Abbott, Endo Pharmaceuticals, Ligand
Pharmaceuticals, and Trimmel. All other authors have no disclosures to
make.
NR 35
TC 176
Z9 181
U1 0
U2 10
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2012
VL 97
IS 6
BP 2050
EP 2058
DI 10.1210/jc.2011-2591
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 970AP
UT WOS:000306100800058
PM 22496507
ER
PT J
AU Heckman, CJ
Darlow, S
Cohen-Filipic, J
Kloss, JD
Manne, SL
Munshi, T
Perlis, CS
AF Heckman, Carolyn J.
Darlow, Susan
Cohen-Filipic, Jessye
Kloss, Jacqueline D.
Manne, Sharon L.
Munshi, Teja
Perlis, Clifford S.
TI Psychosocial Correlates of Sunburn among Young Adult Women
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE sunburn; young adult women; psychosocial correlates; sunscreen; Health
Beliefs Model; skin cancer prevention
ID SUN PROTECTION PRACTICES; INDOOR TANNING BEHAVIORS; SKIN-CANCER;
SUNSCREEN USE; MALIGNANT-MELANOMA; HEALTH BELIEFS; ATTITUDES;
ADOLESCENTS; STUDENTS; NORMS
AB Skin cancer is an increasingly common disease, particularly among young adult women. Sunburn early in life is a risk factor for skin cancer. Few studies have reported on psychosocial correlates of sunburn. The current study consisted of an online survey of undergraduate women from a university in the northeastern part of the USA. A logistic regression demonstrated that young women who reported a history of four or more sunburns were significantly more likely to report fair skin, higher perceived susceptibility to skin cancer, greater perceived benefits of tanning (e.g., appearance enhancement), lower perceived control over skin protection, and more frequent sunscreen use. Sunbathing was not associated with a greater number of sunburns. These results suggest that young women who sunburn more often possess other skin cancer risk factors, are aware of their susceptibility to skin cancer, and try to use sunscreen, but feel limited control over their skin protection behavior and are not less likely to sunbathe than others. Therefore, interventions are needed to assist high risk young women in asserting more control over their sun protection behavior and perhaps improve the effectiveness of the sunscreen or other skin protection methods they do employ.
C1 [Heckman, Carolyn J.; Darlow, Susan; Munshi, Teja; Perlis, Clifford S.] Fox Chase Canc Ctr, Canc Prevent & Control Program, Philadelphia, PA 19111 USA.
[Cohen-Filipic, Jessye] Portland VA Med Ctr, Portland, OR 97239 USA.
[Kloss, Jacqueline D.] Drexel Univ, Dept Psychol, Philadelphia, PA 19104 USA.
[Manne, Sharon L.] Canc Inst New Jersey, Canc Prevent & Control Program, New Brunswick, NJ 08901 USA.
RP Heckman, CJ (reprint author), Fox Chase Canc Ctr, Canc Prevent & Control Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.
EM Carolyn.Heckman@fccc.edu; susan.darlow@fccc.edu; jessyecohen@gmail.com;
jdk29@drexel.edu; mannesl@umdnj.edu; teja.munshi@fccc.edu;
clifford.perlis@fccc.edu
FU Cancer Center Grant [R03CA1504202, P30CA006927]
FX This work was funded by R03CA1504202 (CH) and P30CA006927 (Cancer Center
Grant). The authors would like to thank Jeanne Pomenti, BS for her
technical assistance in the preparation of this manuscript and Sara
Filseth, BA for her assistance with data collection.
NR 48
TC 8
Z9 8
U1 0
U2 11
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN
PY 2012
VL 9
IS 6
BP 2241
EP 2251
DI 10.3390/ijerph9062241
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA 966AM
UT WOS:000305808900016
PM 22829801
ER
PT J
AU Munhall, AC
Wu, YN
Belknap, JK
Meshul, CK
Johnson, SW
AF Munhall, Adam C.
Wu, Yan-Na
Belknap, John K.
Meshul, Charles K.
Johnson, Steven W.
TI NMDA alters rotenone toxicity in rat substantia nigra zona compacta and
ventral tegmental area dopamine neurons
SO NEUROTOXICOLOGY
LA English
DT Article
DE Dendrite; Histology; N-methyl-D-aspartate; Rotenone; Substantia nigra;
Ventral tegmental area
ID PARKINSONS-DISEASE; NEUROTROPHIC FACTOR; COMPLEX-I; RECEPTOR CHANNELS;
BRAIN SLICES; CELL-DEATH; NEUROPROTECTION; CURRENTS; DEGENERATION;
STIMULATION
AB Previous patch-clamp studies by our laboratory showed that acute exposure to the pesticide rotenone augments inward currents evoked by N-methyl-D-aspartate (NMDA) in substantia nigra zona compacta (SNC) dopamine neurons in slices of rat brain. The present experiments were done to search for histological evidence of increased neurotoxicity produced by combined rotenone and NMDA treatments. In horizontal slices of rat midbrain, we found that a 30 min superfusion with 100 nM rotenone caused significant injury to tyrosine hydroxylase (TH)-positive proximal dendrites in dorsal and ventral regions of the SNC and ventral tegmental area (VTA). Moreover, treatment with 100 mu M NMDA potentiated rotenone toxicity. In contrast, treatment with 30 mu M NMDA protected against rotenone-induced injury to dendrites in the ventral SNC and ventral VTA. Interestingly, treatment with 30 mu M NMDA-alone produced an apparent increase in proximal dendrite scores in ventral SNC and dorsal VTA. We conclude that NMDA has concentration-dependent actions on rotenone toxicity that differ according to regional subtype of dopamine neuron. Published by Elsevier Inc.
C1 [Johnson, Steven W.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR 97239 USA.
[Belknap, John K.; Meshul, Charles K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
[Belknap, John K.; Meshul, Charles K.; Johnson, Steven W.] Vet Affairs Med Ctr, Portland, OR 97207 USA.
RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, R&D-61,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM johnsost@ohsu.edu
FU Department of Veterans Affairs; American Parkinson's Disease
Association; Portland Veterans Affairs Parkinson's Disease Research,
Education, and Clinical Center
FX This research was supported by Department of Veterans Affairs Merit
Review grants (SWJ and CKM), a grant from the American Parkinson's
Disease Association (SWJ), and by the Portland Veterans Affairs
Parkinson's Disease Research, Education, and Clinical Center (SWJ).
NR 37
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0161-813X
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD JUN
PY 2012
VL 33
IS 3
BP 429
EP 435
DI 10.1016/j.neuro.2012.04.006
PG 7
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA 951OO
UT WOS:000304730100019
PM 22521663
ER
PT J
AU Marcus, SC
Bridge, JA
Olfson, M
AF Marcus, Steven C.
Bridge, Jeffrey A.
Olfson, Mark
TI Payment Source and Emergency Management of Deliberate Self-Harm
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID QUALITY-OF-CARE; SUICIDE ATTEMPTS; COMPLETED SUICIDE; MENTAL-HEALTH;
FOLLOW-UP; COHORT; RISK; REPEAT; HOSPITALIZATION; PREVENTION
AB Objectives. We investigated whether health insurance type (private vs Medicaid) influences the delivery of acute mental health care to patients with deliberate self-harm.
Methods. Using National Medicaid Analytic Extract Files (2006) and Market-Scan Research Databases (2005-2007), we analyzed claims focusing on emergency episodes of deliberate self-harm of Medicaid- (n = 8228) and privately (n = 2352) insured adults. We analyzed emergency department mental health assessments and outpatient mental health visits in the 30 days following the emergency visit for discharged patients.
Results. Medicaid-insured patients were more likely to be discharged (62.7%), and among discharged patients they were less likely to receive a mental health assessment in the emergency department (47.8%) and more likely to receive follow-up outpatient mental health care (52.9%) than were privately insured patients (46.9%, 57.3%, and 41.2%, respectively).
Conclusions. Acute emergency management of deliberate self-harm is less intensive for Medicaid- than for privately insured patients, although discharged Medicaid-insured patients are more likely to receive follow-up care. Programmatic reforms are needed to improve access to emergency mental health services, especially in hospitals that serve substantial numbers of Medicaid-insured patients. (Am J Public Health. 2012;102:1145-1153. doi:10.2105/AJPH.2011.300598)
C1 [Olfson, Mark] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Olfson, Mark] Columbia Univ, Dept Psychiat, New York, NY USA.
[Marcus, Steven C.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
[Bridge, Jeffrey A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.
[Bridge, Jeffrey A.] Ohio State Univ, Res Inst, Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, Columbus, OH 43210 USA.
RP Olfson, M (reprint author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr, New York, NY 10032 USA.
EM mo49@columbia.edu
FU American Foundation for Suicide Prevention of Columbia University
[2DIG-00005-1207-1208]
FX The American Foundation for Suicide Prevention of Columbia University
supported this study (grant no. 2DIG-00005-1207-1208).
NR 49
TC 6
Z9 6
U1 2
U2 5
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2012
VL 102
IS 6
BP 1145
EP 1153
DI 10.2105/AJPH.2011.300598
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 951LX
UT WOS:000304723200020
PM 22515853
ER
PT J
AU Thase, ME
Kennedy, SH
Larsen, KG
AF Thase, Michael E.
Kennedy, Sidney H.
Larsen, Klaus G.
TI Can a 'true' effect be built on a 'wrong' model? reply
SO BRITISH JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Kennedy, Sidney H.] H Lundbeck & Co AS, Copenhagen, Denmark.
[Larsen, Klaus G.] Univ Toronto, Toronto, ON, Canada.
RP Thase, ME (reprint author), Univ Penn, Sch Med, Suite 689,3535 Market St, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ROYAL COLLEGE OF PSYCHIATRISTS
PI LONDON
PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG,
ENGLAND
SN 0007-1250
J9 BRIT J PSYCHIAT
JI Br. J. Psychiatry
PD JUN
PY 2012
VL 200
IS 6
BP 512
EP 513
DI 10.1192/bjp.200.6.512a
PG 2
WC Psychiatry
SC Psychiatry
GA 959GK
UT WOS:000305300700017
ER
PT J
AU Merrick, DT
AF Merrick, Daniel T.
TI GRP78, Intronic Polymorphisms, and Pharmacogenomics in Non-small Cell
Lung Cancer
SO CHEST
LA English
DT Editorial Material
ID ENDOPLASMIC-RETICULUM
C1 Denver Vet Affairs Med Ctr, Dept Pathol, Denver, CO 80220 USA.
RP Merrick, DT (reprint author), Denver Vet Affairs Med Ctr, Dept Pathol, 113,1055 Clermont St, Denver, CO 80220 USA.
EM Daniel.Merrick@va.gov
FU NCI NIH HHS [P50-CA058187]
NR 8
TC 4
Z9 4
U1 0
U2 1
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUN
PY 2012
VL 141
IS 6
BP 1377
EP 1378
DI 10.1378/chest.11-2662
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 955RT
UT WOS:000305039300004
PM 22670016
ER
PT J
AU Maguen, S
Cohen, B
Cohen, G
Madden, E
Bertenthal, D
Seal, K
AF Maguen, Shira
Cohen, Beth
Cohen, Greg
Madden, Erin
Bertenthal, Daniel
Seal, Karen
TI Gender Differences in Health Service Utilization Among Iraq and
Afghanistan Veterans with Posttraumatic Stress Disorder
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID MENTAL-HEALTH; FEMALE VETERANS; MILITARY SERVICE; CARE SERVICES; VA;
DIAGNOSES; WOMEN; PREVALENCE; SYMPTOMS; EXPOSURE
AB Background: Little is known about gender differences in healthcare use among newly returning veterans with posttraumatic stress disorder (PTSD). We investigated gender differences in Veterans Affairs (VA) medical center health service use among Iraq and Afghanistan veterans with PTSD with and without comorbid depression and alcohol use disorders (AUD).
Methods: Using VA administrative data, bivariate and multivariate statistics were used to examine gender differences in health service use among 159,705 Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) veterans with PTSD seeking VA healthcare from October 7, 2001, to December 31, 2010.
Results: Female veterans with PTSD were more likely to be black and single and to have higher mental health, primary care, and emergency care use compared to men with PTSD. Men were more likely to have higher mental health inpatient use compared to women. Women and men with comorbid PTSD and depression or comorbid PTSD and AUD were more likely to have higher use in all domains compared to their counterparts with PTSD without these comorbid disorders. Women with comorbid PTSD and depression were 12.5 times more likely to have a mental health inpatient hospitalization compared to their female counterparts without depression and twice as likely to have a mental health hospitalization compared to men with comorbid PTSD and depression.
Conclusions: Women with PTSD had higher use than men in almost all areas, as did all veterans with comorbid PTSD and depression and comorbid PTSD and AUD, regardless of gender. Better understanding these health service use differences will allow for targeted evaluation and integrated treatment interventions in veterans with PTSD.
C1 [Maguen, Shira; Cohen, Beth; Cohen, Greg; Madden, Erin; Bertenthal, Daniel; Seal, Karen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Maguen, Shira; Cohen, Beth; Seal, Karen] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Bertenthal, Daniel] Mental Illness Res Educ & Clin Ctr, San Francisco, CA USA.
RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA.
EM shira.maguen@va.gov
FU Department of Defense Concept Award [W81XWH-08-2-0077]; VA Health
Services Research and Development Career Development Award [RCD 06-042]
FX This research was supported by Department of Defense Concept Award Grant
W81XWH-08-2-0077 and VA Health Services Research and Development Career
Development Award RCD 06-042.
NR 33
TC 22
Z9 22
U1 1
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2012
VL 21
IS 6
BP 666
EP 673
DI 10.1089/jwh.2011.3113
PG 8
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA 962VK
UT WOS:000305575100010
PM 22313026
ER
PT J
AU Dodge, HH
Mattek, NC
Austin, D
Hayes, TL
Kaye, JA
AF Dodge, H. H.
Mattek, N. C.
Austin, D.
Hayes, T. L.
Kaye, J. A.
TI In-home walking speeds and variability trajectories associated with mild
cognitive impairment
SO NEUROLOGY
LA English
DT Article
ID ALZHEIMER-DISEASE; OLDER-ADULTS; GAIT; MOBILITY; ABNORMALITY;
DYSFUNCTION; ATTENTION; DEMENTIA; DECLINE; MRI
AB Objective: To determine whether unobtrusive long-term in-home assessment of walking speed and its variability can distinguish those with mild cognitive impairment (MCI) from those with intact cognition.
Methods: Walking speed was assessed using passive infrared sensors fixed in series on the ceiling of the homes of elderly individuals participating in the Intelligent Systems for Assessing Aging Change (ISAAC) cohort study. Latent trajectory models were used to analyze weekly mean speed and walking speed variability (coefficient of variation [COV]).
Results: ISAAC participants living alone included 54 participants with intact cognition, 31 participants with nonamnestic MCI (naMCI), and 8 participants with amnestic MCI at baseline, with a mean follow-up of 2.6 +/- 1.0 years. Trajectory models identified 3 distinct trajectories (fast, moderate, and slow) of mean weekly walking speed. Participants with naMCI were more likely to be in the slow speed group than in the fast (p = 0.01) or moderate (p = 0.04) speed groups. For COV, 4 distinct trajectories were identified: group 1, the highest baseline and increasing COV followed by a sharply declining COV; groups 2 and 3, relatively stable COV; and group 4, the lowest baseline and decreasing COV. Participants with naMCI were more likely to be members of either highest or lowest baseline COV groups (groups 1 or 4), possibly representing the trajectory of walking speed variability for early-and late-stage MCI, respectively.
Conclusion: Walking speed and its daily variability may be an early marker of the development of MCI. These and other real-time measures of function may offer novel ways of detecting transition phases leading to dementia. Neurology (R) 2012; 78: 1946-1952
C1 [Dodge, H. H.; Mattek, N. C.; Austin, D.; Hayes, T. L.; Kaye, J. A.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA.
[Dodge, H. H.; Mattek, N. C.; Kaye, J. A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA.
[Hayes, T. L.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.
[Kaye, J. A.] Portland VA Med Ctr, Neurol Serv, Portland, OR USA.
RP Dodge, HH (reprint author), Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97201 USA.
EM dodgeh@ohsu.edu
OI Kaye, Jeffrey/0000-0002-9971-3478
FU National Institutes of Health [P30-AG024978, R01-AG024059, P30-AG008017,
R01-AG033581]; Intel Corporation
FX Supported by grants from the National Institutes of Health
(P30-AG024978, R01-AG024059, P30-AG008017, and R01-AG033581) and the
Intel Corporation.
NR 40
TC 34
Z9 35
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUN
PY 2012
VL 78
IS 24
BP 1946
EP 1952
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 958ZG
UT WOS:000305278900013
PM 22689734
ER
PT J
AU Restrepo, MI
Anzueto, A
AF Restrepo, Marcos I.
Anzueto, Antonio
TI Global Trends in Community-Acquired Pneumonia Preface
SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
C1 [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm & Crit Care Med, S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX 78229 USA.
[Restrepo, Marcos I.; Anzueto, Antonio] S Texas Vet Hlth Care Syst Audie Murphy VA Hosp, Vet Evidence Res Disseminat & Implementat Ctr VER, San Antonio, TX USA.
RP Restrepo, MI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm & Crit Care Med, S Texas Vet Hlth Care Syst Audie L Murphy Div, 7400 Merton Minter Blvd 11C6, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
RI Restrepo, Marcos/H-4442-2014
FU NHLBI NIH HHS [K23 HL096054]
NR 0
TC 0
Z9 0
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 1069-3424
J9 SEMIN RESP CRIT CARE
JI Semin. Respir. Crit. Care Med.
PD JUN
PY 2012
VL 33
IS 3
BP 211
EP 211
DI 10.1055/s-0032-1315646
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 963PK
UT WOS:000305634500001
PM 22718206
ER
PT J
AU Steinman, MA
Sudore, RL
Peterson, CA
Harlow, JB
Fried, TR
AF Steinman, Michael A.
Sudore, Rebecca L.
Peterson, Carolyn A.
Harlow, John B.
Fried, Terri R.
TI Influence of Patient Age and Comorbid Burden on Clinician Attitudes
Toward Heart Failure Guidelines
SO AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY
LA English
DT Article; Proceedings Paper
CT 34th Annual Meeting of the Society-of-General-Internal-Medicine
CY MAY 04-07, 2011
CL Phoenix, AZ
SP Soc Gen Internal Med
DE aged; clinical practice guidelines; comorbidity; geriatrics; physician
attitudes
ID QUALITY-OF-CARE; ELDERLY-PATIENTS; EFFECTIVE MANAGEMENT; BARRIERS;
TRIAL; THERAPY; RISK; LIFE
AB Background: Clinical practice guidelines have been criticized for insufficient attention to the unique needs of patients of advanced age and with multiple comorbid conditions. However, little empiric research is available to inform this topic.
Methods: We conducted telephone interviews with staff physicians and nurse practitioners in 4 VA health care systems. Respondents were asked to rate the usefulness of national heart failure guidelines for patients of different ages and levels of comorbid burden on a 5-point scale and to comment on the reasons for their ratings.
Results: Of 139 clinicians contacted, 65 (47%) completed the interview. Almost half (49%) were women, and 48 (74%) were general internists or family practitioners. On a 5-point scale assessing the usefulness of clinical practice guidelines for heart failure, the mean (SD) response ranged from 4.4 (0.7) for patients younger than 65 years with few comorbid conditions to 3.5 (1.2) for patients older than 80 years with multiple comorbid conditions (P < 0.001). The difference in perceived usefulness varied more by patient age than by degree of comorbidity (P = 0.02). Four major concepts underlay the perceived usefulness of guidelines across different patient types: (1) harm of treatment and complexity of the patient's clinical condition and pharmacologic needs, (2) expected benefits of treatment, (3) patient preferences and abilities, and (4) confidence in the validity of guideline recommendations.
Conclusion: Clinicians perceive heart failure guidelines to be substantially less useful in patients of older age and with greater comorbid burden. Concerns about the clinical and pharmacologic complexity of these patients and the expected benefits of drug therapy were commonly invoked as reasons for this skepticism. (Am J Geriatr Pharmacother. 2012;10:211-218) Published by Elsevier HS Journals, Inc.
C1 [Steinman, Michael A.; Sudore, Rebecca L.; Peterson, Carolyn A.; Harlow, John B.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA.
[Steinman, Michael A.; Sudore, Rebecca L.; Peterson, Carolyn A.; Harlow, John B.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Harlow, John B.] Med Univ S Carolina, Sch Med, Charleston, SC 29425 USA.
[Fried, Terri R.] Yale Univ, Sch Med, Div Geriatr, New Haven, CT USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU NIA NIH HHS [K23 AG030999, K24 AG028443]
NR 31
TC 4
Z9 4
U1 0
U2 5
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 1543-5946
J9 AM J GERIATR PHARMAC
JI Am. J. Geriatr. Pharmacother.
PD JUN
PY 2012
VL 10
IS 3
BP 211
EP 218
DI 10.1016/j.amjopharm.2012.04.003
PG 8
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA 962LE
UT WOS:000305545800006
PM 22579695
ER
PT J
AU Reidelberger, R
Haver, A
Chelikani, PK
Apenteng, B
Perriotte-Olson, C
Anders, K
Steenson, S
Blevins, JE
AF Reidelberger, Roger
Haver, Alvin
Chelikani, Prasanth K.
Apenteng, Bettye
Perriotte-Olson, Curtis
Anders, Krista
Steenson, Sharalyn
Blevins, James E.
TI Effects of leptin replacement alone and with exendin-4 on food intake
and weight regain in weight-reduced diet-induced obese rats
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE food restriction; hyperphagia; leptin sensitivity; glucagon-like
peptide-1 receptor agonist
ID INTERMITTENT INTRAPERITONEAL INFUSION; Y GASTRIC BYPASS; LOW-DOSE
LEPTIN; BODY-WEIGHT; INTRAVENOUS-INFUSION; RODENT MODELS; GUT HORMONE;
ADIPOSITY; AMYLIN; CHOLECYSTOKININ
AB Weight loss in obese humans produces a relative leptin deficiency, which is postulated to activate potent orexigenic and energy conservation mechanisms to restrict weight loss and promote weight regain. Here we determined whether leptin replacement alone or with GLP-1 receptor agonist exendin-4 attenuates weight regain or promotes greater weight loss in weight-reduced diet-induced obese (DIO) rats. Forty percent restriction in daily intake of a high-fat diet in DIO rats for 4 wk reduced body weight by 12%, body fat by 29%, and plasma leptin by 67% and normalized leptin sensitivity. When food restriction ended, body weight, body fat, and plasma leptin increased rapidly. Daily administration of leptin [3-h intraperitoneal (ip) infusions (4 nmol.kg (-1).h (-1))] at onset and end of dark period for 3 wk did not attenuate hyperphagia and weight regain, nor did it affect mean daily meal sizes or meal numbers. Exendin-4 (50 pmol.kg (-1).h (-1)) infusions during the same intervals prevented postrestriction hyperphagia and weight regain by normalizing meal size. Coadministration of leptin and exendin-4 did not reduce body weight more than exendin-4 alone. Instead, leptin began to attenuate the inhibitory effects of exendin-4 on food intake, meal size, and weight regain by the end of the second week of administration. Plasma leptin in rats receiving leptin was sevenfold greater than in rats receiving vehicle and 17-fold greater than in rats receiving exendin-4. Together, these results do not support the hypothesis that leptin replacement alone or with exendin-4 attenuates weight regain or promotes greater weight loss in weight-reduced DIO rats.
C1 [Reidelberger, Roger; Haver, Alvin; Perriotte-Olson, Curtis] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Vet Affairs Res Serv, Omaha, NE USA.
[Reidelberger, Roger; Haver, Alvin; Chelikani, Prasanth K.; Apenteng, Bettye; Anders, Krista; Steenson, Sharalyn] Creighton Univ, Dept Biomed Sci, Omaha, NE 68178 USA.
[Blevins, James E.] Vet Affairs Puget Sound Hlth Care Syst, Vet Affairs Res Serv, Seattle, WA USA.
[Blevins, James E.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Chelikani, Prasanth K.] Univ Calgary, Gastrointestinal Res Grp, Dept Prod Anim Hlth, Snyder Inst Chron Dis,Fac Vet Med, Calgary, AB, Canada.
RP Reidelberger, R (reprint author), VA NWIHCS 151,4101 Woolworth Ave, Omaha, NE 68105 USA.
EM rogerr@creighton.edu
FU National Institutes of Health [R01-DK-70851, P20-RR-16469]; National
Institutes of Health Diabetes Research Center [P30-DK-17047]; Department
of Veterans Affairs; Veterans Health Administration; Office of Research
and Development; Rehabilitation Research, and Development Service and
Biomedical Laboratory Research and Development
FX This work was performed at the Veterans Affairs Nebraska-Western Iowa
Health Care System and Veterans Affairs Puget Sound Health Care System
and was supported in part by the Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development,
Rehabilitation Research, and Development Service and Biomedical
Laboratory Research and Development. This research was also supported in
part by the National Institutes of Health (R01-DK-70851 and
P20-RR-16469) and the Cellular and Molecular Imaging Core of the
National Institutes of Health Diabetes Research Center (P30-DK-17047).
The contents of this article do not represent the views of the
Department of Veterans Affairs or the US Government.
NR 49
TC 9
Z9 9
U1 0
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JUN
PY 2012
VL 302
IS 12
BP E1576
EP E1585
DI 10.1152/ajpendo.00058.2012
PG 10
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 960XQ
UT WOS:000305426900014
PM 22510712
ER
PT J
AU Velez, JCQ
Ierardi, JL
Bland, AM
Morinelli, TA
Arthur, JM
Raymond, JR
Janech, MG
AF Velez, Juan Carlos Q.
Ierardi, Jessalyn L.
Bland, Alison M.
Morinelli, Thomas A.
Arthur, John M.
Raymond, John R.
Janech, Michael G.
TI Enzymatic processing of angiotensin peptides by human glomerular
endothelial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE angiotensin-converting enzyme; prolylendopeptidase; endothelium
ID CONVERTING-ENZYME; ASPARTYL AMINOPEPTIDASE; PERIPHERAL-TISSUES; ACE2
EXPRESSION; IGA NEPHROPATHY; CLEAVING ENZYME; HUMAN KIDNEY; SYSTEM;
LOCALIZATION; METABOLISM
AB Velez JC, Ierardi JL, Bland AM, Morinelli TA, Arthur JM, Raymond JR, Janech MG. Enzymatic processing of angiotensin peptides by human glomerular endothelial cells. Am J Physiol Renal Physiol 302: F1583-F1594, 2012. First published March 28, 2012; doi: 10.1152/ajprenal.00087.2012.-The intraglomerular renin-angiotensin system (RAS) is linked to the pathogenesis of progressive glomerular diseases. Glomerular podocytes and mesangial cells play distinct roles in the metabolism of angiotensin (ANG) peptides. However, our understanding of the RAS enzymatic capacity of glomerular endothelial cells (GEnCs) remains incomplete. We explored the mechanisms of endogenous cleavage of ANG substrates in cultured human GEnCs (hGEnCs) using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and isotope-labeled peptide quantification. Overall, hGEnCs metabolized ANG II at a significantly slower rate compared with podocytes, whereas the ANG I processing rate was comparable between glomerular cell types. ANG II was the most abundant fragment of ANG I, with lesser amount of ANG-(1-7) detected. Formation of ANG II from ANG I was largely abolished by an ANG-converting enzyme (ACE) inhibitor, whereas ANG-(1-7) formation was decreased by a prolylendopeptidase (PEP) inhibitor, but not by a neprilysin inhibitor. Cleavage of ANG II resulted in partial conversion to ANG-(1-7), a process that was attenuated by an ACE2 inhibitor, as well as by an inhibitor of PEP and prolylcarboxypeptidase. Further fragmentation of ANG-(1-7) to ANG-(1-5) was mediated by ACE. In addition, evidence of aminopeptidase N activity (APN) was demonstrated by detecting amelioration of conversion of ANG III to ANG IV by an APN inhibitor. While we failed to find expression or activity of aminopeptidase A, a modest activity attributable to aspartyl aminopeptidase was detected. Messenger RNA and gene expression of the implicated enzymes were confirmed. These results indicate that hGEnCs possess prominent ACE activity, but modest ANG II-metabolizing activity compared with that of podocytes. PEP, ACE2, prolylcarboxypeptidase, APN, and aspartyl aminopeptidase are also enzymes contained in hGEnCs that participate in membrane-bound ANG peptide cleavage. Injury to specific cell types within the glomeruli may alter the intrarenal RAS balance.
C1 [Velez, Juan Carlos Q.; Ierardi, Jessalyn L.; Bland, Alison M.; Morinelli, Thomas A.; Arthur, John M.; Janech, Michael G.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Velez, Juan Carlos Q.; Arthur, John M.; Janech, Michael G.] Ralph H Johnson Vet Affairs Med Ctr, Med & Res Serv, Charleston, SC USA.
[Raymond, John R.] Med Coll Wisconsin, Dept Med, Div Nephrol, Milwaukee, WI 53226 USA.
RP Velez, JCQ (reprint author), 96 Jonathan Lucas St,Clinical Sci Bldg,Rm 826F, Charleston, SC 29425 USA.
EM velezj@musc.edu
RI Velez, Juan Carlos/N-3782-2016
OI Janech, Michael/0000-0002-3202-4811
FU National Institute of Diabetes and Digestive and Kidney Diseases of the
National Institutes of Health [DK080944-04]; Dialysis Clinics, Inc.;
Ralph H. Johnson Veterans Affairs Med. Ctr.; Veterans Affairs CDA-2
Career Development Award; Nephcure Foundation
FX J.C.V. is supported by the National Institute of Diabetes and Digestive
and Kidney Diseases of the National Institutes of Health, Grant
DK080944-04, Dialysis Clinics, Inc., and the Ralph H. Johnson Veterans
Affairs Med. Ctr. Research Enhancement Award Program. M.G.J. was
supported by a Veterans Affairs CDA-2 Career Development Award and the
Nephcure Foundation Young Investigator Award.
NR 65
TC 18
Z9 19
U1 1
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD JUN
PY 2012
VL 302
IS 12
BP F1583
EP F1594
DI 10.1152/ajprenal.00087.2012
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 960XC
UT WOS:000305425300009
PM 22461301
ER
PT J
AU Vickrey, BG
Hirtz, D
Waddy, S
Cheng, EM
Johnston, SC
AF Vickrey, Barbara G.
Hirtz, Deborah
Waddy, Salina
Cheng, Eric M.
Johnston, S. Claiborne
TI Comparative effectiveness and implementation research: Directions for
Neurology
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID HEALTH-SERVICES RESEARCH; MYOCARDIAL-INFARCTION; ETHNIC DISPARITIES;
CONTROLLED-TRIAL; STROKE; OUTCOMES; WARFARIN; EPILEPSY; THERAPY; ASPIRIN
AB There is an enormous unmet need for knowledge about how new insights from discovery and translational research can yield measurable, population-level improvements in health and reduction in mortality among those having or at risk for neurological disease. Once several, well-conducted randomized controlled trials establish the efficacy of a given therapy, implementation research can generate new knowledge about barriers to uptake of the therapy into widespread clinical care, and what strategies are effective in overcoming those barriers and in addressing health disparities. Comparative effectiveness research aims to elucidate the relative value (including clinical benefit, clinical harms, and/or costs) of alternative efficacious management approaches to a neurological disorder, generally through direct comparisons, and may include comparisons of methodologies for implementation. Congress has recently appropriated resources and established an institute to prioritize funding for such research. Neurologists and neuroscientists should understand the scope and objectives of comparative effectiveness and implementation research, their range of methodological approaches (formal literature syntheses, randomized trials, observational studies, modeling), and existing research resources (centers for literature synthesis, registries, practice networks) relevant to research for neurological conditions, to close the well-documented evidence-to-practice gap. Future directions include building this research resource capacity, producing scientists trained to conduct rigorous comparative effectiveness and implementation research, and embracing innovative strategies to set research priorities in these areas. Ann Neurol 2012;71:732742
C1 [Vickrey, Barbara G.; Cheng, Eric M.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.
[Vickrey, Barbara G.; Cheng, Eric M.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hirtz, Deborah; Waddy, Salina] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA.
[Johnston, S. Claiborne] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Vickrey, BG (reprint author), Univ Calif Los Angeles, Dept Neurol, Box 951769,C128 RNRC,710 Westwood Plaza, Los Angeles, CA 90095 USA.
EM bvickrey@ucla.edu
FU Genentech; Kansas City Area Life Sciences Institute; NINDS; Partners
Neurology; University of Maryland
FX B.G.V.: board membership, National Advisory Neurological Disorders and
Stroke, National Multiple Sclerosis Society, Sports Concussion
Institute; consultancy, EMD Serono, Research Triangle Institute, RAND,
National Academy of Sciences; grants/grants pending, Genentech; speaking
fees, Kansas City Area Life Sciences Institute, Partners Neurology,
University of Maryland; travel expenses, French National Foundation on
Alzheimer's Disease and Related Disorders. E.M.C.: grants/grants
pending, NINDS.
NR 59
TC 11
Z9 12
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD JUN
PY 2012
VL 71
IS 6
BP 732
EP 742
DI 10.1002/ana.22672
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 961YU
UT WOS:000305506300005
PM 22718542
ER
PT J
AU Merkow, RP
Bilimoria, KY
Chow, WB
Merkow, JS
Weyant, MJ
Ko, CY
Bentrem, DJ
AF Merkow, Ryan P.
Bilimoria, Karl Y.
Chow, Warren B.
Merkow, Justin S.
Weyant, Michael J.
Ko, Clifford Y.
Bentrem, David J.
TI Variation in Lymph Node Examination After Esophagectomy for Cancer in
the United States
SO ARCHIVES OF SURGERY
LA English
DT Article
ID US-POPULATION DATABASE; LONG-TERM SURVIVAL; LYMPHADENECTOMY EXTENT;
COLON-CANCER; PANCREATIC-CANCER; PREDICTS SURVIVAL; QUALITY MEASURE;
GASTRIC-CANCER; STAGING SYSTEM; NUMBER
AB Objectives: To evaluate the quality of lymph node examination after esophagectomy for cancer in the United States based on current treatment guidelines (>= 15 nodes) and to assess the association of patient, tumor, and hospital factors with the adequacy of lymph node examination.
Design: Retrospective observational study from 1998 to 2007.
Setting: National cancer database.
Patients: Patients with stage I through III esophageal cancer undergoing esophagectomy and not treated with neoadjuvant chemoradiotherapy.
Main Outcome Measure: Rate of adequate lymph node examination (>= 15 nodes).
Results: A total of 13 995 patients were identified from 639 hospitals. Overall, 4014 patients (28.7%) had at least 15 lymph nodes examined, which increased from 23.5% to 34.4% during the study period. At the hospital level, only 45 centers (7.0%) examined a median of at least 15 lymph nodes. In the most recent period (2005-2007), at least 15 nodes were examined in 38.9% of patients at academic centers vs 28.0% at community hospitals and in 44.1% at high-volume centers vs 29.3% at low-volume centers. On multivariable analysis, hospital type, surgical volume status, and geographic location remained significant predictors of having at least 15 lymph nodes examined.
Conclusions: Fewer than one-third of patients and fewer than 1 in 10 hospitals met the benchmark of examining at least 15 lymph nodes. Hospitals should perform internal process improvement activities to improve guideline adherence.
C1 [Merkow, Ryan P.; Bilimoria, Karl Y.; Bentrem, David J.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA.
[Merkow, Ryan P.; Merkow, Justin S.; Weyant, Michael J.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO USA.
[Chow, Warren B.; Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Chow, Warren B.; Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Bentrem, DJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Surg, 676 St Clair St,Ste 650, Chicago, IL 60611 USA.
EM dbentrem@nmff.org
NR 36
TC 10
Z9 10
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0004-0010
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD JUN
PY 2012
VL 147
IS 6
BP 505
EP 511
DI 10.1001/archsurg.2011.2215
PG 7
WC Surgery
SC Surgery
GA 960YD
UT WOS:000305428500003
PM 22351873
ER
PT J
AU Antiel, RM
Van Arendonk, KJ
Reed, DA
Terhune, KP
Tarpley, JL
Porterfield, JR
Hall, DE
Joyce, DL
Wightman, SC
Horvath, KD
Heller, SF
Farley, DR
AF Antiel, Ryan M.
Van Arendonk, Kyle J.
Reed, Darcy A.
Terhune, Kyla P.
Tarpley, John L.
Porterfield, John R.
Hall, Daniel E.
Joyce, David L.
Wightman, Sean C.
Horvath, Karen D.
Heller, Stephanie F.
Farley, David R.
TI Surgical Training, Duty-Hour Restrictions, and Implications for Meeting
the Accreditation Council for Graduate Medical Education Core
Competencies Views of Surgical Interns Compared With Program Directors
SO ARCHIVES OF SURGERY
LA English
DT Article
ID INSTITUTE-OF-MEDICINE; HOURS ENHANCING SLEEP; OPERATIVE EXPERIENCE;
GENERAL-SURGERY; SUPERVISION; SAFETY; RECOMMENDATIONS; ASSOCIATION;
RESIDENTS; TRAINEES
AB Objective: To describe the perspectives of surgical interns regarding the implications of the new Accreditation Council for Graduate Medical Education (ACGME) duty-hour regulations for their training.
Design: We compared responses of interns and surgery program directors on a survey about the proposed ACGME mandates.
Setting: Eleven general surgery residency programs.
Participants: Two hundred fifteen interns who were administered the survey during the summer of 2011 and a previously surveyed national sample of 134 surgery program directors.
Main Outcome Measures: Perceptions of the implications of the new duty-hour restrictions on various aspects of surgical training, including the 6 ACGME core competencies of graduate medical education, measured using 3-point scales (increase, no change, or decrease).
Results: Of 215 eligible surgical interns, 179 (83.3%) completed the survey. Most interns believed that the new duty-hour regulations will decrease continuity with patients (80.3%), time spent operating (67.4%), and coordination of patient care (57.6%), while approximately half believed that the changes will decrease their acquisition of medical knowledge (48.0%), development of surgical skills (52.8%), and overall educational experience (51.1%). Most believed that the changes will improve or will not alter other aspects of training, and 61.5% believed that the new standards will decrease resident fatigue. Surgical interns were significantly less pessimistic than surgery program directors regarding the implications of the new duty-hour restrictions on all aspects of surgical training (P <.05 for all comparisons).
Conclusions: Although less pessimistic than program directors, interns beginning their training under the new paradigm of duty-hour restrictions have significant concerns about the effect of these regulations on the quality of their training.
C1 [Antiel, Ryan M.; Heller, Stephanie F.; Farley, David R.] Mayo Clin, Dept Surg, Rochester, MN 55905 USA.
[Reed, Darcy A.] Mayo Clin, Dept Primary Care Internal Med, Rochester, MN 55905 USA.
[Van Arendonk, Kyle J.] Johns Hopkins Univ, Dept Surg, Baltimore, MD USA.
[Terhune, Kyla P.; Tarpley, John L.] Vanderbilt Univ, Nashville, TN USA.
[Porterfield, John R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Hall, Daniel E.] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Joyce, David L.] Stanford Univ, Stanford, CA 94305 USA.
[Wightman, Sean C.] Univ Chicago, Chicago, IL 60637 USA.
[Horvath, Karen D.] Univ Washington, Seattle, WA 98195 USA.
RP Farley, DR (reprint author), Mayo Clin, Dept Surg, 200 1st St SW, Rochester, MN 55905 USA.
EM farley.david@mayo.edu
RI Hall, Daniel/H-4843-2013
OI Hall, Daniel/0000-0001-6382-0522
NR 24
TC 23
Z9 23
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0004-0010
EI 1538-3644
J9 ARCH SURG-CHICAGO
JI Arch. Surg.
PD JUN
PY 2012
VL 147
IS 6
BP 536
EP 541
PG 6
WC Surgery
SC Surgery
GA 960YD
UT WOS:000305428500010
PM 22786539
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI Reliability measures in managing GI bleeding
SO GASTROINTESTINAL ENDOSCOPY
LA English
DT Article
ID EPIDEMIOLOGY; DIAGNOSIS
AB Background: Multiple procedures and devices are used in a complex interplay to diagnose and treat GI bleeding.
Objective: To model how a large variety of diagnostic and therapeutic components interact in the successful management of GI bleeding.
Design: The analysis uses the concept of reliability block diagrams from probability theory to model management outcome. Separate components of the management process are arranged in a serial or parallel fashion. If the outcome depends on the function of each component individually, such components are modeled to be arranged in series. If components complement each other and can mutually compensate for each of their failures, such components are arranged in a parallel fashion.
Setting: General endoscopy practice.
Patients: Patients with GI bleeding of unknown etiology.
Interventions: All available endoscopic and radiographic means to diagnose and treat GI bleeding.
Main Outcome Measurements: Process reliability in achieving hemostasis.
Results: Serial arrangements tend to reduce process reliability, whereas parallel arrangements increase it. Whenever possible, serial components should be bridged and complemented by additional alternative (parallel) routes of operation. Parallel components with low individual reliability can still contribute to overall process reliability as long as they function independently of other pre-existing alternatives.
Limitations: Probability of success associated with individual components is partly unknown.
Conclusions: Modeling management of GI bleeding by a reliability block diagram provides a useful tool in assessing the impact of individual endoscopic techniques and administrative structures on the overall outcome. (Gastrointest Endosc 2012;75:1184-9.)
C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
NR 9
TC 1
Z9 1
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0016-5107
J9 GASTROINTEST ENDOSC
JI Gastrointest. Endosc.
PD JUN
PY 2012
VL 75
IS 6
BP 1184
EP 1189
DI 10.1016/j.gie.2012.01.047
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 961HA
UT WOS:000305453700009
PM 22624809
ER
PT J
AU Gidwani, R
Goetz, MB
Kominski, G
Asch, S
Mattocks, K
Samet, JH
Justice, A
Gandhi, N
Needleman, J
AF Gidwani, Risha
Goetz, Matthew Bidwell
Kominski, Gerald
Asch, Steven
Mattocks, Kristin
Samet, Jeffrey H.
Justice, Amy
Gandhi, Neel
Needleman, Jack
TI A BUDGET IMPACT ANALYSIS OF RAPID HUMAN IMMUNODEFICIENCY VIRUS SCREENING
IN VETERANS ADMINISTRATION EMERGENCY DEPARTMENTS
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE HIV; screening; budget impact; Rapid Testing; Emergency Department
ID HEALTH-CARE SETTINGS; COST-EFFECTIVENESS; HIV-INFECTION; ANTIRETROVIRAL
THERAPY; UNITED-STATES; OUTCOMES
AB Background: Human immunodeficiency virus (HIV) screening is cost-effective and recommended in populations with low disease prevalence. However, because screening is not cost-saying, its financial feasibility must be understood. Study Objectives: We forecast the costs of two Emergency Department-based HIV testing programs in the Veterans Administration: 1) implementing a non-targeted screening program and providing treatment for all patients thusly identified (Rapid Testing); and 2) treating patients identified due to late-stage symptoms (Usual Care); to determine which program was the most financially feasible. Methods: Using a dynamic decision-analysis model, we estimated the financial impact of each program over a 7-year period. Costs were driven by patient disease-severity at diagnosis, measured by CD4+ category, and the proportion of patients in each disease-severity category. Cost per CD4+ category was modeled from chart review and database analysis of treatment-naive HIV-positive patients. Distributions of CD4+ counts differed in patients across the Rapid Testing and Usual Care arms. Results: A non-targeted Rapid Testing program was not significantly more costly than Usual Care. Although Rapid Testing had substantial screening costs, they were offset by lower inpatient expenses associated with earlier identification of disease. Assuming an HIV prevalence of 1% and 80% test acceptance, the cost of Rapid Testing was $1,418,088, vs. $1,320,338 for Usual Care (p = 0.5854). Results support implementation of non-targeted rapid HIV screening in integrated systems. Conclusions: This analysis adds a new component of support for HIV screening by demonstrating that rapid, non-targeted testing does not cost significantly more than a diagnostic testing approach. (C) 2012 Elsevier Inc.
C1 [Gidwani, Risha; Goetz, Matthew Bidwell; Asch, Steven] VA Greater Los Angeles Healthcare Syst, QUERI HIV HEPATITIS C, Los Angeles, CA USA.
[Gidwani, Risha; Kominski, Gerald; Needleman, Jack] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Goetz, Matthew Bidwell; Asch, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Mattocks, Kristin; Justice, Amy] W Haven VA Healthcare Syst, West Haven, CT USA.
[Mattocks, Kristin; Justice, Amy] Yale Univ, Sch Med, New Haven, CT USA.
[Samet, Jeffrey H.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Gandhi, Neel] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Gandhi, Neel] Montefiore Med Ctr, Bronx, NY 10467 USA.
RP Gidwani, R (reprint author), VA Greater Los Angeles Healthcare Syst, QUERI HIV HEPATITIS C, Los Angeles, CA USA.
EM rishagidwani@yahoo.com
RI Needleman, Jack/I-5461-2013
OI Needleman, Jack/0000-0002-2875-0589; Samet, Jeffrey/0000-0002-0897-3400;
Goetz, Matthew/0000-0003-4542-992X; Kominski, Gerald/0000-0001-5214-7133
FU VA Health Services Research & Development Service Rapid Response Project
(RRP) [07-283]
FX This work was funded by the VA Health Services Research & Development
Service Rapid Response Project (RRP) 07-283.
NR 18
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
J9 J EMERG MED
JI J. Emerg. Med.
PD JUN
PY 2012
VL 42
IS 6
BP 719
EP 726
DI 10.1016/j.jemermed.2010.11.038
PG 8
WC Emergency Medicine
SC Emergency Medicine
GA 962ZX
UT WOS:000305591000019
PM 21277144
ER
PT J
AU Nedjat-Haiem, FR
Lorenz, KA
Ell, K
Hamilton, A
Palinkas, L
AF Nedjat-Haiem, Frances R.
Lorenz, Karl A.
Ell, Kathleen
Hamilton, Alison
Palinkas, Lawrence
TI Experiences With Advanced Cancer Among Latinas in a Public Health Care
System
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Sociocultural; advanced cancer; low-income Latinas; pain; coping;
religious beliefs
ID QUALITY-OF-LIFE; HISPANIC PATIENTS; LOW-INCOME; EXPLANATORY MODELS;
PATIENT NAVIGATION; BREAST; DEPRESSION; WOMEN; END; COMMUNICATION
AB Context. Cultural dimensions related to illness are triggered at significant times in an illness trajectory, such as at illness onset or when death approaches. These factors influence views on how illness is understood and managed, which is likely more difficult for minority populations. Although Latinos experience barriers to high-quality health care, late-stage cancer diagnoses, and poor health outcomes, little is known about their experiences with advanced, life-threatening cancers.
Objectives. We examined Latinas' experiences with advanced, metastatic cancers to identify sociocultural beliefs that influenced their care.
Methods. We interviewed 24 Latinas taking part in a randomized controlled trial focused on improving quality-of-life outcomes for co-occurring cancer and depression and explored their beliefs about the cause, course, and cure of cancer. This study used a phenomenological analytical approach to explore women's lived experiences of having advanced cancer.
Results. Themes revealed issues about experiencing advanced cancer that included the following: initial reactions to cancer, disbelief about the lack of pain, economic impact, beliefs about the cause, coping with cancer, beliefs about the cure, and confusion about cancer severity. Sociocultural factors influence misunderstanding and confusion about cancer care but also can be a source of strength.
Conclusion. Providers need to become culturally sensitive to the needs of underserved Latinas. Denial or ignorance of these issues can create other problems, such as gaps in patient-centered decision making from diagnosis through the end of life. J Pain Symptom Manage 2012; 43: 1013-1024. Published by Elsevier Inc. on behalf of U.S. Cancer Pain Relief Committee.
C1 [Nedjat-Haiem, Frances R.; Lorenz, Karl A.; Hamilton, Alison] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Ell, Kathleen; Palinkas, Lawrence] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA.
[Hamilton, Alison] Univ Calif Los Angeles, Los Angeles, CA USA.
RP Nedjat-Haiem, FR (reprint author), VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence, Off Acad Affiliat, VA Associated Hlth Postdoctoral Fellowship Progra, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA.
EM nedjatha@gmail.com
FU Office of Academic Affiliations, VA Associated Health Postdoctoral
Fellowship Program, VA Greater Los Angeles, Healthcare System, HSR&D
Center of Excellence; American Cancer Society Doctoral Training Grants
in Oncology Social Work [DSW-06-220-01-SW]; National Cancer Institute
[R01CA105269]
FX This research was supported by the Office of Academic Affiliations, VA
Associated Health Postdoctoral Fellowship Program, VA Greater Los
Angeles, Healthcare System, HSR&D Center of Excellence, the American
Cancer Society Doctoral Training Grants in Oncology Social Work
DSW-06-220-01-SW (F.R. Nedjat-Haiem, Principal Investigator) and the
National Cancer Institute grant R01CA105269 (K. Ell, Principal
Investigator). The authors declare no conflicts of interest.
NR 35
TC 6
Z9 6
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUN
PY 2012
VL 43
IS 6
BP 1013
EP 1024
DI 10.1016/j.jpainsymman.2011.06.018
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA 961HY
UT WOS:000305456500004
PM 22575719
ER
PT J
AU Perez-Rodriguez, MM
Hazlett, EA
Rich, EL
Ripoll, LH
Weiner, DM
Spence, N
Goodman, M
Koenigsberg, HW
Siever, LJ
New, AS
AF Perez-Rodriguez, M. Mercedes
Hazlett, Erin A.
Rich, Erin L.
Ripoll, Luis H.
Weiner, Daniel M.
Spence, Nicole
Goodman, Marianne
Koenigsberg, Harold W.
Siever, Larry J.
New, Antonia S.
TI Striatal activity in borderline personality disorder with comorbid
intermittent explosive disorder: Sex differences
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Borderline personality disorder; Intermittent explosive disorder;
Striatum; Aggression; Positron emission tomography
ID POSITRON-EMISSION-TOMOGRAPHY; BRAIN GLUCOSE-METABOLISM; EVENT-RELATED
FMRI; ACTIVATED FDG-PET; DSM-IV CRITERIA; BASAL GANGLIA;
GENDER-DIFFERENCES; ORBITOFRONTAL CORTEX; IMPULSIVE-AGGRESSION;
NEURONAL-ACTIVITY
AB Borderline Personality Disorder (BPD) is associated with behavioral and emotional dysregulation, particularly in social contexts; however, the underlying pathophysiology at the level of brain function is not well understood. Previous studies found abnormalities in frontal cortical and limbic areas suggestive of poor frontal regulation of downstream brain regions. However, the striatum, which is closely connected with the medial frontal cortices and plays an important role in motivated behaviors and processing of rewarding stimuli, has been understudied in BPD. Here we hypothesized that, in addition to frontal dysfunction, BPD patients may show abnormal striatal function. In this study, 38 BPD patients with intermittent explosive disorder (BPD-IED) and 36 healthy controls (HC) participated in the Point Subtraction Aggression Paradigm (PSAP), a computer game played with a fictitious other player. (18)Fluoro-deoxyglucose positron emission tomography (FOG-PET) measured relative glucose metabolism (rGMR) within caudate and putamen in response to aggression-provoking and non-provoking versions of the PSAP. Male BPD-IED patients had significantly lower striatal rGMR than all other groups during both conditions, although male and female BPD-IED patients did not differ in clinical or behavioral measures. These sex differences suggest differential involvement of frontal-striatal circuits in BPD-IED, and are discussed in relation to striatal involvement in affective learning and social decision-making. Published by Elsevier Ltd.
C1 [Perez-Rodriguez, M. Mercedes; Hazlett, Erin A.; Ripoll, Luis H.; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.; New, Antonia S.] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY 10468 USA.
[Perez-Rodriguez, M. Mercedes; Hazlett, Erin A.; Rich, Erin L.; Ripoll, Luis H.; Weiner, Daniel M.; Spence, Nicole; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.; New, Antonia S.] Mt Sinai Sch Med, Dept Psychiat, MIRECC, Bronx, NY 10468 USA.
[Rich, Erin L.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
RP New, AS (reprint author), James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM antonia.new@mssm.edu
RI Perez Rodriguez, Maria/B-9410-2013
OI Perez Rodriguez, Maria/0000-0001-5137-1993
FU James J. Peters Veterans Affairs Medical Center; National Institutes of
Health (NIH) [1-R01-MH067918-01, 1-R01-MH07911]; Mount Sinai General
Clinical Research Center from the National Center for Research Resources
at the NIH [5-M01 RR00071]
FX This work was supported by the James J. Peters Veterans Affairs Medical
Center and by a grant to ASN from the National Institutes of Health
(NIH) (1-R01-MH067918-01) and to EAH (1-R01-MH07911) and by 5-M01
RR00071 for the Mount Sinai General Clinical Research Center from the
National Center for Research Resources at the NIH.
NR 97
TC 13
Z9 13
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2012
VL 46
IS 6
BP 797
EP 804
DI 10.1016/j.jpsychires.2012.02.014
PG 8
WC Psychiatry
SC Psychiatry
GA 961UD
UT WOS:000305494100016
PM 22464337
ER
PT J
AU Goodman, M
AF Goodman, Marianne
TI Complex PTSD is on the trauma spectrum: Comment on Resick et al. (2012)
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
AB Conceptualizing posttraumatic stress disorder (PTSD) along a spectrum with complex and simple features is integrative and models an approach taken by disciplines in medicine outside of psychiatry. This perspective is offered in the Resick et al. (2012) review. To best delineate the nature and permeability of the border between Complex PTSD and PTSD, an emphasis on clarifying underlying biological processes is needed to move beyond our current reliance on symptomatic description.
C1 [Goodman, Marianne] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Goodman, Marianne] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA.
RP Goodman, M (reprint author), Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
EM marianne.goodman@va.gov
NR 8
TC 8
Z9 8
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2012
VL 25
IS 3
BP 254
EP 255
DI 10.1002/jts.21695
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 962VV
UT WOS:000305576500005
PM 22729976
ER
PT J
AU Lee, AH
Weintraub, D
AF Lee, Angela H.
Weintraub, Daniel
TI Psychosis in Parkinson's disease without dementia: Common and comorbid
with other non-motor symptoms
SO MOVEMENT DISORDERS
LA English
DT Article
DE Parkinson's disease; psychosis; non-demented; cognitively intact
ID DEPRESSIVE SYMPTOMATOLOGY IDS; SLEEP BEHAVIOR DISORDER; COGNITIVE
IMPAIRMENT; DAYTIME SLEEPINESS; HALLUCINATIONS; INVENTORY; SCALE;
INSTRUMENT; MORTALITY
AB Psychosis in Parkinson's disease (PD) is common and associated with a range of negative outcomes. Dementia and psychosis are highly correlated in PD, but the frequency and correlates of psychosis in patients without cognitive impairment are not well understood. One hundred and ninety-one non-demented PD patients at two movement disorders centers participated in a study of neuropsychiatric complications in PD and completed a detailed neurological and neuropsychiatric assessment, including the rater-administered Parkinson Psychosis Rating Scale for hallucinations, delusions, and minor symptoms of psychosis (illusions and misidentification of persons). Psychotic symptoms were present in 21.5% of the sample. Visual hallucinations were most common (13.6%), followed by auditory hallucinations (6.8%), illusions or misidentification of people (7.3%), and paranoid ideation (4.7%). Visual hallucinations and illusions or misidentification of people were the most common comorbid symptoms (3.1%). Depression (P = 0.01) and rapid eye movement behavior disorder symptoms (P = 0.03) were associated with psychosis in a multivariable model. The odds of experiencing psychotic symptoms were approximately five times higher in patients with comorbid disorders of depression and sleep-wakefulness. Even in patients without global cognitive impairment, psychosis in PD is common and most highly correlated with other non-motor symptoms. Screening for psychosis should occur at all stages of PD as part of a broad non-motor assessment. In addition, these findings suggest a common neural substrate for disturbances of perception, mood, sleep-wakefulness, and incipient cognitive decline in PD. (c) 2012 Movement Disorder Society
C1 [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Parkinsons Dis Res Educ & Clin Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Weintraub, Daniel] Mental Illness Res Educ & Clin Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA.
EM daniel.weintraub@uphs.upenn.edu
FU National Institute of Mental Health [067894]; Mental Illness Research,
Education, and Clinical Center at the Philadelphia Veterans Affairs
Medical Center
FX Funding agencies: This work was supported, in part, by grants from the
National Institute of Mental Health (067894) and the Mental Illness
Research, Education, and Clinical Center at the Philadelphia Veterans
Affairs Medical Center.
NR 42
TC 36
Z9 37
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN
PY 2012
VL 27
IS 7
BP 858
EP 863
DI 10.1002/mds.25003
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 962XE
UT WOS:000305581900011
PM 22674352
ER
PT J
AU Chattergoon, NN
Louey, S
Stork, P
Giraud, GD
Thornburg, KL
AF Chattergoon, Natasha N.
Louey, Samantha
Stork, Philip
Giraud, George D.
Thornburg, Kent L.
TI Mid-Gestation Ovine Cardiomyocytes Are Vulnerable to Mitotic Suppression
by Thyroid Hormone
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE fetal heart; cardiomyocyte proliferation; thyroid hormone; p21; cyclin
D1
ID FETAL SHEEP CARDIOMYOCYTES; SIGNAL-REGULATED KINASE; CELL-CYCLE
ACTIVITY; CARDIAC MYOCYTES; NEONATAL-RAT; FETUS; PLACENTA; GROWTH;
PROLIFERATION; HYPERTROPHY
AB Circulating fetal 3,3',5-tri-iodo-L-thyronine (T-3) is maintained at very low levels until a dramatic prepartum surge. 3,3',5-Tri-iodo-L-thyronine inhibits serum-stimulated proliferation in near-term ovine cardiomyocytes, but it is not known whether midgestation myocytes are also inhibited. Because early cessation of cardiomyocyte mitosis would result in an underendowed heart, we hypothesized that 0.67 gestation (100 of 145 days gestation) ovine cardiomyocytes would be insensitive to suppressive growth effects of T-3. These younger cardiomyocytes were grown with T-3 in 10% serum-enriched media for 24 hours. Physiological (0.37, 0.75, and 1.5 nmol/L) concentrations of T-3 dramatically suppressed mitotic activity in cardiomyocytes (P < .001). 3,30,5-Tri-iodo-L-thyronine stimulated phosphorylation of extracellular signal-regulated kinase and AKT (also known as Protein Kinase B [PKB]) signaling pathways. Nevertheless, the protein content of the cell cycle suppressor, p21, increased 2-fold (P < .05), and promoter, cyclin D1, decreased by 50%. Contrary to our hypothesis, elevated levels of T-3 powerfully inhibit proliferation of midgestation fetal cardiomyocytes. Thus, midgestation maternal hyperthyroidism might lead to an underendowed fetal myocardium.
C1 [Chattergoon, Natasha N.; Louey, Samantha; Stork, Philip; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA.
[Louey, Samantha; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Med Cardiovasc Med, Portland, OR 97201 USA.
[Stork, Philip] Oregon Hlth & Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA.
[Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA.
[Giraud, George D.] Portland VA Med Ctr, Portland, OR USA.
RP Thornburg, KL (reprint author), Oregon Hlth & Sci Univ, Heart Res Ctr, 3303 SW Bond Ave,CH15H, Portland, OR 97239 USA.
EM thornbur@ohsu.edu
FU NIH [NICHD P01 HD 34430, NINDS R37, NS045737, NHLBI R21 HL093617, R01
HL102763]; NHLBI [T32HL094294]; M. Lowell Edwards Endowment
FX The author(s) disclosed receipt of the following financial support for
the research, authorship and/or publication of this article: supported
by NIH grants NICHD P01 HD 34430, NINDS R37, NS045737, NHLBI R21
HL093617, and R01 HL102763; NNC was supported by NHLBI training grant
T32HL094294 and KLT was supported by the M. Lowell Edwards Endowment.
NR 44
TC 6
Z9 6
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
J9 REPROD SCI
JI Reprod. Sci.
PD JUN
PY 2012
VL 19
IS 6
BP 642
EP 649
DI 10.1177/1933719111432860
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 963NH
UT WOS:000305627200010
PM 22421446
ER
PT J
AU Ringden, O
Shrestha, S
da Silva, GT
Zhang, MJ
Dispenzieri, A
Remberger, M
Kamble, R
Freytes, CO
Gale, RP
Gibson, J
Gupta, V
Holmberg, L
Lazarus, H
McCarthy, P
Meehan, K
Schouten, H
Milone, GA
Lonial, S
Hari, PN
AF Ringden, O.
Shrestha, S.
da Silva, G. T.
Zhang, M-J
Dispenzieri, A.
Remberger, M.
Kamble, R.
Freytes, C. O.
Gale, R. P.
Gibson, J.
Gupta, V.
Holmberg, L.
Lazarus, H.
McCarthy, P.
Meehan, K.
Schouten, H.
Milone, G. A.
Lonial, S.
Hari, P. N.
TI Effect of acute and chronic GVHD on relapse and survival after
reduced-intensity conditioning allogeneic transplantation for myeloma
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE graft-vs-host disease; reduced intensity; allogeneic; myeloma
ID STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; DIAGNOSED
MULTIPLE-MYELOMA; VERSUS-HOST DISEASE; CHRONIC GRAFT; CHRONIC LEUKEMIA;
EUROPEAN GROUP; RECIPIENTS; TRIAL; CYCLOSPORINE
AB We evaluated the effect of acute and chronic GVHD on relapse and survival after allogeneic hematopoietic SCT (HSCT) for multiple myeloma using non-myeloablative conditioning (NMA) and reduced-intensity conditioning (RIC). The outcomes of 177 HLA-identical sibling HSCT recipients between 1997 and 2005, following NMA (n = 98) or RIC (n = 79) were analyzed. In 105 patients, autografting was followed by planned NMA/RIC allogeneic transplantation. The impact of GVHD was assessed as a time-dependent covariate using Cox models. The incidence of acute GVHD (aGVHD; grades I-IV) was 42% (95% confidence interval (CI), 35-49%) and of chronic GVHD (cGVHD) at 5 years was 59% (95% CI, 49-69%), with 70% developing extensive cGVHD. In multivariate analysis, aGVHD (>= grade I) was associated with an increased risk of TRM (relative risk (RR) = 2.42, P = 0.016), whereas limited cGVHD significantly decreased the risk of myeloma relapse (RR = 0.35, P = 0.035) and was associated with superior EFS (RR = 0.40, P = 0.027). aGVHD had a detrimental effect on survival, especially in those receiving autologous followed by allogeneic HSCT (RR = 3.52, P = 0.001). The reduction in relapse risk associated with cGVHD is consistent with a beneficial graft-vs-myeloma effect, but this did not translate into a survival advantage. Bone Marrow Transplantation (2012) 47, 831-837; doi:10.1038/bmt.2011.192; published online 26 September 2011
C1 [Shrestha, S.; Zhang, M-J; Hari, P. N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA.
[Ringden, O.; Remberger, M.] Karolinska Univ Hosp, Dept Clin Immunol, Stockholm, Sweden.
[da Silva, G. T.] Univ Sao Paulo, Dept Stat, Sao Paulo, Brazil.
[Dispenzieri, A.] Mayo Clin, Rochester, MN USA.
[Kamble, R.] Baylor Coll Med, Dept Hematol & Oncol, Houston, TX 77030 USA.
[Freytes, C. O.] S Texas Vet Hlth Care Syst, Dept Hematol, San Antonio, TX USA.
[Gale, R. P.] Celgene Corp, Dept Hematol & Oncol, Summit, NJ USA.
[Gibson, J.] Royal Prince Alfred Hosp, Dept Haematol, Inst Haematol, Camperdown, NSW 2050, Australia.
[Gupta, V.] Princess Margaret Hosp, Dept Med, Toronto, ON M4X 1K9, Canada.
[Holmberg, L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Lazarus, H.] Univ Hosp Case Med Ctr, Dept Med, Cleveland, OH USA.
[McCarthy, P.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Meehan, K.] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA.
[Schouten, H.] Univ Hosp Maastricht, Dept Internal Med, Maastricht, Netherlands.
[Milone, G. A.] Angelica Ocampo Fundaleu, Buenos Aires, DF, Argentina.
[Lonial, S.] Emory Univ Hosp, Dept Med, Atlanta, GA 30322 USA.
RP Hari, PN (reprint author), Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, 9200 W Wisconsin Ave,Suite C5500, Milwaukee, WI 53226 USA.
EM phari@mcw.edu
OI Dispenzieri, Angela/0000-0001-8780-9512; Hari,
Parameswaran/0000-0002-8800-297X
FU Public Health Service from the National Cancer Institute (NCI)
[U24-CA76518]; National Heart, Lung and Blood Institute (NHLBI);
National Institute of Allergy and Infectious Diseases; NHLBI
[5U01HL069294]; NCI; Health Resources and Services Administration
(HRSA/DHHS) [HHSH 234200637015C]; Office of Naval Research
[N00014-06-1-0704, N00014-08-1-0058]; AABB; Aetna; American Society for
Blood and Marrow Transplantation; Amgen, Inc.; Swedish Cancer Society;
Children's Cancer Foundation; Swedish Research Council; Cancer Society
in Stockholm; Karolinska Institutet
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement U24-CA76518 from the National Cancer Institute (NCI), the
National Heart, Lung and Blood Institute (NHLBI) and the National
Institute of Allergy and Infectious Diseases; a Grant/Cooperative
Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH 234200637015C
with Health Resources and Services Administration (HRSA/DHHS); two
Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval
Research; and grants from AABB; Aetna; American Society for Blood and
Marrow Transplantation, Amgen, Inc.; Anonymous donation to the Medical
College of Wisconsin; Astellas Pharma US, Inc.; Baxter International,
Inc.; Bayer HealthCare Pharmaceuticals; Be the Match Foundation; Biogen
IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum AB; BloodCenter of
Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow
Foundation; Buchanan Family Foundation; Canadian Blood and Marrow
Transplant Group; CaridianBCT; Celgene Corporation; CellGenix, GmbH;
Centers for Disease Control and Prevention; Children's Leukemia Research
Association; ClinImmune Labs; CTI Clinical Trial and Consulting
Services; Cubist Pharmaceuticals; Cylex, Inc.; CytoTherm; DOR BioPharma,
Inc.; Dynal Biotech (an Invitrogen Company); Eisai, Inc.; Enzon
Pharmaceuticals, Inc.; European Group for Blood and Marrow
Transplantation; Gamida Cell, Ltd.; GE Healthcare; Genentech, Inc.;
Genzyme Corporation; Histogenetics, Inc.; HKS Medical Information
Systems; Hospira, Inc.; Infectious Diseases Society of America; Kiadis
Pharma; Kirin Brewery Co., Ltd.; The Leukemia and Lymphoma Society;
Merck and Company; The Medical College of Wisconsin; MGI Pharma, Inc.;
Michigan Community Blood Centers; Millennium Pharmaceuticals, Inc.;
Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.;
National Marrow Donor Program; Nature Publishing Group; New York Blood
Center; Novartis Oncology; Oncology Nursing Society; Osiris
Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pall Life
Sciences; Pfizer, Inc.; Saladax Biomedical, Inc.; Schering Corporation;
Society for Healthcare Epidemiology of America; Soligenix, Inc.;
StemCyte, Inc.; StemSoft Software, Inc.; Sysmex America, Inc.; THERAKOS,
Inc.; Thermogenesis Corporation; Vidacare Corporation; Vion
Pharmaceuticals, Inc.; ViraCor Laboratories; ViroPharma, Inc.; and
Wellpoint, Inc. The views expressed in this article do not reflect the
official policy or position of the National Institute of Health, the
Department of the Navy, the Department of Defense or any other agency of
the US Government. Olle Ringden is supported by grants from the Swedish
Cancer Society, the Children's Cancer Foundation, the Swedish Research
Council, the Cancer Society in Stockholm, and Karolinska Institutet.
NR 28
TC 14
Z9 14
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUN
PY 2012
VL 47
IS 6
BP 831
EP 837
DI 10.1038/bmt.2011.192
PG 7
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 958YF
UT WOS:000305276200010
PM 21946381
ER
PT J
AU Barnes, DE
Palmer, RM
Kresevic, DM
Fortinsky, RH
Kowal, J
Chren, MM
Landefeld, CS
AF Barnes, Deborah E.
Palmer, Robert M.
Kresevic, Denise M.
Fortinsky, Richard H.
Kowal, Jerome
Chren, Mary-Margaret
Landefeld, C. Seth
TI Acute Care For Elders Units Produced Shorter Hospital Stays At Lower
Cost While Maintaining Patients' Functional Status
SO HEALTH AFFAIRS
LA English
DT Article
ID COMPREHENSIVE GERIATRIC ASSESSMENT; RANDOMIZED CONTROLLED-TRIAL; OLDER
PATIENTS; MEDICAL UNIT; METAANALYSIS; OUTCOMES; ADULTS; HOME; ACE;
INTERVENTION
AB Acute Care for Elders Units offer enhanced care for older adults in specially designed hospital units. The care is delivered by interdisciplinary teams, which can include geriatricians, advanced practice nurses, social workers, pharmacists, and physical therapists. In a randomized controlled trial of 1,632 elderly patients, length-of-stay was significantly shorter-6.7 days per patient versus 7.3 days per patient-among those receiving care in the Acute Care for Elders Unit compared to usual care. This difference produced lower total inpatient costs-$9,477 per patient versus $10,451 per patient-while maintaining patients' functional abilities and not increasing hospital readmission rates. The practices of Acute Care for Elders Units, and the principles they embody, can provide hospitals with effective strategies for lowering costs while preserving quality of care for hospitalized elders.
C1 [Barnes, Deborah E.; Landefeld, C. Seth] Univ Calif San Francisco, Mt Zion Ctr Aging, San Francisco, CA 94143 USA.
[Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Palmer, Robert M.] Eastern Virginia Med Sch, Glennan Ctr Geriatr & Gerontol, Norfolk, VA 23501 USA.
[Kresevic, Denise M.] Louis Stokes Vet Affairs Med Ctr, Cleveland, OH USA.
[Fortinsky, Richard H.] Univ Connecticut, Sch Med, Farmington, CT USA.
[Kowal, Jerome] Case Western Reserve Sch Med, Cleveland, OH USA.
[Landefeld, C. Seth] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
RP Barnes, DE (reprint author), Univ Calif San Francisco, Mt Zion Ctr Aging, San Francisco, CA 94143 USA.
EM deborah.barnes@ucsf.edu
FU National Institutes of Health [R01 AG029233, AG10418, K24 AR052667];
S.D. Bechtel Jr. Foundation
FX Some results from this paper were presented to the Society of General
Internal Medicine, Chicago, Illinois, April 23-25, 1998. Support for
this study was provided by the National Institutes of Health (R01
AG029233 and AG10418, principal investigator C. Seth Landefeld; K24
AR052667, principal investigator Mary-Margaret Chren) and the S.D.
Bechtel Jr. Foundation. The authors thank Laura Sands and Katharine
Kirby for performing statistical analyses, Ken Covinsky for providing
comments on the manuscript, and the clinical Acute Care for Elders teams
that have provided care to the authors' patients.
NR 32
TC 19
Z9 19
U1 1
U2 13
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2012
VL 31
IS 6
BP 1227
EP 1236
DI 10.1377/hlthaff.2012.0142
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 957AM
UT WOS:000305130900010
PM 22665834
ER
PT J
AU Quigley, KS
McAndrew, LM
Almeida, L
D'Andrea, EA
Engel, CC
Hamtil, H
Ackerman, AJ
AF Quigley, Karen S.
McAndrew, Lisa M.
Almeida, Liliana
D'Andrea, Elizabeth A.
Engel, Charles C.
Hamtil, Heather
Ackerman, Adam J.
TI Prevalence of Environmental and Other Military Exposure Concerns in
Operation Enduring Freedom and Operation Iraqi Freedom Veterans
SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID GULF-WAR VETERANS; TRAUMATIC BRAIN-INJURY; UNEXPLAINED PHYSICAL
SYMPTOMS; PRIMARY-CARE; HEALTH; SEEKING; STRESS; ASSOCIATION;
POPULATION; COMMUNITY
AB Objective: This study examined the prevalence of self-reported exposures in returning Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) veterans and the relationship of exposure reports to current physical symptoms. Methods: Using self-reports obtained immediately after return from deployment in a cohort of 760 enlisted Army reserve component military personnel, we assessed prevalence rates of environmental and other exposures and the association of these exposures to severity of physical symptoms. Results: Reporting of environmental exposures was relatively low in veterans of OEF/OIF, but reporting more environmental and other exposures, in particular screening positive for a traumatic brain injury, was related to greater physical symptom severity immediately after deployment. Conclusions: Non-treatment-seeking, enlisted Army reserve component personnel reported relatively few exposures immediately after return from deployment; however, more exposures was modestly associated with greater severity of physical symptoms when controlling for predeployment symptoms, gender, and other deployment-related exposures.
C1 [Quigley, Karen S.] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
[Quigley, Karen S.] Edith Nourse Rogers Mem Vet Adm Hosp, Bedford, MA 01730 USA.
[Quigley, Karen S.; McAndrew, Lisa M.; Almeida, Liliana; Hamtil, Heather; Ackerman, Adam J.] NJ WRIISC, Dept Vet Affairs New Jersey Healthcare Syst, E Orange, NJ USA.
[Quigley, Karen S.; McAndrew, Lisa M.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA.
[D'Andrea, Elizabeth A.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Engel, Charles C.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA.
[Engel, Charles C.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA.
[Almeida, Liliana] Alliant Int Univ, CSPP, Los Angeles, CA USA.
[Hamtil, Heather] Rutgers State Univ, Ctr Behav Hlth Serv & Criminal Justice Res, New Brunswick, NJ 08903 USA.
RP Quigley, KS (reprint author), Northeastern Univ, Dept Psychol, 125 Nightingale Hall, Boston, MA 02115 USA.
EM k.quigley@neu.edu
RI Quigley, Karen/B-9003-2013
OI Quigley, Karen/0000-0001-8844-990X
FU Department of Veterans Affairs [IIR 02-296]; NJ WRIISC; Jersey
Healthcare System at Department of Veterans Affairs; Deployment Health
Clinical Center, Walter Reed Army Medical Center
FX This work was supported by a Department of Veterans Affairs, Health
Services Research and Development grant (IIR 02-296) to Dr Quigley while
she was employed. at the NJ WRIISC. Additional funds were provided by
the NJ WRIISC and the Center for Healthcare Knowledge Management (NJ
REAP; VA Health Services Research and Development) at the Department of
Veterans Affairs Now Jersey Healthcare System, and by the Deployment
Health Clinical Center, Walter Reed Army Medical Center.
NR 40
TC 10
Z9 10
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1076-2752
J9 J OCCUP ENVIRON MED
JI J. Occup. Environ. Med.
PD JUN
PY 2012
VL 54
IS 6
SI SI
BP 659
EP 664
DI 10.1097/JOM.0b013e3182570506
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 957MA
UT WOS:000305165900002
PM 22588478
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI PROSTHETIC JOINT INFECTIONS
SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
LA English
DT Letter
ID DENTAL PROCEDURES
C1 Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Friedlander, AH (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU AMER DENTAL ASSOC
PI CHICAGO
PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA
SN 0002-8177
J9 J AM DENT ASSOC
JI J. Am. Dent. Assoc.
PD JUN
PY 2012
VL 143
IS 6
BP 552
EP +
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 957LF
UT WOS:000305163800003
PM 22653926
ER
PT J
AU Spira, AP
Covinsky, K
Rebok, GW
Punjabi, NM
Stone, KL
Hillier, TA
Ensrud, KE
Yaffe, K
AF Spira, Adam P.
Covinsky, Kenneth
Rebok, George W.
Punjabi, Naresh M.
Stone, Katie L.
Hillier, Teresa A.
Ensrud, Kristine E.
Yaffe, Kristine
TI Poor Sleep Quality and Functional Decline in Older Women
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE sleep; actigraphy; function; IADLs; women
ID OSTEOPOROTIC FRACTURES; CARDIOVASCULAR HEALTH; ELDERLY PERSONS;
PERSISTENCE; ACTIVATION; ACTIGRAPHY; COMPLAINTS; COMMUNITY; ADULTS; MEN
AB Objectives To determine whether objectively measured sleep quality predicts 5-year incident instrumental activity of daily living (IADL) impairment and decline in grip strength and gait speed in older women. Design Prospective cohort. Setting Participants' homes, Study of Osteoporotic Fractures sites. Participants Eight hundred seventeen women with a mean age of 82.4 at baseline. Measurements Participants completed 4.1 +/- 0.7 nights of wrist actigraphy at baseline and measures of IADL impairment, grip strength, and gait speed at baseline and 5-year follow-up. Results After 5years of follow-up, approximately 41% of participants had incident impairment in one or more IADLs. The quartile of women with the shortest total sleep time (TST) had 93% greater odds of incident IADL impairment than the longest sleepers (adjusted odds ratio (AOR)=1.93, 95% confidence interval (CI)=1.252.97). Similarly, the quartile of women with the lowest sleep efficiency (SE) had 65% greater odds of impairment than those with the highest (AOR=1.65, 95% CI=1.062.57). Women in the shortest TST quartile had twice the odds of declining grip strength as those with the longest TST (AOR=1.97, 95% CI=1.173.32). Finally, women in the quartiles with the most wake after sleep onset (WASO) and the lowest SE had approximately 90% greater odds of grip strength decline than those with the least WASO (AOR=1.90, 95% CI=1.113.24) and SE (AOR=1.92, 95% CI=1.123.29). Conclusion Findings indicate that shorter sleep duration, greater WASO, and lower SE are risk factors for functional or physical decline in older women.
C1 [Spira, Adam P.; Rebok, George W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Covinsky, Kenneth] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA USA.
[Covinsky, Kenneth] San Francisco VA Med Ctr, San Francisco, CA USA.
[Punjabi, Naresh M.] Johns Hopkins Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA.
[Punjabi, Naresh M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Stone, Katie L.] Calif Pacific Med Ctr Res Inst, San Francisco, CA USA.
[Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA.
[Ensrud, Kristine E.] Minneapolis Vet Affairs Med Ctr, Dept Med, Minneapolis, MN USA.
[Ensrud, Kristine E.] Univ Minnesota, Dept Med, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
RP Spira, AP (reprint author), 624 N Broadway,Hampton House,Rm 794, Baltimore, MD 21205 USA.
EM aspira@jhsph.edu
FU National Institutes of Health (NIH) [R01 AR35582, R01 AR35583, R01
AR35584, R01 AG026720, R01 AG005407, R01 AG027574, R01 AG027576, R01
AG005394, 2R01-HL075078, 5R01-HL089467]; Alzheimer's Association
[IIRG-08-88872]; National Institute on Aging [1K01AG033195,
K24AG031155]; National Institute of Mental Health; National Institute of
Diabetes and Digestive and Kidney Diseases; Department of Defense;
Department of Veterans Affairs
FX Supported by National Institutes of Health (NIH) Grants R01 AG005407,
R01 AR35582, R01 AR35583, R01 AR35584, R01 AG026720, R01 AG005407, R01
AG027574, R01 AG027576, and R01 AG005394, and by and Alzheimer's
Association award IIRG-08-88872. Dr. Spira is supported by a Mentored
Research Scientist Development Award (1K01AG033195) from the National
Institute on Aging. Dr. Yaffe is partially supported by a Midcareer
Investigator Award in Patient-Oriented Research (K24AG031155) from the
National Institute on Aging. Dr. Punjabi was supported by NIH grants
2R01-HL075078 and 5R01-HL089467. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institute on Aging, or the National
Institutes of Health.; Adam Spira is supported by a grant from the
National Institute on Aging (NIA); he received honoraria while serving
as a clinical editor for the International Journal of Sleep and
Wakefulnessu Primary Care, which receives pharmaceutical company
support. Kenneth Covinsky is supported by grants from the NIA. Naresh
Punjabi is supported by National Institutes of Health (NIH) grants
2R01-HL075078 and 5R01-HL089467, and has received grant support from
Resmed for a multicenter clinical trial on the effects of positive
airway pressure therapy for sleep apnea in type 2 diabetes mellitus.
Katie Stone reports that NIH funding has been obtained for this work.
Teresa Hillier received support from the NIA for this work. Kristine
Ensrud received grant support from the NIH (and supporting agencies) as
listed under Funding Sources. Kristine Yaffe has received grants from
the NIA, National Institute of Mental Health, National Institute of
Diabetes and Digestive and Kidney Diseases, Department of Defense,
Department of Veterans Affairs, the Alzheimer's Association, and an
anonymous donor. She has served on data safety monitoring boards for
Pfizer and Medivation, and received honoraria from Novartis as an
advisory board member. She is a member of the boards of the Beeson
Program, the National Institute of Mental Health, and the National
Heart, Lung, and Blood Institute.
NR 25
TC 19
Z9 20
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2012
VL 60
IS 6
BP 1092
EP 1098
DI 10.1111/j.1532-5415.2012.03968.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 957AW
UT WOS:000305131900013
PM 22690985
ER
PT J
AU Williams, BA
Goodwin, JS
Baillargeon, J
Ahalt, C
Walter, LC
AF Williams, Brie A.
Goodwin, James S.
Baillargeon, Jacques
Ahalt, Cyrus
Walter, Louise C.
TI Addressing the Aging Crisis in US Criminal Justice Health Care
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE aging; health disparities; prisoner
ID PRISON; INMATES; SYSTEM
AB The U.S. criminal justice population is aging at a significantly more rapid rate than the overall U.S. population, with the population of older adults in prison having more than tripled since 1990. This increase is at the root of a prison healthcare crisis that is spilling into communities and public healthcare systems because nearly 95% of prisoners are eventually released. The graying prison population is also straining state and local budgets. In prison, older prisoners cost approximately three times as much as younger prisoners to incarcerate, largely because of healthcare costs. In the community, older former prisoners present the least risk of recidivism yet are vulnerable to serious and costly social and medical challenges such as housing instability, poor employability, multiple chronic health conditions, and health-related mortality; however older current and former prisoners are largely ignored in the current geriatrics evidence base. Knowledge about the health, functional, and cognitive status of older prisoners is limited, with even less known about risk factors for long-term poor health outcomes during and after incarceration. This article provides an overview of aging in the criminal justice system. It then describes how geriatric models of care could be adapted to address the mounting older prisoner healthcare crisis and identifies areas where additional research is needed to explore prison-specific models of care for older adults.
C1 [Williams, Brie A.; Ahalt, Cyrus; Walter, Louise C.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94118 USA.
[Williams, Brie A.; Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Goodwin, James S.] Univ Texas Med Branch, Dept Internal Med, Div Geriatr Med, Galveston, TX USA.
[Baillargeon, Jacques] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX USA.
RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, Dept Med, 3333 Calif St,Suite 380, San Francisco, CA 94118 USA.
EM brie.williams@ucsf.edu
FU National Institute of Aging [K23AG033102]; Jacob & Valeria Langeloth
Foundation; University of California at San Francisco; National Cancer
Institute [R01 CA134425]
FX Dr. Williams is supported by the National Institute of Aging
(K23AG033102), The Jacob & Valeria Langeloth Foundation, and the
University of California at San Francisco Program for the Aging Century.
Dr. Walter is supported by National Cancer Institute Contract R01
CA134425. Drs. Williams and Walter are employees of the Department of
Veterans Affairs (VA). The opinions expressed in this manuscript may not
represent those of the VA.
NR 30
TC 28
Z9 28
U1 1
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2012
VL 60
IS 6
BP 1150
EP 1156
DI 10.1111/j.1532-5415.2012.03962.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 957AW
UT WOS:000305131900023
PM 22642489
ER
PT J
AU Kirkpatrick, WR
Wiederhold, NP
Najvar, LK
Bocanegra, RA
Patterson, TF
AF Kirkpatrick, W. R.
Wiederhold, N. P.
Najvar, L. K.
Bocanegra, R. A.
Patterson, T. F.
TI Comparison of disseminated and pulmonary models of invasive
Aspergillosis for the detection of surrogate markers of infection
SO MYCOSES
LA English
DT Meeting Abstract
C1 [Kirkpatrick, W. R.; Wiederhold, N. P.; Najvar, L. K.; Bocanegra, R. A.; Patterson, T. F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Kirkpatrick, W. R.; Najvar, L. K.; Bocanegra, R. A.; Patterson, T. F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Wiederhold, N. P.] Univ Texas Austin, Austin, TX 78712 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
J9 MYCOSES
JI Mycoses
PD JUN
PY 2012
VL 55
SU 4
SI SI
BP 283
EP 283
PG 1
WC Dermatology; Mycology
SC Dermatology; Mycology
GA 956DK
UT WOS:000305069801228
ER
PT J
AU Johansen, KL
Finkelstein, FO
Revicki, DA
Evans, C
Wan, SW
Gitlin, M
Agodoa, IL
AF Johansen, Kirsten L.
Finkelstein, Fredric O.
Revicki, Dennis A.
Evans, Christopher
Wan, Shaowei
Gitlin, Matthew
Agodoa, Irene L.
TI Systematic review of the impact of erythropoiesis-stimulating agents on
fatigue in dialysis patients
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Review
DE anemia; dialysis; ESA; fatigue; hemoglobin
ID RECOMBINANT-HUMAN-ERYTHROPOIETIN; QUALITY-OF-LIFE; CHRONIC
KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; EPOETIN-ALPHA; RECEIVING
HEMODIALYSIS; DARBEPOETIN ALPHA; HEALTH-STATUS; ANEMIA; TRIAL
AB Background. One of the cardinal symptoms of anemia in chronic kidney disease (CKD) patients is fatigue. Recently, results from Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) raised questions about the role of erythropoiesis-stimulating agents (ESAs) in improving fatigue and the appropriate hemoglobin (Hb) target in anemic patients with CKD. These discussions should be considered with all available evidence to determine the level of benefits and risks associated with ESA therapy on fatigue among both early-stage CKD patients and end-stage renal disease patients on dialysis.
Methods. The study was a systematic review of the literature on fatigue in adults on maintenance dialysis therapy. The requirement for inclusion in the review was the measurement of fatigue before and after ESA treatment. Outcomes that were assessed were fatigue as measured by the Kidney Disease Questionnaire, the 36-item Short-Form general health survey, the Nottingham Health Profile, the Profile of Mood States or the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Several different measures of fatigue were used in the studies.
Results. Fifteen articles met the criteria for inclusion, including 10 distinct studies and one extension study. There was one placebo-controlled randomized clinical trial (RCT) and one extension, five single-arm, three high versus low, one intravenous versus subcutaneous and one switch from epoetin alfa to darbepoetin alfa. The only placebo-controlled RCT found a 22-26% improvement in fatigue. Single-arm cohort studies demonstrated a reduction in fatigue after a substantial increase in Hb. Studies with a baseline Hb <10 g/dL and partial correction to a minimum Hb >= 10 g/dL showed an average improvement in fatigue of 34.6%. Studies with a baseline Hb >= 11 g/dL and full correction to a minimum Hb >= 12 g/dL showed an average improvement in fatigue of 5.5%, while studies with no change in Hb (either placebo or control group) showed a decline of 0.7% in fatigue outcomes.
Conclusion. Partial correction of anemia with ESA results in improvement of fatigue among patients on dialysis, most strikingly in those patients with baseline Hb levels <10 g/dL.
C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
[Finkelstein, Fredric O.] Yale Univ, Hosp St Raphael, New Haven, CT USA.
[Revicki, Dennis A.] United BioSource Corp, Bethesda, MD USA.
[Evans, Christopher] Mapi Values, Boston, MA USA.
[Wan, Shaowei; Gitlin, Matthew; Agodoa, Irene L.] Amgen Inc, Thousand Oaks, CA 91320 USA.
RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA USA.
EM Kirsten.Johansen@ucsf.edu
FU Amgen
FX K.L.J. and F.O.F. have received research support from Amgen; D.A.R. and
C.E. have received consulting fees and research support from Amgen;
S.W., M.G. and I.L.A. are employees of Amgen. This study was funded by
Amgen and conceived by employees of Amgen.
NR 34
TC 18
Z9 18
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931-0509
EI 1460-2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JUN
PY 2012
VL 27
IS 6
BP 2418
EP 2425
DI 10.1093/ndt/gfr697
PG 8
WC Transplantation; Urology & Nephrology
SC Transplantation; Urology & Nephrology
GA 952YK
UT WOS:000304832100045
PM 22187314
ER
PT J
AU Hsueh, MT
Eastman, K
McFarland, LV
Raugi, GJ
Reiber, GE
AF Hsueh, Martha T.
Eastman, Kristin
McFarland, Lynne V.
Raugi, Gregory J.
Reiber, Gayle E.
TI Teledermatology Patient Satisfaction in the Pacific Northwest
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE teledermatology; patient satisfaction; store-and-forward; Veterans
Affairs
ID RANDOMIZED CONTROLLED-TRIAL; FORWARD TELEDERMATOLOGY; CONSULT SYSTEM;
TELEMEDICINE; DERMATOLOGY
AB Background: The aim of this quality improvement project is to assess patient satisfaction with a store-and-forward teledermatology project and to identify factors associated with patient satisfaction and dissatisfaction. Subjects and Methods: Veterans receiving care in rural clinics in the Pacific Northwest were surveyed using a 5-point Likert scale about satisfaction with face-to-face care for a skin complaint prior to any teledermatology exposure. One year later, veterans in the same rural clinics were surveyed about satisfaction with teledermatology care using a more comprehensive survey. Ninety-six patients completed the face-to-face satisfaction survey questions, and 501 completed the teledermatology satisfaction survey. Results: Most (78%) of surveyed patients were highly satisfied or satisfied with face-to-face dermatology care. After 1 year of teledermatology, 77% of patients were highly satisfied or satisfied with teledermatology care. The mean patient satisfaction score for teledermatology was equivalent to face-to-face care (4.1 +/- 1.2 and 4.3 +/- 1.0, p= 0.4). Factors associated with teledermatology patient satisfaction included short wait times for initial consultation, a perception that the initial wait time was not too long, a perception that the skin condition was properly treated, and the belief that adequate follow-up was received. Factors associated with teledermatology patient dissatisfaction included perceptions that the skin condition was not properly treated and that inadequate follow-up was received. Conclusions: Teledermatology was widely accepted by the majority of patients receiving care at rural clinics. Patient satisfaction with care received through teledermatology was equivalent to that with face-to-face dermatology.
C1 [Eastman, Kristin; McFarland, Lynne V.; Raugi, Gregory J.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Hsueh, Martha T.; Eastman, Kristin] Univ Washington, Sch Med, Seattle, WA USA.
[Eastman, Kristin; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Rehabil Res & Dev, Seattle, WA 98101 USA.
[Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Primary Med Serv, Dermatol Sect, Seattle, WA 98101 USA.
[Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Specialty Med Serv, Dermatol Sect, Seattle, WA 98101 USA.
RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Metropolitan Pk W,1100 Olive Way,1400, Seattle, WA 98101 USA.
EM lynne.mcfarland@va.gov
FU Veterans Health Administration Office of Rural Health, U.S. Department
of Veterans Affairs; Veterans Health Administration Health Services
Research & Development, U.S. Department of Veterans Affairs
FX We are indebted to Jeff Rodenbaugh for database programming. G.E.R. is
the recipient of a Veterans Affairs Senior Career Scientist award.
Funding for the VISN 20 Rural Teledermatology Project came from the
Veterans Health Administration Office of Rural Health, U.S. Department
of Veterans Affairs. This project was supported by the Veterans Health
Administration Health Services Research & Development, U.S. Department
of Veterans Affairs.
NR 12
TC 18
Z9 18
U1 1
U2 5
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD JUN
PY 2012
VL 18
IS 5
BP 377
EP 381
DI 10.1089/tmj.2011.0181
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 956OA
UT WOS:000305097800009
PM 22489931
ER
PT J
AU Gubner, NR
McKinnon, CS
Cunningham, CL
Phillips, TJ
AF Gubner, N. R.
McKinnon, C. S.
Cunningham, C. L.
Phillips, T. J.
TI VARENICLINE DOES NOT ATTENUATE THE EXPRESSION OF ETHANOL-INDUCED CPP OR
THE DEVELOPMENT OF ETHANOL-INDUCED SENSITIZATION IN DBA/2J MICE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 [Gubner, N. R.; McKinnon, C. S.; Cunningham, C. L.; Phillips, T. J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland VA Med Ctr, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 19A
EP 19A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806000034
ER
PT J
AU Kincaid, CL
Rasmussen, DD
AF Kincaid, C. L.
Rasmussen, D. D.
TI PRAZOSIN, AN alpha 1-ADRENERGIC RECEPTOR ANTAGONIST, DECREASES VOLUNTARY
ALCOHOL INTAKE BY WISTAR RATS IN THE INTERMITTENT ACCESS TO ALCOHOL
(IAA) MODEL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 Univ Washington, VISN Mental Illness Res 20, Educ & Clin Ctr MIRECC, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
Univ Washington, Dept Psychiat, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 22A
EP 22A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806000046
ER
PT J
AU Fryer, SL
Shanbhag, H
Watson, TD
Krystal, JH
Mathalon, DH
AF Fryer, S. L.
Shanbhag, H.
Watson, T. D.
Krystal, J. H.
Mathalon, D. H.
TI FMRI REVEALS DIFFERENTIAL LIMBIC RESPONSE TO ALCOHOL CUE DISTRACTORS
ACROSS STAGES OF ALCOHOL DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94122 USA.
San Francisco VA Med Ctr, San Francisco, CA 92121 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 46A
EP 46A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806000141
ER
PT J
AU Kincaid, CL
Rasmussen, DD
AF Kincaid, C. L.
Rasmussen, D. D.
TI SOURCE (VENDOR) OF WISTAR RATS IS AN IMPORTANT VARIABLE IN THE
INTERMITTENT ACCESS TO ALCOHOL (IAA) MODEL OF INCREASED VOLUNTARY
ALCOHOL DRINKING
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 Univ Washington, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
Univ Washington, Dept Psychiat, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 108A
EP 108A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806000390
ER
PT J
AU Rasmussen, DD
Kincaid, CL
AF Rasmussen, D. D.
Kincaid, C. L.
TI ACOUSTIC STARTLE AMPLITUDE PREDICTS VOLUNTARY ALCOHOL INTAKE DURING
SUBSEQUENT INTERMITTENT ACCESS TO ALCOHOL (IAA)
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 Univ Washington, VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA.
Univ Washington, Dept Psychiat, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 111A
EP 111A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806000401
ER
PT J
AU Rasmussen, DD
Kincaid, CL
Froehlich, JC
AF Rasmussen, D. D.
Kincaid, C. L.
Froehlich, J. C.
TI PRAZOSIN, AN alpha 1-ADRENERGIC RECEPTOR ANTAGONIST, BLOCKS THE EFFECT
OF STRESS ON ANXIETY BEHAVIOR DURING SUBSEQUENT ALCOHOL WITHDRAWAL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 Univ Washington, VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 20, Seattle, WA 98108 USA.
Univ Washington, Dept Psychiat, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 112A
EP 112A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806001004
ER
PT J
AU Lapham, GT
Rubinsky, AD
Williams, EC
Maynard, C
Heagerty, P
Kivlahan, DR
Au, DH
Bradley, KA
AF Lapham, G. T.
Rubinsky, A. D.
Williams, E. C.
Maynard, C.
Heagerty, P.
Kivlahan, D. R.
Au, D. H.
Bradley, K. A.
TI FACTORS ASSOCIATED WITH REPEATED NEGATIVE ALCOHOL SCREENS: IS ANNUAL
ALCOHOL SCREENING UNNECESSARY FOR SOME VA PATIENTS?
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 US Dept Vet Affairs, Seattle, WA 98101 USA.
Univ Washington, Dept Hlth Serv, Seattle, WA 98104 USA.
Grp Hlth Res Inst, Seattle, WA 98101 USA.
RI Maynard, Charles/N-3906-2015
OI Maynard, Charles/0000-0002-1644-7814
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 155A
EP 155A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806001169
ER
PT J
AU Grossbard, JR
Hawkins, EJ
Lapham, GT
Williams, EC
Rubinsky, AD
Chavez, LJ
Bradley, KA
AF Grossbard, J. R.
Hawkins, E. J.
Lapham, G. T.
Williams, E. C.
Rubinsky, A. D.
Chavez, L. J.
Bradley, K. A.
TI RATES OF ALCOHOL MISUSE AND FOLLOW-UP CARE AMONG OEF/OIF VETERANS IN VA:
ASSOCIATIONS WITH SUBSTANCE USE DISORDERS AND PTSD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 VA Puget Sound, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
SUD QuERI, Seattle, WA 98101 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 160A
EP 160A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806001191
ER
PT J
AU Batki, SL
Lasher, BA
Heinz, AJ
Herbst, E
Metzler, T
Prathikanti, S
Waldrop, A
Neylan, TC
Tarasovsky, G
AF Batki, S. L.
Lasher, B. A.
Heinz, A. J.
Herbst, E.
Metzler, T.
Prathikanti, S.
Waldrop, A.
Neylan, T. C.
Tarasovsky, G.
TI RISK-TAKING, IMPULSIVITY, MEMORY & EXECUTIVE FUNCTIONING AS OUTCOME
PREDICTORS IN A TRIAL OF TOPIRAMATE FOR ALCOHOL DEPENDENCE IN VETERANS
WITH PTSD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 UCSF, Dept Psychiat, San Francisco, CA 94121 USA.
San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
NR 0
TC 1
Z9 1
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 226A
EP 226A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806002055
ER
PT J
AU Heinz, AJ
Waldrop, A
Lasher, BA
Herbst, E
Prathikanti, S
Neylan, TC
Metzler, T
Petrakis, I
Tarasovsky, G
Batki, SL
AF Heinz, A. J.
Waldrop, A.
Lasher, B. A.
Herbst, E.
Prathikanti, S.
Neylan, T. C.
Metzler, T.
Petrakis, I.
Tarasovsky, G.
Batki, S. L.
TI COGNITIVE FUNCTIONING, IMPULSIVITY AND RISK-TAKING: RELATIONSHIPS WITH
MEASURES OF CLINICAL SYMPTOMOLOGY IN VETERANS WITH PTSD AND AUD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 UCSF, Dept Psychiat, San Francisco, CA 94121 USA.
San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 226A
EP 226A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806002054
ER
PT J
AU Raskind, MA
Simpson, T
AF Raskind, M. A.
Simpson, T.
TI EFFECTS OF PRAZOSIN ON DRINKING PARAMETERS IN ALCOHOL DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 [Raskind, M. A.; Simpson, T.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Tacoma, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 247A
EP 247A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806002140
ER
PT J
AU Raskind, M
Simpson, T
AF Raskind, M.
Simpson, T.
TI EFFECTS OF PRAZOSIN ON DRINKING PARAMETERS IN ALCOHOL DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
Univ Washington, Seattle, WA 98108 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 318A
EP 318A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806002424
ER
PT J
AU Rasmussen, DD
Froehlich, JC
AF Rasmussen, D. D.
Froehlich, J. C.
TI PRECLINICAL PRAZOSIN STUDIES: DEPENDENCE OF APPROPRIATE DOSE ON DRINKING
HISTORY, AND BENEFIT OF COMBINING PRAZOSIN plus PROPRANOLOL TO DECREASE
RELAPSE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
Univ Washington, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 318A
EP 318A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806002422
ER
PT J
AU Durazzo, TC
Mon, A
Pennington, D
Abe, C
Meyerhoff, DJ
AF Durazzo, T. C.
Mon, A.
Pennington, D.
Abe, C.
Meyerhoff, D. J.
TI CHRONIC CIGARETTE SMOKING IN ALCOHOL USE DISORDERS: ASSOCIATIONS WITH
NEUROBIOLOGICAL ABNORMALITIES IN THE BRAIN REWARD/EXECUTIVE OVERSIGHT
SYSTEM
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 San Francisco VA Med Ctr, San Francisco, CA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 349A
EP 349A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806002546
ER
PT J
AU Schacht, JP
Anton, RF
Randall, PK
Li, X
Henderson, S
Myrick, H
AF Schacht, J. P.
Anton, R. F.
Randall, P. K.
Li, X.
Henderson, S.
Myrick, H.
TI INTERACTING EFFECTS OF NALTREXONE AND OPRM1 AND DAT VARIATION ON THE
NEURAL RESPONSE TO ALCOHOL CUES
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 35th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA)
CY JUN 23-27, 2012
CL San Francisco, CA
SP Res Soc Alcoholism (RSA)
C1 [Schacht, J. P.; Anton, R. F.; Randall, P. K.; Li, X.; Henderson, S.; Myrick, H.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Myrick, H.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2012
VL 36
SU 1
SI SI
BP 366A
EP 366A
PG 1
WC Substance Abuse
SC Substance Abuse
GA 952QA
UT WOS:000304806002616
ER
PT J
AU Hua, P
Feng, WG
Rezonzew, G
Chumley, P
Jaimes, EA
AF Hua, Ping
Feng, Wenguang
Rezonzew, Gabriel
Chumley, Phillip
Jaimes, Edgar A.
TI The transcription factor ETS-1 regulates angiotensin II-stimulated
fibronectin production in mesangial cells
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article
DE chronic kidney disease; renin-angiotensin system
ID NF-KAPPA-B; RECEPTOR TRANSACTIVATION; EXTRACELLULAR-MATRIX;
PROTEIN-SYNTHESIS; POINTED DOMAIN; EXPRESSION; BINDING; GROWTH; GENE;
PHOSPHORYLATION
AB Hua P, Feng W, Rezonzew G, Chumley P, Jaimes EA. The transcription factor ETS-1 regulates angiotensin II-stimulated fibronectin production in mesangial cells. Am J Physiol Renal Physiol 302: F1418-F1429, 2012. First published February 22, 2012; doi:10.1152/ajprenal.00477.2011.-Angiotensin II (ANG II) produced as result of activation of the renin-angiotensin system (RAS) plays a critical role in the pathogenesis of chronic kidney disease via its hemodynamic effects on the renal microcirculation as well as by its nonhemodynamic actions including the production of extracellular matrix proteins such as fibronectin, a multifunctional extracellular matrix protein that plays a major role in cell adhesion and migration as well as in the development of glomerulosclerosis. ETS-1 is an important transcription factor essential for normal kidney development and glomerular integrity. We previously showed that ANG II increases ETS-1 expression and is required for fibronectin production in mesangial cells. In these studies, we determined that ANG II induces phosphorylation of ETS-1 via activation of the type 1 ANG II receptor and that Erk1/2 and Akt/PKB phosphorylation are required for these effects. In addition, we characterized the role of ETS-1 on the transcriptional activation of fibronectin production in mesangial cells. We determined that ETS-1 directly activates the fibronectin promoter and by utilizing gel shift assays and chromatin immunoprecipitation assays identified two different ETS-1 binding sites that promote the transcriptional activation of fibronectin in response to ANG II. In addition, we identified the essential role of CREB and its coactivator p300 on the transcriptional activation of fibronectin by ETS-1. These studies unveil novel mechanisms involved in RAS-induced production of the extracellular matrix protein fibronectin in mesangial cells and establish the role of the transcription factor ETS-1 as a direct mediator of these effects.
C1 [Hua, Ping; Feng, Wenguang; Rezonzew, Gabriel; Chumley, Phillip; Jaimes, Edgar A.] Univ Alabama Birmingham, Div Nephrol, Birmingham, AL 35294 USA.
[Jaimes, Edgar A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Jaimes, EA (reprint author), Univ Alabama Birmingham, Div Nephrol, 1530 3rd Ave S,ZRB 637, Birmingham, AL 35294 USA.
EM ejaimes@uab.edu
FU Veterans Affairs Administration; O'Brien Kidney Center at the University
of Alabama at Birmingham
FX These studies were funded by a Merit Review Award of the Veterans
Affairs Administration (to E. A. Jaimes). We also thank the support of
the O'Brien Kidney Center at the University of Alabama at Birmingham.
NR 49
TC 12
Z9 12
U1 1
U2 3
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD JUN
PY 2012
VL 302
IS 11
BP F1418
EP F1429
DI 10.1152/ajprenal.00477.2011
PG 12
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA 952SN
UT WOS:000304812700008
PM 22357921
ER
PT J
AU Weisbord, SD
AF Weisbord, Steven D.
TI Female Sexual Dysfunction in ESRD: An Underappreciated Epidemic?
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
ID QUALITY-OF-LIFE; CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; ERECTILE
DYSFUNCTION; DIALYSIS; WOMEN; PREVALENCE; SYMPTOMS; INDEX; MEN
C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA.
[Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA.
RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Med Specialty Serv Line, 7E Room 120,111F U, Pittsburgh, PA 15240 USA.
EM weisbordsd@upmc.edu
NR 17
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUN
PY 2012
VL 7
IS 6
BP 881
EP 883
DI 10.2215/CJN.03870412
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 954VE
UT WOS:000304975100003
PM 22580787
ER
PT J
AU Kang, EW
Pike, F
Ramer, S
Abdel-Kader, K
Myaskovsky, L
Dew, MA
Unruh, M
AF Kang, Ea Wha
Pike, Francis
Ramer, Sarah
Abdel-Kader, Khaled
Myaskovsky, Larissa
Dew, Mary Anianda
Unruh, Mark
TI The Association of Mental Health over Time with Cardiac Outcomes in HEMO
Study Patients
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; DIALYSIS
PATIENTS; MAINTENANCE HEMODIALYSIS; PRACTICE PATTERNS; UNITED-STATES;
MORTALITY; DEPRESSION; SF-36
AB Background and objectives Poor mental health over time is significantly associated with cardiovascular morbidity and mortality in the general population, which is the leading cause of death in dialysis patients. Most studies of dialysis patients, however, have investigated the relationship between baseline mental health measurements and all-cause mortality and not mental health measured longitudinally throughout a study and cause-specific mortality.
Design, setting, participants, & measurements This study examined the association of changes in mental health over time with all-cause and cause-specific deaths and cardiac hospitalizations in the Hemodialysis study patients. Mental health was assessed at baseline and annually during the study with short form 36 mental health index scores. Poorer mental health was defined by a mental health index score <= 60.
Results Patients with poorer mental health at baseline were more likely to have less than a high school education and be unmarried, have significantly higher index of coexistent disease scores, and report taking beta-blockers and sleep medications. Low mental health scores over time were independently associated with a decrease in survival time from all-cause mortality by -0.06 (-0.10, -0.03; P<0.001), and they also significantly hastened time to first cardiac hospitalization by -0.08 (-0.13, -0.02; P=0.01) and composite of first cardiac hospitalization or cardiac death by -0.04 (-0.07, -0.02; P<0.001).
Conclusions This study found an independent association between poor mental health over time and all-cause mortality, cardiac hospitalization, and the composite of cardiac death or cardiac hospitalization in hemodialysis patients. The results underscore the importance of attention to mental health related to cardiac complications and even death in dialysis patients. Clin J Am Soc Nephrol 7: 957-964, 2012. doi: 10.2215/CJN.06730711
C1 [Unruh, Mark] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Med Ctr, Pittsburgh, PA 15213 USA.
[Kang, Ea Wha] Natl Hlth Insurance Corp, Dept Med, Ilsan Hosp, Goyangshi, Gyeonggi Do, South Korea.
[Myaskovsky, Larissa] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Myaskovsky, Larissa] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Dew, Mary Anianda] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA.
RP Unruh, M (reprint author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Med Ctr, 200 Lothrop St,PUH C-1111, Pittsburgh, PA 15213 USA.
EM unruh@pitt.edu
OI Abdel-Kader, Khaled/0000-0002-6412-8498
FU NIDDK NIH HHS [K23 DK090304]
NR 46
TC 8
Z9 9
U1 0
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUN
PY 2012
VL 7
IS 6
BP 957
EP 964
DI 10.2215/CJN.06730711
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 954VE
UT WOS:000304975100013
PM 22490873
ER
PT J
AU O'Connor, CM
Mentz, RJ
Cotter, G
Metra, M
Cleland, JG
Davison, BA
Givertz, MM
Mansoor, GA
Ponikowski, P
Teerlink, JR
Voors, AA
Fiuzat, M
Wojdyla, D
Chiswell, K
Massie, BM
AF O'Connor, Christopher M.
Mentz, Robert J.
Cotter, Gad
Metra, Marco
Cleland, John G.
Davison, Beth A.
Givertz, Michael M.
Mansoor, George A.
Ponikowski, Piotr
Teerlink, John R.
Voors, Adriaan A.
Fiuzat, Mona
Wojdyla, Daniel
Chiswell, Karen
Massie, Barry M.
TI The PROTECT in-hospital risk model: 7-day outcome in patients
hospitalized with acute heart failure and renal dysfunction
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Heart failure; Risk model; Risk score; Worsening heart failure
ID INITIATE LIFESAVING TREATMENT; NATIONAL REGISTRY ADHERE; ORGANIZED
PROGRAM; OPTIMIZE-HF; MORTALITY; SURVIVAL; PREDICTORS; IMPACT; SCORE;
ASSOCIATION
AB In patients with acute heart failure (AHF), early worsening heart failure (WHF) predicts a significant proportion of post-discharge readmissions and mortality. We aimed to identify the predictors of 7-day heart failure events or death in patients hospitalized with AHF.
A predictive model and risk score for the short-term primary composite endpoint of 7-day death, HF rehospitalization, or WHF was created using variables collected within 24 h of admission from patients with complete data (n 2015) enrolled in the PROTECT trial of AHF patients. The 7-day composite was experienced by 294 patients (14.6), with a mortality rate of 1.8 (n 37), HF rehospitalization rate of 0.5 (n 9), and WHF rate of 13.1 (n 264). In multivariable analyses, the strongest predictor of short-term morbidity and mortality was higher blood urea nitrogen (BUN) concentration. Additional independent predictors of a worse outcome were lower serum albumin, cholesterol, and systolic blood pressure, as well as higher heart rate and respiratory rate. Model coefficients were converted to an additive risk score for predicting the 7-day composite endpoint with a total point range of 0100. The risk score allowed discrimination of a wide spectrum of risk (4.8 risk with score 35, to 28.7 risk with score 55).
Using the PROTECT 7-day risk model and score, the main determinants of an adverse outcome for AHF patients included impaired metabolic status, neurohormonal activation, and reduced cardiac performance, gauged by BUN, serum albumin and cholesterol levels, systolic blood pressure, heart rate, and respiratory rate.
C1 [O'Connor, Christopher M.] Duke Univ, Med Ctr, Div Cardiol, Duke Clin Res Inst, Durham, NC 27710 USA.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Metra, Marco] Univ Brescia, Pzza Spedali Civili, Brescia, Italy.
[Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England.
[Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Mansoor, George A.] Merck Res Labs, Rahway, NJ USA.
[Ponikowski, Piotr] Kardiol Klin, Wroclaw, Poland.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP O'Connor, CM (reprint author), Duke Univ, Med Ctr, Div Cardiol, Duke Clin Res Inst, Box 3356, Durham, NC 27710 USA.
EM christophe.oconnor@dm.duke.edu
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Davison,
Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016; Metra,
Marco/0000-0001-6691-8568
FU NovaCardia, a subsidiary of Merck; Merck; Abbott; Amgen; Biogen Idec;
Corthera; Cytokinetics; Johnson and Johnson; Scios; Novartis; Relypsa;
Solvay; NovaCardia
FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck.;
C.M.O. is a consultant to Merck which purchased the rights to
rolofylline from NovaCardia, sponsors of the PROTECT study, after
completion of the PROTECT pilot study. G. C. and B. A. D are employees
of Momentum Research Inc., which was contracted to perform work on the
project by Merck & Co, Inc. M. M. has received honoraria and
reimbursements from NovaCardia and from Merck. J.G.C. was on the
Steering Committee for the study, served on the Advisory Board for MSD,
and received payments for both. M. M. G. has received institutional
research support and served on a scientific Advisory Board for Merck. G.
A. M. is an employee of Merck. P. P. has received honoraria from Merck.
J.R.T. has received research funds and consulting fees from Merck for
the conduct of this study and has also received research funds and
consulting fees from Abbott, Amgen, Biogen Idec, Corthera, Cytokinetics,
Johnson and Johnson, Scios, Novartis, Relypsa, and Solvay for research
in related areas. A. A. V. has received speakers and consultancy fees
from Merck. B. M. M. has received consulting fees from NovaCardia and
from Merck. The remaining authors report no relevant conflicts of
interest.
NR 34
TC 44
Z9 44
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1388-9842
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JUN
PY 2012
VL 14
IS 6
BP 605
EP 612
DI 10.1093/eurjhf/hfs029
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 948VH
UT WOS:000304530400008
PM 22535795
ER
PT J
AU Mounzer, R
Langmead, CJ
Wu, BU
Evans, AC
Bishehsari, F
Muddana, V
Singh, VK
Slivka, A
Whitcomb, DC
Yadav, D
Banks, PA
Papachristou, GI
AF Mounzer, Rawad
Langmead, Christopher J.
Wu, Bechien U.
Evans, Anna C.
Bishehsari, Faraz
Muddana, Venkata
Singh, Vikesh K.
Slivka, Adam
Whitcomb, David C.
Yadav, Dhiraj
Banks, Peter A.
Papachristou, Georgios I.
TI Comparison of Existing Clinical Scoring Systems to Predict Persistent
Organ Failure in Patients With Acute Pancreatitis
SO GASTROENTEROLOGY
LA English
DT Article
DE Marker; Organ Failure; Predictors; Pancreas
ID INFLAMMATORY RESPONSE; CLASSIFICATION-SYSTEM; APACHE-II; SEVERITY;
MORTALITY; MARKER; DYSFUNCTION; NECROSIS; INDEX; RISK
AB BACKGROUND & AIMS: It is important to identify patients with acute pancreatitis who are at risk for developing persistent organ failure early in the course of disease. Several scoring systems have been developed to predict which patients are most likely to develop persistent organ failure. We head-to-head compared the accuracy of these systems in predicting persistent organ failure, developed rules that combined these scores to optimize predictive accuracy, and validated our findings in an independent cohort. METHODS: Clinical data from 2 prospective cohorts were used for training (n = 256) and validation (n = 397). Persistent organ failure was defined as cardiovascular, pulmonary, and/or renal failure that lasted for 48 hours or more. Nine clinical scores were calculated when patients were admitted and 48 hours later. We developed 12 predictive rules that combined these scores, in order of increasing complexity. RESULTS: Existing scoring systems showed modest accuracy (areas under the curve at admission of 0.62-0.84 in the training cohort and 0.57-0.74 in the validation cohort). The Glasgow score was the best classifier at admission in both cohorts. Serum levels of creatinine and blood urea nitrogen provided similar levels of discrimination in each set of patients. Our 12 predictive rules increased accuracy to 0.92 in the training cohort and 0.84 in the validation cohort. CONCLUSIONS: The existing scoring systems seem to have reached their maximal efficacy in predicting persistent organ failure in acute pancreatitis. Sophisticated combinations of predictive rules are more accurate but cumbersome to use, and therefore of limited clinical use. Our ability to predict the severity of acute pancreatitis cannot be expected to improve unless we develop new approaches.
C1 [Mounzer, Rawad; Evans, Anna C.; Bishehsari, Faraz; Muddana, Venkata; Slivka, Adam; Whitcomb, David C.; Yadav, Dhiraj; Papachristou, Georgios I.] Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA.
[Langmead, Christopher J.] Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA.
[Wu, Bechien U.; Singh, Vikesh K.; Banks, Peter A.] Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA.
[Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Div Gastroenterol & Hepatol, Pittsburgh, PA USA.
RP Papachristou, GI (reprint author), Presbyterian Univ Hosp, Div Gastroenterol Hepatol & Nutr, M2,C Wing,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM papachri@pitt.edu
FU Doris Duke Clinical Research Fellowship
FX Anna Evans was supported by a Doris Duke Clinical Research Fellowship.
NR 40
TC 83
Z9 91
U1 0
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2012
VL 142
IS 7
BP 1476
EP 1482
DI 10.1053/j.gastro.2012.03.005
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 952GF
UT WOS:000304778700026
PM 22425589
ER
PT J
AU Lieberman, D
AF Lieberman, David
TI Presentation of the Julius M. Friedenwald Medal to Emmet B. Keeffe, MD
SO GASTROENTEROLOGY
LA English
DT Biographical-Item
C1 [Lieberman, David] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA.
[Lieberman, David] Portland VA Med Ctr, Portland, OR USA.
RP Lieberman, D (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA.
NR 2
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD JUN
PY 2012
VL 142
IS 7
BP 1610
EP 1612
DI 10.1053/j.gastro.2012.04.041
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 952GF
UT WOS:000304778700038
PM 22542834
ER
PT J
AU Bernhardt, BA
Zayac, C
Trerotola, SO
Asch, DA
Pyeritz, RE
AF Bernhardt, Barbara A.
Zayac, Cara
Trerotola, Scott O.
Asch, David A.
Pyeritz, Reed E.
TI Cost savings through molecular diagnosis for hereditary hemorrhagic
telangiectasia
SO GENETICS IN MEDICINE
LA English
DT Article
DE cost-effectiveness; economic analysis; genetic screening; genetic
testing; hereditary hemorrhagic telangiectasia
ID PULMONARY ARTERIOVENOUS-MALFORMATIONS; COLORECTAL-CANCER; LYNCH
SYNDROME; HEALTH-CARE; STRATEGIES; MUTATIONS; MEDICINE; OUTCOMES;
IMPACT; TESTS
AB Purpose: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder of vascular development resulting in direct connections between the arterial and venous systems, bypassing capillaries. Symptoms and signs can appear throughout life and marked intrafamilial variability confounds diagnosis based purely on clinical criteria. We set out to determine the impact of genetic testing on the cost of screening for HHT in at-risk relatives.
Methods: We performed economic modeling of idealized pedigrees following two scenarios: repeated clinical screening until an HHT diagnosis could be either affirmed or excluded, and mutation testing in the proband, followed by genetic testing of at-risk relatives and clinical monitoring of only those relatives who test positive for the familial mutation.
Results: Based on actual reimbursement data from our region's largest health insurer, the molecular diagnostic model saved over $22,000 for a family with four relatives at risk for the initial diagnostic work-up. For a cohort of 100 probands, the total savings for the molecular diagnostic model over a reasonable period of follow-up was greater than $9 million.
Conclusion: In this idealized setting in which all probands and at-risk relatives accepted molecular testing, the economic advantages of genetic screening over repeated clinical screening are substantial.
C1 [Bernhardt, Barbara A.; Zayac, Cara; Pyeritz, Reed E.] Univ Penn, Div Translat Med & Human Genet, Philadelphia, PA 19104 USA.
[Bernhardt, Barbara A.; Zayac, Cara; Asch, David A.; Pyeritz, Reed E.] Univ Penn, Raymond & Ruth Perelman Sch Med, Ctr Integrat Genet Healthcare Technol, Philadelphia, PA 19104 USA.
[Bernhardt, Barbara A.; Asch, David A.; Pyeritz, Reed E.] Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA.
[Trerotola, Scott O.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA.
[Asch, David A.; Pyeritz, Reed E.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Pyeritz, Reed E.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Pyeritz, Reed E.] Univ Penn, Dept Genet, Philadelphia, PA 19104 USA.
RP Pyeritz, RE (reprint author), Univ Penn, Div Translat Med & Human Genet, Philadelphia, PA 19104 USA.
EM reed.pyeritz@uphs.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU National Human Genome Research Institute [P50HG004487]
FX We thank Joseph Monkoski for helpful information. This work was
supported by National Human Genome Research Institute grant P50HG004487.
The preparation of this manuscript occurred while R. E. P. was in
residence at the Brocher Foundation, Hermance, Switzerland.
NR 34
TC 5
Z9 5
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
J9 GENET MED
JI Genet. Med.
PD JUN
PY 2012
VL 14
IS 6
BP 604
EP 610
DI 10.1038/gim.2011.56
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA 955GL
UT WOS:000305005000005
PM 22281938
ER
PT J
AU Bates, ML
Fulmer, BR
Farrell, ET
Drezdon, A
Pegelow, DF
Conhaim, RL
Eldridge, MW
AF Bates, Melissa L.
Fulmer, Brendan R.
Farrell, Emily T.
Drezdon, Alyssa
Pegelow, David F.
Conhaim, Robert L.
Eldridge, Marlowe W.
TI Hypoxia recruits intrapulmonary arteriovenous pathways in intact rats
but not isolated rat lungs
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE arteriovenous anastamoses; hypoxia; intrapulmonary shunts; lung;
microspheres
ID PULMONARY GAS-EXCHANGE; HEALTHY HUMANS; VASCULAR PRESSURES; BLOOD
VOLUME; EXERCISE; EPINEPHRINE; STROKE; TRANSPULMONARY; DISTENSIBILITY;
PERFUSION
AB Bates ML, Fulmer BR, Farrell ET, Drezdon A, Pegelow DF, Conhaim RL, Eldridge MW. Hypoxia recruits intrapulmonary arteriovenous pathways in intact rats but not isolated rat lungs. J Appl Physiol 112: 1915-1920, 2012. First published March 15, 2012; doi:10.1152/japplphysiol.00985.2011.-Intrapulmonary arteriovenous anastomoses (IPAVS) directly connect the arterial and venous circulations in the lung, bypassing the capillary network. Here, we used solid, latex microspheres and isolated rat lung and intact, spontaneously breathing rat models to test the hypothesis that IPAVS are recruited by alveolar hypoxia. We found that hypoxia recruits IPAVS in the intact rat, but not the isolated lung. IPAVS are at least 70 mu m in the rat and, interestingly, appear to be recruited when the mixed venous PO2 falls below 22 mmHg. These data provide evidence that large-diameter, direct arteriovenous connections exist in the lung and are recruitable by hypoxia in the intact animal.
C1 [Bates, Melissa L.] Univ Wisconsin, Clin Sci Ctr H6 551, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA.
[Bates, Melissa L.; Fulmer, Brendan R.; Farrell, Emily T.; Drezdon, Alyssa; Pegelow, David F.; Eldridge, Marlowe W.] Univ Wisconsin, Sch Med & Publ Hlth, John Rankin Lab Pulm Med, Madison, WI 53792 USA.
[Eldridge, Marlowe W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biomed Engn, Madison, WI 53792 USA.
[Eldridge, Marlowe W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Kinesiol, Madison, WI 53792 USA.
[Conhaim, Robert L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53792 USA.
[Conhaim, Robert L.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
RP Bates, ML (reprint author), Univ Wisconsin, Clin Sci Ctr H6 551, Sch Med & Publ Hlth, Dept Pediat, 600 Highland Ave, Madison, WI 53792 USA.
EM mlbates@pediatrics.wisc.edu
FU National Institutes of Health [5R01-HL-086897, 5T32-HL-007654]; American
Heart Association
FX This work was supported by grants from the National Institutes of Health
(5R01-HL-086897 and 5T32-HL-007654) and a postdoctoral fellowship from
the American Heart Association.
NR 32
TC 16
Z9 16
U1 0
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD JUN
PY 2012
VL 112
IS 11
BP 1915
EP 1920
DI 10.1152/japplphysiol.00985.2011
PG 6
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 952RS
UT WOS:000304810500014
PM 22422800
ER
PT J
AU Bent, S
Bertoglio, K
Ashwood, P
Nemeth, E
Hendren, RL
AF Bent, Stephen
Bertoglio, Kiah
Ashwood, Paul
Nemeth, Edward
Hendren, Robert L.
TI Brief Report: Hyperbaric Oxygen Therapy (HBOT) in Children with Autism
Spectrum Disorder: A Clinical Trial
SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
LA English
DT Article
DE Autism; Clinical trial; Alternative therapy
ID OXIDATIVE STRESS; MULTICENTER; BRAIN
AB We sought to determine whether HBOT leads to parental reported behavioral changes and alterations in cytokines in children with ASD. Ten children completed 80 sessions of HBOT and all improved by 2 points on the clinician-rated CGI-I scale (much improved) as well as several parent-completed measures of behavior. The lack of a control group limits the ability to determine if improvements were related to HBOT. Enrolled children did not exhibit abnormal cytokine levels at baseline and no significant changes in mean cytokine levels were observed. Although this study was limited by the small sample size and by the variable nature of cytokines, we found no evidence that HBOT affects cytokine levels or that cytokine levels were associated with behavioral changes.
C1 [Bent, Stephen] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Bent, Stephen; Hendren, Robert L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Bent, Stephen] Univ Calif San Francisco, Dept Med, Osher Ctr Integrat Med, San Francisco, CA USA.
[Bent, Stephen] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Bertoglio, Kiah] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA.
[Ashwood, Paul] Univ Calif Davis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
[Nemeth, Edward] CHERISH Fdn, Sacramento, CA USA.
RP Bent, S (reprint author), San Francisco VA Med Ctr, 111-A1,4150 Clement St, San Francisco, CA 94121 USA.
EM Stephen.Bent@ucsf.edu
FU Autism Speaks [AS2311]; NCRR NIH HHS [UL1 RR024131]
NR 17
TC 9
Z9 11
U1 1
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0162-3257
J9 J AUTISM DEV DISORD
JI J. Autism Dev. Disord.
PD JUN
PY 2012
VL 42
IS 6
BP 1127
EP 1132
DI 10.1007/s10803-011-1337-3
PG 6
WC Psychology, Developmental
SC Psychology
GA 949YA
UT WOS:000304613000025
PM 21818676
ER
PT J
AU Goodlin, SJ
AF Goodlin, Sarah J.
TI Hospice Care Following Heart Failure Admission: What Next?
SO JOURNAL OF CARDIAC FAILURE
LA English
DT Editorial Material
ID PALLIATIVE CARE; COMMUNICATION
C1 [Goodlin, Sarah J.] Portland VA Med Ctr, Portland, OR USA.
[Goodlin, Sarah J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Goodlin, Sarah J.] Patient Ctr Educ & Res, Salt Lake City, UT USA.
RP Goodlin, SJ (reprint author), P3 Med Portland VAMC, POB 1034, Portland, OR 97207 USA.
EM sgoodlin@patient-centered.org
NR 13
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 1071-9164
J9 J CARD FAIL
JI J. Card. Fail.
PD JUN
PY 2012
VL 18
IS 6
BP 478
EP 479
DI 10.1016/j.cardfail.2012.03.004
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 957MF
UT WOS:000305166400006
PM 22633305
ER
PT J
AU Yamaleyeva, LM
Lindsey, SH
Varagic, J
Zhang, LL
Gallagher, PE
Chen, AF
Chappell, MC
AF Yamaleyeva, Liliya M.
Lindsey, Sarah H.
Varagic, Jasmina
Zhang, Li Li
Gallagher, Patricia E.
Chen, Alex F.
Chappell, Mark C.
TI Amelioration of Renal Injury and Oxidative Stress by the nNOS Inhibitor
L-VNIO in the Salt-sensitive mRen2. Lewis Congenic Rat
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article
DE albuminuria; renal inflammation; renal cortex; tetrahy-drobiopterin;
8-hydroxy-deoxyguanosine
ID NITRIC-OXIDE SYNTHASE; BLOOD-PRESSURE; SEX-DIFFERENCES; ANGIOTENSIN-II;
HYPERTENSION; KIDNEY; EXPRESSION; MECHANISM; DYSFUNCTION; ESTROGEN
AB Salt sensitivity is a key risk factor for cardiovascular disease and renal injury. Alterations in renal nitric oxide may contribute to salt-dependent increases in blood pressure and tissue damage. Therefore, we assessed the expression of nitric oxide synthase (NOS) isoforms in the kidney and the effects of nNOS inhibition on renal injury, inflammation, and oxidative stress in the female mRen2.Lewis rat (mRen), a model of salt-sensitive hypertension. We find that a high-salt diet (4% sodium) significantly reduced endothelial NOS mRNA (2.6-fold) and protein (1.5-fold) but increased nNOS mRNA (2.4-fold) and protein (1.9-fold) in the renal cortex of these animals. Immunostaining for nNOS also seemed higher in macula densa and cortical tubules of the rats fed a high-salt diet. Circulating nitrate and nitrite levels were reduced, including the tissue levels of the NOS cofactor tetrahydrobiopterin. Cortical markers of oxidative stress (4HNE, 8-OH-deoxyguanosine) and fibrosis were increased; however, mRNA levels of the NAD(P) H oxidase components NOX4, p22phox, and p47phox were reduced. Chronic treatment with the nNOS inhibitor N-5-(1-Imino-3-butenyl)-L-ornithine did not influence systolic blood pressure after 4 weeks but significantly attenuated albuminuria, renal fibrosis, inflammation, and indices of oxidative stress. We conclude that an increase in nNOS expression in conjunction with reduced levels of cortical tetrahydrobiopterin may stimulate oxidative stress and renal injury in the salt-sensitive female mRen2.Lewis rat.
C1 [Yamaleyeva, Liliya M.; Lindsey, Sarah H.; Varagic, Jasmina; Gallagher, Patricia E.; Chappell, Mark C.] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Res Ctr, Winston Salem, NC USA.
[Zhang, Li Li; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Yamaleyeva, LM (reprint author), Wake Forest Sch Med, Hypertens & Vasc Res Ctr, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM lyamaley@wake-health.edu
FU National Heart Lung and Blood Institute, NIH [HL-56973, HL-51952]; NIH
[HL-103974]; American Heart Association Mid-Atlantic Affiliate
[AHA-151521, AHA-2300114, AHA-525586U]; National Institute of General
Medical Science, NIH [R01GM077352]; American Diabetes Association
[7-08-RA-23]
FX Supported by grants from the National Heart Lung and Blood Institute,
NIH, to M.C. Chappell (HL-56973, HL-51952); NIH to S.H. Lindsey
(HL-103974); the American Heart Association Mid-Atlantic Affiliate to
M.C. Chappell (AHA-151521), J. Varagic (AHA-2300114), and to L.M.
Yamaleyeva (AHA-525586U); the National Institute of General Medical
Science, NIH (R01GM077352), and the American Diabetes Association
(7-08-RA-23) to A.F. Chen.
NR 39
TC 7
Z9 7
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0160-2446
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD JUN
PY 2012
VL 59
IS 6
BP 529
EP 538
DI 10.1097/FJC.0b013e31824dd15b
PG 10
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA 956IF
UT WOS:000305082600006
PM 22370956
ER
PT J
AU Fujimoto, WY
Boyko, EJ
Hayashi, T
Kahn, SE
Leonetti, DL
McNeely, MJ
Shuman, WP
AF Fujimoto, Wilfred Y.
Boyko, Edward J.
Hayashi, Tomoshige
Kahn, Steven E.
Leonetti, Donna L.
McNeely, Marguerite J.
Shuman, William P.
TI Risk factors for type 2 diabetes: Lessons learned from Japanese
Americans in Seattle
SO JOURNAL OF DIABETES INVESTIGATION
LA English
DT Review
DE Japanese Americans; Lifestyle; Obesity
ID IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; CORONARY-HEART-DISEASE;
BODY-FAT DISTRIBUTION; FASTING PLASMA-GLUCOSE; EARLY INSULIN-RESPONSE;
5-YEAR FOLLOW-UP; VISCERAL ADIPOSITY; ORAL GLUCOSE; COMPUTED-TOMOGRAPHY
AB Migrant Japanese populations in both the USA and Brazil have for a long time shown a higher prevalence of type 2 diabetes than native Japanese, suggesting an interaction of lifestyle and genetic predisposition in the etiology of type 2 diabetes. The overall objective of the Seattle Japanese American Community Diabetes Study was to learn more about the etiology and pathogenesis of type 2 diabetes in Japanese Americans. This metabolically based epidemiological study included extensive assessments of insulin sensitivity, insulin response, and adiposity with the latter including measurements of body fat distribution by both anthropometry and computed tomography. Because of this, the importance of visceral adiposity as a risk factor for abnormal glucose tolerance, hypertension, coronary heart disease and the metabolic syndrome was shown. In conjunction with an examination of diet and physical activity patterns, the result was a clearer understanding of the etiology and pathogenesis of type 2 diabetes in Japanese Americans. We propose that a lifestyle that fosters increased weight gain, especially in the visceral adipose depot, promotes the development of insulin resistance, which in turn exposes an underlying reduced beta-cell reserve in susceptible individuals, resulting in glucose intolerance and, eventually in many, the development of diabetes. We have shown that it might be possible to delay or prevent the development of diabetes through dietary and exercise interventions in individuals identified as having impaired glucose tolerance. The lessons learned from studying migrant Japanese in Seattle might in many ways be applicable to other populations of Asian origin. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00195.x, 2012)
C1 [Fujimoto, Wilfred Y.; Boyko, Edward J.; Kahn, Steven E.; McNeely, Marguerite J.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA.
[Shuman, William P.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Boyko, Edward J.; Hayashi, Tomoshige] Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Boyko, Edward J.; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Hayashi, Tomoshige] Osaka City Univ, Dept Prevent Med & Environm Hlth, Grad Sch Med, Osaka 558, Japan.
RP Fujimoto, WY (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA.
EM wilfuji@u.washington.edu
OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X
FU Kroc Foundation; American Diabetes Association; National Institutes of
Health [DK-02654, DK-02860, DK-31170, DK-48152, DK-50703, DK-55460,
HL-07028, HL-49293]; United States Department of Veterans Affairs; Japan
Society for the Promotion of Science; Uehara Memorial Foundation;
Nakatomi Foundation; Japanese Ministry of Education, Science, Sports,
and Culture
FX This work was supported by grants from the Kroc Foundation and American
Diabetes Association; National Institutes of Health Grants DK-02654,
DK-02860, DK-31170, DK-48152, DK-50703, DK-55460, HL-07028 and HL-49293;
and facilities and services provided by the Diabetes and Endocrinology
Research Center (DK-17047), Clinical Nutrition Research Unit (DK-35816),
and the General Clinical Research Center (RR-00037) at the University of
Washington. EJB and SEK were also supported by the United States
Department of Veterans Affairs. WYF was also supported by a grant from
the Japan Society for the Promotion of Science as a Visiting Researcher
at the University of Tokyo, and gratefully acknowledges the support and
assistance provided by Dr Kinori Kosaka, Dr Yasuo Akanuma and Dr
Yasunori Kanazawa at the University of Tokyo and Dr Nobusada Kuzuya at
the Asahi Institute in Tokyo. TH was supported by grants from the Uehara
Memorial Foundation, the Nakatomi Foundation, and the Japanese Ministry
of Education, Science, Sports, and Culture as a Visiting Scholar at the
University of Washington. All of the authors have contributed
significantly to the collection and analysis of data, have reviewed and
edited the manuscript, and have agreed to its content and submission for
publication, and none have any financial relationships or support that
might pose a conflict of interest. We thank the many skilled staff
members at the University of Washington, especially Pamela Asberry, Jane
Shofer, Christine Tsunehara, Pamela Yang and the staff of the General
Clinical Research Center for their assistance, and also acknowledge the
collaboration of many colleagues whose contributions are documented by
their co-authorship of the many papers that have resulted from this
research. Last but not least, we are particularly grateful for the
unswerving support and cooperation of the King County Japanese American
community and our Community Advisory Board, without which we would not
have been able to carry out this study.
NR 91
TC 18
Z9 18
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2040-1116
J9 J DIABETES INVEST
JI J. Diabetes Investig.
PD JUN
PY 2012
VL 3
IS 3
BP 212
EP 224
DI 10.1111/j.2040-1124.2012.00195.x
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 953KG
UT WOS:000304865500003
PM 22798980
ER
PT J
AU Carnes, M
Devine, PG
Isaac, C
Manwell, LB
Ford, CE
Byars-Winston, A
Fine, E
Sheridan, J
AF Carnes, Molly
Devine, Patricia G.
Isaac, Carol
Manwell, Linda Baier
Ford, Cecelia E.
Byars-Winston, Angela
Fine, Eve
Sheridan, Jennifer
TI Promoting Institutional Change Through Bias Literacy
SO JOURNAL OF DIVERSITY IN HIGHER EDUCATION
LA English
DT Article
DE gender bias; faculty; STEM; intervention studies; prejudice; academic
medical centers
ID SELF-REGULATION; TRANSTHEORETICAL MODEL; PREJUDICE-REDUCTION; INTERGROUP
CONTACT; PERSPECTIVE-TAKING; QUEEN BEE; WOMEN; DISCRIMINATION;
STEREOTYPES; COMMITMENT
AB The National Science Foundation and others conclude that institutional transformation is required to ensure equal opportunities for the participation and advancement of men and women in academic science, technology, engineering, mathematics, and medicine (STEMM). Such transformation requires changing the habitual attitudes and behaviors of faculty. Approaching implicit bias as a remediable habit, we present the theoretical basis and conceptual model underpinning an educational intervention to promote bias literacy among university faculty as a step toward institutional transformation regarding gender equity. We describe the development and implementation of a Bias Literacy Workshop in detail so others can replicate or adapt it to their setting. Of the 220 (167 faculty and 53 nonfaculty) attendees from the initial 17 departments/divisions offered this workshop, all 180 who completed a written evaluation found the workshop at least "somewhat useful" and 74% found it "very useful." Over 68% indicated increased knowledge of the workshop material. Of the 186 participants who wrote a commitment to engage in new activities to promote gender equity, 87% incorporated specific workshop content. Twenty-four participants were interviewed 4-6 months after attending the workshop; 75% of these not only demonstrated increased bias awareness, but described plans to change-or had actually changed-behaviors because of the workshop. Based on our sample of faculty from a Midwestern university, we conclude that at least one third of STEMM faculty who are invited will attend a 2.5-hr Bias Literacy Workshop, that nearly all will find it useful, and that most will complete a written commitment to promoting gender equity. These findings suggest that this educational intervention May effectively promote institutional change regarding gender equity.
C1 [Carnes, Molly; Isaac, Carol; Manwell, Linda Baier; Byars-Winston, Angela] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA.
[Byars-Winston, Angela] Univ Wisconsin, Dept Med, Div Gen Internal Med, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53715 USA.
[Carnes, Molly; Manwell, Linda Baier; Fine, Eve; Sheridan, Jennifer] Univ Wisconsin, WISELI, Madison, WI 53715 USA.
[Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[Devine, Patricia G.] Univ Wisconsin, Dept Psychol, Madison, WI 53715 USA.
[Ford, Cecelia E.] Univ Wisconsin, Dept English, Madison, WI 53715 USA.
RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA.
EM mlcarnes@wisc.edu
FU NIGMS NIH HHS [R01 GM088477]
NR 76
TC 21
Z9 21
U1 5
U2 38
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1938-8926
J9 J DIVERS HIGH EDUC
JI J. Divers. High. Educ.
PD JUN
PY 2012
VL 5
IS 2
BP 63
EP 77
DI 10.1037/a0028128
PG 15
WC Education & Educational Research; Psychology, Educational; Psychology,
Social
SC Education & Educational Research; Psychology
GA 950ZM
UT WOS:000304690400001
PM 22822416
ER
PT J
AU Masri, KR
Shaver, TS
Shahouri, SH
Wang, S
Anderson, JD
Busch, RE
Michaud, K
Mikuls, TR
Caplan, L
Wolfe, F
AF Masri, Karim R.
Shaver, Timothy S.
Shahouri, Shadi H.
Wang, Shirley
Anderson, James D.
Busch, Ruth E.
Michaud, Kaleb
Mikuls, Ted R.
Caplan, Liron
Wolfe, Frederick
TI Validity and Reliability Problems with Patient Global as a Component of
the ACR/EULAR Remission Criteria as Used in Clinical Practice
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE RHEUMATOID ARTHRITIS; REMISSION; RELIABILITY
ID ARTHRITIS DISEASE-ACTIVITY; HEALTH-ASSESSMENT QUESTIONNAIRE;
RHEUMATOID-ARTHRITIS; AMERICAN-COLLEGE; ACTIVITY INDEX; IMPORTANT
DIFFERENCE; OSTEOARTHRITIS; FIBROMYALGIA; DETERMINANTS; FATIGUE
AB Objective. To investigate what factors influence patient global health assessment (PtGlobal), and how those factors and the reliability of PtGlobal affect the rate, reliability, and validity of recently published American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) rheumatoid arthritis (RA) remission criteria when used in clinical practice.
Methods. We examined consecutive patients with RA in clinical practice and identified 77 who met ACR/EULAR joint criteria for remission (<= 1 swollen joint and <= 1 tender joint). We evaluated factors associated with a PtGlobal > 1, because a PtGlobal <= 1 defined ACR/EULAR remission in this group of patients who had already met ACR/EULAR joint criteria.
Results. Of the 77 patients examined, only 17 (22.1%) had PtGlobal <= 1 and thus fully satisfied ACR/EULAR criteria. A large proportion of patients not in remission by ACR/EULAR criteria had high PtGlobal related to noninflammatory issues, including low back pain, fatigue, and functional limitations, and a number of patients clustered in the range of PtGlobal > 1 and <= 2. However, the minimal detectable difference for PtGlobal was 2.3. In addition, compared with a PtGlobal severity score, a PtGlobal activity score was 3.3% less likely to be abnormal (> 1).
Conclusion. Noninflammatory factors contribute to the level of PtGlobal and result in the exclusion of many patients who would otherwise be in "true" remission according to the ACR/EULAR definition. Reliability problems associated with PtGlobal can also result in misclassification, and may explain the observation of low longterm remission rates in RA. As currently constituted, the use of the ACR/EULAR remission criteria in clinical practice appears to be problematic. (First Release May 15 2012; J Rheumatol 2012;39:1139-45; doi:10.3899/jrheum.111543)
C1 [Wolfe, Frederick] Univ Kansas, Natl Data Bank Rheumat Dis, Sch Med, Wichita, KS 67214 USA.
[Shaver, Timothy S.; Shahouri, Shadi H.; Wang, Shirley; Anderson, James D.] Univ Kansas, Arthrit & Rheumatol Clin Kansas, Sch Med, Wichita, KS 67214 USA.
[Busch, Ruth E.] Wichita State Univ, Arthrit & Rheumatol Clin Kansas, Wichita, KS 67260 USA.
[Michaud, Kaleb] Univ Nebraska Med Ctr, Natl Data Bank Rheumat Dis, Omaha, NE USA.
[Mikuls, Ted R.] Omaha VA Med Ctr, Omaha, NE USA.
[Mikuls, Ted R.] Univ Nebraska, Omaha, NE 68182 USA.
[Caplan, Liron] Denver VA Med Ctr, Denver, CO USA.
[Caplan, Liron] Univ Colorado, Denver, CO 80202 USA.
US Natl Data Bank Rheumat Dis, Wichita, KS USA.
RP Wolfe, F (reprint author), Univ Kansas, Natl Data Bank Rheumat Dis, Sch Med, 1035 N Emporia,Suite 288, Wichita, KS 67214 USA.
EM fwolfe@arthritis-research.org
FU VA HSRD CDA [07-221]
FX Dr. Caplan is supported by VA HSR&D CDA 07-221. The views expressed in
this article are those of the authors and do not necessarily reflect the
position or policy of the US Department of Veterans Affairs or the US
government.
NR 33
TC 28
Z9 28
U1 0
U2 4
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315-162X
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUN
PY 2012
VL 39
IS 6
BP 1139
EP 1145
DI 10.3899/jrheum.111543
PG 7
WC Rheumatology
SC Rheumatology
GA 953SP
UT WOS:000304893800008
PM 22589262
ER
PT J
AU Yeh, CK
Harris, SE
Mohan, S
Horn, D
Fajardo, R
Chun, YHP
Jorgensen, J
MacDougall, M
Abboud-Werner, S
AF Yeh, Chih-Ko
Harris, Stephen E.
Mohan, Sumathy
Horn, Diane
Fajardo, Roberto
Chun, Yong-Hee Patricia
Jorgensen, James
MacDougall, Mary
Abboud-Werner, Sherry
TI Hyperglycemia and xerostomia are key determinants of tooth decay in type
1 diabetic mice
SO LABORATORY INVESTIGATION
LA English
DT Article
DE diabetes; enamel; hyperglycemia; pulpitis; saliva
ID RAT PAROTID-GLAND; SALIVARY-GLAND; SECRETORY AMELOBLASTS; PROTEIN
EXPRESSION; DENTINAL TUBULES; ORAL-HEALTH; MOUSE MODEL; IN-VITRO;
STREPTOZOTOCIN; MELLITUS
AB Insulin-dependent type 1 diabetes mellitus (DM) and oral diseases are closely interrelated. Poor metabolic control in diabetics is associated with a high risk of gingivitis, periodontitis and tooth loss. Salivary flow declines in diabetics and patients suffer from xerostomia. Reduced saliva predisposes to enamel hypomineralization and caries formation; however, the mechanisms that initiate and lead to progression of tooth decay and periodontitis in type 1 DM have not been explored. To address this issue, we analyzed tooth morphology in Akita -/- mice that harbor a point mutation in the Ins2 insulin gene, which leads to progressive hyperglycemia. Mandibles from Akita -/- and wild-type littermates were analyzed by microCT, scanning EM and histology; teeth were examined for amelogenin (Amel) and ameloblastin (Ambn) expression. Mice were injected with pilocarpine to assess saliva production. As hyperglycemia may alter pulp repair, the effect of high glucose levels on the proliferation/differentiation of cultured MD10-F2 pulp cells was also analyzed. Results showed that Akita -/- mice at 6 weeks of age showed chalky white incisors that correlated with marked hyperglycemia and impaired saliva production. MicroCT of Akita -/- teeth revealed excessive enamel wearing and hypomineralization; immunostaining for Amel and Ambn was decreased. A striking feature was invasion of dentinal tubules with Streptococcus mitis and microabcesses that originated in the coronal pulp and progressed to pulp necrosis and periapical periodontitis. High levels of glucose also inhibited MD10-F2 cell proliferation and differentiation. Our findings provide the first evidence that hyperglycemia in combination with reduced saliva in a model of type1 DM leads to decreased enamel mineralization/matrix proteins and predisposes to excessive wearing and decay. Importantly, hyperglycemia adversely affects enamel matrix proteins and pulp repair. Early detection and treatment of hyperglycemia and hyposalivation may provide a useful strategy for preventing the dental complications of diabetes and promoting oral health in this population. Laboratory Investigation (2012) 92, 868-882; doi:10.1038/labinvest.2012.60; published online 26 March 2012
C1 [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA.
[Yeh, Chih-Ko; Abboud-Werner, Sherry] S Texas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr GRECC & Pathol, San Antonio, TX 78229 USA.
[Harris, Stephen E.; Chun, Yong-Hee Patricia] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA.
[Mohan, Sumathy; Horn, Diane; Jorgensen, James; Abboud-Werner, Sherry] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Fajardo, Roberto] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthoped, San Antonio, TX 78229 USA.
[MacDougall, Mary] Univ Alabama Birmingham, Inst Oral Hlth Res, Birmingham, AL USA.
RP Abboud-Werner, S (reprint author), S Texas Vet Healthcare Syst, GRECC, Dept Pathol, San Antonio, TX 78229 USA.
EM abboudwerner@uthscsa.edu
FU National Institutes of Health, NIDCR [DE015857, DE0211084]
FX We thank the micro-CT Core Facility at UTHSCSA for their assistance in
analyzing dental tissues and Drs Alan Lin and Yi Zhou (Comprehensive
Dentistry, UTHSCSA) for assisting with saliva/salivary gland collection.
We also thank Chris Edwards and the Microscopy and Image-analysis
Laboratory at the University of Michigan School of Medicine for scanning
electron microscopic studies. This work has been supported, in part, by
funding from the National Institutes of Health, NIDCR (DE015857, SAW)
and (DE0211084, C-KY).
NR 59
TC 12
Z9 13
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD JUN
PY 2012
VL 92
IS 6
BP 868
EP 882
DI 10.1038/labinvest.2012.60
PG 15
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA 951OT
UT WOS:000304730600006
PM 22449801
ER
PT J
AU McLay, RN
Graap, K
Spira, J
Perlman, K
Johnston, S
Rothbaum, BO
Difede, J
Deal, W
Oliver, D
Baird, A
Bordnick, PS
Spitalnick, J
Pyne, JM
Rizzo, A
AF McLay, Robert N.
Graap, Kenneth
Spira, James
Perlman, Karen
Johnston, Scott
Rothbaum, Barbara O.
Difede, JoAnn
Deal, William
Oliver, David
Baird, Alicia
Bordnick, Patrick S.
Spitalnick, Josh
Pyne, Jeffrey M.
Rizzo, Albert
TI Development and Testing of Virtual Reality Exposure Therapy for
Post-Traumatic Stress Disorder in Active Duty Service Members Who Served
in Iraq and Afghanistan
SO MILITARY MEDICINE
LA English
DT Article
ID PSYCHOMETRIC PROPERTIES; ANXIETY DISORDERS; PTSD; TRIAL; FEAR;
METAANALYSIS; VALIDATION; CLINICIAN; SYMPTOMS
AB This study was an open-label, single-group, treatment-development project aimed at developing and testing a method for applying virtual reality exposure therapy (VRET) to active duty service members diagnosed with combat post-traumatic stress disorder (PTSD). Forty-two service members with PTSD were enrolled, and 20 participants completed treatment. The PTSD Checklist-Military version, Patient Health Questionnaire-9 for depression, and the Beck Anxiety Inventory were used as outcome measures. Of those who completed post-treatment assessment, 75% had experienced at least a 50% reduction in PTSD symptoms and no longer met DSM-IV criteria for PTSD at post treatment. Average PSTD scores decreased by 50.4%, depression scores by 46.6%, and anxiety scores by 36%. Intention-to-treat analyses showed that statistically significant improvements in PTSD, depression, and anxiety occurred over the course of treatment and were maintained at follow up. There were no adverse events associated with VRET treatment. This study provides preliminary support for the use of VRET in combat-related PTSD. Further study will be needed to determine the wider utility of the method and to determine if it offers advantages over other established PTSD treatment modalities.
C1 [McLay, Robert N.; Deal, William; Oliver, David; Baird, Alicia] USN, San Diego Med Ctr, San Diego, CA 92134 USA.
[Graap, Kenneth] CNS Response Inc, Aliso Viejo, CA 92656 USA.
[Spira, James] US Dept Vet Affairs, Natl Ctr PTSD, Pacific Isl Div Vet Hlth Adm, Honolulu, HI 96819 USA.
[Johnston, Scott] USN, Ctr Combat & Operat Stress Control, San Diego, CA 92134 USA.
[Rothbaum, Barbara O.] Emory Univ, Trauma & Anxiety Recovery Program, Dept Psychiat, Sch Med, Atlanta, GA 30306 USA.
[Difede, JoAnn] Weill Cornell Med Coll, Dept Psychiat, New York, NY 10021 USA.
[Bordnick, Patrick S.] Univ Houston, Grad Coll Social Work, Child & Family Ctr Innovat Res, Houston, TX 77204 USA.
[Spitalnick, Josh] Virtually Better Corp, Decatur, GA USA.
[Pyne, Jeffrey M.] Centra, Arkansas Vet Healthcare Syst, Ctr Mental Hlth Outcomes Res, Little Rock, AR 72205 USA.
[Rizzo, Albert] Univ So Calif, Inst Creat Technol, Marina Del Rey, CA 90292 USA.
RP McLay, RN (reprint author), USN, San Diego Med Ctr, 34800 Bob Wilson Dr, San Diego, CA 92134 USA.
FU Office of Naval Research [DOD-N0384]
FX This study was funded by a grant from the Office of Naval Research,
grant number DOD-N0384.
NR 29
TC 12
Z9 13
U1 12
U2 37
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD JUN
PY 2012
VL 177
IS 6
BP 635
EP 642
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 955QP
UT WOS:000305036300004
PM 22730837
ER
PT J
AU Leung, FW
AF Leung, Felix W.
TI COLONOSCOPY Reducing faecal incontinence following colonoscopy
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Editorial Material
AB Faecal incontinence can occur in patients who have undergone a colonoscopy. The incidence of postexamination faecal incontinence in a large Norwegian cohort has now been reported, and the risk of faecal incontinence found to be reduced if CO2 is used instead of air to insufflate the colon.
C1 Vet Affairs Greater Los Angeles Healthcare Syst, Gastroenterol Sect, Sepulveda Ambulatory Care Ctr, N Hill, CA 91343 USA.
RP Leung, FW (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Gastroenterol Sect, Sepulveda Ambulatory Care Ctr, 111G,16111 Plummer St, N Hill, CA 91343 USA.
EM felix.leung@va.gov
NR 10
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JUN
PY 2012
VL 9
IS 6
BP 308
EP 309
DI 10.1038/nrgastro.2012.93
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 955JZ
UT WOS:000305016200003
PM 22585133
ER
PT J
AU Harel, NY
Tseng, BY
AF Harel, Noam Y.
Tseng, Benjamin Y.
TI Cerebral perfusion in acute stroke prognostication Go with the flow, or
know with the quo?
SO NEUROLOGY
LA English
DT Editorial Material
ID PREDICTION
C1 [Harel, Noam Y.] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Harel, Noam Y.] James J Peters VA Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, New York, NY USA.
[Tseng, Benjamin Y.] Univ Texas SW Med Ctr Dallas, Dept Internal Med Cardiol, Dallas, TX 75390 USA.
[Tseng, Benjamin Y.] Texas Hlth Presbyterian Hosp, Inst Exercise & Environm Med, Dallas, TX USA.
RP Harel, NY (reprint author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
EM noam.harel@mssm.edu
NR 10
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JUN
PY 2012
VL 78
IS 23
BP 1811
EP 1812
DI 10.1212/WNL.0b013e318258f867
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 953XC
UT WOS:000304906100005
PM 22573632
ER
PT J
AU Myaskovsky, L
Doebler, DA
Posluszny, DM
Dew, MA
Unruh, M
Crowley-Matoka, M
Switzer, GE
Dabbs, AD
Chang, CCH
DiMartini, AF
Shapiro, R
Tan, HK
AF Myaskovsky, Larissa
Doebler, Donna Almario
Posluszny, Donna M.
Dew, Mary Amanda
Unruh, Mark
Crowley-Matoka, Megan
Switzer, Galen E.
Dabbs, Annette DeVito
Chang, Chung-Chou H.
DiMartini, Andrea F.
Shapiro, Ron
Tan, Henkie
TI Rates and correlates of health maintenance behaviors after living kidney
donation
SO PROGRESS IN TRANSPLANTATION
LA English
DT Article
ID QUALITY-OF-LIFE; TERM-FOLLOW-UP; DONOR NEPHRECTOMY; TRANSPLANTATION;
OUTCOMES; CONSEQUENCES; DISEASE; IMPACT
AB Context and Objective-Donating a kidney may provide an opportunity for donors to reevaluate their health maintenance behaviors (eg, regular exercise, smoking cessation, medical checkups). Although the effect of donation on donors' health, quality of life, and financial outcomes has received growing attention, no studies have examined whether donation is related to changes in health maintenance behaviors. The study aims were to (I) describe and compare kidney donors' health maintenance behaviors before and after donation, and (2) determine the correlates of health maintenance behaviors after donation.
Design, Setting, Participants and Measures-We conducted a telephone-interview study with 85 randomly selected laparoscopic kidney donors in a major US transplant center to assess health behaviors before and after donation, postdonation characteristics (eg, quality of life, postsurgical pain), and demographics.
Results-Sample demographics included a median age of 48 years; 55% were female, 82% were white, 71% were married, and 52% were college graduates. Few health behaviors changed significantly from before to after donation. Only the rate of medical checkups increased after donation (P<.001). Logistic regression was used to examine the association of demographics and postdonation characteristics with postdonation health maintenance behaviors, after adjusting for predonation behavior. Older age, higher income, less postsurgical pain, and better physical functioning were associated with more exercise after donation. Longer time since donation was associated with a higher prevalence of obesity.
Conclusions-These results may help identify donors who are at greater risk for poor health maintenance behaviors after donation and suggest areas of health behavior that should be the focus of education sessions before donation. (Progress in Transplantation. 2012;22:147-154) (C) 2012 NATCO, The Organization for Transplant Professionals doi: http://dx.doi.org/10.7182/pit2012287
C1 [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Myaskovsky, Larissa; Doebler, Donna Almario; Posluszny, Donna M.; Dew, Mary Amanda; Unruh, Mark; Switzer, Galen E.; Dabbs, Annette DeVito; Chang, Chung-Chou H.; DiMartini, Andrea F.; Shapiro, Ron; Tan, Henkie] Univ Pittsburgh, Pittsburgh, PA USA.
[Crowley-Matoka, Megan] Northwestern Univ, Evanston, IL USA.
RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA.
EM larissa.myaskovsky@va.gov
FU UPMC Starzl Transplant Institute [XNV 72-069]; VA Health Services
Research and Development Division [IIR 06-220]
FX Funding for this project was provided by grant XNV 72-069 from the UPMC
Starzl Transplant Institute and grant IIR 06-220 from the VA Health
Services Research and Development Division.
NR 41
TC 5
Z9 5
U1 0
U2 1
PU INNOVISION COMMUNICATIONS
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 1526-9248
J9 PROG TRANSPLANT
JI Prog. Transplant.
PD JUN
PY 2012
VL 22
IS 2
BP 147
EP 154
DI 10.7182/pit2012287
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA 956NA
UT WOS:000305095200006
PM 22878071
ER
PT J
AU Carmody, TP
Delucchi, K
Simon, JA
Duncan, CL
Solkowitz, SN
Huggins, J
Lee, SK
Hall, SM
AF Carmody, Timothy P.
Delucchi, Kevin
Simon, Joel A.
Duncan, Carol L.
Solkowitz, Sharon N.
Huggins, Joy
Lee, Sharon K.
Hall, Sharon M.
TI Expectancies Regarding the Interaction Between Smoking and Substance Use
in Alcohol-Dependent Smokers in Early Recovery
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE smoking cessation; tobacco use; nicotine dependence; alcohol dependence;
expectancies
ID ADDICTION SEVERITY INDEX; FAGERSTROM TOLERANCE QUESTIONNAIRE; NICOTINE
DEPENDENCE; ABUSE TREATMENT; CESSATION INTERVENTIONS; ABSTINENCE;
DISORDERS; TOBACCO; METAANALYSIS; INDIVIDUALS
AB The purpose of this study was to investigate expectancies regarding the interaction between cigarette smoking and use of alcohol among alcohol-dependent smokers in early recovery, using the Nicotine and Other Substances Interaction Expectancies Questionnaire (NOSIE). Participants were 162 veterans, 97% male, with a mean age of 50 years, enrolled in a clinical trial aimed at determining the efficacy of an intensive smoking cessation intervention versus usual care. At baseline, participants were assessed on measures of smoking behavior, abstinence thoughts about alcohol and tobacco use, symptoms of depression, and smoking-substance use interaction expectancies. In addition, biologically verified abstinence from tobacco and alcohol was assessed at 26 weeks. Participants reported that they expected smoking to have less of an impact on substance use than substance use has on smoking (p < .001). Severity of depressive symptoms was significantly associated with the expectancy that smoking provides a way of coping with the urge to use other substances (p < .01). The expectation that smoking increases substance urges/use was predictive of prospectively measured and biologically verified abstinence from smoking at 26 weeks (p < .03). The results add to our knowledge of smoking-substance use interaction expectancies among alcohol-dependent smokers in early recovery and will inform the development of more effective counseling interventions for concurrent alcohol and tobacco use disorders.
C1 [Carmody, Timothy P.; Simon, Joel A.; Duncan, Carol L.; Solkowitz, Sharon N.; Huggins, Joy; Lee, Sharon K.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA.
[Delucchi, Kevin; Hall, Sharon M.] Univ Calif San Francisco, Treatment Res Ctr, Dept Psychiat, San Francisco, CA 94143 USA.
RP Carmody, TP (reprint author), Vet Affairs Med Ctr, Mental Hlth Serv 116B, 4150 Clement St, San Francisco, CA 94121 USA.
EM timothy.carmody@va.gov
FU NIDA NIH HHS [P50 DA009253, P50 DA009253-09, P50 DA09253]
NR 36
TC 8
Z9 8
U1 2
U2 5
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD JUN
PY 2012
VL 26
IS 2
BP 358
EP 363
DI 10.1037/a0024424
PG 6
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA 956NX
UT WOS:000305097500021
PM 21707127
ER
PT J
AU Atwood, CW
AF Atwood, Charles W., Jr.
TI "The Times They Are A Changin:" Home Diagnosis of Sleep Apnea Has
Arrived Commentary on Rosen et al. A multisite randomized trial of
portable sleep studies and positive airway pressure autotitration versus
laboratory-based polysomnography for the diagnosis and treatment of
obstructive sleep apnea: The HomePAP Study. SLEEP 2012;35:757-767
SO SLEEP
LA English
DT Editorial Material
ID OUTCOMES
C1 [Atwood, Charles W., Jr.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Med Ctr, UPMC Sleep Med Ctr, Pittsburgh, PA 15213 USA.
[Atwood, Charles W., Jr.] VA Pittsburgh Healthcare Syst, Pulm Sect, Pittsburgh, PA USA.
[Atwood, Charles W., Jr.] VA Pittsburgh Healthcare Syst, Sleep Disorders Program, Pittsburgh, PA USA.
RP Atwood, CW (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Med Ctr, UPMC Sleep Med Ctr, 3459 5th Ave,NW628 MUH, Pittsburgh, PA 15213 USA.
EM atwoodcw@upmc.edu
NR 8
TC 2
Z9 2
U1 0
U2 0
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
J9 SLEEP
JI Sleep
PD JUN 1
PY 2012
VL 35
IS 6
BP 735
EP 736
DI 10.5665/sleep.1848
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 952CM
UT WOS:000304767300003
PM 22654184
ER
PT J
AU Biering-Sorensen, F
Krassioukov, A
Alexander, MS
Donovan, W
Karlsson, AK
Mueller, G
Perkash, I
Sheel, AW
Wecht, J
Schilero, GJ
AF Biering-Sorensen, F.
Krassioukov, A.
Alexander, M. S.
Donovan, W.
Karlsson, A-K
Mueller, G.
Perkash, I.
Sheel, A. William
Wecht, J.
Schilero, G. J.
TI International Spinal Cord Injury Pulmonary Function Basic Data Set
SO SPINAL CORD
LA English
DT Article
DE spinal cord injury; international data set; pulmonary function;
pneumonia; sleep apnea; ventilator
ID FORCED VITAL CAPACITY; MORTALITY; SLEEP; DEATH; FEV1; FVC
AB Objectives: To develop the International Spinal Cord Injury (SCI) Pulmonary Function Basic Data Set within the framework of the International SCI Data Sets in order to facilitate consistent collection and reporting of basic bronchopulmonary findings in the SCI population.
Setting: International.
Methods: The SCI Pulmonary Function Data Set was developed by an international working group. The initial data set document was revised on the basis of suggestions from members of the Executive Committee of the International SCI Standards and Data Sets, the International Spinal Cord Society (ISCoS) Executive and Scientific Committees, American Spinal Injury Association (ASIA) Board, other interested organizations and societies and individual reviewers. In addition, the data set was posted for 2 months on ISCoS and ASIA websites for comments.
Results: The final International SCI Pulmonary Function Data Set contains questions on the pulmonary conditions diagnosed before spinal cord lesion, if available, to be obtained only once; smoking history; pulmonary complications and conditions after the spinal cord lesion, which may be collected at any time. These data include information on pneumonia, asthma, chronic obstructive pulmonary disease and sleep apnea. Current utilization of ventilator assistance including mechanical ventilation, diaphragmatic pacing, phrenic nerve stimulation and Bi-level positive airway pressure can be reported, as well as results from pulmonary function testing includes: forced vital capacity, forced expiratory volume in one second and peak expiratory flow. The complete instructions for data collection and the data sheet itself are freely available on the website of ISCoS (http://www.iscos.org.uk). Spinal Cord (2012) 50, 418-421; doi:10.1038/sc.2011.183; published online 24 January 2012
C1 [Biering-Sorensen, F.] Rigshosp, Clin Spinal Cord Injuries, Ctr Neurosci, DK-2100 Copenhagen, Denmark.
[Biering-Sorensen, F.] Univ Copenhagen, DK-2100 Copenhagen O, Denmark.
[Krassioukov, A.; Sheel, A. William] Univ British Columbia, ICORD, Vancouver, BC V5Z 1M9, Canada.
[Krassioukov, A.; Sheel, A. William] Vancouver Coastal Hlth, Vancouver, BC, Canada.
[Alexander, M. S.] Renown Rehabil Hosp, Reno, NV USA.
[Donovan, W.] Univ Texas Hlth Sci Ctr, Baylor Coll Med, Houston, TX USA.
[Karlsson, A-K] Sahlgrens Univ Hosp, Gothenburg, Sweden.
[Mueller, G.] Swiss Parapleg Ctr, Clin Trial Unit, Nottwil, Switzerland.
[Perkash, I.] Stanford Univ, Palo Alto, CA 94304 USA.
[Perkash, I.] Vet Adm Palo Alto, Palo Alto, CA USA.
[Wecht, J.; Schilero, G. J.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Wecht, J.; Schilero, G. J.] Mt Sinai Sch Med, New York, NY USA.
RP Biering-Sorensen, F (reprint author), RIGSHOSP TH2091, Clin Spinal Cord Injuries, Ctr Neurosci, 9 Blegdamsvej, DK-2100 Copenhagen O, Denmark.
EM finbs@rh.dk
FU Coloplast A/S, Denmark
FX Coloplast A/S, Denmark has supported the work with this Data Set with an
unconditional grant. We are thankful for comments and suggestions
received from Lawrence Vogel, Susan Charlifue, Gordana Savic and Michael
DeVivo.
NR 15
TC 10
Z9 10
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
J9 SPINAL CORD
JI Spinal Cord
PD JUN
PY 2012
VL 50
IS 6
BP 418
EP 421
DI 10.1038/sc.2011.183
PG 4
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 951LC
UT WOS:000304721100005
PM 22270192
ER
PT J
AU Cervera, R
Bakaeen, FG
Cornwell, LD
Wang, XL
Coselli, JS
LeMaire, SA
Chu, D
AF Cervera, Roberto
Bakaeen, Faisal G.
Cornwell, Lorraine D.
Wang, Xing Li
Coselli, Joseph S.
LeMaire, Scott A.
Chu, Danny
TI Impact of Functional Status on Survival After Coronary Artery Bypass
Grafting in a Veteran Population
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID AORTIC-VALVE-REPLACEMENT; HIGH-RISK PATIENTS; CARDIAC-SURGERY; LATE
MORTALITY; FRAILTY; OLDER; OUTCOMES; AGE; DISEASE; INDEX
AB Background. Although functional impairment has been shown to be an adverse outcome of frailty, little is known of its effect on patients after cardiac operations. We aimed to assess the effect of limited functional status on long-term survival after coronary artery bypass grafting (CABG).
Methods. We reviewed prospectively gathered data from 1,503 consecutive patients who underwent isolated CABG between 1997 and 2009. We compared the outcomes of 318 patients with limited functional status and 1,185 patients without any functional impairment. The mean follow-up period was 65 months (range, 1 to 157 months). We assessed the relationship between functional status impairment and long-term survival by Cox regression analysis adjusted for confounding factors.
Results. Functionally impaired patients were slightly older (63 +/- 9 vs 62 +/- 8 years, p = 0.05) and had more risk factors for adverse outcomes than patients who were functionally unimpaired. After adjustment for potential confounding variables by multivariate logistic regression analysis, preoperative limited functional status was not an independent predictor (odds ratio [95% confidence interval]) of 30-day mortality (1.4 [0.3 to 5.8], p = 0.67) or major adverse cardiac events (1.3 [0.5 to 3.3], p = 0.71), nor was it predictive of reduced long-term survival (10-year hazard ratio 1.0 [0.7 to 1.4], p = 0.85).
Conclusions. Limited functional status was not an independent risk factor for early postoperative complications or death. Long-term survival in patients whose functional status was impaired before they underwent CABG was similar to that of patients who were functionally independent.
C1 [Chu, Danny] Baylor Coll Med, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, Houston, TX 77030 USA.
Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX 77030 USA.
St Lukes Episcopal Hosp, Texas Heart Inst, Div Cardiovasc Surg, Houston, TX USA.
RP Chu, D (reprint author), Baylor Coll Med, Texas Heart Inst, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM dchu@bcm.edu
NR 21
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUN
PY 2012
VL 93
IS 6
BP 1950
EP 1955
DI 10.1016/j.athoracsur.2012.02.071
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 947VG
UT WOS:000304460000038
PM 22560262
ER
PT J
AU Carrick, R
Ge, L
Lee, LC
Zhang, ZH
Mishra, R
Axel, L
Guccione, JM
Grossi, EA
Ratcliffe, MB
AF Carrick, Richard
Ge, Liang
Lee, Lik Chuan
Zhang, Zhihong
Mishra, Rakesh
Axel, Leon
Guccione, Julius M.
Grossi, Eugene A.
Ratcliffe, Mark B.
TI Patient-Specific Finite Element-Based Analysis of Ventricular Myofiber
Stress After Coapsys: Importance of Residual Stress
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID ISCHEMIC MITRAL REGURGITATION; VOLUME REDUCTION SURGERY; DILATED
CARDIOMYOPATHY; PAPILLARY-MUSCLE; REPAIR TECHNIQUE; ANNULOPLASTY; VALVE;
MODEL
AB Background. We sought to determine regional myofiber stress after Coapsys device (Myocor, Inc, Maple Grove, MN) implantation using a finite element model of the left ventricle (LV). Chronic ischemic mitral regurgitation is caused by LV remodeling after posterolateral myocardial infarction. The Coapsys device consists of a single trans-LV chord placed below the mitral valve such that when tensioned it alters LV shape and decreases chronic ischemic mitral regurgitation.
Methods. Finite element models of the LV were based on magnetic resonance images obtained before (preoperatively) and after (postoperatively) coronary artery bypass grafting with Coapsys implantation in a single patient. To determine the effect of Coapsys and LV before stress, virtual Coapsys was performed on the preoperative model. Diastolic and systolic material variables in the preoperative, postoperative, and virtual Coapsys models were adjusted so that model LV volume agreed with magnetic resonance imaging data. Chronic ischemic mitral regurgitation was abolished in the postoperative models. In each case, myofiber stress and pump function were calculated.
Results. Both postoperative and virtual Coapsys models shifted end-systolic and end-diastolic pressure-volume relationships to the left. As a consequence and because chronic ischemic mitral regurgitation was reduced after Coapsys, pump function was unchanged. Coapsys decreased myofiber stress at end-diastole and end-systole in both the remote and infarct regions of the myocardium. However, knowledge of Coapsys and LV prestress was necessary for accurate calculation of LV myofiber stress, especially in the remote zone.
Conclusions. Coapsys decreases myofiber stress at end-diastole and end-systole. The improvement in myofiber stress may contribute to the long-term effect of Coapsys on LV remodeling.
C1 Univ Vermont, Coll Med, Burlington, VT USA.
Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA.
Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
Vet Affairs Med Ctr, San Francisco, CA 94121 USA.
NYU, Dept Cardiothorac Surg, New York, NY USA.
NYU, Dept Radiol, New York, NY 10016 USA.
New York Harbor Vet Affairs Med Ctr, New York, NY USA.
RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA.
EM mark.ratclifte@va.gov
OI GROSSI, eugene/0000-0002-2066-7035; Axel, Leon/0000-0003-0608-4690
FU NIH [R01-HL084431, R01-HL077921, R01-HL086400]; University of Vermont
FX This study was supported by NIH grants R01-HL084431 (M.B.R.),
R01-HL077921 (J.M.G.), and R01-HL086400 (J.M.G.). RC. was supported by a
Summer Research Fellowship from the University of Vermont. This support
is gratefully acknowledged.
NR 30
TC 14
Z9 14
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUN
PY 2012
VL 93
IS 6
BP 1964
EP 1971
DI 10.1016/j.athoracsur.2012.03.001
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 947VG
UT WOS:000304460000040
PM 22560323
ER
PT J
AU Jernigan, MG
Press, EG
Nguyen, MH
Clancy, CJ
Shields, RK
AF Jernigan, Meredith G.
Press, Ellen G.
Nguyen, M. Hong
Clancy, Cornelius J.
Shields, Ryan K.
TI The Combination of Doripenem and Colistin Is Bactericidal and
Synergistic against Colistin-Resistant, Carbapenemase-Producing
Klebsiella pneumoniae
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID RISK-FACTORS; INFECTION; OUTCOMES; PHARMACOKINETICS; ACQUISITION;
PREDICTORS; MORTALITY; IMPACT
AB We tested two-drug combinations of doripenem, colistin, gentamicin, and doxycycline against 12 carbapenemase-producing Klebsiella pneumoniae (KPC) isolates by time-kill. The combination of doripenem and colistin reduced the starting inocula by 2 logs for each isolate (range, 2.02 to 6.01 log(10)) and was bactericidal and synergistic against 75 and 50%, respectively. Among colistin- and pan-drug-resistant isolates, synergy was identified in 60 and 67%, respectively. All other combinations were inferior. We are currently evaluating the combination of doripenem and colistin as a frontline therapy for KPC infection.
C1 [Press, Ellen G.; Nguyen, M. Hong; Clancy, Cornelius J.; Shields, Ryan K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
[Jernigan, Meredith G.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA.
[Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Clancy, CJ (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
EM cjc76@pitt.edu
FU National Center for Research Resources [KL2 RR024154]
FX The project described was supported by award number KL2 RR024154 from
the National Center for Research Resources to R.K.S.
NR 24
TC 37
Z9 44
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2012
VL 56
IS 6
BP 3395
EP 3398
DI 10.1128/AAC.06364-11
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 947LZ
UT WOS:000304432800082
PM 22430958
ER
PT J
AU Roemer, FW
Kwoh, CK
Hannon, MJ
Green, SM
Jakicic, JM
Boudreau, R
Crema, MD
Moore, CE
Guermazi, A
AF Roemer, Frank W.
Kwoh, C. Kent
Hannon, Michael J.
Green, Stephanie M.
Jakicic, John M.
Boudreau, Robert
Crema, Michel D.
Moore, Carolyn E.
Guermazi, Ali
TI Risk factors for magnetic resonance imaging-detected patellofemoral and
tibiofemoral cartilage loss during a six-month period: The Joints On
Glucosamine study
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID SYMPTOMATIC KNEE OSTEOARTHRITIS; RADIOGRAPHIC OSTEOARTHRITIS; DISEASE
PROGRESSION; MULTICENTER OSTEOARTHRITIS; MENISCAL EXTRUSION;
NATURAL-HISTORY; ASSOCIATION; FRAMINGHAM; SYNOVITIS; VOLUME
AB Objective To assess several baseline risk factors that may predict patellofemoral and tibiofemoral cartilage loss during a 6-month period. Methods For 177 subjects with chronic knee pain, 3T magnetic resonance imaging (MRI) of both knees was performed at baseline and followup. Knees were semiquantitatively assessed, evaluating cartilage morphology, subchondral bone marrow lesions, meniscal morphology/extrusion, synovitis, and effusion. Age, sex, and body mass index (BMI), bone marrow lesions, meniscal damage/extrusion, synovitis, effusion, and prevalent cartilage damage in the same subregion were evaluated as possible risk factors for cartilage loss. Logistic regression models were applied to predict cartilage loss. Models were adjusted for age, sex, treatment, and BMI. Results Seventy-nine subregions (1.6%) showed incident or worsening cartilage damage at followup. None of the demographic risk factors was predictive of future cartilage loss. Predictors of patellofemoral cartilage loss were effusion, with an adjusted odds ratio (OR) of 3.5 (95% confidence interval [95% CI] 1.39.4), and prevalent cartilage damage in the same subregion with an adjusted OR of 4.3 (95% CI 1.314.1). Risk factors for tibiofemoral cartilage loss were baseline meniscal extrusion (adjusted OR 3.6 [95% CI 1.310.1]), prevalent bone marrow lesions (adjusted OR 4.7 [95% CI 1.119.5]), and prevalent cartilage damage (adjusted OR 15.3 [95% CI 4.947.4]). Conclusion Cartilage loss over 6 months is rare, but may be detected semiquantitatively by 3T MRI and is most commonly observed in knees with Kellgren/Lawrence grade 3. Predictors of patellofemoral cartilage loss were effusion and prevalent cartilage damage in the same subregion. Predictors of tibiofemoral cartilage loss were prevalent cartilage damage, bone marrow lesions, and meniscal extrusion.
C1 [Roemer, Frank W.] Boston Univ, Med Ctr, Dept Radiol, Quantitat Imaging Ctr, Boston, MA 02118 USA.
[Roemer, Frank W.] Klinikum Augsburg, Augsburg, Germany.
[Kwoh, C. Kent; Hannon, Michael J.; Green, Stephanie M.; Jakicic, John M.; Boudreau, Robert] Univ Pittsburgh, Pittsburgh, PA USA.
[Kwoh, C. Kent] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Crema, Michel D.] Inst Diagnost Imaging, Ribeirao Preto, Brazil.
[Crema, Michel D.] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil.
[Moore, Carolyn E.] Texas Womans Univ, Houston, TX USA.
RP Roemer, FW (reprint author), Boston Univ, Med Ctr, Dept Radiol, Quantitat Imaging Ctr, FGH Bldg,3rd Floor,820 Harrison Ave, Boston, MA 02118 USA.
EM froemer@bu.edu
OI Boudreau, Robert/0000-0003-0162-5187
FU Beverage Institute for Health & Wellness, the Coca Cola Company;
Multidisciplinary Clinical Research Center for Musculoskeletal and Skin
Diseases at the University of Pittsburgh (NIH/National Institute of
Arthritis and Musculoskeletal and Skin Diseases) [P60]; Beverage
Institute for Health Wellness; Jenny Craig; Alere Wellbeing; Facet
Solutions; Genzyme; Stryker; Merck Serono; AstraZeneca; General Electric
Healthcare
FX The Joints On Glucosamine study is funded by a grant from the Beverage
Institute for Health & Wellness, the Coca Cola Company. The statistical
analysis was partially supported by the Multidisciplinary Clinical
Research Center for Musculoskeletal and Skin Diseases at the University
of Pittsburgh (NIH/National Institute of Arthritis and Musculoskeletal
and Skin Diseases P60 grant).; Drs. Roemer and Guermazi own stock or
stock options in Boston Imaging Core Lab; Dr. Roemer is vice president
and Dr. Guermazi is president of Boston Imaging Core Lab. Dr. Kwoh has
received a research grant from the Beverage Institute for Health &
Wellness. Dr. Jakicic has received consulting fees, speaking fees,
and/or honoraria from Jenny Craig and Alere Wellbeing (less than $10,000
each). Dr. Crema owns stock or stock options in Boston Imaging Core Lab.
Dr. Guermazi has received consulting fees, speaking fees, and/or
honoraria from Facet Solutions, Genzyme, and Stryker (less than $10,000
each) and from Merck Serono and AstraZeneca (more than $10,000 each) and
has received a research grant from General Electric Healthcare.
NR 51
TC 29
Z9 29
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD JUN
PY 2012
VL 64
IS 6
BP 1888
EP 1898
DI 10.1002/art.34353
PG 11
WC Rheumatology
SC Rheumatology
GA 948SE
UT WOS:000304522100022
PM 22213129
ER
PT J
AU De Costa, AMA
Schuyler, CA
Walker, DD
Young, MRI
AF De Costa, Anna-Maria A.
Schuyler, Corinne A.
Walker, David D.
Young, M. Rita I.
TI Characterization of the evolution of immune phenotype during the
development and progression of squamous cell carcinoma of the head and
neck
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Article
DE HNSCC; Premalignant; Immunoediting; Th1/Tc1 cells; Th17 cells
ID T-CELLS; PD-1 EXPRESSION; TH17 CELLS; CANCER; MODEL; DYSFUNCTION; MICE;
INFLAMMATION; LYMPHOCYTES; INTERFERON
AB While studies have indicated that squamous cell carcinoma of the head and neck (HNSCC) is associated with immune suppression, these studies did not analyze the immune response at the dysplastic stage. The present study utilized a mouse model of 4-nitroquinoline 1-oxide-induced oral carcinogenesis to examine the alterations in immune phenotype at the premalignant and malignant stages of HNSCC. Cervical lymph nodes of HNSCC-bearing mice were found to contain a greater number of cells, including a greater number of conventional (Tconv) and regulatory (Treg) T cells, compared to cervical lymph nodes of control and premalignant lesion-bearing mice, though the Tconv cells appear to be less proliferative and the Treg cells appear to be less suppressive at the HNSCC stage. Premalignant lesion-bearing mouse lymph nodes consist of a greater percentage of Tconv cells expressing markers for activation, memory, and exhaustion compared to both control and HNSCC-bearing mice. Also, lymph nodes' cells from both premalignant lesion-bearing and HNSCC-bearing mice include increased levels of Th1, Tc1, and Th17 cells, with no differences in levels of Th2 cells, compared to control mice. The data show that while there is the expected increase in immunosuppressive Tregs in lymph nodes when HNSCC is present, there is also an unexpected increase in immune populations usually associated with a beneficial antitumor response, including Tconv cells and Th1 and Tc1 cells. In addition, the results demonstrate that the premalignant stage of HNSCC development is associated with a robust immune response involving an increase in inflammatory Th1, Tc1, and Th17 cells.
C1 [De Costa, Anna-Maria A.; Schuyler, Corinne A.; Young, M. Rita I.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, Charleston, SC 29401 USA.
[De Costa, Anna-Maria A.; Walker, David D.; Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29401 USA.
[De Costa, Anna-Maria A.; Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29401 USA.
RP Young, MRI (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Res Serv 151, Charleston, SC 29401 USA.
EM rita.young@va.gov
FU Medical Research Service of the Department of Veterans Affairs; National
Institutes of Health [RO1 CA128837, RO1 DE018268]
FX This work was supported by the Medical Research Service of the
Department of Veterans Affairs and by grants RO1 CA128837 and RO1
DE018268 from the National Institutes of Health to MRIY.
NR 37
TC 15
Z9 15
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD JUN
PY 2012
VL 61
IS 6
BP 927
EP 939
DI 10.1007/s00262-011-1154-8
PG 13
WC Oncology; Immunology
SC Oncology; Immunology
GA 950AU
UT WOS:000304621900017
PM 22116344
ER
PT J
AU Carrithers, MD
AF Carrithers, Michael D.
TI Current Immunotherapy of Multiple Sclerosis and Future Challenges:
Relevance of Immune-Mediated Repair
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Review
DE Brain; demyelination; immune surveillance; innate immunity; interferon;
lymphocyte; natalizumab
ID PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
CENTRAL-NERVOUS-SYSTEM; CONTROLLED PHASE IIB; DOUBLE-BLIND; T-CELLS;
GLATIRAMER ACETATE; INTERFERON-BETA; IN-VITRO; INTRAMUSCULAR INTERFERON
AB Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system and can cause severe neurological disability. Current immune therapy with beta-interferons, glatiramer acetate, immune suppressives, or selective adhesion molecule inhibitors can reduce the frequency and severity of acute attacks in a majority of patients but have little effect on the progressive phase of the disease. Patients who require aggressive immune therapy are also at risk for the development of potentially fatal opportunistic infections. Here current and emerging immune therapy options are discussed, and immune-mediated strategies to preserve normal immune surveillance and mediate tissue repair are proposed.
C1 [Carrithers, Michael D.] Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA.
[Carrithers, Michael D.] William S Middleton Mem Vet Adm Med Ctr, Neurol Serv, Madison, WI USA.
RP Carrithers, MD (reprint author), Univ Wisconsin, Dept Neurol, 1300 Univ Ave, Madison, WI 53706 USA.
EM carrithers@neurology.wisc.edu
NR 96
TC 3
Z9 3
U1 1
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1389-2010
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PD JUN
PY 2012
VL 13
IS 8
BP 1409
EP 1417
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 949SQ
UT WOS:000304596600005
PM 22339217
ER
PT J
AU Lee, W
Nelson, R
Akmal, Y
Mailey, B
McKenzie, S
Artinyan, A
Ashing-Giwa, KT
Chen, YJ
Garcia-Aguilar, J
Kim, J
AF Lee, Wendy
Nelson, Rebecca
Akmal, Yasir
Mailey, Brian
McKenzie, Shaun
Artinyan, Avo
Ashing-Giwa, Kimlin Tam
Chen, Yi-Jen
Garcia-Aguilar, Julio
Kim, Joseph
TI Racial and ethnic disparities in outcomes with radiation therapy for
rectal adenocarcinoma
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Article
DE Rectal cancer; Radiation; Neoadjuvant; Disparities
ID PATHOLOGICAL COMPLETE RESPONSE; COLORECTAL-CANCER TREATMENTS;
PREOPERATIVE CHEMORADIATION; SOCIOECONOMIC-STATUS; PREDICTIVE FACTORS;
ADJUVANT THERAPY; SURVIVAL; CHEMORADIOTHERAPY; RADIOTHERAPY;
CAPECITABINE
AB Race/ethnicity may modify cancer outcomes and manifest as survival disparities for patients with rectal cancer. Our objective was to determine whether disparate rectal cancer outcomes result from variable efficacy of radiation therapy for major racial/ethnic groups.
The Los Angeles County Cancer Surveillance Program (CSP) identified patients with rectal adenocarcinoma between the years 1988 and 2006. Patients who underwent curative-intent surgery were grouped by race/ethnicity and by receipt (yes vs. no) and timing (neoadjuvant vs. adjuvant) of radiation therapy. The impact of receipt and timing of radiation therapy on overall survival was then assessed.
Of 4,961 patients in CSP, 2,229 (45%) received radiation therapy. Overall, there was no difference in survival among patients according to receipt of radiation therapy. We then examined the radiation cohort, wherein 919 (41%) and 1,310 (59%) patients received neoadjuvant or adjuvant radiation, respectively. Overall, patients who received neoadjuvant compared to adjuvant radiation had improved survival (median survival (MS), 9.4 vs. 6.8 years, respectively; p < 0.001). Among those patients who received neoadjuvant radiation, whites, Hispanics, and Asians had significantly longer survival than blacks (MS, 10.4, 10.4, and 10.4 vs. 4.4 years, respectively; p = 0.003). On multivariate analysis, race/ethnicity was an independent predictor of survival (p = 0.001).
To our knowledge, this is the first study examining the efficacy of radiation therapy for racial/ethnic groups with rectal cancer. Disparate outcomes were observed for the administration of radiation therapy for select racial/ethnic groups. The reasons for these disparities in outcomes should be investigated to better optimize radiation therapy for patients with rectal cancer.
C1 [Lee, Wendy; Akmal, Yasir; Mailey, Brian; Garcia-Aguilar, Julio; Kim, Joseph] City Hope Comprehens Canc Ctr, Dept Surg, Duarte, CA 91010 USA.
[Nelson, Rebecca] City Hope Comprehens Canc Ctr, Dept Biostat, Duarte, CA 91010 USA.
[McKenzie, Shaun] Univ Kentucky, Sch Med, Dept Surg, Lexington, KY 40536 USA.
[Ashing-Giwa, Kimlin Tam] City Hope Comprehens Canc Ctr, Dept Populat Sci, Duarte, CA 91010 USA.
[Chen, Yi-Jen] City Hope Comprehens Canc Ctr, Dept Radiat Oncol, Duarte, CA 91010 USA.
[Artinyan, Avo] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
[Artinyan, Avo] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Res Ctr Excellence, Houston, TX 77030 USA.
[Artinyan, Avo] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Hlth Serv, Houston, TX 77030 USA.
RP Kim, J (reprint author), City Hope Comprehens Canc Ctr, Dept Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM jokim@coh.org
RI Nelson, Rebecca/C-4438-2014
NR 32
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-1958
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD JUN
PY 2012
VL 27
IS 6
BP 737
EP 749
DI 10.1007/s00384-011-1378-2
PG 13
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 947VQ
UT WOS:000304461400007
PM 22159751
ER
PT J
AU So, C
Kirby, KA
Mehta, K
Hoffman, RM
Powell, AA
Freedland, SJ
Sirovich, B
Yano, EM
Walter, LC
AF So, Cynthia
Kirby, Katharine A.
Mehta, Kala
Hoffman, Richard M.
Powell, Adam A.
Freedland, Stephen J.
Sirovich, Brenda
Yano, Elizabeth M.
Walter, Louise C.
TI Medical Center Characteristics Associated with PSA Screening in Elderly
Veterans with Limited Life Expectancy
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE PSA screening; regional variation; elderly; life expectancy
ID PRIMARY-CARE PHYSICIANS; ANTIGEN TEST USE; PROSTATE-CANCER;
COLORECTAL-CANCER; UNITED-STATES; DECISION-MAKING; MEN; OLDER;
DETERMINANTS; COMORBIDITY
AB Although guidelines recommend against prostate-specific antigen (PSA) screening in elderly men with limited life expectancy, screening is common.
We sought to identify medical center characteristics associated with screening in this population.
We conducted a prospective study of 622,262 screen-eligible men aged 70+ seen at 104 VA medical centers in 2003.
Primary outcome was the percentage of men at each center who received PSA screening in 2003, based on VA data and Medicare claims. Men were stratified into life expectancy groups ranging from favorable (age 70-79 with Charlson score = 0) to limited (age 85+ with Charlson score a parts per thousand yen1 or age 70+ with Charlson score a parts per thousand yen4). Medical center characteristics were obtained from the 1999-2000 VA Survey of Primary Care Practices and publicly available VA data sources.
Among 123,223 (20%) men with limited life expectancy, 45% received PSA screening in 2003. Across 104 VAs, the PSA screening rate among men with limited life expectancy ranged from 25-79% (median 43%). Higher screening was associated with the following center characteristics: no academic affiliation (50% vs. 43%, adjusted RR = 1.14, 95% CI 1.04-1.25), a ratio of midlevel providers to physicians a parts per thousand yen3:4 (55% vs. 45%, adjusted RR = 1.20, 95% CI 1.09-1.32) and location in the South (49% vs. 39% in the West, adjusted RR = 1.25, 95% CI 1.12-1.40). Use of incentives and high scores on performance measures were not independently associated with screening. Within centers, the percentages of men screened with limited and favorable life expectancies were highly correlated (r = 0.90).
Substantial practice variation exists for PSA screening in older men with limited life expectancy across VAs. The high center-specific correlation of screening among men with limited and favorable life expectancies indicates that PSA screening is poorly targeted according to life expectancy.
C1 [So, Cynthia] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Kirby, Katharine A.; Mehta, Kala; Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Hoffman, Richard M.] New Mexico VA Hlth Care Syst, Albuquerque, NM USA.
[Hoffman, Richard M.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA.
[Powell, Adam A.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Powell, Adam A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Freedland, Stephen J.] Duke Univ, Durham VA Med Ctr, Durham, NC USA.
[Freedland, Stephen J.] Duke Univ, Duke Prostate Ctr, Durham, NC USA.
[Sirovich, Brenda] White River Junct VA, Windsor, VT USA.
[Yano, Elizabeth M.] UCLA Sch Publ Hlth, VA Greater Los Angeles Hlth Syst, VA HSR&D Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Yano, Elizabeth M.] UCLA Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA.
RP Walter, LC (reprint author), VA Med Ctr 181G, 4150 Clement St, San Francisco, CA 94121 USA.
EM Louise.Walter@ucsf.edu
FU National Cancer Institute at the National Institutes of Health [R01
CA134425]; American Federation for Aging Research; National Institute on
Aging [K-01AG025444]; New Mexico VA Health Care System; White River
Junction VA; VA HSRD [05-195]
FX This work was supported by the National Cancer Institute at the National
Institutes of Health (grant number R01 CA134425) to [LW, RH, AP, and
SF]; the Medical Student Training in Aging Research Program at the
American Federation for Aging Research to [CS]; the National Institute
on Aging (grant number K-01AG025444) to [KM]; the New Mexico VA Health
Care System to [RH]; the White River Junction VA to [BS]; and the VA
HSR&D Research Career Development Award (Project #05-195) to [EY].
NR 46
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2012
VL 27
IS 6
BP 653
EP 660
DI 10.1007/s11606-011-1945-9
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 947BZ
UT WOS:000304402900009
PM 22180196
ER
PT J
AU Pandhi, N
DeVoe, JE
Schumacher, JR
Bartels, C
Thorpe, CT
Thorpe, JM
Smith, MA
AF Pandhi, Nancy
DeVoe, Jennifer E.
Schumacher, Jessica R.
Bartels, Christie
Thorpe, Carolyn T.
Thorpe, Joshua M.
Smith, Maureen A.
TI Number of First-Contact Access Components Required to Improve Preventive
Service Receipt in Primary Care Homes
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE patient-centered medical home; preventive medicine; access to care;
continuity of care; primary care; health care utilization; aging
ID INFLUENZA VACCINATION; SCREENING MAMMOGRAPHY; METAANALYSIS; MORTALITY;
ADULTS; CONTINUITY; COMMUNITY; DEATHS; US
AB A fundamental aim of primary care redesign and the patient-centered medical home is improving access to care. Patients who report having a usual site of care and usual provider are more likely to receive preventive services, but less is known about the influence of specific components of first-contact access (e.g., availability of appointments, advice by telephone) on preventive services receipt.
To examine the relationship between number of first-contact access components and receipt of recommended preventive services.
Secondary survey data analysis.
Five thousand five hundred and seven insured adults who had continuity with a usual primary care physician and participated in the 2003-2006 round of the Wisconsin Longitudinal Survey.
Using multivariable logistic regression, we calculated adjusted risk ratios, adjusted predicted probabilities and 95% confidence intervals for each preventive service.
Experiencing more first-contact access components was significantly associated with a higher rate of receiving cholesterol tests, flu shots and prostate exams but not mammography. There was variation in the number of components needed (between two and seven) to achieve a significant difference.
Having an increasing number of first-access components in a primary care office may improve preventive services receipt, and more components may be required for those services requiring greater provider contact (e.g., prostate exam) versus those that require less (e.g., mammography). In primary care redesign, the largest gains in preventive services receipt likely will come with redesign of multiple components simultaneously. While our study is a necessary step towards broadly understanding the relationship between first-contact access and preventive service receipt, other important questions remain. Certain components may drive greater improvements in the receipt of different services, and the effect of some of these components may depend on individual patient characteristics. Further research is critical for understanding redesign strategies that may optimize preventive service delivery.
C1 [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin Madison, Dept Family Med, Madison, WI USA.
[Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin Madison, Dept Populat Hlth Sci, Madison, WI USA.
[DeVoe, Jennifer E.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA.
[Schumacher, Jessica R.] Univ Florida Gainesville, Dept Hlth Serv Res Management & Policy, Gainesville, FL USA.
[Bartels, Christie] Univ Wisconsin, Dept Med, Rheumatol Sect, Sch Med & Publ Hlth, Madison, WI USA.
[Thorpe, Carolyn T.; Thorpe, Joshua M.] Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA.
[Thorpe, Carolyn T.; Thorpe, Joshua M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA.
[Pandhi, Nancy; Schumacher, Jessica R.; Bartels, Christie; Thorpe, Carolyn T.; Thorpe, Joshua M.; Smith, Maureen A.] Univ Wisconsin, Hlth Innovat Program, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA.
[Smith, Maureen A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth Madison, Madison, WI 53706 USA.
RP Pandhi, N (reprint author), 800 Univ Bay Dr,Box 9445, Madison, WI 53705 USA.
EM nancy.pandhi@fammed.wisc.edu
RI Thorpe, Joshua/C-1188-2013
FU University of Wisconsin Institute for Clinical and Translational
Research (UW ICTR); NIH [1 UL1 RR025011]; National Institute on Aging [l
K08 AG029527, R01 AG09775, R01 AG033285]; Agency for Healthcare Research
and Quality (AHRQ) [K08 HS16181]; University of Wisconsin Carbone Cancer
Center (UWCCC) from the National Cancer Institute [P30 CA014520]; Vilas
Estate Trust; National Science Foundation; Spencer Foundation; Graduate
School of the University of Wisconsin-Madison; UW School of Medicine and
Public Health
FX This project was supported by the Health Innovation Program and the
Community-Academic Partnerships core of the University of Wisconsin
Institute for Clinical and Translational Research (UW ICTR) funded
through an NIH Clinical and Translational Science Award (CTSA), grant
number 1 UL1 RR025011. In addition, Nancy Pandhi is supported by a
National Institute on Aging Mentored Clinical Scientist Research Career
Development Award, grant number l K08 AG029527. Dr. DeVoe's time on this
project was supported by grant number K08 HS16181 from the Agency for
Healthcare Research and Quality (AHRQ). This project was also supported
by the University of Wisconsin Carbone Cancer Center (UWCCC) Support
Grant from the National Cancer Institute, grant number P30 CA014520.
Additional support was provided by the UW School of Medicine and Public
Health from the Wisconsin Partnership Program. This research uses data
from the Wisconsin Longitudinal Study of the University of
Wisconsin-Madison. Since 1991, the WLS has been supported principally by
the National Institute on Aging (R01 AG09775, R01 AG033285), with
additional support from the Vilas Estate Trust, the National Science
Foundation, the Spencer Foundation, and the Graduate School of the
University of Wisconsin-Madison. A public use file of data from the
Wisconsin Longitudinal Study is available from the Wisconsin
Longitudinal Study, University of Wisconsin-Madison, 1180 Observatory
Drive, Madison, Wisconsin, 53706 and at
http://www.ssc.wisc.edu/wlsresearch/data/. The view expressed in this
article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs or the United
States government.
NR 37
TC 5
Z9 5
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2012
VL 27
IS 6
BP 677
EP 684
DI 10.1007/s11606-011-1955-7
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 947BZ
UT WOS:000304402900012
PM 22215269
ER
PT J
AU Chen, B
Covinsky, KE
Cenzer, IS
Adler, N
Williams, BA
AF Chen, Bonnie
Covinsky, Kenneth E.
Cenzer, Irena Stijacic
Adler, Nancy
Williams, Brie A.
TI Subjective Social Status and Functional Decline in Older Adults
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE health disparities; functional decline; geriatrics; socioeconomic
status; determinants of health
ID SELF-RATED HEALTH; SOCIOECONOMIC-STATUS; UNITED-STATES; WHITEHALL-II;
LIFE-COURSE; MORTALITY; INEQUALITIES; AMERICANS; POSITION; OUTCOMES
AB It is unknown whether subjective assessment of social status predicts health outcomes in older adults.
To describe the relationship between subjective social status and functional decline in older adults.
Longitudinal cohort study.
The Health and Retirement Study, a nationally representative survey of community-dwelling older adults (2004-2008).
Two thousand five hundred and twenty-three community-dwelling older adults.
Self-report of social status (SSS), categorized into three groups, reported by participants who marked a 10-rung ladder to represent where they stand in society. Four-year functional decline (new difficulty in any of five activities of daily living, mobility decline and/or death)
Mean age was 64; 46% were male, 85% were white. At baseline, lower SSS was associated with being younger, unmarried, of nonwhite race/ethnicity, higher rates of chronic medical conditions and ADL impairment (P < 0.01). Over 4 years, 50% in the lowest SSS group declined in function, compared to the middle and highest groups (28% and 26%), P-trend < 0.001. Those in the lowest rungs of SSS were at increased risk of 4-year functional decline (unadjusted RR = 1.91, CI 1.-9-2.46). The relationship between a subjective belief that one is worse off than others and functional decline persisted after serial adjustment for demographics, objective SES measures, and baseline health and functional status (RR 1.36, CI 1.08-1.73).
In older adults, the belief that one is in the lowest rungs of social status is a measure of socioeconomic distress and of significant risk for functional decline. These findings suggest that self-report of low subjective social status may give clinicians additional information about which older adults are at high risk for future functional decline.
C1 [Covinsky, Kenneth E.; Cenzer, Irena Stijacic; Williams, Brie A.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
[Covinsky, Kenneth E.; Williams, Brie A.] Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco VA Med Ctr, San Francisco, CA USA.
[Adler, Nancy] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Adler, Nancy] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
[Adler, Nancy] Univ Calif San Francisco, Ctr Hlth & Commun, San Francisco, CA 94143 USA.
RP Williams, BA (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
EM brie.williams@ucsf.edu
FU Brookdale Leadership in Aging Fellowship; National Institute on Aging
[K23AG033102, R01 AG028481, K24 AG029812]; UCSF Hartford Foundation
Center of Excellence; Program for the Aging Century; MacArthur
Foundation Research Network on Socioeconomic Status and Health; Veterans
Affairs Medical Center, San Francisco, California
FX Dr. Williams was funded by the Brookdale Leadership in Aging Fellowship,
the National Institute on Aging (K23AG033102), the UCSF Hartford
Foundation Center of Excellence Physician-Scholar Award and the Program
for the Aging Century. Dr. Covinsky was supported by the National
Institute on Aging (R01 AG028481and K24 AG029812). The R01 was
administered by the Northern California Institute for Research and
Education, and with resources of the San Francisco Veterans Affairs
Medical Center. Dr. Adler received support from the MacArthur Foundation
Research Network on Socioeconomic Status and Health. These funding
sources had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; or preparation,
review, or approval of the manuscript. This work was supported with
resources of the Veterans Affairs Medical Center, San Francisco,
California. Drs. Williams and Covinsky are employees of the Department
of Veterans Affairs. The opinions expressed in this manuscript may not
represent those of the VA.
NR 40
TC 17
Z9 17
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2012
VL 27
IS 6
BP 693
EP 699
DI 10.1007/s11606-011-1963-7
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 947BZ
UT WOS:000304402900014
PM 22215272
ER
PT J
AU Dinh, TA
Alperin, P
Walter, LC
Smith, R
AF Dinh, Tuan A.
Alperin, Peter
Walter, Louise C.
Smith, Robert
TI Impact of Comorbidity on Colorectal Cancer Screening Cost-Effectiveness
Study in Diabetic Populations
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Review
DE colorectal cancer screening; cost-effectiveness analysis; health care
modeling; comorbidity; optimal screening cessation; individualized
guidelines
ID SERVICES TASK-FORCE; FECAL OCCULT BLOOD; ADJUSTED LIFE-YEAR;
UNITED-STATES; PHYSICAL-ACTIVITY; AMERICAN-COLLEGE; WOMENS HEALTH; EQ-5D
INDEX; RISK; COLONOSCOPY
AB Although comorbidity has been shown to affect the benefits and risks of colorectal cancer (CRC) screening, it has not been accounted for in prior cost-effectiveness analyses of CRC screening.
To evaluate the impact of diagnosis of diabetes mellitus, a highly prevalent comorbidity in U.S. adults aged 50 and older, on health and economic outcomes of CRC screening.
Cost-effectiveness analysis using an integrated modeling framework.
Derived from basic and epidemiologic studies, clinical trials, cancer registries, and a colonoscopy database.
U.S. 50-year-old population.
Lifetime.
Costs are based on Medicare reimbursement rates.
Colonoscopy screening at ten-year intervals, beginning at age 50, and discontinued after age 50, 60, 70, 80 or death.
Health outcomes and cost effectiveness.
Diabetes diagnosis significantly affects cost-effectiveness of CRC screening. For the same CRC screening strategy, a person without diabetes at age 50 gained on average 0.07-0.13 life years more than a person diagnosed with diabetes at age 50 or younger. For a population of 1,000 patients diagnosed with diabetes at baseline, increasing stop age from 70 years to 80 years increased quality-adjusted life years (QALYs) gained by 0.3, with an incremental cost-effectiveness ratio of $206,671/QALY. The corresponding figures for 1,000 patients without diabetes are 2.3 QALYs and $46,957/QALY.
Cost-effectiveness results are sensitive to cost of colonoscopy and adherence to colonoscopy screening.
Results depend on accuracy of model assumptions.
Benefits of CRC screening differ substantially for patients with and without diabetes. Screening for CRC in patients diagnosed with diabetes at age 50 or younger is not cost-effective beyond age 70. Screening recommendations should be individualized based on the presence of comorbidities.
C1 [Dinh, Tuan A.; Alperin, Peter] Archimedes Inc, San Francisco, CA 94105 USA.
[Walter, Louise C.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Walter, Louise C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Smith, Robert] Amer Canc Soc, Canc Control Dept, Atlanta, GA 30329 USA.
RP Dinh, TA (reprint author), Archimedes Inc, 201 Mission St,29th Floor, San Francisco, CA 94105 USA.
EM tuan.dinh@archimedesmodel.com
FU National Cancer Institute [1R01CA134425]
FX The authors declare no conflict of interest. This study was carried out
by Archimedes in collaboration with Drs. Smith and Walter. Dr. Walter is
supported by a grant 1R01CA134425 from the National Cancer Institute.
NR 68
TC 6
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2012
VL 27
IS 6
BP 730
EP 738
DI 10.1007/s11606-011-1972-6
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 947BZ
UT WOS:000304402900018
PM 22237663
ER
PT J
AU Vick, A
Kraemer, RR
Morris, JL
Willett, LL
Centor, RM
Estrada, CA
Rodriguez, JM
AF Vick, Amanda
Kraemer, Ryan R.
Morris, Jason L.
Willett, Lisa L.
Centor, Robert M.
Estrada, Carlos A.
Rodriguez, J. Martin
TI A 60-Year-Old Woman with Chorea and Weight Loss
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
DE diagnostic reasoning; clinical problem solving; dual process theory;
illness scripts; chorea; paraneoplastic syndrome
ID STRATEGIES; MODEL
C1 [Vick, Amanda; Kraemer, Ryan R.; Morris, Jason L.; Willett, Lisa L.; Centor, Robert M.; Estrada, Carlos A.; Rodriguez, J. Martin] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Kraemer, Ryan R.; Morris, Jason L.; Centor, Robert M.; Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Estrada, Carlos A.] Vet Affairs Natl Qual Scholars Program, Birmingham, AL USA.
RP Rodriguez, JM (reprint author), Univ Alabama Birmingham, THT 229 1530 3rd Ave S, Birmingham, AL 35294 USA.
EM mrodri2@uab.edu
NR 11
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2012
VL 27
IS 6
BP 747
EP 751
DI 10.1007/s11606-011-1928-x
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 947BZ
UT WOS:000304402900021
PM 22143453
ER
PT J
AU Zorick, T
Lee, B
Mandelkern, MA
Fong, T
Robertson, C
Ghahremani, DG
Brown, AK
Sumerel, B
London, ED
AF Zorick, T.
Lee, B.
Mandelkern, M. A.
Fong, T.
Robertson, C.
Ghahremani, D. G.
Brown, A. K.
Sumerel, B.
London, E. D.
TI Low striatal dopamine receptor availability linked to caloric intake
during abstinence from chronic methamphetamine abuse
SO MOLECULAR PSYCHIATRY
LA English
DT Letter
ID FOOD
C1 [Zorick, T.; Lee, B.; Fong, T.; Ghahremani, D. G.; Brown, A. K.; Sumerel, B.; London, E. D.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Zorick, T.] Greater Los Angeles Vet Adm Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Mandelkern, M. A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
[Robertson, C.; London, E. D.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA.
[London, E. D.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
RP Zorick, T (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
EM elondon@mednet.ucla.edu
FU NCRR NIH HHS [M01 RR000865, MO1 RR00865]; NIDA NIH HHS [P20 DA022539,
R01 DA020726, R01 DA015179]
NR 9
TC 4
Z9 4
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1359-4184
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD JUN
PY 2012
VL 17
IS 6
BP 569
EP 571
DI 10.1038/mp.2011.137
PG 4
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 947TU
UT WOS:000304454700002
PM 22024765
ER
PT J
AU Prohaska, R
Sibon, OCM
Rudnicki, DD
Danek, A
Hayflick, SJ
Verhaag, EM
Vonk, JJ
Margolis, RL
Walker, RH
AF Prohaska, Rainer
Sibon, Ody C. M.
Rudnicki, Dobrila D.
Danek, Adrian
Hayflick, Susan J.
Verhaag, Esther M.
Vonk, Jan J.
Margolis, Russell L.
Walker, Ruth H.
TI Brain, blood, and iron: Perspectives on the roles of erythrocytes and
iron in neurodegeneration
SO NEUROBIOLOGY OF DISEASE
LA English
DT Review
DE Neuroacanthocytosis; Neurodegeneration; Iron; NBIA
ID KINASE-ASSOCIATED NEURODEGENERATION; INFANTILE NEUROAXONAL DYSTROPHY;
INDEPENDENT PHOSPHOLIPASE A(2); HALLERVORDEN-SPATZ-SYNDROME;
DISEASE-LIKE 2; DOMINANT CHOREA-ACANTHOCYTOSIS; LIGHT-POLYPEPTIDE GENE;
KELL-NULL PHENOTYPE; MCLEOD-SYNDROME; HUNTINGTONS-DISEASE
AB The terms "neuroacanthocytosis" (NA) and "neurodegeneration with brain iron accumulation" (NBIA) both refer to groups of genetically heterogeneous disorders, classified together due to similarities of their phenotypic or pathological findings. Even collectively, the disorders that comprise these sets are exceedingly rare and challenging to study. The NBIA disorders are defined by their appearance on brain magnetic resonance imaging, with iron deposition in the basal ganglia. Clinical features vary, but most include a movement disorder. New causative genes are being rapidly identified; however, the mechanisms by which mutations cause iron accumulation and neurodegeneration are not well understood. NA syndromes are also characterized by a progressive movement disorder, accompanied by cognitive and psychiatric features, resulting from mutations in a number of genes whose roles are also basically unknown. An overlapping feature of the two groups, NBIA and NA, is the occurrence of acanthocytes, spiky red cells with a poorly-understood membrane dysfunction. In this review we summarise recent developments in this field, specifically insights into cellular mechanisms and from animal models. Cell membrane research may shed light upon the significance of the erythrocyte abnormality, and upon possible connections between the two sets of disorders. Shared pathophysiologic mechanisms may lead to progress in the understanding of other types of neurodegeneration. Published by Elsevier Inc.
C1 [Walker, Ruth H.] James P Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA.
[Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Prohaska, Rainer] Med Univ Vienna, Max F Perutz Labs, Vienna, Austria.
[Sibon, Ody C. M.; Verhaag, Esther M.; Vonk, Jan J.] Univ Groningen, Sect Radiat & Stress Cell Biol, Dept Cell Biol, Univ Med Ctr Groningen, Groningen, Netherlands.
[Rudnicki, Dobrila D.; Margolis, Russell L.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol,Lab Genet Neurobiol, Baltimore, MD 21205 USA.
[Danek, Adrian] Univ Munich, Neurol Klin & Poliklin, Munich, Germany.
[Hayflick, Susan J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA.
[Hayflick, Susan J.] Oregon Hlth & Sci Univ, Dept Pediat & Neurol, Portland, OR 97201 USA.
[Margolis, Russell L.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Margolis, Russell L.] Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD USA.
RP Walker, RH (reprint author), James P Peters Vet Affairs Med Ctr, Dept Neurol 127, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM ruth.walker@mssm.edu
RI Danek, Adrian/G-7339-2011
OI Danek, Adrian/0000-0001-8857-5383
FU National Institute of Neurological Diseases and Stroke; Office of Rare
Diseases Research; National Institute of Child Health and Human
Development [1R13NS067922-01]; Movement Disorder Society; Advocacy for
Neuroacanthocytosis Patients (UK); Associazione Italiana Sindromi
Neurodegenerative da Accumulo di Ferro (AISNAF) (Italy); NBIA Disorders
Association (USA); Hoffnungsbaum e.V. (Germany); GlaxoSmithKline;
European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA)
[01GM1003]; RP (FWF) [I 438-B13]; OCMS (ZonMW) [113301162]
FX This article reflects presentations and discussion at a meeting entitled
"Brain, Blood and Iron: Joint International Symposium on
Neuroacanthocytosis and Neurodegeneration with Brain Iron Accumulation"
which was held in Bethesda, MD, USA on Oct 1-2 2010. This meeting was
supported by the National Institute of Neurological Diseases and Stroke;
the Office of Rare Diseases Research, and the National Institute of
Child Health and Human Development [1R13NS067922-01], and also by the
Movement Disorder Society, Advocacy for Neuroacanthocytosis Patients
(UK), Associazione Italiana Sindromi Neurodegenerative da Accumulo di
Ferro (AISNAF) (Italy), NBIA Disorders Association (USA), Hoffnungsbaum
e.V. (Germany) and GlaxoSmithKline. Funding by an ERA-Net E-Rare
project, "European Multidisciplinary Initiative on Neuroacanthocytosis
(EMINA)", is gratefully acknowledged by AD (BMBF/DLR grant 01GM1003), RP
(FWF grant I 438-B13), and OCMS (ZonMW grant 113301162).
NR 228
TC 22
Z9 23
U1 1
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
EI 1095-953X
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD JUN
PY 2012
VL 46
IS 3
BP 607
EP 624
DI 10.1016/j.nbd.2012.03.006
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA 950DK
UT WOS:000304629300011
PM 22426390
ER
PT J
AU Madan, A
Archambeau, OG
Milsom, VA
Goldman, RL
Borckardt, JJ
Grubaugh, AL
Tuerk, PW
Frueh, BC
AF Madan, Alok
Archambeau, Olga G.
Milsom, Vanessa A.
Goldman, Rachel L.
Borckardt, Jeffery J.
Grubaugh, Anouk L.
Tuerk, Peter W.
Frueh, B. Christopher
TI More Than Black and White: Differences in Predictors of Obesity Among
Native Hawaiian/Pacific Islanders and European Americans
SO OBESITY
LA English
DT Article
ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; DSM-IV; PACIFIC ISLANDERS;
YOUNG-ADULTS; RISK-FACTORS; WEIGHT; HAWAIIANS; DISORDER; MINI
AB Although Native Hawaiians and Pacific Islanders exhibit the highest rates of obesity and associated chronic diseases of any racial/ethnic group, they remain vastly underrepresented in health research. In a cross-sectional survey of college students (N = 402) we examined BMI and health outcomes in an ethno-racially diverse rural sample of Native Hawaiian/Pacific Islanders (25.1%), Asian Americans (39.8%), and European Americans (35.1%). Measures assessed BMI, health status, health behaviors, frequency of exercise, and symptoms of psychiatric disorders (i.e., depression, anxiety, posttraumatic stress, and substance abuse and dependence). Regression analyses revealed that an overall model of five predictors (gender, race, regular exercise, difficulty sleeping, and anxiety) was significantly associated with obesity (P < 0.001) and correctly classified 84.2% of cases. A 30.7% of Native Hawaiians/Pacific Islanders were obese as compared with 9.2% of European Americans and 10.6% of Asian Americans. These findings suggest that Native Hawaiian/Pacific Islanders are at high risk for obesity and associated medical comorbidities, but that regular physical activity may ameliorate this risk. Further, these results support the consideration of Native Hawaiians/Pacific Islanders as a distinct racial/ethnic subgroup separate from other Asian populations.
C1 [Madan, Alok; Goldman, Rachel L.; Borckardt, Jeffery J.; Grubaugh, Anouk L.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Archambeau, Olga G.; Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA.
[Milsom, Vanessa A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Grubaugh, Anouk L.; Tuerk, Peter W.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Frueh, B. Christopher] Menninger Clin, Houston, TX USA.
RP Madan, A (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
EM madana@musc.edu
OI Goldman, Rachel/0000-0001-6147-3934
FU National Institute of Mental Health [MH074468]; McNair Foundation
FX This work was partially supported by the grant MH074468 from the
National Institute of Mental Health, and from the McNair Foundation.
Elements of the current work were included in O.G.A.'s master's thesis.
NR 18
TC 5
Z9 5
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
J9 OBESITY
JI Obesity
PD JUN
PY 2012
VL 20
IS 6
BP 1325
EP 1328
DI 10.1038/oby.2012.15
PG 4
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 948QO
UT WOS:000304517900034
PM 22286530
ER
PT J
AU Maples, NJ
Copeland, LA
Zeber, JE
Li, XY
Moore, TA
Dassori, A
Velligan, DI
Miller, AL
AF Maples, Natalie J.
Copeland, Laurel Anne
Zeber, John E.
Li, Xueying
Moore, Troy A.
Dassori, Albana
Velligan, Dawn Irene
Miller, Alexander L.
TI Can Medication Management Coordinators Help Improve Continuity of Care
After Psychiatric Hospitalization?
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID ALGORITHM PROJECT; MENTAL-ILLNESS; RISK-FACTORS; SCHIZOPHRENIA;
REHOSPITALIZATION; PATIENT; IMPLEMENTATION; INDIVIDUALS; STRATEGIES;
DISORDER
AB Objective: This demonstration project examined whether medication management coordinators enhanced continuity of care from inpatient facilities to an outpatient public mental health clinic. Methods: From 2004 to 2008, patients (N=325) hospitalized with schizophrenia or schizoaffeetive or bipolar disorder enrolled in a medication management program before discharge or at their first clinic appointment. Medication management coordinators supplemented existing clinic practices by identifying recently hospitalized patients, providing inpatient and outpatient prescribing clinicians with patients' complete medication history, meeting with patients for six months postdischarge to assess clinical status and provide medication education, and advocating guideline-concordant prescribing. Recently discharged patients (N=345) assigned to a different outpatient clinic within the same agency served as the comparison group. Intent-to-treat, repeated-measures analyses for mixed models compared the groups' number of hospital admissions, hospital days, and medication appointments kept and use of nurse or case manager contact hours and emergency or crisis services during the 12 months before enrollment, the six-month intervention, and the six-month follow-up period. Results: After discharge, individuals enrolled in medication management were more likely than comparison patients to attend outpatient appointments, and they had more medication visits and nurse or case manager treatment hours than the comparison group. Use of hospital and crisis or emergency services by all patients decreased. Almost one-third of patients never attended an outpatient appointment after hospital discharge. Conclusions: Although this program succeeded in improving continuity of care, additional interventions may be required to reduce rehospitalization and crisis care. (Psychiatric Services 63:554-560, 2012; doi: 10.1176/appi.ps.201100264)
C1 [Maples, Natalie J.; Li, Xueying; Moore, Troy A.; Velligan, Dawn Irene; Miller, Alexander L.] UT Hlth Sci Ctr San Antonio, Div Schizophrenia & Related Disorders, Dept Psychiat, San Antonio, TX 78229 USA.
[Copeland, Laurel Anne; Zeber, John E.] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX USA.
[Copeland, Laurel Anne; Zeber, John E.] Cent Texas Vet Hlth Care Syst, Temple, TX USA.
[Dassori, Albana] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Maples, NJ (reprint author), UT Hlth Sci Ctr San Antonio, Div Schizophrenia & Related Disorders, Dept Psychiat, 7703 Floyd Curl Dr,MS 7797, San Antonio, TX 78229 USA.
EM maplesn@uthscsa.edu
OI Copeland, Laurel/0000-0002-9478-0209
FU AstraZeneca; U.S. Veterans Health Administration; UT Health Science
Center San Antonio; Scott & White Healthcare; GlaxoSmithKline; Pfizer
FX This demonstration project was funded by AstraZeneca through a grant to
the National Center for Behavioral Health Care Solutions, a 501(c)3
organization affiliated with the Center for Health Care Services.
Additional support was provided by the U.S. Veterans Health
Administration, the UT Health Science Center San Antonio, and Scott &
White Healthcare. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
U.S. Department of Veterans Affairs or the U.S. government.; Dr. Zeber
received a research grant in 2011-2012 from GlaxoSmithKline as principal
investigator for one site of a multisite study unrelated to this
article. Dr. Velligan is a consultant for or on the advisory boards of
Ortho-McNeil Janssen Pharmaceuticals, Teva Pharmaceuticals, AstraZeneca
Pharmaceuticals, Roche Genentech, Abbott Pharmaceuticals, Lilly
Pharmaceuticals, Pfizer Pharmaceuticals, Bristol-Myers Squibb, Amgen,
and Merck and Shire Pharmaceuticals. Dr. Miller is a member of the data
monitoring committee for Otsuka and was on the advisory board of Myriad
RBM in 2010. He has received investigator-initiated grant funding from
Pfizer. The other authors report no competing interests.
NR 25
TC 4
Z9 4
U1 0
U2 4
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD JUN
PY 2012
VL 63
IS 6
BP 554
EP 560
DI 10.1176/appi.ps.201100264
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA 949IE
UT WOS:000304569100007
PM 22476107
ER
PT J
AU Gellis, LA
AF Gellis, Les A.
TI An Investigation of a Cognitive Refocusing Technique To Improve Sleep
SO PSYCHOTHERAPY
LA English
DT Article
DE insomnia; cognitive therapy; behavior therapy; sleep
ID CHRONIC INSOMNIA; VALIDATION; THOUGHTS; INDEX
AB Developing techniques designed to minimize arousing cognitions during the evening may be important to help improve the treatment of insomnia. This investigation assessed an intervention that focused exclusively on enhancing cognitive refocusing at sleep onset to change the content and style of presleep cognitions in order to improve sleep. Individuals with primary insomnia (N = 10; 90% male, mean age = 49.2, SD = 12.6) attended four weekly individual meetings. Sleep quality (the Pittsburgh Sleep Quality Index), insomnia severity (the Insomnia Severity Index), sleep parameters based on one week of sleep diaries, and arousing thought content, were compared at baseline, posttreatment, and at a 1-month follow-up. Adherence was high, and participants showed good ability to engage in the procedure. Significant improvements in sleep quality, insomnia severity, sleep onset latency, total sleep time, and arousing thought content were revealed. Large effect sizes were observed on the majority of sleep variables at follow-up. Preliminary results were encouraging regarding a technique that targets the refocusing of thoughts during the evening in order to improve sleep. Further study regarding the efficacy of this procedure is warranted.
C1 [Gellis, Les A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Gellis, LA (reprint author), Syracuse Univ, Dept Psychol, 430 Huntington Hall, Syracuse, NY 13244 USA.
EM lesgellis@gmail.com
NR 24
TC 3
Z9 3
U1 1
U2 4
PU AMER PSYCHOLOGICAL ASSOC, DIV PSYCHOTHERAPY
PI CORAL GABLES
PA 1390 SOUTH DIXIE HIGHWAY, STE 2222, CORAL GABLES, FL 33146-2946 USA
SN 0033-3204
J9 PSYCHOTHERAPY
JI Psychotherapy
PD JUN
PY 2012
VL 49
IS 2
BP 251
EP 257
DI 10.1037/a0025746
PG 7
WC Psychology, Clinical
SC Psychology
GA 951TH
UT WOS:000304742400018
PM 22309052
ER
PT J
AU Rosenbaum, JT
Ku, J
Ali, A
Choi, D
Suhler, EB
AF Rosenbaum, James T.
Ku, Jennifer
Ali, Amro
Choi, Dongseok
Suhler, Eric B.
TI Patients with Retinal Vasculitis Rarely Suffer from Systemic Vasculitis
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Review
DE retinal vasculitis; vasculitis; Behcet's; granulomatosis with
polyangiitis; polyarteritis nodosa
ID POLYARTERITIS-NODOSA; WEGENERS GRANULOMATOSIS; OCULAR MANIFESTATIONS;
DISEASE; COMPLICATIONS; UVEITIS
AB Objectives: Systemic vasculitis is often mistakenly assumed to be a common cause of retinal vasculitis. We sought to determine the relationship between retinal vasculitis and systemic vasculitis.
Methods: A selected review was performed on 1390 charts of patients attending the uveitis clinic at the Oregon Health and Science University between 1985 and 2010. Included in the review were all patients with diagnoses commonly associated with retinal vasculitis and all patients who were diagnosed with a systemic vasculitis. Retinal vasculitis was identified by perivascular exudates, intraretinal hemorrhage, or cotton wool spots as seen on clinical examination or by vascular occlusion or leakage as identified by fluorescein angiogram.
Results: Two hundred seven or 14.9% of patients with uveitis had retinal vasculitis as a component of the intraocular inflammation. Thirty-five patients had retinal vasculitis that was primary, ie, not associated with a systemic disease, and the dominant manifestation of the uveitis. Fourteen of the patients with retinal vasculitis had Behcet's disease. Only 11 of the 1390 patients with uveitis had a systemic vasculitis. Of these 11, four had retinal vasculitis including 1 secondary to a cytomegalovirus retinitis. Thus, systemic vasculitis was directly responsible for 1.4% or 3 of 207 cases of retinal vasculitis. Nonvasculitic systemic diseases such as sarcoidosis (n = 13), syndromes confined to the eye such as pars planitis (n = 36), and intraocular infections (n = 29) were far more common causes of retinal vasculitis.
Conclusions: Retinal vasculitis is a relatively common feature of uveitis. Patients with retinal vasculitis, however, rarely suffer from 1 of the classical systemic vasculitides. (C) 2012 Elsevier Inc. All rights reserved. Semin Arthritis Rheum 41:859-865
C1 [Rosenbaum, James T.; Ali, Amro; Suhler, Eric B.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97239 USA.
[Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
[Ku, Jennifer; Choi, Dongseok] Oregon Hlth & Sci Univ, Dept Publ Hlth, Portland, OR 97239 USA.
[Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA.
RP Rosenbaum, JT (reprint author), Oregon Hlth & Sci Univ, Dept Ophthalmol, 3181 SW Sam Jackson Pk Rd,L467Ad, Portland, OR 97239 USA.
EM rosenbaj@ohsu.edu
FU Research to Prevent Blindness; William C. Kuzell Foundation; Stan and
Madelle Rosenfeld Family Trust; William and Mary Bauman Foundation
FX This work was supported by Research to Prevent Blindness, the William C.
Kuzell Foundation, the Stan and Madelle Rosenfeld Family Trust, and the
William and Mary Bauman Foundation.
NR 24
TC 11
Z9 11
U1 1
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD JUN
PY 2012
VL 41
IS 6
BP 859
EP 865
DI 10.1016/j.semarthrit.2011.10.006
PG 7
WC Rheumatology
SC Rheumatology
GA 950XL
UT WOS:000304685100012
PM 22177107
ER
PT J
AU Weycker, D
Malin, J
Barron, R
Edelsberg, J
Kartashov, A
Oster, G
AF Weycker, Derek
Malin, Jennifer
Barron, Rich
Edelsberg, John
Kartashov, Alex
Oster, Gerry
TI Comparative Effectiveness of Filgrastim, Pegfilgrastim, and Sargramostim
as Prophylaxis Against Hospitalization for Neutropenic Complications in
Patients With Cancer Receiving Chemotherapy
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Article
DE filgrastim; pegfilgrastim; sargramostim; febrile neutropenia; outcomes
ID COLONY-STIMULATING FACTOR; SINGLE-ADMINISTRATION PEGFILGRASTIM;
BREAST-CANCER; MYELOSUPPRESSIVE CHEMOTHERAPY; FEBRILE NEUTROPENIA;
DOSE-INTENSITY; DOUBLE-BLIND; PHASE-III; RHUGM-CSF; MULTICENTER
AB Background: Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim in preventing hospitalization for febrile neutropenia (FN) during myelosuppressive chemotherapy has not been well characterized and is an important clinical question in oncology.
Methods: This study used a retrospective cohort design and US healthcare claims data. Source population included patients with solid tumors receiving filgrastim, pegfilgrastim, or sargramostim during their first observed course of chemotherapy between July 2001 and June 2007. For each patient, every unique chemotherapy cycle during the course was identified, along with each cycle in which filgrastim, pegfilgrastim, or sargramostim was administered by the fifth day of the cycle (ie, as prophylaxis). Risks of hospitalization for neutropenic complications (broad definition: admission with a diagnosis of neutropenia, fever, or infection; narrow definition: admission with a diagnosis of neutropenia) and for any reason were examined on a cycle-specific basis during all the cycles in which colony-stimulating factor prophylaxis was administered. Unadjusted and adjusted odds ratios (ORs) for hospitalization were estimated.
Results: Risk (unadjusted) of hospitalization for neutropenic complications (narrow definition) was 2.1% for filgrastim prophylaxis (n = 8286), 1.1% for pegfilgrastim prophylaxis (n = 67,247), and 2.5% for sargramostim prophylaxis (n = 1736). Corresponding risks of hospitalization based on the broad definition were 4.0%, 2.6%, and 5.1%. Risks of all-cause hospitalization were 7.9%, 5.3%, and 9.6%, respectively. Adjusted odds of hospitalization were significantly higher for filgrastim [OR (range across the 3 alternative measures of hospitalization): 1.58-1.79; P<0.001] and sargramostim (OR: 1.89-2.68; P<0.001) versus pegfilgrastim.
Conclusions: Risk of hospitalization for neutropenic complications during cancer chemotherapy is lower with pegfilgrastim prophylaxis than with filgrastim or sargramostim prophylaxis.
C1 [Weycker, Derek; Edelsberg, John; Kartashov, Alex; Oster, Gerry] PAI, Four Davis Court, Brookline, MA 02445 USA.
[Malin, Jennifer] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Barron, Rich] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA.
RP Weycker, D (reprint author), PAI, Four Davis Court, Brookline, MA 02445 USA.
EM dweycker@pai2.com
FU Amgen Inc
FX Funding for this research was provided by Amgen Inc, to Policy Analysis
Inc (PAI).
NR 28
TC 19
Z9 19
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3732
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD JUN
PY 2012
VL 35
IS 3
BP 267
EP 274
DI 10.1097/COC.0b013e31820dc075
PG 8
WC Oncology
SC Oncology
GA 946QF
UT WOS:000304367400012
PM 21378538
ER
PT J
AU Alessi, CA
Vitiello, MV
AF Alessi, Cathy A.
Vitiello, Michael V.
TI Sleep Disturbance Among Older Adults in Long-Term Care: A Significant
Problem in an Important Clinical Setting
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Editorial Material
ID HOMES
C1 [Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Geriatr Res Educ & Clin, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
[Vitiello, Michael V.] Univ Washington, Seattle, WA 98195 USA.
RP Alessi, CA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Geriatr Res Educ & Clin, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
EM cathy.alessi@va.gov
OI Vitiello, Michael/0000-0002-9776-0473
NR 12
TC 1
Z9 1
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2012
VL 20
IS 6
BP 457
EP 459
DI 10.1097/JGP.0b013e31825688e4
PG 3
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 945FC
UT WOS:000304257200001
PM 22517060
ER
PT J
AU Martin, JL
Jouldjian, S
Mitchell, MN
Josephson, KR
Alessi, CA
AF Martin, Jennifer L.
Jouldjian, Stella
Mitchell, Michael N.
Josephson, Karen R.
Alessi, Cathy A.
TI A Longitudinal Study of Poor Sleep After Inpatient Post-Acute
Rehabilitation: The Role of Depression and Pre-Illness Sleep Quality
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Aging; depression; rehabilitation; sleep
ID HIP FRACTURE; RATING-SCALE; OLDER-ADULTS; RECOVERY; MORTALITY; SYMPTOMS
AB Objectives: To explore the unique impact of poor sleep and symptoms of depression on sleep quality for up to 1 year after inpatient post-acute rehabilitation among older adults. Design: Prospective longitudinal cohort study. Setting: Two inpatient post-acute rehabilitation facilities. Participants: A total of 245 individuals older than 65 years (mean age = 80 years, 38% women). Interventions: None. Measurements: Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) during the post-acute care stay twice to evaluate pre-illness sleep quality and sleep quality during the post-acute care stay, and again at 3-, 6-, 9-, and 12-month follow-up. Demographics, symptoms of depression, cognitive functioning, and comorbidities were also assessed. Results: Across time points, sleep was significantly disturbed for many individuals. Nested regression models predicting PSQI total score at 3, 6, 9, and 12 months showed that variables entered in Block 1 (age, gender, cognitive functioning, and comorbidities) were significant predictors of poor sleep at 6-month follow-up but not at 3-, 9-, or 12-month follow-up. Depression (Block 2) and pre-illness PSQI total score (Block 3) were significant predictors of PSQI total score at all follow-up time points. PSQI total score during post-acute care (Block 4) explained a significant proportion of variance only at the 3-month follow-up. Conclusions: This study confirms that chronic poor sleep is common among older adults during postacute rehabilitation and resolution of sleep disturbance after acute health events may be a lengthy process. Our findings expand understanding of the role of depressive symptoms and preexisting sleep complaints in predicting poor sleep over time among these vulnerable older adults. (Am J Geriatr Psychiatry 2012; 20:477-484)
C1 [Martin, Jennifer L.; Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Martin, Jennifer L.; Jouldjian, Stella; Mitchell, Michael N.; Josephson, Karen R.; Alessi, Cathy A.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA.
RP Martin, JL (reprint author), VA GRECC 11E, 16111 Plummer St, North Hills, CA 91343 USA.
EM jennifer.martin@va.gov
FU NIA [K23 AG028452]; UCLA Claude Pepper Older Americans Independence
Center [AG-10415]; VA Greater Los Angeles Healthcare System Geriatric
Research, Education and Clinical Center; VA Health Services Research
Development [IIR-01-053-1, IIR 04-321-2, AIA-03-047]
FX This study was supported by NIA K23 AG028452; UCLA Claude Pepper Older
Americans Independence Center (AG-10415), VA Health Services Research &
Development IIR-01-053-1, IIR 04-321-2, and AIA-03-047; and VA Greater
Los Angeles Healthcare System Geriatric Research, Education and Clinical
Center.
NR 24
TC 2
Z9 3
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2012
VL 20
IS 6
BP 477
EP 484
DI 10.1097/JGP.0b013e31824877c1
PG 8
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 945FC
UT WOS:000304257200004
PM 22617164
ER
PT J
AU Fung, CH
Martin, JL
Chung, C
Fiorentino, L
Mitchell, M
Josephson, KR
Jouldjian, S
Alessi, C
AF Fung, Constance H.
Martin, Jennifer L.
Chung, Carol
Fiorentino, Lavinia
Mitchell, Michael
Josephson, Karen R.
Jouldjian, Stella
Alessi, Cathy
TI Sleep Disturbance Among Older Adults in Assisted Living Facilities
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Assisted living facilities; long-term care; sleep
ID NURSING-HOME RESIDENTS; ALZHEIMERS-DISEASE; DEPRESSION; QUALITY;
SYMPTOMS; INSOMNIA; QUESTIONNAIRE; COMORBIDITY; COMPLAINTS; DIAGNOSIS
AB Objectives: To evaluate whether objectively and subjectively measured sleep disturbances persist among older adults in assisted living facilities (ALFs) and to identify predictors of sleep disturbance in this setting. Design: Prospective, observational cohort study. Setting and Participants: A total of 121 residents, age >= 65 years, in 18 ALFs in the Los Angeles area. Measurements: Objective (actigraphy) and subjective (Pittsburgh Sleep Quality Index) sleep measures were collected at baseline and 3- and 6-month follow-up. Predictors of baseline sleep disturbance tested in bivariate analyses and multiple regression models included demographics, Mini-Mental State Examination score, number of comorbidities, nighttime sedating medication use, functional status (activities of daily living; instrumental activities of daily living), restless legs syndrome, and sleep apnea risk. Results: Objective and subjective sleep measures were similar at baseline and 3- and 6-month follow-up (objective nighttime total sleep [hours] 6.3, 6.5, and 6.4; objective nighttime percent sleep 77.2, 77.7, and 78.3; and Pittsburgh Sleep Quality Index total score 8.0, 7.8, and 7.7, respectively). The mean baseline nighttime percent sleep decreased by 2% for each additional unit increase in baseline comorbid conditions (measured as the number of conditions), and increased by 4.5% for each additional unit increase in baseline activities of daily living (measured as the number of activities of daily living), in a multiple regression model. Conclusions: In this study, we found that objectively and subjectively measured sleep disturbances are persistent among ALF residents and are related to a greater number of comorbidities and poorer functional status at baseline. Interventions are needed to improve sleep in this setting. (Am J Geriatr Psychiatry 2012; 20:485-493)
C1 [Fung, Constance H.; Martin, Jennifer L.; Josephson, Karen R.; Jouldjian, Stella; Alessi, Cathy] Vet Adm Greater Los Angeles Healthcare Syst, GRECC, North Hills, CA 91343 USA.
[Martin, Jennifer L.; Chung, Carol; Mitchell, Michael; Alessi, Cathy] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Fiorentino, Lavinia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
RP Fung, CH (reprint author), VA Greater Los Angeles Healthcare Syst, GRECC 11E, 16111 Plummer St, North Hills, CA 91343 USA.
EM Connie.Fung@va.gov
FU VA Advanced Geriatrics Fellowship Program; NIH NIA [K23 AG028452]; NIMH
[T32 MH 019925-11]; UCLA Academic Senate Council on Research; VA Greater
Los Angeles Healthcare System, Geriatric Research, Education and
Clinical Center; VA Health Services Research and Development [IIR
04-321-2]; UCLA Cousins Center for Psychoneuroimmunology; Sepracor Inc.,
Marlborough, MA
FX This study was supported by the VA Advanced Geriatrics Fellowship
Program; NIH NIA K23 AG028452, NIMH T32 MH 019925-11; UCLA Academic
Senate Council on Research; VA Greater Los Angeles Healthcare System,
Geriatric Research, Education and Clinical Center; VA Health Services
Research and Development (IIR 04-321-2); and UCLA Cousins Center for
Psychoneuroimmunology. Additional financial support was provided by
Sepracor Inc., Marlborough, MA. The authors thank the study project
coordinators, Terry Vandenberg, MA, and Rebecca Saia, the research
staff, the staff at the participating facilities, and the ALF residents.
NR 39
TC 8
Z9 8
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2012
VL 20
IS 6
BP 485
EP 493
DI 10.1097/JGP.0b013e318252e3e0
PG 9
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 945FC
UT WOS:000304257200005
PM 22531104
ER
PT J
AU Strakowski, SM
Adler, CM
Almeida, J
Altshuler, LL
Blumberg, HP
Chang, KKD
DelBello, MP
Frangou, S
McIntosh, A
Phillips, ML
Sussman, JE
Townsend, JD
AF Strakowski, Stephen M.
Adler, Caleb M.
Almeida, Jorge
Altshuler, Lori L.
Blumberg, Hilary P.
Chang, Kiki D.
DelBello, Melissa P.
Frangou, Sophia
McIntosh, Andrew
Phillips, Mary L.
Sussman, Jessika E.
Townsend, Jennifer D.
TI The functional neuroanatomy of bipolar disorder: a consensus model
SO BIPOLAR DISORDERS
LA English
DT Article
DE amygdala; bipolar disorder; connectivity; functional magnetic resonance
imaging (fMRI); neuroimaging; prefrontal cortex
ID VENTRAL PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; WHITE-MATTER
INTEGRITY; FACIAL EXPRESSIONS; AMYGDALA; ABNORMALITIES; FMRI;
ADOLESCENTS; ACTIVATION; DEPRESSION
AB Strakowski SM, Adler CM, Almeida J, Altshuler LL, Blumberg HP, Chang KD, DelBello MP, Frangou S, McIntosh A, Phillips ML, Sussman JE, Townsend JD. The functional neuroanatomy of bipolar disorder: a consensus model. ?Bipolar Disord 2012: 14: 313325. (c) 2012 The Authors. Journal compilation (c) 2012 John Wiley & Sons A/S. Objectives: Functional neuroimaging methods have proliferated in recent years, such that functional magnetic resonance imaging, in particular, is now widely used to study bipolar disorder. However, discrepant findings are common. A workgroup was organized by the Department of Psychiatry, University of Cincinnati (Cincinnati, OH, USA) to develop a consensus functional neuroanatomic model of bipolar I disorder based upon the participants work as well as that of others. Methods: Representatives from several leading bipolar disorder neuroimaging groups were organized to present an overview of their areas of expertise as well as focused reviews of existing data. The workgroup then developed a consensus model of the functional neuroanatomy of bipolar disorder based upon these data. Results: Among the participants, a general consensus emerged that bipolar I disorder arises from abnormalities in the structure and function of key emotional control networks in the human brain. Namely, disruption in early development (e.g., white matter connectivity and prefrontal pruning) within brain networks that modulate emotional behavior leads to decreased connectivity among ventral prefrontal networks and limbic brain regions, especially the amygdala. This developmental failure to establish healthy ventral prefrontallimbic modulation underlies the onset of mania and ultimately, with progressive changes throughout these networks over time and with affective episodes, a bipolar course of illness. Conclusions: This model provides a potential substrate to guide future investigations and areas needing additional focus are identified.
C1 [Strakowski, Stephen M.; Adler, Caleb M.; DelBello, Melissa P.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH 45267 USA.
[Almeida, Jorge; Phillips, Mary L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Altshuler, Lori L.; Townsend, Jennifer D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Blumberg, Hilary P.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Chang, Kiki D.] Stanford Univ, Pediat Bipolar Disorders Res Program, Div Child & Adolescent Psychiat, Dept Psychiat & Behav Sci,Sch Med, Stanford, CA 94305 USA.
[Frangou, Sophia] Kings Coll London, Sect Neurobiol Psychosis, Dept Psychosis Studies, Inst Psychiat, London WC2R 2LS, England.
[McIntosh, Andrew; Sussman, Jessika E.] Univ Edinburgh, Div Psychiat, Sch Mol & Clin Med, Edinburgh, Midlothian, Scotland.
[Phillips, Mary L.] Cardiff Univ Sch Med, Dept Psychol Med, Cardiff, S Glam, Wales.
RP Strakowski, SM (reprint author), Univ Cincinnati, Coll Med, Dept Psychiat, 260 Stetson Suite 3200, Cincinnati, OH 45267 USA.
EM stephen.strakowski@uc.edu
RI McIntosh, Andrew/B-9379-2008; Frangou, Sophia/A-2672-2013; Almeida,
Jorge/O-5185-2014
OI McIntosh, Andrew/0000-0002-0198-4588; Almeida, Jorge/0000-0002-1213-1986
FU NIH [P50 MH077138, R01 MH076971, R01 MH088371, 2R01MH070902,
1RC1MH088366, R01MH069747, 5R21MH075944, 1K24MH001848, 1R01MH084955, R01
MH077047, R01 MH080973, R01 MH078043]
FX This workgroup was supported in part by the Department of Psychiatry,
University of Cincinnati College of Medicine, Cincinnati, OH, USA. This
manuscript was supported in part by NIH grants P50 MH077138 (SMS); R01
MH076971 and R01 MH088371 (MLP); 2R01MH070902, 1RC1MH088366, and
R01MH069747 (HPB); 5R21MH075944, 1K24MH001848, and 1R01MH084955 (LLA);
R01 MH077047 (KDC); R01 MH080973 (MPD); and R01 MH078043 (CMA).
NR 72
TC 147
Z9 151
U1 5
U2 31
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2012
VL 14
IS 4
BP 313
EP 325
DI 10.1111/j.1399-5618.2012.01022.x
PG 13
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 947PE
UT WOS:000304441200001
PM 22631617
ER
PT J
AU Townsend, J
Altshuler, LL
AF Townsend, Jennifer
Altshuler, Lori L.
TI Emotion processing and regulation in bipolar disorder: a review
SO BIPOLAR DISORDERS
LA English
DT Review
DE amygdala; bipolar disorder; emotion processing; emotion regulation;
functional neuroimaging; vlPFC
ID INCREASED AMYGDALA ACTIVATION; FACIAL AFFECT RECOGNITION; MEDIAL
PREFRONTAL CORTEX; FUNCTIONAL CONNECTIVITY; NEGATIVE EMOTION; MOOD
DISORDERS; RHESUS-MONKEY; VOLUNTARY SUPPRESSION; ORBITOFRONTAL CORTEX;
COGNITIVE CONTROL
AB Townsend J, Altshuler LL. Emotion processing and regulation in bipolar disorder: a review. ?Bipolar Disord 2012: 14: 326339. (c) 2012 The Authors. Journal compilation (c) 2012 John Wiley & Sons A/S. Objectives: Bipolar disorder (BP) is characterized by a dysfunction of mood, alternating between states of mania/hypomania and depression. Thus, the primary abnormality appears to be an inability to regulate emotion, the result of which is emotional extremes. The purpose of this paper is to review the current functional magnetic resonance imaging (fMRI) literature on adult patients with BP using emotion processing or regulation paradigms. Methods: A search was conducted on PubMed using the keywords: bipolar disorder, fMRI, mania, bipolar depression, bipolar euthymia, emotion, and amygdala. Only those studies that were conducted in adult patients using an emotion activation task were included in the final review. Results: Using tasks that assess neural functioning during emotion processing and emotion regulation, many fMRI studies have examined BP subjects during mania and euthymia. Fewer fMRI studies have been conducted during depression, and fewer still have included the same subjects in multiple mood states. Despite these limitations, these studies have demonstrated specific abnormalities in frontallimbic regions. Using a variety of paradigms, investigators have specifically evaluated the amygdala (a structure within the limbic system known to be critical for emotion) and the prefrontal cortex (PFC) (a region known to have a regulatory function over the limbic system). Conclusions: These investigations reveal that amygdala activation varies as a function of mood state, while the PFC remains persistently hypoactivated across mood states. Emotional dysregulation and lability in mania and depression may reflect disruption of a frontallimbic functional neuroanatomical network.
C1 [Townsend, Jennifer; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Townsend, Jennifer; Altshuler, Lori L.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
FU Forest Laboratories; Sepracor; Eli Lilly Co.
FX LLA has received past funding from Forest Laboratories (advisory board
honoraria, March 2008), Sepracor (advisory board honoraria, January
2010), and Eli Lilly & Co. (consultant, September 2010). JT does not
have any commercial associations that might pose a conflict of interest
in connection with this manuscript.
NR 117
TC 91
Z9 93
U1 9
U2 64
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2012
VL 14
IS 4
BP 326
EP 339
DI 10.1111/j.1399-5618.2012.01021.x
PG 14
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 947PE
UT WOS:000304441200002
PM 22631618
ER
PT J
AU Townsend, JD
Bookheimer, SY
Foland-Ross, LC
Moody, TD
Eisenberger, NI
Fischer, JS
Cohen, MS
Sugar, CA
Altshuler, LL
AF Townsend, Jennifer D.
Bookheimer, Susan Y.
Foland-Ross, Lara C.
Moody, Teena D.
Eisenberger, Naomi I.
Fischer, Jeffrey S.
Cohen, Mark S.
Sugar, Catherine A.
Altshuler, Lori L.
TI Deficits in inferior frontal cortex activation in euthymic bipolar
disorder patients during a response inhibition task
SO BIPOLAR DISORDERS
LA English
DT Article
DE bipolar disorder; fMRI; orbitofrontal cortex; response inhibition;
striatum
ID MEDIAL PREFRONTAL CORTEX; BRAIN ACTIVATION; I DISORDER; FMRI; MANIA;
ABNORMALITIES; MONKEYS; INTERFERENCE; IMPULSIVITY; DYSFUNCTION
AB Townsend JD, Bookheimer SY, Foland-Ross LC, Moody TD, Eisenberger NI, Fischer JS, Cohen MS, Sugar CA, Altshuler LL. Deficits in inferior frontal cortex activation in euthymic bipolar disorder patients during a response inhibition task. ?Bipolar Disord 2012: 14: 442450. (c) 2012 The Authors. Journal compilation (c) 2012 John Wiley & Sons A/S. Objectives: The inferior frontal corticalstriatal network plays an integral role in response inhibition in normal populations. While inferior frontal cortex (IFC) impairment has been reported in mania, this study explored whether this dysfunction persists in euthymia. Methods: Functional magnetic resonance imaging (fMRI) activation was evaluated in 32 euthymic patients with bipolar I disorder and 30 healthy subjects while performing the Go/NoGo response inhibition task. Behavioral data were collected to evaluate accuracy and response time. Within-group and between-group comparisons of activation were conducted using whole-brain analyses to probe significant group differences in neural function. Results: Both groups activated bilateral IFC. However, between-group comparisons showed a significantly reduced activation in this brain region in euthymic patients with bipolar disorder compared to healthy subjects. Other frontal and basal ganglia regions involved in response inhibition were additionally significantly reduced in bipolar disorder patients, in both the medicated and the unmedicated subgroups. No areas of greater activation were observed in bipolar disorder patients versus healthy subjects. Conclusions: Bipolar disorder patients, even during euthymia, have a persistent reduction in activation of brain regions involved in response inhibition, suggesting that reduced activation in the orbitofrontal cortex and striatum is not solely related to the state of mania. These findings may represent underlying trait abnormalities in bipolar disorder.
C1 [Townsend, Jennifer D.; Bookheimer, Susan Y.; Moody, Teena D.; Fischer, Jeffrey S.; Cohen, Mark S.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Foland-Ross, Lara C.] Univ Calif Los Angeles, David Geffen Sch Med, Lab NeuroImaging, Dept Neurol, Los Angeles, CA 90095 USA.
[Foland-Ross, Lara C.] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.
[Moody, Teena D.; Sugar, Catherine A.; Altshuler, Lori L.] Univ Calif Los Angeles, Sch Publ Hlth, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Eisenberger, Naomi I.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Psychol, Los Angeles, CA 90095 USA.
[Sugar, Catherine A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, W Los Angeles Healthcare Ctr, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
RI Cohen, Mark/C-6610-2011
OI Cohen, Mark/0000-0001-6731-4053
FU Stanley Medical Research Institute; National Alliance for Research on
Schizophrenia and Depression; National Institute of Mental Health [K24
MH001848, R21 MH075944, 5F31MH078556]; National Center for Research
Resources [RR12169, RR13642, RR00865]; Forest Laboratories; Sepracor;
Eli Lilly Co.
FX This work was supported by The Stanley Medical Research Institute, the
National Alliance for Research on Schizophrenia and Depression, the
National Institute of Mental Health (K24 MH001848, R21 MH075944 and
5F31MH078556), and the National Center for Research Resources (RR12169,
RR13642 and RR00865). The authors also wish to thank the Brain Mapping
Medical Research Organization, the Brain Mapping Support Foundation, the
Pierson-Lovelace Foundation, The Ahmanson Foundation, the William M. and
Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community
Foundation, the Tamkin Foundation, the Jennifer Jones-Simon Foundation,
the Capital Group Companies Charitable Foundation, the Robson Family,
and the Northstar Fund for generous support.; LLA has received past
funding from Forest Laboratories (advisory board honoraria, March 2008),
Sepracor (advisory board honoraria, January 2010), and Eli Lilly & Co.
(consultant, September 2010). JDT, SYB, LCF-R, TDM, NIE, JSF, MSC, and
CAS do not have any commercial associations that might pose a conflict
of interest in connection with this manuscript.
NR 38
TC 28
Z9 28
U1 3
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD JUN
PY 2012
VL 14
IS 4
BP 442
EP 450
DI 10.1111/j.1399-5618.2012.01020.x
PG 9
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 947PE
UT WOS:000304441200008
PM 22631623
ER
PT J
AU Glynn, SM
AF Glynn, Shirley M.
TI Family Interventions in Schizophrenia: Promise and Pitfalls over 30
Years
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Article
DE Schizophrenia; Family treatment; Psychosocial interventions; Family
therapy; Family interventions; Psychosis; Evidence-based practice;
Relatives
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR THERAPY; SUBSTANCE USE
DISORDERS; SERIOUS MENTAL-ILLNESS; TREATMENT RECOMMENDATIONS; RELATIVES;
PROGRAM; EDUCATION; RECOVERY; OUTCOMES
AB The stress of living with unpredictable, disturbing schizophrenic symptoms can erode interpersonal relationships. Stressful family interactions are associated with poorer prognosis. Several investigators have developed educational or more intensive skills-based family programs to increase illness knowledge and improve prognosis in schizophrenia. An extensive body of research supports the benefits of participating in family-based treatments for schizophrenia, especially those of longer duration and emphasizing skill development, in reducing relapse rates. In spite of the data, these programs are underimplemented and underutilized. Barriers to their use likely arise from patients, relatives, and mental health professionals. Newer programs, which include novel engagement strategies, target subpopulations with poor prognoses, or use innovative technologies, may make these programs more accessible to a wider range of families. Engaging individuals with schizophrenia and their loved ones in a collaborative effort to design new, more consumer-driven family interventions is warranted.
C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst W Los Ange, Semel Inst, Los Angeles, CA 90073 USA.
RP Glynn, SM (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst W Los Ange, Semel Inst, B151j,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM sglynn@ucla.edu
NR 49
TC 7
Z9 7
U1 6
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD JUN
PY 2012
VL 14
IS 3
BP 237
EP 243
DI 10.1007/s11920-012-0265-z
PG 7
WC Psychiatry
SC Psychiatry
GA 940AL
UT WOS:000303862300011
PM 22437626
ER
PT J
AU Zuleger, CL
Albertini, MR
AF Zuleger, Cindy L.
Albertini, Mark R.
TI OMIP-008: Measurement of Th1 and Th2 cytokine polyfunctionality of human
T cells
SO CYTOMETRY PART A
LA English
DT Article
DE immunophenotype; T cells; intracellular cytokine staining; melanoma
C1 [Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI 53705 USA.
[Zuleger, Cindy L.; Albertini, Mark R.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
[Zuleger, Cindy L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Dermatol, Madison, WI USA.
[Albertini, Mark R.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
RP Albertini, MR (reprint author), William S Middleton Mem Vet Adm Med Ctr, Med Serv, Room B-5057,2500 Overlook Terrace, Madison, WI 53705 USA.
EM mralbert@wisc.edu
FU National Cancer Institute [P30 CA014520]; Office of Research and
Development, Biomedical Laboratory Research and Development Service,
Department of Veterans Affairs; Gretchen and Andrew Dawes Melanoma
Research Fund; Ann's Hope Foundation; Steve Leuthold Family; U.S. PHS
[T32AR055893]; Tim Eagle Memorial
FX Grant sponsor: National Cancer Institute; Grant number: P30 CA014520;
Grant sponsors: Office of Research and Development, Biomedical
Laboratory Research and Development Service, Department of Veterans
Affairs; Gretchen and Andrew Dawes Melanoma Research Fund; Ann's Hope
Foundation; Jay Van Sloan Memorial from the Steve Leuthold Family; Tim
Eagle Memorial. Grant sponsor: CLZ was supported by a postdoctoral
fellowship by U.S. PHS; Grant number: T32AR055893.
NR 5
TC 5
Z9 5
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4922
J9 CYTOM PART A
JI Cytom. Part A
PD JUN
PY 2012
VL 81A
IS 6
BP 450
EP 452
DI 10.1002/cyto.a.22035
PG 3
WC Biochemical Research Methods; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 945FO
UT WOS:000304258400005
PM 22431369
ER
PT J
AU Lopes-Virella, MF
Baker, NL
Hunt, KJ
Lyons, TJ
Jenkins, AJ
Virella, G
AF Lopes-Virella, Maria F.
Baker, Nathaniel L.
Hunt, Kelly J.
Lyons, Timothy J.
Jenkins, Alicia J.
Virella, Gabriel
CA DCCT EDIC Study Grp
TI High Concentrations of AGE-LDL and Oxidized LDL in Circulating Immune
Complexes Are Associated With Progression of Retinopathy in Type 1
Diabetes
SO DIABETES CARE
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; COMPLICATIONS TRIAL; ADVANCED GLYCATION; HUMAN
MACROPHAGES; MELLITUS; EPIDEMIOLOGY; LIPOPROTEIN; PRODUCTS; CELLS;
INFLAMMATION
AB OBJECTIVE-To determine whether immunocomplexes (ICs) containing advanced glycation end product (AGE)-LDL (AGE-LDL) and oxidized LDL (oxLDL) contribute to the development of retinopathy over a 16-year period in subjects with type 1 diabetes.
RESEARCH DESIGN AND METHODS-Levels of AGE-LDL and oxLDL in ICs were measured in 517 patients of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Retinopathy was assessed by stereoscopic fundus photography. Cox proportional hazards models were used to assess the effect of AGE-LDL-ICs and oxLDL-ICs on retinopathy progression.
RESULTS-In unadjusted models, higher baseline levels of AGE-LDL-ICs and oxLDL-ICs significantly predicted progression of diabetic retinopathy outcomes. After adjustment by study-design variables (treatment group, retinopathy cohort, duration of type 1 diabetes, and baseline albumin excretion rate [AER], hemoglobin A(1c) (HbA(1c)), and Early Treatment Diabetic Retinopathy Study [ETDRS] score), one SD increase in IC levels was associated with 47% (hazard ratio [HR] 1.47 [95% CI 1.19-1.81]; AGE-LDL-IC) and 45% (1.45 [1.17-1.80]; oxLDL-IC) increased risk of developing proliferative diabetic retinopathy (PDR) and 37% (1.37 [1.12-1.66]; to both ICs) increased risk of progressing to severe nonproliferative retinopathy. Analyses were stratified by retinopathy cohort because results differed between primary and secondary cohorts. For AGE-LDL-ICs, FIR for progression to PDR was 2.38 (95% CI 1.30-4.34) in the primary cohort and attenuated in the secondary cohort (1.29 [1.03-1.62]). Similar results were observed for oxLDL-ICs.
CONCLUSIONS-Increased levels of AGE-LDL and oxLDL in ICs are associated with increased risk for progression to advanced retinopathy in patients with type 1 diabetes, indicating that the antibody response to modified LDL plays a significant role in retinopathy progression.
C1 [Lopes-Virella, Maria F.; Baker, Nathaniel L.; Hunt, Kelly J.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Lopes-Virella, Maria F.; Hunt, Kelly J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Lyons, Timothy J.; Jenkins, Alicia J.] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Oklahoma Diabet Ctr, Oklahoma City, OK USA.
[Lyons, Timothy J.; Jenkins, Alicia J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA.
[Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
EM virellam@musc.edu
FU National Institutes of Health(NIH)/National Heart, Lung, and Blood
Institute [P01-HL-55782]; NIH/National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) [R01-DK-081352, R01-DK-088778];
Juvenile Diabetes Research Foundation [2006-49]; Research Service of the
Ralph H. Johnson VA Medical Center; Division of Diabetes, Endocrinology,
and Metabolic Diseases (NIDDK) of the NIH; National Center for Research
Resources; Genentech Inc.; NIDDK
FX This work was supported by a Program Project funded by the National
Institutes of Health(NIH)/National Heart, Lung, and Blood Institute
(P01-HL-55782), R01 grants funded by NIH/National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) (R01-DK-081352 and
R01-DK-088778), and by a Juvenile Diabetes Research Foundation grant
(2006-49). This work was also supported by the Research Service of the
Ralph H. Johnson VA Medical Center. The DCCT/EDIC was sponsored through
research contracts from the Division of Diabetes, Endocrinology, and
Metabolic Diseases (NIDDK) of the NIH. Additional support was provided
by the National Center for Research Resources through the General
Clinical Research Centers program and by Genentech Inc., through a
Cooperative Research and Development Agreement with the NIDDK. No other
potential conflicts of interest relevant to this article were reported.
NR 41
TC 20
Z9 21
U1 0
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2012
VL 35
IS 6
BP 1333
EP 1340
DI 10.2337/dc11-2040
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 950DY
UT WOS:000304631000023
PM 22511260
ER
PT J
AU de Boer, IH
Katz, R
Chonchol, MB
Fried, LF
Ix, JH
Kestenbaum, B
Mukamal, KJ
Peralta, CA
Siscovick, DS
AF de Boer, Ian H.
Katz, Ronit
Chonchol, Michel B.
Fried, Linda F.
Ix, Joachim H.
Kestenbaum, Bryan
Mukamal, Kenneth J.
Peralta, Carmen A.
Siscovick, David S.
TI Insulin Resistance, Cystatin C, and Mortality Among Older Adults
SO DIABETES CARE
LA English
DT Article
ID HOMEOSTASIS MODEL ASSESSMENT; INCIDENT CARDIOVASCULAR-DISEASE; CHRONIC
KIDNEY-DISEASE; METABOLIC SYNDROME; SERUM CREATININE; HEART-DISEASE;
RISK; POPULATION; HYPERINSULINEMIA; INDIVIDUALS
AB OBJECTIVE-Insulin resistance is a risk factor for cardiovascular and noncardiovascular diseases. Impaired kidney function is linked with insulin resistance and may affect relationships of insulin resistance with health outcomes.
RESEARCH DESIGN AND METHODS-We performed a cohort study of 3,138 Cardiovascular Health Study participants (age >= 65years) without diabetes. Insulin sensitivity index (ISI) was calculated from fasting and 2-h postload insulin and glucose concentrations. Associations of ISI and fasting insulin concentration with all-cause mortality were tested using Cox proportional hazards models, adjusting for demographic variables, prevalent cardiovascular disease, lifestyle variables, waist circumference, and LDL cholesterol. Subsequent models were additionally adjusted for or stratified by glomerular filtration rate estimated using serum cystatin C (eGFR).
RESULTS-A total of 1,810 participants died during the 14.7-year median follow-up. Compared with the highest quartile of ISI, the lowest quartile (most insulin resistant) was associated with 21% (95% CI 6-41) and 11% (-3 to 29) higher risks of death without and with adjustment for eGFR, respectively. Compared with the lowest quartile of fasting insulin concentration, the highest quartile was associated with 22% (4-43) and 4% (-12 to 22) higher risks of death without and with adjustment for eGFR, respectively. Similar attenuation by eGFR was observed when blood pressure, triglycerides, HDL cholesterol, and C-reactive protein were included in models.
CONCLUSIONS-Insulin resistance measured as ISI or fasting insulin concentration is associated with increased risk of death among older adults, adjusting for conventional confounding characteristics. Impaired kidney function may mediate or confound this relationship. Diabetes Care 35:1355-1360,2012
C1 [de Boer, Ian H.; Katz, Ronit; Kestenbaum, Bryan; Siscovick, David S.] Univ Washington, Seattle, WA 98195 USA.
[Chonchol, Michel B.] Univ Colorado, Denver, CO 80202 USA.
[Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Ix, Joachim H.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Peralta, Carmen A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP de Boer, IH (reprint author), Univ Washington, Seattle, WA 98195 USA.
EM deboer@u.washington.edu
FU National Heart, Lung, and Blood Institute [N01-HC-85079, N01-HC-85086,
N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133,
U01-HL-080295]; National Institutes of Health [R01-AG-027002,
R01-DK-087726]; National Institute of Neurologic Disorders and Stroke
FX The research reported in this article was supported by Contracts
N0I-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103,
N01-HC-55222, N01-HC-75150, and N01-HC-45133 and Grant U01-HL-080295
from the National Heart, Lung, and Blood Institute, with additional
contribution from the National Institute of Neurologic Disorders and
Stroke. Additional support came from National Institutes of Health
Grants R01-AG-027002 and R01-DK-087726. A full list of principal CHS
investigators and 10. institutions can be found at hup://www.chs-nhIbi.
org/pi.htm.
NR 36
TC 13
Z9 13
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2012
VL 35
IS 6
BP 1355
EP 1360
DI 10.2337/dcl1-1657
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 950DY
UT WOS:000304631000026
PM 22432118
ER
PT J
AU Houser, CR
Zhang, NH
Peng, ZC
Huang, CS
Cetina, Y
AF Houser, Carolyn R.
Zhang, Nianhui
Peng, Zechun
Huang, Christine S.
Cetina, Yliana
TI Neuroanatomical clues to altered neuronal activity in epilepsy: From
ultrastructure to signaling pathways of dentate granule cells
SO EPILEPSIA
LA English
DT Article
DE Electron microscopy; Extracellular signal-regulated kinase; Fos; Mossy
fiber sprouting; Seizure; Temporal lobe epilepsy
ID TEMPORAL-LOBE EPILEPSY; REGULATED KINASE ACTIVATION; MOSSY FIBER
SYNAPSES; PILOCARPINE-INDUCED SEIZURES; KAPPA-OPIOID RECEPTORS;
LONG-TERM POTENTIATION; ACID-TREATED RATS; SYNAPTIC REORGANIZATION;
HIPPOCAMPAL-FORMATION; FASCIA-DENTATA
AB The dynamic aspects of epilepsy, in which seizures occur sporadically and are interspersed with periods of relatively normal brain function, present special challenges for neuroanatomical studies. Although numerous morphologic changes can be identified during the chronic period, the relationship of many of these changes to seizure generation and propagation remains unclear. Mossy fiber sprouting is an example of a frequently observed morphologic change for which a functional role in epilepsy continues to be debated. This review focuses on neuroanatomically identified changes that would support high levels of activity in reorganized mossy fibers and potentially associated granule cell activation. Early ultrastructural studies of reorganized mossy fiber terminals in human temporal lobe epilepsy tissue have identified morphologic substrates for highly efficacious excitatory connections among granule cells. If similar connections in animal models contribute to seizure activity, activation of granule cells would be expected. Increased labeling with two activity-related markers, Fos and phosphorylated extracellular signalregulated kinase, has suggested increased activity of dentate granule cells at the time of spontaneous seizures in a mouse model of epilepsy. However, neuroanatomical support for a direct link between activation of reorganized mossy fiber terminals and increased granule cell activity remains elusive. As novel activity-related markers are developed, it may yet be possible to demonstrate such functional links and allow mapping of seizure activity throughout the brain. Relating patterns of neuronal activity during seizures to the underlying morphologic changes could provide important new insights into the basic mechanisms of epilepsy and seizure generation.
C1 [Houser, Carolyn R.; Zhang, Nianhui; Peng, Zechun; Huang, Christine S.; Cetina, Yliana] Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Houser, Carolyn R.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA.
[Houser, Carolyn R.] Vet Adm Greater Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
RP Houser, CR (reprint author), Univ Calif Los Angeles, Dept Neurobiol, David Geffen Sch Med, CHS 73-235,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM houser@mednet.ucla.edu
FU Veterans Affairs Medical Research Funds; National Institutes of Health
[NS046524, NS051311]
FX This work was supported by Veterans Affairs Medical Research Funds
(C.R.H.) and the National Institutes of Health grants NS046524 and
NS051311 (C.R.H.). We are grateful to Drs. J.R. Rich, P.S. Dwan, B.E.
Swartz, G.O. Walsh, and A.V. Delgado-Escueta, and to their patients, for
invaluable contributions to our early studies of human temporal lobe
epilepsy tissue. This review is contributed as a tribute to H. Jurgen
Wenzel in recognition of his careful, detailed morphologic studies,
which have been linked consistently to function, and his great interest
in mossy fibers of the dentate gyrus, from their early development
(Wenzel et al., 1981) to their functionally associated transporters
(Wenzel et al., 1997), and to their reorganization in epilepsy (Wenzel
et al., 2000).
NR 73
TC 15
Z9 15
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2012
VL 53
SU 1
SI SI
BP 67
EP 77
DI 10.1111/j.1528-1167.2012.03477.x
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA 945FH
UT WOS:000304257700010
PM 22612811
ER
PT J
AU Kim, H
Miller, LM
Byl, N
Abrams, GM
Rosen, J
AF Kim, Hyunchul
Miller, Levi Makaio
Byl, Nancy
Abrams, Gary M.
Rosen, Jacob
TI Redundancy Resolution of the Human Arm and an Upper Limb Exoskeleton
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Exoskeleton; inverse kinematic; redundancy; swivel angle
ID POWERED EXOSKELETON; INVERSE KINEMATICS; COMPLEX MOVEMENTS;
MICROSTIMULATION; CONFIGURATION; CORTEX
AB The human arm has 7 degrees of freedom (DOF) while only 6 DOF are required to position the wrist and orient the palm. Thus, the inverse kinematics of an human arm has a nonunique solution. Resolving this redundancy becomes critical as the human interacts with a wearable robot and the inverse kinematics solution of these two coupled systems must be identical to guarantee an seamless integration. The redundancy of the arm can be formulated by defining the swivel angle, the rotation angle of the plane defined by the upper and lower arm around a virtual axis that connects the shoulder and wrist joints. Analyzing reaching tasks recorded with a motion capture system indicates that the swivel angle is selected such that when the elbow joint is flexed, the palm points to the head. Based on these experimental results, a new criterion is formed to resolve the human arm redundancy. This criterion was implemented into the control algorithm of an upper limb 7-DOF wearable robot. Experimental results indicate that by using the proposed redundancy resolution criterion, the error between the predicted and the actual swivel angle adopted by the motor control system is less then 5 degrees.
C1 [Kim, Hyunchul] Univ Calif Santa Cruz, Dept Elect Engn, Santa Cruz, CA 95064 USA.
[Kim, Hyunchul] Optodynamics Inc, Songnam 463870, South Korea.
[Miller, Levi Makaio] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA.
[Miller, Levi Makaio] Carbon Design Grp, Seattle, WA 98105 USA.
[Byl, Nancy] Univ Calif San Francisco, Dept Phys Therapy & Rehabil Sci, Sch Med, San Francisco, CA 94158 USA.
[Abrams, Gary M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Abrams, Gary M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Rosen, Jacob] Univ Calif Santa Cruz, Dept Comp Engn, Santa Cruz, CA 95064 USA.
[Rosen, Jacob] Univ Calif Santa Cruz, Bion Lab, Santa Cruz, CA 95064 USA.
RP Kim, H (reprint author), Atromax Inc, Santa Clara, CA USA.
EM hyunchul78@gmail.com; makaio@uw.edu; BylN@ptrehab.ucsf.edu;
Gary.Abrams@ucsf.edu; rosen@ucsc.edu
NR 26
TC 27
Z9 27
U1 2
U2 33
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD JUN
PY 2012
VL 59
IS 6
BP 1770
EP 1779
DI 10.1109/TBME.2012.2194489
PG 10
WC Engineering, Biomedical
SC Engineering
GA 944ZQ
UT WOS:000304242700029
PM 22510944
ER
PT J
AU Lambert, A
Picardeau, M
Haake, DA
Sermswan, RW
Srikram, A
Adler, B
Murray, GA
AF Lambert, Ambroise
Picardeau, Mathieu
Haake, David A.
Sermswan, Rasana W.
Srikram, Amporn
Adler, Ben
Murray, Gerald A.
TI FlaA Proteins in Leptospira interrogans Are Essential for Motility and
Virulence but Are Not Required for Formation of the Flagellum Sheath
SO INFECTION AND IMMUNITY
LA English
DT Article
ID BORRELIA-BURGDORFERI; PERIPLASMIC FLAGELLA; INACTIVATION; MUTAGENESIS;
GENE; INVOLVEMENT; CHEMOTAXIS; TRANSPOSON; MUTANT
AB Spirochetes have periplasmic flagella composed of a core surrounded by a sheath. The pathogen Leptospira interrogans has four flaB (proposed core subunit) and two flaA (proposed sheath subunit) genes. The flaA genes are organized in a locus with flaA2 immediately upstream of flaA1. In this study, flaA1 and flaA2 mutants were constructed by transposon mutagenesis. Both mutants still produced periplasmic flagella. The flaA 1 mutant did not produce FlaA1 but continued to produce FlaA2 and retained normal morphology and virulence in a hamster model of infection but had reduced motility. The flaA2 mutant did not produce either the FlaA1 or the FlaA2 protein. Cells of the flaA2 mutant lacked the distinctive hook-shaped ends associated with L. interrogans and lacked translational motility in liquid and semisolid media. These observations were confirmed with a second, independent flaA2 mutant. The flaA2 mutant failed to cause disease in animal models of acute infection. Despite lacking FlaA proteins, the flagella of the flaA2 mutant were of the same thickness as wild-type flagella, as measured by electron microscopy, and exhibited a normal flagellum sheath, indicating that FlaA proteins are not essential for the synthesis of the flagellum sheath, as observed for other spirochetes. This study shows that FlaA subunits contribute to leptospiral translational motility, cellular shape, and virulence.
C1 [Adler, Ben; Murray, Gerald A.] Monash Univ, Dept Microbiol, Australian Res Council Ctr Excellence Struct & Fu, Clayton, Vic 3168, Australia.
[Sermswan, Rasana W.; Srikram, Amporn] Khon Kaen Univ, Melioidosis Res Ctr, Khon Kaen, Thailand.
[Sermswan, Rasana W.] Khon Kaen Univ, Dept Biochem, Khon Kaen, Thailand.
[Haake, David A.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA.
[Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Lambert, Ambroise] Univ Paris Diderot, Paris, France.
[Lambert, Ambroise; Picardeau, Mathieu] Inst Pasteur, Unite Biol Spirochetes, Paris, France.
RP Adler, B (reprint author), Monash Univ, Dept Microbiol, Australian Res Council Ctr Excellence Struct & Fu, Clayton, Vic 3168, Australia.
EM ben.adler@monash.edu
FU Australian Research Council; National Health and Medical Research
Council; Institut Pasteur; French Ministry of Research [ANR-08-MIE-018];
University Paris Diderot; VA Medical Research funds; Public Health
Service from the National Institute of Allergy and Infectious Diseases
[AI-034431]
FX This work was supported by the Australian Research Council, the National
Health and Medical Research Council, the Institut Pasteur, the French
Ministry of Research (ANR-08-MIE-018), the doctoral program of the
University Paris Diderot, VA Medical Research funds, and Public Health
Service grant AI-034431 from the National Institute of Allergy and
Infectious Diseases.
NR 33
TC 44
Z9 44
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JUN
PY 2012
VL 80
IS 6
BP 2019
EP 2025
DI 10.1128/IAI.00131-12
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 946WH
UT WOS:000304387700008
PM 22451522
ER
PT J
AU Mukherjee, A
Larson, EA
Carlos, AS
Belknap, JK
Rotwein, P
Klein, RF
AF Mukherjee, Aditi
Larson, Emily A.
Carlos, Amy S.
Belknap, John K.
Rotwein, Peter
Klein, Robert F.
TI Congenic mice provide in vivo evidence for a genetic locus that
modulates intrinsic transforming growth factor beta 1-mediated signaling
and bone acquisition
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HEREDITY; GENETICS; TRANSFORMING GROWTH FACTOR; BONE STRENGTH;
OSTEOPOROSIS
ID QUANTITATIVE TRAIT LOCI; INHIBITS OSTEOBLAST DIFFERENTIATION; TGF-BETA
ACTIVATION; MINERAL DENSITY; MECHANICAL-PROPERTIES; PARATHYROID-HORMONE;
COMPLEX TRAITS; OSTEOPOROSIS; MOUSE; IDENTIFICATION
AB Osteoporosis, the most common skeletal disorder, is characterized by low bone mineral density (BMD) and an increased risk of fragility fractures. BMD is the best clinical predictor of future osteoporotic fracture risk, but is a complex trait controlled by multiple environmental and genetic determinants with individually modest effects. Quantitative trait locus (QTL) mapping is a powerful method for identifying chromosomal regions encompassing genes involved in shaping complex phenotypes, such as BMD. Here we have applied QTL analysis to male and female genetically-heterogeneous F2 mice derived from a cross between C57BL/6 and DBA/2 strains, and have identified 11 loci contributing to femoral BMD. Further analysis of a QTL on mouse chromosome 7 following the generation of reciprocal congenic strains has allowed us to determine that the high BMD trait, which tracks with the DBA/2 chromosome and exerts equivalent effects on male and female mice, is manifested by enhanced osteogenic differentiation of mesenchymal stem cells (MSCs) in vitro and by increased growth of metatarsal bones in short-term primary culture. An insertion/deletion DNA polymorphism in Ltbp4 exon 12 that causes the in-frame removal of 12 codons in the DBA/2-derived gene maps within 0.6?Mb of the marker most tightly linked to the QTL. LTBP4, one of four paralogous mouse proteins that modify the bioavailability of the transforming growth factor beta (TGF-beta) family of growth factors, is expressed in differentiating MSC-derived osteoblasts and in long bones, and reduced responsiveness to TGF-beta 1 is observed in MSCs of mice homozygous for the DBA/2 chromosome 7. Taken together, our results identify a potential genetic and biochemical relationship between decreased TGF-beta 1mediated signaling and enhanced femoral BMD that may be regulated by a variant LTBP4 molecule. (C) 2012 American Society for Bone and Mineral Research.
C1 [Larson, Emily A.; Carlos, Amy S.; Klein, Robert F.] Oregon Hlth & Sci Univ, Bone & Mineral Res Unit, Dept Med, Portland, OR 97201 USA.
[Mukherjee, Aditi; Rotwein, Peter] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.
[Belknap, John K.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA.
[Belknap, John K.; Klein, Robert F.] Portland VA Med Ctr, Portland, OR USA.
RP Klein, RF (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Res Unit CR113, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.
EM kleinro@ohsu.edu
FU National Institutes of Health [R01 DK42748, P50 AA10760, R01 AR44659];
VA Medical Research Service
FX These studies were supported in part by National Institutes of Health
grants R01 DK42748 (to PR), P50 AA10760 (to JKB), R01 AR44659 (to RFK),
and the VA Medical Research Service (to RFK). We thank Dr. Lynn Sakai
for polyclonal antibodies to LTBP4.
NR 59
TC 8
Z9 8
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2012
VL 27
IS 6
BP 1345
EP 1356
DI 10.1002/jbmr.1590
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 943QY
UT WOS:000304141500012
PM 22407846
ER
PT J
AU Heckman, CJ
Cohen-Filipic, J
AF Heckman, Carolyn J.
Cohen-Filipic, Jessye
TI Brief Report: Ultraviolet Radiation Exposure, Considering Acculturation
Among Hispanics (Project URECAH)
SO JOURNAL OF CANCER EDUCATION
LA English
DT Article
DE Hispanics; Skin cancer; Prevention; Acculturation
ID SUN PROTECTION PRACTICES; BEHAVIORS
AB Very few studies have examined acculturation of Hispanics as it relates to skin cancer prevention attitudes and behaviors. This pilot study used the Abbreviated Acculturation Rating Scale for Mexican Americans-II to classify 14-25-year-old Hispanics as traditional, bicultural, or acculturated. More acculturated individuals reported significantly higher perceived benefits of ultraviolet radiation exposure and lower worry about skin damage than traditional individuals. Bicultural individuals reported using sunscreen significantly more often than acculturated individuals. These preliminary data suggest that more acculturated Hispanic young adults may demonstrate riskier skin cancer-related attitudes and behaviors than others.
C1 [Heckman, Carolyn J.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Cohen-Filipic, Jessye] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Heckman, CJ (reprint author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.
EM Carolyn.Heckman@fccc.edu; JessyeCohen@gmail.com
FU NCI NIH HHS [K07 CA108685, K07 CA108685-05]
NR 15
TC 7
Z9 7
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-8195
J9 J CANCER EDUC
JI J. Cancer Educ.
PD JUN
PY 2012
VL 27
IS 2
BP 342
EP 346
DI 10.1007/s13187-011-0308-x
PG 5
WC Oncology; Education, Scientific Disciplines; Public, Environmental &
Occupational Health
SC Oncology; Education & Educational Research; Public, Environmental &
Occupational Health
GA 943SC
UT WOS:000304144500021
PM 22228464
ER
PT J
AU Ghosh, PM
Shu, ZJ
Zhu, B
Lu, ZD
Ikeno, YJ
Barnes, JL
Yeh, CK
Zhang, BX
Katz, MS
Kamat, A
AF Ghosh, Paramita M.
Shu, Zhen-Ju
Zhu, Bing
Lu, Zhongding
Ikeno, Yuji
Barnes, Jeffrey L.
Yeh, Chih-Ko
Zhang, Bin-Xian
Katz, Michael S.
Kamat, Amrita
TI Role of beta-adrenergic receptors in regulation of hepatic fat
accumulation during aging
SO JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID ISOLATED RAT HEPATOCYTES; LIVER-DISEASE; MYOCARDIAL-INFARCTION;
METABOLIC SYNDROME; ADENYLATE-CYCLASE; FISCHER-344 RATS; ADIPOSE-TISSUE;
AGE; EXPRESSION; ADRENOCEPTOR
AB Excessive fat accumulation in liver (hepatic steatosis) predisposes to hepatic functional and structural impairment and overall metabolic risk. Previous studies noted an association between hepatic steatosis and age in humans and rodents. However, the mechanisms leading to age-associated hepatic fat accumulation remain unknown. Earlier work from our group showed that beta-adrenergic receptor (beta-AR) levels and beta-AR-stimulated adenylyl cyclase activity increase in rat liver during aging. Herewe investigated whether age-associated increases in beta-AR signaling play a role in augmenting hepatic lipid accumulation. We demonstrate an increase in hepatic lipid content during senescence and a significant correlation between hepatic fat content and stimulation of adenylyl cyclase activity by the beta-AR agonist isoproterenol in rat liver. Isoproterenol administration to young and old rodents in vivo increased hepatic lipid accumulation. Furthermore, in vitro overexpression of b1-and b2-AR subtypes in hepatocytes from young rodents increased cellular lipid content, whereas inhibition of beta-ARs by receptor subtype-specific inhibitors reduced lipid levels in hepatocytes from senescent animals. Isoproterenol-induced hepatic lipid accumulation in vivo was prevented by the beta-AR nonselective blocker propranolol, suggesting a novel therapeutic effect of this class of drugs in hepatic steatosis. Acipimox, which inhibits adipose tissue lipolysis, did not alter isoproterenolmediated hepatic fat accumulation; thus beta-AR responsive hepatic lipid accumulation does not appear to be related primarily to altered lipolysis. These findings suggest that augmented hepatic beta-AR signaling during aging may increase lipid accumulation in liver and advocate a possible role for beta-adrenergic blockers in preventing or retarding the development of hepatic steatosis. Journal of Endocrinology (2012) 213, 251-261
C1 [Ghosh, Paramita M.; Yeh, Chih-Ko; Zhang, Bin-Xian; Katz, Michael S.; Kamat, Amrita] S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr 182, San Antonio, TX 78229 USA.
[Shu, Zhen-Ju; Barnes, Jeffrey L.; Zhang, Bin-Xian; Katz, Michael S.; Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Zhu, Bing; Lu, Zhongding; Yeh, Chih-Ko; Katz, Michael S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA.
[Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ikeno, Yuji; Yeh, Chih-Ko; Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
RP Kamat, A (reprint author), S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr 182, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM kamat@uthscsa.edu
FU Department of Veterans Affairs VISN 17; American Heart Association;
Kronos Longevity Research Institute
FX Grant sponsor: Department of Veterans Affairs VISN 17 award to A K;
grant sponsor: American Heart Association grant in aid to A K; and grant
sponsor: Kronos Longevity Research Institute award to M S K.
NR 53
TC 16
Z9 16
U1 1
U2 5
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 0022-0795
J9 J ENDOCRINOL
JI J. Endocrinol.
PD JUN
PY 2012
VL 213
IS 3
BP 251
EP 261
DI 10.1530/JOE-11-0406
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 946PZ
UT WOS:000304366600006
PM 22457517
ER
PT J
AU Danczyk, RC
Mitchell, EL
Burk, C
Singh, S
Liem, TK
Landry, GJ
Petersen, BD
Moneta, GL
AF Danczyk, Rachel C.
Mitchell, Erica L.
Burk, Chad
Singh, Sarguni
Liem, Timothy K.
Landry, Gregory J.
Petersen, Bryan D.
Moneta, Gregory L.
TI Comparing patient outcomes between multiple ipsilateral iliac artery
stents and isolated iliac artery stents
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT 26th Annual Meeting of the Western-Vascular-Society
CY SEP 17-20, 2011
CL Kauai, HI
SP Western Vasc Soc
ID PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; AORTOILIAC OCCLUSIVE DISEASE;
CONSENSUS-CLASS-C; ENDOVASCULAR TREATMENT; PREDICTORS; LESIONS;
MULTICENTER; EXPERIENCE; ISCHEMIA; THERAPY
AB Objective: Endovascular stents are accepted therapy for iliac artery stenoses and occlusions. Surgery is the recommended therapy for patients with severe iliac artery disease, including those with the combination of ipsilateral common iliac artery (CIA) and external iliac artery (EIA) stenoses/occlusions. This study compared patient outcomes, including late open conversion rates, for combined ipsilateral CIA and EIA stenting vs CIA or EIA stents alone.
Methods: Between 1998 and 2010, 588 patients underwent iliac artery stenting at two institutions. Patient comorbidities and outcomes were retrospectively reviewed, and analyses were performed using multivariate regression and Kaplan-Meier methods.
Results: There were 436 extremities with CIA stents, 195 with EIA stents, and 157 with CIA and EIA stents. The groups did not differ significantly in demographics, comorbidities, or treatment indications. During follow-up, 183 patients died, 95 underwent an endovascular reintervention, and 48 required late open conversion. For patients in the CIA or EIA stent group, the mean +/- standard error survival was 5.3 +/- 0.3 years, secondary endovascular intervention-free survival was 7.4 +/- 0.6 years, late open conversion-free survival was 9.8 +/- 0.4 years, and amputation-free survival was 7.6 +/- 0.4 years. In the CIA and EIA stent group, survival was 6.1 +/- 0.6 years, secondary endovascular intervention-free survival was 7.2 +/- 0.6 years, late open conversion-free survival was 9.0 +/- 1.1 years, and amputation-free survival was 8.4 +/- 0.5 years. Survival, reintervention-free survival, late open conversion-free survival, and amputation-free survival were all similar between patient groups (all P > .05). CIA and EIA stenting in combination was not a predictor of death, reintervention, late open conversion, or amputation.
Conclusions: Outcomes are similar for patients with CIA or EIA stents and for those with combined ipsilateral CIA and EIA stents. Late open conversions for iliac artery stent failure are uncommon and not influenced by the location or extent of prior iliac artery stent placement. Endovascular therapy for aortoiliac disease should be extended to consider selected patients with ipsilateral CIA and EIA stenoses/occlusions. (J Vasc Surg 2012; 55: 1637-46.)
C1 [Danczyk, Rachel C.; Mitchell, Erica L.; Burk, Chad; Singh, Sarguni; Liem, Timothy K.; Landry, Gregory J.; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Div Vasc Surg, Portland, OR 97239 USA.
[Petersen, Bryan D.] Oregon Hlth & Sci Univ, Dotter Inst, Portland, OR 97239 USA.
[Petersen, Bryan D.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA.
RP Mitchell, EL (reprint author), Oregon Hlth & Sci Univ, Div Vasc Surg, OP11, Portland, OR 97239 USA.
EM mitcheer@ohsu.edu
NR 21
TC 3
Z9 4
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2012
VL 55
IS 6
BP 1637
EP U411
DI 10.1016/j.jvs.2011.12.048
PG 16
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 944MF
UT WOS:000304206000014
PM 22360919
ER
PT J
AU Cook, DB
Stegner, AJ
Nagelkirk, PR
Meyer, JD
Togo, F
Natelson, BH
AF Cook, Dane B.
Stegner, Aaron J.
Nagelkirk, Paul R.
Meyer, Jacob D.
Togo, Fumiharu
Natelson, Benjamin H.
TI Responses to Exercise Differ for Chronic Fatigue Syndrome Patients with
Fibromyalgia
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE PAIN; FATIGUE; IMPEDANCE CARDIOGRAPHY; STROKE VOLUME; RPE
ID PHYSIOLOGICAL-RESPONSES; CARDIOVASCULAR-RESPONSE; RESISTANCE EXERCISE;
WOMEN; ILLNESS; MUSCLE; PAIN; SYMPTOMS; CAPACITY
AB COOK, D. B., A. J. STEGNER, P. R. NAGELKIRK, J. D. MEYER, F. TOGO, and B. H. NATELSON. Responses to Exercise Differ for Chronic Fatigue Syndrome Patients with Fibromyalgia. Med. Sci. Sports Exerc., Vol. 44, No. 6, pp. 1186-1193, 2012. Chronic fatigue syndrome (CFS) and fibromyalgia (FM) are chronic multisymptom illnesses with substantial clinical and diagnostic overlap. We have previously shown that, when controlling for aerobic fitness and accounting for comorbid FM, CFS patients do not exhibit abnormal cardiorespiratory responses during maximal aerobic exercise compared with healthy controls, despite differences in pain and exertion. Purpose: The purpose of the present study was to examine cardiac and perceptual responses to steady-state submaximal exercise in CFS patients and healthy controls. Methods: Twenty-one CFS patients (13 CFS with comorbid FM (CFS + FM)) and 14 controls completed 20 min of submaximal cycling exercise. Impedance cardiography was used to determine cardiac responses during exercise. Systolic blood pressure (SBP), RPE, and leg muscle pain were also measured. Data were analyzed using a doubly multivariate, repeated-measures MANOVA to model the exercise response. Results: There was a significant multivariate time-by-group interaction (P < 0.05). The CFS + FM group exhibited an exercise response characterized by higher stroke index, ventilatory equivalents for oxygen and carbon dioxide and RPE, lower SBP, and similar HR responses compared to controls. Conclusions: The present results extend on our previous work with maximal exercise and show that CFS and CFS + FM differ in their responses to steady-state exercise. These results highlight the importance of accounting for comorbid conditions when conducting CFS research, particularly when examining psychophysiological responses to exercise.
C1 [Cook, Dane B.; Stegner, Aaron J.; Meyer, Jacob D.] Univ Wisconsin Madison, Dept Kinesiol, Madison, WI 53706 USA.
[Cook, Dane B.; Stegner, Aaron J.] William S Middleton Mem Vet Adm Med Ctr, Res Serv, Madison, WI USA.
[Nagelkirk, Paul R.] Ball State Univ, Sch Phys Educ Sport & Exercise Sci, Muncie, IN 47306 USA.
[Togo, Fumiharu] Univ Tokyo, Grad Sch Educ, Tokyo, Japan.
[Natelson, Benjamin H.] Beth Israel Deaconess Med Ctr, Pain & Fatigue Study Ctr, New York, NY 10003 USA.
RP Cook, DB (reprint author), Univ Wisconsin Madison, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA.
EM dcook@education.wisc.edu
FU National Institutes of Health [AI-32247]
FX This research was supported by the National Institutes of Health grant
AI-32247.
NR 40
TC 11
Z9 11
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD JUN
PY 2012
VL 44
IS 6
BP 1186
EP 1193
DI 10.1249/MSS.0b013e3182417b9a
PG 8
WC Sport Sciences
SC Sport Sciences
GA 944TQ
UT WOS:000304227100027
PM 22157881
ER
PT J
AU Taylor, JJ
Borckardt, JJ
George, MS
AF Taylor, Joseph J.
Borckardt, Jeffrey J.
George, Mark S.
TI Endogenous opioids mediate left dorsolateral prefrontal cortex
rTMS-induced analgesia
SO PAIN
LA English
DT Article
DE Pain modulation; Endogenous opioids; rTMS; Analgesia; Prefrontal cortex
ID TRANSCRANIAL MAGNETIC STIMULATION; ROSTRAL VENTROMEDIAL MEDULLA;
ANTERIOR CINGULATE CORTEX; PERIAQUEDUCTAL GRAY; HEALTHY-VOLUNTEERS;
PLACEBO ANALGESIA; BRAIN-STEM; CORTICAL PROJECTIONS; PAIN THRESHOLDS;
MOOD DISORDERS
AB The concurrent rise of undertreated pain and opiate abuse poses a unique challenge to physicians and researchers alike. A focal, noninvasive form of brain stimulation called repetitive transcranial magnetic stimulation (rTMS) has been shown to produce acute and chronic analgesic effects when applied to dorsolateral prefrontal cortex (DLPFC), but the anatomical and pharmacological mechanisms by which prefrontal rTMS induces analgesia remain unclear. Data suggest that DLPFC mediates top-down analgesia via gain modulation of the supraspinal opioidergic circuit. This potential pathway might explain how prefrontal rTMS reduces pain. The purpose of this sham-controlled, double-blind, crossover study was to determine whether left DLPFC rTMS-induced analgesia was sensitive to l-opioid blockade. Twenty-four healthy volunteers were randomized to receive real or sham TMS after either intravenous saline or naloxone pretreatment. Acute hot and cold pain via quantitative sensory testing and hot allodynia via block testing on capsaicin-treated skin were assessed at baseline and at 0, 20, and 40 minutes after TMS treatment. When compared to sham, real rTMS reduced hot pain and hot allodynia. Naloxone pretreatment significantly reduced the analgesic effects of real rTMS. These results demonstrate that left DLPFC rTMS-induced analgesia requires opioid activity and suggest that rTMS drives endogenous opioidergic pain relief in the human brain. Further studies with chronic dosing regimens of drugs that block or augment the actions of opiates are needed to determine whether TMS can augment opiates in chronic or postoperative pain management. (C) 2012 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.
C1 [Taylor, Joseph J.] Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Dept Psychiat, Charleston, SC 29414 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Taylor, JJ (reprint author), Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Dept Psychiat, 67 President St,Room 504 N, Charleston, SC 29414 USA.
EM taylorjj@musc.edu
FU NIDA NIH HHS [F30 DA033748]
NR 72
TC 32
Z9 32
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3959
J9 PAIN
JI Pain
PD JUN
PY 2012
VL 153
IS 6
BP 1219
EP 1225
DI 10.1016/j.pain.2012.02.030
PG 7
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 945BZ
UT WOS:000304249100017
PM 22444187
ER
PT J
AU Yagi, M
Murray, J
Strand, K
Blystone, S
Interlandi, G
Suda, Y
Sobel, M
AF Yagi, Mayumi
Murray, Jacqueline
Strand, Kurt
Blystone, Scott
Interlandi, Gianluca
Suda, Yasuo
Sobel, Michael
TI Heparin modulates the conformation and signaling of platelet integrin
alpha IIb beta 3
SO THROMBOSIS RESEARCH
LA English
DT Article
DE Heparin; Integrin alpha IIb beta 3 (platelet glycoprotein IIbIIIa);
Platelet activation; Src kinase; Surface plasmon resonance; Tyrosine
phosphorylation
ID PERCUTANEOUS CORONARY INTERVENTION; MOLECULAR-WEIGHT HEPARIN;
UNFRACTIONATED-HEPARIN; TYROSINE PHOSPHORYLATION; BINDING DOMAIN;
LIGAND-BINDING; ACTIVATION; AGGREGATION; ADHESION; IIIA
AB Introduction: The glycosaminoglycan heparin has been shown to bind to platelet integrin alpha IIb beta 3 and induce platelet activation and aggregation, although the relationship between binding and activation is unclear. We analyzed the interaction of heparin and alpha IIb beta 3 in detail, to obtain a better understanding of the mechanism by which heparin acts on platelets.
Methods: We assessed conformational changes in alpha IIb beta 3 by flow cytometry of platelets exposed to unfractionated heparin. In human platelets and K562 cells engineered to express alpha IIb beta 3, we assayed the effect of heparin on key steps in integrin signaling: phosphorylation of the beta 3 chain cytoplasmic tail, and activation of src kinase. We measured the heparin binding affinity of purified alpha IIb beta 3, and of recombinant fragments of alpha IIb and beta 3, by surface plasmon resonance.
Results and conclusions: Heparin binding results in conformational changes in alpha IIb beta 3, similar to those observed upon ligand binding. Heparin binding alone is not sufficient to induce tyrosine phosphorylation of the integrin beta 3 cytoplasmic domain, but the presence of heparin increased both beta 3 phosphorylation and src kinase activation in response to ligand binding. Specific recombinant fragments derived from alpha IIb bound heparin, while recombinant beta 3 did not bind. This pattern of heparin binding, compared to the crystal structure of alpha IIb beta 3, suggests that heparin-binding sites are located in clusters of basic amino acids in the headpiece and/or leg domains of alpha IIb. Binding of heparin to these clusters may stabilize the transition of alpha IIb beta 3 to an open conformation with enhanced affinity for ligand, facilitating outside-in signaling and platelet activation. Published by Elsevier Ltd.
C1 [Yagi, Mayumi; Murray, Jacqueline; Strand, Kurt; Sobel, Michael] VA Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA.
[Murray, Jacqueline; Sobel, Michael] Univ Washington, Dept Surg, Div Vasc Surg, Seattle, WA 98195 USA.
[Blystone, Scott] SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY USA.
[Interlandi, Gianluca] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
[Suda, Yasuo] Kagoshima Univ, Dept Nanostruct & Adv Mat, Grad Sch Sci & Engn, Kagoshima 890, Japan.
RP Yagi, M (reprint author), VA Puget Sound Hlth Care Syst, Res & Dev 151, Seattle Div, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM myagi@uw.edu
FU National Institutes of Health [HL39903]; Department of Veterans Affairs
FX This work was supported by grants from the National Institutes of Health
(HL39903) and the Department of Veterans Affairs to MS.
NR 38
TC 6
Z9 6
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD JUN
PY 2012
VL 129
IS 6
BP 743
EP 749
DI 10.1016/j.thromres.2011.11.054
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 945HG
UT WOS:000304263100013
PM 22197178
ER
PT J
AU Aspinall, SL
Smith, KJ
Good, CB
Zhao, X
Stone, RA
Tonnu-Mihara, IQ
Cunningham, FE
AF Aspinall, S. L.
Smith, K. J.
Good, C. B.
Zhao, X.
Stone, R. A.
Tonnu-Mihara, I. Q.
Cunningham, F. E.
TI INCREMENTAL COST-EFFECTIVENESS OF PHARMACIST-MANAGED
ERYTHROPOIESIS-STIMULATING AGENTS CLINICS FOR NON-DIALYSIS CHRONIC
KIDNEY DISEASE PATIENTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Aspinall, S. L.; Good, C. B.; Cunningham, F. E.] VA Ctr Medicat Safety, Hines, IL USA.
[Smith, K. J.; Stone, R. A.] Univ Pittsburgh, Pittsburgh, PA USA.
[Zhao, X.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Tonnu-Mihara, I. Q.] VA Long Beach Healthcare Syst, Long Beach, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2012
VL 15
IS 4
BP A155
EP A156
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 947XP
UT WOS:000304468200806
ER
PT J
AU Forrest, G
Larson, K
Crompton, M
Patel, H
Boening, AJ
AF Forrest, G.
Larson, K.
Crompton, M.
Patel, H.
Boening, A. J.
TI HEALTH OUTCOMES WITH DAPTOMYCIN (DAP) IN THE TREATMENT OF METHICILLIN
RESISTANT STAPHYLOCOCCUS AUREUS BACTEREMIA (MRSA-B) WITH VANCOMYCIN
(VAN) MINIMUM INHIBITORY CONCENTRATION (MIC)=2 mu G/Ml
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Forrest, G.] OHSU, Portland, OR USA.
[Forrest, G.] Portland VA Med Ctr, Portland, OR USA.
[Larson, K.; Crompton, M.; Patel, H.; Boening, A. J.] Cubist Pharmaceut Inc, Lexington, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2012
VL 15
IS 4
BP A237
EP A237
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 947XP
UT WOS:000304468201425
ER
PT J
AU Sansgiry, S
Naik, AD
Brown, AC
Latini, DM
AF Sansgiry, S.
Naik, A. D.
Brown, A. C.
Latini, D. M.
TI VARIATION IN ATTACHMENT STYLE AND HEALTH OUTCOMES OF DIABETES PATIENTS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Sansgiry, S.; Naik, A. D.] Baylor Coll Med, VA HSR&D Ctr Excellence, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
[Latini, D. M.] San Francisco VA Med Ctr, Baylor Coll Med, Scott Dept Urol, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2012
VL 15
IS 4
BP A184
EP A185
PG 2
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 947XP
UT WOS:000304468201151
ER
PT J
AU Spiegel, B
Poysophon, P
Snyder, B
Agarwal, N
Yen, L
Hodgkins, P
Cohen, E
Vu, M
Kurzbard, N
Atia, M
Sheen, V
Kaneshiro, M
Fuller, G
Bolus, R
AF Spiegel, B.
Poysophon, P.
Snyder, B.
Agarwal, N.
Yen, L.
Hodgkins, P.
Cohen, E.
Vu, M.
Kurzbard, N.
Atia, M.
Sheen, V
Kaneshiro, M.
Fuller, G.
Bolus, R.
TI RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH DIVERTICULITIS INPATIENT
ADMISSIONS: AN ANALYSIS OF THE ECONOMIC BURDEN OF DIVERTICULITIS
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Spiegel, B.; Poysophon, P.; Snyder, B.; Agarwal, N.; Cohen, E.; Vu, M.; Kurzbard, N.; Atia, M.; Sheen, V; Kaneshiro, M.; Fuller, G.; Bolus, R.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90048 USA.
[Yen, L.; Hodgkins, P.] Shire Dev LLC, Wayne, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2012
VL 15
IS 4
BP A139
EP A139
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 947XP
UT WOS:000304468200722
ER
PT J
AU Lanternier, F
Sun, HY
Ribaud, P
Singh, N
Kontoyiannis, DP
Lortholary, O
AF Lanternier, Fanny
Sun, Hsin-Yun
Ribaud, Patricia
Singh, Nina
Kontoyiannis, Dimitrios P.
Lortholary, Olivier
TI Mucormycosis in Organ and Stem Cell Transplant Recipients
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID INVASIVE FUNGAL-INFECTIONS; LIPOSOMAL AMPHOTERICIN-B; SURVEILLANCE
NETWORK TRANSNET; MOLD INFECTIONS; HEMATOLOGIC MALIGNANCY; ANTIFUNGAL
THERAPY; MURINE ZYGOMYCOSIS; RHIZOPUS-ORYZAE; IRON OVERLOAD;
RISK-FACTORS
AB Mucormycosis is a devastating invasive fungal disease whose incidence has increased during the past decade. Mucormycosis now represents a major threat in transplant recipients, accounting for 2% and 8% of invasive fungal infections in recent cohorts of solid-organ and allogeneic stem-cell transplant recipients, respectively. Mucormycosis most often occurs late, >3 months after transplantation, although cases occurring early have been observed, especially among liver transplant recipients and in cases of graft-transmitted infection. Recent guidelines have emphasized the direct examination of the involved fluid or tissue and culture from a sterile site as the most appropriate diagnostic strategy and the use of lipid formulations of amphotericin B and major surgery when feasible as the most appropriate first-line therapeutic strategy for mucormycosis in organ and stem cell transplant recipients.
C1 [Lanternier, Fanny; Lortholary, Olivier] Univ Paris 05, Hop Necker Enfants Malad, Ctr Infect Necker Pasteur, F-75105 Paris, France.
[Lanternier, Fanny; Lortholary, Olivier] IHU Imagine, Paris, France.
[Lanternier, Fanny; Lortholary, Olivier] Ctr Natl Reference Mycol & Antifong, Inst Pasteur, Paris, France.
[Lortholary, Olivier] CNRS, URA 3012, Paris, France.
[Sun, Hsin-Yun; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
[Ribaud, Patricia] Univ Paris 07, UFR Denis Diderot, F-75221 Paris 05, France.
[Ribaud, Patricia] Hop St Louis, Assistance Publ Hop Paris, Serv Hematol Greffe Moelle, Paris, France.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA.
RP Lortholary, O (reprint author), Univ Paris 05, Hop Necker Enfants Malad, Ctr Infect Necker Pasteur, 149 Rue Sevres, F-75105 Paris, France.
EM olivier.lortholary@nck.aphp.fr
OI SUN, HSIN-YUN/0000-0003-0074-7721
NR 62
TC 37
Z9 39
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2012
VL 54
IS 11
BP 1629
EP 1636
DI 10.1093/cid/cis195
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 942MO
UT WOS:000304048400020
PM 22431807
ER
PT J
AU Musher, DM
Stager, C
AF Musher, Daniel M.
Stager, Charles
TI Diagnosis of Clostridium difficile Infection
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Letter
C1 [Musher, Daniel M.] Baylor Coll Med, Houston, TX 77030 USA.
[Stager, Charles] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Lab Serv Care Line, Infect Dis Sect, Houston, TX 77030 USA.
[Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Stager, Charles] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.
RP Musher, DM (reprint author), Baylor Coll Med, Houston, TX 77030 USA.
EM dmusher@bcm.edu
NR 4
TC 6
Z9 6
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 1
PY 2012
VL 54
IS 11
BP 1675
EP 1675
DI 10.1093/cid/cis259
PG 1
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 942MO
UT WOS:000304048400027
PM 22503848
ER
PT J
AU Borrero, S
Mor, MK
Zhao, XH
McNeil, M
Ibrahim, S
Hayes, P
AF Borrero, Sonya
Mor, Maria K.
Zhao, Xinhua
McNeil, Melissa
Ibrahim, Said
Hayes, Patricia
TI Contraceptive care in the VA health care system
SO CONTRACEPTION
LA English
DT Article
DE VA; Women's health; Contraception; Race/ethnicity
ID OF-VETERANS-AFFAIRS; INTRAUTERINE-DEVICE; WOMEN VETERANS; DELIVERY;
AVAILABILITY; ORGANIZATION; PHYSICIANS; INNOVATION; KNOWLEDGE; ATTITUDES
AB Background: Little is known about contraceptive care within the Veterans Affairs (VA) health care system. This study was conducted to assess the prevalence of documented contraception by race/ethnicity within the VA and to examine the association between receiving primary care in women's health clinics (WHCs) and having a documented contraceptive method.
Study Design: We examined national VA administrative and pharmacy data for 103,950 female veterans aged 18-45 years who made at least one primary care clinic visit in 2008. Multivariable regression models were used to examine the associations between race/ethnicity and receipt of care in a WHC with having a method of contraception while controlling for confounders.
Results: Only 22% of women veterans had a documented method of contraception during 2008. After adjusting for potential confounders, Hispanic and African-American women were significantly less likely to have a method compared to whites [odds ratio (OR): 0.82; 95% confidence interval (CI): 0.76-0.88 and OR: 0.85; 95% CI: 0.81-0.89, respectively]. Women who went to WHCs were significantly more likely to have a method of contraception compared to women who went to traditional primary care clinics (OR: 2.05; 95% CI: 1.97-2.14).
Conclusions: Overall contraceptive prevalence in the VA is low, but receiving care in a WHC is associated with a significantly higher likelihood of having a contraceptive method. Published by Elsevier Inc.
C1 [Borrero, Sonya; Mor, Maria K.; Zhao, Xinhua] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA.
[Borrero, Sonya; McNeil, Melissa] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA.
[Mor, Maria K.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
[Ibrahim, Said] Philadelphia Vet Adm, Med Ctr, Philadelphia, PA 19104 USA.
[Ibrahim, Said] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Hayes, Patricia] US Dept Vet Affairs, Women Vet Hlth Strateg Hlth Care Grp, Off Publ Hlth & Environm Hazards, Washington, DC 20420 USA.
RP Borrero, S (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA.
EM borrerosp@upmc.edu
FU Department of Veterans Affairs, Veteran Health Administration, Office of
Research and Development, VISN 4 CHERP
FX This study was supported by the Department of Veterans Affairs, Veteran
Health Administration, Office of Research and Development, VISN 4 CHERP
Pilot Project Award (PI: Sonya Borrero). Dr. Borrero had full access to
all the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis. The contents of this
manuscript do not represent the views of the Department of Veterans
Affairs or the United States Government. The abstract of this manuscript
was presented at The Society of General Internal Medicine annual meeting
in Phoenix, AZ, in May 2011.
NR 20
TC 11
Z9 11
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
J9 CONTRACEPTION
JI Contraception
PD JUN
PY 2012
VL 85
IS 6
BP 580
EP 588
DI 10.1016/j.contraception.2011.10.010
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 944FP
UT WOS:000304185000009
PM 22176794
ER
PT J
AU Cecere, LM
Slatore, CG
Uman, JE
Evans, LE
Udris, EM
Bryson, CL
Au, DH
AF Cecere, Laura M.
Slatore, Christopher G.
Uman, Jane E.
Evans, Laura E.
Udris, Edmunds M.
Bryson, Chris L.
Au, David H.
TI Adherence to Long-Acting Inhaled Therapies among Patients with Chronic
Obstructive Pulmonary Disease (COPD)
SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
LA English
DT Article
DE Medication adherence; Pulmonary diseases; Chronic disease;
Pharmacoepidemiology
ID CLINICAL-TRIAL; MEDICATION NONADHERENCE; ASTHMATIC-PATIENTS;
CORTICOSTEROIDS; MANAGEMENT; BELIEFS; PERSISTENCE; VALIDATION; CHILDREN;
UNDERUSE
AB Background: Long-acting inhaled medications are an important component of the treatment of patients with chronic obstructive pulmonary disease (COPD), yet few studies have examined the determinants of medication adherence among this patient population. Objective: We sought to identify factors associated with adherence to long-acting beta-agonists (LABA) and inhaled corticosteroids (ICS) among patients with COPD. Methods: We performed secondary analysis of baseline data collected in a randomized trial of 376 Veterans with spirometrically confirmed COPD. We used electronic pharmacy records to assess adherence, defined as a medication possession ratio of >= 0.80. We investigated the following exposures: patient characteristics, disease severity, medication regimen complexity, health behaviors, confidence in self-management, and perceptions of provider skill. We performed multivariable logistic regression, clustered by provider, to estimate associations. Results: Of the 167 patients prescribed LABA, 54% (n = 90) were adherent to therapy while only 40% (n = 74) of 184 the patients prescribed ICS were adherent. Higher adherence to LABA and ICS was associated with patient perception of their provider as being an "expert" in diagnosing and managing lung disease [For LABA: OR = 21.70 (95% CI 6.79, 69.37); For ICS OR = 7.93 (95% CI 1.71, 36.67)]. Factors associated with adherence to LABA, but not ICS, included: age, education, race, COPD severity, smoking status, and confidence in self-management. Conclusions: Adherence to long-acting inhaled medications among patients with COPD is poor, and determinants of adherence likely differ by medication class. Patient perception of clinician expertise in lung disease was the factor most highly associated with adherence to long-acting therapies.
C1 [Cecere, Laura M.; Uman, Jane E.; Udris, Edmunds M.; Bryson, Chris L.; Au, David H.] Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Cecere, Laura M.; Au, David H.] Univ Washington, Dept Med, Div Pulm & Crit Care Med, Seattle, WA USA.
[Slatore, Christopher G.] Dept Vet Affairs Med Ctr, Portland, OR USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
[Evans, Laura E.] NYU, Med Ctr, Div Pulm & Crit Care Med, Dept Med, New York, NY 10016 USA.
RP Cecere, LM (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM lcecere@u.washington.edu
OI Slatore, Christopher/0000-0003-0958-8122
FU VA Advanced Fellowship Program in Health Services Research and
Development [TPM 61-037]; Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development [IIR 02-292];
Portland VA Medical Center, Portland, OR; Firland Foundation
FX This material is based upon work supported by a VA Advanced Fellowship
Program in Health Services Research and Development [TPM 61-037] and a
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development grant [IIR 02-292]. Dr. Slatore is supported
by a Veterans Affairs HSR&D Career Development Award and resources from
the Portland VA Medical Center, Portland, OR. Additional support also
comes from the Firland Foundation. The views expressed in this article
are those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs. Some of the results of
this work were presented in abstract form at the American Thoracic
Society International Conference, in Denver, Colorado on May 15, 2011.
NR 35
TC 23
Z9 23
U1 1
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1541-2555
J9 COPD
JI COPD-J. Chronic Obstr. Pulm. Dis.
PD JUN
PY 2012
VL 9
IS 3
BP 251
EP 258
DI 10.3109/15412555.2011.650241
PG 8
WC Respiratory System
SC Respiratory System
GA 942ZM
UT WOS:000304090200008
PM 22497533
ER
PT J
AU Sosenko, JM
Skyler, JS
Herold, KC
Palmer, JP
AF Sosenko, Jay M.
Skyler, Jay S.
Herold, Kevan C.
Palmer, Jerry P.
CA Type 1 Diabet TrialNet Study Grp
Diabet Prevention Trial-Type 1
TI The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral
Glucose Tolerance Testing in the Diabetes Prevention Trial-Type 1
SO DIABETES
LA English
DT Article
ID BETA-CELL FUNCTION; INSULIN-RESISTANCE; C-PEPTIDE;
CLINICAL-MANIFESTATIONS; NATURAL-HISTORY; RISK SCORE; MELLITUS; ONSET;
SECRETION; RELATIVES
C1 [Sosenko, Jay M.; Skyler, Jay S.] Univ Miami, Miller Sch Med, Div Endocrinol, Miami, FL 33136 USA.
[Herold, Kevan C.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
[Palmer, Jerry P.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Endocrinol Metab & Nutr, Seattle, WA 98195 USA.
RP Sosenko, JM (reprint author), Univ Miami, Miller Sch Med, Div Endocrinol, Miami, FL 33136 USA.
EM jsosenko@med.miami.edu
RI Skyler, Jay/F-4211-2016
OI Gallagher, Mary/0000-0002-5844-2309
FU Type 1 Diabetes TrialNet Study Group; National Institutes of Health
(NTH) through the National Institute of Diabetes and Digestive and
Kidney Diseases; National Institute of Allergy and Infectious Diseases;
Eunice Kennedy Shriver National Institute of Child Health and Human
Development [U01 DK-061010, U01 DK-061016, U01 DK-061034, U01 DK-061036,
U01 DK-061040, U01 DK-061041, U01 DK-061042, U01 DK-061055, U01
DK-061058, U01 DK-084565, U01 DK-085453, U01 DK-085461, U01 DK-085463,
U01 DK-085466, U01 DK-085499, U01 DK-085505, U01 DK-085509,
HHSN267200800019C]; National Center for Research Resources [UL1
RR-024131, UL1 RR-024139, UL1 RR-024153, UL1 RR-024975, UL1 RR-024982,
UL1 RR-025744, UL1 RR-025761, UL1 RR-025780, UL1 RR-029890, UL1
RR-031986]; General Clinical Research Center [M01 RR-00400]; Juvenile
Diabetes Research Foundation International (JDRF); ADA
FX The sponsor of the study was the Type 1 Diabetes TrialNet Study Group.
Type 1 Diabetes TrialNet Study Group is a clinical trials network funded
by the National Institutes of Health (NTH) through the National
Institute of Diabetes and Digestive and Kidney Diseases, the National
Institute of Allergy and Infectious Diseases, and the Eunice Kennedy
Shriver National Institute of Child Health and Human Development,
through the cooperative agreements U01 DK-061010, U01 DK-061016, U01
DK-061034, U01 DK-061036, U01 DK-061040, U01 DK-061041, U01 DK-061042,
U01 DK-061055, U01 DK-061058, U01 DK-084565, U01 DK-085453, U01
DK-085461, U01 DK-085463, U01 DK-085466, U01 DK-085499, U01 DK-085505,
and U01 DK-085509, and a contract HHSN267200800019C; the National Center
for Research Resources, through Clinical Translational Science Awards
UL1 RR-024131, UL1 RR-024139, UL1 RR-024153, UL1 RR-024975, UL1
RR-024982, UL1 RR-025744, UL1 RR-025761, UL1 RR-025780, UL1 RR-029890,
and UL1 RR-031986, and General Clinical Research Center Award M01
RR-00400; the Juvenile Diabetes Research Foundation International
(JDRF); and the ADA. The contents of this article are solely the
responsibility of the authors and do not necessarily represent the
official views of the NIH, JDRF, or ADA.
NR 50
TC 19
Z9 20
U1 0
U2 6
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
J9 DIABETES
JI Diabetes
PD JUN
PY 2012
VL 61
IS 6
BP 1331
EP 1337
DI 10.2337/db11-1660
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 948FX
UT WOS:000304490100004
PM 22618768
ER
PT J
AU Rapuano, BE
Lee, JJE
MacDonald, DE
AF Rapuano, Bruce E.
Lee, Jani J. E.
MacDonald, Daniel E.
TI Titanium alloy surface oxide modulates the conformation of adsorbed
fibronectin to enhance its binding to alpha(5)beta(1) integrins in
osteoblasts
SO EUROPEAN JOURNAL OF ORAL SCIENCES
LA English
DT Article
DE conformation; fibronectin; integrins; osteoblast; titanium alloy
ID HUMAN PLASMA FIBRONECTIN; ATOMIC-FORCE MICROSCOPY; AMINO-ACID-SEQUENCE;
CELL-ADHESION; CHEMICAL-MODIFICATION; BONE SIALOPROTEIN; SYNERGY SITE;
NET CHARGE; IN-VITRO; ATTACHMENT
AB Rapuano BE, Lee JJE, MacDonald DE. Titanium alloy surface oxide modulates the conformation of adsorbed fibronectin to enhance its binding to a5 beta 1 integrins in osteoblasts. ?Eur J Oral Sci 2012; 120: 185194. (C) 2012 Eur J Oral Sci Our laboratory has previously demonstrated that heat (600 degrees C) or radiofrequency plasma glow discharge (RFGD) pretreatment of a titanium alloy (Ti6Al4V) increased the net negative charge of the alloy's surface oxide and the attachment of osteoblastic cells to adsorbed fibronectin. The purpose of the current study was to investigate the biological mechanism by which these surface pretreatments enhance the capacity of fibronectin to stimulate osteoblastic cell attachment. Each pretreatment was found to increase the binding (measured by ELISA) of a monoclonal anti-fibronectin Ig to the central integrin-binding domain of adsorbed fibronectin, and to increase the antibody's inhibition of osteogenic cell attachment (measured by hexosaminidase assay). Pretreatments also increased the binding (measured by ELISA) of anti-integrin IgGs to the a5 and beta 1 integrin subunits that became attached to fibronectin during cell incubation. These findings suggest that negatively charged surface oxides of Ti6Al4V cause conformational changes in fibronectin that increase the availability of its integrin-binding domain to a5 beta 1 integrins.
C1 [Rapuano, Bruce E.; Lee, Jani J. E.; MacDonald, Daniel E.] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA.
[MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY USA.
[MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY USA.
RP MacDonald, DE (reprint author), Cornell Univ, Weill Med Coll, Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.
EM dem14@columbia.edu
FU NIH [RO1 DE017695]; National Center for Research Resources, NIH [C06-
RR12538-01]
FX The project described was supported by Grant Number NIH RO1 DE017695
(awarded to D.E.M.). This material is also the result of work supported
with resources and the use of facilities at the James J. Peters VA
Medical Center, Bronx, New York. This investigation was also conducted
at the HSS research facility constructed with support of Grant C06-
RR12538-01 from the National Center for Research Resources, NIH. We
would like to acknowledge Dr Stephen Doty and Tony Labisserie for their
help with scanning electron microscopy. Special thanks go to Tiffany
Leung, Ryan Jeong, and Kyle Hackshaw for their technical assistance.
NR 51
TC 14
Z9 15
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0909-8836
J9 EUR J ORAL SCI
JI Eur. J. Oral Sci.
PD JUN
PY 2012
VL 120
IS 3
BP 185
EP 194
DI 10.1111/j.1600-0722.2012.954_e.x
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 944HC
UT WOS:000304188900002
PM 22607334
ER
PT J
AU Thompson, GR
Wiederhold, NP
Najvar, LK
Bocanegra, R
Kirkpatrick, WR
Graybill, JR
Patterson, TF
AF Thompson, George R., III
Wiederhold, Nathan P.
Najvar, Laura K.
Bocanegra, Rosie
Kirkpatrick, William R.
Graybill, John R.
Patterson, Thomas F.
TI A murine model of Cryptococcus gattii meningoencephalitis
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE cryptococcal meningoencephalitis; C; gattii; Cryptococcus neoformans;
posaconazole; fluconazole
ID NEOFORMANS; MENINGITIS; OUTBREAK; FLUCONAZOLE; FLUCYTOSINE; GENOTYPE;
VARIETY
AB Meningoencephalitis caused by Cryptococcus gattii is associated with significant morbidity and the need for aggressive therapy, and often necessitates neurosurgical intervention. We adapted a previously described murine model of cryptococcal meningoencephalitis due to Cryptococcus neoformans to that caused by C. gattii.
Mice were inoculated intracranially with either C. gattii (genotype VGIIa) or C. neoformans. In virulence studies, different C. gattii infecting inocula were compared with a fixed inoculum of C. neoformans, and differences were assessed by survival, brain tissue fungal burden, serum antigen titres and histopathological changes within brain tissue. For treatment, fluconazole or posaconazole (10 mg/kg orally twice daily) was initiated 24 h post-inoculation.
C. gattii was more virulent than C. neoformans, as evident by shorter median survival, earlier histopathological changes and higher serum antigen titres. However, no differences in fungal burden or dissemination to other organs were observed among the various groups. In treatment studies, both fluconazole and posaconazole improved the median survival of mice infected with either species. However, neither regimen improved the percentage of animals surviving to the predetermined study endpoint.
These results demonstrate the virulence of C. gattii meningoencephalitis and the potential of this model for the assessment of new treatment strategies.
C1 [Thompson, George R., III] Univ Calif Davis, Div Infect Dis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
[Thompson, George R., III] Univ Calif Davis, Div Infect Dis, Dept Internal Med, Davis, CA 95616 USA.
[Wiederhold, Nathan P.; Najvar, Laura K.; Bocanegra, Rosie; Kirkpatrick, William R.; Graybill, John R.; Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Internal Med, San Antonio, TX 78229 USA.
[Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
[Patterson, Thomas F.] S Texas Vet Hlth Care Syst, Div Infect Dis, Dept Internal Med, San Antonio, TX USA.
RP Thompson, GR (reprint author), Univ Calif Davis, Div Infect Dis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
EM grthompson@ucdavis.edu
OI Wiederhold, Nathan/0000-0002-2225-5122
FU National Institutes of Health/National Institute of Allergy and
Infectious Diseases [N01-AI-25475]; Pfizer; Schering-Plough; Merck;
Basilea; Astellas
FX This work was supported by a contract from the National Institutes of
Health/National Institute of Allergy and Infectious Diseases
(N01-AI-25475) to J. R. G. and T. F. P.; G. R. T. has received research
support from Pfizer. N. P. W. has received research support from Pfizer,
Schering-Plough, Merck, Basilea and Astellas. J. R. G. has received
research support from Pfizer, Merck and Astellas, and has been paid to
act as a consultant for Merck. T. F. P. has received research grants
from Astellas, Basilea, Merck and Pfizer (to the University of Texas
Health Science Center at San Antonio), and has been paid to act as a
consultant for Astellas, Basilea, Merck, Pfizer and Toyoma. All other
authors: none to declare.
NR 19
TC 13
Z9 13
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUN
PY 2012
VL 67
IS 6
BP 1432
EP 1438
DI 10.1093/jac/dks060
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 942RJ
UT WOS:000304064400020
PM 22378683
ER
PT J
AU Huttner, B
Jones, M
Rubin, MA
Madaras-Kelly, K
Nielson, C
Goetz, MB
Neuhauser, MM
Samore, MH
AF Huttner, Benedikt
Jones, Makoto
Rubin, Michael A.
Madaras-Kelly, Karl
Nielson, Christopher
Goetz, Matthew Bidwell
Neuhauser, Melinda M.
Samore, Matthew H.
TI Double trouble: how big a problem is redundant anaerobic antibiotic
coverage in Veterans Affairs medical centres?
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
DE antibiotic stewardship; anaerobes; metronidazole; inappropriate
antibiotic use
ID METRONIDAZOLE; THERAPY
AB Objectives: To assess the prevalence of, and the variation in, avoidable use of metronidazole in the Veterans Affairs (VA) healthcare system
Methods: Barcode Medication Administration (BCMA) data were retrospectively assessed for all patients hospitalized between January 2006 and December 2010 in acute-care wards of all VA medical centres (VAMCs) with complete BCMA data and at least 10 acute-care non-intensive care unit (ICU) beds. Potentially avoidable metronidazole days of therapy (DOT) were defined as the administration of metronidazole with anotheranti-anaerobic antibiotic on the same day for at least two consecutive days during the same hospitalization. Metronidazole was not considered redundant in combination with another anti-anaerobic agent within 28 days after a positive test for Clostridium difficile and during hospitalizations associated with discharge diagnosis codes for cholecystitis or cholangitis.
Results: A total of 128 VAMCs satisfied the inclusion criteria. Over the study period there were a total of 782821 DOT of metronidazole (57.4 DOT per 1000 patient-days), of which 183267 (23.4%) fulfilled the criteria for avoidable metronidazole DOT. The percentage of avoidable metronidazole DOT remained stable over the study period (22.8% in 2006 and 22.9% in 2010) despite a decrease in overall metronidazole use. There was wide variation in the percentage of avoidable metronidazole DOT among facilities (2010: median 20.3%, IQR 15.3%-29.4%). Piperacillin/tazobactam was the most commonly administered drug on avoidable metronidazole DOT (56.8%).
Conclusions: Potentially avoidable use of metronidazole affected about a quarter of all days when metronidazole was given. The combination of metronidazole with piperacillin/tazobactam was particularly common and represents a possible target for antibiotic stewardship interventions.
C1 [Huttner, Benedikt; Jones, Makoto; Rubin, Michael A.; Samore, Matthew H.] VA Salt Lake City Hlth Care Syst, IDEAS Ctr, Salt Lake City, UT 84148 USA.
[Huttner, Benedikt; Jones, Makoto; Rubin, Michael A.; Samore, Matthew H.] Univ Utah, Div Epidemiol, Salt Lake City, UT 84132 USA.
[Madaras-Kelly, Karl] Boise VA Med Ctr, Boise, ID 83702 USA.
[Madaras-Kelly, Karl] Idaho State Univ, Coll Pharm, Meridian, ID 83713 USA.
[Nielson, Christopher] VA Sierra Nevada Hlth Care Syst, Reno, NV 89502 USA.
[Goetz, Matthew Bidwell] VA Greater LA Healthcare Syst, Los Angeles, CA 90073 USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Neuhauser, Melinda M.] Dept Vet Affairs Pharm Benefit Management Serv, Hines, IL USA.
RP Huttner, B (reprint author), VA Salt Lake City Hlth Care Syst, IDEAS Ctr, 500 Foothill Dr, Salt Lake City, UT 84148 USA.
EM huttner.benedikt@gmail.com
RI Huttner, Benedikt/M-5616-2014
OI Huttner, Benedikt/0000-0002-1749-9464; Goetz,
Matthew/0000-0003-4542-992X
FU George E. Wahlen Department of Veterans Affairs Medical Center, Salt
Lake City, UT, USA [CDA 10-030-02]; Geneva University Hospitals,
Switzerland
FX This material is the result of work supported with resources and the use
of facilities at the George E. Wahlen Department of Veterans Affairs
Medical Center, Salt Lake City, UT, USA, a career development award (to
M. J., CDA 10-030-02) and a fellowship grant from Geneva University
Hospitals, Switzerland (to B. H.).
NR 10
TC 10
Z9 11
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD JUN
PY 2012
VL 67
IS 6
BP 1537
EP 1539
DI 10.1093/jac/dks074
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 942RJ
UT WOS:000304064400037
PM 22398652
ER
PT J
AU Chirinos, JA
AF Chirinos, Julio A.
TI Arterial Stiffness: Basic Concepts and Measurement Techniques
SO JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
LA English
DT Article
DE Arterial stiffness; Compliance; Distensibility; Pulse wave velocity;
Elastic modulus
ID PRESSURE WAVE-FORMS; ALL-CAUSE MORTALITY; CAROTID-ARTERY;
CARDIOVASCULAR-DISEASE; AORTIC STIFFNESS; IN-VIVO; NONINVASIVE
EVALUATION; HYPERTENSIVE PATIENTS; CLINICAL-APPLICATIONS;
HEALTHY-INDIVIDUALS
AB Arterial stiffness is highly relevant to cardiovascular disease. Arterial stiffness is central to the pathogenesis of isolated systolic hypertension and directly impacts left ventricular afterload, pressure pulsatility in the arterial tree, and its penetration into the microvasculature of target organs such as the brain and kidney. Arterial stiffness is affected by various risk factors and biologic processes. Measurements of arterial stiffness may therefore not only provide information about prevalent processes, but also valuable information regarding the cumulative history of risk factor exposure. Available studies consistently demonstrate that large artery stiffness, measured via carotid-femoral pulse wave velocity, independently predicts the risk of incident cardiovascular events in clinical and community-based cohorts. Understanding the basic principles and definitions related to arterial stiffness is therefore desirable for cardiovascular clinicians and researchers. This introductory paper reviews basic physical principles and definitions regarding arterial stiffness and the most important non-invasive methods for its quantification in vivo.
C1 Univ Penn, Perelman Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Chirinos, JA (reprint author), Univ Penn, Perelman Sch Med, Philadelphia VA Med Ctr, Rm 8B111,Univ & Woodland Av, Philadelphia, PA 19104 USA.
EM julio.chirinos@uphs.upenn.edu
NR 56
TC 39
Z9 39
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1937-5387
J9 J CARDIOVASC TRANSL
JI J. Cardiovasc. Transl. Res.
PD JUN
PY 2012
VL 5
IS 3
SI SI
BP 243
EP 255
DI 10.1007/s12265-012-9359-6
PG 13
WC Cardiac & Cardiovascular Systems; Medicine, Research & Experimental
SC Cardiovascular System & Cardiology; Research & Experimental Medicine
GA 943HK
UT WOS:000304111300001
PM 22447229
ER
PT J
AU Fiorentino, L
Saxbe, D
Alessi, CA
Woods, DL
Martin, JL
AF Fiorentino, Lavinia
Saxbe, Darby
Alessi, Cathy A.
Woods, Diana Lynn
Martin, Jennifer L.
TI Diurnal Cortisol and Functional Outcomes in Post-Acute Rehabilitation
Patients
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Cortisol; Older adults; Rehabilitation; Inpatient; Functional Status
ID PITUITARY-ADRENAL AXIS; NURSING-HOME RESIDENTS; UNDER-THE-CURVE;
OLDER-PEOPLE; YOUNG-ADULTS; DEMENTIA; DECLINE; DISEASE; CARDIA; CLOCK
AB Background. Cortisol is a stress-related hormone with a robust circadian rhythm where levels typically peak in the morning hours and decline across the day. Although acute cortisol increases resulting from stressors are adaptive, chronic elevated cortisol levels are associated with poor functioning. Studies have shown age-related changes in cortisol levels. The present study investigated the relationship between salivary diurnal cortisol and functional outcomes among older adults undergoing inpatient post-acute rehabilitation.
Methods. Thirty-two older adults (mean age 78 years; 84% men) in a Veterans Administration inpatient post-acute rehabilitation unit were studied. Functional outcomes were assessed with the motor component of the Functional Independence Measure (mFIM; where mFIM change = discharge - admission score). Saliva samples were collected on 1 day at wake time, 45 minutes later, 11:30 am, 2 pm, 4:30 pm, and bedtime. We analyzed the relationship between cortisol measures and functional outcomes, demographics, and health measures.
Results. The analyses consistently showed that greater functional improvement (mFIM change) from admission to discharge was associated with lower comorbidity scores and higher cortisol levels at 2 pm, 4: 30 pm, and bedtime. A morning cortisol rise was also associated with greater mFIM change.
Conclusions. Measurement of cortisol in saliva may be a useful biological marker for identification of patients who are "at risk" of lower benefits from inpatient rehabilitation services and who may require additional assistance or intervention during their post-acute care stay.
C1 [Alessi, Cathy A.; Martin, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, North Hills, CA 91343 USA.
[Fiorentino, Lavinia] Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92103 USA.
[Saxbe, Darby] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
[Alessi, Cathy A.; Martin, Jennifer L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Woods, Diana Lynn] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA.
RP Martin, JL (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, 16111 Plummer St,Bldg 25,Room B136, North Hills, CA 91343 USA.
EM jennifer.martin@va.gov
FU National Institute of Mental Health [T32 MH019934, MH080002, T32
MH019925-11]; National Institute on Aging at the National Institutes of
Health [K23 AG028452]; Veterans Administration Health Services Research
& Development Service [IIR 01-053-1, IIR 04-321-2, AIA 03-047]; Veterans
Affairs Greater Los Angeles Healthcare System, Geriatric Research,
Education and Clinical Center
FX This work was supported by the National Institute of Mental Health [T32
MH019934 (Jeste), MH080002 (Jeste), and T32 MH019925-11 (Irwin)] and the
National Institute on Aging [K23 AG028452 (J.L.M.)] at the National
Institutes of Health; Veterans Administration Health Services Research &
Development Service (IIR 01-053-1, C. A. A.; IIR 04-321-2, C. A. V.; and
AIA 03-047 J.L.M.); and the Veterans Affairs Greater Los Angeles
Healthcare System, Geriatric Research, Education and Clinical Center.
NR 22
TC 2
Z9 2
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD JUN
PY 2012
VL 67
IS 6
BP 677
EP 682
DI 10.1093/gerona/glr230
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 942OM
UT WOS:000304054700013
PM 22219521
ER
PT J
AU D'Souza, DC
Fridberg, DJ
Skosnik, PD
Williams, A
Roach, B
Singh, N
Carbuto, M
Elander, J
Schnakenberg, A
Pittman, B
Sewell, RA
Ranganathan, M
Mathalon, D
AF D'Souza, Deepak Cyril
Fridberg, Daniel J.
Skosnik, Patrick D.
Williams, Ashley
Roach, Brian
Singh, Nagendra
Carbuto, Michelle
Elander, Jacqueline
Schnakenberg, Ashley
Pittman, Brian
Sewell, R. Andrew
Ranganathan, Mohini
Mathalon, Daniel
TI Dose-Related Modulation of Event-Related Potentials to Novel and Target
Stimuli by Intravenous Delta(9)-THC in Humans
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE Delta(9)-THC; cannabinoids; cannabis; P300; perception; psychosis
ID CANNABINOID CB1 RECEPTOR; SELECTIVE ATTENTION; METABOTROPIC GLUTAMATE;
MEDIATED INHIBITION; MARIJUANA SMOKING; EVOKED-POTENTIALS; NOVELTY
DETECTION; AUDITORY-STIMULI; FREQUENT USERS; HUMAN BRAIN
AB Cannabinoids induce a host of perceptual alterations and cognitive deficits in humans. However, the neural correlates of these deficits have remained elusive. The current study examined the acute, dose-related effects of delta-9-tetrahydrocannabinol (Delta(9)-THC) on psychophysiological indices of information processing in humans. Healthy subjects (n = 26) completed three test days during which they received intravenous Delta(9)-THC (placebo, 0.015 and 0.03 mg/kg) in a within-subject, double-blind, randomized, cross-over, and counterbalanced design. Psychophysiological data (electroencephalography) were collected before and after drug administration while subjects engaged in an event-related potential (ERP) task known to be a valid index of attention and cognition (a three-stimulus auditory 'oddball' P300 task). Delta(9)-THC dose-dependently reduced the amplitude of both the target P300b and the novelty P300a. Delta(9)-THC did not have any effect on the latency of either the P300a or P300b, or on early sensory-evoked ERP components preceding the P300 (the N100). Concomitantly, Delta(9)-THC induced psychotomimetic effects, perceptual alterations, and subjective 'high' in a dose-dependent manner. Delta(9)-THC -induced reductions in P3b amplitude correlated with Delta(9)-THC-induced perceptual alterations. Lastly, exploratory analyses examining cannabis use status showed that whereas recent cannabis users had blunted behavioral effects to Delta(9)-THC, there were no dose-related effects of Delta(9)-THC on P300a/b amplitude between cannabis-free and recent cannabis users. Overall, these data suggest that at doses that produce behavioral and subjective effects consistent with the known properties of cannabis, Delta(9)-THC reduced P300a and P300b amplitudes without altering the latency of these ERPs. Cannabinoid agonists may therefore disrupt cortical processes responsible for context updating and the automatic orientation of attention, while leaving processing speed and earlier sensory ERP components intact. Collectively, the findings suggest that CB1R systems modulate top-down and bottom-up processing. Neuropsychopharmacology (2012) 37, 1632-1646; doi:10.1038/npp.2012.8; published online 15 February 2012
C1 [D'Souza, Deepak Cyril; Skosnik, Patrick D.; Williams, Ashley; Singh, Nagendra; Carbuto, Michelle; Elander, Jacqueline; Schnakenberg, Ashley; Pittman, Brian; Sewell, R. Andrew; Ranganathan, Mohini] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT 06519 USA.
[D'Souza, Deepak Cyril; Skosnik, Patrick D.; Williams, Ashley; Singh, Nagendra; Carbuto, Michelle; Elander, Jacqueline; Schnakenberg, Ashley; Pittman, Brian; Sewell, R. Andrew; Ranganathan, Mohini; Mathalon, Daniel] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Roach, Brian; Mathalon, Daniel] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Roach, Brian; Mathalon, Daniel] San Francisco VA Med Ctr, Mental Hlth Serv Line, San Francisco, CA USA.
[D'Souza, Deepak Cyril; Fridberg, Daniel J.; Skosnik, Patrick D.; Williams, Ashley; Singh, Nagendra; Carbuto, Michelle; Elander, Jacqueline; Schnakenberg, Ashley; Sewell, R. Andrew; Ranganathan, Mohini] VA Connecticut Healthcare Syst, Psychiat Serv, West Haven, CT 06516 USA.
RP D'Souza, DC (reprint author), VA Connecticut Healthcare Syst, Psychiat Serv, 116A,950 Campbell Ave, West Haven, CT 06516 USA.
EM deepak.dsouza@yale.edu
OI Mathalon, Daniel/0000-0001-6090-4974
FU Department of Veterans Affairs; National Institute of Mental Health;
National Institute of Drug Abuse [R21 DA020750]; National Institute of
Alcoholism and Alcohol Abuse (NIAAA); Yale Center for Clinical
Investigation (YCCI); NARSAD; AstraZeneca, Inc; Pfizer, Inc.; Abbott
Laboratories; Eli Lilly; Organon; Pfizer; Sanofi; Astra Zeneca
FX We acknowledge support from the (1) Department of Veterans Affairs, (2)
National Institute of Mental Health, (3) National Institute of Drug
Abuse, (4) National Institute of Alcoholism and Alcohol Abuse (NIAAA),
and (5) the Yale Center for Clinical Investigation (YCCI). This research
project was funded in part by grants from NIDA (R21 DA020750 to DCD) and
a NARSAD Young Investigator Award to PDS. We also thank Angelina
Genovese, RNC, MBA; Michelle San Pedro, RN; Elizabeth O'Donnell, RN;
Brenda Breault, RN, BSN; Sonah Yoo, RPh; Rachel Galvan, RPh; and Willie
Ford of the Neurobiological Studies Unit at the VA Connecticut
Healthcare System, West Haven Campus for their central contributions to
the success of this project.; Daniel Fridberg, Patrick Skosnik, Ashley
Williams, Brian Roach, Nagendra Singh, Michelle Carbuto, Jacqueline
Elander, Ashley Schnakenberg, Brian Pittman, and Andrew Sewell report no
financial relationships with commercial interests. Dr Mathalon reports
research funding from AstraZeneca, Inc, consulting fees from Pfizer,
Inc., and that his name is included under a provisional patent titled 'A
non-invasive biomarker of human cortical plasticity and cognition',
USPTO serial number 61/140 833. Mohini Ranganathan has in the past 3
years or currently receives research grant support administered through
Yale University School of Medicine from Eli Lilly. Deepak Cyril D'Souza
has in the past 3 years or currently receives research grant support
administered through Yale University School of Medicine from Astra
Zeneca, Abbott Laboratories, Eli Lilly, Organon, Pfizer, and Sanofi; he
is a consultant for Bristol Meyers Squibb.
NR 93
TC 35
Z9 36
U1 3
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUN
PY 2012
VL 37
IS 7
BP 1632
EP 1646
DI 10.1038/npp.2012.8
PG 15
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 942LO
UT WOS:000304045700008
PM 22334121
ER
PT J
AU Lotfipour, S
Mandelkern, M
Alvarez-Estrada, M
Brody, AL
AF Lotfipour, Shahrdad
Mandelkern, Mark
Alvarez-Estrada, Miguel
Brody, Arthur L.
TI A Single Administration of Low-Dose Varenicline Saturates alpha 4 beta
2* Nicotinic Acetylcholine Receptors in the Human Brain
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE cigarettes; nicotinic receptors; addiction; varenicline; withdrawal;
thalamus
ID PARTIAL AGONIST VARENICLINE; GENETICALLY-MODIFIED MICE; IN-VIVO;
WITHDRAWAL SYMPTOMS; TOBACCO WITHDRAWAL; BINDING-PROPERTIES;
SMOKING-CESSATION; PRENATAL-EXPOSURE; MATERNAL-SMOKING; DRUG-USE
AB The primary objective of this project was to determine the alpha 4 beta 2* nicotinic acetylcholine receptor (nAChR) occupancy in human brain of a single low dose of varenicline (0.5 mg), and to explore the relationship between receptor occupancy by varenicline and tobacco withdrawal symptoms (*denoting other putative nAChR subunits). Otherwise healthy smokers (n = 9) underwent two positron emission tomography (PET) sessions with the selective alpha 4 beta 2* radioligand 2-FA. For the PET sessions, participants received either a low dose of varenicline (0.5 mg) or matching placebo pill (double-blind, random order) before imaging. For both sessions, participants received bolus plus continuous infusions of 2-FA, were scanned for 1 h after allowing the radiotracer to reach a steady state, smoked to satiety, and were scanned for 2 more hours. We estimated the fractional receptor occupancy by a single dose of varenicline (0.5 mg) and the corresponding varenicline dissociation constant (K-V), along with the effect of low-dose varenicline, pill placebo, and smoking-to-satiety on withdrawal rating scales. The data are compatible with 100% occupancy of alpha 4 beta 2* nAChRs by a single dose of varenicline, with a 90% lower confidence limit of 89% occupancy for the thalamus and brainstem. The corresponding 90% upper limit on effective K-V with respect to plasma varenicline was 0.49 nM. Smoking to satiety, but not low-dose varenicline, significantly reduced withdrawal symptoms. Our findings demonstrate that low-dose varenicline results in saturation of alpha 4 beta 2* nAChRs in the thalamus and brainstem without reducing withdrawal symptoms. Neuropsychopharmacology (2012) 37, 1738-1748; doi:10.1038/npp.2012.20; published online 7 March 2012
C1 [Lotfipour, Shahrdad] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, MacDonald Res Labs, Los Angeles, CA 90095 USA.
[Lotfipour, Shahrdad; Brody, Arthur L.] Univ Calif Los Angeles, Hatos Ctr Neuropharmacol, Semel Inst, Los Angeles, CA 90095 USA.
[Lotfipour, Shahrdad; Mandelkern, Mark; Alvarez-Estrada, Miguel; Brody, Arthur L.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Mandelkern, Mark] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA.
RP Lotfipour, S (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, MacDonald Res Labs, 675 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM shahrdad@ucla.edu
RI Lotfipour, Shahrdad/K-8335-2014
OI Lotfipour, Shahrdad/0000-0002-2425-1096
FU Pfizer Pharmaceutical Corporation [WS653344]; NIMH [MH17140]; NIDA [R01
DA20872]; Richard Metzner Chair in Clinical Neuropharmacology
FX We thank Karen Ta, Jaime La Charite, Betram Nweke, Stuart Mirell, Van
Cayetano, Chien Nguyen, Judah Farahi, Andrew Leuchter, Hans Rollema,
Maziar Maghsoodnia, Alison Curtin, Ron Waldorf, Diep Seversen, and
Josephine Ribe for their assistance on the study. This work was funded
by Pfizer Pharmaceutical Corporation (Grant number: WS653344) (SL) and,
in part, by T-32 NIMH post-doctoral fellowship (MH17140) (SL), NIDA (R01
DA20872) (ALB), and the Richard Metzner Chair in Clinical
Neuropharmacology (ALB).
NR 52
TC 13
Z9 13
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
EI 1740-634X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUN
PY 2012
VL 37
IS 7
BP 1738
EP 1748
DI 10.1038/npp.2012.20
PG 11
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 942LO
UT WOS:000304045700018
PM 22395733
ER
PT J
AU Zinzow, HM
Resnick, HS
McCauley, JL
Amstadter, AB
Ruggiero, KJ
Kilpatrick, DG
AF Zinzow, Heidi M.
Resnick, Heidi S.
McCauley, Jenna L.
Amstadter, Ananda B.
Ruggiero, Kenneth J.
Kilpatrick, Dean G.
TI Prevalence and risk of psychiatric disorders as a function of variant
rape histories: results from a national survey of women
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Rape; Sexual assault; Posttraumatic stress disorder; Depression; Alcohol
abuse; Drug abuse; Comorbidity
ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL ASSAULT; INCAPACITATED RAPE;
MENTAL-HEALTH; SUBSTANCE USE; ALCOHOL; SAMPLE; COMMUNITY; VIOLENCE;
COMORBIDITY
AB Rape is an established risk factor for mental health disorders, such as posttraumatic stress disorder (PTSD), major depressive episodes (MDE), and substance use disorders. The majority of studies have not differentiated substance-involved rape or examined comorbid diagnoses among victims. Therefore, the aim of the present study was to estimate the prevalence of common trauma-related psychiatric disorders (and their comorbidity) in a national sample of women, with an emphasis on distinguishing between rape tactics. A secondary objective was to estimate the risk for psychiatric disorders among victims of variant rape tactics, in comparison to non-victims.
A nationally representative population-based sample of 3,001 non-institutionalized, civilian, English or Spanish speaking women (aged 18-86 years) participated in a structured telephone interview assessing rape history and DSM-IV criteria for PTSD, MDE, alcohol abuse (AA), and drug abuse (DA). Descriptive statistics and multivariate logistic regression analyses were employed.
Women with rape histories involving both substance facilitation and forcible tactics reported the highest current prevalence of PTSD (36%), MDE (36%), and AA (20%). Multivariate models demonstrated that this victim group was also at highest risk for psychiatric disorders, after controlling for demographics and childhood and multiple victimization history. Women with substance-facilitated rapes reported higher prevalence of substance abuse in comparison to women with forcible rape histories. Comorbidity between PTSD and other psychiatric disorders was higher among rape victims in comparison to non-rape victims.
Researchers and clinicians should assess substance-facilitated rape tactics and attend to comorbidity among rape victims. Empirically supported treatments are needed to address the complex presentations observed among women with variant rape histories.
C1 [Zinzow, Heidi M.] Clemson Univ, Dept Psychol, Clemson, SC 29634 USA.
[Resnick, Heidi S.; McCauley, Jenna L.; Amstadter, Ananda B.; Ruggiero, Kenneth J.; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Zinzow, HM (reprint author), Clemson Univ, Dept Psychol, 418 Brackett Hall, Clemson, SC 29634 USA.
EM hzinzow@clemson.edu
FU National Institute of Justice [2005-WG-BX-0006]; NIDA
[1R01DA023099-01A2]
FX The research design and data collection were supported by National
Institute of Justice Grant #2005-WG-BX-0006 (principal investigator:
Dean G. Kilpatrick). Support for manuscript preparation was provided by
NIDA 1R01DA023099-01A2 (principal investigator: Heidi Resnick). Views
expressed in this article do not necessarily represent those of the
agencies supporting this research.
NR 27
TC 19
Z9 19
U1 7
U2 23
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD JUN
PY 2012
VL 47
IS 6
BP 893
EP 902
DI 10.1007/s00127-011-0397-1
PG 10
WC Psychiatry
SC Psychiatry
GA 944AT
UT WOS:000304171300006
PM 21603967
ER
PT J
AU Singh, JA
Wells, GA
Christensen, R
Tanjong, E
MacDonald, J
Tugwell, P
Buchbinder, R
AF Singh, J. A.
Wells, G. A.
Christensen, R.
Tanjong, E.
MacDonald, J.
Tugwell, P.
Buchbinder, R.
CA Biol Safety Study Grp
TI ADVERSE EFFECTS OF BIOLOGICS: A NETWORK META-ANALYSIS AND COCHRANE
OVERVIEW
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Wells, G. A.] McMaster Univ, Ottawa, ON, Canada.
[Christensen, R.] Univ Denmark, Copenhagen, Denmark.
[Tanjong, E.; Tugwell, P.] Univ Ottawa, Montreal, PQ, Canada.
[MacDonald, J.] Univ Washington, Seattle, WA 98195 USA.
[Buchbinder, R.] Monash Univ, Monash, Australia.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2012
VL 71
SU 3
BP 628
EP 628
PG 1
WC Rheumatology
SC Rheumatology
GA V31QQ
UT WOS:000208898503315
ER
PT J
AU Bikle, DD
AF Bikle, Daniel D.
TI Vitamin D and Bone
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Vitamin D; Vitamin D receptor; CYP27B1; 25hydroxyvitamin; 1,25
dihydroxyvitamin D; 24,25 dihydroxyvitamin D; Bone; Chondrocytes;
Osteoblasts; Osteoclasts
AB All cells comprising the skeleton-chondrocytes, osteoblasts, and osteoclasts-contain both the vitamin D receptor and the enzyme CYP27B1 required for producing the active metabolite of vitamin D, 1,25 dihydroxyvitamin D. Direct effects of 25 hydroxyvitamin D and 1,25 dihydroxyvitamin D on these bone cells have been demonstrated. However, the major skeletal manifestations of vitamin D deficiency or mutations in the vitamin D receptor and CYP27B1, namely rickets and osteomalacia, can be corrected by increasing the intestinal absorption of calcium and phosphate, indicating the importance of indirect effects. On the other hand, these dietary manipulations do not reverse defects in osteoblast or osteoclast function that lead to osteopenic bone. This review discusses the relative importance of the direct versus indirect actions of vitamin D on bone, and provides guidelines for the clinical use of vitamin D to prevent/treat bone loss and fractures.
C1 [Bikle, Daniel D.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Bikle, DD (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111N, San Francisco, CA 94121 USA.
EM Daniel.bikle@ucsf.edu
FU National Institutes of Health [RO1 DK054793, AR055924, AR050023]
FX D.D. Bikle: has received grant support from the National Institutes of
Health (RO1 DK054793, AR055924, and AR050023); and receives loyalties
from Lange textbook chapter.
NR 86
TC 37
Z9 39
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
EI 1544-2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD JUN
PY 2012
VL 10
IS 2
BP 151
EP 159
DI 10.1007/s11914-012-0098-z
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V35YS
UT WOS:000209181600007
PM 22544628
ER
PT J
AU Rapuano, BE
Hackshaw, K
MacDonald, DE
AF Rapuano, Bruce E.
Hackshaw, Kyle
MacDonald, Daniel E.
TI Heat or radiofrequency plasma glow discharge treatment of a titanium
alloy stimulates osteoblast gene expression in the MC3T3 osteoprogenitor
cell line
SO JOURNAL OF PERIODONTAL AND IMPLANT SCIENCE
LA English
DT Article
DE Cell differentiation; Dental implants; Fibronectins; Integrin
alpha5beta1; Osteoblasts
AB Purpose: The purpose of this study was to determine whether increasing the Ti6Al4V surface oxide negative charge through heat (600 degrees C) or radiofrequency plasma glow discharge (RFGD) pretreatment, with or without a subsequent coating with fibronectin, stimulated osteoblast gene marker expression in the MC3T3 osteoprogenitor cell line.
Methods: Quantitative real-time polymerase chain reaction was used to measure changes over time in the mRNA levels for osteoblast gene markers, including alkaline phosphatase, bone sialoprotein, collagen type I (alpha 1), osteocalcin, osteopontin and parathyroid hormone-related peptide (PTH-rP), and the osteoblast precursor genes Runx2 and osterix.
Results: Osteoprogenitors began to differentiate earlier on disks that were pretreated with heat or RFGD. The pretreatments increased gene marker expression in the absence of a fibronectin coating. However, pretreatments increased osteoblast gene expression for fibronectin-coated disks more than uncoated disks, suggesting a surface oxide-mediated specific enhancement of fibronectin's bioactivity. Heat pretreatment had greater effects on the mRNA expression of genes for PTH-rP, alkaline phosphatase and osteocalcin while RFGD pretreatment had greater effects on osteopontin and bone sialoprotein gene expression.
Conclusions: The results suggest that heat and RFGD pretreatments of the Ti6Al4V surface oxide stimulated osteoblast differentiation through an enhancement of (a) coated fibronectin's bioactivity and (b) the bioactivities of other serum or matrix proteins. The quantitative differences in the effects of the two pretreatments on osteoblast gene marker expression may have arisen from the unique physico-chemical characteristics of each resultant oxide surface. Therefore, engineering the Ti6Al4V surface oxide to become more negatively charged can be used to accelerate osteoblast differentiation through fibronectin-dependent and independent mechanisms.
C1 [Rapuano, Bruce E.; Hackshaw, Kyle; MacDonald, Daniel E.] Cornell Univ, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA.
[MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY USA.
[MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY 10027 USA.
RP MacDonald, DE (reprint author), Columbia Univ, Langmuir Ctr Colloids & Interfaces, 911 SW Mudd Bldg,500 West 120th St, New York, NY 10027 USA.
EM dem14@columbia.edu
FU National Center for Research Resources, NIH [C06-RR12538-01]; [NIH RO1
DE017695]
FX The project described was supported by Grant Number NIH RO1 DE017695
(Awarded to DEM). This material is also the result of work supported
with resources and the use of facilities at the James J. Peters VA
Medical Center, Bronx, New York. This investigation was also conducted
at the HSS research facility constructed with support of Grant
C06-RR12538-01 from the National Center for Research Resources, NIH. We
would like to acknowledge Dr. Xiaoyu Hu for technical advice with the
qRT-PCR analyses. Special thanks goes to Paul Lee, Carrie Guan, and Jani
Jae Eun Lee for the preparation and treatment of titanium alloy disks.
NR 38
TC 6
Z9 6
U1 3
U2 6
PU KOREAN ACAD PERIODONTOLOGY
PI SEOUL
PA OFFICIAL B-D 2212, 163 SINMUNRO 1-GA, JONGNO-GU, SEOUL, 110-990, SOUTH
KOREA
SN 2093-2278
EI 2093-2286
J9 J PERIODONTAL IMPLAN
JI J. Periodontal Implant Sci.
PD JUN
PY 2012
VL 42
IS 3
BP 95
EP 104
DI 10.5051/jpis.2012.42.3.95
PG 10
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA V34HG
UT WOS:000209076900006
PM 22803011
ER
PT J
AU Allen, NE
Javdani, S
Lehrner, AL
Walden, AL
AF Allen, Nicole E.
Javdani, Shabnam
Lehrner, Amy L.
Walden, Angela L.
TI "Changing the Text": Modeling Council Capacity to Produce
Institutionalized Change
SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article
DE Councils; Institutionalized change; Coordinating councils; Coalitions;
Domestic violence; Intimate partner violence; Interagency coordination
ID VIOLENCE COORDINATING COUNCILS; COMMUNITY-HEALTH COALITIONS;
SUBSTANCE-ABUSE PREVENTION; GOVERNANCE PROCESSES; PARTICIPATION;
EMPOWERMENT; PARTNERSHIPS; OUTCOMES; IMPLEMENTATION; PERSPECTIVE
AB Collaboration is a ubiquitous approach to change, but is notoriously difficult and not definitively linked to desirable outcomes. Not surprisingly, the collaboration literature is replete with numerous facilitators and barriers to collaborative efforts. The current study aimed to develop a parsimonious model of factors influencing the success of collaborative efforts both internal and external to the council, including, (a) features of the council environment, (b) intermediate outcomes including the empowerment of members in the council context and the degree to which councils have generated social capital and (c) the extent to which collaborative efforts are occurring in a community context supportive of their aims. In particular, this study examines whether these factors affect the extent to which councils are positioned to achieve institutionalized change, or changes "in the text" that govern front line providers' (e.g., police, advocates) practices in the community response to intimate partner violence. Results suggest that perceived member empowerment, generation of social capital, and supportive community context are the most important predictors of the extent to which councils foster shifts in institutionalized change. Features of the council environment are only indirectly related to the degree to which institutionalized change is ultimately fostered as mediated by the generation of social capital. This suggests that the ability of members to act as change agents and the extent to which those in power support council efforts figure more prominently to facilitate or constrain council efforts than council functioning itself.
C1 [Allen, Nicole E.; Javdani, Shabnam; Walden, Angela L.] Univ Illinois, Dept Psychol, Champaign, IL 61820 USA.
[Lehrner, Amy L.] James J Peters VA Med Ctr, Traumat Stress Studies Div, Bronx, NY USA.
RP Allen, NE (reprint author), Univ Illinois, Dept Psychol, 603 E Daniel St, Champaign, IL 61820 USA.
EM allenne@illinois.edu
OI Javdani, Shabnam/0000-0003-3949-1970
NR 50
TC 13
Z9 13
U1 2
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0091-0562
J9 AM J COMMUN PSYCHOL
JI Am. J. Community Psychol.
PD JUN
PY 2012
VL 49
IS 3-4
BP 317
EP 331
DI 10.1007/s10464-011-9460-z
PG 15
WC Public, Environmental & Occupational Health; Psychology,
Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA 939HR
UT WOS:000303800600002
PM 21842302
ER
PT J
AU Gunduz-Bruce, H
Reinhart, RMG
Roach, BJ
Gueorguieva, R
Oliver, S
D'Souza, DC
Ford, JM
Krystal, JH
Mathalon, DH
AF Gunduz-Bruce, Handan
Reinhart, Robert M. G.
Roach, Brian J.
Gueorguieva, Ralitza
Oliver, Stephen
D'Souza, Deepak C.
Ford, Judith M.
Krystal, John H.
Mathalon, Daniel H.
TI Glutamatergic Modulation of Auditory Information Processing in the Human
Brain
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Glutamate; ketamine; MMN; N-acetylcysteine; NMDA; P300
ID MISMATCH NEGATIVITY MMN; HUMAN SELECTIVE ATTENTION; N-ACETYL-CYSTEINE;
HEALTHY-VOLUNTEERS; P300 AMPLITUDE; GLUTATHIONE PRECURSOR;
MENSTRUAL-CYCLE; SYSTEM X(C)(-); IN-VIVO; SCHIZOPHRENIA
AB Background: Auditory mismatch negativity (MMN) and P300 event-related potentials (ERPs) are reduced in schizophrenia patients and healthy volunteers administered the N-methyl-D-aspartate glutamate receptor antagonist, ketamine. In rodents, N-acetylcysteine (NAC), a stimulator of the cystine-glutamate exchanger, attenuates the cognitive and behavioral effects of N-methyl-D-aspartate receptor antagonists. On the basis of these findings, we tested whether NAC would reduce ketamine effects on behavior, MMN, and P300 in healthy humans.
Methods: This randomized, double-blind, placebo-controlled study consisted of 2 test days during which subjects (n = 16) were administered oral NAC (3000 mg in divided doses) or matching placebo 165 min before the infusion of saline and then ketamine (as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min, and then .29 mg/kg for 40 min) in a fixed order. Behavioral and ERP data including auditory MMN and P300 were collected during each test day.
Results: Ketamine produced psychotic-like positive symptoms, reductions in working memory and sustained attention performance, and amplitude reductions for the frequency- and intensity-deviant MMNs and P300. NAC pretreatment did not reduce the behavioral or ERP effects of ketamine. In addition, NAC reduced frequency-deviant MMN amplitude and increased target and novelty P3 amplitudes. The decrements in frequency-deviant MMN amplitude produced by ketamine and NAC were not additive.
Conclusions: NAC did not attenuate the effects of ketamine in humans, in contrast to previous studies in animals. NAC merits further investigation as a cognitive enhancing agent due to its ability to increase the P300 amplitude.
C1 [Gunduz-Bruce, Handan; D'Souza, Deepak C.; Krystal, John H.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Gunduz-Bruce, Handan; Gueorguieva, Ralitza; Oliver, Stephen; D'Souza, Deepak C.; Ford, Judith M.; Krystal, John H.; Mathalon, Daniel H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Reinhart, Robert M. G.] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA.
[Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Ford, Judith M.; Mathalon, Daniel H.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
RP Gunduz-Bruce, H (reprint author), VA Connecticut Healthcare Syst, 116-A,950 Campbell Ave, West Haven, CT 06516 USA.
EM handan.gunduz-bruce@yale.edu
OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974;
Gueorguieva, Ralitza/0000-0003-0944-5973
FU National Alliance for Research in Schizophrenia and Affective Disorders
(NARSAD); National Institute on Alcohol Abuse and Alcoholism [K05 AA
14906, 2P50 AA 012870]; US Department of Veterans Affairs Alcohol
Research Center, National Center Post Traumatic Stress Disorder,
Clinical Neurosciences Division, West Haven, Connecticut; VA
Schizophrenia Biological Research Center; National Institute of Mental
Health [MH40052, MH 58262, MH067967]; Astra Zeneca; Abbott Laboratories;
Eli Lilly; Organon; Pfizer; Sanofi; Department of Veterans Affairs;
Janssen Research Foundation; [R01 MH076989]
FX This study was supported by a National Alliance for Research in
Schizophrenia and Affective Disorders (NARSAD) Hammerschlag Young
Investigator Award to Dr. Gunduz-Bruce. Part of the data was previously
presented as a poster at the 2007 annual meeting of the American College
of Neuropsychopharmacology. We are thankful to the Biostudies Laboratory
Nursing Staff; Angelina M. Genovese, RNC, MBA; Elizabeth O'Donnell, RN;
Michelle Sanpedro, RN; and Brenda Breault, RN, BSN, for their
outstanding nursing; and Sonah Perry, R.Ph., for excellent Research
Pharmacy support. We also thank all the research participants. This
study was also partly supported by funding from the National Institute
on Alcohol Abuse and Alcoholism, K05 AA 14906, National Institute on
Alcohol Abuse and Alcoholism, 2P50 AA 012870, US Department of Veterans
Affairs Alcohol Research Center, National Center Post Traumatic Stress
Disorder, Clinical Neurosciences Division, West Haven, Connecticut, to
JHK; R01 MH076989 to DHM; VA Schizophrenia Biological Research Center,
and grants from the National Institute of Mental Health (MH40052, MH
58262, MH067967) and NARSAD to JMF.; Drs. Gunduz-Bruce, Gueorguieva,
Ford, and Mathalon and Mr. Reinhart, Mr. Roach, and Mr. Oliver report no
biomedical financial interests or potential conflict of interests. Dr.
D'Souza reports research grant support from Astra Zeneca, Abbott
Laboratories, Eli Lilly, Organon, Pfizer, and Sanofi. Dr. Krystal
reports serving as consultant for the following companies (the
Individual Consultant Agreements listed are <$10,000/year): Aisling
Capital, LLC, AstraZeneca Pharmaceuticals, Brintnall and Nicolini,
Easton Associates, Gilead Sciences, GlaxoSmith-Kline, Janssen
Pharmaceuticals, Lundbeck Research USA, Medivation, Merz
Pharmaceuticals, MK Medical Communications, F. Hoffmann-La Roche, SK
Holdings, Takeda Industries, and Teva Pharmaceutical Industries. Dr.
Krystal also serves for the Scientific Advisory Board of Abbott
Laboratories, Bristol-Myers Squibb, Eisai, Eli Lilly, Forest
Laboratories, Lohocla Research Corporation, Mnemosyne Pharmaceuticals,
Naurex, Pfizer Pharmaceuticals, and Shire Pharmaceuticals. Dr. Krystal
holds Exercisable Warrant Options that include Tetragenex
Pharmaceuticals (value <$150), and he serves as Board of Directors for
the Coalition for Translational Research in Alcohol and Substance Use
Disorders. Dr. Krystal is a President Elect for American College of
Neuropsychopharmacology and receives research support from Department of
Veterans Affairs and Janssen Research Foundation (provided drug and some
study support to the Department of Veterans Affairs). Dr. Krystal
receives >$10,000 as the Editor of Biological Psychiatry. Patents and
Inventions for Dr. Krystal include: 1) Seibyl JP, Krystal JH, Charney
DS. Dopamine and noradrenergic reuptake inhibitors in treatment of
schizophrenia. Patent #:5,447,948. September 5, 1995; 2) co-inventor
with Dr. Gerard Sanacora on a filed patent application by Yale
University related to targeting the glutamatergic system for the
treatment of neuropsychiatric disorders (PCTWO06108055A1); and 3)
Intranasal Administration of Ketamine to Treat Depression (pending).
NR 75
TC 28
Z9 29
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JUN 1
PY 2012
VL 71
IS 11
BP 969
EP 977
DI 10.1016/j.biopsych.2011.09.031
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 939MH
UT WOS:000303814800009
PM 22036036
ER
PT J
AU Yomogida, K
Chou, Y
Pang, J
Baravati, B
Maniaci, BJ
Wu, S
Zhu, Y
Chu, CQ
AF Yomogida, Kentaro
Chou, Yuan
Pang, Jonathan
Baravati, Bobby
Maniaci, Brian J.
Wu, Shili
Zhu, Yong
Chu, Cong-Qiu
TI Streptavidin suppresses T cell activation and inhibits IL-2 production
and CD25 expression
SO CYTOKINE
LA English
DT Article
DE Streptavidin; Biotin; T Cell activation; Interleukin 2; Interleukin 2
receptor
ID JURKAT CELLS; PRETARGETED RADIOIMMUNOTHERAPY; RENAL-TRANSPLANTATION;
CHAIN IMMUNOTOXIN; BIOTIN DEFICIENCY; BINDING-PROTEIN; FUSION PROTEIN;
REJECTION; DIFFERENTIATION; BIOTINYLATION
AB Streptavidin is widely used as a detection tool in biology research because of its high affinity and specificity binding to biotin. Biotin-streptavidin system has also been explored for detection of infection and tumor in clinical medicine. Here, we show immunosuppressive property of streptavidin on T cell activation and proliferation. Upon CD3 and CD28 stimulation, CD4(+) T cells produce interleukin 2 (IL-2) and express IL-2 receptor alpha chain (CD25). Addition of streptavidin in T cell culture suppressed IL-2 synthesis and CD25 expression with no cytotoxicity. The immunosuppressive effect of streptavidin was reversed by excessive biotin. Conjugated to a single chain anti-CD7 variable fragment (scFvCD7), streptavidin was directly delivered to T cells and showed substantially more profound suppressive effect on T cell activation. These results suggest that streptavidin could potentially be used as a novel immunomodulator. Published by Elsevier Ltd.
C1 [Yomogida, Kentaro; Chou, Yuan; Chu, Cong-Qiu] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR USA.
[Yomogida, Kentaro; Chou, Yuan; Chu, Cong-Qiu] Portland VA Med Ctr, Portland, OR USA.
[Pang, Jonathan; Baravati, Bobby; Maniaci, Brian J.; Wu, Shili; Zhu, Yong] VivoScript Inc, Costa Mesa, CA USA.
RP Chu, CQ (reprint author), 3181 SW Sam Jackson Pk Rd 0P09, Portland, OR 97239 USA.
EM chuc@ohsu.edu
FU NIH [AR055254]; Portland VA Medical Center
FX This work was supported by a Grant from NIH to C.Q.C. (AR055254) and
Portland VA Medical Center.
NR 46
TC 4
Z9 6
U1 0
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
J9 CYTOKINE
JI Cytokine
PD JUN
PY 2012
VL 58
IS 3
BP 431
EP 436
DI 10.1016/j.cyto.2012.02.007
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 941FA
UT WOS:000303947900018
PM 22410319
ER
PT J
AU Walker, DD
Reeves, TD
de Costa, AM
Schuyler, C
Young, MRI
AF Walker, David D.
Reeves, Travis D.
de Costa, Anna-Maria
Schuyler, Corinne
Young, M. Rita I.
TI Immunological modulation by 1 alpha,25-dihydroxyvitamin D-3 in patients
with squamous cell carcinoma of the head and neck
SO CYTOKINE
LA English
DT Article
DE Cytokines; Head and neck cancer; HNSCC; Vitamin D
ID ENDOTHELIAL GROWTH-FACTOR; CANCER-PATIENTS; PERIPHERAL-BLOOD; CD34(+)
CELLS; DENDRITIC CELLS; VITAMIN-D; IMMUNITY; DIFFERENTIATION;
CARCINOGENESIS; IMMUNOTHERAPY
AB Prior studies showing that treatment of head and neck squamous cell carcinoma (HNSCC) patients with 1 alpha,25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3] stimulated intratumoral immune infiltration were extended to analysis of cytokine profiles in the periphery and in oral tissues. Most prominent was the disparity between cytokine levels in plasma and in either pathologically normal oral tissue or HNSCC tissue from patients that were untreated or treated with 1,25(OH)(2)D-3. Levels of IL-6 and IL-10, but not IL-2, IFN-gamma or TNF-alpha, tended to be increased in the plasma of HNSCC patients and 1,25(OH)(2)D-3 further increased plasma levels of all of these cytokines. While these cytokines tended to be increased in HNSCC tissue, 1,25(OH)(2)D-3 resulted in variable cytokine responses that showed a general tendency toward further increased levels. Levels of IL-8 and VEGF were increased in plasma and tissue of untreated HNSCC patients, and were further increased in plasma, but not in tissues, of patients treated with 1,25(OH)(2)D-3. Levels of IL-1 alpha and IL-1 beta were similar in plasma of controls and HNSCC patients, but were increased in HNSCC tissues. In contrast to that seen in plasma where 1,25(OH)(2)D-3 increased levels of IL-1 alpha and IL-1 beta, this was not seen in tissue following 1,25(OH)(2)D-3 treatment. These results show a discordant relationship between systemic and intratumoral cytokine profiles and suggest a tendency of 1,25(OH)(2)D(3)to increase a multitude of cytokines within tumor tissue. Published by Elsevier Ltd.
C1 [Walker, David D.; Reeves, Travis D.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.
[de Costa, Anna-Maria] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC USA.
Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC USA.
[Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC USA.
RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, 109 Bee St, Charleston, SC 29401 USA.
EM david.walker4@gmail.com; reevestd@musc.edu; clarkann@musc.edu;
schuylec@musc.edu; rita.young@va.gov
FU Biomedical Laboratory and Clinical Sciences of the Department of
Veterans Affairs; National Institute of Health [I01-CX000100,
R01-CA128837, R01-DE018268]
FX This work has been supported by awards from the Biomedical Laboratory
and Clinical Sciences Programs of the Department of Veterans Affairs and
by grants from the National Institute of Health (MRIY, I01-CX000100,
R01-CA128837 and R01-DE018268).
NR 28
TC 7
Z9 7
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
J9 CYTOKINE
JI Cytokine
PD JUN
PY 2012
VL 58
IS 3
BP 448
EP 454
DI 10.1016/j.cyto.2012.03.002
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 941FA
UT WOS:000303947900020
PM 22450225
ER
PT J
AU Rose, DE
Tisnado, DM
Tao, ML
Malin, JL
Adams, JL
Ganz, PA
Kahn, KL
AF Rose, Danielle E.
Tisnado, Diana M.
Tao, May L.
Malin, Jennifer L.
Adams, John L.
Ganz, Patricia A.
Kahn, Katherine L.
TI Prevalence, Predictors, and Patient Outcomes Associated with Physician
Co-management: Findings from the Los Angeles Women's Health Study
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Quality of care; physician practice style; physician co-management;
patient ratings of care; breast cancer care; provider network
restrictions
ID PRIMARY-CARE PHYSICIANS; BREAST-CANCER SURVIVORS; QUALITY-OF-CARE;
FINANCIAL INCENTIVES; SPECIALTY-CARE; SYSTEM; SATISFACTION; GENERALIST;
INTERFACE; PATTERNS
AB Background Physician co-management, representing joint participation in the planning, decision-making, and delivery of care, is often cited in association with coordination of care. Yet little is known about how physicians manage tasks and how their management style impacts patient outcomes. Objectives To describe physician practice style using breast cancer as a model. We characterize correlates and predictors of physician practice style for 10 clinical tasks, and then test for associations between physician practice style and patient ratings of care. Methods We queried 347 breast cancer physicians identified by a population-based cohort of women with incident breast cancer regarding care using a clinical vignette about a hypothetical 65-year-old diabetic woman with incident breast cancer. To test the association between physician practice style and patient outcomes, we linked medical oncologists responses to patient ratings of care (physician n = 111; patient n = 411). Results After adjusting for physician and practice setting characteristics, physician practice style varied by physician specialty, practice setting, financial incentives, and barriers to referrals. Patients with medical oncologists who co-managed tasks had higher patient ratings of care. Conclusion Physician practice style for breast cancer is influenced by provider and practice setting characteristics, and it is an important predictor of patient ratings. We identify physician and practice setting factors associated with physician practice style and found associations between physician co-management and patient outcomes (e.g., patient ratings of care).
C1 [Rose, Danielle E.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, Sepulveda, CA 91343 USA.
[Tisnado, Diana M.; Kahn, Katherine L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Tao, May L.] Ctr Radiat Therapy Beverly Hills, Beverly Hills, CA USA.
[Adams, John L.] RAND Corp, Santa Monica, CA USA.
[Ganz, Patricia A.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Publ Hlth, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA.
RP Rose, DE (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Provider Behav, 16111 Plummer St 152, Sepulveda, CA 91343 USA.
EM droseash@gmail.com
FU California Breast Cancer Research program [7PB-0126S]; National Cancer
Institute; Agency for Health Care Research and Quality
[1-R01-CA81338-01A1]; University of California, Los Angeles; Resource
Centers for Minority Aging Research Center for Health Improvement of
Minority Elderly (RCMAR/CHIME) under NIH/NIA [P30-AG021684]; UCLA;
National Cancer Institute [R25 CA087949]
FX This research was funded by the California Breast Cancer Research
program grant 7PB-0126S and the National Cancer Institute and the Agency
for Health Care Research and Quality grant 1-R01-CA81338-01A1. Dr.
Tisnado received support from the University of California, Los Angeles,
Resource Centers for Minority Aging Research Center for Health
Improvement of Minority Elderly (RCMAR/CHIME) under NIH/NIA Grant
P30-AG021684, and the content does not necessarily represent the
official views of the NIA or the NIH. Dr. Rose received support from the
UCLA Cancer Education and Career Development Program, National Cancer
Institute grant R25 CA087949. We thank the two anonymous referees for
suggestions that significantly strengthened the analyses. We acknowledge
Diane Fitzpatrick and Ann Zisser for their data collection efforts
(under supervision); Fang Ashlee Hu for programming and data management,
and Judith Magee for administrative support. The views expressed in this
article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs or the United
States government.
NR 47
TC 4
Z9 4
U1 2
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2012
VL 47
IS 3
BP 1091
EP 1116
DI 10.1111/j.1475-6773.2011.01359.x
PN 1
PG 26
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 939HN
UT WOS:000303800200012
PM 22171977
ER
PT J
AU Chung, M
Newberry, SJ
Ansari, MT
Yu, WW
Wu, H
Lee, J
Suttorp, M
Gaylor, JM
Motala, A
Moher, D
Balk, EM
Shekelle, PG
AF Chung, Mei
Newberry, Sydne J.
Ansari, Mohammed T.
Yu, Winifred W.
Wu, Helen
Lee, Jounghee
Suttorp, Marika
Gaylor, James M.
Motala, Aneesa
Moher, David
Balk, Ethan M.
Shekelle, Paul G.
TI Two methods provide similar signals for the need to update systematic
reviews
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Review
DE Evidence-based methodology; Systematic reviews; Comparative
effectiveness reviews; Omega-3 fatty acids; Cardiovascular disease risk
factors; Cancer; Cognitive function
ID OMEGA-3-FATTY-ACIDS; GUIDELINES
AB Objective: Apply and compare two methods that identify signals for the need to update systematic reviews, using three Evidence-based Practice Center reports on omega-3 fatty acids as test cases.
Study Design and Setting: We applied the RAND method, which uses domain (subject matter) expert guidance, and a modified Ottawa method, which uses quantitative and qualitative signals. For both methods, we conducted focused electronic literature searches of recent studies using the key terms from the original reports. We assessed the agreement between the methods and qualitatively assessed the merits of each system.
Results: Agreement between the two methods was "substantial" or better (kappa > 0.62) in three of the four systematic reviews. Overall agreement between the methods was "substantial" (kappa = 0.64, 95% confidence interval [Cl] 0.45-0.83).
Conclusion: The RAND and modified Ottawa methods appear to provide similar signals for the possible need to update systematic reviews in this pilot study. Future evaluation with a broader range of clinical topics and eventual comparisons between signals to update reports and the results of full evidence review updates will be needed. We propose a hybrid approach combining the best features of both methods, which should allow efficient review and assessment of the need to update. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Chung, Mei; Yu, Winifred W.; Lee, Jounghee; Gaylor, James M.; Balk, Ethan M.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Tufts Evidence Based Practice Ctr, Boston, MA 02111 USA.
[Newberry, Sydne J.; Wu, Helen; Suttorp, Marika; Motala, Aneesa; Shekelle, Paul G.] So Calif Evidence Based Practice Ctr, RAND Hlth, Santa Monica, CA USA.
[Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Ansari, Mohammed T.; Moher, David] Univ Ottawa, Evidence Based Practice Ctr, Ottawa Methods Ctr, Clin Epidemiol Program,Ottawa Hosp Res Inst, Ottawa, ON, Canada.
RP Chung, M (reprint author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Tufts Evidence Based Practice Ctr, Box 63,800 Washington St, Boston, MA 02111 USA.
EM mchung1@tuftsmedicalcenter.org
OI , /0000-0002-6834-7583; Wu, Helen/0000-0001-7775-5282; Moher , David
/0000-0003-2434-4206
FU NHLBI NIH HHS [T32 HL069772]
NR 16
TC 14
Z9 14
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD JUN
PY 2012
VL 65
IS 6
BP 660
EP 668
DI 10.1016/j.jclinepi.2011.12.004
PG 9
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 940PA
UT WOS:000303904300011
PM 22464414
ER
PT J
AU Kopp, RP
Stroup, SP
Schroeck, FR
Freedland, SJ
Millard, F
Terris, MK
Aronson, WJ
Presti, JC
Amling, CL
Kane, CJ
AF Kopp, Ryan P.
Stroup, Sean P.
Schroeck, Florian R.
Freedland, Stephen J.
Millard, Frederick
Terris, Martha K.
Aronson, William J.
Presti, Joseph C., Jr.
Amling, Christopher L.
Kane, Christopher J.
TI Are Repeat Prostate Biopsies Safe? A Cohort Analysis From the SEARCH
Database
SO JOURNAL OF UROLOGY
LA English
DT Article
DE biopsy; prostatic neoplasms; prostatectomy; recurrence; diagnosis
ID INTRAEPITHELIAL NEOPLASIA; NEEDLE BIOPSIES; HIGH-GRADE; CANCER;
PROPHYLAXIS; INFECTION; TRENDS; MEN
AB Purpose: Patients question whether multiple biopsy sessions cause worse prostate cancer outcomes. Therefore, we investigated whether there is an association between the number of prior biopsy sessions and biochemical recurrence after radical prostatectomy.
Materials and Methods: Men in the SEARCH (Shared Equal Access Regional Cancer Hospital) database who underwent radical prostatectomy between 1988 and 2010 after a known number of prior biopsies were included in the analysis. Number of biopsy sessions (range 1 to 8) was examined as a continuous and categorical (1, 2 and 3 to 8) variable. Biochemical recurrence was defined as a prostate specific antigen greater than 0.2 ng/ml, 2 values at 0.2 ng/ml or secondary treatment for an increased prostate specific antigen. The association between number of prior biopsy sessions and biochemical recurrence was analyzed using the Cox proportional hazards model. Kaplan-Meier estimates of freedom from biochemical recurrence were compared among the groups.
Results: Of the 2,739 men in the SEARCH database who met the inclusion criteria 2,251 (82%) had only 1 biopsy, 365(13%) had 2 biopsies and 123 (5%) had 3 or more biopsies. More biopsy sessions were associated with higher prostate specific antigen (p < 0.001), greater prostate weight (p < 0.001), lower biopsy Gleason sum (p = 0.01) and more organ confined (pT2) disease (p = 0.017). The Cox proportional hazards model demonstrated no association between number of biopsy sessions as a continuous or categorical variable and biochemical recurrence. Kaplan-Meier estimates of freedom from biochemical recurrence were similar across biopsy groups (log rank p = 0.211).
Conclusions: Multiple biopsy sessions are not associated with an increased risk of biochemical recurrence in men undergoing radical prostatectomy. Multiple biopsy sessions appear to select for a low risk cohort.
C1 [Kopp, Ryan P.; Stroup, Sean P.; Kane, Christopher J.] Univ Calif San Diego, Div Urol, San Diego, CA 92103 USA.
[Stroup, Sean P.; Millard, Frederick; Kane, Christopher J.] Moores UCSD Canc Ctr, Sect Urol Oncol, La Jolla, CA USA.
[Stroup, Sean P.; Kane, Christopher J.] Vet Affairs San Diego Med Ctr, Urol Sect, La Jolla, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA.
[Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, Joseph C., Jr.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA.
[Schroeck, Florian R.; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC USA.
[Freedland, Stephen J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
[Freedland, Stephen J.] Duke Univ, Sch Med, Duke Prostate Ctr, Durham, NC USA.
[Freedland, Stephen J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA.
[Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA.
RP Kane, CJ (reprint author), Univ Calif San Diego, Div Urol, 200 W Arbor Dr,8897, San Diego, CA 92103 USA.
EM ckane@ucsd.edu
OI Terris, Martha/0000-0002-3843-7270; Schroeck,
Florian/0000-0002-1860-2611
FU Department of Veterans Affairs; Department of Defense; Prostate Cancer
Research Program; NIH [R01CA100938, P50 CA92131-01A1]; Georgia Cancer
Coalition; American Urological Association Foundation
FX Supported by the Department of Veterans Affairs, the Department of
Defense, Prostate Cancer Research Program (SJF), NIH R01CA100938 (WJA),
NIH Specialized Programs of Research Excellence Grant P50 CA92131-01A1
(WJA), Georgia Cancer Coalition (MKT) and the American Urological
Association Foundation/Astellas Rising Star in Urology Award (SJF).
Views and opinions of and endorsements by the author(s) do not reflect
those of the U.S. Army, U.S. Navy or the Department of Defense.
NR 18
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD JUN
PY 2012
VL 187
IS 6
BP 2056
EP 2060
DI 10.1016/j.juro.2012.01.083
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 939OK
UT WOS:000303821300033
PM 22498218
ER
PT J
AU Hung, WW
Ross, JS
Boockvar, KS
Siu, AL
AF Hung, William W.
Ross, Joseph S.
Boockvar, Kenneth S.
Siu, Albert L.
TI Association of Chronic Diseases and Impairments With Disability in Older
Adults A Decade of Change?
SO MEDICAL CARE
LA English
DT Article
DE chronic disease; impairment; disability; prevalence trends
ID VISUAL FUNCTION QUESTIONNAIRE; LATE-LIFE DISABILITY; COGNITIVE
IMPAIRMENT; FUNCTIONAL DISABILITY; DIABETES-MELLITUS; WOMENS HEALTH;
UNITED-STATES; POPULATION; RETIREMENT; TRENDS
AB Background: Little is known about how the relationship between chronic disease, impairment, and disability has changed over time among older adults.
Objective: To examine how the associations of chronic disease and impairment with specific disability have changed over time.
Research Design: Repeated cross-sectional analysis, followed by examining the collated sample using time interaction variables, of 3 recent waves of the Health and Retirement Study.
Subjects: The subjects included 10,390, 10,621 and 10,557 community-dwelling adults aged 65 years and above in 1998, 2004, and 2008.
Measurements: Survey-based history of chronic diseases including hypertension, heart disease, heart failure, stroke, diabetes, cancer, chronic lung disease, and arthritis; impairments, including cognition, vision, and hearing; and disability, including mobility, complex activities of daily living (ADL), and self-care ADL.
Results: Over time, the relationship of chronic diseases and impairments with disability was largely unchanged; however, the association between hypertension and complex ADL disability weakened from 1998 to 2004 and 2008 [odds ratio (OR) = 1.24; 99% confidence interval (CI), 1.06-1.46; OR = 1.07; 99% CI, 0.90-1.27; OR = 1.00; 99% CI, 0.83-1.19, respectively], as it did for hypertension and self-care disability (OR = 1.32; 99% CI, 1.13-1.54; OR= 0.97; 99% CI, 0.82-1.14; OR = 0.99; 99% CI, 0.83-1.17). The association between diabetes and self-care disability strengthened from 1998 to 2004 and 2008 (OR = 1.21; 99% CI, 1.01-1.46; OR = 1.37; 99% CI, 1.15-1.64; OR = 1.52; 99% CI, 1.29-1.79), as it also did for lung disease and self-care disability (OR = 1.64; 99% CI, 1.33-2.03; OR = 1.63; 99% CI, 1.32-2.01; OR = 2.11; 99% CI, 1.73-2.57).
Conclusions: Although relationships between diseases, impairments, and disability were largely unchanged, disability became less associated with hypertension and more with diabetes and lung disease.
C1 [Hung, William W.; Boockvar, Kenneth S.; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Hung, William W.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA.
[Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
[Boockvar, Kenneth S.] Jewish Home Lifecare, New York, NY USA.
[Hung, William W.; Boockvar, Kenneth S.; Siu, Albert L.] James J Peters VA Hlth Serv Res & Dev Res Enhance, Bronx, NY USA.
RP Hung, WW (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM william.hung@mssm.edu
OI Boockvar, Kenneth/0000-0003-1165-5558
FU John A Hartford Foundation Center of Excellence; New York Academy of
Medicine; National Institute on Aging [K08 AG032886, U01AG009740];
American Federation of Aging Research; Greenwall Foundation
FX W.W.H. is a John A Hartford Foundation Center of Excellence Scholar and
a New York Academy of Medicine Hoar Fellow. J.S.R. is currently
supported by the National Institute on Aging (K08 AG032886) and by the
American Federation of Aging Research through the Paul B. Beeson Career
Development Award Program. K. S. B. is supported by the Greenwall
Foundation. The Health and Retirement Study is sponsored by the National
Institute on Aging (grant number U01AG009740) and conducted by the
Institute for Social Research at the University of Michigan.
NR 35
TC 20
Z9 22
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUN
PY 2012
VL 50
IS 6
BP 501
EP 507
DI 10.1097/MLR.0b013e318245a0e0
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 941ST
UT WOS:000303985900006
PM 22584885
ER
PT J
AU Okunseri, C
Okunseri, E
Thorpe, JM
Xiang, Q
Szabo, A
AF Okunseri, Christopher
Okunseri, Elaye
Thorpe, Joshua M.
Xiang, Qun
Szabo, Aniko
TI Medications Prescribed in Emergency Departments for Nontraumatic Dental
Condition Visits in the United States
SO MEDICAL CARE
LA English
DT Article
DE dental care; dental service utilization; emergency service; medications
ID ETHNIC DISPARITIES; CARE; ANALGESIA; PAIN; MANAGEMENT; PATIENT
AB Background: Prior research has documented factors associated with nontraumatic dental condition (NTDC) visits to emergency departments (EDs), but little is known about the care received by patients in EDs for NTDC visits.
Objective: We examined national trends in prescription of analgesics and antibiotics in EDs for NTDC visits in the United States.
Research Design: We analyzed data from the National Hospital Ambulatory Medical Care survey from 1997 to 2007. We used a multivariable logistic regression model to examine factors associated with receiving analgesics and antibiotics for NTDC visits in EDs.
Results: Overall 74% received at least 1 analgesic, 56% received at least 1 antibiotic, and 13% received no medication at all during NTDC visits to EDs. The prescription of medications at EDs for NTDC visits steadily increased over time for analgesics (odds ratio = 1.11/y, P < 0.0001) and antibiotics (odds ratio = 1.06/y,P < 0.0001). In the multivariable analysis, self-pay patients had significantly higher adjusted odds of receiving antibiotics, whereas those with nondental reasons for visits and children (0-4 y) had significantly lower adjusted odds of receiving a prescription for antibiotics in EDs for NTDC visits. Children (0-4 y), adults (53-72 y), and older adults (73 y and older) had lower adjusted odds (P < 0.001) of receiving analgesics.
Conclusions: Nationally, analgesic and antibiotic prescriptions for NTDC visits to EDs have increased substantially over time. Selfpay patients had significantly higher odds of being prescribed antibiotics. Adults over 53 years and especially those 73 years and older had significantly lower odds of receiving analgesics in EDs for NTDC visits.
C1 [Okunseri, Christopher; Okunseri, Elaye] Marquette Univ, Dept Clin Serv, Sch Dent, Milwaukee, WI 53201 USA.
[Thorpe, Joshua M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Thorpe, Joshua M.] Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Xiang, Qun; Szabo, Aniko] Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA.
RP Okunseri, C (reprint author), Marquette Univ, Dept Clin Serv, Sch Dent, Room 356,POB 1881, Milwaukee, WI 53201 USA.
EM christopher.okunseri@mu.edu
RI Szabo, Aniko/F-9656-2012; Thorpe, Joshua/C-1188-2013
FU National Institute of Health [1R15DE021196-01]
FX Supported by the National Institute of Health Grant #1R15DE021196-01.
The authors declare no conflict of interest.
NR 25
TC 19
Z9 19
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD JUN
PY 2012
VL 50
IS 6
BP 508
EP 512
DI 10.1097/MLR.0b013e318245a575
PG 5
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 941ST
UT WOS:000303985900007
PM 22584886
ER
PT J
AU Genta, RM
Sonnenberg, A
AF Genta, R. M.
Sonnenberg, A.
TI Non-Helicobacter pylori gastritis is common among paediatric patients
with inflammatory bowel disease
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID FOCALLY ENHANCED GASTRITIS; CROHNS-DISEASE; ULCERATIVE-COLITIS;
PEPTIC-ULCER; INFECTION; MORTALITY; BIOPSIES; DUODENUM
AB Background
Helicobacter-negative gastritis and duodenitis occur more often in patients with inflammatory bowel disease (IBD) than in non-IBD controls. Preliminary evidence suggests that they are particularly common among children.
Aim
To study the age-specific occurrence of gastritis and duodenitis among paediatric IBD patients.
Methods
From a computerised database of surgical pathology reports, we selected 344 IBD patients and 4241 non-IBD controls between the age 0 and 21 years, who underwent colonoscopy and oesophago-gastro-duodenoscopy with biopsy results from both procedures.
Results
Helicobacter-negative chronic active gastritis was found in 2% of controls and 20% of IBD patients (Crohn's disease (CD) 26%, ulcerative colitis (UC) 13%). Duodenitis was found in 2% of controls and 17% of IBD patients (Crohn's disease 28%, UC 8%). Similar prevalence rates were observed in male and female patients. The most striking age-specific patterns were seen in Crohn's disease, with chronic active gastritis being highest in the 59 years age-group and declining in all subsequent age-groups. The age-specific rise and fall of duodenitis appeared more protracted, reaching a peak at age 1014 years and then gradually declining.
Conclusions
Helicobacter-negative gastritis and duodenitis occur significantly more often in paediatric IBD patients than in non-IBD controls, as well as in adult IBD patients. Such upper gastrointestinal inflammation appears to be particularly common in patients with Crohn's disease.
C1 [Genta, R. M.] Miraca Life Sci, Irving, TX USA.
[Genta, R. M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Genta, R. M.] Dallas VA Med Ctr, Dallas, TX USA.
[Sonnenberg, A.] Portland VA Med Ctr, Portland, OR USA.
[Sonnenberg, A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr P3 GI, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
FU Takeda Pharmaceuticals
FX Declaration of personal interests: Robert M. Genta is employed by Miraca
Life Sciences, Irving, TX, USA. Amnon Sonnenberg is supported by a grant
from Takeda Pharmaceuticals.
NR 22
TC 12
Z9 13
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0269-2813
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD JUN
PY 2012
VL 35
IS 11
BP 1310
EP 1316
DI 10.1111/j.1365-2036.2012.05090.x
PG 7
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA 934IF
UT WOS:000303437000007
PM 22486730
ER
PT J
AU Stephens, CE
Newcomer, R
Blegen, M
Miller, B
Harrington, C
AF Stephens, Caroline E.
Newcomer, Robert
Blegen, Mary
Miller, Bruce
Harrington, Charlene
TI Emergency Department Use by Nursing Home Residents: Effect of Severity
of Cognitive Impairment
SO GERONTOLOGIST
LA English
DT Article
DE cognitive impairment; nursing home; emergency department;
hospitalization; ambulatory care-sensitive condition
ID MINIMUM DATA SET; FACILITY RESIDENTS; TRANSITIONAL CARE; ADVANCED
DEMENTIA; AMBULATORY-CARE; OLDER-PEOPLE; HOSPITALIZATION; HEALTH;
DECISIONS; MDS
AB To examine the 1-year prevalence and risk of emergency department (ED) use and ambulatory care-sensitive (ACS) ED use by nursing home (NH) residents with different levels of severity of cognitive impairment (CI).
We used multinomial logistic regression to estimate the effect of CI severity on the odds of any ED visit and any ACS ED visit in a 2006 national random sample of NH residents, controlling for predisposing, enabling, and need characteristics.
Of 132,753 NH residents, 62% had at least one ED visit and approximately 24% had at least one ACS ED visit in 2006. The probability of any ED visit or any ACS ED visit varied with the severity of resident CI. Residents with mild CI had up to15% higher odds of any ED or any ACS ED visit and those with more moderate CI had 9% higher odds of an ACS ED visit compared with those without CI. The probability of any ED visit was negatively associated with advanced dementia (adjusted odds ratio = 0.60; 95% CI = 0.55-0.65).
Earlier identification of persons with mild CI may facilitate patient, family, and staff education, as well as advanced care planning to reduce ACS ED visits. Both ACS ED use and hospitalizations, adjusted for case mix, should be used as quality indicators to help ensure greater accountability for high-quality NH care and more appropriate utilization of ED resources.
C1 [Stephens, Caroline E.; Newcomer, Robert; Harrington, Charlene] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA.
[Stephens, Caroline E.] San Francisco VA Med Ctr, Div Geriatr Palliat & Extended Care, San Francisco, CA USA.
[Blegen, Mary] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Miller, Bruce] Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA 94143 USA.
RP Stephens, CE (reprint author), Univ Calif San Francisco, Dept Social & Behav Sci, 3333 Calif St,Suite 455, San Francisco, CA 94143 USA.
EM caroline.stephens@ucsf.edu
NR 42
TC 11
Z9 11
U1 1
U2 8
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD JUN
PY 2012
VL 52
IS 3
BP 383
EP 393
DI 10.1093/geront/gnr109
PG 11
WC Gerontology
SC Geriatrics & Gerontology
GA 936OM
UT WOS:000303599900009
PM 22056961
ER
PT J
AU Menschikowski, M
Hagelgans, A
Fuessel, S
Mareninova, OA
Neumeister, V
Wirth, MP
Siegert, G
AF Menschikowski, Mario
Hagelgans, Albert
Fuessel, Susanne
Mareninova, Olga A.
Neumeister, Volker
Wirth, Manfred P.
Siegert, Gabriele
TI Serum Levels of Secreted Group IIA Phospholipase A(2) in Benign
Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation
or Neoplasia?
SO INFLAMMATION
LA English
DT Article
DE prostate cancer; benign prostatic hyperplasia; secreted phospholipase
A(2); C-reactive protein; inflammation
ID C-REACTIVE PROTEIN; PROGNOSTIC MARKER; EXPRESSION; DISEASES; RISK;
ANTIGEN; INTERLEUKIN-6; ASSOCIATION; INCIDENT; ENZYMES
AB Secreted group IIA phospholipase A(2) (sPLA(2)-IIA) is markedly up-regulated in human prostate cancer (PCa) specimens and in some PCa-derived cell lines, indicating an important role of this enzyme in tumourigenesis. In this study, we measured levels of sPLA(2)-IIA, C-reactive protein (CRP), and prostate-specific antigen (PSA) in serum samples obtained from patients with benign prostatic hyperplasia (BPH) and with PCa of different stages. We found that serum levels of sPLA(2)-IIA and CRP in BPH and PCa patients were significantly elevated compared to those of healthy individuals, but the concentrations of these inflammatory biomarkers did not differ between patients with BPH or PCa. Furthermore, serum levels of sPLA(2)-IIA correlated with concentrations of CRP, but not with PSA, Gleason grade or tumour stage. In conclusion, these findings suggest that cancer-related changes are not exclusive factors contributing to elevated serum sPLA(2)-IIA levels and emphasize the utility of sPLA(2)-IIA as a circulating marker of inflammation in patients with BPH and PCa.
C1 [Menschikowski, Mario; Hagelgans, Albert; Neumeister, Volker; Siegert, Gabriele] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, D-01307 Dresden, Germany.
[Fuessel, Susanne; Wirth, Manfred P.] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dept Urol, D-01307 Dresden, Germany.
[Mareninova, Olga A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Menschikowski, M (reprint author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany.
EM Mario.Menschikowski@uniklinikum-dresden.de
NR 40
TC 9
Z9 9
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD JUN
PY 2012
VL 35
IS 3
BP 1113
EP 1118
DI 10.1007/s10753-011-9418-1
PG 6
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 933SI
UT WOS:000303382400041
PM 22189868
ER
PT J
AU So, K
Ganguly, K
Jimenez, J
Gastpar, MC
Carmena, JM
AF So, Kelvin
Ganguly, Karunesh
Jimenez, Jessica
Gastpar, Michael C.
Carmena, Jose M.
TI Redundant information encoding in primary motor cortex during natural
and prosthetic motor control
SO JOURNAL OF COMPUTATIONAL NEUROSCIENCE
LA English
DT Article
DE Mutual information; Neural ensemble; Motor control; Brain-machine
interface; Electrophysiology; Primary motor cortex
ID CORTICAL-NEURONS; POPULATION CODES; MOVEMENT DIRECTION; ARM MOVEMENTS;
DISCHARGE; SYNERGY; REORGANIZATION; INDEPENDENCE; INTERFACE
AB Redundant encoding of information facilitates reliable distributed information processing. To explore this hypothesis in the motor system, we applied concepts from information theory to quantify the redundancy of movement-related information encoded in the macaque primary motor cortex (M1) during natural and neuroprosthetic control. Two macaque monkeys were trained to perform a delay center-out reaching task controlling a computer cursor under natural arm movement (manual control, 'MC'), and using a brain-machine interface (BMI) via volitional control of neural ensemble activity (brain control, 'BC'). During MC, we found neurons in contralateral M1 to contain higher and more redundant information about target direction than ipsilateral M1 neurons, consistent with the laterality of movement control. During BC, we found that the M1 neurons directly incorporated into the BMI ('direct' neurons) contained the highest and most redundant target information compared to neurons that were not incorporated into the BMI ('indirect' neurons). This effect was even more significant when comparing to M1 neurons of the opposite hemisphere. Interestingly, when we retrained the BMI to use ipsilateral M1 activity, we found that these neurons were more redundant and contained higher information than contralateral M1 neurons, even though ensembles from this hemisphere were previously less redundant during natural arm movement. These results indicate that ensembles most associated to movement contain highest redundancy and information encoding, which suggests a role for redundancy in proficient natural and prosthetic motor control.
C1 [So, Kelvin; Jimenez, Jessica; Gastpar, Michael C.; Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Berkeley, CA 94720 USA.
[Ganguly, Karunesh] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Gastpar, Michael C.] Ecole Polytech Fed Lausanne, Sch Comp & Commun Sci, EPFL, Lausanne, Switzerland.
[Carmena, Jose M.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.
[Carmena, Jose M.] Univ Calif Berkeley, UCB UCSF Joint Grad Grp Bioengn, Berkeley, CA 94720 USA.
[Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA.
RP Carmena, JM (reprint author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, 754 Sutardja Dai Hall, Berkeley, CA 94720 USA.
EM carmena@eecs.berkeley.edu
FU National Science Foundation CDI; Department of Veterans Affairs,
Veterans Health Administration, Rehabilitation Research and Development;
American Heart Association/American Stroke Association
FX The research reported here was supported by the National Science
Foundation CDI Type-I grant to M.C.G. and J.M.C., and the Department of
Veterans Affairs, Veterans Health Administration, Rehabilitation
Research and Development, and the American Heart Association/American
Stroke Association to K.G.
NR 26
TC 4
Z9 4
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5313
J9 J COMPUT NEUROSCI
JI J. Comput. Neurosci.
PD JUN
PY 2012
VL 32
IS 3
BP 555
EP 561
DI 10.1007/s10827-011-0369-1
PG 7
WC Mathematical & Computational Biology; Neurosciences
SC Mathematical & Computational Biology; Neurosciences & Neurology
GA 936KO
UT WOS:000303589500011
PM 22042443
ER
PT J
AU Garrido, MM
Allison, KC
Bergeron, MJ
Dowd, B
AF Garrido, Melissa M.
Allison, Kirk C.
Bergeron, Mark J.
Dowd, Bryan
TI Hospital Religious Affiliation and Outcomes for High-Risk Infants
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE infant mortality; hospital ownership; religious affiliation
ID BIRTH-WEIGHT INFANTS; OF-LIFE; EMERGENCY CONTRACEPTION; MORTALITY-RATES;
INTENSIVE-CARE; NEONATAL CARE; UNITED-STATES; SERVICES; END; PROVISION
AB The effect of hospital organizational affiliation on perinatal outcomes is unknown. Using the 2004 American Hospital Association Annual Survey and Healthcare Cost and Utilization Project State Inpatient Databases, the authors examined relationships among organizational affiliation, equipment and service availability and provision, and in-hospital mortality for 5,133 infants across five states born with very low and extremely low birth weight and congenital anomalies. In adjusted bivariate probit selection models, the authors found that government hospitals had significantly higher mortality rates than not-for-profit nonreligious hospitals. Mortality differences among other types of affiliation (Catholic, not-for-profit religious, not-for-profit nonreligious, and for-profit) were not statistically significant. This is encouraging as health care reform efforts call for providers at facilities with different institutional values to coordinate care across facilities. Although there are anecdotes of facility religious affiliation being related to health care decisions, the authors did not find evidence of these relationships in their data.
C1 [Garrido, Melissa M.] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Garrido, Melissa M.] Mt Sinai Sch Med, New York, NY USA.
[Allison, Kirk C.; Dowd, Bryan] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA.
[Bergeron, Mark J.] Univ Minnesota, Sch Med, St Paul, MN 55108 USA.
RP Garrido, MM (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM melissa.garrido@mssm.edu
OI Garrido, Melissa/0000-0002-8986-3536
FU Wessner Foundation; MacLaurinCSF
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This grant
was supported in part by funding to Dr. Dowd from the Wessner Foundation
and MacLaurinCSF.
NR 52
TC 1
Z9 1
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD JUN
PY 2012
VL 69
IS 3
BP 316
EP 338
DI 10.1177/1077558711432156
PG 23
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 933YB
UT WOS:000303401900004
PM 22203647
ER
PT J
AU Kahn, JM
Werner, RM
Carson, SS
Iwashyna, TJ
AF Kahn, Jeremy M.
Werner, Rachel M.
Carson, Shannon S.
Iwashyna, Theodore J.
TI Variation in Long-Term Acute Care Hospital Use After Intensive Care
SO MEDICAL CARE RESEARCH AND REVIEW
LA English
DT Article
DE mechanical ventilation; intensive care; long-term acute care; post-acute
care utilization; practice variation
ID PROLONGED MECHANICAL VENTILATION; MEDICARE; OUTCOMES; ILLNESS; TRIAL;
UNITS
AB Long-term acute care hospitals (LTACs) are an increasingly common discharge destination for patients recovering from intensive care. In this article the authors use U.S. Medicare claims data to examine regional- and hospital-level variation in LTAC utilization after intensive care to determine factors associated with their use. Using hierarchical regression models to control for patient characteristics, this study found wide variation in LTAC utilization across hospitals, even controlling for LTAC access within a region. Several hospital characteristics were independently associated with increasing LTAC utilization, including increasing hospital size, for-profit ownership, academic teaching status, and colocation of the LTAC within an acute care hospital. These findings highlight the need for research into LTAC admission criteria and the incentives driving variation in LTAC utilization across hospitals.
C1 [Kahn, Jeremy M.] Univ Pittsburgh, Dept Crit Med, Sch Med, Pittsburgh, PA 15261 USA.
[Kahn, Jeremy M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Carson, Shannon S.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Iwashyna, Theodore J.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
RP Kahn, JM (reprint author), Univ Pittsburgh, Dept Crit Med, Sch Med, Scaife Hall,Room 602-B,3550 Terrace St, Pittsburgh, PA 15261 USA.
EM kahnjm@upmc.edu
OI Iwashyna, Theodore/0000-0002-4226-9310
FU United States National Institutes of Health [R01HL096651]
FX This work was funded by the United States National Institutes of Health
(R01HL096651).
NR 20
TC 17
Z9 18
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1077-5587
J9 MED CARE RES REV
JI Med. Care Res. Rev.
PD JUN
PY 2012
VL 69
IS 3
BP 339
EP 350
DI 10.1177/1077558711432889
PG 12
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 933YB
UT WOS:000303401900005
PM 22311957
ER
PT J
AU Bartzokis, G
AF Bartzokis, George
TI Neuroglialpharmacology: Myelination as a shared mechanism of action of
psychotropic treatments
SO NEUROPHARMACOLOGY
LA English
DT Review
DE White matter; Oligodendrocyte; Intracortical myelin; Medication; MRI;
NG2 cells; Neuregulin; ErbB; DISC1; IGF1; Reelin; Cdk; MAPK; mTOR;
Leptin
ID GROWTH-FACTOR-I; CENTRAL-NERVOUS-SYSTEM; GLYCOGEN-SYNTHASE KINASE-3;
WHITE-MATTER ABNORMALITIES; ACTIVATED PROTEIN-KINASE; NICOTINIC
ACETYLCHOLINE-RECEPTOR; OLIGODENDROCYTE PROGENITOR CELLS; DORSOLATERAL
PREFRONTAL CORTEX; SEIZURES INDUCE PROLIFERATION; NG2-EXPRESSING
GLIAL-CELLS
AB Current psychiatric diagnostic schema segregate symptom clusters into discrete entities, however, large proportions of patients suffer from comorbid conditions that fit neither diagnostic nor therapeutic schema. Similarly, psychotropic treatments ranging from lithium and antipsychotics to serotonin reuptake inhibitors (SSRIs) and acetylcholinesterase inhibitors have been shown to be efficacious in a wide spectrum of psychiatric disorders ranging from autism, schizophrenia (SZ), depression, and bipolar disorder (BD) to Alzheimer's disease (AD). This apparent lack of specificity suggests that psychiatric symptoms as well as treatments may share aspects of pathophysiology and mechanisms of action that defy current symptom-based diagnostic and neuron-based therapeutic schema.
A myelin-centered model of human brain function can help integrate these incongruities and provide novel insights into disease etiologies and treatment mechanisms. Available data are integrated herein to suggest that widely used psychotropic treatments ranging from antipsychotics and antidepressants to lithium and electroconvulsive therapy share complex signaling pathways such as Akt and glycogen synthase kinase-3 (GSK3) that affect myelination, its plasticity, and repair. These signaling pathways respond to neurotransmitters, neurotrophins, hormones, and nutrition, underlie intricate neuroglial communications, and may substantially contribute to the mechanisms of action and wide spectra of efficacy of current therapeutics by promoting myelination. Imaging and genetic technologies make it possible to safely and non-invasively test these hypotheses directly in humans and can help guide clinical trial efforts designed to correct myelination abnormalities. Such efforts may provide insights into novel avenues for treatment and prevention of some of the most prevalent and devastating human diseases. Published by Elsevier Ltd.
C1 [Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Los Angeles, CA 90095 USA.
[Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Div Brain Mapping, Lab Neuroimaging,Dept Neurol, Los Angeles, CA 90095 USA.
[Bartzokis, George] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA.
[Bartzokis, George] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA.
RP Bartzokis, G (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA.
EM gbar@ucla.edu
RI Bartzokis, George/K-2409-2013
FU Pfizer; Janssen; Novartis; NIH [MH066029, AG027342]; Research and
Psychiatry Services of the Department of Veterans Affairs; RCS
Foundation
FX George Bartzokis has consulted for and received research funding from
Pfizer, Janssen, and Novartis, and consulted for Bristol-Myers Squibb
Company.; This work was supported in part by NIH grants (MH066029;
AG027342), Research and Psychiatry Services of the Department of
Veterans Affairs, and the RCS Foundation. The author thanks Lori L
Altshuler, M.D., and Keith H. Nuechterlein, Ph.D. for reading the
manuscript and providing helpful suggestions.
NR 271
TC 47
Z9 48
U1 2
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD JUN
PY 2012
VL 62
IS 7
BP 2137
EP 2153
DI 10.1016/j.neuropharm.2012.01.015
PG 17
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 931MG
UT WOS:000303223400001
PM 22306524
ER
PT J
AU Shabani, S
Dobbs, LK
Ford, MM
Mark, GP
Finn, DA
Phillips, TJ
AF Shabani, Shkelzen
Dobbs, Lauren K.
Ford, Matthew M.
Mark, Gregory P.
Finn, Deborah A.
Phillips, Tamara J.
TI A genetic animal model of differential sensitivity to methamphetamine
reinforcement
SO NEUROPHARMACOLOGY
LA English
DT Article
DE Methamphetamine; Addiction; Oral self-administration; Reinforcement;
Appetitive; Aversive
ID RECOMBINANT INBRED MICE; C57BL/6J MICE; D-AMPHETAMINE; BEHAVIORAL
SENSITIZATION; ETHANOL SEEKING; NATURAL REWARDS; DRUG; RATS; ALCOHOL;
COCAINE
AB Sensitivity to reinforcement from methamphetamine (MA) likely influences risk for MA addiction, and genetic differences are one source of individual variation. Generation of two sets of selectively bred mouse lines for high and low MA drinking has shown that genetic factors influence MA intake, and pronounced differences in sensitivity to rewarding and aversive effects of MA play a significant role. Further validation of these lines as a unique genetic model relevant to MA addiction was obtained using operant methods to study MA reinforcement High and low MA drinking line mice were used to test the hypotheses that: 1) oral and intracerebroventricular (ICV) MA serve as behavioral reinforcers, and 2) MA exhibits greater reinforcing efficacy in high than low MA drinking mice. Operant responses resulted in access to an MA or non-MA drinking tube or intracranial delivery of MA. Behavioral activation consequent to orally consumed MA was determined. MA available for consumption maintained higher levels of reinforced instrumental responding in high than low MA drinking line mice, and MA intake in the oral operant procedure was greater in high than low MA drinking line mice. Behavioral activation was associated with amount of MA consumed during operant sessions. High line mice delivered more MA via ICV infusion than did low line mice across a range of doses. Thus, genetic risk factors play a critical role in the reinforcing efficacy of MA and the oral self-administration procedure is suitable for delineating genetic contributions to MA reinforcement. Published by Elsevier Ltd.
C1 [Shabani, Shkelzen; Dobbs, Lauren K.; Ford, Matthew M.; Mark, Gregory P.; Finn, Deborah A.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
[Shabani, Shkelzen; Dobbs, Lauren K.; Ford, Matthew M.; Mark, Gregory P.; Finn, Deborah A.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA.
[Finn, Deborah A.; Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Phillips, TJ (reprint author), Portland VA Med Ctr VAMC, R&D 32,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM shabanis@scripps.edu; dobbsl@ohsu.edu; fordma@ohsu.edu; markg@ohsu.edu;
finnd@ohsu.edu; phillipt@ohsu.edu
OI Ford, Matthew/0000-0002-1204-1980
FU Department of Veterans Affairs; NIDA [T32 DA07262]; NIDA Center [P50
DA018165]; NIAAA [K01 AA016849]
FX We thank Andrew Fredericks and Becca Rieger for their help collecting
oral operant self-administration data. We also thank Tammie Painter,
Marcia Ramaker and Nathan Klett for their help with ICV data collection.
This work was supported by the Department of Veterans Affairs, NIDA T32
DA07262, and NIDA Center grant P50 DA018165. In addition, NIAAA K01
AA016849 provided some salary support. The oral operant
self-administration and locomotor activity studies were in part
supported with resources and the use of facilities at the Portland VA
Medical Center.
NR 54
TC 14
Z9 15
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD JUN
PY 2012
VL 62
IS 7
BP 2169
EP 2177
DI 10.1016/j.neuropharm.2012.01.002
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 931MG
UT WOS:000303223400003
PM 22280875
ER
PT J
AU Forman, EM
Chapman, JE
Herbert, JD
Goetter, EM
Yuen, EK
Moitra, E
AF Forman, Evan M.
Chapman, Jason E.
Herbert, James D.
Goetter, Elizabeth M.
Yuen, Erica K.
Moitra, Ethan
TI Using Session-by-Session Measurement to Compare Mechanisms of Action for
Acceptance and Commitment Therapy and Cognitive Therapy
SO BEHAVIOR THERAPY
LA English
DT Article
DE ACT; CBT; psychotherapy mechanisms; mediation
ID BEHAVIORAL TREATMENT; CONFIDENCE-LIMITS; CONTROLLED TRIAL; DEPRESSION;
ANXIETY; MEDIATION; PREVENT; RELAPSE; QUESTIONNAIRE; RELIABILITY
AB Debate continues about the extent to which postulated mechanisms of action of cognitive behavior therapies (CBT), including standard CBT (i.e., Beckian cognitive therapy [CT]) and acceptance and commitment therapy (ACT) are supported by mediational analyses. Moreover, the distinctiveness of CT and ACT has been called into question. One contributor to ongoing uncertainty in this arena is the lack of time-varying process data. In this study, 174 patients presenting to a university clinic with anxiety or depression who had been randomly assigned to receive either ACT or CT completed an assessment of theorized mediators and outcomes before each session. Hierarchical linear modeling of session-by-session data revealed that increased utilization of cognitive and affective change strategies relative to utilization of psychological acceptance strategies mediated outcome for CT, whereas for ACT the mediation effect was in the opposite direction. Decreases in self-reported dysfunctional thinking, cognitive "defusion" (the ability to see one's thoughts as mental events rather than necessarily as representations of reality), and willingness to engage in behavioral activity despite unpleasant thoughts or emotions were equivalent mediators across treatments. These results have potential implications for the theoretical arguments behind, and distinctiveness of, CT and ACT.
C1 [Forman, Evan M.] Drexel Univ, Dept Psychol, Philadelphia, PA 19102 USA.
[Yuen, Erica K.] Med Univ S Carolina, Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
[Moitra, Ethan] Brown Univ, Providence, RI 02912 USA.
RP Forman, EM (reprint author), Drexel Univ, Dept Psychol, 245 N 15th St,MS 626, Philadelphia, PA 19102 USA.
EM evan.forman@drexel.edu
RI Forman, Evan/I-1042-2012
NR 61
TC 36
Z9 36
U1 6
U2 43
PU ASSOC ADV BEHAVIOR THERAPY
PI NEW YORK
PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA
SN 0005-7894
J9 BEHAV THER
JI Behav. Therapy
PD JUN
PY 2012
VL 43
IS 2
BP 341
EP 354
PG 14
WC Psychology, Clinical
SC Psychology
GA 920GZ
UT WOS:000302393600010
PM 22440070
ER
PT J
AU Seyedali, M
Czerniecki, JM
Morgenroth, DC
Hahn, ME
AF Seyedali, Mahyo
Czerniecki, Joseph M.
Morgenroth, David C.
Hahn, Michael E.
TI Co-contraction patterns of trans-tibial amputee ankle and knee
musculature during gait
SO JOURNAL OF NEUROENGINEERING AND REHABILITATION
LA English
DT Article
DE Electromyography; Myoelectric control; Trans-tibial amputees; Activation
patterns; Muscle amplitude
ID MUSCLE-ACTIVITY; WALKING SPEEDS; EMG PROFILES; CHILDREN; PROSTHESIS;
LOCOMOTION; INDEX; JOINT
AB Background: Myoelectric control of upper extremity powered prostheses has been used clinically for many years, however this approach has not been fully developed for lower extremity prosthetic devices. With the advent of powered lower extremity prosthetic components, the potential role of myoelectric control systems is of increasing importance. An understanding of muscle activation patterns and their relationship to functional ambulation is a vital step in the future development of myoelectric control. Unusual knee muscle co-contractions have been reported in both limbs of trans-tibial amputees. It is currently unknown what differences exist in co-contraction between trans-tibial amputees and controls. This study compares the activation and co-contraction patterns of the ankle and knee musculature of trans-tibial amputees (intact and residual limbs), and able-bodied control subjects during three speeds of gait. It was hypothesized that residual limbs would have greater ankle muscle co-contraction than intact and able-bodied control limbs and that knee muscle co-contraction would be different among all limbs. Lastly it was hypothesized that the extent of muscle co-contraction would increase with walking speed.
Methods: Nine unilateral traumatic trans-tibial amputees and five matched controls participated. Surface electromyography recorded activation from the Tibialis Anterior, Medial Gastrocnemius, Vastus Lateralis and Biceps Femoris of the residual, intact and control limbs. A series of filters were applied to the signal to obtain a linear envelope of the activation patterns. A co-contraction area (ratio of the integrated agonist and antagonist activity) was calculated during specific phases of gait.
Results: Co-contraction of the ankle muscles was greater in the residual limb than in the intact and control limbs during all phases of gait. Knee muscle co-contraction was greater in the residual limb than in the control limb during all phases of gait.
Conclusion: Co-contractions may represent a limb stiffening strategy to enhance stability during phases of initial foot-contact and single limb support. These strategies may be functionally necessary for amputee gait; however, the presence of co-contractions could confound future development of myoelectric controls and should thus be accounted for.
C1 [Seyedali, Mahyo; Czerniecki, Joseph M.; Morgenroth, David C.; Hahn, Michael E.] VA Puget Sound, Dept Vet Affairs VA, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Seattle, WA 98108 USA.
[Seyedali, Mahyo; Hahn, Michael E.] Univ Washington, Dept Mech Engn, Seattle, WA 98105 USA.
[Czerniecki, Joseph M.; Morgenroth, David C.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Hahn, ME (reprint author), VA Puget Sound, Dept Vet Affairs VA, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM mhahn@uoregon.edu
OI Morgenroth, David/0000-0002-0226-7775
FU Department of Veterans Affairs, Veterans Health Administration,
Rehabilitation Research and Development Service; Department of Defense
[W81XWH-09-2-0142]
FX This research was supported by the Department of Veterans Affairs,
Veterans Health Administration, Rehabilitation Research and Development
Service. Additionally, this research was funded by a Department of
Defense grant (W81XWH-09-2-0142). We gratefully acknowledge the
supporting efforts of Janice Pecoraro and Elise Wright.
NR 35
TC 5
Z9 5
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-0003
J9 J NEUROENG REHABIL
JI J. NeuroEng. Rehabil.
PD MAY 28
PY 2012
VL 9
AR 29
DI 10.1186/1743-0003-9-29
PG 9
WC Engineering, Biomedical; Neurosciences; Rehabilitation
SC Engineering; Neurosciences & Neurology; Rehabilitation
GA 026IJ
UT WOS:000310268300001
PM 22640660
ER
PT J
AU Grady, D
Katz, MH
Berkowitz, SA
AF Grady, Deborah
Katz, Mitchell H.
Berkowitz, Seth A.
TI A Role for Opioids in Chronic Pain Management reply
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA 94115 USA.
[Katz, Mitchell H.] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA.
RP Grady, D (reprint author), Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, 1635 Divisadero St,Ste 600, San Francisco, CA 94115 USA.
EM Deborah.Grady@ucsf.edu
NR 2
TC 0
Z9 0
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD MAY 28
PY 2012
VL 172
IS 10
BP 824
EP 825
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 948FK
UT WOS:000304488800019
ER
PT J
AU Gabbita, SP
Srivastava, MK
Eslami, P
Johnson, MF
Kobritz, NK
Tweedie, D
Greig, NH
Zemlan, FP
Sharma, SP
Harris-White, ME
AF Gabbita, S. Prasad
Srivastava, Minu K.
Eslami, Pirooz
Johnson, Ming F.
Kobritz, Naomi K.
Tweedie, David
Greig, Nigel H.
Zemlan, Frank P.
Sharma, Sherven P.
Harris-White, Marni E.
TI Early intervention with a small molecule inhibitor for tumor necrosis
factor-alpha prevents cognitive deficits in a triple transgenic mouse
model of Alzheimer's disease
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Alzheimer's disease; memory; neuroinflammation; thalidomide;
thiothalidomide; tumor necrosis factor-alpha
ID CENTRAL-NERVOUS-SYSTEM; BETA-AMYLOID STIMULATION; MARROW-DERIVED CELLS;
BLOOD-BRAIN-BARRIER; TNF-ALPHA; NEURODEGENERATIVE DISEASES; PERISPINAL
ETANERCEPT; SYNAPTIC PLASTICITY; HEMATOPOIETIC-CELLS; THERAPEUTIC TARGET
AB Background: Chronic neuroinflammation is an important component of Alzheimer's disease and could contribute to neuronal dysfunction, injury and loss that lead to disease progression. Multiple clinical studies implicate tumor necrosis factor-alpha as an inflammatory mediator of neurodegeneration in patients with Alzheimer's because of elevated levels of this cytokine in the cerebrospinal fluid, hippocampus and cortex. Current Alzheimer's disease interventions are symptomatic treatments with limited efficacy that do not address etiology. Thus, a critical need exists for novel treatments directed towards modifying the pathophysiology and progression.
Methods: To investigate the effect of early immune modulation on neuroinflammation and cognitive outcome, we treated triple transgenic Alzheimer's disease mice (harboring PS1(M146V), APP(Swe), and tau(P301L) transgenes) with the small molecule tumor necrosis factor-alpha inhibitors, 3,6'-dithiothalidomide and thalidomide, beginning at four months of age. At this young age, mice do not exhibit plaque or tau pathology but do show mild intraneuronal amyloid beta protein staining and a robust increase in tumor necrosis factor-alpha. After 10 weeks of treatment, cognitive performance was assessed using radial arm maze and neuroinflammation was assessed using biochemical, stereological and flow cytometric endpoints.
Results: 3,6'-dithiothalidomide reduced tumor necrosis factor-alpha mRNA and protein levels in the brain and improved working memory performance and the ratio of resting to reactive microglia in the hippocampus of triple transgenic mice.
In comparison to non-transgenic controls, triple transgenic Alzheimer's disease mice had increased total numbers of infiltrating peripheral monomyelocytic/granulocytic leukocytes with enhanced intracytoplasmic tumor necrosis factor-alpha, which was reduced after treatment with 3,6'-dithiothalidomide.
Conclusions: These results suggest that modulation of tumor necrosis factor-alpha with small molecule inhibitors is safe and effective with potential for the long-term prevention and treatment of Alzheimer's disease.
C1 [Srivastava, Minu K.; Eslami, Pirooz; Johnson, Ming F.; Kobritz, Naomi K.; Sharma, Sherven P.; Harris-White, Marni E.] Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Srivastava, Minu K.; Eslami, Pirooz; Johnson, Ming F.; Kobritz, Naomi K.; Sharma, Sherven P.; Harris-White, Marni E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA.
[Gabbita, S. Prasad; Zemlan, Frank P.] P2D Biosci, Cincinnati, OH 45242 USA.
[Tweedie, David; Greig, Nigel H.] NIA, NIH, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA.
RP Harris-White, ME (reprint author), Univ Calif Los Angeles, Vet Adm Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 151, Los Angeles, CA 90073 USA.
EM marni@ucla.edu
FU Veterans Administration; Michael J. Fox Foundation; Alzheimer's Drug
Discovery Foundation; Intramural Research Program of NIA, NIH
FX The authors would like to thank Dr. Russell Brown at Eastern Tennessee
State University for assistance with the design and analysis of the
Radial Arm Maze experiments, Dr. Louis Hersh at the University of
Kentucky for providing breeding pairs of 3 x Tg mice and Dr. Kenneth
Hensley at the University of Toledo for assistance with data
interpretation and critical scientific review of the manuscript. This
work was supported by Veterans Administration Merit Funding (MEHW and
SPS), Michael J. Fox Foundation (SPG), Alzheimer's Drug Discovery
Foundation (MEHW and SPG) and the Intramural Research Program of NIA,
NIH (DT and NHG).
NR 81
TC 26
Z9 27
U1 2
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD MAY 25
PY 2012
VL 9
AR 99
DI 10.1186/1742-2094-9-99
PG 16
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 976PV
UT WOS:000306597700001
PM 22632257
ER
PT J
AU Mathalon, DH
Ford, JM
AF Mathalon, Daniel H.
Ford, Judith M.
TI Neurobiology of schizophrenia: search for the elusive correlation with
symptoms
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE schizophrenia; positive symptoms; negative symptoms; neurobiology;
correlation; reliability; validity; rating scales
ID TRANSCRANIAL MAGNETIC STIMULATION; PSYCHIATRIC RATING-SCALE;
HEALTHY-VOLUNTEERS; WORKING-MEMORY; KETAMINE; DYSFUNCTION; NEGATIVITY;
ANTAGONIST; PSYCHOSIS; DEFICITS
AB In the last half-century, human neuro science methods provided a way to study schizophrenia in vivo, and established that it is associated with subtle abnormalities in brain structure and function. However, efforts to understand the neurobiological bases of the clinical symptoms that the diagnosis is based on have been largely unsuccessful. In this paper, we provide an overview of the conceptual and methodological obstacles that undermine efforts to link the severity of specific symptoms to specific neurobiological measures. These obstacles include small samples, questionable reliability and validity of measurements, medication confounds, failure to distinguish state and trait effects, correlation-causation ambiguity, and the absence of compelling animal models of specific symptoms to test mechanistic hypotheses derived from brain-symptom correlations. We conclude with recommendations to promote progress in establishing brain-symptom relationships.
C1 [Mathalon, Daniel H.; Ford, Judith M.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA.
[Mathalon, Daniel H.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA.
EM daniel.mathalon@ucsf.edu
OI Mathalon, Daniel/0000-0001-6090-4974
FU CSRD VA [I01 CX000497]; NIMH NIH HHS [R01 MH076989]
NR 43
TC 16
Z9 16
U1 2
U2 14
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD MAY 25
PY 2012
VL 6
AR 136
DI 10.3389/fnhum.2012.00136
PG 6
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA 953HT
UT WOS:000304858500001
PM 22654745
ER
PT J
AU Mantegazza, AR
Guttentag, SH
El-Benna, J
Sasai, M
Iwasaki, A
Shen, H
Laufer, TM
Marks, MS
AF Mantegazza, Adriana R.
Guttentag, Susan H.
El-Benna, Jamel
Sasai, Miwa
Iwasaki, Akiko
Shen, Hao
Laufer, Terri M.
Marks, Michael S.
TI Adaptor Protein-3 in Dendritic Cells Facilitates Phagosomal Toll-like
Receptor Signaling and Antigen Presentation to CD4(+) T Cells
SO IMMUNITY
LA English
DT Article
ID HERMANSKY-PUDLAK-SYNDROME; MHC CLASS-II; AP-3 ADAPTER;
CROSS-PRESENTATION; BETA-3A SUBUNIT; SORTING SIGNALS; IMMUNE-RESPONSE;
SYNDROME TYPE-2; TRAFFICKING; MUTATIONS
AB Effective major histocompatibility complex-II (MHC-II) antigen presentation from phagocytosed particles requires phagosome-intrinsic Toll-like receptor (TLR) signaling, but the molecular mechanisms underlying TLR delivery to phagosomes and how signaling regulates antigen presentation are incompletely understood. We show a requirement in dendritic cells (DCs) for adaptor protein-3 (AP-3) in efficient TLR recruitment to phagosomes and MHC-II presentation of antigens internalized by phagocytosis but not receptor-mediated endocytosis. DCs from AP-3-deficient pearl mice elicited impaired CD4(+) T cell activation and Th1 effector cell function to particulate antigen in vitro and to recombinant Listeria monocytogenes infection in vivo. Whereas phagolysosome maturation and peptide:MHC-II complex assembly proceeded normally in pearl DCs, peptide:MHC-II export to the cell surface was impeded. This correlated with reduced TLR4 recruitment and proinflammatory signaling from phagosomes by particulate TLR ligands. We propose that AP-3-dependent TLR delivery from endosomes to phagosomes and subsequent signaling mobilize peptide:MHC-II export from intracellular stores.
C1 [Mantegazza, Adriana R.; Marks, Michael S.] Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.
[Mantegazza, Adriana R.; Marks, Michael S.] Univ Penn, Perelman Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA.
[Mantegazza, Adriana R.; Marks, Michael S.] Univ Penn, Perelman Sch Med, Dept Physiol, Philadelphia, PA 19104 USA.
[Shen, Hao] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
[Laufer, Terri M.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Guttentag, Susan H.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.
[El-Benna, Jamel] Univ Paris 07, INSERM, U773, Fac Med, F-75018 Paris, France.
[Sasai, Miwa; Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.
[Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Marks, MS (reprint author), Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19104 USA.
EM marksm@mail.med.upenn.edu
RI Guttentag, Susan/D-8705-2013
OI Guttentag, Susan/0000-0003-4420-5879; Marks, Michael/0000-0001-7435-7262
FU National Institutes of Health [R01 EY015625, R21 AI092398, R21 AI079724,
R01 AI081884, R01 AI064705]; University Research Foundation from the
University of Pennsylvania; HPS Network; United States Veterans
Administration
FX We thank R. Steinman, M. Pepper Pew, M. Jenkins, A. Rudensky, J. Liboon,
S. Chatterjee, A. Fisher, S. Ross, S. Akira, P. Oliver, L. Eisenlohr, M.
Chou, and C. Lopez for generous gifts of reagents; A. Stout, P. Zhang,
S. Leach, A. Sitaram, and C. Lopez Haber for technical assistance; and
the Amigorena laboratory for experimental protocols. This work was
supported by National Institutes of Health grants R01 EY015625 (to
M.S.M.), R21 AI092398 (to A.R.M. and M.S.M.), R21 AI079724 (to H.S.),
and R01 AI081884 and R01 AI064705 (to A.I); a University Research
Foundation grant from the University of Pennsylvania (to M.S.M.); Donna
and Richard Appel and the HPS Network (to S.H.G.); and a research grant
from the United States Veterans Administration (to T.M.L.).
NR 57
TC 25
Z9 26
U1 1
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD MAY 25
PY 2012
VL 36
IS 5
BP 782
EP 794
DI 10.1016/j.immuni.2012.02.018
PG 13
WC Immunology
SC Immunology
GA 954VL
UT WOS:000304976000012
PM 22560444
ER
PT J
AU Loewenstein, G
Asch, DA
Friedman, JY
Melichar, LA
Volpp, KG
AF Loewenstein, George
Asch, David A.
Friedman, Joelle Y.
Melichar, Lori A.
Volpp, Kevin G.
TI Can behavioural economics make us healthier?
SO BRITISH MEDICAL JOURNAL
LA English
DT Editorial Material
ID FINANCIAL INCENTIVES; ASYMMETRIC PATERNALISM; MEDICATION ADHERENCE;
RANDOMIZED-TRIAL; COPAYMENTS; VETERANS; INCREASE; SMOKING; IMPACT
AB Behavioural economics is becoming increasingly popular as a way to improve public health. George Loewenstein and colleagues point out some of the pitfalls and warn that it cannot be used as a substitute for conventional policies to tackle fundamental problems
C1 [Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
[Loewenstein, George; Asch, David A.; Friedman, Joelle Y.; Volpp, Kevin G.] Univ Penn, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Asch, David A.; Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Melichar, Lori A.] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA.
RP Loewenstein, G (reprint author), Carnegie Mellon Univ, Dept Social & Decis Sci, 208 Porter Hall,5000 Forbes Ave, Pittsburgh, PA 15213 USA.
EM GL20@andrew.cmu.edu
OI Asch, David/0000-0002-7970-286X
NR 31
TC 17
Z9 17
U1 3
U2 28
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BRIT MED J
JI Br. Med. J.
PD MAY 23
PY 2012
VL 344
AR e3482
DI 10.1136/bmj.e3482
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 949QT
UT WOS:000304591500011
PM 22623635
ER
PT J
AU Volpp, KG
Loewenstein, G
Asch, DA
AF Volpp, Kevin G.
Loewenstein, George
Asch, David A.
TI Assessing Value in Health Care Programs
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID DISEASE
C1 [Volpp, Kevin G.; Asch, David A.] Univ Penn Sch, Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Loewenstein, George; Asch, David A.] Univ Penn, Penn CMU Roybal Ctr Behav Econ & Hlth P30, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Loewenstein, George; Asch, David A.] Univ Penn, Leonard Davis Inst Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Asch, David A.] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Asch, David A.] Univ Penn, Dept Hlth Care Management, Wharton Sch Decis Sci, Philadelphia, PA 19104 USA.
[Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
RP Volpp, KG (reprint author), Univ Penn Sch, Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM volpp70@wharton.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU NIA NIH HHS [P30 AG034546]
NR 9
TC 7
Z9 7
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 23
PY 2012
VL 307
IS 20
BP 2153
EP 2154
DI 10.1001/jama.2012.3619
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 945YX
UT WOS:000304315200021
PM 22618919
ER
PT J
AU Hung, WW
Egol, KA
Zuckerman, JD
Siu, AL
AF Hung, William W.
Egol, Kenneth A.
Zuckerman, Joseph D.
Siu, Albert L.
TI Hip Fracture Management Tailoring Care for the Older Patient
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RANDOMIZED-CONTROLLED-TRIAL; QUALITY-OF-LIFE; FEMORAL-NECK;
ELDERLY-PATIENTS; RISK-FACTORS; BIPOLAR HEMIARTHROPLASTY; FUNCTIONAL
RECOVERY; HOSPITAL DISCHARGE; HOME EXERCISE; VITAMIN-D
AB Hip fracture is a potentially devastating condition for older adults. Hip fracture leads to pain and immobilization with complications ranging from delirium to functional loss and death. Although a mainstay of treatment is orthopedic repair, a multidisciplinary comanagement approach, including medical specialists and rehabilitation, may maximize patient recovery. Using the case of Mr W, an older man who sustained a fall and hip fracture, we present evidence-based components of care both in the hospital and outpatient settings. Preoperatively, clinicians should correct medical abnormalities and consider the appropriateness, timing, and type of surgical repair in the context of the patient's life expectancy and goals of care. Perioperative care should include prophylaxis with antibiotics, chemoprophylaxis for venous thromboembolism, and correction of major clinical abnormalities prior to surgery. Pain control, delirium, and pressure ulcer prevention are important inpatient care elements. Multidisciplinary models incorporating these care elements can decrease complications during inpatient stay. Rehabilitation strategies should be tailored to patient needs; early mobilization followed by rehabilitation exercises in institutional, home, and group settings should be considered to maximize restoration of locomotive abilities. Attention to care transitions is necessary and treatment for osteoporosis should be considered. The road to recovery for hip fracture patients is long and most patients may not regain their prefracture functional status. Understanding and anticipating issues that may arise in the older patient with hip fracture, while delivering evidence-based care components, is necessary to maximize patient recovery.
C1 [Hung, William W.; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Hung, William W.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Hung, William W.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Dev Res Enhancement Award Program, Bronx, NY USA.
[Hung, William W.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Hlth Serv Res, Bronx, NY USA.
[Egol, Kenneth A.; Zuckerman, Joseph D.] NYU, Hosp Joint Dis, Dept Orthopaed Surg, New York, NY USA.
RP Hung, WW (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.
EM william.hung@mssm.edu
FU Exactech; Orthopaedic Research & Education Foundation; Orthopaedic
Trauma Association; New York Academy of Medicine; Claude D. Pepper Older
Americans Independence Center at Mount Sinai School of Medicine
[P30-AG028741]; SCAN Foundation
FX All authors have completed and submitted the ICMJE Form for Disclosure
of Potential Conflicts of Interest. Dr Egol reports receipt of
consultancy fees and royalties from Exactech; grants or pending grants
from the Orthopaedic Research & Education Foundation and the Orthopaedic
Trauma Association; and holding stock/stock options with Johnson &
Johnson. The other authors report no disclosures.; Dr Hung is currently
supported by the New York Academy of Medicine Hoar Fellowship. This
article was supported in part by the Claude D. Pepper Older Americans
Independence Center at Mount Sinai School of Medicine (P30-AG028741).
The Care of the Aging Patient series is made possible by funding from
The SCAN Foundation.
NR 86
TC 53
Z9 58
U1 4
U2 22
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 23
PY 2012
VL 307
IS 20
BP 2185
EP 2194
DI 10.1001/jama.2012.4842
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 945YX
UT WOS:000304315200028
PM 22618926
ER
PT J
AU Tseng, ZH
Secemsky, EA
Dowdy, D
Vittinghoff, E
Moyers, B
Wong, JK
Havlir, DV
Hsue, PY
AF Tseng, Zian H.
Secemsky, Eric A.
Dowdy, David
Vittinghoff, Eric
Moyers, Brian
Wong, Joseph K.
Havlir, Diane V.
Hsue, Priscilla Y.
TI Sudden Cardiac Death in Patients With Human Immunodeficiency Virus
Infection
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE AIDS; arrhythmia; death; sudden
ID LEFT-VENTRICULAR DYSFUNCTION; CONGESTIVE-HEART-FAILURE;
MYOCARDIAL-INFARCTION; ANTIRETROVIRAL THERAPY; HIV; MORTALITY;
POPULATION; COMMUNITY; DISEASE; COHORT
AB Objectives The aim of this study was to determine the incidence and clinical characteristics of sudden cardiac death (SCD) in patients with human immunodeficiency virus (HIV) infection.
Background As the HIV-infected population ages, cardiovascular disease prevalence and mortality are increasing, but the incidence and features of SCD have not yet been described.
Methods The records of 2,860 consecutive patients in a public HIV clinic in San Francisco between April 2000 and August 2009 were examined. Identification of deaths, causes of death, and clinical characteristics were obtained by search of the National Death Index and/or clinic records. SCDs were determined using published retrospective criteria: 1) the International Classification of Diseases-10th Revision, code for all cardiac causes of death; and (2) circumstances of death meeting World Health Organization criteria.
Results Of 230 deaths over a median of 3.7 years of follow-up, 30 (13%) met SCD criteria, 131 (57%) were due to acquired immune deficiency syndrome (AIDS), 25 (11%) were due to other (natural) diseases, and 44 (19%) were due to overdoses, suicides, or unknown causes. SCDs accounted for 86% of all cardiac deaths (30 of 35). The mean SCD rate was 2.6 per 1,000 person-years (95% confidence interval: 1.8 to 3.8), 4.5-fold higher than expected. SCDs occurred in older patients than did AIDS deaths (mean 49.0 vs. 44.9 years, p = 0.02). Compared with AIDS and natural deaths combined, SCDs had a higher prevalence of prior myocardial infarction (17% vs. 1%, p < 0.0005), cardiomyopathy (23% vs. 3%, p < 0.0005), heart failure (30% vs. 9%, p = 0.004), and arrhythmias (20% vs. 3%, p = 0.003).
Conclusions SCDs account for most cardiac and many non-AIDS natural deaths in HIV-infected patients. Further investigation is needed to ascertain underlying mechanisms, which may include inflammation, antiretroviral therapy interruption, and concomitant medications. (J Am Coll Cardiol 2012;59:1891-6) (C) 2012 by the American College of Cardiology Foundation
C1 [Tseng, Zian H.; Moyers, Brian] Univ Calif San Francisco, Cardiac Electrophysiol Sect, Div Cardiol, San Francisco, CA 94143 USA.
[Secemsky, Eric A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Dowdy, David] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Wong, Joseph K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Havlir, Diane V.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA 94143 USA.
[Hsue, Priscilla Y.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94143 USA.
RP Tseng, ZH (reprint author), Univ Calif San Francisco, Cardiac Electrophysiol Sect, Div Cardiol, 500 Parnassus Ave,MU-433,Box 1354, San Francisco, CA 94143 USA.
EM zhtseng@medicine.ucsf.edu
FU National Heart, Lung, and Blood Institute [5R01 HL102090, 5R01 HL095130,
5R01 HL091526]; Veterans Affairs Merit Review grant [R01 NS501132];
National Institutes of Health [K24 AI51982]
FX This work was supported by grants 5R01 HL102090 (Dr. Tseng), 5R01
HL095130 (Dr. Hsue), and 5R01 HL091526 (Dr. Hsue) from the National
Heart, Lung, and Blood Institute; Veterans Affairs Merit Review grant
R01 NS501132 (Dr. Wong); and grant K24 AI51982 (Dr. Havlir) from the
National Institutes of Health. Dr. Tseng has also received minor
honorarium from Biotronik. All other authors have reported that they
have no relationships relevant to the contents of this paper to
disclose.
NR 27
TC 72
Z9 73
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 22
PY 2012
VL 59
IS 21
BP 1891
EP 1896
DI 10.1016/j.jacc.2012.02.024
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 942PF
UT WOS:000304057200008
PM 22595409
ER
PT J
AU Song, YH
Tai, JHY
Bartsch, SM
Zimmerman, RK
Muder, RR
Lee, BY
AF Song, Yeohan
Tai, Julie H. Y.
Bartsch, Sarah M.
Zimmerman, Richard K.
Muder, Robert R.
Lee, Bruce Y.
TI The potential economic value of a Staphylococcus aureus vaccine among
hemodialysis patients
SO VACCINE
LA English
DT Article
DE Staphylococcus aureus; Vaccine; Economics; Hemodialysis;
Cost-effectiveness
ID COST-EFFECTIVENESS ANALYSIS; LONG-TERM HEMODIALYSIS;
METHICILLIN-RESISTANT; CLINICAL-OUTCOMES; CONJUGATE VACCINE;
RISK-FACTORS; BACTEREMIA; MANAGEMENT; INFECTION; DIALYSIS
AB Staphylococcus aureus infections are a substantial problem for hemodialysis patients. Several vaccine candidates are currently under development, with hemodialysis patients being one possible target population. To determine the potential economic value of an S. aureus vaccine among hemodialysis patients, we developed a Markov decision analytic computer simulation model. When S. aureus colonization prevalence was 1%, the incremental cost-effectiveness ratio (ICER) of vaccination was <=$25,217/quality-adjusted life year (QALY). Vaccination became more cost-effective as colonization prevalence, vaccine efficacy, or vaccine protection duration increased or vaccine cost decreased. Even at 10% colonization prevalence, a 25% efficacious vaccine costing $100 prevented 29 infections, 21 infection-related hospitalizations, and 9 inpatient deaths per 1000 vaccinated HD patients. Our results suggest that an S. aureus vaccine would be cost-effective (i.e., ICERs <= $50,000/QALY) among hemodialysis patients over a wide range of S. aureus prevalence, vaccine costs and efficacies, and vaccine protection durations and delineate potential target parameters for such a vaccine. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Lee, Bruce Y.] Univ Pittsburgh, Publ Hlth Computat & Operat Res Grp, Publ Hlth Computat & Operat Res PHICOR, Pittsburgh, PA 15213 USA.
[Song, Yeohan; Tai, Julie H. Y.; Bartsch, Sarah M.; Lee, Bruce Y.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15260 USA.
[Song, Yeohan; Tai, Julie H. Y.; Bartsch, Sarah M.; Lee, Bruce Y.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Zimmerman, Richard K.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15261 USA.
[Muder, Robert R.] VA Pittsburgh Healthcare Syst, Div Infect Dis, Pittsburgh, PA 15240 USA.
RP Lee, BY (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res Grp, Publ Hlth Computat & Operat Res PHICOR, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA.
EM ysongmd@umich.edu; juliehy@pitt.edu; smm168@pitt.edu; zimmrk@upmc.edu;
robert.muder@va.gov; BYL1@pitt.edu
OI Zimmerman, Richard/0000-0001-5941-6092
FU National Institute of General Medical Sciences Models of Infectious
Disease Agent Study (MIDAS) [5U54GM088491-02]; Pennsylvania Department
of Health (DOH) [4100047864]
FX This work was supported by the National Institute of General Medical
Sciences Models of Infectious Disease Agent Study (MIDAS) grant
5U54GM088491-02 and the Pennsylvania Department of Health (DOH) grant
4100047864. The funders had no role in the design and conduct of the
study; collection, management, analysis, and interpretation of the data;
and preparation, review, or approval of the manuscript.
NR 78
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY 21
PY 2012
VL 30
IS 24
BP 3675
EP 3682
DI 10.1016/j.vaccine.2012.03.031
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 951SY
UT WOS:000304741500024
PM 22464963
ER
PT J
AU Abbas, KS
Li, A
Rivero, G
Mitsiades, N
Yellapragada, S
AF Abbas, Kanza S.
Li, Ang
Rivero, Gustavo
Mitsiades, Nicholas
Yellapragada, Sarvari
TI Survival outcome of veterans with myelodysplastic syndrome (MDS) treated
with statins.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Baylor Coll Med, Houston, TX 77030 USA.
Baylor Coll Med, Dan L Duncan Canc Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e17018
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801859
ER
PT J
AU Corless, CL
Neff, T
Heinrich, MC
Beadling, C
AF Corless, Christopher L.
Neff, Tanaya
Heinrich, Michael C.
Beadling, Carol
TI Combining semiconductor-based sequencing with amplicon-based cancer gene
panels: A rapid next-gen approach to clinical cancer genotyping.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10591
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803550
ER
PT J
AU D'Ambrosio, L
Brusa, F
D'Ascenzo, F
Cavallero, E
Biondi-Zoccai, G
Boccone, P
Bironzo, P
Levin, GN
Eckel, RH
Milani, RV
Sagalowsky, AI
Gasparini, M
Grignani, G
Gaita, F
Ciuffreda, L
Aglietta, M
AF D'Ambrosio, Lorenzo
Brusa, Federica
D'Ascenzo, Fabrizio
Cavallero, Erica
Biondi-Zoccai, Giuseppe
Boccone, Paola
Bironzo, Paolo
Levin, Glenn N.
Eckel, Robert H.
Milani, Richard V.
Sagalowsky, Arthur I.
Gasparini, Mauro
Grignani, Giovanni
Gaita, Fiorenzo
Ciuffreda, Libero
Aglietta, Massimo
TI Risk of adverse cardiovascular events (CVE) and incident diabetes
mellitus (DM) in patients (pts) with prostate cancer (PC) treated with
androgen deprivation therapy (ADT): A meta-analysis of adjusted
observational results
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Inst Canc Res & Treatment, Candiolo, Italy.
Ctr Oncol & Ematol Subalpino, Turin, Italy.
Univ Turin, Div Cardiol, Turin, Italy.
Univ Modena & Reggio Emilia, Div Cardiol, Modena, Italy.
Baylor Coll Med, Cardiac Care Unit, Houston, TX 77030 USA.
Michael E DeBakey Med Ctr, Houston, TX USA.
Univ Colorado, Aurora, CO USA.
Ochsner Med Ctr, Div Cardiol, New Orleans, LA USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Politecn Torino, Dept Math, I-10128 Turin, Italy.
Univ Turin, Div Cardiol, Corso Dogliotti, Italy.
AOU S Giovanni Battista Molinette, Div Oncol, Turin, Italy.
RI Milani, Richard/A-6045-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e15192
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802859
ER
PT J
AU Desai, P
Braun, E
Dehghan-Paz, I
Gattuso, P
Canar, J
Cobleigh, MA
AF Desai, Palak
Braun, Eduardo
Dehghan-Paz, Irene
Gattuso, Paolo
Canar, Jeff
Cobleigh, Melody A.
TI Synchronous bilateral breast cancer (SBBC): Concordance of receptor
status between right and left breast
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Rush Univ, Med Ctr, Chicago, IL 60612 USA.
US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
Rush Univ, Natl Surg Adjuvant Breast & Bowel Project, Med Ctr, Chicago, IL 60612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 572
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800078
ER
PT J
AU Gartrell, BA
Hahn, NM
Hutson, TE
Sonpavde, G
Hauke, RJ
Starodub, A
Small, AC
Tsao, CK
Galsky, MD
AF Gartrell, Benjamin Adam
Hahn, Noah M.
Hutson, Thomas E.
Sonpavde, Guru
Hauke, Ralph J.
Starodub, Alexander
Small, Alexander C.
Tsao, Che-Kai
Galsky, Matt D.
TI Phase II trial of gemcitabine and cisplatin plus ipilimumab as
first-line treatment for metastatic urothelial carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
Texas Oncol, Houston, TX USA.
Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Dept Med, Houston, TX 77030 USA.
Nebraska Canc Specialists, Omaha, NE USA.
Goshen Ctr Canc Care, Goshen, IN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4676
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803064
ER
PT J
AU Goldkorn, A
Ely, B
Quinn, DI
Tangen, CM
Tai, YC
Twardowski, P
Van Veldhuizen, PJ
Agarwal, N
Anthony, M
Monk, CJP
Garzotto, M
Mack, PC
Lara, P
Higano, CS
Hussain, M
Vogelzang, NJ
Cote, RJ
Thompson, IM
AF Goldkorn, Amir
Ely, Benjamin
Quinn, David I.
Tangen, Catherine M.
Tai, Yu-Chong
Twardowski, Przemyslaw
Van Veldhuizen, Peter J.
Agarwal, Neeraj
Anthony, Michael
Monk, Carducci J. P.
Garzotto, Mark
Mack, Philip C.
Lara, Primo
Higano, Celestia S.
Hussain, Maha
Vogelzang, Nicholas J.
Cote, Richard J.
Thompson, Ian Murchie
CA Southwest Oncology Grp
TI Results of telomerase activity measurements from live circulating tumor
cells captured on a slot microfilter in a phase III SWOG-coordinated
prostate cancer trial (S0421)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
SWOG Stat Ctr, Seattle, WA USA.
CALTECH, Pasadena, CA 91125 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Kansas, Ctr Canc, Westwood, KS USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Ohio State Univ, Columbus, OH 43210 USA.
Portland VA Med Ctr, Portland, OR USA.
Univ Calif Davis, Davis, CA 95616 USA.
Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4663
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803108
ER
PT J
AU Hahn, NM
Daneshmand, S
Posadas, EM
Koch, MO
Bihrle, R
Foster, R
Masterson, TA
Cheng, L
Liu, ZY
Breen, T
Fleming, MT
Lance, R
Ryan, CW
Corless, CL
Galsky, MD
Alva, AS
Mitchell, C
Shen, SS
Lerner, SP
Sonpavde, G
AF Hahn, Noah M.
Daneshmand, Siamak
Posadas, Edwin M.
Koch, Michael O.
Bihrle, Richard
Foster, Richard
Masterson, Timothy A.
Cheng, Liang
Liu, Ziyue
Breen, Timothy
Fleming, Mark T.
Lance, Ray
Ryan, Christopher W.
Corless, Christopher L.
Galsky, Matt D.
Alva, Ajjai Shivaram
Mitchell, Carmen
Shen, Steven S.
Lerner, Seth P.
Sonpavde, Guru
TI A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive
urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group
GU07-122 trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA.
Indiana Univ, Med Ctr, Indianapolis, IN USA.
Indiana Univ, Indianapolis, IN 46204 USA.
Indiana Univ, Med Ctr, Dept Pathol & Lab Med, Indianapolis, IN USA.
Indiana Univ, Div Biostat, Indianapolis, IN 46204 USA.
Hoosier Oncol Grp, Indianapolis, IN USA.
US Oncol Res, The Woodlands, TX USA.
Virginia Oncol Associates, Hampton, VA USA.
Eastern Virginia Med Sch, Norfolk, VA 23501 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97201 USA.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Baylor Coll Med, Houston, TX 77030 USA.
Methodist Hosp, Houston, TX 77030 USA.
Texas Oncol, Houston, TX USA.
Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Med Oncol, Houston, TX 77030 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4586
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802889
ER
PT J
AU Kim, B
He, R
Antonio, ALM
Asch, SM
Malin, J
AF Kim, Benjamin
He, Ren
Antonio, Anna Liza M.
Asch, Steven M.
Malin, Jennifer
TI Comparative effectiveness of erlotinib versus no treatment for advanced
non-small cell lung cancer patients in the Veterans Administration.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 UCSF Sch Med, San Francisco, CA USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
Univ Calif Los Angeles, Greater Los Angeles Vet Adm Hlth Care Syst, Los Angeles, CA USA.
Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6105
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803168
ER
PT J
AU Lerner, SP
Sternberg, CN
Younes, M
Calabro, F
Cerbone, L
Chandrashekar, A
Mitchell, C
Shen, SS
Sonpavde, G
AF Lerner, Seth P.
Sternberg, Cora N.
Younes, Mamoun
Calabro, Fabio
Cerbone, Linda
Chandrashekar, A.
Mitchell, Carmen
Shen, Steven S.
Sonpavde, Guru
TI Phase II trial of tamoxifen for progressive advanced urothelial
carcinoma following prior chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Baylor Coll Med, Houston, TX 77030 USA.
San Camillo & Forlanini Hosp, Rome, Italy.
Univ Texas Hlth Sci Ctr, Houston, TX USA.
San Camillo Forlanini Hosp, Rome, Italy.
Methodist Hosp, Houston, TX 77030 USA.
Texas Oncol, Houston, TX USA.
Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e15003
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803021
ER
PT J
AU Levitt, JM
Chan, KS
Jian, WG
Lerner, SP
Sonpavde, G
AF Levitt, Jonathan M.
Chan, Keith S.
Jian, Weiguo
Lerner, Seth P.
Sonpavde, Guru
TI The preclinical activity of lenalidomide in urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Baylor Coll Med, Houston, TX 77030 USA.
Texas Oncol, Houston, TX USA.
Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA e15002
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803112
ER
PT J
AU Musuuza, JS
Sherman, ME
Knudsen, KJ
Sweeney, H
Tyler, CV
Koroukian, SM
AF Musuuza, Jackson S.
Sherman, Marion E.
Knudsen, Kraig J.
Sweeney, HelenAnne
Tyler, Carl V.
Koroukian, Siran M.
TI Analyzing excess mortality from cancer among individuals with mental
illness.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ Wisconsin, Dept Populat Hlth Sci, Sch Med & Publ Hlth, Madison, WI USA.
US Dept Vet Affairs, Joint Ambulatory Care Ctr, Pensacola, FL USA.
Ohio Dept Mental Hlth, Columbus, OH USA.
Cleveland Clin Hosp, Fairview Hosp, Cleveland, OH USA.
Case Western Reserve Univ, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 1598
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009801312
ER
PT J
AU Quinn, DI
Tangen, CM
Hussain, M
Lara, P
Goldkorn, A
Garzotto, M
Mack, PC
Carducci, MA
Monk, JP
Twardowski, P
Van Veldhuizen, PJ
Agarwal, N
Higano, CS
Vogelzang, NJ
Thompson, IM
AF Quinn, David I.
Tangen, Catherine M.
Hussain, Maha
Lara, Primo
Goldkorn, Amir
Garzotto, Mark
Mack, Philip C.
Carducci, Michael Anthony
Monk, J. P.
Twardowski, Przemyslaw
Van Veldhuizen, Peter J.
Agarwal, Neeraj
Higano, Celestia S.
Vogelzang, Nicholas J.
Thompson, Ian Murchie
TI SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus
docetaxel and placebo (P) for men with advanced castrate resistant
prostate cancer (CRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
SWOG Stat Ctr, Seattle, WA USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Univ Calif Davis, Sacramento, CA 95817 USA.
Portland VA Med Ctr, Portland, OR USA.
Johns Hopkins Univ, Baltimore ECOG, Baltimore, MD USA.
Ohio State Univ, CALGB, Columbus, OH 43210 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Kansas, Ctr Canc, Westwood, KS USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA.
Comprehens Canc Ctr NV, US Oncol Res, Las Vegas, NV USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4511
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009803074
ER
PT J
AU Small, AC
Tsao, CK
Moshier, EL
Gartrell, BA
Wisnivesky, JP
Godbold, JH
Smith, CB
Sonpavde, G
Oh, WK
Galsky, MD
AF Small, Alexander C.
Tsao, Che-Kai
Moshier, Erin L.
Gartrell, Benjamin Adam
Wisnivesky, Juan P.
Godbold, James H.
Smith, Cardinale B.
Sonpavde, Guru
Oh, William K.
Galsky, Matt D.
TI Prevalence and characteristics of patients with stage IV solid tumors
who receive no anticancer therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY USA.
Texas Oncol, Houston, TX USA.
Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 6065
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802050
ER
PT J
AU Sonpavde, G
Amiel, G
Margulis, V
Link, RE
Lerner, SP
Raj, G
Mayer, WA
Palapattu, GS
Lotan, Y
Sagalowsky, AI
Higgins, LC
Tello, SA
Pavia-Jimenez, A
VonMerveldt, D
Brugarolas, J
AF Sonpavde, Guru
Amiel, Gilad
Margulis, Vitaly
Link, Richard E.
Lerner, Seth P.
Raj, Ganesh
Mayer, Wesley A.
Palapattu, Ganesh S.
Lotan, Yair
Sagalowsky, Arthur I.
Higgins, Linda C.
Tello, Sebrina A.
Pavia-Jimenez, Andrea
VonMerveldt, Dendra
Brugarolas, James
TI Neoadjuvant therapy preceding cytoreductive nephrectomy to develop
individualized first-line therapy with everolimus for advanced renal
cell carcinoma (RCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Texas Oncol, Houston, TX USA.
Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Dept Med, Houston, TX 77030 USA.
Baylor Coll Med, Houston, TX 77030 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Methodist Hosp, Houston, TX 77030 USA.
Weill Cornell Med Coll, Houston, TX USA.
Univ Texas Southwestern, Dallas, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA TPS4678
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802866
ER
PT J
AU Tsao, CK
Small, AC
Kates, M
Gartrell, BA
Wisnivesky, JP
Sonpavde, G
Palese, M
Hall, S
Oh, WK
Galsky, MD
AF Tsao, Che-Kai
Small, Alexander C.
Kates, Max
Gartrell, Benjamin Adam
Wisnivesky, Juan P.
Sonpavde, Guru
Palese, Michael
Hall, Simon
Oh, William K.
Galsky, Matt D.
TI Trends in the use of cytoreductive nephrectomy for metastatic renal cell
carcinoma in the VEGFR tyrosine kinase inhibitor era
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
Mt Sinai Sch Med, Div Gen Internal Med, New York, NY USA.
Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY USA.
Texas Oncol, Houston, TX USA.
Baylor Coll Med, Dept Med, Sect Med Oncol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
Mt Sinai Sch Med, Dept Urol, New York, NY USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 4623
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009802603
ER
PT J
AU Vogelzang, NJ
Ely, B
Fink, LM
Goldkorn, A
Tangen, CM
Twardowski, P
Van Veldhuizen, PJ
Agarwal, N
Carducci, MA
Monk, JP
Datar, RH
Garzotto, M
Mack, PC
Lara, P
Higano, CS
Hussain, M
Quinn, DI
Cote, RJ
Thompson, IM
AF Vogelzang, Nicholas J.
Ely, Benjamin
Fink, Louis M.
Goldkorn, Amir
Tangen, Catherine M.
Twardowski, Przemyslaw
Van Veldhuizen, Peter J.
Agarwal, Neeraj
Carducci, Michael Anthony
Monk, J. P.
Datar, Ram H.
Garzotto, Mark
Mack, Philip C.
Lara, Primo
Higano, Celestia S.
Hussain, Maha
Quinn, David I.
Cote, Richard J.
Thompson, Ian Murchie
TI Circulating tumor cell counts (CTC) as prognostic of overall survival
(OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic
castration resistant prostate cancer (mCRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY JUN 01-06, 2012
CL Chicago, IL
SP Amer Soc Clin Oncol (ASCO)
C1 Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
US Oncol Res, Las Vegas, NV USA.
SWOG Stat Ctr, Seattle, WA USA.
Nevada Canc Inst, Las Vegas, NV USA.
Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Kansas, Ctr Canc, Westwood, KS USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Johns Hopkins Univ, Baltimore ECOG, Baltimore, MD USA.
Ohio State Univ, CALGB, Columbus, OH 43210 USA.
Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
Portland VA Med Ctr, Portland, OR USA.
Univ Calif Davis, Sacramento, CA 95817 USA.
Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2012
VL 30
IS 15
SU S
MA 10503
PG 1
WC Oncology
SC Oncology
GA 131QQ
UT WOS:000318009800014
ER
PT J
AU Jim, B
Ghanta, M
Qipo, A
Fan, Y
Chuang, PY
Cohen, HW
Abadi, M
Thomas, DB
He, JC
AF Jim, Belinda
Ghanta, Mythili
Qipo, Andi
Fan, Ying
Chuang, Peter Y.
Cohen, Hillel W.
Abadi, Maria
Thomas, David B.
He, John Cijiang
TI Dysregulated Nephrin in Diabetic Nephropathy of Type 2 Diabetes: A Cross
Sectional Study
SO PLOS ONE
LA English
DT Article
ID SLIT-DIAPHRAGM PROTEIN; GLOMERULAR PROTEIN; NEPHROTIC SYNDROME; PODOCYTE
NUMBER; KIDNEY-DISEASE; EXPRESSION; RAT; MICROALBUMINURIA; INHIBITION;
EXCRETION
AB Background: Podocyte specific proteins are dysregulated in diabetic nephropathy, though the extent of their expression loss is not identical and may be subject to different regulatory factors. Quantifying the degree of loss may help identify the most useful protein to use as an early biomarker of diabetic nephropathy.
Methodology/Principal Findings: Protein expression of synaptopodin, podocin and nephrin were quantified in 15 Type 2 diabetic renal biopsies and 12 control patients. We found statistically significant downregulation of synaptopodin (P < 0.0001), podocin (P = 0.0002), and nephrin (P < 0.0001) in kidney biopsies of diabetic nephropathy as compared with controls. Urinary nephrin levels (nephrinuria) were then measured in 66 patients with Type 2 diabetes and 10 healthy controls by an enzyme-linked immunosorbent assay (Exocell, Philadelphia, PA). When divided into groups according to normo-, micro-, and macroalbuminuria, nephrinuria was found to be present in 100% of diabetic patients with micro-and macroalbuminuria, as well as 54% of patients with normoalbuminuria. Nephrinuria also correlated significantly with albuminuria (rho = 0.89, P < 0.001), systolic blood pressure (rho = 0.32, p = 0.007), and correlated negatively with serum albumin (rho = 20.48, P < 0.0001) and eGFR (rho = 20.33, p = 0.005).
Conclusions/Significance: These data suggest that key podocyte-specific protein expressions are significantly and differentially downregulated in diabetic nephropathy. The finding that nephrinuria is observed in a majority of these normoalbuminuric patients demonstrates that it may precede microalbuminuria. If further research confirms nephrinuria to be a biomarker of pre-clinical diabetic nephropathy, it would shed light on podocyte metabolism in disease, and raise the possibility of new and earlier therapeutic targets.
C1 [Jim, Belinda; Ghanta, Mythili; Qipo, Andi] Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Div Nephrol, Bronx, NY 10467 USA.
[Fan, Ying] Shanghai Jiao Tong Univ, Dept Nephrol, Affiliated Peoples Hosp 6, Shanghai 200030, Peoples R China.
[Chuang, Peter Y.; He, John Cijiang] Mt Sinai Sch Med, Div Nephrol, Dept Med, New York, NY USA.
[Cohen, Hillel W.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Abadi, Maria] Albert Einstein Coll Med, Dept Pathol, Jacobi Med Ctr, Bronx, NY 10467 USA.
[Thomas, David B.] Nephrocor, Uniondale, NY USA.
[He, John Cijiang] James J Peters VA Med Ctr, Dept Med Bronx, Div Nephrol, New York, NY USA.
RP Jim, B (reprint author), Albert Einstein Coll Med, Jacobi Med Ctr, Dept Med, Div Nephrol, Bronx, NY 10467 USA.
EM bun.jim@nbhn.net
OI Cohen, Hillel/0000-0002-4524-0898
FU VA Merit Award; NIH [1R01 DK078897]; National Center for Research
Resources (NCRR), a component of the National Institutes of Health (NIH)
[UL1 RR025750, KL2 RR025749, TL1 RR025748]; NIH roadmap for Medical
Research
FX Dr. JC He is funded by the VA Merit Award and NIH 1R01 DK078897. This
publication was supported in part by the Clinical Translational Science
Award (CTSA) Grant UL1 RR025750, KL2 RR025749 and TL1 RR025748 from the
National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH), and NIH roadmap for Medical
Research. Its contents are solely the responsibility of the authors and
do not necessary represent the official view of the NCRR or NIH. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 36
TC 41
Z9 50
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2012
VL 7
IS 5
AR e36041
DI 10.1371/journal.pone.0036041
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UQ
UT WOS:000305341200005
PM 22615747
ER
PT J
AU Homma, S
Thompson, JLP
Pullicino, PM
Levin, B
Freudenberger, RS
Teerlink, JR
Ammon, SE
Graham, S
Sacco, RL
Mann, DL
Mohr, JP
Massie, BM
Labovitz, AJ
Anker, SD
Lok, DJ
Ponikowski, P
Estol, CJ
Lip, GYH
Di Tullio, MR
Sanford, AR
Mejia, V
Gabriel, AP
del Valle, ML
Buchsbaum, R
AF Homma, Shunichi
Thompson, John L. P.
Pullicino, Patrick M.
Levin, Bruce
Freudenberger, Ronald S.
Teerlink, John R.
Ammon, Susan E.
Graham, Susan
Sacco, Ralph L.
Mann, Douglas L.
Mohr, J. P.
Massie, Barry M.
Labovitz, Arthur J.
Anker, Stefan D.
Lok, Dirk J.
Ponikowski, Piotr
Estol, Conrado J.
Lip, Gregory Y. H.
Di Tullio, Marco R.
Sanford, Alexandra R.
Mejia, Vilma
Gabriel, Andre P.
del Valle, Mirna L.
Buchsbaum, Richard
CA WARCEF Investigators
TI Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ATRIAL-FIBRILLATION; VENTRICULAR DYSFUNCTION; ANTITHROMBOTIC THERAPY;
MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; DOUBLE-BLIND; ANTICOAGULATION;
STROKE; PREVENTION; ENALAPRIL
AB BACKGROUND
It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm.
METHODS
We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [+/- SD], 3.5 +/- 1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause.
RESULTS
The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P=0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but this finding was only marginally significant (P=0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P=0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intracranial hemorrhage did not differ significantly between the two treatment groups (0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P=0.82).
CONCLUSIONS
Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage. The choice between warfarin and aspirin should be individualized.
C1 [Homma, Shunichi; Thompson, John L. P.; Levin, Bruce; Mohr, J. P.; Di Tullio, Marco R.; Sanford, Alexandra R.; Mejia, Vilma; Gabriel, Andre P.; del Valle, Mirna L.; Buchsbaum, Richard] Columbia Univ, Med Ctr, New York, NY 10032 USA.
[Pullicino, Patrick M.] Univ Kent, Canterbury, Kent, England.
[Lip, Gregory Y. H.] Univ Birmingham, Ctr Cardiovasc Sci, Birmingham, W Midlands, England.
[Freudenberger, Ronald S.] Lehigh Valley Hosp, Allentown, PA USA.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.; Ammon, Susan E.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Graham, Susan] SUNY Buffalo, Buffalo, NY 14260 USA.
[Sacco, Ralph L.] Univ Miami, Miami, FL USA.
[Mann, Douglas L.] Washington Univ, St Louis, MO 63130 USA.
[Labovitz, Arthur J.] Univ S Florida, Tampa, FL USA.
[Anker, Stefan D.] Charite, D-13353 Berlin, Germany.
[Anker, Stefan D.] IRCCS San Raffaele, Ctr Clin & Basic Res, Rome, Italy.
[Lok, Dirk J.] Hosp Deventer, Deventer, Netherlands.
[Ponikowski, Piotr] Mil Hosp, Wroclaw, Poland.
[Estol, Conrado J.] Ctr Neurol Tratamiento & Rehabil, Buenos Aires, DF, Argentina.
RP Homma, S (reprint author), Columbia Univ, Med Ctr, PH 3-342,622 W 168th St, New York, NY 10032 USA.
RI Ponikowski, Piotr/O-6454-2015
OI Ponikowski, Piotr/0000-0002-3391-7064; Mann, Douglas
/0000-0002-2516-0145; Kohsaka, Shun/0000-0003-3779-2972
FU National Institute of Neurological Disorders and Stroke [U01-NS-043975,
U01-NS-039143]; St. Jude Medical; Boehringer Ingelheim; United
Healthcare; Amgen; Cytokinetics; Novartis; NovaCardia/Merck; American
College of Cardiology; Bosch Healthcare; GlaxoSmithKline; Helsinn;
LoneStar Heart; Professional Dietetics; PsiOxus; Relypsa; SHL
Telemedicine; Thermo Fisher; Vifor Pharma; Bayer; Coridea; Corthera;
Johnson Johnson; Pfizer; Respicardia; Abbott; Merck Serono;
Sanofi-Aventis; Servier; Astellas; AstraZeneca; Biotronik; Bristol-Myers
Squibb; Merck; Portola; National Institute of Neurological Disorders and
Stroke; WARCEF [NCT00041938]
FX Funded by the National Institute of Neurological Disorders and Stroke;
WARCEF ClinicalTrials.gov number, NCT00041938.; Supported by grants
(U01-NS-043975 [to Dr. Homma] and U01-NS-039143 [to Dr. Thompson]) from
the National Institute of Neurological Disorders and Stroke.; Dr. Homma
reports receiving payment from AGA Medical (now St. Jude Medical) for
his work as a member of a data and safety monitoring board and
consulting fees from Boehringer Ingelheim; Dr. Levin, receiving
consulting fees from United Healthcare; Dr. Teerlink, receiving
consulting fees from Amgen and grant support from Amgen, Cytokinetics,
and Novartis on behalf of himself and from NovaCardia/Merck on behalf of
himself and his institution; Dr. Graham, owning stock in March
Pharmaceuticals, Medtronic, and Pfizer; Dr. Labovitz, receiving grant
support from Boehringer Ingelheim on behalf of his institution, lecture
fees from Boehringer Ingelheim, and fees for the development of
educational presentations from the American College of Cardiology; Dr.
Anker, receiving consulting fees from Amgen, Bosch Healthcare,
GlaxoSmithKline, Helsinn, LoneStar Heart, Novartis, Professional
Dietetics, PsiOxus, Relypsa, SHL Telemedicine, and Thermo Fisher, grant
support from Vifor Pharma, and lecture fees from Novartis, holding
patents with Brahms AG and Charite Berlin, and receiving royalties from
Imperial College; Dr. Ponikowski, receiving consulting fees from Bayer,
Boehringer Ingelheim, Coridea, Corthera, Johnson & Johnson, Pfizer,
Respicardia, and Vifor Pharma, grant support from Vifor Pharma on behalf
of himself and his institution, and lecture fees from Abbott, Boehringer
Ingelheim, Merck Serono, Pfizer, Respicardia, Sanofi-Aventis, Servier,
and Vifor Pharma; and Dr. Lip, receiving consulting fees from Astellas,
AstraZeneca, Bayer, Biotronik, Boehringer Inhelheim, Bristol-Myers
Squibb, Pfizer, Merck, Portola, and Sanofi-Aventis, speakers bureau fees
from Bayer, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, and
Sanofi-Aventis, and payment for the development of educational
presentations from Bayer, Boehringer Ingelheim, and Merck. No other
potential conflict of interest relevant to this article was reported.
NR 28
TC 171
Z9 175
U1 0
U2 28
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 17
PY 2012
VL 366
IS 20
BP 1859
EP 1869
DI 10.1056/NEJMoa1202299
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 942WU
UT WOS:000304083000005
PM 22551105
ER
PT J
AU Gandy, S
DeKosky, ST
AF Gandy, Sam
DeKosky, Steven T.
TI APOE epsilon 4 Status and Traumatic Brain Injury on the Gridiron or the
Battlefield
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID ENCEPHALOPATHY; FOOTBALL
C1 [DeKosky, Steven T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
[Gandy, Sam] Ctr Cognit Hlth, New York, NY 10029 USA.
[Gandy, Sam] NFL Neurol Program, New York, NY 10029 USA.
[Gandy, Sam] Alzheimers Dis Res Ctr, New York, NY 10029 USA.
[Gandy, Sam] Mt Sinai Sch Med, New York, NY 10029 USA.
[Gandy, Sam] James J Peters VA Med Ctr, New York, NY 10029 USA.
RP Gandy, S (reprint author), Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
EM samuel.gandy@mssm.edu; dekosky@virginia.edu
FU NIA NIH HHS [P50 AG005138]; RRD VA [I01 RX000684]
NR 5
TC 7
Z9 7
U1 0
U2 3
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 16
PY 2012
VL 4
IS 134
AR 134ed4
DI 10.1126/scitranslmed.3004274
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 943KY
UT WOS:000304121500001
PM 22593171
ER
PT J
AU Kelley, KW
McBane, S
Thomas, T
Karr, S
AF Kelley, Kristi W.
McBane, Sarah
Thomas, Tyan
Karr, Samantha
TI Serving as a preceptor to pharmacy students: Tips on maintaining the
desire to inspire
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Editorial Material
C1 [Kelley, Kristi W.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
[Kelley, Kristi W.] Baptist Hlth Syst Inc, Continu Clin, Trinity Med Ctr, Birmingham, AL 35213 USA.
[McBane, Sarah] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
[Thomas, Tyan] Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA USA.
[Thomas, Tyan] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Karr, Samantha] Midwestern Univ, Coll Pharm Glendale, Glendale, AZ USA.
RP Kelley, KW (reprint author), Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
EM watsokm@auburn.edu
NR 3
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 15
PY 2012
VL 69
IS 10
BP 826
EP +
DI 10.2146/ajhp110292
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 073VC
UT WOS:000313770200005
PM 22555078
ER
PT J
AU Childs, L
Alexander, E
Duong, MT
AF Childs, Lindsey
Alexander, Earnest
Minh-Tri Duong
TI Risk evaluation and mitigation strategies: Assessment of a medical
center's policies and procedures
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE Administration; Compliance; Computers; Education; Food and Drug
Administration (US); Hospitals; Quality assurance; Risk management;
Storage; Toxicity
AB Purpose. The results of a hospital's initiative to evaluate and improve compliance with federally mandated risk evaluation and mitigation strategies (REMS) are presented.
Summary. Food and Drug Administration approved REMS plans are required for more than 145 drugs, but clear guidance on strategies for achieving REMS compliance is lacking. As a first step toward determining the extent of REMS compliance at a large medical center, a systematic assessment was conducted to ascertain existing policies and procedures for the use of drugs subject to REMS requirements applicable in the inpatient setting. About 123 drugs with such "inpatient-applicable" REMS requirements were identified; of those, 10 had been ordered by hospital providers during a specified 18-month time frame and were included in the assessment of policies and procedures. The assessment revealed that the hospital lacked a formal REMS policy and had no REMS-compliant procedures in place for 7 evaluated drugs (ambrisentan, buprenorphine naloxone, darbepoetin alfa, epoetin alfa, oxycodone controlled-release tablets, prasugrel, and pregabalin). Pursuant to the compliance assessment, new procedures to help ensure the safe use of those 7 drugs were developed, and REMS-focused educational programs, order-entry system enhancements, and drug storage modifications were implemented.
Conclusion. Quality-improvement initiatives including staff education, incorporation of REMS requirements into existing policy, development of an electronic resource, and creation of a separate storage section for drugs subject to REMS were implemented at a large academic medical center to help ensure compliance with inpatient-applicable REMS requirements.
C1 [Childs, Lindsey] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Childs, Lindsey; Alexander, Earnest; Minh-Tri Duong] Tampa Gen Hosp, Serv Pharm, Tampa, FL 33606 USA.
[Alexander, Earnest] Tampa Gen Hosp, Clin Pharm Serv, Tampa, FL 33606 USA.
[Minh-Tri Duong] Tampa Gen Hosp, Residency Programs, Tampa, FL 33606 USA.
RP Childs, L (reprint author), S Texas Vet Hlth Care Syst, 7400 Merton Minter St, San Antonio, TX 78229 USA.
EM lmchilds000410@gmail.com
NR 6
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 15
PY 2012
VL 69
IS 10
BP 885
EP 889
DI 10.2146/ajhp110356
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 073VC
UT WOS:000313770200012
PM 22555085
ER
PT J
AU Schiros, CG
Dell'Italia, LJ
Gladden, JD
Clark, D
Aban, I
Gupta, H
Lloyd, SG
McGiffin, DC
Perry, G
Denney, TS
Ahmed, MI
AF Schiros, Chun G.
Dell'Italia, Louis J.
Gladden, James D.
Clark, Donald, III
Aban, Inmaculada
Gupta, Himanshu
Lloyd, Steven G.
McGiffin, David C.
Perry, Gilbert
Denney, Thomas S., Jr.
Ahmed, Mustafa I.
TI Magnetic Resonance Imaging With 3-Dimensional Analysis of Left
Ventricular Remodeling in Isolated Mitral Regurgitation Implications
Beyond Dimensions
SO CIRCULATION
LA English
DT Article
DE magnetic resonance imaging; surgery; ventricular dysfunction left;
ventricular remodeling
ID VALVE-REPLACEMENT; PERFORMANCE; SURGERY; ECHOCARDIOGRAPHY;
RECONSTRUCTION; DETERMINANTS; DYSFUNCTION; PREDICTION; GEOMETRY;
SURVIVAL
AB Background-Although surgery is indicated in patients with mitral regurgitation (MR) when left ventricular (LV) end-systolic (LVES) dimension is >40 mm, LV ejection fraction may decrease after mitral valve surgery. We hypothesize that significant LV remodeling before surgery is not reflected by standard echocardiographic parameters measured at the base of the heart.
Methods and Results-Ninety-four patients (age, 54 +/- 11 years; 38% female) with degenerative isolated MR underwent cine magnetic resonance imaging with tissue tagging and 3-dimensional analysis. In 51 control subjects (age, 44 +/- 14 years; 53% female), the relation between LVES volume (LVESV) and LVES dimension was quadratic, whereas in 94 MR patients, this relation was cubic, indicating a greater increase in LVESV per LVES dimension among MR patients. Moreover, magnetic resonance imaging LVESV from summated serial short-axis slices was significantly greater than LVESV assessed with the Bullet formula in MR patients, attributed to a more spherical remodeling distal to the tips of the papillary muscles (P<0.001). Thirty-five patients underwent mitral valve repair per current guideline recommendations. LV ejection fraction decreased from 61 +/- 7% to 54 +/- 8% (P<0.0001) and maximum shortening decreased significantly below normal at 1 year postoperatively (P<0.0001). Despite normalization of LV stroke volume and LV end-diastolic volume/mass ratio, there was a persistent significant increase in distal LVES 3-dimensional radius/wall thickness ratio and LVESV index after surgery.
Conclusions-Despite apparently preserved LVES dimension, MR patients demonstrate significant spherical mid to apical LVES remodeling that contributes to higher LVESV than predicted by standard geometry-based calculations. Decreased LV strain after surgery suggests that a volumetric analysis of LV remodeling and function may be preferred to evaluate disease progression in isolated MR.
C1 [Schiros, Chun G.; Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Samuel Ginn Coll Engn, Auburn, AL 36849 USA.
[Dell'Italia, Louis J.; Gupta, Himanshu; Lloyd, Steven G.; Perry, Gilbert] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Dell'Italia, Louis J.; Gladden, James D.; Clark, Donald, III; Gupta, Himanshu; Lloyd, Steven G.; McGiffin, David C.; Ahmed, Mustafa I.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
RP Ahmed, MI (reprint author), Univ Alabama Birmingham, Dept Med, UAB Ctr Heart Failure Res, Div Cardiol, 434 BMR2,901 19th St S, Birmingham, AL 35294 USA.
EM mahmed@uab.edu
FU National Institutes of Health Specialized Center of Clinically Oriented
Research in Cardiac Dysfunction [P50-HL077100]
FX This work was supported by National Institutes of Health Specialized
Center of Clinically Oriented Research in Cardiac Dysfunction
P50-HL077100.
NR 36
TC 24
Z9 25
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 15
PY 2012
VL 125
IS 19
BP 2334
EP +
DI 10.1161/CIRCULATIONAHA.111.073239
PG 13
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 981YQ
UT WOS:000307009202013
PM 22496130
ER
PT J
AU Esterberg, M
Compton, M
AF Esterberg, Michelle
Compton, Michael
TI Family history of psychosis negatively impacts age at onset, negative
symptoms, and duration of untreated illness and psychosis in
first-episode psychosis patients
SO PSYCHIATRY RESEARCH
LA English
DT Article
DE Age at onset; Duration of untreated psychosis (DUP); Family history;
First-episode psychosis; Schizophrenia
ID SCHIZOPHRENIA SPECTRUM DISORDERS; GENDER-DIFFERENCES; SPORADIC
SCHIZOPHRENIA; SEX-DIFFERENCES; EPISODE; RISK; PSYCHOPATHOLOGY;
DETERMINANTS; TRANSMISSION; FAMILIALITY
AB Family history (FH) of psychosis has been a focus of investigations attempting to explain the heterogeneity in schizophrenia. Previous studies have demonstrated that FH is associated with earlier age at onset, severity of positive and negative symptoms, and the duration of untreated illness (DUI). The current study examined the impact of FH on the clinical presentation and help-seeking behaviors of a well-characterized, first-episode sample. The present study utilized the Symptom Onset in Schizophrenia (SOS) Inventory, the Positive and Negative Syndrome Scale (PANSS), and structured interviews on FH to examine these relationships in a large (n = 152) sample of predominantly African American patients. Results showed that patients with a first-degree FH of psychosis had a younger age at onset of both the prodrome and psychosis, but did not differ in duration of prodromal period. Furthermore, FH and sex interacted to influence severity of negative, but not positive symptoms. Finally, FH interacted with sex to influence both the DUI and DUP in that only males with FH had longer DUI and DUP. The findings have implications for understanding the impact of specific family-related mechanisms on both clinical and help-seeking factors, as well as for informing future family-based intervention efforts. Published by Elsevier Ireland Ltd.
C1 [Esterberg, Michelle] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Mental Hlth Serv, Seattle, WA 98108 USA.
[Compton, Michael] George Washington Univ, Sch Med & Hlth Sci, Dept Psychiat & Behav Sci, Washington, DC 20037 USA.
RP Esterberg, M (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Mental Hlth Serv, Mail Stop S-116,1660 S Columbian Way, Seattle, WA 98108 USA.
EM michelle.esterberg@va.gov; mcompton@mfa.gwu.edu
FU National Institute of Mental Health [K23 MH067589, R01 MH081011]
FX This work was supported by grants K23 MH067589 and R01 MH081011 from the
National Institute of Mental Health to the second author (MTC).
NR 61
TC 16
Z9 16
U1 3
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0165-1781
J9 PSYCHIAT RES
JI Psychiatry Res.
PD MAY 15
PY 2012
VL 197
IS 1-2
BP 23
EP 28
DI 10.1016/j.psychres.2012.03.001
PG 6
WC Psychiatry
SC Psychiatry
GA 975WE
UT WOS:000306541400005
PM 22503358
ER
PT J
AU Huang, G
Wang, D
Khan, UI
Zeb, I
Manson, JE
Miller, V
Hodis, HN
Budoff, MJ
Merriam, GR
Harman, MS
Brinton, EA
Cedars, MI
Su, YL
Lobo, RA
Naftolin, F
Santoro, N
Taylor, HS
Wildman, RP
AF Huang, Gary
Wang, Dan
Khan, Unab I.
Zeb, Irfan
Manson, Joann E.
Miller, Virginia
Hodis, Howard N.
Budoff, Matthew J.
Merriam, George R.
Harman, Mitchell S.
Brinton, Eliot A.
Cedars, Marcelle I.
Su, Yali
Lobo, Rogerio A.
Naftolin, Frederick
Santoro, Nanette
Taylor, Hugh S.
Wildman, Rachel P.
TI Associations between retinol-binding protein 4 and cardiometabolic risk
factors and subclinical atherosclerosis in recently postmenopausal
women: cross-sectional analyses from the KEEPS study
SO CARDIOVASCULAR DIABETOLOGY
LA English
DT Article
DE Retinol-binding protein 4; Subclinical atherosclerosis; Risk factors;
Women
ID CORONARY-ARTERY CALCIUM; INTIMA-MEDIA THICKNESS; INSULIN-RESISTANCE;
CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; SERUM
RETINOL-BINDING-PROTEIN-4; GLUCOSE-TOLERANCE; NONOBESE SUBJECTS;
OBESITY; OVERWEIGHT
AB Background: The published literature regarding the relationships between retinol-binding protein 4 (RBP4) and cardiometabolic risk factors and subclinical atherosclerosis is conflicting, likely due, in part, to limitations of frequently used RBP4 assays. Prior large studies have not utilized the gold-standard western blot analysis of RBP4 levels.
Methods: Full-length serum RBP4 levels were measured by western blot in 709 postmenopausal women screened for the Kronos Early Estrogen Prevention Study. Cross-sectional analyses related RBP4 levels to cardiometabolic risk factors, carotid artery intima-media thickness (CIMT), and coronary artery calcification (CAC).
Results: The mean age of women was 52.9 (+/- 2.6) years, and the median RBP4 level was 49.0 (interquartile range 36.9-61.5) mu g/mL. Higher RBP4 levels were weakly associated with higher triglycerides (age, race, and smoking-adjusted partial Spearman correlation coefficient = 0.10; P = 0.01), but were unrelated to blood pressure, cholesterol, C-reactive protein, glucose, insulin, and CIMT levels (all partial Spearman correlation coefficients <= 0.06, P > 0.05). Results suggested a curvilinear association between RBP4 levels and CAC, with women in the bottom and upper quartiles of RBP4 having higher odds of CAC (odds ratio [95% confidence interval] 2.10 [1.07-4.09], 2.00 [1.02-3.92], 1.64 [0.82-3.27] for the 1st, 3rd, and 4th RBP4 quartiles vs. the 2nd quartile). However, a squared RBP4 term in regression modeling was non-significant (P = 0.10).
Conclusions: In these healthy, recently postmenopausal women, higher RBP4 levels were weakly associated with elevations in triglycerides and with CAC, but not with other risk factors or CIMT. These data using the gold standard of RBP4 methodology only weakly support the possibility that perturbations in RBP4 homeostasis may be an additional risk factor for subclinical coronary atherosclerosis.
C1 [Huang, Gary; Wang, Dan; Wildman, Rachel P.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Wildman, Rachel P.] Albert Einstein Coll Med, Bronx, NY 10461 USA.
[Khan, Unab I.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
[Zeb, Irfan; Budoff, Matthew J.] Harbor UCLA, Los Angeles Biomed Res Inst, Div Cardiol, Torrance, CA USA.
[Manson, Joann E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Miller, Virginia] Mayo Clin, Dept Surg, Rochester, MN USA.
[Miller, Virginia] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN USA.
[Hodis, Howard N.] Univ So Calif, Keck Sch Med, Atherosclerosis Res Unit, Los Angeles, CA 90033 USA.
[Merriam, George R.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Merriam, George R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Harman, Mitchell S.] Kronos Longev Res Inst, Phoenix, AZ USA.
[Brinton, Eliot A.] Univ Utah, Sch Med, Dept Cardiovasc Genet, Salt Lake City, UT USA.
[Cedars, Marcelle I.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA.
[Su, Yali] SliverCreek Technol, Gilbert, AZ USA.
[Lobo, Rogerio A.] Columbia Univ, Coll Med, Dept Obstet & Gynecol, New York, NY USA.
[Naftolin, Frederick] NYU, Dept Obstet & Gynecol, Sch Med, New York, NY 10016 USA.
[Santoro, Nanette] Univ Colorado Denver, Sch Med, Dept Obstet & Gynecol & Womens Hlth, Aurora, CO USA.
[Taylor, Hugh S.] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.
RP Wildman, RP (reprint author), Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
EM Rachel.wildman@einstein.yu.edu
FU Aurora Foundation; National Institutes of Health (NIH) [HL90639, 1 UL1
RR024150, Mayo CTSA 1 UL1 RR024150]; Mayo Foundation [CTSA UL1
RR024139]; National Center for Research Resources (NCRR) [UL1 RR024131];
NIH [HL094581]
FX KEEPS is funded by grants from the Aurora Foundation to the Kronos
Longevity Research Institute, National Institutes of Health (NIH)
HL90639 to VMM, 1 UL1 RR024150, Mayo CTSA 1 UL1 RR024150, the Mayo
Foundation, CTSA UL1 RR024139 and UL1 RR024131 from the National Center
for Research Resources (NCRR), a component of at NIH and NIH Roadmap for
Medical Research. The manuscript's contents are solely the
responsibility of the authors and do not necessarily represent the
official view of NCRR or NIH. Information on NCRR is available at
http://www.ncrr.nih.gov. Study medications were supplied in part by
Bayer Health Care and by Abbott Pharmaceuticals. RBP4, insulin, and CRP
assays were funded by NIH grant HL094581 to Dr. Wildman.
NR 40
TC 10
Z9 11
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2840
J9 CARDIOVASC DIABETOL
JI Cardiovasc. Diabetol.
PD MAY 15
PY 2012
VL 11
AR 52
DI 10.1186/1475-2840-11-52
PG 8
WC Cardiac & Cardiovascular Systems; Endocrinology & Metabolism
SC Cardiovascular System & Cardiology; Endocrinology & Metabolism
GA 973MA
UT WOS:000306363000001
PM 22587616
ER
PT J
AU Alef, MJ
Tzeng, E
Zuckerbraun, BS
AF Alef, Matthew J.
Tzeng, Edith
Zuckerbraun, Brian S.
TI Nitric oxide and nitrite-based therapeutic opportunities in intimal
hyperplasia
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Review
DE Xanthine oxidoreductase; Nitric oxide; Arginase; Nitrate; Vascular
injury
ID SMOOTH-MUSCLE-CELLS; MEDIATED GENE-TRANSFER; PERIPHERAL
ARTERIAL-DISEASE; CYCLIC GUANOSINE-MONOPHOSPHATE; INHIBITS NEOINTIMAL
FORMATION; L-ARGININE SUPPLEMENTATION; VIVO ISCHEMIA-REPERFUSION;
REVERSED VEIN GRAFTS; RAT CAROTID ARTERIES; IN-STENT RESTENOSIS
AB Vascular intimal hyperplasia (IH) limits the long term efficacy of current surgical and percutaneous therapies for atherosclerotic disease. There are extensive changes in gene expression and cell signaling in response to vascular therapies, including changes in nitric oxide (NO) signaling. NO is well recognized for its vasoregulatory properties and has been investigated as a therapeutic treatment for its vasoprotective abilities. The circulating molecules nitrite (NO2-) and nitrate (NO3-), once thought to be stable products of NO metabolism, are now recognized as important circulating reservoirs of NO and represent a complementary source of NO in contrast to the classic L-arginine-NO-synthase pathway. Here we review the background of IH, its relationship with the NO and nitrite/nitrate pathways, and current and future therapeutic opportunities for these molecules. Published by Elsevier Inc.
C1 [Alef, Matthew J.; Tzeng, Edith; Zuckerbraun, Brian S.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA.
[Tzeng, Edith; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Zuckerbraun, BS (reprint author), F1200 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
FU BLRD VA [I01 BX000635]
NR 163
TC 9
Z9 9
U1 1
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
EI 1089-8611
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD MAY 15
PY 2012
VL 26
IS 4
SI SI
BP 285
EP 294
DI 10.1016/j.niox.2012.03.014
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 958UJ
UT WOS:000305265900013
PM 22504069
ER
PT J
AU Banks, WA
AF Banks, William A.
TI Drug delivery to the brain in Alzheimer's disease: Consideration of the
blood-brain barrier
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Blood-brain barrier; Alzheimer's disease; Drug delivery; Cerebrospinal
fluid; Biologicals; Peptides; Regulatory proteins; Transport;
Transmembrane diffusion; P-glycoprotein
ID AMYLOID-BETA-PEPTIDE; CENTRAL-NERVOUS-SYSTEM; AGED SAMP8 MICE;
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MICROVASCULAR ENDOTHELIAL-CELLS;
ACTIVATING POLYPEPTIDE PACAP; SENESCENCE-ACCELERATED MICE;
P-GLYCOPROTEIN EXPRESSION; GLUCAGON-LIKE PEPTIDES; NECROSIS-FACTOR-ALPHA
AB The successful treatment of Alzheimer's disease (AD) will require drugs that can negotiate the blood brain barrier (BBB). However, the BBB is not simply a physical barrier, but a complex interface that is in intimate communication with the rest of the central nervous system (CNS) and influenced by peripheral tissues. This review examines three aspects of the BBB in AD. First, it considers how the BBB may be contributing to the onset and progression of AD. In this regard, the BBB itself is a therapeutic target in the treatment of AD. Second, it examines how the BBB restricts drugs that might otherwise be useful in the treatment of AD and examines strategies being developed to deliver drugs to the CNS for the treatment of AD. Third, it considers how drug penetration across the AD BBB may differ from the BBB of normal aging. In this case, those differences can complicate the treatment of CNS diseases such as depression, delirium, psychoses, and pain control in the AD population. Published by Elsevier B.V.
C1 [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Banks, WA (reprint author), Bldg 1,Rm 810A,1660 S Columbian Way, Seattle, WA 98108 USA.
EM wabanks1@uw.edu
FU VA Merit Review; [RO1 AG029839]
FX This works was supported by VA Merit Review and RO1 AG029839.
NR 195
TC 39
Z9 40
U1 8
U2 69
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD MAY 15
PY 2012
VL 64
IS 7
BP 629
EP 639
DI 10.1016/j.addr.2011.12.005
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 943OA
UT WOS:000304132500006
PM 22202501
ER
PT J
AU Wheeler, C
Nabors, LB
Barnum, S
Yang, XH
Hu, XZ
Schoeb, TR
Chen, DQ
Ardelt, AA
King, PH
AF Wheeler, Crystal
Nabors, L. Burt
Barnum, Scott
Yang, Xiuhua
Hu, Xianzhen
Schoeb, Trenton R.
Chen, Dongquan
Ardelt, Agnieszka A.
King, Peter H.
TI Sex hormone-dependent attenuation of EAE in a transgenic mouse with
astrocytic expression of the RNA regulator HuR
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE RNA binding protein; Posttranscriptional gene regulation; RNA stability;
AU-rich element; Estrogen
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; MEDIATED
TRANSLATION; STABILITY; PROTEINS; ESTROGEN; REGION; MICE
AB In experimental autoimmune encephalomyelitis (EAE) and other neurodegenerative diseases, astrocytes play an important role in promoting or attenuating the inflammatory response through induction of different cytokines and growth factors. HuR plays a major role in regulating many of these factors by modulating RNA stability and translational efficiency. Here, we engineered transgenic mice to express HuR in astrocytes using the human glial fibrillary acidic protein promoter and found that female transgenic mice had significantly less clinical disability and histopathological changes in the spinal cord. Ovariectomy prior to EAE induction abrogated the protective effect. Our findings support a role for the astrocyte and posttranscriptional regulation in hormonally-mediated attenuation of EAE. Published by Elsevier B.V.
C1 [Wheeler, Crystal; Nabors, L. Burt] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA.
[Nabors, L. Burt; Yang, Xiuhua; King, Peter H.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA.
[Barnum, Scott; Hu, Xianzhen] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
[Schoeb, Trenton R.; King, Peter H.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[Chen, Dongquan] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL 35294 USA.
[Ardelt, Agnieszka A.] Univ Chicago, Dept Neurol, Med Ctr, Chicago, IL 60637 USA.
[King, Peter H.] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA.
[King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.
RP King, PH (reprint author), Sparks Ctr, Suite 260,1720-7th Ave S, Birmingham, AL 35233 USA.
EM pking@uab.edu
FU VA Merit Review; NIH [R01 NS064133, R01 CA112397, R01 NS46032]; UAB
Transgenic and Microarray Facilities [P30 CA013148-39]; UAB Neuroscience
Blueprint Core [NS57098]
FX This work was supported by a VA Merit Review, and NIH R01 NS064133
(PHK), R01 CA112397 (LBN), R01 NS46032 (SRB), the UAB Transgenic and
Microarray Facilities (P30 CA013148-39), and the UAB Neuroscience
Blueprint Core (NS57098). Histology services were provided by the UAB
Comparative Pathology Laboratory.
NR 19
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD MAY 15
PY 2012
VL 246
IS 1-2
BP 34
EP 37
DI 10.1016/j.jneuroim.2012.02.014
PG 4
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 942FA
UT WOS:000304026900005
PM 22445740
ER
PT J
AU Sigel, K
Wisnivesky, J
Gordon, K
Dubrow, R
Justice, A
Brown, ST
Goulet, J
Butt, AA
Crystal, S
Rimland, D
Rodriguez-Barradas, M
Gibert, C
Park, LS
Crothers, K
AF Sigel, Keith
Wisnivesky, Juan
Gordon, Kirsha
Dubrow, Robert
Justice, Amy
Brown, Sheldon T.
Goulet, Joseph
Butt, Adeel A.
Crystal, Stephen
Rimland, David
Rodriguez-Barradas, Maria
Gibert, Cynthia
Park, Lesley S.
Crothers, Kristina
TI HIV as an independent risk factor for incident lung cancer
SO AIDS
LA English
DT Article
DE HIV; immunosuppression; incidence; lung cancer; non-AIDS-defining
malignancy; smoking
ID ACTIVE ANTIRETROVIRAL THERAPY; WOMENS INTERAGENCY HIV; INJECTION-DRUG
USERS; DEFINING MALIGNANCIES; CIGARETTE-SMOKING; INFECTED PATIENTS;
UNITED-STATES; AIDS; IMMUNODEFICIENCY; MORTALITY
AB Background: It is unclear whether the elevated rate of lung cancer among HIV-infected persons is due to biological effects of HIV, surveillance bias, or excess smoking. We compared the incidence of lung cancer between HIV-infected and demographically similar HIV-uninfected patients, accounting for smoking and stage of lung cancer at diagnosis.
Design: Data from the Veterans Aging Cohort Study Virtual Cohort were linked to data from the Veterans Affairs Central Cancer Registry, resulting in an analytic cohort of 37 294 HIV-infected patients and 75 750 uninfected patients.
Methods: We calculated incidence rates of pathologically confirmed lung cancer by dividing numbers of cases by numbers of person-years at risk. We used Poisson regression to determine incidence rate ratios (IRRs), adjusting for age, sex, race/ethnicity, smoking prevalence, previous bacterial pneumonia, and chronic obstructive pulmonary disease.
Results: The incidence rate of lung cancer in HIV-infected patients was 204 cases per 100 000 person-years [95% confidence interval (CI) 167-249] and among uninfected patients was 119 cases per 100 000 person-years (95% CI 110-129). The IRR of lung cancer associated with HIV infection remained significant after multivariable adjustment (IRR 1.7; 95% CI 1.5-1.9). Lung cancer stage at presentation did not differ between HIV-infected and uninfected patients.
Conclusion: In our cohort of demographically similar HIV-infected and uninfected patients, HIV infection was an independent risk factor for lung cancer after controlling for potential confounders including smoking. The similar stage distribution between the two groups indicated that surveillance bias was an unlikely explanation for this finding. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Sigel, Keith; Wisnivesky, Juan; Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
[Gordon, Kirsha; Dubrow, Robert; Justice, Amy; Goulet, Joseph] Yale Univ, Sch Med, Vet Affairs VA Connecticut Healthcare Syst, New Haven, CT USA.
[Gordon, Kirsha; Dubrow, Robert; Justice, Amy; Goulet, Joseph] Yale Univ, Sch Publ Hlth, Vet Affairs VA Connecticut Healthcare Syst, New Haven, CT USA.
[Brown, Sheldon T.] James J Peters Vet Affairs VA Med Ctr, Bronx, NY USA.
[Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Butt, Adeel A.] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates.
[Crystal, Stephen] Rutgers State Univ, New Brunswick, NJ 08903 USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta Vet Affairs VA Med Ctr, Decatur, GA 30033 USA.
[Rodriguez-Barradas, Maria] Michael E DeBakey Vet Affairs VA Med Ctr, Houston, TX USA.
[Rodriguez-Barradas, Maria] Baylor Coll Med, Houston, TX 77030 USA.
[Gibert, Cynthia] George Washington Univ, Sch Med, Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Crothers, Kristina] Univ Washington, Dept Internal Med, Div Pulm & Crit Care Med, Sch Med, Seattle, WA USA.
RP Sigel, K (reprint author), 17 E 102nd St,6th Floor, New York, NY 10029 USA.
EM keith.sigel@mssm.edu
OI Goulet, Joseph/0000-0002-0842-804X; Sigel, Keith/0000-0002-4051-4861;
Crothers, Kristina/0000-0001-9702-0371
FU National Center for Research Resources [KL2RR029885]; National Institute
on Alcohol and Alcohol Abuse [3U01 AA 13566]; National Institute of
Aging [K23 AG00826]; Robert Wood Johnson Generalist Faculty Scholar
Award; National Institute on Aging, National Institute of Mental Health;
Veterans Health Administration; Veterans Health Administration Office of
Research and Development and Public Health Strategic Healthcare Group;
National Heart, Lung, and Blood Institute [NIH/NHLBI R01 HL090342];
Novartis Pharmaceuticals; GlaxoSmithKline
FX This study was supported by the National Center for Research Resources
(KL2RR029885 to K. S.), National Institute on Alcohol and Alcohol Abuse
(3U01 AA 13566), National Institute of Aging (K23 AG00826), Robert Wood
Johnson Generalist Faculty Scholar Award, an interagency agreement
between National Institute on Aging, National Institute of Mental Health
and the Veterans Health Administration, and the Veterans Health
Administration Office of Research and Development and Public Health
Strategic Healthcare Group (to A.C.J.), and National Heart, Lung, and
Blood Institute (NIH/NHLBI R01 HL090342 to K. C.).; J.P.W. reports
receiving lecture honorarium from Novartis Pharmaceuticals, and a
research grant from GlaxoSmithKline.
NR 34
TC 77
Z9 77
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD MAY 15
PY 2012
VL 26
IS 8
BP 1017
EP 1025
DI 10.1097/QAD.0b013e328352d1ad
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 937JY
UT WOS:000303656000013
PM 22382152
ER
PT J
AU Fan, VS
Gaziano, JM
Lew, R
Bourbeau, J
Adams, SG
Leatherman, S
Thwin, SS
Huang, GD
Robbins, R
Sriram, PS
Sharafkhaneh, A
Mador, MJ
Sarosi, G
Panos, RJ
Rastogi, P
Wagner, TH
Mazzuca, SA
Shannon, C
Colling, C
Liang, MH
Stoller, JK
Fiore, L
Niewoehner, DE
AF Fan, Vincent S.
Gaziano, J. Michael
Lew, Robert
Bourbeau, Jean
Adams, Sandra G.
Leatherman, Sarah
Thwin, Soe Soe
Huang, Grant D.
Robbins, Richard
Sriram, Peruvemba S.
Sharafkhaneh, Amir
Mador, M. Jeffery
Sarosi, George
Panos, Ralph J.
Rastogi, Padmashri
Wagner, Todd H.
Mazzuca, Steven A.
Shannon, Colleen
Colling, Cindy
Liang, Matthew H.
Stoller, James K.
Fiore, Louis
Niewoehner, Dennis E.
TI A Comprehensive Care Management Program to Prevent Chronic Obstructive
Pulmonary Disease Hospitalizations A Randomized, Controlled Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID SELF-MANAGEMENT; ACUTE EXACERBATIONS; ACTION PLAN; COPD; HEALTH;
METAANALYSIS; MORTALITY; DIAGNOSIS; EDUCATION; RECOVERY
AB Background: Improving a patient's ability to self-monitor and manage changes in chronic obstructive pulmonary disease (COPD) symptoms may improve outcomes.
Objective: To determine the efficacy of a comprehensive care management program (CCMP) in reducing the risk for COPD hospitalization.
Design: A randomized, controlled trial comparing CCMP with guideline-based usual care. (ClinicalTrials.gov registration number: NCT00395083)
Setting: 20 Veterans Affairs hospital-based outpatient clinics.
Participants: Patients hospitalized for COPD in the past year.
Intervention: The CCMP included COPD education during 4 individual sessions and 1 group session, an action plan for identification and treatment of exacerbations, and scheduled proactive telephone calls for case management. Patients in both the intervention and usual care groups received a COPD informational booklet; their primary care providers received a copy of COPD guidelines and were advised to manage their patients according to these guidelines. Patients were randomly assigned, stratifying by site based on random, permuted blocks of variable size.
Measurements: The primary outcome was time to first COPD hospitalization. Staff blinded to study group performed telephone-based assessment of COPD exacerbations and hospitalizations, and all hospitalizations were blindly adjudicated. Secondary outcomes included non-COPD health care use, all-cause mortality, health-related quality of life, patient satisfaction, disease knowledge, and self-efficacy.
Results: Of the eligible patients, 209 were randomly assigned to the intervention group and 217 to the usual care group. Citing serious safety concerns, the data monitoring committee terminated the intervention before the trial's planned completion after 426 (44%) of the planned total of 960 patients were enrolled. Mean follow-up was 250 days. When the study was stopped, the 1-year cumulative incidence of COPD-related hospitalization was 27% in the intervention group and 24% in the usual care group (hazard ratio, 1.13 [95% CI, 0.70 to 1.80]; P = 0.62). There were 28 deaths from all causes in the intervention group versus 10 in the usual care group (hazard ratio, 3.00 [CI, 1.46 to 6.17]; P = 0.003). Cause could be assigned in 27 (71%) deaths. Deaths due to COPD accounted for the largest difference: 10 in the intervention group versus 3 in the usual care group (hazard ratio, 3.60 [CI, 0.99 to 13.08]; P = 0.053).
Limitations: Available data could not fully explain the excess mortality in the intervention group. Ability to assess the quality of the educational sessions provided by the case managers was limited.
Conclusion: A CCMP in patients with severe COPD had not decreased COPD-related hospitalizations when the trial was stopped prematurely. The CCMP was associated with unanticipated excess mortality, results that differ markedly from similar previous trials. A data monitoring committee should be considered in the design of clinical trials involving behavioral interventions.
C1 [Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA.
Vet Affairs Boston Healthcare Syst, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Montreal Chest Inst, Montreal, PQ, Canada.
S Texas Vet Hlth Care Syst, San Antonio, TX USA.
Dept Vet Affairs Cooperat Studies Program, Washington, DC USA.
Phoenix Vet Affairs Med Ctr, Phoenix, AZ USA.
N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA.
Michael E DeBakey VA Med Ctr, Houston, TX USA.
Vet Affairs Western New York Healthcare Syst, Buffalo, NY USA.
Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA.
Dallas Vet Affairs Med Ctr, Dallas, TX USA.
Vet Affairs Palo Alto Healthcare Syst, Menlo Pk, CA USA.
Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA.
Indiana Univ Sch Med, Indianapolis, IN USA.
Vet Affairs Cooperat Studies Program Clin Res Pha, Albuquerque, NM USA.
Minneapolis Vet Affairs Healthcare Syst, Minneapolis, MN USA.
Cleveland Clin, Cleveland, OH 44106 USA.
RP Fan, VS (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, 1600 S Columbian Way, Seattle, WA 98108 USA.
EM vincent.fan@va.gov
OI Sriram, P.S/0000-0002-6103-3573
FU Veterans Affairs Cooperative Study Program; Veterans Affairs Office of
Research and Development [560]
FX Veterans Affairs Cooperative Study Program.; By the Cooperative Studies
Program (CSP #560), Veterans Affairs Office of Research and Development.
NR 43
TC 133
Z9 133
U1 4
U2 24
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 15
PY 2012
VL 156
IS 10
BP 673
EP U46
DI 10.7326/0003-4819-156-10-201205150-00003
PG 18
WC Medicine, General & Internal
SC General & Internal Medicine
GA 944IQ
UT WOS:000304193400013
PM 22586006
ER
PT J
AU Hayden, SJ
Albert, TJ
Watkins, TR
Swenson, ER
AF Hayden, Shailaja J.
Albert, Tyler J.
Watkins, Timothy R.
Swenson, Erik R.
TI Anemia in Critical Illness Insights into Etiology, Consequences, and
Management
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Review
DE anemia; red blood cell; transfusion; erythropoietin; critical illness
ID BLOOD-CELL TRANSFUSION; RANDOMIZED CONTROLLED-TRIAL; ACUTE LUNG INJURY;
RESPIRATORY-DISTRESS-SYNDROME; RECOMBINANT-HUMAN-ERYTHROPOIETIN; ACUTE
MYOCARDIAL-INFARCTION; SEVERE ISOVOLEMIC ANEMIA; PLACEBO-CONTROLLED
TRIAL; CHRONIC KIDNEY-DISEASE; INTENSIVE-CARE UNITS
AB Anemia is common in the intensive care unit, and may be associated with adverse consequences. However, current options for correcting anemia are not without problems and presently lack convincing efficacy for improving survival in critically ill patients. In this article we review normal red blood cell physiology; etiologies of anemia in the intensive care unit; its association with adverse outcomes; and the risks, benefits, and efficacy of various management strategies, including blood transfusion, erythropoietin, blood substitutes, iron therapy, and minimization of diagnostic phlebotomy.
C1 [Hayden, Shailaja J.; Albert, Tyler J.; Watkins, Timothy R.; Swenson, Erik R.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Watkins, Timothy R.] Puget Sound Blood Ctr, Res Inst, Seattle, WA 98104 USA.
[Albert, Tyler J.; Swenson, Erik R.] Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA.
RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Box S-111-PULM,1660 S Columbian Way, Seattle, WA 98108 USA.
EM eswenson@u.washington.edu
FU National Institutes of Health, National Institute of General Medical
Sciences [K23GM086729]; Department of Veterans Affairs
FX Supported by a grant from the National Institutes of Health, National
Institute of General Medical Sciences (K23GM086729; T.R.W.); supported
by a Merit Review grant from the Department of Veterans Affairs
(E.R.S.). No source of support was used in the creation of this
manuscript. None of the authors has a financial relationship with a
commercial entity that has an interest in the subject of this
manuscript.
NR 117
TC 33
Z9 34
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1073-449X
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD MAY 15
PY 2012
VL 185
IS 10
BP 1049
EP 1057
DI 10.1164/rccm.201110-1915CI
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 936WJ
UT WOS:000303620400008
PM 22281832
ER
PT J
AU Sandoval, KE
Farr, SA
Banks, WA
Crider, AM
Morley, JE
Witt, KA
AF Sandoval, Karin E.
Farr, Susan A.
Banks, William A.
Crider, Albert M.
Morley, John E.
Witt, Ken A.
TI Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases
extracellular and intracellular A beta(1-42) trimers
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE NNC 26-9100; Somatostatin receptor subtype-4; Neprilysin; Amyloid-beta
oligomers
ID AMYLOID PRECURSOR PROTEIN; A-BETA LEVELS; ALZHEIMERS-DISEASE; SAMP8
MICE; SYNAPTIC PLASTICITY; OBJECT RECOGNITION; COGNITIVE DEFICITS;
PLAQUE-FORMATION; TRANSGENIC MICE; MEMORY
AB Soluble amyloid beta-protein (A beta) oligomers are primary mediators of synaptic dysfunction associated with the progression of Alzheimer's disease. Such A beta oligomers exist dependent on their rates of aggregation and metabolism. Use of selective somatostatin receptor-subtype agonists have been identified as a potential means to mitigate A beta accumulation in the brain, via regulation of the enzyme neprilysin. Herein, we first evaluated the impact of the somatostatin receptor subtype-4 agonist 1-[3-[N-(5-Bromopyridin-2-yl)-N-(3,4-dichlorobenzyl)amino]propyl]-3-[3-(1H-imidazol-4-yl)propyl]thiourea (NNC 26-9100) on learning and memory in 12-month SAMP8 mice (i.c.v. injection). NNC 26-9100 (0.2 mu g-dose) was shown to enhance both learning (T-maze) and memory (object recognition) compared to vehicle controls. Cortical and hippocampal tissues were evaluated subsequent to NNC 26-9100 (0.2 mu g) or vehicle administration for changes in neprilysin activity, along with protein expression of amyloid-precursor protein (APP), neprilysin, and A beta(1-42) oligomers within respective cellular fractions (extracellular, intracellular and membrane). NNC 26-9100 increased neprilysin activity in cortical tissue, with an associated protein expression increase in the extracellular fraction and decreased in the intracellular fraction. A decrease in intracellular APP expression was found with treatment in both cortical and hippocampal tissues. NNC 26-9100 also significantly decreased expression of A beta(1-42) trimers within both the extracellular and intracellular cortical fractions. No expression changes were found in membrane fractions for any protein. These finding suggest the potential use of selective SSTR4 agonists to mitigate toxic oligomeric forms of A beta(1-42) in critical regions of the brain identified with learning and memory decline. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Sandoval, Karin E.; Crider, Albert M.; Witt, Ken A.] So Illinois Univ, Sch Pharm, Dept Pharmaceut Sci, Edwardsville, IL 62026 USA.
[Farr, Susan A.; Morley, John E.] Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, St Louis, MO USA.
[Farr, Susan A.; Morley, John E.] St Louis Univ, Sch Med, Div Geriatr, Dept Internal Med, St Louis, MO 63103 USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Internal Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Witt, KA (reprint author), So Illinois Univ, Sch Pharm, Dept Pharmaceut Sci, Campus Box 2000, Edwardsville, IL 62026 USA.
EM kwitt@siue.edu
FU Alzheimer's Drug Discovery Foundation [261105.01]; VA Merit Review;
National Institutes of Health National Institute on Aging [R21AG029318]
FX This work was supported by the Alzheimer's Drug Discovery Foundation
(Grant: 261105.01), VA Merit Review, and the National Institutes of
Health National Institute on Aging (Grant: R21AG029318).
NR 42
TC 6
Z9 8
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAY 15
PY 2012
VL 683
IS 1-3
BP 116
EP 124
DI 10.1016/j.ejphar.2012.03.020
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 934HY
UT WOS:000303436200015
PM 22449380
ER
PT J
AU Xu, GG
McMahan, CA
Hildreth, K
Garcia, RA
Herbert, DC
Walter, CA
AF Xu, Guogang
McMahan, C. Alex
Hildreth, Kim
Garcia, Rebecca A.
Herbert, Damon C.
Walter, Christi A.
TI Ionizing radiation-induced mutant frequencies increase transiently in
male germ cells of older mice
SO MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
LA English
DT Article
DE Ionizing radiation; Age; Mutagenesis; Spermatogenic cells; lacI mouse
ID MOUSE MUTATION ASSAY; PARENTAL AGE; PATERNAL-AGE; SPERMATOGENIC CELLS;
HETEROZYGOUS MICE; TRANSGENIC MICE; EXCISION-REPAIR; APERT-SYNDROME;
TIME COURSES; RISK
AB Spontaneous mutant frequency in the male germline increases with age, thereby increasing the risk of siring offspring with genetic disorders. In the present study we investigated the effect of age on ionizing radiation-induced male germline mutagenesis. lad transgenic mice were treated with ionizing radiation at 4-, 15- and 26-month-old, and mutant frequencies were determined for pachytene spermatocytes and round spermatids at 15 days or 49 days after ionizing radiation treatment. Cells collected 15 days after treatment were derivatives of irradiated differentiating spermatogenic cells while cells collected 49 days later were derivatives of spermatogonial stem cells. The results showed that (1) spontaneous mutant frequency increased in spermatogenic cells recovered from nonirradiated old mice (26-months-old), particularly in the round spermatids; (2) mutant frequencies were significantly increased in round spermatids obtained from middle-aged mice (15-months-old) and old age mice (26-months-old) at 15 and 49 days after irradiation compared to the sham-treated old mice; and (3) pachytene spermatocytes obtained from 15- or 26-month-old mice displayed a significantly increased mutant frequency at 15 days post irradiation. This study indicates that age modulates the mutagenic response to ionizing radiation in the male germline. Published by Elsevier B.V.
C1 [Xu, Guogang; Hildreth, Kim; Garcia, Rebecca A.; Herbert, Damon C.; Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[McMahan, C. Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Walter, Christi A.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
[Walter, Christi A.] Audie Murphy Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Walter, CA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
EM walter@uthscsa.edu
FU NIH [AG24364, AG21163]
FX This work was supported by NIH grants AG24364 and AG21163 to Dr. C.A.
Walter. The contents are solely the responsibility of the authors, and
do not necessarily represent the official views of the NIH or VHCS.
NR 41
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1383-5718
J9 MUTAT RES-GEN TOX EN
JI Mutat. Res. Genet. Toxicol. Environ. Mutagen.
PD MAY 15
PY 2012
VL 744
IS 2
BP 135
EP 139
DI 10.1016/j.mrgentox.2012.01.003
PG 5
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 932NO
UT WOS:000303298000003
PM 22314132
ER
PT J
AU Khanna, A
Bush, AL
Swint, JM
Peskin, MF
Street, RL
Naik, AD
AF Khanna, Abhinav
Bush, Amber L.
Swint, J. Michael
Peskin, Melissa Fleschler
Street, Richard L., Jr.
Naik, Aanand D.
TI Hemoglobin A(1c) improvements and better diabetes-specific quality of
life among participants completing diabetes self-management programs: A
nested cohort study
SO HEALTH AND QUALITY OF LIFE OUTCOMES
LA English
DT Article
DE Diabetes-specific quality of life; Diabetes; Quality of life;
Diabetes-39; Self-management; Hemoglobin A(1c)
ID REPORTED HEALTH; CANCER-PATIENTS; OUTCOMES; SURVIVAL; PEOPLE; SCALE;
CARE; CHEMOTHERAPY; COMORBIDITY; VALIDATION
AB Background: Numerous primary care innovations emphasize patient-centered processes of care. Within the context of these innovations, greater understanding is needed of the relationship between improvements in clinical endpoints and patient-centered outcomes. To address this gap, we evaluated the association between glycosylated hemoglobin (HbA(1c)) and diabetes-specific quality of life among patients completing diabetes self-management programs.
Methods: We conducted a retrospective cohort study nested within a randomized comparative effectiveness trial of diabetes self-management interventions in 75 diabetic patients. Multiple linear regression models were developed to examine the relationship between change in HbA(1c) from baseline to one-year follow-up and Diabetes-39 (a diabetes-specific quality of life measure) at one year.
Results: HbA(1c) levels improved for the overall cohort from baseline to one-year follow-up (t (74) = 3.09, p =.0029). One-year follow up HbA(1c) was correlated with worse overall quality of life (r = 0.33, p = 0.004). Improvements in HbA(1c) from baseline to one-year follow-up were associated with greater D-39 diabetes control (beta = 0.23, p = .04) and D-39 sexual functioning (beta = 0.25, p = .03) quality of life subscales.
Conclusions: Improvements in HbA(1c) among participants completing a diabetes self-management program were associated with better diabetes-specific quality of life. Innovations in primary care that engage patients in self-management and improve clinical biomarkers, such as HbA(1c), may also be associated with better quality of life, a key outcome from the patient perspective.
C1 [Khanna, Abhinav; Bush, Amber L.; Street, Richard L., Jr.; Naik, Aanand D.] Baylor Coll Med, Houston, TX 77030 USA.
[Bush, Amber L.; Street, Richard L., Jr.; Naik, Aanand D.] Michael E DeBakey VA Med Ctr 152, Houston Hlth Serv Res & Dev, Ctr Excellence, Houston, TX 77030 USA.
[Swint, J. Michael; Peskin, Melissa Fleschler] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA.
[Street, Richard L., Jr.] Texas A&M Univ, Dept Commun, College Stn, TX 77843 USA.
RP Naik, AD (reprint author), Baylor Coll Med, 1 Baylor Plaza, Houston, TX 77030 USA.
EM anaik@bcm.edu
FU Agency for Healthcare Research and Quality, Centers for Research and
Education on Therapeutics [U18HS016093]; Clinical Scientist Development
Award from the Doris Duke Charitable Foundation; National Institute of
Aging [K23AG027144]; Houston Health Services Research and Development
Center of Excellence at the Michael E. DeBakey Veterans Affairs Medical
Center [HFP90-020]
FX The EPIC study was supported by a grant from the Agency for Healthcare
Research and Quality, Centers for Research and Education on Therapeutics
(U18HS016093; principalinvestigator, Dr Suarez-Almazor). Additional
support for the EPIC Study was provided by a Clinical Scientist
Development Award from the Doris Duke Charitable Foundation (principal
investigator, Dr Naik). Dr Naik received additional support from the
National Institute of Aging (K23AG027144) and the Houston Health
Services Research and Development Center of Excellence (HFP90-020) at
the Michael E. DeBakey Veterans Affairs Medical Center.
NR 44
TC 12
Z9 13
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7525
J9 HEALTH QUAL LIFE OUT
JI Health Qual. Life Outcomes
PD MAY 14
PY 2012
VL 10
AR 48
DI 10.1186/1477-7525-10-48
PG 7
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 986YZ
UT WOS:000307384900001
PM 22583609
ER
PT J
AU Slatore, CG
Cecere, LM
LeTourneau, JL
O'Neil, ME
Duckart, JP
Wiener, RS
Farjah, F
Cooke, CR
AF Slatore, Christopher G.
Cecere, Laura M.
LeTourneau, Jennifer L.
O'Neil, Maya E.
Duckart, Jonathan P.
Wiener, Renda Soylemez
Farjah, Farhood
Cooke, Colin R.
TI Intensive Care Unit Outcomes Among Patients With Lung Cancer in the
Surveillance, Epidemiology, and End Results-Medicare Registry
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CODE STATUS; LIFE; TRENDS; STATES; AGGRESSIVENESS; ADMISSION;
MULTICENTER; POPULATION; MORTALITY; CARCINOMA
AB Purpose
Lung cancer is the leading cause of cancer-related mortality. Intensive care unit (ICU) use among patients with cancer is increasing, but data regarding ICU outcomes for patients with lung cancer are limited.
Patients and Methods
We used the Surveillance, Epidemiology, and End Results (SEER) -Medicare registry (1992 to 2007) to conduct a retrospective cohort study of patients with lung cancer who were admitted to an ICU for reasons other than surgical resection of their tumor. We used logistic and Cox regression to evaluate associations of patient characteristics and hospital mortality and 6-month mortality, respectively. We calculated adjusted associations for mechanical ventilation receipt with hospital and 6-month mortality.
Results
Of the 49,373 patients with lung cancer admitted to an ICU for reasons other than surgical resection, 76% of patients survived the hospitalization, and 35% of patients were alive 6 months after discharge. Receipt of mechanical ventilation was associated with increased hospital mortality (adjusted odds ratio, 6.95; 95% CI, 6.89 to 7.01; P < .001), and only 15% of these patients were alive 6 months after discharge. Of all ICU patients with lung cancer, the percentage of patients who survived 6 months from discharge was 36% for patients diagnosed in 1992 and 32% for patients diagnosed in 2005, whereas it was 16% and 11% for patients who received mechanical ventilation, respectively.
Conclusion
Most patients with lung cancer enrolled in Medicare who are admitted to an ICU die within 6 months of admission. To improve patient-centered care, these results should guide shared decision making between patients with lung cancer and their clinicians before an ICU admission.
C1 [Slatore, Christopher G.; LeTourneau, Jennifer L.; O'Neil, Maya E.; Duckart, Jonathan P.] Portland Vet Affairs VA Med Ctr, Portland, Dorset, England.
[Slatore, Christopher G.; LeTourneau, Jennifer L.; O'Neil, Maya E.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Cecere, Laura M.] Univ Washington, Sch Med, Seattle, WA USA.
[Cecere, Laura M.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Wiener, Renda Soylemez] Edith Nourse Rogers Mem VA Hosp, Bedford, England.
[Wiener, Renda Soylemez] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Farjah, Farhood] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Cooke, Colin R.] Univ Michigan, Ann Arbor, MI 48109 USA.
RP Slatore, CG (reprint author), 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM christopher.slatore@va.gov
OI Wiener, Renda/0000-0001-7712-2135; Slatore,
Christopher/0000-0003-0958-8122; Cooke, Colin/0000-0001-9713-5371
FU University of Washington Division of Pulmonary and Critical Care
Medicine; Veterans Affairs (VA) Health Services [10-025, TPM 61-037];
National Cancer Institute [K07 CA 138772]; Robert Wood Johnson
Foundation
FX Supported by a University of Washington Division of Pulmonary and
Critical Care Medicine Endowment Grant (C. G. S), a Veterans Affairs
(VA) Health Services Research and Development Career Development Award
(Grant No. 10-025, C. G. S.), a VA Health Services Research and
Development Fellowship (Grant. No. TPM 61-037; L. M. C.), a career
development award from the National Cancer Institute (K07 CA 138772; R.
S. W.), and the Robert Wood Johnson Foundation Clinical Scholars Program
(C.R.C).
NR 39
TC 28
Z9 29
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 10
PY 2012
VL 30
IS 14
BP 1686
EP 1691
DI 10.1200/JCO.2011.40.0846
PG 6
WC Oncology
SC Oncology
GA 940TA
UT WOS:000303914800022
PM 22473159
ER
PT J
AU Hempel, S
Newberry, SJ
Maher, AR
Wang, Z
Miles, JNV
Shanman, R
Johnsen, B
Shekelle, PG
AF Hempel, Susanne
Newberry, Sydne J.
Maher, Alicia R.
Wang, Zhen
Miles, Jeremy N. V.
Shanman, Roberta
Johnsen, Breanne
Shekelle, Paul G.
TI Probiotics for the Prevention and Treatment of Antibiotic-Associated
Diarrhea A Systematic Review and Meta-analysis
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID HELICOBACTER-PYLORI ERADICATION; PLACEBO-CONTROLLED TRIAL;
LACTOBACILLUS-ACIDOPHILUS CL1285; CLOSTRIDIUM-DIFFICILE DIARRHEA;
SACCHAROMYCES-BOULARDII; DOUBLE-BLIND; TRIPLE THERAPY; CLINICAL-TRIAL;
BIFIDOBACTERIUM-LACTIS; CONTAINING YOGURT
AB Context Probiotics are live microorganisms intended to confer a health benefit when consumed. One condition for which probiotics have been advocated is the diarrhea that is a common adverse effect of antibiotic use.
Objective To evaluate the evidence for probiotic use in the prevention and treatment of antibiotic-associated diarrhea (AAD).
Data Sources Twelve electronic databases were searched (DARE, Cochrane Library of Systematic Reviews, CENTRAL, PubMed, EMBASE, CINAHL, AMED, MANTIS, TOXLINE, ToxFILE, NTIS, and AGRICOLA) and references of included studies and reviews were screened from database inception to February 2012, without language restriction.
Study Selection Two independent reviewers identified parallel randomized controlled trials (RCTs) of probiotics (Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, and/or Bacillus) for the prevention or treatment of AAD.
Data Extraction Two independent reviewers extracted the data and assessed trial quality.
Results A total of 82 RCTs met inclusion criteria. The majority used Lactobacillus-based interventions alone or in combination with other genera; strains were poorly documented. The pooled relative risk in a DerSimonian-Laird random-effects meta-analysis of 63 RCTs, which included 11 811 participants, indicated a statistically significant association of probiotic administration with reduction in AAD (relative risk, 0.58; 95% CI, 0.50 to 0.68; P<.001; I-2, 54%; [risk difference, -0.07; 95% CI, -0.10 to -0.05], [number needed to treat, 13; 95% CI, 10.3 to 19.1]) in trials reporting on the number of patients with AAD. This result was relatively insensitive to numerous subgroup analyses. However, there exists significant heterogeneity in pooled results and the evidence is insufficient to determine whether this association varies systematically by population, antibiotic characteristic, or probiotic preparation.
Conclusions The pooled evidence suggests that probiotics are associated with a reduction in AAD. More research is needed to determine which probiotics are associated with the greatest efficacy and for which patients receiving which specific antibiotics. JAMA. 2012;307(18):1959-1969 www.jama.com
C1 [Hempel, Susanne; Newberry, Sydne J.; Shanman, Roberta; Johnsen, Breanne; Shekelle, Paul G.] RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90401 USA.
[Maher, Alicia R.; Wang, Zhen; Miles, Jeremy N. V.] RAND Corp, Santa Monica, CA USA.
[Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA.
[Maher, Alicia R.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
RP Hempel, S (reprint author), RAND Hlth, So Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90401 USA.
EM susanne_hempel@rand.org
RI Wang, Zhen/D-5991-2013
OI Wang, Zhen/0000-0002-9368-6149
FU HHSA [290-2007-10062-I]; National Institutes of Health (NIH) Office of
Dietary Supplements; NIH National Center for Complementary and
Alternative Medicine; US Food and Drug Administration (USFDA) Center for
Food Safety and Applied Nutrition; Department of Veterans Affairs; RAND
Corporation
FX The RAND Corporation internally funded this review, building on the
literature database established for contract HHSA 290-2007-10062-I, an
evidence report on the safety of probiotics commissioned by the Agency
for Healthcare Research and Quality and funded jointly by the National
Institutes of Health (NIH) Office of Dietary Supplements, the NIH
National Center for Complementary and Alternative Medicine, and the US
Food and Drug Administration (USFDA) Center for Food Safety and Applied
Nutrition. Dr Shekelle reports support from the Department of Veterans
Affairs.
NR 96
TC 206
Z9 236
U1 9
U2 104
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 9
PY 2012
VL 307
IS 18
BP 1959
EP 1969
DI 10.1001/jama.2012.3507
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 938OD
UT WOS:000303741900030
PM 22570464
ER
PT J
AU Chao, LL
Lenoci, M
Neylan, TC
AF Chao, Linda L.
Lenoci, Maryann
Neylan, Thomas C.
TI Effects of post-traumatic stress disorder on occipital lobe function and
structure
SO NEUROREPORT
LA English
DT Article
DE functional magnetic resonance imaging; lateral occipital complex;
occipital cortex; post-traumatic stress disorder
ID SCRIPT-DRIVEN IMAGERY; POSITRON-EMISSION-TOMOGRAPHY; CHILDHOOD
SEXUAL-ABUSE; SYMPTOM PROVOCATION; PTSD; CORTEX; RESPONSES; AMYGDALA
AB Although there is evidence for strong connectivity between the amygdala and the visual cortex and some evidence for reduced occipital lobe gray matter volume in patients with post-traumatic stress disorder (PTSD), few studies have directly examined the effects of PTSD on occipital function. The current study used functional and structural MRI to examine occipital cortex function and structure in male combat veterans with and without PTSD. Left occipital gray matter volume was reduced in PTSD patients relative to the controls and correlated negatively with the severity of PTSD symptoms. Functional activity in the lateral occipital complex to aversive and nonaversive pictures presented in novel and repeated presentations was not altered by PTSD. These findings suggest that PTSD adversely affects occipital lobe volume but not the reactivity of the lateral occipital complex to generally aversive, trauma nonspecific stimuli. NeuroReport 23:412-419 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Chao, Linda L.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA 94121 USA.
[Chao, Linda L.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Chao, Linda L.; Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Lenoci, Maryann; Neylan, Thomas C.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA.
RP Chao, LL (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St,114M, San Francisco, CA 94121 USA.
EM linda.chao@ucsf.edu
FU Department of Defense [W81XWH-05-2-0094]; Mental Illness Research and
Education Clinical Center of the US Veterans Health Administration;
Veterans Administration Medical Center, San Francisco, California
FX This work was supported by a grant from the Department of Defense
(W81XWH-05-2-0094) to Linda L. Chao. The authors thank Dr Charles Marmar
for helpful discussions about the study design, Jacqueline Thao Mai for
technical assistance, and the research participants. This work was also
supported by the Mental Illness Research and Education Clinical Center
of the US Veterans Health Administration and the resources and
facilities at the Veterans Administration Medical Center, San Francisco,
California.
NR 25
TC 18
Z9 18
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD MAY 9
PY 2012
VL 23
IS 7
BP 412
EP 419
DI 10.1097/WNR.0b013e328352025e
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 927ZF
UT WOS:000302948500002
PM 22453299
ER
PT J
AU Hegarty, CE
Foland-Ross, LC
Narr, KL
Townsend, JD
Bookheimer, SY
Thompson, PM
Altshuler, LL
AF Hegarty, Catherine E.
Foland-Ross, Lara C.
Narr, Katherine L.
Townsend, Jennifer D.
Bookheimer, Susan Y.
Thompson, Paul M.
Altshuler, Lori L.
TI Anterior cingulate activation relates to local cortical thickness
SO NEUROREPORT
LA English
DT Article
DE anterior cingulate cortex; cortical thickness; functional magnetic
resonance imaging; response inhibition
ID RESPONSE-INHIBITION; BRAIN; SCHIZOPHRENIA; CHILDREN; CORTEX; ROBUST;
MODEL; FMRI
AB Few studies have examined the relationship between local anatomic thickness of the cortex and the activation signals arising from it. Using structural and functional MRI, we examined whether a relationship exists between cortical thickness and brain activation. Twenty-eight participants were asked to perform the Go/NoGo response inhibition task known to activate the anterior cingulate and the prefrontal cortex. Structural data of the same regions were simultaneously collected. We hypothesized that cortical thickness in these brain regions would positively correlate with brain activation. Data from the structural MRI were aligned with those of functional MRI activation. There was a positive linear correlation between cortical thickness and activation during response inhibition in the right anterior cingulate cortex (Brodmann's Area 24). No significant thickness-activation correlations were found in the prefrontal cortex. Correlations between cortical thickness and activation may occur only in certain brain regions. NeuroReport 23:420-424 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Foland-Ross, Lara C.] Stanford Univ, Dept Psychol, Mood & Anxiety Disorders Lab, Stanford, CA 94305 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, W Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA.
RP Altshuler, LL (reprint author), UCLA Neuropsychiat Inst & Hosp, 300 Med Plaza,Suite 1544,Box 957057, Los Angeles, CA 90095 USA.
EM laltshuler@mednet.ucla.edu
OI Hegarty, Catherine/0000-0003-4976-774X
FU National Institute of Mental Health [5R21 MH075944, K24 MH001848, R01
MH084955, 5F31MH078556]; Abbott Laboratories; Forest Laboratories
FX For their financial support of this study, the authors gratefully
acknowledge the National Institute of Mental Health [5R21 MH075944 (LA),
K24 MH001848 (LA), R01 MH084955 (LA), and 5F31MH078556 (LF)].; Dr
Altshuler has received past (and potential future) funding from Abbott
Laboratories (research support and consulting honoraria); Forest
Laboratories (consulting and speakers bureau honoraria); GlaxoSmithKline
(speakers bureau honoraria); and no past, but potential future honoraria
from Astra-Zeneca (speakers bureau) and Merck and Co. (consulting). Drs
Bookheimer, Foland-Ross, Narr and Thompson, Hegarty, and Townsend report
no financial relationships with commercial interests.
NR 23
TC 8
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD MAY 9
PY 2012
VL 23
IS 7
BP 420
EP 424
DI 10.1097/WNR.0b013e3283525a95
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 927ZF
UT WOS:000302948500003
PM 22440976
ER
PT J
AU Stephen, TL
Wilson, BS
Laufer, TM
AF Stephen, Tom Li
Wilson, Bridget S.
Laufer, Terri M.
TI Subcellular distribution of Lck during CD4 T-cell maturation in the
thymic medulla regulates the T-cell activation threshold
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE autoreactivity; thymic selection; T cell receptor signaling
ID PROTEIN-TYROSINE-PHOSPHATASE; SRC-FAMILY KINASES; CLASS-II MHC; ANTIGEN
RECEPTOR; POSITIVE SELECTION; THYMOCYTE SENSITIVITY;
ELECTRON-MICROSCOPY; CENTRAL TOLERANCE; EXPRESSION; SIGNALS
AB Mature peripheral T cells respond to foreign but not to self-antigens. During development in the thymus, deletion of high-affinity self-reactive immature thymocytes contributes to tolerance of mature T cells. However, double-positive thymocytes are positively selected to survive if they respond to self-peptide-MHC complexes; thus, there must be mechanisms to prevent overt reactivity to those same complexes in the periphery. "Developmental tuning" is the active process through which T-cell receptor (TCR)-associated signaling pathways of single-positive (SP) thymocytes are attenuated to respond appropriately to self-peptide-MHC complexes in the periphery. We previously showed that MHC class II expression in the thymic medulla was necessary to tune CD4(+) SP (CD4 SP) thymocytes. CD4 SP thymocytes from mice lacking medullary MHC class II expression had inappropriately enhanced proximal TCR signaling to low-affinity self-ligands that was associated with altered cellular distribution of the tyrosine kinase Lck. Now, we report that activation of both tuned and untuned CD4 SP thymocytes is Lck-dependent. Untuned CD4 SP cells contain a pool of Lck with increased basal phosphorylation that is not associated with the CD4 coreceptor. Phosphorylation of this pool of Lck decreases with tuning. Immunogold transmission electron microscopy of membrane sheets permitted direct visualization of Lck. In the absence of tuning, a significant proportion of Lck and the TCR subunit CD3 zeta are expressed on the same protein island; this close association of Lck and the TCR probably explains the enhanced activation of untuned CD4 SP cells. Thus, changes in membrane topography during thymic maturation determine the set point for TCR responsiveness.
C1 [Stephen, Tom Li; Laufer, Terri M.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Wilson, Bridget S.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA.
[Wilson, Bridget S.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
[Laufer, Terri M.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA 19104 USA.
RP Laufer, TM (reprint author), Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
EM tlaufer@mail.med.upenn.edu
FU National Institutes of Health [R01 AI068819]; Arthritis Foundation
FX We thank Mary Ann Raymond-Stintz at the University of New Mexico for
assistance with plasma membrane sheet preparations and TEM analysis.
This work was supported by National Institutes of Health Grant R01
AI068819 (to T. M. L.) and an Arthritis Foundation postdoctoral
fellowship (to T. L. S.).
NR 53
TC 7
Z9 7
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 8
PY 2012
VL 109
IS 19
BP 7415
EP 7420
DI 10.1073/pnas.1119272109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 942ZQ
UT WOS:000304090600061
PM 22529380
ER
PT J
AU Li, YH
Siegel, DL
Scholler, N
Kaplan, DE
AF Li, Yonghai
Siegel, Donald L.
Scholler, Nathalie
Kaplan, David E.
TI Validation of glypican-3-specific scFv isolated from paired
display/secretory yeast display library
SO BMC BIOTECHNOLOGY
LA English
DT Article
ID HUMAN HEPATOCELLULAR-CARCINOMA; PHASE-II; IN-VITRO; MARKER; EXPRESSION;
ANTIBODY; CELLS; GENERATION; PROTEIN; GROWTH
AB Background: Glypican-3 (GPC3) is a heparan-sulfate proteoglycan frequently expressed on the cell membrane of malignant hepatocytes in hepatocellular carcinoma. The capacity for screening potential antibodies in vitro using human hepatocellular lines is critical to ensure binding to this highly post-translationally modified glycophosphatidylinositiol linked protein. We hypothesized that we could utilize a recently described paired display/secretory yeast library to isolate human-derived scFv against glypican-3 for potential diagnostic and/or therapeutic application.
Results: Using two different biotinylated antigen targets, a synthesized 29mer fragment GPC3(550-558) and a truncated GPC3(368-548) fused with glutathione S-transferase (GST) we enriched the yeast display library to greater than 30% target-specific yeast with both positive selection and depletion of streptavidin-and GST-specific clones. After cloning of scFv cDNA from the enriched sub-library, scFv specificity was validated by ELISA for binding to recombinant protein from prokaryotic and eukaryotic sources and ultimately naturally presented human protein on the cell membrane of human hepatocellular cell lines. Specificity was confirmed using non-expressing cell lines and shRNA knockdown. Ultimately, five unique scFv with affinity EC50 ranging from 5.0-110.9nM were identified.
Conclusions: Using a paired display/secretory yeast library, five novel and unique scFvs for potential humoral or chimeric therapeutic development in human hepatocellular carcinoma were isolated and characterized.
C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA.
[Li, Yonghai; Kaplan, David E.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
[Siegel, Donald L.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Scholler, Nathalie] Univ Penn, Dept Obstet & Gynecol, Ctr Res Reprod & Womens Hlth, Penn Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
RP Kaplan, DE (reprint author), Philadelphia VA Med Ctr, Med & Res Serv, Philadelphia, PA 19104 USA.
EM dakaplan@mail.med.upenn.edu
RI Scholler, Nathalie/O-9003-2014
OI Kaplan, David E./0000-0002-3839-336X
FU McCabe Family Research Foundation [R21 CA149908]; Veterans Health
Administration; University of Pennsylvania
FX This work was supported by R21 CA149908 (DEK), McCabe Family Research
Foundation, and Research Career Development Award from the Veterans
Health Administration (DEK), academic development funds from the
University of Pennsylvania (DEK). The authors would like to thank Aizhi
Zhao for his technical assistance. The content of this article does not
reflect the views of the VA or of the US Government.
NR 32
TC 3
Z9 4
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6750
J9 BMC BIOTECHNOL
JI BMC Biotechnol.
PD MAY 7
PY 2012
VL 12
AR 23
DI 10.1186/1472-6750-12-23
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 992EH
UT WOS:000307757900001
PM 22564378
ER
PT J
AU Nunez, AL
Jhala, NC
Carroll, AJ
Mikhail, FM
Reddy, VVB
Xian, RR
Jhala, DN
AF Nunez, Amberly L.
Jhala, Nirag C.
Carroll, Andrew J.
Mikhail, Fady M.
Reddy, Vishnu V. B.
Xian, Rena R.
Jhala, Darshana N.
TI Endoscopic ultrasound and endobronchial ultrasound-guided fine-needle
aspiration of deep-seated lymphadenopathy: Analysis of 1338 cases
SO CYTOJOURNAL
LA English
DT Article
DE Endoscopic ultrasound; endobronchial ulatrsound; fine-needle aspiration;
mediastinum; flow cytometry; fluorescence in situ hybridization; lymph
node; lymphoma
ID B-CELL LYMPHOMA; FLOW-CYTOMETRY; CENTER EXPERIENCE; RECURRENT LYMPHOMA;
DIAGNOSIS; BIOPSY; SUBCLASSIFICATION; CYTOMORPHOLOGY; CLASSIFICATION;
ACCURATE
AB Background: We retrospectively studied 1338 samples of lymph nodes obtained by endoscopic and endobronchial ultrasound-guided fine needle aspiration biopsy (EUS and EBUS-FNAB) with an objective of characterizing the utility of this diagnostic modality in the assessment of deep-seated lymphadenopathy. The secondary aims were to establish the utility in the diagnosis of lymphoma and to determine the number of passes required to obtain adequate cellularity for flow cytometric analysis. Materials and Methods: On-site assessment was performed by a cytopathologist using Diff-Quik (American Scientific Products, McGraw Park, IL) stain. In addition, Papanicolaou and immunohistochemical stains were performed and additional samples were sent for flow cytometric analyses (n = 145). The final cytologic diagnosis was correlated with surgical pathology diagnosis and/or clinical follow-up. In select cases, fluorescence in situ hybridization analysis with specific probes was performed on Diff-Quik smears. Results: Both morphology as well as ancillary studies (flow cytometry or immunohistochemical stain and/or fluorescence in situ hybridization) show that EUS and EBUS-FNA are effective techniques to detect and stage intrathoracic and intra-abdominal tumors. Operating characteristics show that these are highly sensitive (89) and specific (100) techniques for the diagnosis of lymphoma. At least two passes provided an average of 5.66 million cells (range, 0.12-62.32 million) for lymphoma cases. Conclusions: EUS and EBUS-FNA are powerful modalities to stage malignancies and at least two passes can provide adequate cells for flow cytometric analysis. We also demonstrate that fluorescence in situ hybridization analysis can be performed on Diff-Quik-stained and mounted smears.
C1 [Nunez, Amberly L.; Reddy, Vishnu V. B.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Carroll, Andrew J.; Mikhail, Fady M.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.
[Jhala, Nirag C.; Xian, Rena R.; Jhala, Darshana N.] Univ Penn, Philadelphia, PA 19104 USA.
[Jhala, Nirag C.; Reddy, Vishnu V. B.; Xian, Rena R.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
RP Nunez, AL (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM alinda@uab.edu; nirag.jhala@uphs.upenn.edu; acarroll@uab.edu;
fmikhail@uab.edu; vreddy@uab.edu; rena.xian@uphs.upenn.edu;
darshana.jhala@uphs.upenn.edu
OI Reddy, Vishnu/0000-0001-5474-3289
NR 28
TC 11
Z9 11
U1 0
U2 2
PU MEDKNOW PUBLICATIONS
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0974-5963
J9 CYTOJOURNAL
JI CytoJournal
PD MAY 5
PY 2012
VL 9
AR 14
DI 10.4103/1742-6413.95845
PG 10
WC Pathology
SC Pathology
GA 976CF
UT WOS:000306557400002
PM 22615712
ER
PT J
AU Zhang, ZL
Wu, XM
Duan, J
Hinrichs, D
Wegmann, K
Zhang, GL
Hall, M
Rosenbaum, JT
AF Zhang, Zili
Wu, Xiumei
Duan, Jie
Hinrichs, David
Wegmann, Keith
Zhang, Gary L.
Hall, Mark
Rosenbaum, James T.
TI Low Dose Rapamycin Exacerbates Autoimmune Experimental Uveitis
SO PLOS ONE
LA English
DT Article
ID INDUCED CELL-DEATH; OF-THE-LITERATURE; MAMMALIAN TARGET; T-CELLS;
METABOLIC-REGULATION; CYCLOSPORINE-A; MTOR; SIROLIMUS; MICE; ACTIVATION
AB Background: Rapamycin, a potent immune modulator, is used to treat transplant rejection and some autoimmune diseases. Uveitis is a potentially severe inflammatory eye disease, and 2 clinical trials of treating uveitis with rapamycin are under way. Unexpectedly, recent research has demonstrated that low dose rapamycin enhances the memory T cell population and function. However, it is unclear how low dose rapamycin influences the immune response in the setting of uveitis.
Design and Methods: B10.RIII mice were immunized to induce experimental autoimmune uveitis (EAU). Ocular inflammation of control and rapamycin-treated mice was compared based on histological change. ELISPOT and T cell proliferation assays were performed to assess splenocyte response to ocular antigen. In addition, we examined the effect of rapamycin on activation-induced cell death (AICD) using the MitoCapture assay and Annexin V staining.
Results: Administration of low dose rapamycin exacerbated EAU, whereas treating mice with high dose rapamycin attenuated ocular inflammation. The progression of EAU by low dose rapamycin coincided with the increased frequency of antigen-reactive lymphocytes. Lastly, fewer rapamycin-treated T cells underwent AICD, which might contribute to exaggerated ocular inflammation and the uveitogenic immune response.
Conclusion: These data reveal a paradoxical role for rapamycin in uveitis in a dose-dependent manner. This study has a potentially important clinical implication as rapamycin might cause unwanted consequences dependent on dosing and pharmacokinetics. Thus, more research is needed to further define the mechanism by which low dose rapamycin augments the immune response.
C1 [Zhang, Zili; Wu, Xiumei; Duan, Jie; Zhang, Gary L.; Hall, Mark] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.
[Hinrichs, David; Wegmann, Keith] Portland VA Med Ctr, Portland, OR USA.
[Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
[Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
RP Zhang, ZL (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA.
EM zhangzi@ohsu.edu; rosenbaj@ohsu.edu
FU National Institutes of Health [EY016788, EY013093, EY006484]; Stan and
Madelle Rosenfeld Family Trust; William and Mary Bauman Foundation;
Research to Prevent Blindness; William C. Kuzell Foundation
FX This work was supported by National Institutes of Health Grants EY016788
(ZZ), EY013093 (JTR), and EY006484 (JTR). Funds from the Stan and
Madelle Rosenfeld Family Trust, the William and Mary Bauman Foundation,
Research to Prevent Blindness and William C. Kuzell Foundation also
supported this work. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 56
TC 14
Z9 15
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 4
PY 2012
VL 7
IS 5
AR e36589
DI 10.1371/journal.pone.0036589
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959WV
UT WOS:000305349800085
PM 22574188
ER
PT J
AU Xu, GS
Liu, K
Anderson, J
Patrene, K
Lentzsch, S
Roodman, GD
Ouyang, HJ
AF Xu, Guoshuang
Liu, Kai
Anderson, Judy
Patrene, Kenneth
Lentzsch, Suzanne
Roodman, G. David
Ouyang, Hongjiao
TI Expression of XBP1s in bone marrow stromal cells is critical for myeloma
cell growth and osteoclast formation
SO BLOOD
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; TRANSCRIPTION FACTOR XBP-1; MULTIPLE-MYELOMA;
DIFFERENTIATION; MICROENVIRONMENT; DISEASE; STRESS; IDENTIFICATION;
PATHOGENESIS; IRE1-ALPHA
AB BM stromal cells (BMSCs) are key players in the microenvironmental support of multiple myeloma (MM) cell growth and bone destruction. A spliced form of the X-boxbinding protein-1 (XBP1s), a major proximal effector of unfolded protein response signaling, is highly expressed in MM cells and plays an indispensable role in MM pathogenesis. In the present study, we found that XBP1s is induced in the BMSCs of the MM microenvironment. XBP1s overexpression in healthy human BMSCs enhanced gene and/or protein expression of VCAM-1, IL-6, and receptor activator of NF-kappa B ligand (RANKL), enhancing BMSC support of MM cell growth and osteoclast formation in vitro and in vivo. Conversely, deficiency of XBP1 in healthy donor BMSCs displayed a range of effects on BMSCs that were opposite to those cells with overexpression of XBP1s. Knock-down of XBP1 in MM patient BM-SCs greatly compromised their increased VCAM-1 protein expression and IL-6 and RANKL secretion in response to TNF alpha and reversed their enhanced support of MM-cell growth and osteoclast formation. Our results demonstrate that XBP1s is a pathogenic factor underlying BMSC support of MM cell growth and osteoclast formation and therefore represents a therapeutic target for MM bone disease. (Blood. 2012;119(18):4205-4214)
C1 [Xu, Guoshuang; Liu, Kai; Anderson, Judy; Patrene, Kenneth; Lentzsch, Suzanne; Roodman, G. David; Ouyang, Hongjiao] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol & Oncol, Pittsburgh, PA USA.
[Xu, Guoshuang] Fourth Mil Med Univ PLA, Xijing Hosp, Dept Nephrol, Xian, Peoples R China.
[Lentzsch, Suzanne] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Roodman, G. David] VA Med Ctr, Pittsburgh, PA USA.
[Ouyang, Hongjiao] Univ Pittsburgh, Sch Dent Med, Dept Comprehens Care Restorat Dent & Endodont, Pittsburgh, PA USA.
RP Ouyang, HJ (reprint author), VA Pittsburgh Healthcare Syst, R&D 151-U,2W-143 Univ Dr C, Pittsburgh, PA 15240 USA.
EM hoo1@pitt.edu
FU Multiple Myeloma Research Foundation; National Institutes of
Health/National Institute of Dental and Craniofacial Research
[DE017439]; VA Merit Review
FX This work was supported by the Multiple Myeloma Research Foundation (to
H.O.), a National Institutes of Health/National Institute of Dental and
Craniofacial Research grant (DE017439 to H.O.), and by a Multiple
Myeloma Research Foundation and VA Merit Review Grant (to G.D.R).
NR 34
TC 24
Z9 25
U1 1
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 3
PY 2012
VL 119
IS 18
BP 4205
EP 4214
DI 10.1182/blood-2011-05-353300
PG 10
WC Hematology
SC Hematology
GA 959BL
UT WOS:000305284600017
PM 22427205
ER
PT J
AU Singh, JA
AF Singh, Jasvinder A.
TI Stem cells and other innovative intra-articular therapies for
osteoarthritis: what does the future hold?
SO BMC MEDICINE
LA English
DT Editorial Material
DE osteoarthritis; intra-articular; novel; treatment; gene therapy; stem
cell
ID CRUCIATE LIGAMENT TRANSECTION; FIBROBLAST GROWTH FACTOR-18; RANDOMIZED
CONTROLLED-TRIAL; PLATELET-RICH PLASMA; BOTULINUM-TOXIN-A;
QUALITY-OF-LIFE; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; IN-VIVO;
OARSI RECOMMENDATIONS
AB Osteoarthritis (OA), the most common type of arthritis in the world, is associated with suffering due to pain, productivity loss, decreased mobility and quality of life. Systemic therapies available for OA are mostly symptom modifying and have potential gastrointestinal, renal, hepatic, and cardiac side effects. BMC Musculoskeletal Disorders recently published a study showing evidence of reparative effects demonstrated by homing of intra-articularly injected autologous bone marrow stem cells in damaged cartilage in an animal model of OA, along with clinical and radiographic benefit. This finding adds to the growing literature showing the potential benefit of intra-articular (IA) bone marrow stem cells. Other emerging potential IA therapies include IL-1 receptor antagonists, conditioned autologous serum, botulinum toxin, and bone morphogenetic protein-7. For each of these therapies, trial data in humans have been published, but more studies are needed to establish that they are safe and effective. Several additional promising new OA treatments are on the horizon, but challenges remain to finding safe and effective local and systemic therapies for OA. Please see related article: http://www.biomedcentral.com/1471-2474/12/259
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Birmingham VA Med Ctr, Med Serv, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
NR 59
TC 5
Z9 5
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD MAY 2
PY 2012
VL 10
AR 44
DI 10.1186/1741-7015-10-44
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 951HV
UT WOS:000304712400001
PM 22551396
ER
PT J
AU Pletcher, MJ
Kertesz, SG
AF Pletcher, Mark J.
Kertesz, Stefan G.
TI Long-term Marijuana Use and Pulmonary Function Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID RECRUITMENT; CARDIA
C1 [Pletcher, Mark J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Pletcher, MJ (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
EM mpletcher@epi.ucsf.edu
NR 2
TC 0
Z9 0
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 2
PY 2012
VL 307
IS 17
BP 1796
EP 1797
DI 10.1001/jama.2012.3607
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 933TV
UT WOS:000303386800011
ER
PT J
AU Pae, CU
Bodkin, JA
Portland, KB
Thase, ME
Patkar, AA
AF Pae, Chi-Un
Bodkin, J. Alexander
Portland, Kimberly Blanchard
Thase, Michael E.
Patkar, Ashwin A.
TI Safety of Selegiline Transdermal System in Clinical Practice: Analysis
of Adverse Events From Postmarketing Exposures
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID MAJOR DEPRESSIVE DISORDER; MONOAMINE-OXIDASE INHIBITORS; DOUBLE-BLIND;
PARALLEL-GROUP; DRUG SAFETY; TRIAL; SURVEILLANCE; PRODUCT; FDA
AB Objective: The objective of this analysis is to present the safety profile of selegiline transdermal system (STS) in clinical practice after US Food and Drug Administration approval by analyzing reported postmarketing adverse events (AEs).
Method: Deidentified data were obtained on AEs, regardless of causality, as collected and compiled in the pharmaceutical company's adverse event collection systems/databases after the launch of STS in the United States. All reports of hypertensive crisis, suicide attempts, and STS overdoses were carefully examined to independently determine relation of the AE to STS.
Results: From April 2006 to October 2010, a total of 3,155 AEs in 1,516 patients were reported (5.2% of the total exposures; N = 29,141), regardless of causality. The most frequently reported categories of AEs were general disorders (no. of AEs = 1,037, 3.6%) and central nervous system (CNS) disorders (no. of AEs = 574, 2.0%). A total of 266 reports (0.9%) were classified as serious AEs; CNS disorders (no. of AEs = 71, 26.7%) and cardiac and vascular disorders (no. of AEs = 44, 16.5%) were most common. There were 13 self-reports of possible hypertensive events or hypertension, although objective clinical data were not submitted in any of these cases. Thirteen drug-drug interactions (0.04%) were reported, and 5 were classified as serious.
Conclusions: The most commonly reported AEs were application site reactions and insomnia. Very few patients reported a hypertensive event, and there were no objectively confirmed reports of hypertensive crisis with food at any STS dose. Therapeutic doses of STS appear to have a safety profile in clinical practice that is consistent with that observed in clinical trials. However, given the relatively modest exposure numbers, continued safety monitoring is recommended. J Clin Psychiatry 2012;73(5):661-668 (c) Copyright 2012 Physicians Postgraduate Press, Inc.
C1 [Pae, Chi-Un; Patkar, Ashwin A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27705 USA.
[Pae, Chi-Un] Catholic Univ Korea, Coll Med, Seoul, South Korea.
[Bodkin, J. Alexander] McLean Hosp, Clin Psychopharmacol Res Program, Belmont, MA 02178 USA.
[Portland, Kimberly Blanchard] Mylan Specialty LP, Basking Ridge, NJ USA.
[Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Patkar, AA (reprint author), Duke Univ, Med Ctr, Dept Psychiat, 2218 Elder St,Suite B-2, Durham, NC 27705 USA.
EM pae@catholic.ac.kr; ashwin.patkar@duke.edu
FU GlaxoSmithKline Korea; GlaxoSmithKline; AstraZeneca Korea; Janssen
Pharmaceuticals Korea; Eli Lilly Korea; KHIDI; Otsuka Korea; Wyeth
Korea; Ministry of Health and Welfare; Korea Research Foundation; Korean
Institute of Science and Technology Evaluation and Planning; Pfizer;
Shire; Merck; Bristol Myers Squibb; Otsuka; CeNeRx; Eli Lilly; National
Institute of Mental Health; Agency for Healthcare Research and Quality;
Sepracor; National Institutes of Health (National Institute on Drug
Abuse/National Institute on Alcohol Abuse and Alcoholism); Duke
Endowment; AstraZeneca; Forest; Cephalon; Janssen; Jazz; McNeil;
Organon; Orphan; Lundbeck; Titan; Sunovion; Mylan Specialty LP, Basking
Ridge, New Jersey
FX Dr Pae has received research grants from GlaxoSmithKline Korea,
GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli
Lilly Korea, KHIDI, Otsuka Korea, Wyeth Korea, Ministry of Health and
Welfare, Korea Research Foundation, and Korean Institute of Science and
Technology Evaluation and Planning; has received honoraria from and is
on the speakers bureaus of GlaxoSmithKline Korea, Pfizer Korea, Lundbeck
Korea, Sandoz Korea, AstraZeneca Korea, Jeil Pharmaceuticals, Eisai
Korea, Janssen Korea, Eli Lilly Korea, and Otsuka Korea; and has stock
holdings in Dongwha Pharmaceuticals. Dr Bodkin has received
grant/research support from Pfizer, Shire, Merck, Bristol Myers Squibb,
Otsuka, and CeNeRx; has been on the speakers bureau of Bristol-Myers
Squibb; and has been a consultant to Bristol-Myers Squibb, Alkermes, and
Mylan. Dr Portland is an employee of Mylan. Dr Thase has provided
scientific consultation to AstraZeneca, Bristol-Myers Squibb, Mylan, Eli
Lilly, Forest, Gerson Lehman Group, GlaxoSmithKline, Guidepoint Global,
H. Lundbeck A/S, MedAvante, Merck, Neuronetics, Novartis, Otsuka,
Ortho-McNeil, PamLab, Pfizer (formerly Wyeth-Ayerst Laboratories),
Schering-Plough (formerly Organon), Shire US, Supernus, Takeda
(Lundbeck), and Transcept; has been on the speakers bureaus of
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer
(formerly Wyeth-Ayerst Laboratories); receives grant funding from Eli
Lilly, GlaxoSmithKline, National Institute of Mental Health, Agency for
Healthcare Research and Quality, and Sepracor; has equity holdings in
MedAvante; and receives royalty income from American Psychiatric
Foundation, Guilford Publications, Herald House, Oxford University
Press, and W W Norton & Co. His wife is employed as the Group Scientific
Director for Embryon-formerly Advogent. Dr Patkar has received research
support from National Institutes of Health (National Institute on Drug
Abuse/National Institute on Alcohol Abuse and Alcoholism), Duke
Endowment, AstraZeneca, Forest, Cephalon, Janssen, Jazz, McNeil,
Organon, Orphan, Merck, Lundbeck, Pfizer, Titan, Shire, and Sunovion;
has been a consultant to/advisory board member for Forest, Gilead,
Mylan, Titan, and Reckitt Benckiser; and has been on the speakers
bureaus of Alkermes, Bristol-Myers Squibb, Mylan, Pfizer, and Sunovion.;
Sponsored by Mylan Specialty LP, Basking Ridge, New Jersey.
NR 25
TC 17
Z9 18
U1 1
U2 5
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAY
PY 2012
VL 73
IS 5
BP 661
EP 668
DI 10.4088/JCP.12m07648
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 090SI
UT WOS:000314999900009
PM 22697192
ER
PT J
AU Steinman, MA
Lee, SJ
Peterson, CA
Fung, KZ
Goldstein, MK
AF Steinman, Michael A.
Lee, Sei J.
Peterson, Carolyn A.
Fung, Kathy Z.
Goldstein, Mary K.
TI A Clinically Guided Approach for Improving Performance Measurement for
Hypertension
SO MEDICAL CARE
LA English
DT Article
DE quality of health care; quality indicators; health care; hypertension;
physician's prescribing practices
ID QUALITY-OF-CARE; ELECTRONIC HEALTH RECORDS; CORONARY-ARTERY-DISEASE;
TREATMENT INTENSIFICATION; BLOOD-PRESSURE; MEDICATION; GUIDELINES;
ADHERENCE; OUTCOMES; PAY
AB Background: Performance measures often fail to account for legitimate reasons why patients do not achieve recommended treatment targets.
Methods: We tested a novel performance measurement system for blood pressure (BP) control that was designed to mimic clinical reasoning. This clinically guided approach focuses on (1) exempting patients for whom tight BP control may not be appropriate or feasible and (2) assessing BP over time. Trained abstractors conducted structured chart reviews of 201 adults with hypertension in 2 VA health care systems. Results were compared with traditional methods of performance measurement.
Results: Among 201 veterans, 183 (91%) were male, and the mean age was 71 +/- 11 years. Using the clinically guided approach, 61 patients (30%) were exempted from performance measurement. The most common reasons for exemption were inadequate opportunity to manage BP (35 patients, 17%) and the use of 4 or more anti-hypertensive medications (19 patients, 9%). Among patients eligible for performance measurement, there was little agreement on the presence of controlled versus uncontrolled BP when comparing the most recent BP (the traditional approach) with an integrated assessment of BP control (kappa 0.14). After accounting for clinically guided exemptions and methods of BP assessment, only 15 of 72 patients (21%) whose last BP was >= 140/90 mm Hg were classified as problematic by the clinically guided approach.
Conclusions: Many patients have legitimate reasons for not achieving tight BP control, and the methods used for BP assessment have marked effects on whether a patient is classified as having adequate or inadequate BP control.
C1 [Steinman, Michael A.; Lee, Sei J.; Peterson, Carolyn A.; Fung, Kathy Z.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA.
[Steinman, Michael A.; Lee, Sei J.; Peterson, Carolyn A.; Fung, Kathy Z.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Goldstein, Mary K.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA.
[Goldstein, Mary K.] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA.
RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.
EM mike.steinman@ucsf.edu
FU Department of Veterans Affairs (VA) Health Services Research &
Development Service [CDTA 01-013, IAF 06-080-02, CPI 99-275, IMV
04-062]; National Institutes on Aging; American Federation for Aging
Research [K23 AG030999]; San Francisco Veterans Affairs Medical Center
Health Services Research and Development Research Enhancement Award
Program; NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]
FX Supported by the Department of Veterans Affairs (VA) Health Services
Research & Development Service (CDTA 01-013 and related to IAF
06-080-02, CPI 99-275, and IMV 04-062) and by the National Institutes on
Aging and the American Federation for Aging Research (K23 AG030999), and
further supported with resources of the San Francisco Veterans Affairs
Medical Center Health Services Research and Development Research
Enhancement Award Program. Dr Lee was supported by NIH/NCRR/OD UCSF-CTSI
Grant number KL2 RR024130.
NR 30
TC 0
Z9 0
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAY
PY 2012
VL 50
IS 5
BP 399
EP 405
DI 10.1097/MLR.0b013e318245a147
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 083IH
UT WOS:000314456400007
PM 22627680
ER
PT J
AU Karr, S
Kelley, KW
McBane, S
Thomas, T
AF Karr, Samantha
Kelley, Kristi W.
McBane, Sarah
Thomas, Tyan
TI Overcoming practice site challenges in clinical faculty positions
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Editorial Material
ID PHARMACY; PRACTITIONERS
C1 [Karr, Samantha] Midwestern Univ, Coll Pharm Glendale, Glendale, AZ 85308 USA.
[Kelley, Kristi W.] Auburn Univ, Harrison Sch Pharm, Auburn, AL 36849 USA.
[Kelley, Kristi W.] Baptist Hlth Syst Inc, Trinity Med Ctr, Continu Clin, Birmingham, AL USA.
[McBane, Sarah] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA.
[Thomas, Tyan] Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA USA.
[Thomas, Tyan] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Karr, S (reprint author), Midwestern Univ, Coll Pharm Glendale, 19555 N 59th Ave, Glendale, AZ 85308 USA.
EM skarrx@midwestern.edu
NR 13
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD MAY 1
PY 2012
VL 69
IS 9
BP 738
EP +
DI 10.2146/ajhp110289
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 073VA
UT WOS:000313770000005
PM 22517019
ER
PT J
AU Kamboh, MI
Demirci, FY
Wang, X
Minster, RL
Carrasquillo, MM
Pankratz, VS
Younkin, SG
Saykin, AJ
Jun, G
Baldwin, C
Logue, MW
Buros, J
Farrer, L
Pericak-Vance, MA
Haines, JL
Sweet, RA
Ganguli, M
Feingold, E
DeKosky, ST
Lopez, OL
Barmada, MM
AF Kamboh, M. I.
Demirci, F. Y.
Wang, X.
Minster, R. L.
Carrasquillo, M. M.
Pankratz, V. S.
Younkin, S. G.
Saykin, A. J.
Jun, G.
Baldwin, C.
Logue, M. W.
Buros, J.
Farrer, L.
Pericak-Vance, M. A.
Haines, J. L.
Sweet, R. A.
Ganguli, M.
Feingold, E.
DeKosky, S. T.
Lopez, O. L.
Barmada, M. M.
CA Alzheimers Dis Neuroimaging Initia
TI Genome-wide association study of Alzheimer's disease
SO TRANSLATIONAL PSYCHIATRY
LA English
DT Article
DE Alzheimer's disease; genome-wide association study; meta-analysis;
PPP1R3B; PTK2B; single-nucleotide polymorphisms
ID IDENTIFIES VARIANTS; COMMON VARIANTS; APOE; SUSCEPTIBILITY; POPULATION;
RISK; LOCI; CLU; POLYMORPHISM; PROGRESS
AB In addition to apolipoprotein E (APOE), recent large genome-wide association studies (GWASs) have identified nine other genes/loci (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and ABCA7) for late-onset Alzheimer's disease (LOAD). However, the genetic effect attributable to known loci is about 50%, indicating that additional risk genes for LOAD remain to be identified. In this study, we have used a new GWAS data set from the University of Pittsburgh (1291 cases and 938 controls) to examine in detail the recently implicated nine new regions with Alzheimer's disease (AD) risk, and also performed a meta-analysis utilizing the top 1% GWAS single-nucleotide polymorphisms (SNPs) with P < 0.01 along with four independent data sets (2727 cases and 3336 controls) for these SNPs in an effort to identify new AD loci. The new GWAS data were generated on the Illumina Omni1-Quad chip and imputed at similar to 2.5 million markers. As expected, several markers in the APOE regions showed genome-wide significant associations in the Pittsburg sample. While we observed nominal significant associations (P < 0.05) either within or adjacent to five genes (PICALM, BIN1, ABCA7, MS4A4/MS4A6E and EPHA1), significant signals were observed 69-180 kb outside of the remaining four genes (CD33, CLU, CD2AP and CR1). Meta-analysis on the top 1% SNPs revealed a suggestive novel association in the PPP1R3B gene (top SNP rs3848140 with P = 3.05E-07). The association of this SNP with AD risk was consistent in all five samples with a meta-analysis odds ratio of 2.43. This is a potential candidate gene for AD as this is expressed in the brain and is involved in lipid metabolism. These findings need to be confirmed in additional samples. Translational Psychiatry (2012) 2, e117; doi:10.1038/tp.2012.45; published online 15 May 2012
C1 [Kamboh, M. I.; Demirci, F. Y.; Wang, X.; Minster, R. L.; Feingold, E.; Barmada, M. M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
[Kamboh, M. I.; Lopez, O. L.] Univ Pittsburgh, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA.
[Kamboh, M. I.; Sweet, R. A.; Ganguli, M.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15261 USA.
[Carrasquillo, M. M.; Pankratz, V. S.; Younkin, S. G.] Mayo Clin, Coll Med, Dept Neurosci, Jacksonville, FL 32224 USA.
[Saykin, A. J.] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, Indianapolis, IN USA.
[Saykin, A. J.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN USA.
[Jun, G.; Baldwin, C.; Logue, M. W.; Buros, J.; Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Med, Genet Program, Boston, MA 02215 USA.
[Jun, G.; Logue, M. W.; Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
[Jun, G.; Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Opthalmol, Boston, MA 02215 USA.
[Baldwin, C.] Boston Univ, Sch Med & Publ Hlth, Ctr Human Genet, Boston, MA 02215 USA.
[Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Neurol, Boston, MA 02215 USA.
[Farrer, L.] Boston Univ, Sch Med & Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
[Pericak-Vance, M. A.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA.
[Haines, J. L.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
[Sweet, R. A.; Lopez, O. L.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Sweet, R. A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
[DeKosky, S. T.] Univ Virginia, Sch Med, Off Dean, Charlottesville, VA 22908 USA.
[DeKosky, S. T.] Univ Virginia, Sch Med, Dept Neurol, Charlottesville, VA 22908 USA.
RP Kamboh, MI (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA.
EM kamboh@pitt.edu
RI Haines, Jonathan/C-3374-2012; Saykin, Andrew/A-1318-2007; MORAN,
CATHERINE/C-9539-2015
OI Saykin, Andrew/0000-0002-1376-8532; Logue, Mark/0000-0001-9347-7892;
Farrer, Lindsay/0000-0001-5533-4225; Buros,
Jacqueline/0000-0001-9588-4889; Demirci, F. Yesim/0000-0001-6907-9843;
Kamboh, M. Ilyas/0000-0002-3453-1438; Barmada, M
Michael/0000-0002-3604-6460; Feingold, Eleanor/0000-0003-2898-6484
FU National Institute on Aging [AG030653, AG005133, AG027224, AG07562,
AG023651, AG18023]; Alzheimer's Disease Neuroimaging Initiative (ADNI)
(National Institutes of Health Grant) [U01 AG024904, RC2 AG036535];
National Institute of Biomedical Imaging and Bioengineering; Canadian
Institutes of Health Research; NIH [P30 AG010129, K01 AG030514]; Dana
Foundation; NIA National Cell Repository for Alzheimer's Disease (NCRAD)
[U24 AG021886]; [R01 AG19771]; [P30 AG10133]
FX This study was supported by the National Institute on Aging grants
AG030653 (MIK), AG005133 (ADRC), AG027224 (RAS), AG07562 and AG023651
(MG) and AG18023 (SGY). We thank Drs Peter Gregersen and Annette Lee of
the Feinstein Institute of Medical Research where the genotyping of the
discovery sample was performed. We acknowledge Drs Neill R
Graff-Radford, Dennis W Dickson and Ronald C Petersen for their key
contribution in collecting the Mayo replication sample. One of the
replication data sets was funded by the Alzheimer's Disease Neuroimaging
Initiative (ADNI) (National Institutes of Health Grant U01 AG024904; RC2
AG036535). ADNI is funded by the National Institute on Aging, the
National Institute of Biomedical Imaging and Bioengineering, and through
generous contributions from the following: Abbott; Alzheimer's
Association; Alzheimer's Drug Discovery Foundation; Amorfix Life
Sciences; AstraZeneca; Bayer HealthCare; BioClinica; Biogen Idec;
Bristol-Myers Squibb Company; Eisai; Elan Pharmaceuticals; Eli Lilly and
Company; F Hoffmann-La Roche and its affiliated company Genentech; GE
Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research
& Development, LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Medpace; Merck & Co.; Meso Scale Diagnostics, LLC.;
Novartis Pharmaceuticals Corporation; Pfizer; Servier; Synarc; and
Takeda Pharmaceutical Company. The Canadian Institutes of Health
Research is providing funds to support ADNI clinical sites in Canada.
Private sector contributions are facilitated by the Foundation for the
National Institutes of Health (http://www.fnih.org). The grantee
organization is the Northern California Institute for Research and
Education, and the study is coordinated by the Alzheimer's Disease
Cooperative Study at the University of California, San Diego. ADNI data
are disseminated by the Laboratory for Neuro Imaging at the University
of California, Los Angeles. This research was also supported by NIH
grants P30 AG010129, K01 AG030514 and the Dana Foundation. Some sample
collection was supported by the NIA National Cell Repository for
Alzheimer's Disease (NCRAD; U24 AG021886) and additional support for
data analysis was provided by R01 AG19771 and P30 AG10133.. We thank the
following people for their contributions to the ADNI genotyping project:
Tatiana Foroud, Kelley Faber, Li Shen, Steven G Potkin, Matthew J
Huentelman, David W Craig, Sungeun Kim, Kwangsik Nho and Bryan M
DeChairo.
NR 30
TC 72
Z9 73
U1 8
U2 25
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2158-3188
J9 TRANSL PSYCHIAT
JI Transl. Psychiatr.
PD MAY
PY 2012
VL 2
AR e117
DI 10.1038/tp.2012.45
PG 7
WC Psychiatry
SC Psychiatry
GA 062CC
UT WOS:000312895700010
PM 22832961
ER
PT J
AU Rice, TR
Sher, L
AF Rice, Timothy R.
Sher, Leo
TI Suicidal behavior in war veterans
SO EXPERT REVIEW OF NEUROTHERAPEUTICS
LA English
DT Review
DE OEF/OIF; Operation Enduring Freedom/Operation Iraqi Freedom;
post-traumatic mood disorder; suicidal behavior; suicidal ideation;
suicide; suicide risk factors; traumatic brain injury; veteran
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; RANDOMIZED
CONTROLLED-TRIAL; NATIONAL COMORBIDITY SURVEY; VIETNAM THEATER VETERANS;
MENTAL-HEALTH PROBLEMS; PERSIAN-GULF-WAR; TERM-FOLLOW-UP; US-AIR-FORCE;
RISK-FACTORS
AB Expert Rev. Neurother. 12(5), 611-624 (2012) Military veterans represent a unique, heterogeneous population with suicide prevalence rates, risk factors and preventative management needs that differ from those of the rest of community. Veterans worldwide receive high proportions of their healthcare from community providers, and sensitivity to these distinct needs is required for optimized care. An overview of the recent prevalence-study literature, with a focus upon statistical design, is presented in order to provide a critical orientation within this field with high levels of popular media attention. Attention to psychiatric comorbidity, subthreshold symptomology, select signature disorders of contemporary conflicts (namely, post-traumatic stress disorder and traumatic brain injury), and veteran life narratives before, within and beyond military service will guide our review of risk factor assessment and management strategies. This critical review of the literature provides an overview of this active field of neuropsychiatric research with a select focus upon these topics of special interest.
C1 [Rice, Timothy R.; Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Rice, Timothy R.; Sher, Leo] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA.
RP Rice, TR (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1425 Madison Ave,Box 1230, New York, NY 10029 USA.
EM timothy.rice@mssm.edu
NR 164
TC 7
Z9 7
U1 14
U2 27
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1473-7175
J9 EXPERT REV NEUROTHER
JI Expert Rev. Neurother.
PD MAY
PY 2012
VL 12
IS 5
BP 611
EP 624
DI 10.1586/ERN.12.31
PG 14
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 056FP
UT WOS:000312474100018
PM 22550989
ER
PT J
AU Thliveris, AT
Clipson, L
Sommer, LL
Schoenike, BA
Hasenstein, JR
Schlamp, CL
Alexander, CM
Newton, MA
Dove, WF
Amos-Landgraf, JM
AF Thliveris, Andrew T.
Clipson, Linda
Sommer, Lacy L.
Schoenike, Barry A.
Hasenstein, Jason R.
Schlamp, Cassandra L.
Alexander, Caroline M.
Newton, Michael A.
Dove, William F.
Amos-Landgraf, James M.
TI Regulated Expression of Chromobox Homolog 5 Revealed in Tumors of
Apc(Min/+) ROSA11 Gene Trap Mice
SO G3-GENES GENOMES GENETICS
LA English
DT Article
DE WNT signaling; cancer progenitor; lacZ reporter; Cre drivers
ID UCSC GENOME BROWSER; SEQUENCE DATABASE; STEM-CELLS; MOUSE;
HETEROCHROMATIN; TRANSCRIPTS; HP1; EUKARYOTES; NEOPLASIA; ADENOMAS
AB The gene-trap lacZ reporter insertion, ROSA11, in the Cbx5 mouse gene illuminates the regulatory complexity of this locus in Apc(Min/+) mice. The insertion site of the beta-Geo gene-trap element lies in the 24-kb intron proximal to the coding region of Cbx5. Transcript analysis indicates that two promoters for Cbx5 flank this insertion site. Heterozygotes for the insertion express lacZ widely in fetal tissues but show limited expression in adult tissues. In the intestine, strong expression is limited to proliferative zones of crypts and tumors. Homozygotes for ROSA11, found at a lower than Mendelian frequency, express reduced levels of the coding region transcript in normal tissues, using a downstream promoter. Analysis via real-time polymerase chain reaction indicates that the upstream promoter is the dominant promoter in normal epithelium and tumors. Bioinformatic analysis of the Cbx5 locus indicates that WNT and its target transcription factor MYC can establish a feedback loop that may play a role in regulating the self-renewal of the normal intestinal epithelium and its tumors.
C1 [Clipson, Linda; Hasenstein, Jason R.; Alexander, Caroline M.; Dove, William F.; Amos-Landgraf, James M.] Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA.
[Thliveris, Andrew T.; Sommer, Lacy L.; Schlamp, Cassandra L.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
[Schoenike, Barry A.] Univ Wisconsin, Dept Neurosci, Madison, WI 53706 USA.
[Newton, Michael A.] Univ Wisconsin, Dept Stat, Madison, WI 53706 USA.
[Newton, Michael A.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA.
[Dove, William F.] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.
[Thliveris, Andrew T.] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI 53705 USA.
RP Dove, WF (reprint author), Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.
EM dove@oncology.wisc.edu
RI Amos-Landgraf, James/K-9288-2013
OI Amos-Landgraf, James/0000-0003-2535-7746
FU National Cancer Institute [R37 CA63677, U01 CA84227]; Helmerich Chair
from the Retina Research Foundation
FX We thank Phil Soriano for his generous gift of the R11 strain; Karen
Gould for the initial discovery of the R11 intestinal expression
pattern; Alexandra Shedlovsky for making the congenic strain; Ryan Burch
and Dawn Albrecht for assistance with experiments; and Jane Weeks,
Harlene Edwards, and other members of the Histotechology Facility for
expert support. This study was supported by National Cancer Institute
grants R37 CA63677 and U01 CA84227 to WFD and the Helmerich Chair from
the Retina Research Foundation to A.T.T. This is publication 3649 from
the Laboratory of Genetics, University of Wisconsin-Madison.
NR 41
TC 3
Z9 3
U1 0
U2 3
PU GENETICS SOC AM
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 2160-1836
J9 G3-GENES GENOM GENET
JI G3-Genes Genomes Genet.
PD MAY 1
PY 2012
VL 2
IS 5
BP 569
EP 578
DI 10.1534/g3.112.002436
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 055YH
UT WOS:000312453500006
PM 22670227
ER
PT J
AU Emmons, RR
Cirnigliaro, CM
Jensen, AM
Kirshblum, SC
Bauman, WA
AF Emmons, Racine R.
Cirnigliaro, Christopher M.
Jensen, A. Marley
Kirshblum, Steven C.
Bauman, William A.
TI Association of Apolipoprotein B with Postprandial Lipemic Responses in
Persons with Chronic Spinal Cord Injury
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Meeting Abstract
C1 [Emmons, Racine R.] William Paterson Univ, Wayne, NJ USA.
[Cirnigliaro, Christopher M.; Jensen, A. Marley; Bauman, William A.] James J Peters VA Med Ctr, Bronx, NY USA.
[Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD MAY
PY 2012
VL 44
SU 2
BP 261
EP 261
PG 1
WC Sport Sciences
SC Sport Sciences
GA 027OT
UT WOS:000310363301381
ER
PT J
AU Hula, WD
Fergadiotis, G
Martin, N
AF Hula, William D.
Fergadiotis, Gerasimos
Martin, Nadine
TI Model Choice and Sample Size in Item Response Theory Analysis of Aphasia
Tests
SO AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY
LA English
DT Article
DE aphasia; psychometrics; assessment
ID CONFIRMATORY FACTOR-ANALYSIS; RASCH MODEL; MONTE-CARLO; ABILITY;
REHABILITATION; VALIDITY; OUTCOMES; CURVES; LIKERT
AB Purpose: The purpose of this study was to identify the most appropriate item response theory (IRT) measurement model for aphasia tests requiring 2-choice responses and to determine whether small samples are adequate for estimating such models.
Method: Pyramids and Palm Trees (Howard & Patterson, 1992) test data that had been collected from individuals with aphasia were analyzed, and the resulting item and person estimates were used to develop simulated test data for 3 sample size conditions. The simulated data were analyzed using a standard 1-parameter logistic (1-PL) model and 3 models that accounted for the influence of guessing: augmented 1-PL and 2-PL models and a 3-PL model. The model estimates obtained from the simulated data were compared to their known true values.
Results: With small and medium sample sizes, an augmented 1-PL model was the most accurate at recovering the known item and person parameters; however, no model performed well at any sample size. Follow-up simulations confirmed that the large influence of guessing and the extreme easiness of the items contributed substantially to the poor estimation of item difficulty and person ability.
Conclusion: Incorporating the assumption of guessing into IRT models improves parameter estimation accuracy, even for small samples. However, caution should be exercised in interpreting scores obtained from easy 2-choice tests, regardless of whether IRT modeling or percentage correct scoring is used.
C1 [Hula, William D.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hula, William D.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
[Fergadiotis, Gerasimos] Arizona State Univ, Tempe, AZ USA.
[Martin, Nadine] Temple Univ, Philadelphia, PA 19122 USA.
RP Hula, WD (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
EM william.hula@va.gov
FU Veterans Affairs Rehabilitation Research & Development Career
Development Award [C7476W]; VA Pittsburgh Healthcare System Geriatric
Research Education and Clinical Center; National Institutes of Health
(National Institute on Deafness and Other Communication Disorders)
[DC01924-15]
FX This research was supported by Veterans Affairs Rehabilitation Research
& Development Career Development Award C7476W, the VA Pittsburgh
Healthcare System Geriatric Research Education and Clinical Center, and
Grant DC01924-15 from the National Institutes of Health (National
Institute on Deafness and Other Communication Disorders) to Temple
University (PI N. Martin). The authors also gratefully acknowledge the
support and assistance of Heather Harris Wright and Michelene
Kalinyak-Fliszar. The contents of this paper do not represent the views
of the Department of Veterans Affairs or the U.S. Government.
NR 52
TC 1
Z9 1
U1 0
U2 5
PU AMER SPEECH-LANGUAGE-HEARING ASSOC
PI ROCKVILLE
PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA
SN 1058-0360
J9 AM J SPEECH-LANG PAT
JI Am. J. Speech-Lang. Pathol.
PD MAY 1
PY 2012
VL 21
IS 2
BP S38
EP S50
DI 10.1044/1058-0360(2011/11-0090)
PG 13
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA 019SZ
UT WOS:000309760900003
PM 22230175
ER
PT J
AU Vigen, R
Shetterly, S
Magid, DJ
O'Connor, PJ
Margolis, KL
Schmittdiel, J
Ho, PM
AF Vigen, Rebecca
Shetterly, Susan
Magid, David J.
O'Connor, Patrick J.
Margolis, Karen L.
Schmittdiel, Julie
Ho, P. Michael
TI A Comparison Between Antihypertensive Medication Adherence and Treatment
Intensification as Potential Clinical Performance Measures
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE hypertension; performance measures; medication adherence; treatment
intensification; quality of care
ID BLOOD-PRESSURE CONTROL; CORONARY-ARTERY-DISEASE; ASSOCIATION TASK-FORCE;
COLLEGE-OF-CARDIOLOGY; AMERICAN-COLLEGE; DIABETES-MELLITUS;
HYPERTENSION; CARE; QUALITY; THERAPY
AB Background-Medication adherence and treatment intensification have been advocated as performance measures to assess the quality of care provided. Whereas previous studies have shown that adherence and treatment intensification (TI) of antihypertensive medications is associated with blood pressure (BP) control at the patient level, less is known about whether adherence and TI is associated with BP control at the clinic level.
Methods and Results-We included 162 879 patients among 89 clinics in the Cardiovascular Research Network Hypertension Registry with incident hypertension who were started on antihypertensive medications. Adherence was measured by the proportion of days covered (PDC). TI was defined by the standard based method with scores ranging between -1 to 1 and categorized as: -1 indicated no TI occurred when BP was elevated; 0 indicated TI occurred when BP was elevated; and 1 indicated that TI was made at all visits, even when BP was not elevated. Logistic regression models assessed the association between adherence and TI with blood pressure control (BP <= 140/90 at the clinic visit closest to 12 months after study entry) at the patient and clinic levels. Mean adherence was 0.77 +/- 0.28 (PDC +/- SD) at the patient level and 0.78 +/- 0.05 at the clinic level. Mean TI was 0.026 +/- 0.23 at the patient level and 0.01 +/- 0.04 at the clinic level. At the patient level, for each 0.25 increase in adherence and TI, the odds (OR) of achieving blood pressure control increased by 28% and 55%, respectively [OR for adherence, 1.28 (1.26-1.29), and for TI, 1.55 (1.53-1.57)]. At the clinic level, each 0.04 increment increase in treatment intensification was associated with a 25% increased odds of achieving blood pressure control (OR, 1.24; 95% CI, 1.21-1.27). In contrast, there was an inverse association between increasing adherence and BP control (OR, 0.93; 95% confidence interval, 0.90-0.95).
Conclusions-Patient adherence to antihypertensive medications is not associated with BP control at the clinic level and may not be suitable as a performance measure. TI is associated with BP control, but its use as a performance measure may be constrained by challenges in measuring it and by concerns about unintended consequences of aggressive hypertension treatment in some subgroups of patients. (Circ Cardiovasc Qual Outcomes. 2012; 5: 276-282.)
C1 [Vigen, Rebecca; Ho, P. Michael] Univ Colorado, Denver, CO 80202 USA.
[Shetterly, Susan; Magid, David J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[O'Connor, Patrick J.; Margolis, Karen L.] HealthPartners Res Fdn, Minneapolis, MN USA.
[Schmittdiel, Julie] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA.
[Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA.
RP Vigen, R (reprint author), Denver VAMC, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA.
EM Rebecca.vigen@ucdenver.edu
FU Cardiovascular Outcomes Research Fellowship through a Department of
Veterans Affairs Graduate Medical Education Enhancement Grant; Berman
Center [HHSN268201100027C]; Assessing Accuracy of Blood Pressure
Measurement in HealthPartners Usual Clinical Care [A12-046]; [HL
089471]; [HL 093345]; [DK 079861]; [HL 102144];
[NIH/R01HL093345-01]; [KPNC/U19 HL091179]; [NHLBI/1R01HL089451-01A1];
[NHLBI/R01 HL090965-01]; [NHLBI/N01-WH-3-2101]; [NIA/U01AG029824];
[NHLBI/1R01HL102144-01]
FX Dr Vigen was supported by a Cardiovascular Outcomes Research Fellowship
through a Department of Veterans Affairs Graduate Medical Education
Enhancement Grant.; Dr O'Connor was supported by Research Grants HL
089471, HL 093345, DK 079861, and HL 102144. Dr Margolis was supported
by Research Grants NIH/R01HL093345-01; Berman Center/HHSN268201100027C;
KPNC/U19 HL091179; NHLBI/1R01HL089451-01A1; NHLBI/R01 HL090965-01;
NHLBI/N01-WH-3-2101; NIA/U01AG029824; NHLBI/1R01HL102144-01; A12-046
Assessing Accuracy of Blood Pressure Measurement in HealthPartners Usual
Clinical Care.
NR 16
TC 7
Z9 8
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1941-7705
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD MAY
PY 2012
VL 5
IS 3
BP 276
EP 282
DI 10.1161/CIRCOUTCOMES.112.965665
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 002NO
UT WOS:000308539100009
PM 22576846
ER
PT J
AU Hou, JG
Wu, LJ
Moore, S
Ward, C
York, M
Atassi, F
Fincher, L
Nelson, N
Sarwar, A
Lai, EC
AF Hou, Jyhgong Gabriel
Wu, Laura J.
Moore, Suzanne
Ward, Constance
York, Michele
Atassi, Farah
Fincher, Linda
Nelson, Naomi
Sarwar, Aliya
Lai, Eugene C.
TI Assessment of appropriate medication administration for hospitalized
patients with Parkinson's disease
SO PARKINSONISM & RELATED DISORDERS
LA English
DT Article
DE Parkinson's disease; Hospitalization; Medication administration;
Medication schedule
ID EXCESS LENGTH; COMPLICATIONS; ADMISSIONS; MANAGEMENT; FREQUENCY;
ADHERENCE; EVENTS; STAY; CARE
AB Background: For Parkinson's disease (PD) patients, adherence to a regular PD medication schedule is important in achieving optimal symptom control. There are few published studies quantifying PD medication administrations in hospitalized PD patients.
Methods: Hospitalization records for 100 veterans with idiopathic PD and admitted to our center were reviewed to determine the on time rate and contraindicated medication doses. A barcode based computerized medication administration system within the electronic medical record provided information of the exact time the medication was given to a patient.
Results: Eighty-nine idiopathic PD patients met study inclusion criteria. Among them, 87 were on levodopa monotherapy or in combination with other PD medications. Two patients were on dopamine agonists only. A total of 3873 doses of PD medications were prescribed during hospitalization. Among 675 incorrect medication administrations, 322 doses were omitted, 300 doses late by >= 30 min, and 53 doses given early by >= 30 min. Contraindicated medications were prescribed for 19 patients. The correct administration percentage was lower during the first 2 days post-admission compared to subsequent days (mean 74.6% vs. 82.8%) and higher for patients who had neurological consultations (mean 85.5% vs. 76.5%). Correct administration rates were better for patient-based medication schedules (85.6%) than with hospital-based schedules (77.5%), but did not achieve statistical significance.
Conclusion: Adherence to regular PD medication dosing schedules during hospitalization is problematic, but improves with specialist consultation. Staff involved in the admission process for PD patients should work to safeguard against disruption of the prescribed home dosing schedule. Published by Elsevier Ltd.
C1 [Hou, Jyhgong Gabriel; Wu, Laura J.; Moore, Suzanne; Ward, Constance; York, Michele; Atassi, Farah; Fincher, Linda; Nelson, Naomi; Sarwar, Aliya] Baylor Coll Med, Dept Neurol, Parkinsons Dis Res Educ & Clin Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Wu, Laura J.] SUNY Stony Brook, Dept Neurol, Med Ctr, Stony Brook, NY 11794 USA.
[Atassi, Farah; Lai, Eugene C.] Methodist Neurol Inst, Dept Neurol, Houston, TX 77030 USA.
RP Hou, JG (reprint author), Baylor Coll Med, Dept Neurol, Parkinsons Dis Res Educ & Clin Ctr, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
EM jhou@bcm.edu
FU Department of Veterans Affairs
FX This study is sponsored by the Department of Veterans Affairs.
NR 29
TC 14
Z9 14
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8020
J9 PARKINSONISM RELAT D
JI Parkinsonism Relat. Disord.
PD MAY
PY 2012
VL 18
IS 4
BP 377
EP 381
DI 10.1016/j.parkreldis.2011.12.007
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA 991CK
UT WOS:000307678900014
PM 22236581
ER
PT J
AU Kaczorowski, DJ
Scott, MJ
Pibris, JP
Afrazi, A
Nakao, A
Edmonds, RD
Kim, S
Kwak, JH
Liu, YJ
Fan, J
Billiar, TR
AF Kaczorowski, David J.
Scott, Melanie J.
Pibris, John P.
Afrazi, Amin
Nakao, Atsunori
Edmonds, Rebecca D.
Kim, Sodam
Kwak, Joon H.
Liu, Yujian
Fan, Jie
Billiar, Timothy R.
TI Mammalian DNA Is an Endogenous Danger Signal That Stimulates Local
Synthesis and Release of Complement Factor B
SO MOLECULAR MEDICINE
LA English
DT Article
ID ISCHEMIA-REPERFUSION INJURY; PLASMACYTOID DENDRITIC CELLS;
COLLAGEN-INDUCED ARTHRITIS; INNATE IMMUNE-RESPONSES; TOLL-LIKE
RECEPTOR-4; ACUTE-RENAL-FAILURE; TNF-ALPHA; INFLAMMATORY RESPONSES;
ENDOTHELIAL-CELLS; CYTOPLASMIC DNA
AB Complement factor B plays a critical role in ischemic tissue injury and autoimmunity. Factor B is dynamically synthesized and released by cells outside of the liver, but the molecules that trigger local factor B synthesis and release during endogenous tissue injury nave not been identified. We determined that factor B is upregulated early after cold ischemia-eperfusion in mice, using a heterotopic heart transplant model. These data suggested upregulation of factor B by damage-associated molecular patterns (DAMPs), but multiple common DAMPs did not induce factor B in RAW264.7 mouse macrophages. However, exogenous DNA induced factor B mRNA and protein expression in RAW cells in vitro, as well as in peritoneal and alveolar macrophages in vivo. To determine the cellular mechanisms involved in DNA-induced factor B upregulation we then investigated the role of multiple known DNA receptors or binding partners. We stimulated peritoneal macrophages from wild-type (WT), toll-like receptor 9 (TLR9)-deficient, receptor for advanced glycation end products (RAGE)(-/-) and myeloid differentiation factor 88 (MyD88)(-/-) mice, or mouse macrophages deficient in high-mobility group box proteins (HMGBs). DNA-dependent activator of interferon-regulatory factors (DAI) or absent in melanoma 2 (AIM2), with DNA in the presence or absence of lipofection reagent. Reverse transcription-polymerase chain reaction, Western blotting and immunocytochemical analysis were employed for analysis. Synthesis of factor B was independent of TLR9, RAGE, DAI and AIM2, but was dependent on HMGBs, MyD88, p38 and NF-kappa B. Our data therefore show that mammalian DNA is an endogenous molecule that stimulates factor B synthesis and release from macrophages via HMGBs, MyD88, p38 and NF-kappa B signaling. This activation of the immune system likely contributes to damage following sterile injury such as hemorrhagic shock and ischemia-reperfusion. Online address: http://www.molmed.org doi: 10.2119/molmed.2012.00011
C1 [Scott, Melanie J.; Pibris, John P.; Afrazi, Amin; Nakao, Atsunori; Edmonds, Rebecca D.; Kim, Sodam; Kwak, Joon H.; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
[Kaczorowski, David J.] Univ Penn, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
[Liu, Yujian; Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA USA.
RP Billiar, TR (reprint author), Univ Pittsburgh, Med Ctr, Dept Surg, Presbyterian Univ Hosp, F1281,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM billiartr@upmc.edu
FU National Institutes of Health [P50-GM-53789]; American College of
Surgeons Resident Research Scholarships
FX This work was supported by National Institutes of Health grant
P50-GM-53789 (TR Billiar). DJ Kaczorowski and RD Edmonds are each
recipients of American College of Surgeons Resident Research
Scholarships. We thank M Bo, H Liao and D Reiser for technical
assistance.
NR 52
TC 10
Z9 10
U1 0
U2 2
PU FEINSTEIN INST MED RES
PI MANHASSET
PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA
SN 1076-1551
J9 MOL MED
JI Mol. Med.
PD MAY
PY 2012
VL 18
IS 5
BP 851
EP 860
DI 10.2119/molmed.2012.00011
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA 983TY
UT WOS:000307142800014
PM 22526919
ER
PT J
AU Chitsaz, S
Gundiah, N
Blackshear, C
Tegegn, N
Yan, KS
Azadani, AN
Hope, M
Tseng, EE
AF Chitsaz, Sam
Gundiah, Namrata
Blackshear, Charlie
Tegegn, Nebiyu
Yan, Kimberly S.
Azadani, Ali N.
Hope, Michael
Tseng, Elaine E.
TI Correlation of Calcification on Excised Aortic Valves by Micro-Computed
Tomography with Severity of Aortic Stenosis
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article
ID ELECTRON-BEAM TOMOGRAPHY; MULTIDETECTOR ROW CT; CALCIUM;
ECHOCARDIOGRAPHY; QUANTIFICATION; MARKER; AREA
AB Background and aim of the study: The quantification of incidentally found aortic valve calcification on computed tomography (CT) is not performed routinely, as data relating to the accuracy of aortic valve calcium for estimating the severity of aortic stenosis (AS) is neither consistent nor validated. As aortic valve calcium quantification by CT is confounded by wall and coronary ostial calcification, as well as motion artifact, the ex-vivo micro-computed tomography (micro-CT) of stenotic aortic valves allows a precise measurement of the amounts of calcium present. The study aim, using excised aortic valves from patients with confirmed AS, was to determine if the amount of calcium on micro-CT correlated with the severity of AS.
Methods: Each of 35 aortic valves that had been excised from patients during surgical valve replacement were examined using micro-CT imaging. The amount of calcium present was determined by absolute and proportional values of calcium volume in the specimen. Subsequently, the correlation between calcium volume and preoperative mean aortic valve gradient (MAVG), peak transaortic velocity (V-max), and aortic valve area (AVA) on echocardiography, was evaluated.
Results: The mean calcium volume across all valves was 603.2 +/- 398.5 mm(3), and the mean ratio of calcium volume to total valve volume was 0.36 +/- 0.16. The mean aortic valve gradient correlated positively with both calcium volume and ratio (r = 0.72, p <0.001). V-max also correlated positively with the calcium volume and ratio (r = 0.69 and 0.76 respectively; p <0.001). A logarithmic curvilinear model proved to be the best fit to the correlation. A calcium volume of 480 mm(3) showed sensitivity and specificity of 0.76 and 0.83, respectively, for a diagnosis of severe AS, while a calcium ratio of 0.37 yielded sensitivity and specificity of 0.82 and 0.94, respectively.
Conclusion: A radiological estimation of calcium amount by volume, and its proportion to the total valve volume, were shown to serve as good predictive parameters for severe AS. An estimation of the calcium volume may serve as a complementary measure for determining the severity of AS when aortic valve calcification is identified on CT imaging. The Journal of Heart Valve Disease 2012;21:320-327
C1 [Chitsaz, Sam; Gundiah, Namrata; Blackshear, Charlie; Tegegn, Nebiyu; Yan, Kimberly S.; Azadani, Ali N.; Tseng, Elaine E.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Chitsaz, Sam; Gundiah, Namrata; Blackshear, Charlie; Tegegn, Nebiyu; Yan, Kimberly S.; Azadani, Ali N.; Tseng, Elaine E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Gundiah, Namrata] Indian Inst Sci, Dept Mech Engn, Bangalore 560012, Karnataka, India.
[Hope, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
RP Tseng, EE (reprint author), UCSF Med Ctr, 500 Parnassus Ave,Suite W405,Box 0118, San Francisco, CA 94143 USA.
EM elaine.tseng@ucsfmedctr.org
RI Chitsaz, Sam/C-4586-2008
NR 21
TC 4
Z9 4
U1 1
U2 4
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET,
ENGLAND
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD MAY
PY 2012
VL 21
IS 3
BP 320
EP 327
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 977OY
UT WOS:000306675500008
PM 22808832
ER
PT J
AU Littman, AJ
Boyko, EJ
McDonell, MB
Fihn, SD
AF Littman, Alyson J.
Boyko, Edward J.
McDonell, Mary B.
Fihn, Stephan D.
TI Evaluation of a Weight Management Program for Veterans
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID OBESITY; INTERVENTIONS; PREVALENCE; FACILITIES; ADULTS
AB Introduction
To improve the health of overweight and obese veterans, the Department of Veterans Affairs (VA) developed the MOVE! Weight Management Program for Veterans. The aim of this evaluation was to assess its reach and effectiveness.
Methods
We extracted data on program involvement, demographics, medical conditions, and outcomes from VA administrative databases in 4 Western states. Eligibility criteria for MOVE! were being younger than 7 0 years and having a body mass index (BMI, in kg/m(2)) of at least 30.0, or 25.0 to 29.9 with an obesity-related condition. To evaluate reach, we estimated the percentage of eligible veterans who participated in the program and their representativeness. To evaluate effectiveness, we estimated changes in weight and BMI using multivariable linear regression.
Results
Less than 5% of eligible veterans participated, of whom half had only a single encounter. Likelihood of participation was greater in women, those with a higher BMI, and those with more primary care visits, sleep apnea, or a mental health condition. Likelihood of participation was lower among those who were younger than 5 5 (vs 55-64), widowed, current smokers, and residing farther from the medical center (>= 3 0 vs <30 miles). At 6- and 12-month follow-up, participants lost an average of 1.3 lb (95% confidence interval [CI], -2.6 to -0.02 lb) and 0.9 lb (95% CI, -2.0 to 0.1 lb) more than nonparticipants, after covariate adjustment. More intensive treatment (>= 6 encounters) was associated with greater weight loss at 12 months (-3.7 lb; 95% CI, -5.1 to -2.3 lb).
Conclusion
Few eligible patients participated in the program during the study period, and overall estimates of effectiveness were low.
C1 [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[McDonell, Mary B.] Off Analyt & Business Intelligence, VHA Off Informat & Analyt, Seattle, WA USA.
[Boyko, Edward J.; Fihn, Stephan D.] Univ Washington, Dept Med, Seattle, WA USA.
[Littman, Alyson J.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
RP Littman, AJ (reprint author), VA Puget Sound Hlth Care Syst 152E, Seattle Epidemiol Res & Informat Ctr, 1100 Ol Way,Ste 1400, Seattle, WA 98101 USA.
EM alyson@u.washington.edu
FU Quality Enhancement Research Initiative [RRP-07-279]; Cooperative
Studies Program; VA Puget Sound Health Care System, Department of
Veterans Affairs; VA Rehabilitation Research and Development Career
Development Award [6982]
FX This study was supported in part by the Quality Enhancement Research
Initiative (RRP-07-279), the Cooperative Studies Program, and VA Puget
Sound Health Care System, Department of Veterans Affairs. Dr Littman was
supported by a VA Rehabilitation Research and Development Career
Development Award (#6982). Dr Leila Kahwati provided valuable feedback
on program components, study analysis, and interpretation.
NR 19
TC 7
Z9 8
U1 0
U2 3
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD MAY
PY 2012
VL 9
AR 110267
DI 10.5888/pcd9.110267
PG 12
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 977HU
UT WOS:000306648100007
ER
PT J
AU Morgenroth, DC
Gellhorn, AC
Suri, P
AF Morgenroth, David C.
Gellhorn, Alfred C.
Suri, Pradeep
TI Osteoarthritis in the Disabled Population: A Mechanical Perspective
SO PM&R
LA English
DT Article
ID COMPARTMENT KNEE OSTEOARTHRITIS; TRANS-TIBIAL AMPUTATION; BONE-MINERAL
DENSITY; TO-STEP TRANSITIONS; REACTION FORCE DATA; SPINAL-CORD-INJURY;
LOW-BACK-PAIN; HUMAN WALKING; PROSTHETIC FEET; AMPUTEE GAIT
AB Primary disabling conditions, such as amputation, not only limit mobility, but also predispose individuals to secondary musculoskeletal impairments, such as osteoarthritis (OA) of the intact limb joints, that can result in additive disability. Altered gait biomechanics that cause increased loading of the intact limb have been suggested as a cause of the increased prevalence of intact limb knee and hip osteoarthritis in this population. Optimizing socket fit and prosthetic alignment, as well as developing and prescribing prosthetic feet with improved push-off characteristics, can lead to reduced asymmetric loading of the intact limb and therefore are potential strategies to prevent and treat osteoarthritis in the amputee population. Research on disabled populations associated with altered biomechanics offers an opportunity to focus on the mechanical risk factors associated with this condition. Continued research into the causes of secondary disability and the development of preventive strategies are critical to enable optimal rehabilitation practices to maximize function and quality of life in patients with disabilities. PM R 2012;4:S20-S27
C1 [Morgenroth, David C.] Vet Affairs Puget Sound Healthcare Syst, RR&D Res Ctr, Seattle, WA USA.
[Morgenroth, David C.; Gellhorn, Alfred C.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Suri, Pradeep] Vet Affairs Boston Healthcare Syst, Div Phys Med & Rehabil, Boston, MA USA.
[Suri, Pradeep] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Suri, Pradeep] Spaulding Rehabil Hosp, Boston, MA USA.
[Suri, Pradeep] New England Baptist Hosp, Boston, MA USA.
RP Morgenroth, DC (reprint author), RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA.
EM dmorgen@uw.edu
FU NIH [K12 HD001097]
FX 8B, NIH (grant #K12 HD001097)
NR 94
TC 32
Z9 34
U1 4
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1934-1482
J9 PM&R
JI PM&R
PD MAY
PY 2012
VL 4
IS 5
SU 1
BP S20
EP S27
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 966YJ
UT WOS:000305873000004
PM 22632698
ER
PT J
AU Mutluoglu, M
Uzun, G
Turhan, V
Gorenek, L
Ay, H
Lipsky, BA
AF Mutluoglu, Mesut
Uzun, Gunalp
Turhan, Vedat
Gorenek, Levent
Ay, Hakan
Lipsky, Benjamin A.
TI How reliable are cultures of specimens from superficial swabs compared
with those of deep tissue in patients with diabetic foot ulcers?
SO JOURNAL OF DIABETES AND ITS COMPLICATIONS
LA English
DT Article
DE Diabetic foot ulcer; Swab culture; Tissue biopsy; Wound microbiology
ID RESISTANT STAPHYLOCOCCUS-AUREUS; INFECTION; MICROBIOLOGY; MANAGEMENT;
CONSENSUS; ISCHEMIA; DISEASE; WOUNDS; BURDEN; BIOPSY
AB Purpose: To assess the reliability of cultures of superficial swabs (SS) by comparing them with cultures of concomitantly obtained deep tissue (DT) specimens in patients with diabetic foot ulcers.
Methods: We reviewed clinical and microbiological data from patients with diabetes who presented during a two-year period to our hyperbaric medicine center with a foot ulcer. We identified patients who had at least one concomitantly collected SS and DT pair of specimens sent for culture.
Results: A total of 89 culture pairs were available from 54 eligible patients, 33 (61.1%) of whom were hospitalized. Wounds were infected in 47 (87.0%) of the patients and 28 (51.9%) patients had received antibiotic therapy within the previous month. Overall, 65(73%) of the SS and DT pairs had identical culture results, but in 11(16.9%) cases the cultures were sterile; thus, only 54 (69.2%) of the 78 culture-positive pairs had identical results. Compared with DT, SS cultures yielded >= 1 extra organism in 10 (11.2%) cases, missed at least one organism in 8 (9.0%), and were completely different in 6 (6.7%). When compared to DT culture results, SS cultures had a positive predictive value of 84.4%, negative predictive value of 44.0%, and overall accuracy of 73.0%.
Conclusions: In patients with diabetic foot ulcers, results of specimens for culture taken by SS did not correlate well with those obtained by DT. This suggests that SS specimens may be less reliable for guiding antimicrobial therapy than DT specimens. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Mutluoglu, Mesut; Uzun, Gunalp; Ay, Hakan] GATA Haydarpasa Teaching Hosp, Dept Underwater & Hyperbar Med, TR-34668 Istanbul, Turkey.
[Turhan, Vedat; Gorenek, Levent] GATA Haydarpasa Teaching Hosp, Dept Infect Dis & Clin Microbiol, TR-34668 Istanbul, Turkey.
[Lipsky, Benjamin A.] Univ Washington, Primary Care Clin, VA Puget Sound, Seattle, WA 98108 USA.
RP Mutluoglu, M (reprint author), Haydarpasa Teaching Hosp, Gulhane Mil Med Acad, Dept Underwater & Hyperbar Med, TR-34668 Istanbul, Turkey.
EM drmutluoglu@gmail.com; balipsky@uw.edu
RI mutluoglu, mesut/B-4451-2009
OI Lipsky, Benjamin A./0000-0001-9886-5114; Mutluoglu,
Mesut/0000-0002-1112-5779; Uzun, Gunalp/0000-0002-8717-6230
NR 25
TC 14
Z9 15
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8727
J9 J DIABETES COMPLICAT
JI J. Diabetes Complications
PD MAY-JUN
PY 2012
VL 26
IS 3
BP 225
EP 229
DI 10.1016/j.jdiacomp.2012.03.015
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 960BH
UT WOS:000305362500013
PM 22520404
ER
PT J
AU Narayanavari, SA
Sritharan, M
Haake, DA
Matsunaga, J
AF Narayanavari, Suneel A.
Sritharan, Manjula
Haake, David A.
Matsunaga, James
TI Multiple leptospiral sphingomyelinases (or are there?)
SO MICROBIOLOGY-SGM
LA English
DT Review
ID BACILLUS-CEREUS SPHINGOMYELINASE; INTERROGANS SEROVAR HARDJO;
STAPHYLOCOCCUS-AUREUS; BETA-TOXIN; NEUTRAL SPHINGOMYELINASE; BINDING
PROTEIN; HEMOLYSIN; LAI; EXPRESSION; MATRIX
AB Culture supernatants of leptospiral pathogens have long been known to haemolyse erythrocytes. This property is due, at least in part, to sphingomyelinase activity. Indeed, genome sequencing reveals that pathogenic Leptospira species are richly endowed with sphingomyelinase homologues: five genes have been annotated to encode sphingomyelinases in Leptospira interrogans. Such redundancy suggests that this class of genes is likely to benefit leptospiral pathogens in their interactions with the mammalian host. Surprisingly, sequence comparison with bacterial sphingomyelinases for which the crystal structures are known reveals that only one of the leptospiral homologues has the active site amino acid residues required for enzymic activity. Based on studies of other bacterial toxins, we propose that leptospiral sphingomyelinase homologues, irrespective of their catalytic activity, may possess additional molecular functions that benefit the spirochaete. Potential secretion pathways and roles in pathogenesis are discussed, including nutrient acquisition, dissemination, haemorrhage and immune evasion. Although leptospiral sphingomyelinase-like proteins are best known for their cytolytic properties, we believe that a better understanding of their biological role requires the examination of their sublytic properties as well.
C1 [Narayanavari, Suneel A.; Sritharan, Manjula] Univ Hyderabad, Dept Anim Sci, Hyderabad 500134, Andhra Pradesh, India.
[Haake, David A.] VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA.
[Haake, David A.; Matsunaga, James] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Haake, David A.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.
[Haake, David A.] Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA USA.
[Matsunaga, James] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA.
RP Narayanavari, SA (reprint author), Univ Hyderabad, Dept Anim Sci, Hyderabad 500134, Andhra Pradesh, India.
EM leptolysin@gmail.com
FU Public Health Service National Institute of Allergy and Infectious
Diseases [AI-034431]; VA Medical Research Funds; United States India
Educational Foundation (USIEF)
FX S. A. N. would like to acknowledge the United States India Educational
Foundation (USIEF) for financial support in the form of Fulbright Nehru
Doctoral and Professional Research Fellowship. This study was supported
by Public Health Service National Institute of Allergy and Infectious
Diseases grant AI-034431 (to D. A. H.) and VA Medical Research Funds (to
J. M. and D. A. H.). We thank Ben Adler (Monash University) for
providing the sphingomyelinase sequences of Lept. interrogans serovars
Manilae and Pomona.
NR 60
TC 9
Z9 10
U1 0
U2 3
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD MAY
PY 2012
VL 158
BP 1137
EP 1146
DI 10.1099/mic.0.057737-0
PN 5
PG 10
WC Microbiology
SC Microbiology
GA 960GL
UT WOS:000305375900001
PM 22422753
ER
PT J
AU Furmaga, H
Carreno, FR
Frazer, A
AF Furmaga, Havan
Carreno, Flavia Regina
Frazer, Alan
TI Vagal Nerve Stimulation Rapidly Activates Brain-Derived Neurotrophic
Factor Receptor TrkB in Rat Brain
SO PLOS ONE
LA English
DT Article
ID TREATMENT-RESISTANT DEPRESSION; HIPPOCAMPAL-NEURONS; GROWTH-FACTOR;
SIGNAL-TRANSDUCTION; TYROSINE KINASE; FACTOR BDNF; SEROTONIN
TRANSPORTER; ANTIDEPRESSANT ACTION; TRUNCATED RECEPTORS; GENE-EXPRESSION
AB Background: Vagal nerve stimulation (VNS) has been approved for treatment-resistant depression. Many antidepressants increase expression of brain-derived neurotrophic factor (BDNF) in brain or activate, via phosphorylation, its receptor, TrkB. There have been no studies yet of whether VNS would also cause phosphorylation of TrkB.
Methods: Western blot analysis was used to evaluate the phosphorylation status of TrkB in the hippocampus of rats administered VNS either acutely or chronically. Acute effects of VNS were compared with those caused by fluoxetine or desipramine (DMI) whereas its chronic effects were compared with those of sertraline or DMI.
Results: All treatments, given either acutely or chronically, significantly elevated phosphorylation of tyrosines 705 and 816 on TrkB in the hippocampus. However, only VNS increased the phosphorylation of tyrosine 515, with both acute and chronic administration causing this effect. Pretreatment with K252a, a nonspecific tyrosine kinase inhibitor, blocked the phosphorylation caused by acute VNS at all three tyrosines. Downstream effectors of Y515, namely Akt and ERK, were also phosphorylated after acute treatment with VNS, whereas DMI did not cause this effect.
Conclusion: VNS rapidly activates TrkB phosphorylation and this effect persists over time. VNS-induced phosphorylation of tyrosine 515 is distinct from the effect of standard antidepressant drugs.
C1 [Furmaga, Havan; Carreno, Flavia Regina; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Frazer, Alan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
RP Furmaga, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
EM frazer@uthscsa.edu
FU National Institute of Mental Health grant [R01 MH082933]; Cyberonics,
Inc.
FX This work was supported by National Institute of Mental Health grant R01
MH082933 (Alan Frazer). The funder had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.; Drs. Furmaga and Carreno have no competing interests to
declare. Previously, Dr. Frazer received financial compensation as a
consultant for Cyberonics, Inc. and had also obtained grant support from
them for a preclinical study. This does not alter the authors' adherence
to all the PLoS ONE policies on sharing data and materials.
NR 66
TC 28
Z9 29
U1 3
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 1
PY 2012
VL 7
IS 5
AR e34844
DI 10.1371/journal.pone.0034844
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UN
UT WOS:000305340700007
PM 22563458
ER
PT J
AU Palyo, SA
Schopmeyer, KA
McQuaid, JR
AF Palyo, Sarah A.
Schopmeyer, Kathryn A.
McQuaid, John R.
TI Tele-Pain Management: Use of Videoconferencing Technology in the
Delivery of an Integrated Cognitive-Behavioral and Physical Therapy
Group Intervention
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE chronic pain; pain management; telehealth; depression
AB Chronic pain has been recognized as a highly prevalent problem, and interdisciplinary treatments have been shown to be effective in the treatment of chronic pain. An integrated cognitive behavioral and physical therapy group protocol has been developed and then implemented at remote sites using videoconferencing technology to provide pain management for veterans. The treatment model is summarized and recommendations are made for addressing challenges in implementing this type of treatment via videoconferencing.
C1 [Palyo, Sarah A.; McQuaid, John R.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA.
[Palyo, Sarah A.; McQuaid, John R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Schopmeyer, Kathryn A.] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA 94121 USA.
RP Palyo, SA (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, 4150 Clement St,116B, San Francisco, CA 94121 USA.
EM sarah.palyo@va.gov
NR 0
TC 4
Z9 4
U1 0
U2 1
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2012
VL 9
IS 2
SI SI
BP 200
EP 202
DI 10.1037/a0025987
PG 3
WC Psychology, Clinical
SC Psychology
GA 957WO
UT WOS:000305198000008
PM 22662734
ER
PT J
AU Barnwell, SVS
Juretic, MA
Hoerster, KD
Van de Plasch, R
AF Barnwell, Sara V. Smucker
Juretic, Meghan A.
Hoerster, Katherine D.
Van de Plasch, Richard
TI VA Puget Sound Telemental Health Service to Rural Veterans: A Growing
Program
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE telemental health; telepsychology; telehealth; veteran
AB The VA Puget Sound Health Care System Telemental Health program connects veterans with psychologists, psychiatrists, and social workers via live clinical video teleconferencing. Providers deliver care to veterans in rural Veteran Affairs medical centers, community-based outpatient clinics and residences, and thus, increase access to specialty mental health care for rural and medically underserved veteran communities.
C1 [Van de Plasch, Richard] Dept Vet Affairs Med Ctr, VISN Pacific NW Mental Illness Res Educ & Clin Ct, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA.
[Barnwell, Sara V. Smucker; Hoerster, Katherine D.; Van de Plasch, Richard] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP Barnwell, SVS (reprint author), VA Puget Sound Hlth Care Syst, S-116-MHC,1660 S Columbian Way, Seattle, WA 98108 USA.
EM ssmucker@post.harvard.edu
NR 0
TC 7
Z9 7
U1 2
U2 3
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2012
VL 9
IS 2
SI SI
BP 209
EP 211
DI 10.1037/a0025999
PG 3
WC Psychology, Clinical
SC Psychology
GA 957WO
UT WOS:000305198000011
PM 22662737
ER
PT J
AU Hayden, LJ
Glynn, SM
Hahn, TJ
Randall, F
Randolph, E
AF Hayden, Lisa J.
Glynn, Shirley M.
Hahn, Theodore J.
Randall, Frychettya
Randolph, Eugenia
TI The Use of Internet Technology for Psychoeducation and Support With
Dementia Caregivers
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE internet technology; Alzheimer's disease; dementia; caregiver support;
randomized trial
AB A large randomized trial evaluated the benefits of online education, support, and self-care promotion for caregivers of persons with dementia. Anecdotal reports from participants indicated enjoyment of the materials, convenient access from home, and support from professionals and other caregivers. A substantial number of screened caregivers experienced obstacles of access, cost, and time regarding use of technology. Telephone options are being explored, and future caregiving generations are expected to have increased exposure and willingness to use computer technology, such as the program described here.
C1 [Hayden, Lisa J.; Randolph, Eugenia] VA Greater Los Angeles Healthcare Syst W Los Angl, Res Serv, Los Angeles, CA 90073 USA.
[Glynn, Shirley M.; Randall, Frychettya] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Hahn, Theodore J.] VA Greater Los Angeles Healthcare Syst W Los Angl, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
[Hahn, Theodore J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
RP Hayden, LJ (reprint author), VA Greater Los Angeles Healthcare Syst W Los Angl, Res Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM lisa.hayden@va.gov
RI LOPES, LAIS/F-7380-2012
NR 1
TC 9
Z9 10
U1 5
U2 23
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
J9 PSYCHOL SERV
JI Psychol. Serv.
PD MAY
PY 2012
VL 9
IS 2
SI SI
BP 215
EP 218
DI 10.1037/a0027056
PG 4
WC Psychology, Clinical
SC Psychology
GA 957WO
UT WOS:000305198000013
PM 22662739
ER
PT J
AU Wong, MH
Chapin, OC
Johnson, MD
AF Wong, Mandi H.
Chapin, Olivia C.
Johnson, Meshell D.
TI LPS-Stimulated Cytokine Production in Type I Cells Is Modulated by the
Renin-Angiotensin System
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE cytokines; alveolar Type I cells; angiotensin Type 1 receptor;
angiotensin-converting enzyme 2; lipopolysaccharide
ID ALVEOLAR EPITHELIAL-CELLS; INDUCED LUNG INJURY; CONVERTING
ENZYME-INHIBITOR; NECROSIS-FACTOR-ALPHA; PRIMARY CULTURE; AT(1)
RECEPTOR; CXC CHEMOKINES; TNF-ALPHA; RAT MODEL; LIPOPOLYSACCHARIDE
AB The alveolar epithelium serves as a barrier to the entry of potential respiratory pathogens. Alveolar Type II (TII) cells have immunomodulatory functions, but whether Type I (TI) cells, which comprise approximately 95% of the alveolar epithelium, also play a role in immunity is unknown. Because the renin-angiotensin system (RAS) is emerging as an important mediator of inflammation, and angiotensin-converting enzyme 2 (ACE2), an element of the RAS, has been implicated in lung injury, we hypothesize that TI cells canproduce cytokines in response to LPS stimulation, and that this inflammation can be modulated by the RAS. Alveolar TI cells were isolated from adult Sprague-Dawley rat lungs that had been injured with an intratracheal instillation of LPS. PCR was performed to determine whether TI cells expressed transcripts for TNF-alpha, IL-6, or IL-1 beta at baseline and after lung injury. Immunocytochemical and protein analysis detected angiotensin II (Ang II) and ACE2, as well as angiotensin Type 1 receptor (AT1R) and Type 2 receptor (AT2R), in TI cells. To separate cell-specific responses, primary TI cells were isolated, cultured, and exposed to LPS, Ang II, or specific inhibitors of AT1R or AT2R. Cytokine production was assayed by ELISA. LPS stimulated the production of all cytokines, whereas ACE2 and losartan, an AT1R inhibitor, blocked elements of the LPS-induced cytokine response. Primary TI cells produce cytokines when treated with LPS, contain important components of the RAS, and can modulate LPS-induced cytokine production via the RAS, suggesting a role for TI cells in the innate immune response of the lung.
C1 [Wong, Mandi H.; Johnson, Meshell D.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Wong, Mandi H.; Johnson, Meshell D.] No Calif Inst Res & Educ, San Francisco, CA USA.
[Chapin, Olivia C.; Johnson, Meshell D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Johnson, MD (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111-D, San Francisco, CA 94121 USA.
EM meshell.johnson@ucsf.edu
FU Department of Veterans Affairs; Northern California Institute for
Research and Education; National Institutes of Health [HL088025]
FX This work was supported by grants from the Department of Veterans
Affairs and the Northern California Institute for Research and
Education, and by grant HL088025 from the National Institutes of Health
(M.D.J).
NR 44
TC 11
Z9 13
U1 0
U2 7
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD MAY
PY 2012
VL 46
IS 5
BP 641
EP 650
DI 10.1165/rcmb.2011-0289OC
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 956CX
UT WOS:000305068500011
PM 22205632
ER
PT J
AU Shacka, JJ
AF Shacka, John J.
TI Mouse models of neuronal ceroid lipofuscinoses: Useful pre-clinical
tools to delineate disease pathophysiology and validate therapeutics
SO BRAIN RESEARCH BULLETIN
LA English
DT Review
DE NCL; Lysosome; Autophagy; Cathepsin D; Apoptosis; Therapeutic
ID PALMITOYL-PROTEIN THIOESTERASE-1; LYSOSOMAL STORAGE DISEASE;
TRIPEPTIDYL-PEPTIDASE-I; CATHEPSIN-D DEFICIENCY; DEGENERATION MND MOUSE;
CENTRAL-NERVOUS-SYSTEM; ENZYME-REPLACEMENT THERAPY; JUVENILE
BATTEN-DISEASE; CELL-DEATH PATHWAYS; LATE INFANTILE NCL
AB The neuronal ceroid lipofuscinoses (NCL, also known as Batten disease) is a devastating neurodegenerative diseases caused by mutations in either soluble enzymes or membrane-associated structural proteins that result in lysosome dysfunction. Different forms of NCL were defined initially by age of onset, affected population and/or type of storage material but collectively represent the most prevalent pediatric hereditary neurovisceral storage disorder. Specific gene mutations are now known for each subclass of NCL in humans that now largely define the disease: cathepsin D (CTSD) for congenital (CLN10 form); palmitoyl protein thioesterase 1 (PPT1) for infantile (CLN1 form); tripeptidyl peptidase 1 (TPP1) for classic late infantile (CLN2 form); variant late infantile-CLN5, CLN6 or CLN8 for variant late infantile forms; and CLN3 for juvenile (CLN3 form). Several mouse models of NCL have been developed, or in some cases exist sporadically, that exhibit mutations producing a progressive neurodegenerative phenotype similar to that observed in human NCL The study of these mouse models of NCL has dramatically advanced our knowledge of NCL pathophysiology and in some cases has helped delineate the function of proteins mutated in human NCL In addition, NCL mutant mice have been tested for several different therapeutic approaches and as such they have become important pre-clinical models for validating treatment options. In this review we will assess the current state of mouse models of NCL with regards to their unique pathophysiology and how these mice have helped investigators achieve a better understanding of human NCL disease and therapy. This article is part of a Special Issue entitled 'Mose Models'. Published by Elsevier Inc.
C1 [Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.
[Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Shacka, JJ (reprint author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.
EM shacka@uab.edu
RI di Ronza, Alberto/H-7674-2016
OI di Ronza, Alberto/0000-0002-9813-5143
FU VA Merit Review Award [1 I01 BX000957-01]
FX I wish to thank Rhonda Carr and Barry Bailey for expert technical
assistance, and to Kathryn Davidson for expert technical support in
preparation of this manuscript. I wish to also thank the UAB
Neuroscience Molecular Detection Core (P30 NS47466; Kevin Roth, MD, PhD,
Director; Terry Lewis, Technical Director) for their help in preparation
of this manuscript. Dr. Shacka is supported by a VA Merit Review Award
(1 I01 BX000957-01).
NR 171
TC 23
Z9 23
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD MAY 1
PY 2012
VL 88
IS 1
SI SI
BP 43
EP 57
DI 10.1016/j.brainresbull.2012.03.003
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 950EB
UT WOS:000304631300005
PM 22502604
ER
PT J
AU Piette, EW
Werth, VP
AF Piette, Evan W.
Werth, Victoria P.
TI Dapsone in the Management of Autoimmune Bullous Diseases
SO IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Dapsone; Autoimmune bullous disease; Review
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; DERMATITIS-HERPETIFORMIS; ACQUISITA;
PEMPHIGUS; DIAGNOSIS; ERUPTION; COLCHICINE; DERMATOSIS; THERAPY; WOMAN
AB Dapsone is used in the treatment of autoimmune bullous diseases (AIBD), a group of disorders resulting from autoimmunity directed against basement membrane and/or intercellular adhesion molecules on cutaneous and mucosal surfaces. This review summarizes the limited published data evaluating dapsone as a therapy for AIBD.
C1 [Piette, Evan W.; Werth, Victoria P.] Perelman Ctr Adv Med, Dept Dermatol, Philadelphia, PA 19104 USA.
[Werth, Victoria P.] Philadelphia VA Med Ctr, Div Dermatol, Philadelphia, PA USA.
RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, Suite 1-330A,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU National Institutes of Health [NIH K24-AR 02207]
FX Funding: National Institutes of Health, including NIH K24-AR 02207
(V.P.W.).
NR 41
TC 9
Z9 9
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8561
J9 IMMUNOL ALLERGY CLIN
JI Immunol. Allerg. Clin. North Am.
PD MAY
PY 2012
VL 32
IS 2
BP 317
EP +
DI 10.1016/j.iac.2012.04.011
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA 955RP
UT WOS:000305038900013
PM 22560144
ER
PT J
AU Drager, KK
du Sac, P
AF Drager, Kristin K.
du Sac, Prairie
TI IMPROVING PATIENT OUTCOMES WITH COMPRESSION-ONLY CPR: WILL BYSTANDER CPR
RATES IMPROVE?
SO JOURNAL OF EMERGENCY NURSING
LA English
DT Article
ID HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; CHEST
COMPRESSION; SURVIVAL
C1 [Drager, Kristin K.] William S Middleton Mem Vet Adm Med Ctr, Emergency Dept, Madison, WI USA.
[Drager, Kristin K.] William S Middleton Mem Vet Adm Med Ctr, ACLS, Madison, WI USA.
[Drager, Kristin K.] St Xavier Univ, Clin Nurse Leader Program, Chicago, IL USA.
RP Drager, KK (reprint author), William S Middleton Mem Vet Adm Med Ctr, Emergency Dept, Madison, WI USA.
EM Kristin.Drager@va.gov
NR 10
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0099-1767
J9 J EMERG NURS
JI J. Emerg. Nurs.
PD MAY
PY 2012
VL 38
IS 3
BP 234
EP 238
DI 10.1016/j.jen.2011.02.008
PG 5
WC Emergency Medicine; Nursing
SC Emergency Medicine; Nursing
GA 953FN
UT WOS:000304852400009
PM 21514650
ER
PT J
AU Pena, A
Estrada, CA
Soniat, D
Taylor, B
Burton, M
AF Pena, Adolfo
Estrada, Carlos A.
Soniat, Debbie
Taylor, Benjamin
Burton, Michael
TI Nominal group technique: A brainstorming tool for identifying areas to
improve pain management in hospitalized patients
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID PRODUCTIVITY LOSS; CARE
AB BACKGROUND: Pain management in hospitalized patients remains a priority area for improvement; effective strategies for consensus development are needed to prioritize interventions. OBJECTIVE: To identify challenges, barriers, and perspectives of healthcare providers in managing pain among hospitalized patients. DESIGN: Qualitative and quantitative group consensus using a brainstorming technique for quality improvementthe nominal group technique (NGT). SETTING: One medical, 1 medical-surgical, and 1 surgical hospital unit at a large academic medical center. PARTICIPANTS: Nurses, resident physicians, patient care technicians, and unit clerks. MEASUREMENTS: Responses and ranking to the NGT question: What causes uncontrolled pain in your unit? RESULTS: Twenty-seven health workers generated a total of 94 ideas. The ideas perceived contributing to a suboptimal pain control were grouped as system factors (timeliness, n = 18 ideas; communication, n = 11; pain assessment, n = 8), human factors (knowledge and experience, n = 16; provider bias, n = 8; patient factors, n = 19), and interface of system and human factors (standardization, n = 14). Knowledge, timeliness, provider bias, and patient factors were the top ranked themes. CONCLUSIONS: Knowledge and timeliness are considered main priorities to improve pain control. NGT is an efficient tool for identifying general and context-specific priority areas for quality improvement; teams of healthcare providers should consider using NGT to address their own challenges and barriers. Journal of Hospital Medicine 2012; (c) 2011 Society of Hospital Medicine
C1 [Estrada, Carlos A.] Univ Alabama Birmingham, Birmingham Vet Affair Med Ctr, Vet Affair Natl Qual Scholars Program, Birmingham, AL 35294 USA.
[Pena, Adolfo] St Joseph Hosp, Sect Hosp Med, London, KY USA.
[Estrada, Carlos A.; Soniat, Debbie; Taylor, Benjamin] Univ Alabama Birmingham, Div Gen Internal Med, Birmingham, AL USA.
[Estrada, Carlos A.; Soniat, Debbie; Taylor, Benjamin] Univ Hosp, Birmingham, AL USA.
[Burton, Michael] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA.
RP Estrada, CA (reprint author), Univ Alabama Birmingham, Birmingham Vet Affair Med Ctr, Vet Affair Natl Qual Scholars Program, FOT 732,510 20th St S, Birmingham, AL 35294 USA.
EM cestrada@uab.edu
FU Veterans Affairs National Quality Scholars Program
FX Drs. Pena, Burton, and Estrada were supported by the Veterans Affairs
National Quality Scholars Program. The opinions expressed in this
article are those of the authors alone and do not reflect the views of
the Department of Veterans Affairs.
NR 24
TC 11
Z9 11
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
J9 J HOSP MED
JI J. Hosp. Med.
PD MAY-JUN
PY 2012
VL 7
IS 5
BP 416
EP 420
DI 10.1002/jhm.1900
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 953LA
UT WOS:000304867600010
PM 22190453
ER
PT J
AU Dell'Italia, LJ
AF Dell'Italia, Louis J.
TI Anatomy and Physiology of the Right Ventricle
SO CARDIOLOGY CLINICS
LA English
DT Article
DE Right ventricle; Anatomy; Physiology
ID CANINE RIGHT VENTRICLE; PRESSURE-VOLUME RELATIONSHIP; PULMONARY ARTERIAL
SYSTEM; TIME-VARYING ELASTANCE; MYOCARDIAL BLOOD-FLOW; RIGHT ATRIAL
PRESSURE; PULSE WAVE VELOCITY; OPEN-CHEST DOGS; OXYGEN-METABOLISM;
POSTEXTRASYSTOLIC POTENTIATION
AB Under normal baseline conditions the unique anatomy, myocardial ultrastructure, and coronary physiology of the right ventricle (RV) reflect a high-volume low-pressure pump. Early work described the RV as a passive conduit with minimal pumping capability. It is now appreciated that through a mechanism of ventricular interdependence, RV systolic function and diastolic load are extremely important in the prognosis and treatment of congestive heart failure, cardiac transplantation, pulmonary hypertension, congenital heart disease, and left ventricle assist devices. Magnetic resonance imaging with three-dimensional analysis has shown the complex geometry of the RV and the interaction of both ventricles within the pericardium.
C1 Birmingham VA Med Ctr, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
RP Dell'Italia, LJ (reprint author), Birmingham VA Med Ctr, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
EM loudell@uab.edu
NR 135
TC 24
Z9 27
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8651
J9 CARDIOL CLIN
JI Cardiol. Clin.
PD MAY
PY 2012
VL 30
IS 2
BP 167
EP +
DI 10.1016/j.cc1.2012.03.009
PG 22
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 949JN
UT WOS:000304572600004
PM 22548810
ER
PT J
AU Marcum, ZA
Gellad, WF
AF Marcum, Zachary A.
Gellad, Walid F.
TI Medication Adherence to Multidrug Regimens
SO CLINICS IN GERIATRIC MEDICINE
LA English
DT Article
DE Medication; Adherence; Polypharmacy; Elderly; Geriatric
ID PRIMARY-CARE PATIENTS; OLDER-ADULTS; PREDICTIVE-VALIDITY;
ELDERLY-PATIENTS; BLOOD-PRESSURE; POLYPHARMACY; HEALTH; NONADHERENCE;
PERSISTENCE; COST
AB Polypharmacy and medication adherence present a unique challenge for the older adult, their caregiver(s), and the health care team. There appears to be an association in the literature between polypharmacy and poorer medication adherence in older adults. However, the heterogeneity of how adherence is defined in the literature limits the certainty of this conclusion. Nonetheless, improving medication adherence to maximize the therapeutic benefit of pharmacotherapy remains a cornerstone of geriatric care. We discuss strategies for limiting polypharmacy and improving adherence and suggest ideas for future research focused on identifying and translating safe and effective interventions to improve adherence into routine clinical practice.
C1 [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15206 USA.
[Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Dept Med Geriatr, Pittsburgh, PA 15213 USA.
[Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med Gen Med, Pittsburgh, PA 15213 USA.
[Gellad, Walid F.] RAND Hlth, Pittsburgh, PA 15213 USA.
RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA.
EM Walid.gellad@va.gov
FU National Institute on Aging [P30AG024827]; VA Career Development Award
[09-207]
FX Dr Marcum is supported by a National Institute on Aging grant
(P30AG024827), and Dr Gellad is supported by a VA Career Development
Award (09-207).
NR 44
TC 26
Z9 28
U1 1
U2 8
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0749-0690
J9 CLIN GERIATR MED
JI Clin. Geriatr. Med.
PD MAY
PY 2012
VL 28
IS 2
BP 287
EP +
DI 10.1016/j.cger.2012.01.008
PG 15
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 949JJ
UT WOS:000304572200010
PM 22500544
ER
PT J
AU Barnett, B
Ciocca, M
Goenka, R
Barnett, L
Wu, JM
Laufer, T
Burkhardt, J
Cancro, M
Reiner, S
AF Barnett, Burton
Ciocca, Maria
Goenka, Radhika
Barnett, Lisa
Wu, Junmin
Laufer, Terri
Burkhardt, Janis
Cancro, Michael
Reiner, Steven
TI Asymmetric division of germinal center B cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Barnett, Burton; Ciocca, Maria; Barnett, Lisa; Wu, Junmin; Laufer, Terri; Burkhardt, Janis; Reiner, Steven] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Barnett, Burton; Ciocca, Maria; Wu, Junmin; Reiner, Steven] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
[Goenka, Radhika; Cancro, Michael] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Barnett, Burton; Ciocca, Maria; Barnett, Lisa; Wu, Junmin; Laufer, Terri; Burkhardt, Janis] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Laufer, Terri] Univ Penn, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Burkhardt, Janis] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Reiner, Steven] Columbia Univ Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700669
ER
PT J
AU Ding, YN
Hsu, HC
Druey, K
Wu, Q
Li, J
Yang, PA
Zajac, A
Mountz, J
AF Ding, Yanna
Hsu, Hui-Chen
Druey, Kirk
Wu, Qi
Li, Jun
Yang, PingAr
Zajac, Allan
Mountz, John
TI IL-17-induced Rgs16 expression is essential for follicular T helper cell
localization in the germinal centers of autoimmune BXD2 mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Ding, Yanna; Hsu, Hui-Chen; Wu, Qi; Li, Jun; Yang, PingAr; Zajac, Allan; Mountz, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Druey, Kirk] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701305
ER
PT J
AU Li, H
Hsu, HC
Li, J
Yang, PA
Wu, Q
Cua, D
Oukka, M
Mountz, J
AF Li, Hao
Hsu, Hui-Chen
Li, Jun
Yang, PingAr
Wu, Qi
Cua, Daniel
Oukka, Mohamed
Mountz, John
TI IL-23 induces IRF5 and polarizes inflammatory M1 macrophages to promote
inflammation in a mouse model of arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Li, Hao; Hsu, Hui-Chen; Li, Jun; Yang, PingAr; Wu, Qi; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
[Cua, Daniel] Merck Res Labs, Merck Res Lab, Palo Alto, CA USA.
[Oukka, Mohamed] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702083
ER
PT J
AU Li, H
Hsu, HC
Li, J
Yang, P
Wu, Q
Cua, D
Oukka, M
Mountz, J
AF Li, Hao
Hsu, Hui-Chen
Li, Jun
Yang, PingAr
Wu, Qi
Cua, Daniel
Oukka, Mohamed
Mountz, John
TI IL-23 inhibits autoimmunity by facilitating clearance of apoptotic
bodies in the marginal zone
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Li, Hao; Hsu, Hui-Chen; Li, Jun; Yang, PingAr; Wu, Qi; Mountz, John] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
[Cua, Daniel] Merck Res Lab, Palo Alto, CA USA.
[Oukka, Mohamed] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659702062
ER
PT J
AU Li, J
Hsu, HC
Yang, PA
Wu, Q
Li, H
Spalding, D
Chatham, W
Kimberly, R
Bridges, S
Mountz, J
AF Li, Jun
Hsu, Hui-Chen
Yang, PingAr
Wu, Qi
Li, Hao
Spalding, David
Chatham, W.
Kimberly, Robert
Bridges, S.
Mountz, John
TI Death Receptor 5 (DR5) marks the highly pathogenic interacting GM-CSF+ T
helper cells and IL-23(+) macrophages rendering it as an attractive
therapeutic target of autoimmunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Li, Jun; Hsu, Hui-Chen; Yang, PingAr; Wu, Qi; Li, Hao; Spalding, David; Chatham, W.; Kimberly, Robert; Bridges, S.; Mountz, John] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Hsu, Hui-Chen; Yang, PingAr; Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700272
ER
PT J
AU Mountz, J
Wang, J
New, J
Yang, P
Wu, Q
Druey, K
Hsu, HC
AF Mountz, John
Wang, John
New, James
Yang, PingAr
Wu, Qi
Druey, Kirk
Hsu, Hui-Chen
TI IL-17-induced Regulator of G-protein Signaling orchestrates germinal
center kinetics in the onset of autoimmunity in BXD2 mice
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Mountz, John; Wang, John; New, James; Yang, PingAr; Wu, Qi; Hsu, Hui-Chen] Univ Alabama Birmingham, Birmingham, AL USA.
[Mountz, John] Birmingham VA Med Ctr, Birmingham, AL USA.
[Druey, Kirk] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659701457
ER
PT J
AU Paintlia, M
Paintlia, A
Singh, A
Singh, I
AF Paintlia, Manjeet
Paintlia, Ajaib
Singh, Avtar
Singh, Inderjit
TI Endogenous S-Nitrosothiol Induced hypertrophic Astrogliosis has
potential to maintain CNS homeostasis under pathological Conditions
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Paintlia, Manjeet; Paintlia, Ajaib; Singh, Avtar; Singh, Inderjit] MUSC, Charleston, SC USA.
[Singh, Avtar] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700556
ER
PT J
AU Zhang, X
Suzuki, E
Karam, E
Williams, S
Gikeson, G
AF Zhang, Xian
Suzuki, Eiji
Karam, Eva
Williams, Sarah
Gikeson, Gary
TI Fli-1 transcription factor directly regulates expression of inflammatory
chemokine MCP-1
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Zhang, Xian; Suzuki, Eiji; Karam, Eva; Williams, Sarah; Gikeson, Gary] Med Univ S Carolina, Charleston, SC 29425 USA.
[Zhang, Xian; Gikeson, Gary] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700113
ER
PT J
AU Li, X
Priest, RA
Woodward, WJ
Siddiqui, F
Beer, TM
Garzotto, MG
Rooney, WD
Springer, CS
AF Li, Xin
Priest, Ryan A.
Woodward, William J.
Siddiqui, Faisal
Beer, Tomasz M.
Garzotto, Mark G.
Rooney, William D.
Springer, Charles S., Jr.
TI Cell membrane water exchange effects in prostate DCE-MRI
SO JOURNAL OF MAGNETIC RESONANCE
LA English
DT Article
DE Dynamic-Contrast-Enhanced; Water exchange; Contrast reagent; Prostate
cancer
ID CONTRAST-ENHANCED-MRI; CR BOLUS-TRACKING; SHUTTER-SPEED; IN-VIVO;
CANCER; BENIGN; DIFFERENTIATION; TISSUES; MUSCLE; NMR
AB Prostate Dynamic-Contrast-Enhanced (DCE) MRI often exhibits fast and extensive global contrast reagent (CR) extravasation - measured by K-trans, a pharmacokinetic parameter proportional to its rate. This implies that the CR concentration [CR] is high in the extracellular, extravascular space (EES) during a large portion of the DCE-MRI study. Since CR is detected indirectly, through water proton signal change, the effects of equilibrium transcytolemmal water exchange may be significant in the data and thus should be admitted in DCE-MRI pharmacokinetic modeling. The implications for parameter values were investigated through simulations, and analyses of actual prostate data, with different models. Model parameter correlation and precision were also explored. A near-optimal version of the exchange-sensitized model was found. Our results indicate that Delta K-trans (the K-trans difference returned by this version and a model assuming exchange to be effectively infinitely fast) may be a very useful biomarker for discriminating malignant from benign prostate tissue. Using an exchange-sensitized model, we find that the mean intracellular water lifetime (tau(i)) - an exchange measure - can be meaningfully mapped for the prostate. Our results show prostate glandular zone differences in tau(i) values. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Li, Xin; Woodward, William J.; Rooney, William D.; Springer, Charles S., Jr.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, WM Keck Fdn High Field MRI Lab, Portland, OR 97239 USA.
[Priest, Ryan A.; Siddiqui, Faisal] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA.
[Priest, Ryan A.; Siddiqui, Faisal] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA.
[Beer, Tomasz M.] Oregon Hlth & Sci Univ, Dept Hematol Oncol, Portland, OR 97239 USA.
[Garzotto, Mark G.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR 97239 USA.
[Beer, Tomasz M.; Springer, Charles S., Jr.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
[Garzotto, Mark G.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Li, X (reprint author), Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, WM Keck Fdn High Field MRI Lab, Mail Code L452, Portland, OR 97239 USA.
EM lxin@ohsu.edu
OI Springer, Charles/0000-0002-5966-2135
FU Medical Research Foundation of Oregon; NIH [R01-EB00422, R01-NS40801,
UL1RR024140-04S1]
FX Grant Support: Medical Research Foundation of Oregon (XL), NIH:
R01-EB00422 (CSS), R01-NS40801 (CSS,WDR), computational support provided
by an administrative supplement NIH UL1RR024140-04S1, and RSNA Research
and Education Foundation: Research Medical Student Grant #RMS0801 (FS).
We thank Dr. Charles Thomas for continued support and encouragement.
NR 32
TC 10
Z9 10
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1090-7807
J9 J MAGN RESON
JI J. Magn. Reson.
PD MAY
PY 2012
VL 218
BP 77
EP 85
DI 10.1016/j.jmr.2012.03.019
PG 9
WC Biochemical Research Methods; Physics, Atomic, Molecular & Chemical;
Spectroscopy
SC Biochemistry & Molecular Biology; Physics; Spectroscopy
GA 948GK
UT WOS:000304491400012
PM 22578558
ER
PT J
AU Gennatas, ED
Cholfin, JA
Zhou, J
Crawford, RK
Sasaki, DA
Karydas, A
Boxer, AL
Bonasera, SJ
Rankin, KP
Gorno-Tempini, ML
Rosen, HJ
Kramer, JH
Weiner, M
Miller, BL
Seeley, WW
AF Gennatas, E. D.
Cholfin, J. A.
Zhou, J.
Crawford, R. K.
Sasaki, D. A.
Karydas, A.
Boxer, A. L.
Bonasera, S. J.
Rankin, K. P.
Gorno-Tempini, M. L.
Rosen, H. J.
Kramer, J. H.
Weiner, M.
Miller, B. L.
Seeley, W. W.
TI COMT Val(158)Met genotype influences neurodegeneration within
dopamine-innervated brain structures
SO NEUROLOGY
LA English
DT Article
ID FRONTOTEMPORAL LOBAR DEGENERATION; ALZHEIMERS-DISEASE; MESSENGER-RNA;
DEMENTIA; SCHIZOPHRENIA; ATROPHY; POLYMORPHISM; PATTERNS; RISK
AB Objective: We sought to determine whether the Val(158)Met polymorphism in the catechol-O-methyltransferase (COMT) gene influences neurodegeneration within dopamine-innervated brain regions.
Methods: A total of 252 subjects, including healthy controls and patients with Alzheimer disease, behavioral variant frontotemporal dementia, and semantic dementia, underwent COMT genotyping and structural MRI.
Results: Whole-brain voxel-wise regression analyses revealed that COMT Val(158)Met Val allele dosage, known to produce a dose-dependent decrease in synaptic dopamine (DA) availability, correlated with decreased gray matter in the region of the ventral tegmental area (VTA), ventromedial prefrontal cortex, bilateral dorsal midinsula, left dorsolateral prefrontal cortex, and right ventral striatum. Unexpectedly, patients carrying a Met allele showed greater VTA volumes than age-matched controls. Gray matter intensities within COMT-related brain regions correlated with cognitive and behavioral deficits.
Conclusions: The results are consistent with the hypothesis that increased synaptic DA catabolism promotes neurodegeneration within DA-innervated brain regions. Neurology (R) 2012;78:1663-1669
C1 [Gennatas, E. D.; Cholfin, J. A.; Zhou, J.; Crawford, R. K.; Sasaki, D. A.; Karydas, A.; Boxer, A. L.; Rankin, K. P.; Gorno-Tempini, M. L.; Rosen, H. J.; Kramer, J. H.; Miller, B. L.; Seeley, W. W.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94122 USA.
[Bonasera, S. J.] Univ Nebraska Med Ctr, Dept Internal Med, Div Geriatr, Omaha, NE USA.
[Weiner, M.] San Francisco Vet Adm Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
RP Seeley, WW (reprint author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94122 USA.
EM wseeley@memory.ucsf.edu
RI Gorno-Tempini, Maria Luisa/E-7203-2012
OI Bonasera, Stephen/0000-0001-6808-2821
FU National Institute of Aging [AG19724, AG1657303]; Larry L. Hillblom
Foundation [2005/2T]; National Institute of Mental Health (NIMH) [K08
MH065938]; Stephen D. Bechtel Foundation
FX Supported by grants from the National Institute of Aging (AG19724 and
AG1657303 to B. L. M.), the Larry L. Hillblom Foundation (grant 2005/2T
to W. W. S.), National Institute of Mental Health (NIMH grant K08
MH065938 to S.J.B.), and the Stephen D. Bechtel Foundation to S.J.B.
NR 25
TC 13
Z9 14
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAY
PY 2012
VL 78
IS 21
BP 1663
EP 1669
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 948UB
UT WOS:000304527000011
PM 22573634
ER
PT J
AU Okonkwo, OC
Xu, G
Dowling, NM
Bendlin, BB
LaRue, A
Hermann, BP
Koscik, R
Jonaitis, E
Rowley, HA
Carlsson, CM
Asthana, S
Sager, MA
Johnson, SC
AF Okonkwo, O. C.
Xu, G.
Dowling, N. M.
Bendlin, B. B.
LaRue, A.
Hermann, B. P.
Koscik, R.
Jonaitis, E.
Rowley, H. A.
Carlsson, C. M.
Asthana, S.
Sager, M. A.
Johnson, S. C.
TI Family history of Alzheimer disease predicts hippocampal atrophy in
healthy middle-aged adults
SO NEUROLOGY
LA English
DT Article
ID NORMAL INDIVIDUALS; MATERNAL HISTORY; TEMPORAL-LOBE; APOLIPOPROTEIN-E;
GRAY-MATTER; BASE-LINE; VOLUME; CHILDREN; STATISTICS; TRIALS
AB Objective: To evaluate the longitudinal influence of family history (FH) of Alzheimer disease (AD) and apolipoprotein E epsilon 4 allele (APOE4) on brain atrophy and cognitive decline over 4 years among asymptomatic middle-aged individuals.
Methods: Participants were cognitively healthy adults with (FH+) (n = 60) and without (FH-) (n = 48) a FH of AD (mean age at baseline 54 years) enrolled in the Wisconsin Registry for Alzheimer's Prevention. They underwent APOE genotyping, cognitive testing, and an MRI scan at baseline and 4 years later. A covariate-adjusted voxel-based analysis interrogated gray matter (GM) modulated probability maps at the 4-year follow-up visit as a function of FH and APOE4. We also examined the influence of parent of origin on GM atrophy. Parallel analyses investigated the effects of FH and APOE4 on cognitive decline.
Results: Neither FH nor APOE4 had an effect on regional GM or cognition at baseline. Longitudinally, a FH x APOE4 interaction was found in the right posterior hippocampus, which was driven by a significant difference between the FH+ and FH- subjects who were APOE4-. In addition, a significant FH main effect was observed in the left posterior hippocampus. No significant APOE4 main effects were detected. Persons with a maternal history of AD were just as likely as those with a paternal history of AD to experience posterior hippocampal atrophy. There was no longitudinal decline in cognition within the cohort.
Conclusion: Over a 4-year interval, asymptomatic middle-aged adults with FH of AD exhibit significant atrophy in the posterior hippocampi in the absence of measurable cognitive changes. This result provides further evidence that detectable disease-related neuroanatomic changes do occur early in the AD pathologic cascade. Neurology (R) 2012;78:1769-1776
C1 [Okonkwo, O. C.; Xu, G.; Bendlin, B. B.; Carlsson, C. M.; Asthana, S.; Johnson, S. C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
[Okonkwo, O. C.; Xu, G.; Dowling, N. M.; Bendlin, B. B.; LaRue, A.; Hermann, B. P.; Koscik, R.; Jonaitis, E.; Rowley, H. A.; Carlsson, C. M.; Asthana, S.; Sager, M. A.; Johnson, S. C.] Univ Wisconsin, Sch Med, Alzheimers Dis Res Ctr, Madison, WI 53706 USA.
[Okonkwo, O. C.; Xu, G.; Dowling, N. M.; Bendlin, B. B.; LaRue, A.; Hermann, B. P.; Koscik, R.; Jonaitis, E.; Rowley, H. A.; Carlsson, C. M.; Asthana, S.; Sager, M. A.; Johnson, S. C.] Univ Wisconsin, Sch Med, Wisconsin Alzheimers Inst, Madison, WI 53706 USA.
[Dowling, N. M.] Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI 53706 USA.
RP Johnson, SC (reprint author), William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
EM scj@medicine.wisc.edu
OI Bendlin, Barbara/0000-0002-0580-9875
FU NIA [AG021155, AG027161, P50-AG033514]; Veterans Administration
[I01CX000165]; Clinical and Translational Science Award [UL1-RR025011];
Helen Bader Foundation; Northwestern Mutual Foundation; Extendicare
Foundation; Clinical Center of the William S. Middleton Memorial
Veterans Hospital, Madison, WI.
FX Supported by NIA grants AG021155 (S.C.J.), AG027161 (M.A.S.), and
P50-AG033514 (S.A.); by Veterans Administration Merit Review grant
I01CX000165 (S.C.J.); and by a Clinical and Translational Science Award
(UL1-RR025011) to the University of Wisconsin, Madison. Portions of this
research were supported by the Helen Bader Foundation, Northwestern
Mutual Foundation, Extendicare Foundation, and the Veterans
Administration including facilities and resources at the Geriatric
Research Education and Clinical Center of the William S. Middleton
Memorial Veterans Hospital, Madison, WI.
NR 39
TC 16
Z9 16
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD MAY
PY 2012
VL 78
IS 22
BP 1769
EP 1776
DI 10.1212/WNL.0b013e3182583047
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 948UZ
UT WOS:000304529600017
PM 22592366
ER
PT J
AU Khaled, S
Gupta, KB
Kucik, DF
AF Khaled, Saman
Gupta, Kiran B.
Kucik, Dennis F.
TI Ionizing Radiation Increases Adhesiveness of Human Aortic Endothelial
Cells via a Chemokine-Dependent Mechanism
SO RADIATION RESEARCH
LA English
DT Article
ID ATOMIC-BOMB SURVIVORS; ADHESION MOLECULES; LEUKOCYTE ADHESION; AVIDITY
REGULATION; P-SELECTIN; ATHEROSCLEROSIS; INFLAMMATION; MICE; DISEASE;
EXPRESSION
AB Exposure to radiation from a variety of sources is associated with increased risk of heart disease and stroke. Since radiation also induces inflammation, a possible mechanism is a change in the adhesiveness of vascular endothelial cells, triggering pro-atherogenic accumulation of leukocytes. To investigate this mechanism at the cellular level, the effect of X rays on adhesiveness of cultured human aortic endothelial cells (HAECs) was determined. HAECs were grown as monolayers and exposed to 0 to 30 Gy X rays, followed by measurement of adhesiveness under physiological shear stress using a flow chamber adhesion assay. Twenty-four hours after irradiation, HAEC adhesiveness was increased, with a peak effect at 15 Gy. Radiation had no significant effect on surface expression of the endothelial adhesion molecules ICAM-1 and VCAM-1. Antibody blockade of the leukocyte integrin receptors for ICAM-1 and VCAM-1, however, abolished the radiation-induced adhesiveness. Since these leukocyte integrins can be activated by chemokines presented on the endothelial cell surface, the effect of pertussis toxin (PTX), an inhibitor of chemokine-mediated integrin activation, was tested. PTX specifically inhibited radiation-induced adhesiveness, with no significant effect on nonirradiated cells. Therefore, radiation induces increased adhesiveness of aortic endothelial cells through chemokine-dependent signaling from endothelial cells to leukocytes, even in the absence of increased expression of the adhesion molecules involved. (C) 2012 by Radiation Research Society
C1 [Khaled, Saman; Gupta, Kiran B.; Kucik, Dennis F.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
[Kucik, Dennis F.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA.
[Kucik, Dennis F.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Kucik, DF (reprint author), Univ Alabama Birmingham, Dept Pathol, 640A Kaul Bldg,720 S 20th St, Birmingham, AL 35294 USA.
EM Kucik@uab.edu
FU National Space Biomedical Research Institute through NASA [NCC 9-58]
FX This work was supported by the National Space Biomedical Research
Institute through NASA NCC 9-58.
NR 37
TC 16
Z9 18
U1 0
U2 6
PU RADIATION RESEARCH SOC
PI LAWRENCE
PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA
SN 0033-7587
EI 1938-5404
J9 RADIAT RES
JI Radiat. Res.
PD MAY
PY 2012
VL 177
IS 5
BP 594
EP 601
DI 10.1667/RR2557.1
PG 8
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology,
Nuclear Medicine & Medical Imaging
GA 948JD
UT WOS:000304498600008
PM 22087741
ER
PT J
AU Braunstein, I
Klein, R
Okawa, J
Werth, VP
AF Braunstein, I.
Klein, R.
Okawa, J.
Werth, V. P.
TI The interferon-regulated gene signature is elevated in subacute
cutaneous lupus erythematosus and discoid lupus erythematosus and
correlates with the cutaneous lupus area and severity index score
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Article
ID DISEASE-ACTIVITY; EXPRESSION; RECRUITMENT; ASSOCIATION; LESIONS; CELLS
AB Background There is increased expression of type I interferon (IFN)-regulated proteins in the blood and target tissues of patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Patients with SLE have increased IFN-regulated gene expression pointing towards a possible underlying genetic defect.
Objectives To determine expression levels of five type I IFN-regulated genes that are highly expressed in SLE in the peripheral blood of patients with CLE and to correlate the expression levels with cutaneous disease activity.
Methods Peripheral blood was obtained from 10 healthy controls and 30 patients with CLE, including eight with concomitant SLE. Total RNA was extracted and reverse transcribed into complementary DNA. Gene expression levels were measured by real-time polymerase chain reaction. Gene expression was normalized to GAPDH, standardized to healthy controls and then summed to calculate an IFN score for each patient. Disease activity was assessed with the Cutaneous Lupus Area and Severity Index (CLASI).
Results Patients with subacute CLE (SCLE) and discoid lupus erythematosus (DLE) had elevated IFN scores compared with healthy controls regardless of concomitant SLE (P < 0 01 with SLE and P < 0 05 without SLE). There was no difference between patients with tumid lupus erythematosus (TLE) and healthy controls. The IFN score correlated with CLASI scores (Spearman's rho = 0 55, P = 0 0017).
Conclusions Patients with SCLE and DLE have an IFN signature, as seen in SLE. The level of gene expression correlates with cutaneous disease activity. These findings support a shared pathogenesis between SLE and some subtypes of CLE.
C1 [Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Dermatol Sect, Philadelphia, PA 19104 USA.
Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
RP Werth, VP (reprint author), Philadelphia Vet Affairs Med Ctr, Dermatol Sect, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM werth@mail.med.upenn.edu
FU Department of Veterans Affairs Veterans Health Administration, Office of
Research and Development, Biomedical Laboratory Research and
Development; National Institutes of Health (NIH) [K24-AR 02207]
FX The study was supported by a Merit Review Grant from the Department of
Veterans Affairs Veterans Health Administration, Office of Research and
Development, Biomedical Laboratory Research and Development and by the
National Institutes of Health (NIH K24-AR 02207) to V.P.W.
NR 13
TC 23
Z9 23
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-0963
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD MAY
PY 2012
VL 166
IS 5
BP 971
EP 975
DI 10.1111/j.1365-2133.2012.10825.x
PG 5
WC Dermatology
SC Dermatology
GA 950PQ
UT WOS:000304661600012
PM 22242767
ER
PT J
AU Osborn, CY
Egede, LE
AF Osborn, Chandra Y.
Egede, Leonard E.
TI The relationship between depressive symptoms and medication nonadherence
in type 2 diabetes: the role of social support
SO GENERAL HOSPITAL PSYCHIATRY
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; CORONARY-HEART-DISEASE; GLYCEMIC CONTROL;
RANDOMIZED-TRIAL; CARE MANAGEMENT; DOUBLE-BLIND; ADHERENCE;
METAANALYSIS; MEDIATION; ASSOCIATION
AB Objective: Medication adherence promotion interventions are needed that target modifiable behavioral factors contributing to the link between depressive symptoms and poor adherence to diabetes self-care behaviors. In an effort to identify what factors contribute to this link, we examined the role of social support as a mediator of the relationship between depressive symptoms and medication nonadherence.
Method: We recruited 139 subjects with type 2 diabetes. Using an indirect effect test with bias-corrected (BC) bootstrapping, we tested whether depressive symptoms had an indirect effect on medication nonadherence through a lack of social support.
Results: More depressive symptoms were associated with medication nonadherence (total effect=.06, P<.001), more depressive symptoms were associated with less social support (direct effect of the predictor on the mediator=.96, P=.02), and less social support was associated with medication nonadherence (direct effect of the mediator on the outcome=-.01, P<.01). While the relationship between more depressive symptoms and medication nonadherence persisted with social support in the predicted pathway, the degree of this relationship was partially explained by a relationship between more depressive symptoms and less social support (indirect effect=.01, 95% BC bootstrapped confidence interval of .0005 to .0325).
Conclusion: Providing social support to patients with diabetes who have symptoms of depression may ameliorate some of the deleterious effects of depressive symptoms on medication nonadherence, but social support alone is not enough. (C) 2012 Elsevier Inc. All rights reserved.
C1 Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
[Osborn, Chandra Y.] Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA.
[Osborn, Chandra Y.] Vanderbilt Univ, Dept Biomed Informat, Sch Med, Nashville, TN 37232 USA.
[Osborn, Chandra Y.] Vanderbilt Univ, Vanderbilt Diabet Res & Training Ctr, Sch Med, Nashville, TN 37232 USA.
[Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC 29401 USA.
[Egede, Leonard E.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA.
EM egedel@musc.edu
FU National Institutes of Health (NIH) [NIDDK K01 DK087894]; NTH [NIDDK K24
DK093699]
FX Dr. Osborn is supported by a National Institutes of Health (NIH) Career
Development Award (NIDDK K01 DK087894). Dr. Egede is supported by an NTH
Career Development Award (NIDDK K24 DK093699).
NR 41
TC 22
Z9 24
U1 3
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-8343
J9 GEN HOSP PSYCHIAT
JI Gen. Hosp. Psych.
PD MAY-JUN
PY 2012
VL 34
IS 3
BP 249
EP 253
DI 10.1016/j.genhosppsych.2012.01.015
PG 5
WC Psychiatry
SC Psychiatry
GA 944XR
UT WOS:000304237600006
PM 22401705
ER
PT J
AU Sher, L
AF Sher, Leo
TI Bipolar Psychopharmacotherapy: Caring for the Patient
SO JOURNAL OF NERVOUS AND MENTAL DISEASE
LA English
DT Book Review
C1 [Sher, Leo] Mt Sinai Sch Med, New York, NY USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
RP Sher, L (reprint author), Mt Sinai Sch Med, New York, NY USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3018
J9 J NERV MENT DIS
JI J. Nerv. Ment. Dis.
PD MAY
PY 2012
VL 200
IS 5
BP 454
EP 454
PG 1
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 946ET
UT WOS:000304335000014
ER
PT J
AU Lipsky, BA
Kuss, M
Edmonds, M
Reyzelman, A
Sigal, F
AF Lipsky, Benjamin A.
Kuss, Michael
Edmonds, Michael
Reyzelman, Alexander
Sigal, Felix
TI Topical Application of a Gentamicin-Collagen Sponge Combined with
Systemic Antibiotic Therapy for the Treatment of Diabetic Foot
Infections of Moderate Severity A Randomized, Controlled, Multicenter
Clinical Trial
SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION
LA English
DT Article
ID IN-VITRO ACTIVITY; RESISTANT STAPHYLOCOCCUS-AUREUS; CALCIUM-SULFATE
PELLETS; ANTIMICROBIAL AGENTS; FLUOROQUINOLONES; MANAGEMENT; SYNERGY
AB Background: The aim of this pilot study was to determine the safety and potential benefit of adding a topical gentamicin-collagen sponge to standard of care (systemic antibiotic therapy plus standard diabetic wound management) for treating diabetic foot infections of moderate severity.
Methods: We randomized 56 patients with moderately infected diabetic foot ulcers in a 2:1 ratio to receive standard of care plus the gentamicin-collagen sponge (treatment group, n=38) or standard of care only (control group, n = 18) for up to 28 days of treatment. Investigators performed clinical, microbiological, and safety assessments at regularly scheduled intervals and collected pharmacokinetic samples from patients treated with the gentamicin-collagen sponge. Test of cure was clinically assessed 14 days after all antibiotic therapy was stopped.
Results: On treatment day 7, we noted clinical cure in no treatment patients and three control patients (P=.017). However, for evaluable patients at the test-of-cure visit, the treatment group had a significantly higher proportion of patients with clinical cure than did the control group (22 of 22 [100.0%] versus 7 of 10 [70.0%]; P=.024). Patients in the treatment group also had a higher rate of eradication of baseline pathogens at all visits (P <=.038) and a reduced time to pathogen eradication (P<.001). Safety data were similar for both groups.
Conclusions: Topical application of the gentamicin-collagen sponge seems safe and may improve clinical and microbiological outcomes of diabetic foot infections of moderate severity when combined with standard of care. These pilot data suggest that a larger trial of this treatment is warranted. (J Am Podiatr Med Assoc 102(3): 223-232, 2012)
C1 [Lipsky, Benjamin A.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Sch Med, Seattle, WA 98116 USA.
[Kuss, Michael] Premier Res Grp Ltd, Austin, TX USA.
[Edmonds, Michael] Kings Coll Hosp London, London, England.
[Reyzelman, Alexander] Clin Res Ctr, Castro Valley, CA USA.
[Sigal, Felix] Pacific Clin Ctr, Los Angeles, CA USA.
RP Lipsky, BA (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Sch Med, S-111-PCC,1660 S Columbian Way, Seattle, WA 98116 USA.
EM balipsky@uw.edu
OI Lipsky, Benjamin A./0000-0001-9886-5114
FU Innocoll Technologies Ltd.
FX This study was funded in whole by Innocoll Technologies Ltd.
NR 21
TC 16
Z9 19
U1 0
U2 7
PU AMER PODIATRIC MED ASSOC
PI BETHESDA
PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621 USA
SN 8750-7315
J9 J AM PODIAT MED ASSN
JI J. Am. Podiatr. Med. Assoc.
PD MAY-JUN
PY 2012
VL 102
IS 3
BP 223
EP 232
PG 10
WC Orthopedics
SC Orthopedics
GA 945OW
UT WOS:000304286900007
PM 22659765
ER
PT J
AU Derose, SF
Gabayan, GZ
Chiu, VY
Sun, BC
AF Derose, Stephen F.
Gabayan, Gelareh Z.
Chiu, Vicki Y.
Sun, Benjamin C.
TI Patterns and Preexisting Risk Factors of 30-Day Mortality After a
Primary Discharge Diagnosis of Syncope or Near Syncope
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID EMERGENCY ROOM PATIENTS; SHORT-TERM; PROSPECTIVE VALIDATION; EXTERNAL
VALIDATION; SERIOUS OUTCOMES; PREDICT PATIENTS; FOLLOW-UP; RULE;
STRATIFICATION; POPULATION
AB Objectives: The risk of short-term mortality after an emergency department (ED) visit for syncope is poorly understood, resulting in prognostic uncertainty and frequent hospital admission. The authors determined patterns and risk factors for short-term mortality after a diagnosis of syncope or near syncope to aid in medical decision-making.
Methods: A retrospective cohort study was performed of adult members of Kaiser Permanente Southern California seen at 11 EDs from 2002 to 2006 with a primary discharge diagnosis of syncope or near syncope (International Classification of Diseases, Ninth Revision [ICD-9] 780.2). The outcome was 30-day mortality. Proportional hazards time-to-event regression models were used to identify risk factors.
Results: There were 22,189 participants with 23,951 ED visits, resulting in 307 deaths by 30 days. A relatively lower risk of death was reached within 2 weeks for ages 18 to 59 years, but not until 3 months or more for ages 60 and older. Preexisting comorbidities associated with increased mortality included heart failure (hazard ratio [HR] = 14.3 in ages 18 to 59 years, HR = 3.09 in ages 60 to 79 years, HR = 2.34 in ages 80 years plus; all p < 0.001), diabetes (HR = 1.49, p = 0.002), seizure (HR = 1.65, p = 0.016), and dementia (HR = 1.41, p = 0.034). If the index visit followed one or more visits for syncope in the previous 30 days, it was associated with increased mortality (HR = 1.86, p = 0.024). Absolute risk of death at 30 days was under 0.2% in those under 60 years without heart failure and more than 2.5% across all ages in those with heart failure.
Conclusions: The low risk of death after an ED visit for syncope or near syncope in patients younger than 60 years old without heart failure may be helpful when deciding who to admit for inpatient evaluation. The presence of one or more comorbidities that predict death and a prior visit for syncope should be considered in clinical decisions and risk stratification tools for patients with syncope. Close clinical follow-up seems advisable in patients 60 years and older due to a prolonged risk of death. ACADEMIC EMERGENCY MEDICINE 2012; 19: 488-496 (C) 2012 by the Society for Academic Emergency Medicine
C1 [Derose, Stephen F.; Chiu, Vicki Y.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA.
[Gabayan, Gelareh Z.; Sun, Benjamin C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Gabayan, Gelareh Z.; Sun, Benjamin C.] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Med, Los Angeles, CA USA.
RP Derose, SF (reprint author), Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA.
EM stephen.f.derose@kp.org
FU American Geriatrics Society [20051687]; University of California, Los
Angeles, National Institutes of Aging [AG 02-004]; UCLA Older Americans
Independence Center, NIH/NIA [P30-AG028748]; Greater Los Angeles
Veteran's Affairs Health Services Research and Development Fellowship
FX This research was supported by grants from American Geriatrics Society
Dennis Jahnigen Career Development Award (20051687, BCS) and University
of California, Los Angeles, National Institutes of Aging K12 Mentored
Clinical Scientist Development Program in Geriatrics (AG 02-004, BCS).
Dr. Sun received support from the UCLA Older Americans Independence
Center, NIH/NIA Grant P30-AG028748, and the content does not necessarily
represent the official views of the National Institute on Aging or the
National Institutes of Health.; We thank the Greater Los Angeles
Veteran's Affairs Health Services Research and Development Fellowship
for their support of Dr. Gabayan. We thank Robert Weiss, UCLA School of
Public Health Professor of Biostatistics, for his helpful manuscript
review.
NR 47
TC 5
Z9 5
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1069-6563
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD MAY
PY 2012
VL 19
IS 5
BP 488
EP 496
DI 10.1111/j.1553-2712.2012.01336.x
PG 9
WC Emergency Medicine
SC Emergency Medicine
GA 943OI
UT WOS:000304133300002
PM 22594351
ER
PT J
AU Craft, S
AF Craft, Suzanne
TI Insulin and Alzheimer Disease reply
SO ARCHIVES OF NEUROLOGY
LA English
DT Letter
C1 [Craft, Suzanne] Univ Washington, Sch Med, Vet Affairs Puget Sound Healthcare Syst, Seattle, WA 98108 USA.
RP Craft, S (reprint author), Univ Washington, Sch Med S GRECC 182, Vet Affairs Puget Sound Healthcare Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM scraft@uw.edu
NR 4
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAY
PY 2012
VL 69
IS 5
BP 671
EP 671
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 941ZO
UT WOS:000304009100022
ER
PT J
AU Sher, L
AF Sher, Leo
TI Educating health care professionals about suicide prevention
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA.
RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Leo.Sher@mssm.edu
NR 5
TC 0
Z9 0
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD MAY
PY 2012
VL 46
IS 5
BP 481
EP 482
DI 10.1177/0004867411434722
PG 2
WC Psychiatry
SC Psychiatry
GA 944EI
UT WOS:000304181700015
PM 22535300
ER
PT J
AU Yoo, SE
Chen, LJ
Na, R
Liu, YH
Rios, C
Van Remmen, H
Richardson, A
Ran, QT
AF Yoo, Si-Eun
Chen, Liuji
Na, Ren
Liu, Yuhong
Rios, Carmen
Van Remmen, Holly
Richardson, Arlan
Ran, Qitao
TI Gpx4 ablation in adult mice results in a lethal phenotype accompanied by
neuronal loss in brain
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Gpx4; Knockout mice; Lipid peroxidation; Mitochondria;
Neurodegeneration; Apoptosis; Oxidative stress
ID HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS;
ALZHEIMERS-DISEASE; CYTOCHROME-C; SUPEROXIDE-PRODUCTION;
LIPID-PEROXIDATION; INDUCED APOPTOSIS; CELL-DEATH; MOUSE;
GLUTATHIONE-PEROXIDASE-4
AB Glutathione peroxidase 4 (Gpx4) is an antioxidant defense enzyme important in reducing hydroperoxides in membrane lipids and lipoproteins. Gpx4 is essential for survival of embryos and neonatal mice; however, whether Gpx4 is required for adult animals remains unclear. In this study, we generated a floxed Gpx4 mouse (Gpx4(f/f)) in which exons 2-4 of Gpx4 gene are flanked by loxP sites. We then cross-bred the Gpx4(f/f) mice with a tamoxifen (tam)-inducible Cre transgenic mouse (R26CreER mice) to obtain mice in which the Gpx4 gene could be ablated by tam administration (Gpx4(f/f)/Cre mice). After treatment with tam, adult Gpx4(f/f)/Cre mice (6-9 months of age) showed a significant reduction of Gpx4 levels (a 75-85% decrease) in tissues such as brain, liver, lung, and kidney. Tam-treated Gpx4(f/f)/Cre mice lost body weight and died within 2 weeks, indicating that Gpx4 is essential for survival of adult animals. Tam-treated Gpx4(f/f)/Cre mice exhibited increased mitochondrial damage, as evidenced by the elevated 4-hydroxylnonenal (4-HNE) level, decreased activities of electron transport chain complexes I and IV, and reduced ATP production in liver. Tam treatment also significantly elevated apoptosis in Gpx4(f/f)/Cre mice. Moreover, tam-treated Gpx4(f/f)/Cre mice showed neuronal loss in the hippocampus region and had increased astrogliosis. These data indicate that Gpx4 is essential for mitochondria integrity and survival of neurons in adult animals. Published by Elsevier Inc.
C1 [Yoo, Si-Eun; Chen, Liuji; Na, Ren; Liu, Yuhong; Rios, Carmen; Van Remmen, Holly; Richardson, Arlan; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Yoo, Si-Eun] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Chen, Liuji; Rios, Carmen; Van Remmen, Holly; Richardson, Arlan; Ran, Qitao] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Van Remmen, Holly; Richardson, Arlan; Ran, Qitao] S Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA.
RP Ran, QT (reprint author), 15355 Lambda Dr, San Antonio, TX 78245 USA.
EM ran@uthscsa.edu
FU NIH [P01 AG19316, P01AG020591]; San Antonio Nathan Shock Aging Center
[1P30-AG13319]; Department of Veteran Affairs
FX This work was supported by NIH Grants P01 AG19316 and P01AG020591, the
San Antonio Nathan Shock Aging Center (1P30-AG13319), and a Merit Review
grant (Q.R.) from the Department of Veteran Affairs.
NR 34
TC 18
Z9 18
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAY 1
PY 2012
VL 52
IS 9
BP 1820
EP 1827
DI 10.1016/j.freeradbiomed.2012.02.043
PG 8
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 944DB
UT WOS:000304177500034
PM 22401858
ER
PT J
AU Condray, R
Siegle, GJ
Keshavan, MS
Steinhauer, SR
AF Condray, Ruth
Siegle, Greg J.
Keshavan, Matcheri S.
Steinhauer, Stuart R.
TI Effects of word frequency on semantic memory in schizophrenia:
Electrophysiological evidence for a deficit in linguistic access (vol
75, pg 141, 2010)
SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY
LA English
DT Correction
C1 [Condray, Ruth] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA.
VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15206 USA.
RP Condray, R (reprint author), Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, 3811 OHara St, Pittsburgh, PA 15213 USA.
EM condrayr@upmc.com
NR 1
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-8760
J9 INT J PSYCHOPHYSIOL
JI Int. J. Psychophysiol.
PD MAY
PY 2012
VL 84
IS 2
BP 226
EP 231
DI 10.1016/j.ijpsycho.2011.05.011
PG 6
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
Psychology, Experimental
SC Psychology; Neurosciences & Neurology; Physiology
GA 941JW
UT WOS:000303960500016
ER
PT J
AU Perez, VB
Ford, JM
Roach, BJ
Woods, SW
McGlashan, TH
Srihari, VH
Loewy, RL
Vinogradov, S
Mathalon, DH
AF Perez, Veronica B.
Ford, Judith M.
Roach, Brian J.
Woods, Scott W.
McGlashan, Thomas H.
Srihari, Vinod H.
Loewy, Rachel L.
Vinogradov, Sophia
Mathalon, Daniel H.
TI Error Monitoring Dysfunction Across the Illness Course of Schizophrenia
SO JOURNAL OF ABNORMAL PSYCHOLOGY
LA English
DT Article
DE schizophrenia; prodrome; at-risk; error-related negativity; performance
monitoring
ID ANTERIOR CINGULATE CORTEX; CROSSMODAL DIVIDED ATTENTION; MEDIAL
FRONTAL-CORTEX; CHOICE REACTION TASKS; LATE ERP COMPONENTS;
EVENT-RELATED FMRI; BRAIN ACTIVITY; INTERRATER RELIABILITY;
PREDICTIVE-VALIDITY; PRODROMAL SYNDROMES
AB Response monitoring abnormalities have been reported in chronic schizophrenia patients, but it is unknown whether they predate the onset of psychosis, are present in early stages of illness, or are late-developing abnormalities associated with illness progression. Response-synchronized event-related potentials (ERP) recorded during a picture-word matching task yielded error-related negativity (ERN), correct-response negativity (CRN), and error positivity (Pe) from 84 schizophrenia patients (SZ), 48 clinical high risk patients (CHR), and their age-matched healthy controls (HC; n = 110 and 88, respectively). A sub-sample of 35 early illness schizophrenia patients (ESZ) was compared to 93 age-matched HC and the CHR patients (after statistically removing the effects of normal aging). Relative to HC, 1) SZ, ESZ, and CHR had smaller ERNs, and 2) SZ and ESZ had larger CRNs and smaller Pes. Within the SZ, longer illness duration was associated with larger CRNs but was unrelated to ERN or Pe. CHR and ESZ did not differ on ERN or CRN, although Pe was smaller in ESZ than CHR. These results indicate that while ERN, CRN, and Pe abnormalities are present early in the illness, only the ERN abnormality is evident prior to psychosis onset, and only the CRN abnormality appears to worsen progressively over the illness course. Brain regions subserving response monitoring may be compromised early in the illness and possibly during its clinical prodrome.
C1 [Perez, Veronica B.; Ford, Judith M.; Roach, Brian J.; Loewy, Rachel L.; Vinogradov, Sophia; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Perez, Veronica B.; Ford, Judith M.; Roach, Brian J.; Vinogradov, Sophia; Mathalon, Daniel H.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA.
[Woods, Scott W.; McGlashan, Thomas H.; Srihari, Vinod H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
RP Mathalon, DH (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
EM daniel.mathalon@ucsf.edu
OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974;
Srihari, Vinod/0000-0003-1556-2332
FU NIMH NIH HHS [K02 MH067967, R01 MH058262, R01 MH076989, RC1 MH088971,
T32 MH089920, T32 MH089920-01]
NR 98
TC 21
Z9 21
U1 3
U2 14
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0021-843X
J9 J ABNORM PSYCHOL
JI J. Abnorm. Psychol.
PD MAY
PY 2012
VL 121
IS 2
BP 372
EP 387
DI 10.1037/a0025487
PG 16
WC Psychology, Clinical; Psychology, Multidisciplinary
SC Psychology
GA 943NQ
UT WOS:000304131400008
PM 22060947
ER
PT J
AU Bergman, BC
Howard, D
Schauer, IE
Maahs, DM
Snell-Bergeon, JK
Eckel, RH
Perreault, L
Rewers, M
AF Bergman, Bryan C.
Howard, David
Schauer, Irene E.
Maahs, David M.
Snell-Bergeon, Janet K.
Eckel, Robert H.
Perreault, Leigh
Rewers, Marian
TI Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to
Type 1 Diabetes
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID CORONARY-ARTERY CALCIFICATION; GLUCOSE-METABOLISM;
CARDIOVASCULAR-DISEASE; MELLITUS; COMPLICATIONS; MECHANISMS; DISPOSAL;
DEFECT; WOMEN; LIVER
AB Context: Type 1 diabetes is known to be a state of insulin resistance; however, the tissues involved in whole-body insulin resistance are less well known. It is unclear whether insulin resistance is due to glucose toxicity in the post-Diabetes Control and Complications Trial era of tighter glucose control.
Objective: We performed this study to determine muscle and liver insulin sensitivity individuals with type 1 diabetes after overnight insulin infusion to lower fasting glucose concentration.
Design, Patients, and Methods: Fifty subjects [25 controls without and 25 individuals with type 1 diabetes (diabetes duration 22.9 +/- 1.7 yr, without known end organ damage] were frequency matched on age and body mass index by group and studied. After 3 d of dietary control and overnight insulin infusion to normalize glucose, we performed a three-stage hyperinsulinemic/euglycemic clamp infusing insulin at 4, 8, and 40 mU/m(2).min. Glucose metabolism was quantified using an infusion of [6,6-H-2(2)] glucose. Hepatic insulin sensitivity was measured using the insulin IC50 for glucose rate of appearance (Ra), whereas muscle insulin sensitivity was measured using the glucose rate of disappearance during the highest insulin dose.
Results: Throughout the study, glucose Ra was significantly greater in individuals compared with those without type 1 diabetes. The concentration of insulin required for 50% suppression of glucose Ra was 2-fold higher in subjects with type 1 diabetes. Glucose rate of disappearance was significantly lower in individuals with type 1 diabetes during the 8-and 40-mU/m(2).min stages.
Conclusion: Insulin resistance in liver and skeletal muscle was a significant feature in type 1 diabetes. Nevertheless, the etiology of insulin resistance was not explained by body mass index, percentage fat, plasma lipids, visceral fat, and physical activity and was also not fully explained by hyperglycemia. (J Clin Endocrinol Metab 97: 1663-1672, 2012)
C1 [Bergman, Bryan C.; Howard, David; Schauer, Irene E.; Eckel, Robert H.; Perreault, Leigh] Univ Colorado, Div Endocrinol Metab & Diabet, Dept Med, Aurora, CO 80045 USA.
[Snell-Bergeon, Janet K.; Rewers, Marian] Univ Colorado, Sch Med, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80045 USA.
[Schauer, Irene E.] Denver Vet Affairs Med Ctr, Denver, CO 80262 USA.
RP Bergman, BC (reprint author), Univ Colorado, Div Endocrinol Metab & Diabet, Dept Med, Anschutz Med Campus,POB 6511,MS 8106, Aurora, CO 80045 USA.
EM bryan.bergman@ucdenver.edu
OI Bergman, Bryan/0000-0002-9561-1052
FU National Institutes of Health's National Heart, Lung, and Blood
Institute [R01 HL-61753, R01 HL-079611]; Clinical Translational Research
Center at the University of Colorado Denver [M01 RR000051, RR-00036];
Barbara Davis Center for Childhood Diabetes (Denver, CO); National
Institutes of Health Diabetes Endocrinology Research Center [P30
DK57516]; National Institute for Diabetes and Digestive and Kidney
Diseases [K01 DK066219, K23 DK075360]; American Diabetes Association
[1-10-JF-50]
FX This work was supported by the National Institutes of Health's National
Heart, Lung, and Blood Institute Grants R01 HL-61753 and R01 HL-079611,
and Clinical Translational Research Center at the University of Colorado
Denver Grants M01 RR000051 and RR-00036 as well as the Barbara Davis
Center for Childhood Diabetes (Denver, CO). Support was also provided by
the National Institutes of Health Diabetes Endocrinology Research Center
Clinical Investigation Core Grant P30 DK57516; National Institute for
Diabetes and Digestive and Kidney Diseases Grants K01 DK066219 (to
B.C.B.) and K23 DK075360 (to D.M.M.); and the American Diabetes
Association Junior Faculty Award 1-10-JF-50 (to J.K.S.-B.).
NR 42
TC 29
Z9 29
U1 0
U2 4
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2012
VL 97
IS 5
BP 1663
EP 1672
DI 10.1210/jc.2011-3172
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 940TL
UT WOS:000303915900059
PM 22362823
ER
PT J
AU Burney, BO
Hayes, TG
Smiechowska, J
Cardwell, G
Papusha, V
Bhargava, P
Konda, B
Auchus, RJ
Garcia, JM
AF Burney, Basil O.
Hayes, Teresa G.
Smiechowska, Joanna
Cardwell, Gina
Papusha, Victor
Bhargava, Peeyush
Konda, Bhavana
Auchus, Richard J.
Garcia, Jose M.
TI Low Testosterone Levels and Increased Inflammatory Markers in Patients
with Cancer and Relationship with Cachexia
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID LOW SERUM TESTOSTERONE; ERECTILE DYSFUNCTION; HYPOGONADAL MEN; GRIP
STRENGTH; OLDER MEN; SURVIVORS; ANOREXIA; MASS; INTERLEUKIN-6;
ASSOCIATIONS
AB Context: Male cancer patients suffer from fatigue, sexual dysfunction, and decreased functional performance and muscle mass. These symptoms are seen in men with hypogonadism and/or inflammatory conditions. However, the relative contribution of testosterone and inflammation to symptom burden in cancer has not been well-established.
Objective: The aim of this study was to measure testosterone levels in male cancer patients and determine the relationship between testosterone, inflammation, and symptom burden.
Design/Setting: This cross-sectional study enrolled patients from a tertiary-care center.
Subjects/Outcome Measures: Subjects included males with cancer-cachexia (CC; n = 45) and cancer without cachexia (CNC; n = 50), as well as noncancer controls (CO; n = 45). Total testosterone (TT), bioavailable testosterone, C-reactive protein (CRP), and IL-6 were measured in plasma. Functional performance was assessed by the ECOG (Eastern Cooperative Oncology Group) and KPS (Karnofsky Performance Scales), and sexual function was assessed by the IIEF (International Index of Erectile Function).
Results: Low testosterone levels were seen in more than 70% of CC cases. TT was lower in CC compared to CNC(P < 0.05). Also, CC had lower bioavailable testosterone, grip strength, IIEF scores, appendicular lean body mass, and fat mass and higher IL-6 and CRP compared to controls (P <= 0.05). ECOG and KPS were lower in CC and CNC compared to controls (P <= 0.05). On multiple regression analysis, TT, albumin, and CRP predicted symptoms differentially in cancer patients.
Conclusions: CC patients have higher inflammation and lower testosterone, grip strength, functional status, erectile function, fat mass, and appendicular lean body mass. Inflammation, TT, and albumin are associated with heavier symptom burden in this population. Interventional trials are needed to determine whether testosterone replacement and/or antiinflammatory agents benefit cancer patients. (J Clin Endocrinol Metab 97: E700-E709, 2012)
C1 [Garcia, Jose M.] Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Hayes, Teresa G.] Michael E DeBakey VA Med Ctr, Div Hematol & Oncol, Houston, TX 77030 USA.
[Smiechowska, Joanna] Michael E DeBakey VA Med Ctr, Div Geriatr, Houston, TX 77030 USA.
[Konda, Bhavana] Univ Miami, Miller Sch Med, Dept Med, Atlantis, FL 33136 USA.
[Auchus, Richard J.] Univ Michigan, Div Metab Endocrinol & Diabet, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Smiechowska, Joanna; Garcia, Jose M.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
[Bhargava, Peeyush] Michael E DeBakey VA Med Ctr, Dept Radiol, Houston, TX 77030 USA.
RP Garcia, JM (reprint author), Baylor Coll Med, Div Endocrinol Diabet & Metab, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,Bldg 109,Room 210, Houston, TX 77030 USA.
EM jgarcia1@bcm.edu
FU Abbott; MERIT from the Department of Veterans Affairs [I01-BX000507];
Clinical Scientist Award in Translational Research from the
Burroughs-Welcome Fund [1005954]
FX This work was supported by an unrestricted grant from Abbott and a MERIT
grant from the Department of Veterans Affairs (to J.M.G.; I01-BX000507).
R.J.A. is supported by a Clinical Scientist Award in Translational
Research (no. 1005954) from the Burroughs-Welcome Fund.
NR 47
TC 23
Z9 25
U1 1
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2012
VL 97
IS 5
BP E700
EP E709
DI 10.1210/jc.2011-2387
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 940TL
UT WOS:000303915900001
PM 22419719
ER
PT J
AU Wang, S
Wong, ML
Hamilton, N
Ben Davoren, J
Jahan, TM
Walter, LC
AF Wang, Sunny
Wong, Melisa L.
Hamilton, Nathan
Ben Davoren, J.
Jahan, Thierry M.
Walter, Louise C.
TI Impact of Age and Comorbidity on Non-Small-Cell Lung Cancer Treatment in
Older Veterans
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID COMBINED-MODALITY THERAPY; HEALTH-CARE UTILIZATION; QUALITY-OF-LIFE;
ELDERLY-PATIENTS; PHASE-III; MEDICARE BENEFICIARIES; CHEMOTHERAPY
REGIMENS; VINORELBINE; CISPLATIN; ONCOLOGY
AB Purpose
Because comorbidity affects cancer treatment outcomes, guidelines recommend considering comorbidity when making treatment decisions in older patients with lung cancer. Yet, it is unclear whether treatment is targeted to healthier older adults who might reasonably benefit.
Patients and Methods
Receipt of first-line guideline-recommended treatment was assessed for 20,511 veterans age >= 65 years with non-small-cell lung cancer (NSCLC) in the Veterans Affairs (VA) Central Cancer Registry from 2003 to 2008. Patients were stratified by age (65 to 74, 75 to 84, >= 85 years), Charlson comorbidity index score (0, 1 to 3, >= 4), and American Joint Committee on Cancer stage (I to II, IIIA to IIIB, IIIB with malignant effusion to IV). Comorbidity and patient characteristics were obtained from VA claims and registry data. Multivariate analysis identified predictors of receipt of guideline-recommended treatment.
Results
In all, 51% of patients with local, 35% with regional, and 27% with metastatic disease received guideline-recommended treatment. Treatment rates decreased more with advancing age than with worsening comorbidity for all stages, such that older patients with no comorbidity had lower rates than younger patients with severe comorbidity. For example, 50% of patients with local disease age 75 to 84 years with no comorbidity received surgery compared with 57% of patients age 65 to 74 years with severe comorbidity (P < .001). In multivariate analysis, age and histology remained strong negative predictors of treatment for all stages, whereas comorbidity and nonclinical factors had a minor effect.
Conclusion
Advancing age is a much stronger negative predictor of treatment receipt among older veterans with NSCLC than comorbidity. Individualized decisions that go beyond age and include comorbidity are needed to better target NSCLC treatments to older patients who may reasonably benefit.
C1 [Wang, Sunny; Hamilton, Nathan; Ben Davoren, J.; Walter, Louise C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Wang, Sunny; Jahan, Thierry M.] Univ Calif San Francisco, Thorac Oncol Program, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
RP Wang, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111H1, San Francisco, CA 94121 USA.
EM sunny.wang@ucsf.edu
FU San Francisco Veterans Affairs (VA) Medical Center; University of
California at San Francisco (UCSF) Helen Diller Family Comprehensive
Cancer Center; Division of Hematology/Oncology, Department of Medicine
at USCF; USCF Pathways Funding Agency; Philip R. Lee Program; Department
of General Internal Medicine, UCSF; San Francisco VA Medical Center;
National Cancer Institute, National Institutes of Health [R01 CA134425];
Eli Lilly; Genentech/OSI Pharmaceuticals; ImClone Systems; Morphotek;
Pfizer
FX Supported by the San Francisco Veterans Affairs (VA) Medical Center (S.
W.); the Thoracic Oncology Program, University of California at San
Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, and
the Division of Hematology/Oncology, Department of Medicine at USCF (S.
W. and T.M.J.); the USCF Pathways Funding Agency, the Philip R. Lee
Program, and the Department of General Internal Medicine, UCSF (M. L.
W.); San Francisco VA Medical Center (J.B.D.); and by Grant No. R01
CA134425 from the National Cancer Institute, National Institutes of
Health, and the San Francisco VA Medical Center (L. C. W.).; Sunny Wang,
Eli Lilly, Genentech/OSI Pharmaceuticals, ImClone Systems, Morphotek,
Pfizer; Thierry M. Jahan, Eli Lilly, Genentech/OSI Pharmaceuticals,
ImClone Systems, Morphotek, Pfizer
NR 61
TC 53
Z9 55
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 1
PY 2012
VL 30
IS 13
BP 1447
EP 1455
DI 10.1200/JCO.2011.39.5269
PG 9
WC Oncology
SC Oncology
GA 939ZJ
UT WOS:000303859400013
PM 22454424
ER
PT J
AU Shen, KZ
Johnson, SW
AF Shen, Ke-Zhong
Johnson, Steven W.
TI Regulation of polysynaptic subthalamonigral transmission by D2, D3 and
D4 dopamine receptors in rat brain slices
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID NIGRA PARS RETICULATA; SUBSTANTIA-NIGRA; NUCLEUS NEURONS;
PARKINSONS-DISEASE; GLOBUS-PALLIDUS; BASAL GANGLIA; IN-VITRO;
CEREBRAL-CORTEX; MESSENGER-RNA; LOCALIZATION
AB Dopamine depletion in experimental models of Parkinson's disease promotes burst firing of neurons in the subthalamic nucleus (STN) and substantia nigra zona reticulata (SNR). A synaptically generated form of burst firing has been shown to arise from complex excitatory postsynaptic currents (EPSCs) that are evoked in SNR neurons by STN stimulation. The present experiments were designed to characterize actions of dopamine on complex EPSCs in slices of rat brain. Using patch pipettes to record whole-cell currents under voltage clamp, dopamine (30 mu M) caused a reversible 64% reduction in complex EPSC charge. This effect was partially mimicked by D2, D3 and D4 receptor agonists, and the action of dopamine could be nearly completely blocked by the combined effects of the D2/3 antagonist sulpiride and the D4 antagonist L-745,870. Local application of dopamine to the STN caused a larger inhibition of the complex EPSC (55% reduction) than did dopamine application to the SNR (15% reduction). Simple, monophasic EPSCs, which were evoked in SNR neurons by stimulating the SNR close to the recording pipette, were inhibited to a smaller extent compared to complex EPSCs. Bursts of action potentials evoked in SNR neurons by STN stimulation were inhibited by dopamine to a greater extent than was spontaneous firing. These results show that dopamine D2-like receptors inhibit complex EPSCs and burst discharges in the SNR by acting within the STN to suppress transmission in the subthalamonigral pathway. Dopamine receptor-mediated inhibition of polysynaptic connections in the STN might be beneficial in the treatment of Parkinson's disease.
C1 [Shen, Ke-Zhong; Johnson, Steven W.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Johnson, Steven W.] Portland VA Med Ctr, Portland, OR 97207 USA.
RP Johnson, SW (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
EM johnsost@ohsu.edu
FU United States Public Health Service [NS38715, NS060662]; Portland
Veterans Affairs Parkinson's Disease Research, Education, and Clinical
Center
FX This work was supported by United States Public Health Service grants
NS38715 and NS060662, and by the Portland Veterans Affairs Parkinson's
Disease Research, Education, and Clinical Center.
NR 38
TC 3
Z9 3
U1 1
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3751
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD MAY
PY 2012
VL 590
IS 10
BP 2273
EP 2284
DI 10.1113/jphysiol.2011.225672
PG 12
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 942ZK
UT WOS:000304090000014
PM 22371474
ER
PT J
AU Xu, HP
Covinsky, KE
Stallard, E
Thomas, J
Sands, LP
AF Xu, Huiping
Covinsky, Kenneth E.
Stallard, Eric
Thomas, Joseph, III
Sands, Laura P.
TI Insufficient Help for Activity of Daily Living Disabilities and Risk of
All-Cause Hospitalization
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE activities of daily living; disability; hospitalization; insufficient
help
ID UNMET NEED; OLDER-ADULTS; PERSONAL ASSISTANCE; ELDERLY-PATIENTS; CARE;
SERVICES; HOME; CONSEQUENCES; VALIDATION; CAREGIVERS
AB OBJECTIVES To determine whether insufficient help for activity of daily living (ADL) disability, a potentially modifiable condition, significantly increases disabled older adults risk of future hospital admissions.
DESIGN Prospective study.
SETTING Community-living participants with ADL disabilities in the 1994, 1999, and 2004 National Long-Term Care Survey (NLTCS).
PARTICIPANTS Medicare recipients with one or more ADL disabilities completed 5,884 surveys.
MEASUREMENTS Times to hospital admission in the year after the NLTCS community survey were obtained from linked Medicare claims. Insufficient ADL help for each ADL limitation was determined from a series of questions common to the three NLTCS community surveys.
RESULTS Insufficient help for one or more ADL limitations was reported in 22% of surveys. Respondents to 3,629 surveys did not experience a hospital admission in the year after the survey. Of the remaining 2,255 surveys, one admission occurred for 382 surveys, two admissions for 525 surveys, three admissions for 193 surveys, and four or more admissions for 155 surveys. Participants reporting insufficient help were 14% (hazard ratio = 1.14, 95% confidence interval = 1.011.28) more likely to experience one or more hospitalizations than those who did not report insufficient help after controlling for demographic characteristics, comorbidities, prior hospitalizations, and level of ADL disability.
CONCLUSION Self-reports of insufficient help provide prognostic information beyond what typical health assessments can capture. Greater recognition and referral for insufficient help for ADL disability may result in lower rates of hospitalization in a population that is at high risk of hospitalization. J Am Geriatr Soc 60:927-933, 2012.
C1 [Sands, Laura P.] Purdue Univ, Sch Nursing, W Lafayette, IN 47907 USA.
[Xu, Huiping] Indiana Univ, Sch Med, Indianapolis, IN USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Stallard, Eric] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC USA.
[Thomas, Joseph, III] Purdue Univ, Ctr Aging & Life Course, Ctr Hlth Outcomes Res & Policy, Regenstrief Ctr Healthcare Engn,Coll Pharm, W Lafayette, IN 47907 USA.
RP Sands, LP (reprint author), Purdue Univ, Sch Nursing, 502 N Univ St, W Lafayette, IN 47907 USA.
EM lsands@purdue.edu
RI Sands, Laura/E-8919-2015
OI Sands, Laura/0000-0003-2446-4486
FU National Institutes of Health [R01AG034160]
FX This research was supported by Grant R01AG034160 from the National
Institutes of Health to Dr. Sands. Drs. Xu, Covinsky, Thomas, and Sands
and Prof. Stallard do not have any financial interest or personal
conflicts with the methodologies discussed in this manuscript.
NR 31
TC 10
Z9 11
U1 1
U2 12
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2012
VL 60
IS 5
BP 927
EP 933
DI 10.1111/j.1532-5415.2012.03926.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 942HE
UT WOS:000304033900016
PM 22587855
ER
PT J
AU Finlayson, E
Zhao, SJ
Boscardin, WJ
Fries, BE
Landefeld, CS
Dudley, RA
AF Finlayson, Emily
Zhao, Shoujun
Boscardin, W. John
Fries, Brant E.
Landefeld, C. Seth
Dudley, R. Adams
TI Functional Status After Colon Cancer Surgery in Elderly Nursing Home
Residents
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE functional decline; nursing home residents; surgery
ID CARE; COMORBIDITY; ADULTS; MDS
AB OBJECTIVES To determine functional status and mortality rates after colon cancer surgery in older nursing home residents.
DESIGN Retrospective cohort study.
SETTING Nursing homes in the United States.
PARTICIPANTS Six thousand eight hundred twenty-two nursing home residents aged 65 and older who underwent surgery for colon cancer in the United States between 1999 and 2005.
MEASUREMENTS Changes in functional status were assessed before and after surgery using the Minimum Data Set Activity of Daily Living (MDS-ADL) summary scale, a 28-point scale in which score increases as functional dependence increases. Regression techniques were used to identify patient characteristics associated with mortality and functional decline 1 year after surgery.
RESULTS On average, residents who underwent colectomy had a 3.9-point worsening in MDS-ADL score at 1 year. One year after surgery, rates of mortality and sustained functional decline were 53% and 24%, respectively. In multivariate analysis, older age (=80 vs 6569, adjusted relative risk (ARR) = 1.53, 95% confidence interval (CI) = 1.152.04, P < .001), readmission after surgical hospitalization (ARR = 1.15, 95% CI = 1.031.29, P = .02), surgical complications (ARR = 1.11, 95% CI = 1.021.21, P = .01), and functional decline before surgery (ARR = 1.21, 95% CI = 1.111.32, P < .001) were associated with functional decline at 1 year.
CONCLUSION Mortality and sustained functional decline are common after colon cancer surgery in nursing home residents. Initiatives aimed at improving surgical outcomes are needed in this vulnerable population. J Am Geriatr Soc 60:967-973, 2012.
C1 [Finlayson, Emily; Dudley, R. Adams] Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA.
[Finlayson, Emily; Zhao, Shoujun] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Boscardin, W. John; Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Boscardin, W. John; Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA.
[Fries, Brant E.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA.
[Fries, Brant E.] Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA.
[Dudley, R. Adams] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Finlayson, E (reprint author), Philip R Lee Inst Hlth Policy Studies, 3333 Calif St, San Francisco, CA 94118 USA.
EM emily.finlayson@ucsfmedctr.org
FU National Institute on Aging [K08AG028965]
FX Dr. Finlayson was supported by a National Institute on Aging/Paul B.
Beeson Clinical Scientist Development Award in Aging (K08AG028965).
NR 19
TC 28
Z9 28
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0002-8614
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2012
VL 60
IS 5
BP 967
EP 973
DI 10.1111/j.1532-5415.2012.03915.x
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 942HE
UT WOS:000304033900023
PM 22428583
ER
PT J
AU Cannuscio, CC
Alley, DE
Pagan, JA
Soldo, B
Krasny, S
Shardell, M
Asch, DA
Lipman, TH
AF Cannuscio, Carolyn C.
Alley, Dawn E.
Pagan, Jose A.
Soldo, Beth
Krasny, Sarah
Shardell, Michelle
Asch, David A.
Lipman, Terri H.
TI Housing strain, mortgage foreclosure, and health
SO NURSING OUTLOOK
LA English
DT Article
DE Housing security; Housing strain; Material resources; Housing policy;
Economic strain; Health disparities
AB Background: Foreclosure rates have risen rapidly since 2005, reaching historically high levels. The purpose of this study was to examine the health implications of the current housing crisis.
Methods: We conducted a cross-sectional online consumer panel survey including residents of California, Arizona, Nevada, and Florida (n = 798) to determine the feasibility of contacting distressed homeowners via the Internet and to assess mental and physical health among respondents across the spectrum from those having no housing strain to those in loan default or home foreclosure.
Results: Homeowners in default or foreclosure exhibited poorer mental health and more physical symptoms than renters, homeowners with moderate strain, and homeowners with no strainofollowing a gradient that was consistent across multiple health indicators.
Conclusions: Internet panel sampling was an efficient method of contacting distressed homeowners. Record-high foreclosure rates may have broad implications for nursing and public health. Homeowners in default or foreclosure represent an identifiable high-risk group that may benefit from coordinated, affordable health and social services. Cite this article: Cannuscio, C. C., Alley, D. E., Pagan, J. A., Soldo, B., Krasny, S., Shardell, M., Asch, D. A., & Lipman, T. H. (2012, JUNE). Housing strain, mortgage foreclosure, and health. Nursing Outlook, 60(3), 134-142. doi:10.1016/j.outlook.2011.08.004.
C1 [Lipman, Terri H.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA.
[Lipman, Terri H.] Univ Penn, Ctr Publ Hlth Initiat, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.; Shardell, Michelle; Asch, David A.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Cannuscio, Carolyn C.; Shardell, Michelle] Univ Penn, Dept Family Med & Community Hlth, Philadelphia, PA 19104 USA.
[Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol Publ Hlth, Baltimore, MD 21201 USA.
[Pagan, Jose A.] Univ N Texas Hlth Sci Ctr, Dept Hlth Management & Policy, Ft Worth, TX USA.
[Soldo, Beth] Univ Penn, Populat Aging Res Ctr, Ctr Populat Studies, Philadelphia, PA 19104 USA.
[Krasny, Sarah] Univ Penn, Huntsman Program Int Studies & Business, Sch Arts & Sci, Philadelphia, PA 19104 USA.
[Krasny, Sarah] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
RP Lipman, TH (reprint author), Univ Penn, Sch Nursing, Room 224,Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM lipman@nursing.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU Robert Wood Johnson Foundation Health Society; University of
Pennsylvania Center for Public Health Initiatives; Office of Practice
and Community Affairs, University of Pennsylvania School of Nursing;
Department of Veterans Affairs, Office of Health Services Research and
Development, Center for Health Equity Research and Promotion
FX We gratefully acknowledge the support provided by Jeannette Schroeder,
as well as funding support from the Robert Wood Johnson Foundation
Health & Society Scholars Program, University of Pennsylvania Center for
Public Health Initiatives, and the Office of Practice and Community
Affairs, University of Pennsylvania School of Nursing, Investment for
the Future Funds. Drs. Asch and Cannusio are supported by the Department
of Veterans Affairs, Office of Health Services Research and Development,
Center for Health Equity Research and Promotion. The contents of this
article do not represent the views of the Department of Veteran Affairs
or the United States government.
NR 0
TC 22
Z9 23
U1 1
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
J9 NURS OUTLOOK
JI Nurs. Outlook
PD MAY-JUN
PY 2012
VL 60
IS 3
BP 134
EP 142
DI 10.1016/j.outlook.2011.08.004
PG 9
WC Nursing
SC Nursing
GA 944DK
UT WOS:000304178400006
PM 22000689
ER
PT J
AU Chen, BB
Glasser, JR
Coon, TA
Mallampalli, RK
AF Chen, B. B.
Glasser, J. R.
Coon, T. A.
Mallampalli, R. K.
TI F-box protein FBXL2 exerts human lung tumor suppressor-like activity by
ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle
arrest
SO ONCOGENE
LA English
DT Article
DE ubiquitin; camodulin; lung
ID CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; D1 DEGRADATION;
CALCIUM-CONCENTRATION; REGULATORY ENZYME; CALMODULIN; CANCER;
PHOSPHORYLATION; EXPRESSION; KINASE; IDENTIFICATION
AB Dysregulated behavior of cell cycle proteins and their control by ubiquitin E3 ligases is an emerging theme in human lung cancer. Here, we identified and characterized the activity of a novel F-box protein, termed FBXL2, belonging to the SCF (Skip-Cullin1-F-box protein) E3 ligase family. Ectopically expressed FBXL2 triggered G2/M-phase arrest, induced chromosomal anomalies and increased apoptosis of transformed lung epithelia by mediating polyubiquitination and degradation of the mitotic regulator, cyclin D3. Unlike other F-box proteins that target phosphodegrons within substrates, FBXL2 uniquely recognizes a canonical calmodulin (CaM)-binding motif within cyclin D3 to facilitate its polyubiquitination. CaM bound and protected cyclin D3 from FBXL2 by direct intermolecular competition with the F-box protein for access within this motif. The chemotherapeutic agent vinorelbine increased apoptosis of human lung carcinoma cells by inducing FBXL2 expression and cyclin D3 degradation, an effect accentuated by CaM knockdown. Depletion of endogenous FBXL2 stabilized cyclin D3 levels, accelerated cancer cell growth and increased cell viability after vinorelbine treatment. Last, ectopic expression of FBXL2 significantly inhibited the growth and migration of tumorogenic cells and tumor formation in athymic nude mice. These observations implicate SCFFBXL2 as an indispensible regulator of mitosis that serves as a tumor suppressor. Oncogene (2012) 31, 2566-2579; doi:10.1038/onc.2011.432; published online 24 October 2011
C1 [Mallampalli, R. K.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, UPMC Montefiore,Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA.
[Mallampalli, R. K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA.
[Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, UPMC Montefiore,Acute Lung Injury Ctr Excellence, NW 628, Pittsburgh, PA 15213 USA.
EM mallampallirk@upmc.edu
FU US Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development; US Department of Veterans Affairs; National Institutes of
Health [HL096376, HL097376, HL098174]
FX We thank AF Stewart for critical review of the manuscript and helpful
suggestions. This material is based upon work supported, in part, by the
US Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Biomedical Laboratory Research and
Development. This work was supported by a Merit Review Award from the US
Department of Veterans Affairs and National Institutes of Health R01
grants HL096376, HL097376 and HL098174 (to RKM). The contents presented
do not represent the views of the Department of Veterans Affairs or the
United States Government.
NR 56
TC 31
Z9 33
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD MAY
PY 2012
VL 31
IS 20
BP 2566
EP 2579
DI 10.1038/onc.2011.432
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 944ID
UT WOS:000304191800007
PM 22020328
ER
PT J
AU Messamore, E
AF Messamore, Erik
TI Niacin subsensitivity is associated with functional impairment in
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Niacin; Schizophrenia; Niacin; Laser Doppler flowmetry; Psychiatric
status rating scales
ID SKIN-FLUSH RESPONSE; CATALEPTIC BEHAVIOR; NICOTINIC-ACID; FATTY-ACIDS;
CYCLOOXYGENASE INHIBITORS; POSSIBLE INVOLVEMENT; HEALTHY CONTROLS;
ABSENT RESPONSE; EARLY PSYCHOSIS; CHALLENGE TEST
AB Objective: Sensitivity to the skin flush effect of niacin is reduced in a portion of patients with schizophrenia. Though this peripheral physiological abnormality has been widely replicated, its relevance to neuropsychiatric manifestations of the illness has been unclear. The goal of this study was to determine if the niacin response abnormality in schizophrenia is associated with functional impairment.
Methods: Following psychiatric assessment, a Global Assessment of Functioning (GAF) score was assigned to each of 40 volunteers with schizophrenia. For each subject, the blood flow responses to several concentrations of topical methylnicotinate were recorded. Blood flow was measured objectively, using laser Doppler flowmetry. From the dose-response data, EC50 values were derived. GAF scores were assigned without knowledge of the participants' niacin response data.
Results: There was a significant negative correlation between GAF scores and EC50 values for methylnicotinate (Pearson r=-0.42; p=0.007).
Conclusions: Reduced niacin sensitivity is associated with greater functional impairment among patients with schizophrenia. These findings raise the possibility that a subset of schizophrenia patients possesses a biochemical abnormality that reduces niacin sensitivity in the skin and contributes to functional impairment from the disease. Published by Elsevier B.V.
C1 [Messamore, Erik] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA.
[Messamore, Erik] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
RP Messamore, E (reprint author), Portland VA Med Ctr, Div Mental Hlth, P35C,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM Erik.Messamore@va.gov
FU NIMH [R03 MH070434]; VA Career Development Award
FX Funding for this study was provided by NIMH grant R03 MH070434 and by a
VA Career Development Award (to the author). Neither the NIMH nor VA
funding sources had any further role in study design; in the collection,
analysis and interpretation of data; in the writing of the report; and
in the decision to submit the paper for publication. The contents of
this article do not represent the views of the Department of Veterans
Affairs or the United States Government.
NR 47
TC 7
Z9 7
U1 2
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2012
VL 137
IS 1-3
BP 180
EP 184
DI 10.1016/j.schres.2012.03.001
PG 5
WC Psychiatry
SC Psychiatry
GA 941AI
UT WOS:000303933800029
PM 22445461
ER
PT J
AU Smith, MJ
Horan, WP
Karpouzian, TM
Abram, SV
Cobia, DJ
Csernansky, JG
AF Smith, Matthew J.
Horan, William P.
Karpouzian, Tatiana M.
Abram, Samantha V.
Cobia, Derin J.
Csernansky, John G.
TI Self-reported empathy deficits are uniquely associated with poor
functioning in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Social cognition; Community functioning; Functional capacity
ID SOCIAL COGNITION; NEUROCOGNITIVE DEFICITS; MIND; NEUROSCIENCE; DISORDER;
OPPORTUNITIES; METAANALYSIS; WORKSHOP; RECOVERY; CNTRICS
AB Background: Social cognitive deficits have been proposed to be among the causes of poor functional outcome in schizophrenia. Empathy, or sharing and understanding the unique emotions and experiences of other people, is one of the key elements of social cognition, and prior studies suggest that empathic processes are impaired in schizophrenia. The current study examined whether impairments in self-reported empathy were associated with poor functioning, above and beyond the influences of neurocognitive deficits and psychopathology.
Methods: Individuals with schizophrenia (n=46) and healthy controls (n=37) completed the Interpersonal Reactivity Index (IRI), a measure of emotional and cognitive empathy. Participants also completed a neuropsychological test battery, clinical ratings of psychopathology, and functional outcome measures assessing both functional capacity and community functioning. After testing for between-group differences, we assessed the relationships between self-reported empathy and the measures of functioning, neurocognition, and psychopathology. Regression analyses examined whether empathic variables predicted functional outcomes.
Results: Individuals with schizophrenia reported lower IRI scores for perspective-taking and empathic concern, and higher IRI scores for personal distress than controls. Among individuals with schizophrenia, lower perspective-taking, greater disorganized symptoms, and deficits in working memory and episodic memory were correlated with poorer functional capacity and community functioning. Lower scores for perspective-taking explained significant incremental variance in both functional capacity (Delta R-2=.09, p <.05) and community functioning (Delta R-2=.152, p <.01) after accounting for relevant neurocognitive and psychopathological variables.
Conclusions: Impaired perspective-taking, a component of cognitive empathy, is associated with poor functioning even after taking into account the influences of neurocognitive deficits and psychopathology. These findings support further efforts to clarify the underlying causes of empathic disturbances and suggest that treatments for these disturbances may help functional recovery in schizophrenia. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Smith, Matthew J.; Karpouzian, Tatiana M.; Abram, Samantha V.; Cobia, Derin J.; Csernansky, John G.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA.
[Horan, William P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Horan, William P.] VISN22 MIRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Smith, MJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, 446 E Ontario St,Suite 1000, Chicago, IL 60611 USA.
EM matthewsmith@northwestern.edu
OI Smith, Matthew/0000-0002-0079-1477; Cobia, Derin/0000-0003-2339-958X
FU Department of Psychiatry and Behavioral Sciences at Northwestern
University Feinberg School of Medicine; Northwestern University
Schizophrenia Research Group
FX Sources of Support: Support for the preparation of this paper was
provided by the Department of Psychiatry and Behavioral Sciences at
Northwestern University Feinberg School of Medicine and the Northwestern
University Schizophrenia Research Group.
NR 62
TC 38
Z9 40
U1 3
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2012
VL 137
IS 1-3
BP 196
EP 202
DI 10.1016/j.schres.2012.01.012
PG 7
WC Psychiatry
SC Psychiatry
GA 941AI
UT WOS:000303933800032
PM 22321668
ER
PT J
AU Irani, F
Seligman, S
Kamath, V
Kohler, C
Gur, RC
AF Irani, Farzin
Seligman, Sarah
Kamath, Vidyulata
Kohler, Christian
Gur, Ruben C.
TI A meta-analysis of emotion perception and functional outcomes in
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Emotion perception; Social cognition; Schizophrenia; Functional outcome;
Quality of life; Meta-analysis
ID FACIAL-AFFECT RECOGNITION; SOCIAL COGNITION; TRAINING-PROGRAM; FLAT
AFFECT; OTHER-RACE; REMEDIATION; DEFICITS; NEUROCOGNITION; EXPRESSIONS;
COMPETENCE
AB Introduction: Emotion perception (EP) is impaired in schizophrenia, is stable across clinical state, resistant to antipsychotic treatment and linked to symptom severity. Given its pervasive nature, there is a need to quantitatively examine whether this dysfunction impacts functional outcomes. We used a meta-analytic strategy to combine results from several studies and examine synthesized effect sizes.
Methods: A Meta-analysis of Observational Studies in Epidemiology standard was used to extract data following a PubMed and PsychInfo search. Studies reporting correlations between measures of EP and functional outcomes in schizophrenia spectrum disorders were selected. The impact of potential methodological (task type), demographic (sex, age, race, education, marital status) and clinical (age of onset, duration of illness, setting, symptoms, anti-psychotic medication) moderators on effect sizes were examined.
Results: Twenty-five studies met inclusion criteria and included 1306 patients who were 37 years old, with 12 years of education, 64% male and 63% Caucasian. There was a significant relationship between EP and functional outcomes in individuals with schizophrenia or schizoaffective disorder, with effect sizes in the medium range. Medium to large range positive correlations were observed between emotion identification and functional outcome domains involving social problem solving, social skills and community functioning. Significant moderators included task type (emotion identification tasks), sex (% male in sample), race (% Caucasian in sample) and clinical symptoms (negative and positive).
Conclusions: Emotion identification deficits are associated with functional impairments in schizophrenia and moderated by sex, race and symptoms. This has implications for treatment efforts to improve outcomes. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Irani, Farzin; Seligman, Sarah; Kamath, Vidyulata; Kohler, Christian; Gur, Ruben C.] Univ Penn, Sch Med, Neuropsychiat Sect, Dept Psychiat, Philadelphia, PA 19104 USA.
[Gur, Ruben C.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Irani, Farzin] Immaculata Univ, Dept Grad Psychol, Immaculata, PA USA.
RP Irani, F (reprint author), Univ Penn, Sch Med, Neuropsychiat Sect, Dept Psychiat, 10th Floor,Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.
EM firani@upenn.edu
OI Rycroft, Sarah/0000-0002-9041-0825
FU NIMH [T32MH019112]
FX FI is supported by a training grant from NIMH (T32MH019112); the NIMH
had no further role in the study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the
decision to submit the paper for publication.
NR 70
TC 47
Z9 50
U1 0
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAY
PY 2012
VL 137
IS 1-3
BP 203
EP 211
DI 10.1016/j.schres.2012.01.023
PG 9
WC Psychiatry
SC Psychiatry
GA 941AI
UT WOS:000303933800033
PM 22341200
ER
PT J
AU Spiegel, BMR
AF Spiegel, Brennan M. R.
TI Treatment Center Characteristics Associated with Better Outcomes: A Role
for the Medical Director?
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID DIALYSIS; MORTALITY; HEMODIALYSIS; ADEQUACY; PROGRAM; QUALITY
C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
EM bspiegel@mednet.ucla.edu
NR 12
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0894-0959
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD MAY-JUN
PY 2012
VL 25
IS 3
BP 296
EP 298
DI 10.1111/j.1525-139X.2012.01077.x
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA 944HP
UT WOS:000304190200011
PM 22607212
ER
PT J
AU Yee, HS
Chang, MF
Pocha, C
Lim, J
Ross, D
Morgan, TR
Monto, A
AF Yee, Helen S.
Chang, Michael F.
Pocha, Christine
Lim, Joseph
Ross, David
Morgan, Timothy R.
Monto, Alexander
TI Update on the Management and Treatment of Hepatitis C Virus Infection:
Recommendations from the Department of Veterans Affairs Hepatitis C
Resource Center Program and the National Hepatitis C Program Office
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
ID SUSTAINED VIROLOGICAL RESPONSE; TREATMENT-NAIVE PATIENTS; GENOTYPE 1
INFECTION; CHRONIC HCV INFECTION; PEGINTERFERON ALPHA-2A; PLUS
RIBAVIRIN; LIVER FIBROSIS; RANDOMIZED-TRIAL; TRANSIENT ELASTOGRAPHY;
PEGYLATED INTERFERON
AB Chronic hepatitis C virus (HCV) infection affects approximately 1.3% of the United States population and 4% of veterans who use Department of Veterans Affairs medical services. Chronic HCV is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease requiring liver transplantation in the United States. Management of chronic HCV is aimed at halting disease progression, preventing cirrhosis decompensation, reducing the risk of HCC, and treating extrahepatic complications of the infection. As part of a comprehensive HCV management strategy, peginterferon alfa and ribavirin, along with the addition of a hepatitis C protease inhibitor therapy for many genotype 1-infected patients, are the current standard of care. Antiviral therapy should be provided to those individuals who are clinically stable, have moderate liver disease or compensated cirrhosis, and are motivated to pursue therapy. Many patients have comorbid medical and psychiatric conditions, which may affect their adherence to antiviral therapy or worsen while on antiviral therapy. To optimally manage hepatitis C and associated comorbidities, patients benefit from multidisciplinary teams that can provide HCV-specific care and treatment. Sustained virologic response is associated with "cure" of chronic HCV, and results in improved liver disease outcomes and prolonged survival.
C1 [Yee, Helen S.; Chang, Michael F.; Pocha, Christine; Lim, Joseph; Monto, Alexander] US Dept Vet Affairs, Hepatitis Resource Ctr Program C, Washington, DC USA.
[Yee, Helen S.; Monto, Alexander] US Dept Vet Affairs, Med Ctr, San Francisco, CA USA.
[Chang, Michael F.] US Dept Vet Affairs, Med Ctr, Portland, OR USA.
[Pocha, Christine] US Dept Vet Affairs, Med Ctr, Minneapolis, MN USA.
[Lim, Joseph] US Dept Vet Affairs, Med Ctr, West Haven, CT USA.
[Ross, David] Vet Hlth Adm, Off Publ Hlth Clin Publ Hlth, Washington, DC USA.
[Morgan, Timothy R.] US Dept Vet Affairs, Med Ctr, Long Beach, CA USA.
RP Monto, A (reprint author), 4150 Clement St,111B, San Francisco, CA 94121 USA.
EM Alexander.monto@va.gov
NR 93
TC 59
Z9 63
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAY
PY 2012
VL 107
IS 5
BP 669
EP 689
DI 10.1038/ajg.2012.48
PG 21
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 937SU
UT WOS:000303679700005
PM 22525303
ER
PT J
AU McFarland, LV
AF McFarland, Lynne V.
TI The Role of Compassion in the Practice of Evidence-Based Medicine
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Editorial Material
ID DIFFICILE-ASSOCIATED DISEASE
AB Patients with diseases having a high failure rate with standard treatments typically enroll in randomized clinical trials of new investigational treatments. Not all potential therapies are amenable to these types of designs and thus may be offered compassionately; however, claims of efficacy are thus viewed with caution. In a paper in this issue, 43 patients with recurrent Clostridium difficile infections were treated with fecal microbiota transplants using a compassionate use protocol. By using standardized healthy donor stool preparations and following standardized protocols, the 92% response rate can be viewed with more confidence than other case series reports.
C1 [McFarland, Lynne V.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Dept Vet Affairs, Seattle, WA 98101 USA.
[McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA.
RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Dept Vet Affairs, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM lynne.mcfarland@va.gov
NR 10
TC 0
Z9 0
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAY
PY 2012
VL 107
IS 5
BP 768
EP 769
DI 10.1038/ajg.2011.489
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 937SU
UT WOS:000303679700016
PM 22552243
ER
PT J
AU Boardman, CR
Sonnenberg, A
AF Boardman, Charles R.
Sonnenberg, Amnon
TI A Watched Pot Can Boil: Interval Cancer in Tightly Surveyed Barrett's
Esophagus
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID ADENOCARCINOMA; SURVEILLANCE; PREVALENCE
C1 [Boardman, Charles R.; Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA.
[Boardman, Charles R.; Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 9
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD MAY
PY 2012
VL 107
IS 5
BP 793
EP 794
DI 10.1038/ajg.2012.27
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 937SU
UT WOS:000303679700024
PM 22552249
ER
PT J
AU Behr, S
Weinstein, S
Aslam, R
Jung, A
Sebro, R
Yee, J
AF Behr, S.
Weinstein, S.
Aslam, R.
Jung, A.
Sebro, R.
Yee, J.
TI Can CT Performed for Nonspecific Abdominal Pain Reliably Exclude Acute
Cholecystitis?
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Roentgen-Ray-Society
CY APR 29-MAY 04, 2012
CL Vancouver, CANADA
SP Amer Roentgen Ray Soc
C1 [Behr, S.; Weinstein, S.; Aslam, R.; Jung, A.; Sebro, R.; Yee, J.] Univ Calif San Francisco, San Francisco Med Ctr, San Francisco, CA 94143 USA.
[Weinstein, S.; Aslam, R.; Jung, A.; Yee, J.] San Francisco VA Med Ctr, San Francisco, CA USA.
EM stefage00@yahoo.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2012
VL 198
IS 5
SU S
PG 1
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 937OI
UT WOS:000303667400468
ER
PT J
AU Lalwani, N
Bhargava, P
Moshiri, M
Lee, J
Wang, C
Bastawrous, S
Vaidya, S
Dighe, M
AF Lalwani, N.
Bhargava, P.
Moshiri, M.
Lee, J.
Wang, C.
Bastawrous, S.
Vaidya, S.
Dighe, M.
TI Abdominal Oncologic Emergencies: Imaging Appearances and Therapeutic
Options
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Roentgen-Ray-Society
CY APR 29-MAY 04, 2012
CL Vancouver, CANADA
SP Amer Roentgen Ray Soc
C1 [Lalwani, N.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Bhargava, P.; Moshiri, M.; Lee, J.; Wang, C.; Bastawrous, S.; Vaidya, S.; Dighe, M.] Univ Washington, Shoreline, WA USA.
[Bhargava, P.; Bastawrous, S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM bhargp@uw.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2012
VL 198
IS 5
SU S
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 937OI
UT WOS:000303667400465
ER
PT J
AU Lalwani, N
Bhargava, P
Dighe, M
Shanbhogue, A
Nagar, A
AF Lalwani, N.
Bhargava, P.
Dighe, M.
Shanbhogue, A.
Nagar, A.
TI Primary and Secondary Sclerosing Cholangitis: Current Update and Role of
Imaging
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Roentgen-Ray-Society
CY APR 29-MAY 04, 2012
CL Vancouver, CANADA
SP Amer Roentgen Ray Soc
C1 [Lalwani, N.; Shanbhogue, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Bhargava, P.; Dighe, M.] Univ Washington, Seattle, WA 98195 USA.
[Bhargava, P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Nagar, A.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
EM neerajlalwani@hotmail.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2012
VL 198
IS 5
SU S
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 937OI
UT WOS:000303667400367
ER
PT J
AU Rosenthal, P
Massoglia, D
Lundy, K
Gebregziabher, M
Gilbert, G
AF Rosenthal, P.
Massoglia, D.
Lundy, K.
Gebregziabher, M.
Gilbert, G.
TI Under Our Noses: A Reformulation of Our Understanding of Incidental
Paranasal Sinusitis and Its Application in Interpreting Routine Sinus
Imaging
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Roentgen-Ray-Society
CY APR 29-MAY 04, 2012
CL Vancouver, CANADA
SP Amer Roentgen Ray Soc
C1 [Rosenthal, P.; Massoglia, D.; Lundy, K.; Gebregziabher, M.; Gilbert, G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
EM peter.rosenthal@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2012
VL 198
IS 5
SU S
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 937OI
UT WOS:000303667400604
ER
PT J
AU Sebro, R
Aparici, CM
Pampaloni, MH
AF Sebro, R.
Aparici, Mari C.
Pampaloni, Hernandez M.
TI Comparison Between True Whole-Body and Limited Whole-Body FDG PET/CT
Studies in Oncology Patients
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Roentgen-Ray-Society
CY APR 29-MAY 04, 2012
CL Vancouver, CANADA
SP Amer Roentgen Ray Soc
C1 [Sebro, R.; Aparici, Mari C.; Pampaloni, Hernandez M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Aparici, Mari C.] San Francisco VA Med Ctr, San Francisco, CA USA.
EM ronnie.sebro@radiology.ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2012
VL 198
IS 5
SU S
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 937OI
UT WOS:000303667400684
ER
PT J
AU Weinstein, S
Osei-Bonsu, S
Sajewicz, A
Yee, J
AF Weinstein, S.
Osei-Bonsu, S.
Sajewicz, A.
Yee, J.
TI MDCT of the Postoperative Colon: Normal Findings and Common
Complications
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Roentgen-Ray-Society
CY APR 29-MAY 04, 2012
CL Vancouver, CANADA
SP Amer Roentgen Ray Soc
C1 [Weinstein, S.; Yee, J.] Univ Calif San Francisco, San Francisco Med Ctr, San Francisco, CA 94143 USA.
[Weinstein, S.; Yee, J.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Osei-Bonsu, S.] Chicago Med Sch, N Chicago, IL USA.
[Sajewicz, A.] Redwood Reg Med Grp, Santa Rosa, CA USA.
EM stefage00@yahoo.com
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD MAY
PY 2012
VL 198
IS 5
SU S
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 937OI
UT WOS:000303667400466
ER
EF